
<html lang="en"     class="pb-page"  data-request-id="147b4b58-3511-4c45-97e3-fa5374edf982"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b00843;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-10;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic" /></meta><meta name="dc.Creator" content="Vigneshwaran  Namasivayam" /></meta><meta name="dc.Creator" content="Murugesan  Vanangamudi" /></meta><meta name="dc.Creator" content="Victor G.  Kramer" /></meta><meta name="dc.Creator" content="Sonali  Kurup" /></meta><meta name="dc.Creator" content="Peng  Zhan" /></meta><meta name="dc.Creator" content="Xinyong  Liu" /></meta><meta name="dc.Creator" content="Jacob  Kongsted" /></meta><meta name="dc.Creator" content="Siddappa N.  Byrareddy" /></meta><meta name="dc.Description" content="Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the development of anti-..." /></meta><meta name="Description" content="Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the development of anti-..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 5, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00843" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00843" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00843" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00843" /></link>
        
    
    

<title>The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00843" /></meta><meta property="og:title" content="The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0001.jpeg" /></meta><meta property="og:description" content="Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the development of anti-HIV treatment. Among the HIV-1 RT inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have gained a definitive place due to their unique antiviral potency, high specificity, and low toxicity in antiretroviral combination therapies used to treat HIV. Until now, &gt;50 structurally diverse classes of compounds have been reported as NNRTIs. Among them, six NNRTIs were approved for HIV-1 treatment, namely, nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), etravirine (ETR), rilpivirine (RPV), and doravirine (DOR). In this perspective, we focus on the six NNRTIs and lessons learned from their journey through development to clinical studies. It demonstrates the obligatory need of understanding the physicochemical and biological principles (lead optimization), resistance mutations, synthesis, and clinical requirements for drugs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00843"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00843">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00843&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00843&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00843&amp;href=/doi/10.1021/acs.jmedchem.8b00843" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4851-4883</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01492" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00193" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Vigneshwaran Namasivayam</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vigneshwaran Namasivayam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Institute, Pharmaceutical Chemistry II, University of Bonn, 53121 Bonn, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +49228735228. E-mail: <a href="/cdn-cgi/l/email-protection#9ceaf2fdf1fdeff5eadce9f2f5b1fef3f2f2b2f8f9"><span class="__cf_email__" data-cfemail="285e464945495b415e685d4641054a474646064c4d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vigneshwaran++Namasivayam">Vigneshwaran Namasivayam</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3031-3377" title="Orcid link">http://orcid.org/0000-0003-3031-3377</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Murugesan Vanangamudi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Murugesan Vanangamudi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal and Pharmaceutical Chemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi, Andhra Pradesh 517102, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Murugesan++Vanangamudi">Murugesan Vanangamudi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victor G. Kramer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victor G. Kramer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck Canada Inc., Kirkland, Quebec H9H 4M7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victor+G.++Kramer">Victor G. Kramer</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sonali Kurup</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sonali Kurup</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Roosevelt University, Schaumburg, Illinois 60173, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sonali++Kurup">Sonali Kurup</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4722-7862" title="Orcid link">http://orcid.org/0000-0003-4722-7862</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peng Zhan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng Zhan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Zhan">Peng Zhan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9675-6026" title="Orcid link">http://orcid.org/0000-0002-9675-6026</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinyong Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinyong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, P.R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinyong++Liu">Xinyong Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacob Kongsted</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacob Kongsted</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, DK-5230, Odense M, Denmark</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacob++Kongsted">Jacob Kongsted</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7725-2164" title="Orcid link">http://orcid.org/0000-0002-7725-2164</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Siddappa N. Byrareddy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Siddappa N. Byrareddy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha 68198-5880, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Siddappa+N.++Byrareddy">Siddappa N. Byrareddy</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6889-4640" title="Orcid link">http://orcid.org/0000-0002-6889-4640</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00843&amp;href=/doi/10.1021%2Facs.jmedchem.8b00843" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4851–4883</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 5, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 May 2018</li><li><span class="item_label"><b>Published</b> online</span>5 December 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00843</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4851%26pageCount%3D33%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DVigneshwaran%2BNamasivayam%252C%2BMurugesan%2BVanangamudi%252C%2BVictor%2BG.%2BKramer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D10%26contentID%3Dacs.jmedchem.8b00843%26title%3DThe%2BJourney%2Bof%2BHIV-1%2BNon-Nucleoside%2BReverse%2BTranscriptase%2BInhibitors%2B%2528NNRTIs%2529%2Bfrom%2BLab%2Bto%2BClinic%26numPages%3D33%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4883%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00843"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3858</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">53</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00843" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Vigneshwaran&quot;,&quot;last_name&quot;:&quot;Namasivayam&quot;},{&quot;first_name&quot;:&quot;Murugesan&quot;,&quot;last_name&quot;:&quot;Vanangamudi&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;G. Kramer&quot;},{&quot;first_name&quot;:&quot;Sonali&quot;,&quot;last_name&quot;:&quot;Kurup&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Zhan&quot;},{&quot;first_name&quot;:&quot;Xinyong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;Kongsted&quot;},{&quot;first_name&quot;:&quot;Siddappa&quot;,&quot;last_name&quot;:&quot;N. Byrareddy&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4851-4883&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00843&quot;},&quot;abstract&quot;:&quot;Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the development of anti-HIV treatment. Among the HIV-1 RT inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have gained a definitive place due to their unique antiviral potency, high specificity, and low toxicity in antiretroviral combination therapies used to treat HIV. Until now, &gt;50 structurally diverse classes of compounds have been reported as NNRTIs. Among them, six NNRTIs were approved for HIV-1 treatment, namely, nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), etravirine (ETR), rilpivirine (RPV), and doravirine (DOR). In this perspective, we focus on the six NNRTIs and lessons learned from their journey through development to clinical studies. It demonstrates the obligatory need of understanding the physicochemical and biological principles (lead optimization), resistance mutations, synthesis, and clinical &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00843&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00843" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00843&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00843" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00843&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00843" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00843&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00843&amp;href=/doi/10.1021/acs.jmedchem.8b00843" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00843" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00843" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (10 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00843%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DNamasivayam%26date%3D2019%26atitle%3DThe%2BJourney%2Bof%2BHIV-1%2BNon-Nucleoside%2BReverse%2BTranscriptase%2BInhibitors%2B%2528NNRTIs%2529%2Bfrom%2BLab%2Bto%2BClinic%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D10%26spage%3D4851%26epage%3D4883%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=292035" title="Viruses">Viruses</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/jmcmar.2019.62.issue-10/20190523/jmcmar.2019.62.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Human immunodeficiency virus (HIV) infection is now pandemic. Targeting HIV-1 reverse transcriptase (HIV-1 RT) has been considered as one of the most successful targets for the development of anti-HIV treatment. Among the HIV-1 RT inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have gained a definitive place due to their unique antiviral potency, high specificity, and low toxicity in antiretroviral combination therapies used to treat HIV. Until now, >50 structurally diverse classes of compounds have been reported as NNRTIs. Among them, six NNRTIs were approved for HIV-1 treatment, namely, nevirapine (NVP), delavirdine (DLV), efavirenz (EFV), etravirine (ETR), rilpivirine (RPV), and doravirine (DOR). In this perspective, we focus on the six NNRTIs and lessons learned from their journey through development to clinical studies. It demonstrates the obligatory need of understanding the physicochemical and biological principles (lead optimization), resistance mutations, synthesis, and clinical requirements for drugs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acquired immune deficiency syndrome (AIDS) is caused by human immunodeficiency virus (HIV) infection and is today considered one of the most highly reviewed antiviral drug targets.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6">(1−6)</a> According to the Joint United Nations Program on HIV/AIDS (UNAIDS) report 2017, more than 36 million people are today living with HIV, including 2.1 million children under the age of 15 years. Among these only ∼18 million are on antiretroviral therapy.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although AIDS-associated death has been significantly reduced as per 2016 data (1 million) as compared to 2005 (1.9 million), the number of new infections unfortunately remains constant per year. One of the primary reasons for the reduction of AIDS-related mortality is the introduction of combination antiretroviral therapy (also called cART). However, most of the currently available drugs for clinical use are prone to development of drug resistance.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Briefly, cART targets multiple points of the replication cycle and typically include two nucleoside reverse transcriptase inhibitors (NRTIs), and either a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor (InSTI).<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a></div><div class="NLM_p">HIV virus enters the host cell and uses host cell machinery to replicate, which eventually leads to significant weakening of the host immune system. HIV-1 replication is a multistep process, and each step is crucial for successful viral replication and therefore a potential target for antiretroviral drugs. Briefly, the life cycle begins when it binds to a CD4<sup>+</sup> receptor, which is present on the surface of a T-lymphocyte. In addition to binding to a CD4<sup>+</sup> receptor, HIV must bind to one of the chemokine receptors such as CCR5 or CXCR4 in order to enter into a cell (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). These receptors interact with viral envelope proteins such as glycoproteins gp120 and trans-membrane gp41 protein. When HIV-1 approaches the host cell surface, gp120 binds to the CD4<sup>+</sup> receptor, and this further promotes binding with the coreceptor, which leads to a conformational change in gp120 which allows gp120 to unfold into the host cell membrane and folds back on itself to induce fusion of their membranes. Viral nucleocapsid enters the host cell and releases the RNA strands and key enzymes such as reverse transcriptase (RT), integrase (IN) and protease (PR). To replicate inside the host cell, the viral DNA polymerase uses the host RNA primer, especially tRNA<sup>lys3</sup>, in order to synthesize single-strand viral DNA (−), subsequently, it is hybridized with a viral RNA template to form a RNA:DNA hybrid. Further, the RNase H (ribonuclease H) domain of reverse transcriptase (RT) removes the RNA strand from the hybrid and further assists the formation of a purine-rich sequence of HIV RNA (also called “polypurine tract” or PPT), which serves as a primer for the synthesis of viral DNA strand (+). RNase H plays a crucial role in the removal of the PPT portion after priming of (+) DNA synthesis (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). The polymerase then continues to convert the remaining viral DNA into double-stranded viral DNA (dsDNA). Subsequently, IN takes the dsDNA into the nucleus and integrates viral DNA into the host cell genome. Activation of the cell induces the transcription of pro-viral DNA into viral mRNA. The viral mRNA then translocates into the cytoplasm, where it is used as a blueprint to build longer blocks of the new virus. For instance, part of the viral mRNA is translated as polyproteins gag (structural) and pol (replication), the latter as a gag-pol fusion following a frame shift event. Protease enzyme (PR) processes some of the viral proteins and digestion of a longer viral protein into smaller individual core proteins; this step is crucial in order to create an infectious virus. At this stage of the process, viral genetic material and key enzymes are assembled with coproteins and form a viral capsid, which leaves the host cell with envelope proteins at the surface of the host cell.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) The overall architecture of HIV-1 is shown and (B) three-dimensional structure of HIV-1 RT (p66/p51) in complex with nucleic acids is highlighted in different colors. (C) A brief timeline of HIV-1 drug development and in particular the drugs identified for RT are highlighted. The two-dimensional (2D) representation of approved NNRTI drugs is depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Drugs that interfere at key replication steps will stop the replication of virus: (1) blocking of viral entry into the host cell with entry inhibitors, including fusion inhibitors (FIs), (2) inhibition of reverse transcriptase stops the further step in the replication process either by nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), or nucleotide analogue reverse-transcriptase inhibitor (NtRTI), (3) inhibition of integration of viral DNA with host genetic material by blocking integrase activity (InSTI), (4) protease inhibitor (PI) that blocks further viral maturation.<a onclick="showRef(event, 'ref1 ref5 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref1 ref5 ref11 ref12">(1,5,11,12)</a></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  Reverse Transcriptase (RT) Inhibitors</h3><div class="NLM_p">Reverse transcriptase (RT) is an RNA-dependent DNA polymerase that utilizes a strand of RNA to synthesize double-stranded viral DNA.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> On the basis of the binding site and chemical class of compounds, RT inhibitors are classified into NRTIs and NNRTIs.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C shows a brief milestone in the development of HIV-1 drugs, and the important RT inhibitors are highlighted. The list of currently approved NNRTIs with their key parameters is shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The NRTIs are initially phosphorylated at the deoxyribose moiety in the host cell by cellular kinases, subsequently, deoxynucleotide triphosphate (i.e., NNRT-triphosphates) is incorporated into a growing strand of DNA acting as “chain-terminators” in the RT active site (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The NNRTIs are also called allosteric inhibitors, which bind to a hydrophobic pocket distal to the active site within RT. The allosteric site-binding pocket is also termed the non-nucleoside inhibitor-binding pocket (NNIBP), which influences the geometry of the RT active site and interferes with viral DNA synthesis.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Approved RT-Targeting Drugs<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">generic</th><th class="colsep0 rowsep0" align="center">brand</th><th class="colsep0 rowsep0" align="center">manufacturer</th><th class="colsep0 rowsep0" align="center">FDA approved date</th><th class="colsep0 rowsep0" align="center">recommended dose (mg)</th><th class="colsep0 rowsep0" align="center">serum half-life (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nevirapine</td><td class="colsep0 rowsep0" align="center">Viramune</td><td class="colsep0 rowsep0" align="center">Boehringer Ingelheim</td><td class="colsep0 rowsep0" align="center">21 June, 1996</td><td class="colsep0 rowsep0" align="center">200 b.i.d.</td><td class="colsep0 rowsep0" align="center">25–30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">delavirdine<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">Rescriptor</td><td class="colsep0 rowsep0" align="center">Upjohn, Pharmacia, Pfizer</td><td class="colsep0 rowsep0" align="center">4 April, 1997</td><td class="colsep0 rowsep0" align="center">400 qd</td><td class="colsep0 rowsep0" align="center">2–11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">efavirenz</td><td class="colsep0 rowsep0" align="center">Sustiva</td><td class="colsep0 rowsep0" align="center">Bristol-Myers Squibb</td><td class="colsep0 rowsep0" align="center">17 September, 1998</td><td class="colsep0 rowsep0" align="center">600 qd</td><td class="colsep0 rowsep0" align="center">40–55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">etravirine</td><td class="colsep0 rowsep0" align="center">Intelence</td><td class="colsep0 rowsep0" align="center">Tibotec, Johnson and Johnson</td><td class="colsep0 rowsep0" align="center">18 January 2008</td><td class="colsep0 rowsep0" align="center">200 b.i.d.</td><td class="colsep0 rowsep0" align="center">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rilpivirine</td><td class="colsep0 rowsep0" align="center">Edurant</td><td class="colsep0 rowsep0" align="center">Tibotec, Johnson and Johnson</td><td class="colsep0 rowsep0" align="center">20 May, 2011</td><td class="colsep0 rowsep0" align="center">25 qd</td><td class="colsep0 rowsep0" align="center">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">doravirine</td><td class="colsep0 rowsep0" align="center">Pifeltro</td><td class="colsep0 rowsep0" align="center">Merck</td><td class="colsep0 rowsep0" align="center">30 August, 2018</td><td class="colsep0 rowsep0" align="center">100 qd</td><td class="colsep0 rowsep0" align="center">11–15</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The approved drugs generic name, brand name, manufacture, date of approval, recommended daily dosage in mg, and serum half-life of the drugs in hours are provided.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Discontinued by FDA. q.d: once a day, b.i.d: two times a day.</p></div></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Ligand binding pockets of HIV-1 RT are shown with nevirapine (gray) and zidovudine (green), and the key structural domains are highlighted including the non-nucleoside inhibitor-binding pocket (NNIBP) (see text for details). (B) NNIBP of HIV-1 RT including important secondary structural domains and amino acid residues in the pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Overall, the NNIBP is largely hydrophobic and comprises amino acids L100, V106, T107, V108, V179, Y181, Y188, G190, F227, W229, L234, and Y318 that can interact through their side chains (cf. <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The pocket also includes a few nonhydrophobic residues including K103, K101, and P236. The size of the NNIBP greatly varies depending on the position of the β10 strand (residues 232–234), β11 strand (residues 239–241), and the P236 hairpin loop of RT (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). A small NNIBP includes a hydrogen bond between the carbonyl oxygen of P236 and the nitrogen of K103. Larger NNIBPs do not include such a hydrogen bond and instead provide an expanded volume for NNRTI binding.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.2.  Mechanism of Resistance</h3><div class="NLM_p">The allosteric binding site is not crucial to RT function and is not directly involved in substrate binding or viral DNA synthesis. As a consequence, point mutations can occur within the NNIBP that hinder NNRTI binding to NNIBP but do not interfere with RT’s role in viral DNA synthesis. A rapid selection of drug-resistant HIV-1 strains in cell culture as well as in HIV-1 infected patients has been observed with NNRTIs.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Primary and secondary resistance-associated mutations occur within or near the NNIBP and reduce the efficacy of NNRTIs.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">Because of the rapid development of resistance, NNRTIs cannot be applied as monotherapy in the management of HIV,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and the major NNRTI resistance mutations include K103N/S, V106A/M, Y181C/I/V, Y188L/C/H, and G190A/S/E.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> The minor mutations usually occur in combination with one of the major NNRTI resistance mutations and include L100I, K101P, P225H, F227L, M230L, and K238T. In addition, double mutants also frequently occur in the RT and these include K103N/Y181C and K103N/L100I.</div><div class="NLM_p">The first-generation NNRTIs, including nevirapine (NVP) and efavirenz (EFV), show a significant loss of activity with single-point mutations such as Y181C, P236L, and K103N, and the second-generation NNRTIs etravirine (ETR) and rilpivirine (RPV) show loss of activity against mutants such as K101E, E138K, and Y181V. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the effectiveness of NNRTIs has been limited by the rapid emergence of drug resistance from new viral strains, thus the development of novel NNRTIs with more potency, improved resistance profiles and less toxicity is required. The reported X-ray crystal structures with the approved NNRTI drugs are listed in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf" class="ext-link">Table S1</a>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Venn diagram showing the most common clinically significant NNRTI-resistance mutations published for NNRTI approved drugs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Because of the combined availability of supercomputing facilities and sophisticated computational chemistry and biophysical approaches, computer-aided drug design plays an important role in designing novel and effective drug candidates for HIV-1.<a onclick="showRef(event, 'ref2 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref2 ref28 ref29 ref30">(2,28−30)</a> For instance, in silico approaches, such as virtual screening, quantitative structure–activity relationship (QSAR), and pharmacophore modeling, are often used for identification and optimization of lead compounds. Recently, artificial intelligence (AI) approaches such as neural network (NN), etc., have also expanded to drug discovery projects, particularly in pharmaceutical and data analytics companies.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> AI approaches are particularly demanding to mine and find relationship patterns from the massive chemical data and protein sequence information toward the development of novel drug candidates. On the other hand, learning from known drugs would also help to improve the discovery and design process. Such learning could potentially be used to design new medicinal chemistry approaches that possibly could make new connections between the data. Thus, the scientific perspectives of these six NNRTIs from development to clinic will be very valuable information in the development of next-generation NNRTIs. In this perspective, we have summarized the most important drug development processes which include lead identification, lead optimization, pharmacokinetic optimization, synthetic procedures, clinical evaluation studies, etc. In addition, detailed information on protein–ligand interactions and mutations has been included to explain the mechanism of resistance of NNRTIs.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">2.  Discovery and Development of Nevirapine (NVP)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nevirapine (also known as BI-RG-587) was the first NNRTI drug emerged as a selective noncompetitive inhibitor/NNRTI drug developed from the tricyclic pyridobenzo- and dipyridodiazepinones series by Boehringer Ingelheim Pharmaceuticals, Inc.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> In 1990, compound BI-RG-587 was identified from high-throughput screening (HTS) of a large collection of the company’s internal compound database. Among the screened compounds, compound pyrido[2,3-<i>b</i>][1,4]benzodiazepinones (<b>1</b>) was shown as a weak HIV-1 RT enzyme inhibitor with an IC<sub>50</sub> of 6 μM, and structurally similar isomeric compounds, such as pyrido[2,3-<i>b</i>][1,5]benzodiazepinones (<b>2</b>), dipyrido[3,2-<i>b</i>:2′,3′-<i>e</i>][1,4]diazepinones (<b>3</b>), and dibenzo[<i>b</i>,<i>e</i>][1,4]diazepinones (<b>4</b>),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> were also screened against HIV-1 RT.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.1.  Lead Optimization</h3><div class="NLM_p">Molecular hybridization and bioisosterism are two classical concepts that were primarily used in the lead optimization. In the case of NVP development, both concepts were successfully applied. For instance, compounds <b>3</b> and <b>4</b> are hybridization products of <b>1</b> and <b>2</b>. For synthetic purposes, compound <b>2</b> was chosen as a lead structure and further structural modifications were introduced. The <i>N</i>-alkylated (5 and 11 positions) derivative of compound <b>2</b> 6,11-dihydro-11-ethyl-6-methyl-5<i>H</i>-pyrido[2,3-<i>b</i>][1,5]benzodiazepinone (<b>5a</b>) was developed and found to be active against HIV-1 RT with an IC<sub>50</sub> value of 350 nM. Later, compound <b>3</b> was optimized from compound <b>2</b> by <i>N</i>-alkylation, and this led to the identification of a potent dipyrido compound (<b>5b</b>). Although dipyrido compound <b>5b</b> showed a strong inhibition in HIV-1 RT, because of the fast metabolism through <i>N</i>-dealkylation (N5-methyl and N11-ethyl) by CYP450, the activity of <b>5b</b> was drastically reduced. On the basis of the knowledge from SAR study and metabolism profiling, the methyl group was moved from the N5 to the C4 position at the aromatic ring and yielded a metabolically stable compound (<b>6</b>) with improved potency (compared to <b>5b</b>).<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> It is worth noting that moving a methyl group from the N5 position to the aromatic ring helped to show a favorable interaction with Y181 at the NNIBP site and improved the overall binding affinity toward HIV-1 RT. Moreover, substitution of the 4-methyl group in the aromatic ring significantly reduced the <i>N</i>-deethylation at the 11th position because CYP450 oxidation takes place at the 4-methyl group and the rate of 4-methyl hydroxylation is very slow as compared to <i>N</i>-dealkylation (cf. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Key steps and intermediate compounds in the lead optimization process of NVP. The possible sites of CYP450 metabolism are indicated with yellow spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">From the detailed SAR studies, it was found that the N11-position is key for HIV-1 RT inhibition, for instance, smaller alkyl groups, such as methyl, ethyl (<b>7</b>), or cyclopropyl (<b>8</b>), improve the binding affinity and pharmacokinetic properties. Later, these compounds were chosen for detailed preclinical studies.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.2.  Metabolism of NVP</h3><div class="NLM_p last">NVP undergoes an extensive CYP450 oxidative metabolism, which primarily occurs in liver microsomes at the C-2, C-3, and C-4 methyl and C-8 positions (by CYP3A4 and 2B6) resulting in five major metabolites: 2-hydroxy-nevirapine, 3-hydroxy-nevirapine, 4-hydroxymethyl-nevirapine, 4-carboxy-nevirapine, and 8-hydroxy-nevirapine (cf. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38">(35−38)</a> Hydroxylated primary metabolites undergo glucuronidation by UGT enzymes. Because of low protein binding, 90% of NVP is immediately absorbed.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.3.  RT–NVP Interactions</h3><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> demonstrates key interactions for NVP within the NNIBP of HIV-1. It occupies the hydrophobic pocket made up of L100, V106, V179, Y181, Y188, G190, F227, W229, L234, and Y318. Hydrophobic and stacking interactions have been observed between the two pyrimidine rings and the alkyl substitutions of NVP and L100 and V106 and the aromatic side chains of Y188 and Y181.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Binding mode of NVP (green) with important amino acid residues in the binding pocket of HIV-1 RT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V81">3V81</a>) and hydrophobic pockets are encircled in red and (B) schematic representation of ligand pharmacophore models are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.4.  Resistance of NVP</h3><div class="NLM_p last">Resistance to NVP has resulted from one or more of the amino acid substitutions K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L, and M230L.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Among these, K103N, Y181C, and G190A substitutions appeared frequently.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> On the basis of the three-dimensional structure of NVP in mutant RT compared to wild-type RT, the interactions between the two-pyrimidine rings of NVP and the aromatic side chains of Y181 and Y188 could explain the significant reduction in inhibition when Y181C and Y188C mutations emerge.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The mutations G190A and L100I sterically hinder the binding of NVP to NNIBP.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> The mutants G190A and K103N possibly affect the flexibility of the β-strand, and this diminishes the overall binding affinity NNRTIs.<a onclick="showRef(event, 'ref42 ref44'); return false;" href="javascript:void(0);" class="ref ref42 ref44">(42,44)</a> NVP is a fairly rigid molecule with no linker fragments that could allow for flexibility. Because of the rigidity of its structure, this molecule cannot adapt to point mutations within the NNIBP and resistance develops rapidly to NVP.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.5.  Clinical Trials of NVP</h3><div class="NLM_p">NVP was approved for use in HIV-1 infected adults on the basis of two clinical trials, namely BI 1090 and BI 1046 (INCAS Trial, a randomized trial conducted in Italy, The Netherlands, Canada, and Australia). Trial BI 1090 was a double-blind, placebo-controlled, randomized study initiated in 1995.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The 2249 HIV-1 infected patients with CD4<sup>+</sup> cells <200 cells/mm<sup>3</sup> were randomized into a NVP + lamivudine (3TC) + background therapy (BT) arm or a 3TC + BT arm. The patient’s median CD4<sup>+</sup> count at baseline was 96 cells/mm<sup>3</sup>, and HIV-RNA baseline was 4.58 log<sub>10</sub> copies/mL. Eighty-nine percent of patients were treatment experienced. The percentage of responders (HIV-1 RNA < 50 copies/mL) at week 48 were 18% for the NVP arm and 2% for the placebo arm.</div><div class="NLM_p">BI 1046 (INCAS trial) was a placebo-controlled, double-blind, randomized three-arm clinical trial comparing nevirapine (NVP) + zidovudine (AZT) + didanosine (ddI), NVP + AZT, and AZT + ddI.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> There were 151 HIV-1 infected patients with CD4<sup>+</sup> counts between 200 and 600 cells/mm<sup>3</sup> entered into the study. The patients had a median baseline CD4<sup>+</sup> count of 376 cells/mm<sup>3</sup>, and baseline RNA was 4.41 log<sub>10</sub>copies/mL. Patients with HIV-1 viral loads <400 copies/mL at 48 weeks were 45%, 19%, and 0% for the NVP + AZT + ddI arm, the AZT + ddI arm, and the NVP + AZT arm, respectively.</div><div class="NLM_p last">NVP is available as 100, 200, and 400 mg tablets and a 50 mg/5 mL oral suspension. It can be taken with or without food. The standard adult dose is 200 mg (1 tablet) daily for the first 2 weeks of treatment and 200 mg, twice daily, thereafter. NVP is no longer recommended as first-line or salvage therapy in U.S. treatment guidelines. Severe rash and hepatotoxicity have been reported as adverse events associated with NVP.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> It is also characterized by a low barrier to resistance, where the emergence of one mutation compromising NVP efficacy can compromise future treatment with other NNRTIs.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.6.  Commercial Synthesis of NVP</h3><div class="NLM_p">Synthesis of NVP (and its derivatives) was first reported by Merluzzi et al. and Grozinger et al. starting from 2-chloro-3-nitro-4-methylpyridine (<b>9</b>) and 2-chloronicotinoyl chloride (<b>11</b>).<a onclick="showRef(event, 'ref37 ref50'); return false;" href="javascript:void(0);" class="ref ref37 ref50">(37,50)</a> Compound <b>9</b> was used as a precursor for building 2-chloro-3-amino-4-methylpyridine (<b>10</b>) by hydrogenation over 5% Rh/C. Precursors <b>10</b> and <b>11</b> were reacted together in solvent system 1,4-dioxane, cyclohexane, and pyridine to obtain <b>12</b> in 65% yield followed by the reaction with cyclopropyl amine in xylene at 110 °C to give <b>13</b> in 83% yield. Compound <b>13</b>, on cyclization under basic conditions (NaH in diglyme) at 160 °C, afforded NVP (<b>8</b>) in 67% yield (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0019.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of NVP (<b>8</b>) by Merluzzi et al.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and Grozinger et al.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As described above in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, compound <b>9</b> was the main block for the synthesis of NVP. In earlier reports<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> on synthesis on NVP, <b>9</b> was prepared from <b>14</b> due to complications in separation of two regioisomers (1:13.2) formed during the reaction; production of <b>9</b> on a bigger scale was a bottleneck. Therefore, a subsequent advancement was reported in which <b>10</b> was synthesized from <b>17</b>, which was commercially accessible in bulk quantities. To get rid of hydroxyl groups in compound <b>17</b>, it was subjected to halogenation by POCl<sub>3</sub> at 110–140 °C and subsequently dehalogenated by reduction over Pd-C. To convert the nitrile group into an amine, <b>19</b> was partially hydrolyzed by Amberlite IRA-400 and subsequently subjected to Hofmann reaction to give <b>21</b> with 75% yield. Halogenation of <b>21</b> by Cl<sub>2</sub>/HCl given <b>10</b> in 84% yield (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref34 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref34 ref51 ref52 ref53 ref54">(34,51−54)</a></div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0020.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Key Building Blocks Required for NVP (<b>8</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alternatively, Grozinger et al.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> attempted a synthesis of NVP from <b>18</b> with an idea that the 6-chloro group can be dehalogenated in the last step and keeping it might help in cyclization. Compound <b>18</b> was hydrolyzed using H<sub>2</sub>SO<sub>4</sub> and subjected to Hofmann reaction to form <b>23</b> in 92% yield. Similar to <b>10</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, <b>23</b> was also reacted with <b>11</b> to obtain <b>24</b> (89% yield) and followed by reaction with cyclopropylamine to give <b>22</b> in 84% yield. Cyclization of compound <b>22</b> by NaH and dehalogenation over Pd-C/H<sub>2</sub> gave NVP (<b>13</b>) in 72% yield. The main shortcoming of this method was insolubility issues with <b>23</b> when attempting to produce NVP (<b>8</b>) at bulk scale (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref37 ref55'); return false;" href="javascript:void(0);" class="ref ref37 ref55">(37,55)</a></div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0021.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of NVP (<b>8</b>) Proposed by Grozinger et al.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the above methods (<a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) are best known for synthesis of NVP, the described methods had a few drawbacks; cyclopropyl amine was more likely to vaporize in the process of synthesizing <b>13</b> and the process needed to be done in a sealed vessel in order to avoid the vaporization. However, <b>13</b> was not very stable at high temperature (>145 °C) and prone to explode at such high temperature. Thus, these methods were improved again by reacting cyclopropyl amine with <b>24</b> at 77–100 °C to achieve <b>25</b> followed by basic hydrolysis and activation of the carbonyl group by SOCl<sub>2.</sub> The resultant product <b>27</b> reacted with <b>10</b> to form <b>13</b>. Ring closure of <b>13</b> was achieved by sodium bis(trimethylsilyl)amide (NaHMDS) in THF to obtain the product, NVP (<b>8</b>) (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0022.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Recent Synthetic Procedure Developed for NVP (<b>8</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">However, because this method uses expensive reagents including NaHMDS, the method was modified again by facilitating the SNAr at 80 °C by adding KI in the transformation from <b>12</b> to <b>13</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Likewise, the reaction of <b>13</b> to <b>8</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) was also optimized at 130 °C.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">3.  Discovery and Development of Delavirdine (DLV)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Delavirdine (DLV) is the second NNRTI drug candidate approved by the FDA for clinical use in 1997 and can be one of the components of cART. At the time of its introduction, DLV was recommended as first-line therapy in combination with other NRTIs.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> DLV shows greater ligand flexibility in comparison with NVP and other NNRTIs but is less effective against various mutants.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.1.  Lead Optimization</h3><div class="NLM_p">The initial hit molecule of DLV mesylate (also known as <b>PNU-90152</b>) was first identified in 1992 by Upjohn scientists from a chemical library of 1500 structurally diverse compounds and shows very similar structural features tobis(heteroaryl)piperazine (BHAP).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> During computational filtration followed by in vitro screening of HIV-1 RT inhibition, several compounds showed weak to moderate inhibition. Among these compounds, pyridylpiperazine derivative (<b>PNU-80493E</b>) was identified with an IC<sub>50</sub> of 20 μM (ED<sub>50</sub> 2 μM), which is weakly potent than AZT (ED<sub>50</sub> 0.07 μM), but <b>PNU-80493E</b> showed better selectivity for polymerase α and δ as compared to AZT. In addition, <b>PNU-80493E</b> also had a better cytotherapeutic ratio (CC<sub>50</sub>/ED<sub>50</sub>) as compared to AZT. Other compounds that possessed phenylpiperazines moieties showed less potency compared to <b>PNU-80493E</b>. Therefore, this compound was chosen as the lead compound for further optimization.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p">The lead compound was further optimized through SAR studies, and before introducing an indole group in the lead molecule, the linker between piperazine and the trisubstituted phenyl ring was optimized. Although a carbonyl spacer group did not increase the binding affinity as compared to an alkyl linker, introducing a hydrogen bond acceptor (carbonyl group) greatly improved the binding affinity with HIV-1 RT as seen in the crystal structure (cf. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). The lead compound <b>U-85199E</b> was further modified by introducing an indole moiety in the place of the phenyl ring which led to several potent compounds.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Key steps, techniques, and intermediate compounds in the lead optimization process of DLV. The possible sites of CYP450 metabolism are indicated with a yellow and cyan spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) The 2D ligand interaction diagram of RT and DLV (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM">1KLM</a>). The important amino acids residues in the binding pocket are shown. (B) The 3D representation of DLV indicating the conformational flexibility by specifying the number of rotatable bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Further, Romero et al.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> explored anti-HIV potency of indol-2-yl substituted arylpiperazines, in particular positions X and Y, were extensively optimized in wild-type and mutants, e.g., P236L and Y181C (cf. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Additionally, the flexibility of the molecules also increased to accommodate in the binding site of RT (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). In total, six possible clinical candidates (including <b>U-85199E</b>) against the HIV RT enzyme were chosen and metabolic stability was optimized at the 5-position of indole and <i>N</i>-alkyl group. Compounds substituted with 5-methoxy and 5-fluoro congeners (U-87201, U88352, and U88353) at indole led to less metabolic deactivation via hydroxylation. Likewise, <i>N</i>-alkyl substituents such as bulky <i>N</i>-isopropylamine and <i>N</i>-teritarybutyl amine created the sterically hindered region to reduce the rate of <i>N</i>-dealkylation metabolic conversion. These structural modifications resulted in superior oral bioavailability in laboratory animals followed by good antiviral potency.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.2.  Pharmacokinetic Studies of DLV</h3><div class="NLM_p last">On the basis of pharmacokinetic studies of six compounds (cf. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), <b>PNU-87201E</b> (atevirdine mesylate salt form) was chosen as the first-generation drug candidate which showed better physical and metabolic stability.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The total plasma clearance of atevirdine mesylate was found to be approximately two times slower compared to unsubstituted indole analogues such as <b>U-85961</b> and <b>U-88204</b>.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In addition, <b>PNU-87201E</b> demonstrated good oral bioavailability in animals (50 ± 20% in female beagle dogs, 62 ± 20% in male rats) and drug concentrations in serum greatly exceeded those required for in vitro antiviral activity (<i>C</i><sub>max</sub> = 16–33 μM, <i>T</i><sub>max</sub>= 1 h, in female beagle dogs; <i>C</i><sub>max</sub> = 4.6–17.4 μM, <i>T</i><sub>max</sub> = 0.5–1 h, in male rats). Moreover, in preclinical studies, atevirdine mesylate (<b>U-87201E</b>) proved to have a good margin of safety upon multiple dosing.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Further, the metabolic stability due to indole substituent, central spacer, and pyridine heterocyclic was also studied. On the basis of the toxicokinetic studies, three compounds showed better profiles, e.g., 5-substituted indole PNU-90152, the 6-substituted indole PNU-89388, and the (alkylamino)piperidine PNU-90328. Among these three analogues, only PNU-90152 inhibited HIV-1 replication in cell culture and exhibited the highest serum concentrations as well as good tolerability.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.3.  Metabolism of DLV</h3><div class="NLM_p last">DLV is primarily metabolized in the liver by cytochrome P450 3A4. The key metabolic process includes <i>N</i>-dealkylation, hydroxylation of <i>N</i>-dealkyldelavirdine, amidic hydrolysis, and hydroxylation at the pyridine ring (cf. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf" class="ext-link">Figure S1</a>). From metabolic studies in mouse, rat, dog, monkey, rabbit, and human, <i>N</i>-desisopropyldelavirdine is the major metabolite which undergoes hydroxylation either at C-4′ or C-6′ position of the pyridine ring and subsequently conjugates with sulfate. In addition, DLV is also directly hydroxylated at the C-6′ pyridine ring and forms hydroxylated 6′-pyridinoldelavirdine as major metabolite. A minor portion of DLV is hydrolyzed at the amide bond by indole carboxylic acid and <i>N</i>-isopropylpyridinepiperazine.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> All metabolites are inactive and primarily excreted renally.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.4.  RT–DLV Interactions</h3><div class="NLM_p last">The greater size of DLV allows interaction with more residues in the NNIBP as compared to NVP (cf. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Compared to NVP, DLV introduces new interactions, which include hydrogen bonding between a carbonyl spacer group to K102 and K103 and hydrophobic interactions with P236. The piperazine ring as a linker molecule allows interactions with V106 and the indole ring of DLV forms hydrogen bonding to the main chain of K103 and a hydrophobic interaction with P236. The isopropylamino and pyridine group of DLV are positioned in close proximity for aromatic interactions with Y181, Y188, and W229.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.5.  Resistance of DLV</h3><div class="NLM_p">The common resistance mutations for DLV include L100I, K103N, and Y181C and also P236L.<a onclick="showRef(event, 'ref54 ref64'); return false;" href="javascript:void(0);" class="ref ref54 ref64">(54,64)</a> Although DLV makes extensive hydrophobic contacts with the P236 side chain via its indole ring in the NNRTI binding pocket, the mutation P236L significantly reduces the potency of DLV. The possible reason could be the extreme molecular flexibility and in particular at the carbonyl and sulfonamide groups (terminal), which reduce the binding affinity of the indole ring toward P236L mutation. Furthermore, a study by Romero et al.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> showed that removal of the terminal sulfonamide group (i.e., unsubstituted indole at R<sub>3</sub> and R<sub>4</sub> position) increases its potency against P236L mutants but significantly reduced its effectiveness against Y181C mutant<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and showed very poor pharmacokinetic properties.</div><div class="NLM_p last">Although the P236L mutation confers resistance against DLV, it increases the effectiveness of other NNRTIs. While DLV is also selective for the P236L mutation, only 6% of DLV- resistant HIV isolates from patients receiving DLV monotherapy contain the P236L mutation, whereas 80% include the K103N mutation.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> It has been suggested that the P236L mutation confers a replication defect in comparison to wild-type that accounts for a predominance of the K103N mutant compared to P236L. Interestingly, P236L confers resistance to DLV but it does not decrease susceptibility to other NNRTIs, and therefore failing therapy with DLV does not result in NNRTI cross-resistance.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> DLV is unique in its capacity to induce a G190A and G190E mutation that demonstrates enhanced inhibition of RT function.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> The increased susceptibility to RT inhibition by DLV is explained based on G190E RT being less processive compared to G190A RT or wild-type HIV-1 RT with regard to both polymerase and RNase H function.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.6.  Clinical Trials of DLV</h3><div class="NLM_p">DLV was approved on the basis of two clinical trials: study 21 part II and study 13C.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Both studies were double-blind, placebo-controlled, randomized trials evaluating DLV in HIV-1 infected patients.<a onclick="showRef(event, 'ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77">(75−77)</a> Both trials enrolled patients who were treatment-naïve or treatment-experienced. Study 21 part II compared DLV + AZT + 3TC, DLV + AZT, and AZT + 3TC in 373 HIV-1 infected patients. Intent to treat analysis of patients with viral loads <400 copies/mL at 54 weeks was 45%, 2%, and 14% for the DLV + AZT + 3TC arm, DLV + AZT arm, and AZT + 3TC arm, respectively. Study 13C randomized 345 HIV-1 infected patients into two arms. The first arm was DLV + AZT + either ddI, 3TC, or zalcitabine (ddC). The comparator arm was AZT + either ddI, 3TC, or ddC. The proportion of patients with viral loads <400 copies/mL at 54 weeks was 29% for the DLV arm and 10% for the non-DLV containing arm.</div><div class="NLM_p">DLV is rarely used today and is not recommended in the U.S. Department of Health and Human Services (DHHS) or International Antiviral Society (IAS) HIV treatment guidelines due to high pill burden, dosing schedule, and drug interactions.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The most common adverse event is severe rash, which occurred in 18% of patients in clinical trials.<a onclick="showRef(event, 'ref74 ref79'); return false;" href="javascript:void(0);" class="ref ref74 ref79">(74,79)</a></div><div class="NLM_p last">DLV and NVP were studied during a time before the utility of cART was determined. Regimens were suboptimal by today’s standards; the efficacy of a three-drug regimen (anchor + NRTI backbone) had not been established. As such, many of the clinical trials described were not differentiated by treatment-naive or treatment-experienced patients. Indeed, many patients during this time had previously been treated with monotherapy AZT and harbored NRTI resistance mutations prior to enrolment.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">3.7.  Commercial Synthesis of DLV</h3><div class="NLM_p">Synthesis of DLV was initially reported by Romero et al.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> Piperazine (<b>28</b>) was reacted with 2-chloro-3-nitro pyridine (<b>29</b>) and followed by protection of amine as <i>t</i>-butyloxycarbamate to obtain <b>30</b> (96% yield). The nitro group in <b>30</b> was reduced by hydrogenation on Pd-C and subsequently condensed with acetone to form imine, which was reduced by sodium cyanoborohydride to form <b>31</b> (91% yield). The <i>t</i>-butylcarbamate group in <b>31</b> was deprotected by TFA and reacted with <b>32</b> using peptide coupling agents 1,1′-carbonyldiimidazole/<i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (CDI/EDC) to obtain <b>33</b> (74% yield). The nitro group in <b>33</b> was reduced by hydrogenation on Pd/C and reacted with mesityl chloride in the presence of pyridine as a base to obtain DLV (<b>34</b>) (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0023.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of DLV by Romero et al.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the above method was very efficient in preparation of a number of DLV derivatives, it had a few drawbacks concerning bulk scale production. For instance, Pd/C was responsible for increasing the cost of production and purification of side products generated by CDI/EDC at bulk scale was problematic. These issues were solved by replacing Pd/C with a low-cost Raney Ni, and coupling agents CDI/EDC were also replaced by preactivation of the carboxylic group using SOCl<sub>2</sub> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Compound <b>36</b> was obtained from <b>35</b> by ester hydrolysis using potassium hydroxide in methanol followed by reduction of nitro group using Raney Ni (an alternative to Pd-C) in >90% yield. Mesylation of <b>36</b> was done by mesityl chloride and sodium carbonate to obtain <b>37</b> (83% yield). Compound <b>37</b> was coupled to <b>39</b> by preactivation of carboxylic group with thionyl chloride to give DLV (<b>34</b>) in 63% yield (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0024.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Modified Synthetic Procedure of DLV (<b>34</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite this method providing a reasonable yield in each step, <b>38</b> was moisture sensitive and it was difficult to maintain dry conditions at bulk scale. Recently, another method has been reported in which <b>40</b> was reduced using Fe powder and a cheaper alternative to Pd-C/Raney Ni to obtain <b>41</b>. This was followed by mesylation using mesityl chloride/pyridine to attain <b>42</b> in 89% yield. Then, <b>42</b> was reacted with <b>39</b> at 60 °C to give DLV (<b>34</b>) in 63% yield (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><figure id="sch7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0025.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Recent Synthetic Procedure Developed for DLV (<b>34</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">4.  Discovery and Development of Efavirenz (EFV)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The third approved NNRTI drug for the treatment of HIV-1 infection is efavirenz (EFV, DMP 266, <b>L-743,726</b>), which belongs to the series of benzoxazinones. This drug exhibited potent inhibition against wild-type HIV-1 RT enzyme (<i>K</i><sub>i</sub> = 2.93 nM) as well as a panel of NNRTI-resistant single RT mutant viruses with 95% inhibitory concentrations of <1.5 μM.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">4.1.  Lead Optimization</h3><div class="NLM_p">The initial prototype for the development of EFV was initiated with a benzothiadiazine compound <b>NSC287474</b>, which showed potent activity against a variety of HIV-1 strains.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> In the development process of EFV, the bioisosteric replacement strategy was utilized to obtain the lead compound <b>L-608,788</b>.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">The combined introduction of acetylene and cyclopropyl improved the activity but decreased the oral bioavailability. A variety of aryl groups were explored at the acetylene group and identified cyclopropylarylethynylquinazolin-2(1<i>H</i>)-ones), a racemic mixture (IC<sub>50</sub> = 23.2 nM), enhanced the potency against HIV-RT and also improved oral bioavailability.<a onclick="showRef(event, 'ref86 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref86 ref87 ref88">(86−88)</a> Furthermore, the obtained (−)-4(S) enantiomer was found to be the active enantiomer (IC<sub>50</sub> = 12 nM), and the other one (+)-4(S) identified was inactive (IC<sub>50</sub> = 9300 nM).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Initial structural modification of quinazolines with alkylbenzoxazepinones, benzothiadiazepines decreased the activity and 1,4-dihydro-2<i>H</i>-3,1-benzoxazin-2-ones (<b>L-743,726</b> or efavirenz, EFV) was found to be a potent NNRTI. Because of possible oxidative metabolism of <i>N</i>-methyl or NH- groups at position 3, it was further optimized with bioisosteres. Subsequent studies with different substituents (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) on the benzoxazinone ring explain why bulky substituents at position 6 were not allowed due to a decrease in activity. Attempts to replace the cyclopropylacetylene group at the C4 position with small heterocyclic (furan, pyridine) or alkoxy groups (saturated or unsaturated) yielded only equivalent or less potent molecules in comparison to EFV. Later studies demonstrated that the CF<sub>3</sub> group is essential and improves the potency by reducing p<i>K</i><sub>a</sub> and forming strong hydrogen bond interactions with the enzyme.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Later, molecular modeling studies predicted different interactions for the molecules by replacing the benzoxazinone with indolin-2-one ring, which improves the activity.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div><figure id="fig8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0009.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lead compounds and important compounds synthesized and tested in the process of EFV lead optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.2.  Metabolism of EFV</h3><div class="NLM_p last">EFV undergoes cytochrome P450 oxidative metabolism and primarily occurs in liver microsomes at C-7 and C-8 methyl positions, resulting in two major metabolites: 7- and 8-hydroxy-efavirenz, respectively (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf" class="ext-link">Figure S2</a>). The minor 7-hydroxy-efavirenz metabolite undergoes additional metabolic conversion to 8,14-dihydroxy-efavirenz. The hydroxyl metabolites are excreted in urine in the form of glucuronide conjugates. However, in rat, 8-hydroxy-efavirenz is identified as a major metabolite which conjugates with sulfate. The presence of a triple bond was expected to be a potential risk in formation of reactive metabolites.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> In particular, the metabolites identified from rats, monkey, and humans revealed that rats produce a unique glutathione adduct and cause nephrotoxicity<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> because a lack of specific glutathione S-transferase (GST) and related enzymes in human and monkey might result in the absence of glutathione adducts. Detailed studies revealed that decreasing the cycloproponal metabolite or inhibiting the γ-glutamyltranspeptidase reduces the nephrotoxicity in rats.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">4.3.  RT–EFV Interaction</h3><div class="NLM_p">The benzoxazin-2-one ring is bound between the side chains of L100 and V106 and makes edge-on contacts with Y318 and V179. Hydrogen bonds are observed between the benzoxazin-2-one NH and carbonyl group and the backbone carbonyl oxygen and backbone amine of K101. The nitrogen of the benzoxazin-2-one ring of EFV is also located close to the side chain of K103, allowing for a van der Waals interaction (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). The cyclopropyl–propynyl group is situated in a pocket flanked by the aromatic side chains of Y181, Y188, F227, and W229.</div><figure id="fig9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0010.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) The binding mode of EFV in the binding pocket of HIV-1 RT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JKH">1JKH</a>) with important amino acids in the pocket and (B) the 2D ligand interaction diagram of EFV is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.4.  Resistance of EFV</h3><div class="NLM_p last">EFV has a different resistance profile compared to NVP and DLV. Resistance resulting in reduced susceptibility in cell culture to EFV has nonetheless been observed. EFV has a somewhat greater barrier to resistance compared to NVP and DLV and is considered a second-generation NNRTI.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The propynyl–cyclopropyl group of EFV is smaller than the aromatic pyridine ring of NVP.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Consequently, interactions with mutable Y181 and Y188 side chains are more limited compared to NVP. Thus, the Y181C and Y188C mutations do not have as much of an effect on EFV binding compared to NVP.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> This is consistent with the three-dimensional structure of EFV with Y181C RT. K103N substitution also caused a decrease in susceptibility to EFV, although the decrease in affinity due to the K103N mutation was less for EFV compared to NVP.<a onclick="showRef(event, 'ref83 ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref83 ref95 ref96">(83,95,96)</a> A hydrogen bond was observed for EFV, but not for NVP, with the backbone carbonyl of K103.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The ability of the smaller EFV molecule to rearrange in the mutated K103N NNIBP compared to the bulkier, rigid structure of NVP could explain the different binding affinities.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The G190A and L100I mutations sterically hinder binding to EFV, similar to NVP. Resistance to EFV has also resulted from one or more of the amino acid substitutions L100I, K101P, G190A/S, V106M, Y188L, G190A/S/E, F227L, and M230L that sterically hinder binding to EFV similar to NVP.<a onclick="showRef(event, 'ref26 ref97'); return false;" href="javascript:void(0);" class="ref ref26 ref97">(26,97)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.5.  Clinical Trials of EFV</h3><div class="NLM_p">EFV was the third NNRTI approved by the FDA. It gained approval for use in HIV-1 infected adults in 1998 on the basis of two clinical trials. Study 006 enrolled 1266 HIV-1 infected patients into an open-label trial who were randomized to either an EFV + AZT + 3TC arm, an EFV + indinavir (IDV) arm, or an IDV + AZT + 3TC arm. Median CD4<sup>+</sup> count at baseline was 345 cells/mm<sup>3</sup>; median baseline HIV-1 RNA was 4.8 log<sub>10</sub> copies/mL. Virologic response (viral load <400 copies/mL) at 48 weeks was 70% for the EFV + AZT + 3TC arm, 53% for the EFV + IDV arm, and 48% for the IDV + AZT + 3TC arm.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> This result demonstrated the increased efficacy of EFV + 2 NRTIs compared to IDV + 2 NRTIs or IDV + EFV. The combination of EFV + 2 NRTIs was shown as a potent combination of antiretroviral agents.</div><div class="NLM_p">AIDS Clinical Trials Group (ACTG) 364 enrolled 196 NRTI-experienced patients into a double-blind, randomized, placebo-controlled study. Patients were randomized to one of three arms; EFV + nelfinavir (NFV) + NRTIs, EFV + NRTIs, or NFV + NRTIs. All patients were assigned new NRTIs based on their past NRTI exposure. Baseline CD4<sup>+</sup> cell count was 389 cells/mm<sup>3</sup>; baseline HIV-1 RNA was 8130 copies/mL. At 48 weeks, the percentage of patients with viral loads <500 copies/mL was 78% for the EFV + NFV + NRTIs, 63% for the EFV + NRTIs, and 40% for NFV + NRTIs.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> This study demonstrated that in treatment-experienced patients the combination of EFV + NFV + 2 NRTIs was the most effective in suppressing viral loads compared to only 1 NNRTI or PI + 2 NRTIs.</div><div class="NLM_p last">EFV was the most widely used in treatment-naive patients among the three NNRTIs approved in the late 1990s. Its most common formulation is a fixed-dose combination with tenofovir disproxil fumarate (TDF)/emtricitabine (FTC), making it the first one pill once a day tablet. The standard dose of EFV, either alone or in combination, is 600 mg per day. It is currently recommended as an alternative regimen in the DHHS guidelines based on its widespread use and virologic efficacy; however, patients on EFV-based regimens have exhibited relatively high rates of neuropsychiatric/central nervous system side effects, affecting overall tolerability.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.6.  Commercial Synthesis of EFV</h3><div class="NLM_p">Synthesis of EFV was first reported by Young et al.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> and subsequent advancements were made over the years.<a onclick="showRef(event, 'ref101 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref103">(101−103)</a> Reports from Pierce et al. (from Merck and duPont)<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> and Dai et al. (Lonza Ltd.)<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> represent reasonable approaches for the synthesis of EFV at bulk scale. The scientists from Lonza’s Ltd. made advancements by using 1,4-dichlorobenzene because of the necessity of amine moiety to be protected by a protecting group if present at the beginning, and using 1,4-dichlorobenzene may shorten the route by avoiding amine protection. Considering this information, Correia et al. discovered a new route to EFV by flow synthesis.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">Pierce et al.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> started the synthesis from 4-chloro aniline (<b>43</b>), and in order to introduce the trifluoroacetyl group meta to chloro, the amino group was protected as <i>t</i>-butyl carbamate and subsequently reacted with <i>n</i>-BuLi/ethyl trifluoroacetate. The deprotection of <i>t</i>-butyl carbamate in <b>45</b> by HCl-CH<sub>3</sub>COOH gave <b>46</b>, which was purified by crystallization at 5 °C and isolated in 87% yield. For further reactions, <b>46</b> was needed in neutralized form; therefore, it was stirred with NaOAc in MTBE to provide <b>47</b>. <i>p</i>-Methoxybenzylation of <b>47</b> was done by <i>p</i>-methoxy benzyl alcohol, an inexpensive and less toxic alternative to the previous reports<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> to form <b>48</b> (90% yield). Compound <b>48</b> was enantioselectively alkynylated using <b>49</b> in the presence of ligand <b>50</b> in THF–toluene–hexane mixture at −50 °C and gave <b>51</b> in 98% yield and >99.5% enantiomeric excess (ee). Cyclization of <b>51</b> by COCl<sub>2</sub>/TEA in 95% yield followed by <i>p</i>-methoxy benzyl deprotection by ceric ammonium nitrate gave EFV (<b>53</b>) in 76% yield. However, <i>p</i>-methoxy benzyl deprotection and ceric ammonium nitrate were responsible for the generation of side products like <i>p</i>-methoxybenzaldehyde and some cerium salts. Therefore, an alternative method was explored in which <b>51</b> was reacted with DDQ in toluene to give <b>54a</b>/<b>54b</b> followed by reaction with NaOH–MeOH, which gave amino alcohol <b>55</b> (94% yield), and the side product <i>p</i>-methoxybenzaldehyde was converted into <i>p</i>-methoxy benzyl alcohol by reduction with NaBH<sub>4</sub>. Ring closure of <b>55</b> was achieved by phosgene to obtain EFV (<b>53</b>) in 95% yield (>99.5% purity, >99.5% enantiomeric excess or ee after crystallization with THF–heptane), and alternative attempts of ring closure of <b>55</b> by methyl carbamate only gave EFV in 83% yield and using <i>p</i>-nitrophenylcarbamate achieved EFV in 94% yield after recrystallization (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>).</div><figure id="sch8" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0026.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis Steps of EFV Developed by Pierce et al.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the procedure from Merck and DuPont provide good yields (<90%) in the majority of steps, Chen et al.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> reported an alternative procedure in which protection of anilinic amine can be avoided by using Me<sub>2</sub>Zn and <b>57</b> in the presence of additives (2,2-dimethyl propionicacid, 2,2,2-trichloroethanol) and reacted with <b>56</b> at −10 °C to form <b>55</b> in 95.2% yield (99.8% purity, 99.3% ee) (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). Subsequent advancement in the reaction scheme was made by Dai et al. from Lonza in which protection/deprotection of anilinic moiety was bypassed by starting the synthesis from 1,4-dichlorobenzene.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><figure id="sch9" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0027.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Advancements in the Synthesis of EFV by Chen et al.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">5.  Discovery and Development of Etravirine (ETR) and Rilpivirine (RPV)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">5.1.  Lead Optimization</h3><div class="NLM_p">The development of the diarylpyrimidine (DAPY) series as NNRTIs was started in 1987 by Janssen Pharmaceuticals in collaboration with the Rega Institute for Medical Research. The search was initiated by screening 600 compounds on the MT-4 cell-based anti-HIV assay. Among those screened, 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-<i>jk</i>][1,4]benzodiazepin-2(1<i>H</i>)-one (TIBO, R14458) was recognized as the first NNRTI which inhibited HIV-1 replication at a moderate level.<a onclick="showRef(event, 'ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref108 ref109">(108,109)</a> Subsequently, the hydrophobic ring was broken and analogues of α-anilinophenylacetamide (α-APA) were synthesized and named loviride.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> These two scaffolds exhibited excellent potency against wild-type HIV-1 but had lesser potency against the common NNRTI-resistant mutants.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Later in the same year, further steps were taken by increasing the space between the two ring fragments and cyclization of the linker, which resulted in a new class of diaryltriazine (DATA, R106168) and revealed high activity against wild-type and mutant strains, in particular the G190A mutant, but reduced potency against the double mutants L100I/K103N.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Consequently, the central triazine ring replaced with the bioisostere pyrimidine and continued the development of new prototype diarylpyrimidine (DAPY) analogue of TMC120 (dapivirine, DPV or R147681) to improve the solubility, bioavailability, pharmacokinetics, and potency against HIV-1 double mutations.</div><div class="NLM_p">In collaboration with Tibotec Pharmaceuticals Ltd. and the International Partnership for Microbicides (IPM), DPV was developed as a vaginal microbicide to prevent/decrease the rate of sexual transmission of HIV-1.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The unsubstituted pyrimidine ring of dapivirine was further optimized with a bromine atom introduced at the 5-position and amine group at the 6-position, which led to the identification of etravirine (ETR).<a onclick="showRef(event, 'ref72 ref114'); return false;" href="javascript:void(0);" class="ref ref72 ref114">(72,114)</a> ETR shows high potency against wild-type and mutant strains include L100I, K103N, V106A, Y181C, Y188L, L100I/K103N, and K103N/Y181C.<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115,116)</a> Further, the help of medicinal chemists, crystallographers, and computational approaches resulted in the discovery of the cyanovinyl DAPY derivative called as <b>TMC278</b> (rilpivirine, RPV).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> The extended cyanovinyl group of RPV makes the compound highly active with an IC<sub>50</sub> < 5 nM against both wild-type and many clinically relevant mutants by interacting directly with the highly conserved W229 residue of RT. The development of ETR and RPV took about 20 years (1987–2001) from TIBO to DAPY series by long-term optimization (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). These two drugs are very active against mutant strains through diverse modes of interaction within the highly flexible NNRTI binding site of RT through molecular flexibility and conformational interconversion for “wiggling” and “jiggling” models.<a onclick="showRef(event, 'ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref117 ref118">(117,118)</a> In addition, Ren et al. have proposed alternative binding models using benzophenone derivatives such as “up- and down” position models.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><figure id="fig10" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0011.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Key lead optimization process of ETR and RPV</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">5.2.  Metabolism of ETR</h3><div class="NLM_p last">The elimination half-life of ETR is 30–40 h which is fairly long due to the high protein bound (99.9%) affinity (mainly to the albumin protein and α1-acid glycoprotein). The metabolism of ETR is largely catalyzed by cytochrome P450 subtypes 3A, 2C9, and 2C19. The key hydroxylation process at the dimethylbenzonitrile moiety causes two forms of monohydroxy-etravirine as major metabolites (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf" class="ext-link">Figure S3</a>). Later, the metabolites were further hydrolyzed to form dihydroxy-etravirine. Subsequently, the metabolites undergo glucuronide conjugation by means of uridinediphosphateglucuronosyltransferase (UGT).<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">5.3.  Metabolism of RPV</h3><div class="NLM_p last">RPV is metabolized by cytochrome P450 3A4 and 3A5. The key metabolic process is hydroxylation at the dimethylphenylacrylonitrile (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf" class="ext-link">Figure S4</a>). A total of seven different metabolites were identified using tandem mass spectral analysis. Among these, four form as oxygenated RPV metabolites with two mono- (M1, M2) and hydroxy-RPV (M3, M4) each. The remaining three conjugate form metabolites as <i>N</i>-linked and <i>O</i>-linked glucuronidations (M5-M7) by UGT subtypes 1A1 and 1A4.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">5.4.  RT–ETR Interaction</h3><div class="NLM_p">ETR binds to NNIBP in a horseshoe conformation<a onclick="showRef(event, 'ref20 ref21 ref123 ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref123 ref124 ref125">(20,21,123−125)</a> and demonstrates single-digit nanomolar potencies against both wild-type and mutant HIV-1 isolates (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). The pyrimidine scaffold of ETR is positioned between L100 and V179.<a onclick="showRef(event, 'ref72 ref118'); return false;" href="javascript:void(0);" class="ref ref72 ref118">(72,118)</a> The primary amine and bromo substituents point toward an opening in the pocket between K101 on the p66 subunit and E138 of the p51 subunit. A hydrogen bond is observed between the N<sup>1</sup> pyrimidine nitrogen and the carbonyl oxygen from the K101 main chain. A hydrogen bond is also observed between the primary amine and carbonyl group of the E138 side chain. The benzonitrile substitution occupies a subpocket comprised of V106, P225, P236, F227, Y318, H235, P236, and L234. K103 is located closely to the benzonitrile group and is possibly involved in van der Waals interactions. The dimethylcyanophenyl substituent is positioned in a subpocket lined with the aromatic side chains, which include Y188, W229, and F227. The positioning of the cyano groups of the benzonitrile and dimethylcyanophenyl substitutions on either side of F227 results in the horseshoe shape observed for ETR within the NNIBP.</div><figure id="fig11" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0012.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. 2D protein–ligand interaction diagram for (A) ETR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MEC">3MEC</a>) and (B) RPV (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZD1">2ZD1</a>) and the important amino acids in the NNIBP of RT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">5.5.  RT–RPV Interaction</h3><div class="NLM_p last">RPV occupies a similar position as ETR in the NNIBP,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> and a horseshoe conformation is observed between the two cyano substitutions. Two hydrogen bonds are observed to bind to the main chain atoms of K101. The first is between the pyrimidine N and the backbone NH of K101 and the second between the aniline NH and the backbone carbonyl of K101. In the absence of a primary amino substitution on the pyrimidine scaffold, no interactions are observed with the E138 side chain within NNIBP. The benzonitrile substitution occupies a subpocket comprising of V106, P225, P236, F227, Y318, H235, P236, and L234. The (<i>E</i>)-3-(3,5- dimethylphenyl)acrylonitrile occupies the subpocket made up of W229, Y188, F227, and L234. The cyanovinyl group interacts closely with W229 and F227.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">5.6.  Resistance of ETR and RPV</h3><div class="NLM_p">ETR retains activity against several RT resistant variants with K103N, Y181C, Y188L, and G190A mutations.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> ETR is a highly potent and flexible molecule that can adapt to the steric interference caused by G190A and Y181C mutations (cf. <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Also, fewer interactions were observed with the residues Y181 and Y188 of NNIBP, allowing for greater tolerance of the Y181C and Y188L mutations compared to NVP and EFV.</div><figure id="fig12" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0013.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Schematic representation of (A) ETR bound to K103N mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MED">3MED</a>) and (B) RPV bound to K103N/L100I double mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZE2">2ZE2</a>) in the NNIBP of RT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additionally, ETR retains activity against the K103N mutants owing to interactions with main chain residues 100–103.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The mutated asparagine side chain is located below ETR, and the horseshoe conformation maintains binding interaction within NNIBP in the K103N RT mutant. A decrease in susceptibility was observed for ETR in clinical trials for RT mutants with amino acid substitutions at L100I, Y181I/V, or G190S/E.<a onclick="showRef(event, 'ref126 ref129'); return false;" href="javascript:void(0);" class="ref ref126 ref129">(126,129)</a> Cross-resistance to NVP, DLV, and EFV is likely after virologic failure with an ETR containing regimen.</div><div class="NLM_p">RPV has activity against resistance-associated mutations seen for earlier NNRTIs. Similar to ETR, RPV has retained activity against several RT resistant variants with K103N, Y181C, Y188L, and G190A mutations<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> and form interactions with Y181 and Y188, which allows greater tolerance toward Y181C and Y188L mutants in comparison to NVP and EFV.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">Owing to the flexibility of its structure, the conformation adopted by RPV in the L100I/K103N double mutant RT differs significantly from the binding mode in wild-type RT to accommodate for changes in the binding pocket caused by the K103N/L100I mutation. Similarly, for RPV bound to the K103N/Y181C double mutant RT, loss of the aromatic ring interaction caused by the Y181C mutation is compensated by interactions between the cyanovinyl group of RPV and the aromatic side chain of Y183.</div><div class="NLM_p">A slight repositioning of the amino acid chains allows for complementarity between the NNIBP and RPV in wild-type and mutant forms of HIV-1 RT. However, K101E and K101P mutations have emerged that impair NNRTI binding and cause a significant reduction in efficacy up to 243-fold to RPV and >50-fold to EFV.</div><div class="NLM_p">However, a distinct resistance profile with new amino acid substitutions have emerged.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> A comparison of the potency of EFV and RPV in a single infectivity assay is shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency Values Obtained for EFV and RPV Using a Single Infectivity Assay in Wild-Type and Mutant RTs<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">reverse transcriptase</th><th class="colsep0 rowsep0" align="center">EFV (EC<sub>50</sub>, nM)</th><th class="colsep0 rowsep0" align="center">RPV (EC<sub>50</sub>, nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">wild-type</td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="center">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K103N</td><td class="colsep0 rowsep0" align="center">806</td><td class="colsep0 rowsep0" align="center">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K101P</td><td class="colsep0 rowsep0" align="center">870</td><td class="colsep0 rowsep0" align="center">1142</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Y181C</td><td class="colsep0 rowsep0" align="center">41</td><td class="colsep0 rowsep0" align="center">51</td></tr></tbody></table></div></div><div class="NLM_p">A decreased susceptibility to RPV has been observed for L100I, K101E/P, Y181I/V, E138 K/A/Q/G, V179I/L, Y188L, H221Y, F227C/L, and M230L.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The K101P mutations cause a significant reduction in efficacy for RPV compared to EFV (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The K101P mutation has been suggested to enhance misincorporation by producing an RT enzyme that is more likely to generate new mutations in the viral genome.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The K101E mutation also confers high resistance to RPV.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The E138A/G/K/Q/R mutation in combination with the M184I mutation significantly decreases susceptibility to RPV and ETR.<a onclick="showRef(event, 'ref24 ref134'); return false;" href="javascript:void(0);" class="ref ref24 ref134">(24,134)</a> The E138K substitution was suggested to unfavorably impact the dissociation/association equilibrium for the RPV in complex with RT, thereby reducing RPV-mediated RT inhibition. A combination of E138K and M184I showed a 4-fold reduction in susceptibility to RPV compared with 2-fold for the single mutant E138K.<a onclick="showRef(event, 'ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref135 ref136">(135,136)</a> Cross-resistance to EFV, ETR, and NVP is expected to lead virological failure and development of RPV resistance.</div><div class="NLM_p last">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the Y181C mutation caused a slight decrease in efficacy for RPV and EFV in Y181C RT compared to wild-type RT. The Y181I and Y181V substitutions also conferred 15- and 12-fold decreased susceptibility to RPV, respectively.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">5.7.  Clinical Trials of ETR</h3><div class="NLM_p">ETR was approved for use by the FDA in 2008 and is the fourth NNRTI approved for the management of HIV-1 infection. The clinical efficacy results from the phase III demonstrate undetectable viral load in patients experienced with ARV therapy (DUET) 1 and 2 trials.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The trials were identical, and the pooled results established efficacy in treatment experienced HIV-1 infected patients.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> These patients had prior exposure to EFV, DLV, NVP, and enfuvirtide (T-20). All patients had at least one NNRTI mutation and three or more protease inhibitor mutations. Patients were randomized to an ETR + background regimen or a placebo + background regimen arm. Median baseline CD4<sup>+</sup> count was 99 cells/mm<sup>3</sup> in the ETR arm and 109 in the placebo arm. Median baseline plasma viral load was 4.8 log<sub>10</sub> copies/mL. Virologic response at 48 weeks, defined as viral load <50 copies/mL, was achieved by 60% of patients in the ETR + background regimen and 38% in the placebo arm.</div><div class="NLM_p last">ETR is unique among the approved NNRTIs in that it is indicated specifically for use in treatment-experienced patients. It has not been studied in treatment-naive patients with a phase III clinical program. Its resistance profile represents an increased genetic barrier to resistance and virologic efficacy against many common NNRTIs such as Y181C and G190S.<a onclick="showRef(event, 'ref49 ref140'); return false;" href="javascript:void(0);" class="ref ref49 ref140">(49,140)</a> The recommended daily dose is 200 mg twice daily per day, and it is available in 25 mg, 100 mg, and 200 mg tablets. It must be taken with a meal in order to increase systemic exposure. DHHS guidelines do not recommend ETR as part of an initial regimen for treatment-naïve patients, citing a lack of data in this population.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">5.8.  Clinical Trials of RPV</h3><div class="NLM_p">The FDA approved RPV in 2011, making it the fifth NNRTI approved for use in HIV-1 disease management. It has been approved for use in treatment-naive adults on the basis of the ECHO and THRIVE phase 3 registration trials.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> In ECHO, the arms consisted of RPV + TDF)/FTC and EFV + TDF/FTC. In THRIVE, the arms consisted of RPV vs EFV each with investigator-selected NRTI combinations of either TDF/FTC, AZT + 3TC, or abacavir (ABC) + 3TC. Randomization of patients was baseline viral load-dependent, with 48–54% of patients harboring viral loads <100000 copies/mL.</div><div class="NLM_p last">Pooled data from both trials reports 76% of patients in the RPV arm suppressed viral load to <50 copies/mL at week 96 vs 77% of patients in the EFV arm.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> RPV is available in a number of different combinations; in addition to a standalone 25 mg tablet, it has been coformulated with TDF/FTC into one tablet that must be taken once a day. It has also been coformulated with tenofovir alfenamide fumarate (TAF)/FTC into a one pill once a day regimen. RPV is one-half of the first two-drug combination approved for use as maintenance therapy in HIV-1 infected patients; it is coformulated with the integrase inhibitor dolutegravir (DTG). This is likewise a one pill once a day regimen. The recommended daily dose of RPV in 25 mg and must be taken with a meal. Systemic exposure was found to be 40% lower under fasting conditions. RPV is recommended as an alternative regimen for treatment-naïve patients in the U.S. Department of Health and Human Services (DHHS) guidelines based on its virologic efficacy and lower rates of CNS adverse events, lipid effects, and rash compared to EFV. However, RPV is not recommended in patients with HIV-1 RNA viral loads of >100000 copies/mL or a CD4<sup>+</sup> count <200 cells/mm<sup>3</sup> based on the lower rates of virologic suppression in patients with these characteristics during the phase III clinical trial program.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">5.9.  Commercial Synthesis of ETR</h3><div class="NLM_p">Synthesis of ETR was first reported by De Corte et al.<a onclick="showRef(event, 'ref113 ref143'); return false;" href="javascript:void(0);" class="ref ref113 ref143">(113,143)</a> in which 4-cyanophenyl guanidine (<b>58</b>) and diethyl malonate were reacted together in the presence of sodium ethoxide to obtain pyrimidinediol (<b>59</b>) in 76% yield and followed by halogenation with POCl<sub>3</sub> at 80–90 °C to form <b>60</b> (86% yield). The bromo group in <b>60</b> was introduced by the reaction with Br<sub>2</sub> to give <b>61</b> (78% yield).</div><div class="NLM_p">Compound <b>61</b> reacted with <b>62</b> in the solvent system NMP and 1,4-dioxane to obtain <b>63</b> (45% yield) (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>), followed by reaction with NH<sub>3</sub> in 2-propanol to give ETR (<b>64</b>) in 41% yield.</div><figure id="sch10" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0028.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Initial Synthetic Procedure for ETR Proposed by De Corte et al.<a onclick="showRef(event, 'ref113 ref143'); return false;" href="javascript:void(0);" class="ref ref113 ref143">(113,143)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the lower yield in the last two steps and longer reaction time (4 days) in the last step, further advancements were made by Joshi et al. (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>).<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> It was speculated that poor yield (41%) in amination step in the preparation of <b>64</b> was due to the bromide group adjacent to the reaction site; therefore, attempts were made to do bromination after the amination step.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Compound <b>65</b> reacts with <b>66</b> in the presence of DIEA in 1,4-dioxane at 70 °C to form <b>67</b> with an 80% yield, and then <b>67</b> reacts with <b>68</b> in the presence of NaH/<i>t</i>-BuOK to give <b>69a</b> as the main product and <b>69b</b> as a side product. However, the formation of <b>69b</b> was lowered by cooling down the reaction to −15 °C. Compound <b>69</b> on reaction with aq NH<sub>3</sub> at 120 °C in 12 h gave <b>70</b> with 2–3% of side product formed because of <b>69b</b> in the reaction mixture. Side products were removed by crystallization using dioxane to give <b>70</b> in 82% yield, which on bromination by liquid Br<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub> at 0–5 °C gave ETR (<b>64</b>) in 80% yield.</div><figure id="sch11" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0029.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Modified Synthesis of ETR (<b>64</b>) by Joshi et al.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To improve overall yield and reaction time, subsequent advancements were made by Fier et al. by using their recently developed chemistry on SNAr reaction by AgF<sub>2</sub> (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>).<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> The initial building block <b>72</b> was made by SNAr reaction between <b>71</b> and <b>66</b> using K<sub>2</sub>CO<sub>3</sub> in DMF to obtain <b>72</b> in 91% yield. Compound <b>72</b> on reaction with <b>68</b> at 165 °C and <i>t</i>-butyloxycarbamate protection resulted in <b>73</b> in 88% yield. Fluorination of <b>73</b> with AgF<sub>2</sub> followed by reaction with NH<sub>3</sub>/<i>i</i>-PrOH at 80 °C and <i>t</i>-butyloxycarbamate deprotection gave ETR (<b>64</b>) in 56% yield.</div><figure id="sch12" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0030.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Modified Synthesis Scheme of ETR (<b>64</b>) by Fier et al.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">5.10.  Commercial Synthesis of RPV</h3><div class="NLM_p">RPV was invented by Janssen Pharmaceuticals and Tibotec.<a onclick="showRef(event, 'ref117 ref146 ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref117 ref146 ref147 ref148">(117,146−148)</a> The two key building blocks, <b>77</b> and <b>83</b> (<a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>), were the main requirements for the synthesis of RPV.<a onclick="showRef(event, 'ref117 ref146 ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref117 ref146 ref147 ref148 ref149">(117,146−149)</a> Compound <b>77</b> was prepared from thiouracil (<b>74</b>), which was commercially available in bulk scale. Thiouracil (<b>74</b>) was alkylated by MeI/NaOH at 60 °C to form <b>75</b> in 90% yield, followed by reaction with <b>68</b> at 150 °C, resulted in <b>76</b> in 70% yield. The halogenation of <b>76</b> was done with POCl<sub>3</sub> to obtain <b>77</b> in 80% yield.<a onclick="showRef(event, 'ref117 ref146 ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref117 ref146 ref147 ref148 ref149">(117,146−149)</a> Compound <b>83</b>, another key intermediate, was prepared in four steps from 3,5-4-bromo-2,6-dimethylaniline (<b>78</b>). The amino group in <b>78</b> was protected as dimethylformamidine using <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (<b>79</b>) to form <b>80</b>, which was subsequently reacted with <i>n</i>-BuLi to give <b>81</b>. Compound <b>81</b> on Wadsworth–Emmons reaction with (diethoxyphosphinyl)acetonitrile followed by dimethylformamide protection by ZnCl<sub>2</sub> yielded <b>83</b>. The compounds <b>77</b> and <b>83</b> were reacted together at 150 °C to obtain RPV (<b>84</b>).</div><figure id="sch13" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0031.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthetic Procedure Developed for RPV (<b>84</b>) by Janssen Pharmaceuticals</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In another route for RPV, ethyl 4-amino-3,5- dimethylbenzoate (<b>85</b>) was reacted with <b>77</b> at 150 °C to form <b>86</b>, which on reduction with LiAlH<sub>4</sub> followed by oxidation with MnO<sub>2</sub> resulted in the aldehyde derivative <b>87</b>. Likewise, in the preparation of <b>81</b>, Wadsworth–Emmons reaction with (diethoxyphosphinyl)acetonitrile through a rather complex system <b>87</b> also yielded RPV (<b>84</b>) (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>).</div><figure id="sch14" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0032.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Modified Synthetic Process of RPV (<b>84</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Later it was reported that <b>88</b> and <b>77</b> can also react without using any precursor for aldehyde moiety or any additional protection on aldehyde group to obtain <b>89</b>, which was followed by Wadsworth–Emmons reaction with (diethoxyphosphinyl)acetonitrile to provide RPV (<b>84</b>) (<a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>).</div><figure id="sch15" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0033.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Alternative Synthetic Procedure Developed for RPV (<b>84</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently various advancements were made to make RPV (<b>84</b>) by the introduction of an acrylonitrile moiety through the Heck reaction (<a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>). Compounds <b>90</b> and <b>77</b> were reacted at 150 °C to form <b>91</b>, which was reacted with acrylonitrile using Pd(OAc)<sub>2</sub>/P(<i>o</i>-tol)<sub>3</sub> to obtain RPV (<b>84</b>) (<i>E</i>:<i>Z</i> 96:4).</div><figure id="sch16" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0034.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of RPV (<b>84</b>) by Heck Reaction<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Advancement was made for the production of RPV at bulk scale using the Heck reaction. The iodo analogue (<b>93</b>) was used instead of the bromo analogue in the Heck reaction, and use of expensive ligands in Heck reaction was avoided by the use of Pd/C 0.5%, although this method provided a mixture of <i>E</i>:<i>Z</i> isomers (<b>83</b>:<b>83a</b> 80:20); they could be converted to major <i>E</i> isomer (<i>E</i>:<i>Z</i> 98:2) by treatment with 6 N HCl to give <b>83</b> in 70% yield (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>).<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><figure id="sch17" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0035.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Block <b>83</b> by Heck Reaction</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57">5.11.  RPV-Based Long Acting Antiviral Agents</h3><div class="NLM_p last">Recently, ViiV Healthcare developed two new long-acting injectable nanosuspensions of antiretrovirals, cabotegravir (INSTIs) and RPV (NNRTI), for the treatment of chronic HIV infection. The crystalline nanoparticle formulations have two different drugs with different inhibition mechanisms. The LATTE-2 (long acting antiretroviral treatment enabling) study was conducted to evaluate the long-acting HIV-1 viral suppression and comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens of cabotegravir and RPV compared to oral cabotegravir plus abacavir–lamivudine through 96 weeks.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> This combination regimen was found to be well-tolerated, with no adverse reactions and few withdrawals due to adverse effects were observed. Moreover, this combination is administered once every 4 or 8 weeks, and it maintains viral suppression in about 90% of people who started therapy with an undetectable viral load.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">6.  Other NNRTIs in Clinical Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59">6.1.  Elsulfavirine</h3><div class="NLM_p">Elsulfavirine, initially developed by Viriom, is a prodrug of VM1500A (cf. <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) that has been approved (June 2017) in Russia for use in treatment-naive HIV-1 infected patients. The drug exhibited in vitro antiviral potency with an EC<sub>50</sub> value of 1.2 nM and serum-adjusted EC<sub>50</sub> value of 13.8 nM against the wt HIV RT and a broad range of mutant clinical HIV isolates as well as no cross-resistance with other NNRTIs. The orally formulated prodrug Elsulfavirine is transformed into VM1500A, is rapidly taken up into the red blood cells (RBCs), and gets accumulated reversibly through binding to RBC carbonic anhydrase. Hence, RBCs act as a reservoir that slowly releases the drug back to plasma, and from plasma to the peripheral blood mononuclear cell, the target cells. This preclinical phenomenon may provide more advantages than long-acting oral and parenteral formulation development as a result of infrequent dosing, improving patients’ compliance and likely improving the long-term treatment and prevention of HIV/AIDS.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a></div><figure id="fig13" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0014.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. 2D chemical structures of NNRTIs in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The approval of elsulfavirine came after a phase IIb, double-blind, randomized study comparing elsulfavirine vs EFV with TDF/FTC. There were 120 patients enrolled. Baseline CD4<sup>+</sup> counts were similar between the 2 arms: elsulfavirine, 349 cells/mm<sup>3</sup>, and EFV, 379 cells/mm<sup>3</sup>. Baseline HIV viral load was 4.7 log<sub>10</sub> copies/mL. At 48 weeks, a modified intent to treat analysis showed 81% of patients in the elsulfavirine arm had suppressed to <50 copies/mL compared to 73.7% of patients in the EFV arm. Elsulfavirine has not been approved for use outside Russia.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div><div class="NLM_p last">The recommended dose of elsulfavirine is 20 mg once daily in addition to an NRTI backbone (TDF/FTC). Patients administered elsulfavirine reported fewer CNS and skin adverse events when compared to the EFV group. The long half-life of VM1500A has prompted a preclinical study of long-acting injectable formulations as well as an oral, once-weekly formulation.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60">6.2.  Doravirine</h3><div class="NLM_p">Merck has developed a next-generation NNRTI, doravirine, which commenced by intergrating a tetrazolethioacetanilides scaffold (<b>94</b>) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) and related acetanilide <i>para</i>-sulfonamide series from GW-8248 (<b>95</b>) to form a novel class of diaryl ether NNRTIs (<b>96</b>). In this new class of diarylether derivatives, the benzophenone moiety in <b>95</b> has been replaced by a 1,3-phenoxy fragment.<a onclick="showRef(event, 'ref156 ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref156 ref157 ref158">(156−158)</a> The diaryl class of the compound showed only moderate inhibition of wt HIV RT and clinically relevant mutants K103N and Y181C. However, the SAR of this class is interesting and showed that remarkable enhancement in potency occurred with low nanomolar inhibition against the wild-type HIV RT (IC<sub>50</sub> = 0.1 nM), K103N (IC<sub>50</sub> = 0.2 nM), and Y181C (IC<sub>50</sub> = 0.3 nM) enzymes by the insertion of a chlorine atom at the 3-position of ring B followed by mono- and disubstitution of ring A that resulted in highly potent inhibitors (<b>97</b>).<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></div><figure id="fig14" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0015.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Schematic representation of doravirine design and lead optimization process.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The diaryl ether phenoxyacetanilides undergoes rapid in vivo clearance due to metabolic hydrolytic reactions carried out at the anilide group of the molecule. Hence, a wide range of heterocyclic amide isosteres were substituted in the acetanilide moiety and the resulting indazole derivative (<b>98</b>) showed an excellent enzymatic potency toward wt HIV RT (IC<sub>50</sub> = 1.1 nM), clinically relevant mutants (K103N, IC<sub>50</sub> = 1.1 nM, and Y181C, IC<sub>50</sub> = 2.6 nM), and improved in vivo metabolic stability. Further replacement of indazole by 6-amino-7-azaindazole found an optimal preclinical candidate (<b>99</b>) and was labeled MK-4965, which exhibited improved bioavailability with in vivo clearance in rats and beagle dogs and low potential for drug–drug interactions.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p">Further developments were initiated to increase the human pharmacokinetic properties by Roche in which the side chains were modified by the elimination of oxygen atom. Exploration of heteroaryl replacements resulted in forming a 2-pyridone derivative <b>100</b> and found promising potency values against both wt HIV RT (IC<sub>50</sub> = 2.5 nM) and mutants K103N (IC<sub>50</sub> = 3.7 nM) and Y181C (IC<sub>50</sub> = 3.1 nM).<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a> Optimization with small lipophilic substituents like halogens, alkyl groups, fluorinated alkyl groups, and thioethers were performed at the 4-position of the 2-pyridone core. The 4-trifluoromethyl analogue <b>101</b> showed improved plasma stability and excellent wtHIV-1 RT and double mutant (K103N/Y183C) enzyme inhibition. Because of highly ordered intermolecular H-bonding in the pyrazolopyridine side chain, it has poor solubility and oral absorption (15% and 9% of bioavailability rats and dogs, respectively).<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The isosteric replacement of pyrazolopyridine with methyltriazolinone moiety <b>102</b> proved to have a significantly better pharmacokinetic profile along with high potency against the clinically relevant single and double mutants when compared to standard NNRTIs efavirenz and rilpivirine (cf. <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Later, compound <b>102</b> was selected for preclinical development and assigned as MK-1439 followed by USAN name doravirine.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><div class="NLM_p">Doravirine (DOR) has recently been approved by the FDA (July 2018) for the treatment of ART-naive HIV-1 infected adults (cf. <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). A dose of 100 mg of doravirine, in combination with TDF/FTC, has been evaluated against ritonavir-boosted darunavir (DRV/r) and EFV in the phase III trials DRIVE-FORWARD and DRIVE-AHEAD, respectively. The DRIVE-FORWARD study compared DOR to once-daily ritonavir-boosted darunavir (DRV+r), each administered in combination with TDF/FTC or abacavir (ABC)/3TC in treatment-naïve adults. DRIVE-AHEAD study compared DOR/3TC/TDF to EFV/FTC/TDF in treatment-naive adults.</div><div class="NLM_p last">In DRIVE-FORWARD, 769 HIV-1 infected patients were enrolled and randomized to either the DOR or DRV/r arm. Doravirine was noninferior to DRV/r, with 84% of participants in the DOR arm vs 80% in the DRV/r arm with HIV-1 RNA < 50 copies/mL at week 48.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Both regimens were well-tolerated and safe. In DRIVE-AHEAD, doravirine was noninferior to EFV with 84% of participants in the DOR arm vs 81% in the EFV arm with HIV-1 RNA < 50 copies/mL at week 48. Fixed dose combination of doravirine/lamivudine/TDF is noninferior to EFV/emtricitabine/TDF in treatment-naive adults with HIV-1 infection: week 48 results of phase 3 DRIVE-AHEAD study.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> There were fewer discontinuations due to reasons other than virologic failure in the DOR arm with lower rates of neuropsychiatric AEs. On the basis of these phase 3 trials, doravirine has been shown to be noninferior to both EFV and boosted darunavir. Doravirine is currently being evaluated in treatment-switch studies.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">7.  Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62">7.1.  Structural Features of NNRTIs for Binding within NNIBP</h3><div class="NLM_p">Key functional groups and molecular conformations that are found among NNRTIs include a core scaffold that binds within the NNIBP and orients its pendant substitutions for interactions with the NNIBP.<a onclick="showRef(event, 'ref85 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref85 ref167 ref168">(85,167,168)</a> Varied scaffolds have been tolerated, including a diazepin-6-one in NVP, a piperazine in DLV, a benzoxazine in EFV, and a pyrimidine in ETR and RPV. The choice of scaffold has been suggested to control the flexibility of the overall NNRTI and its ability to reposition itself in wild-type and mutant HIV-1 RT. The core scaffold is substituted with planar, aromatic, or heterocyclic rings that allow for hydrophobic/π–π stacking interactions with the side chains of residues Y181, Y188, W229, F227, V106, P236, L100, L234, and Y318. Substitutions on the aromatic rings include halogens, nitrile, and alkyl groups that influence the potency of HIV-1 RT inhibition. The core scaffold is further substituted with moieties that are able to form hydrogen bonds with the backbone of K101, K103, and P236. Linker fragments between the pendant aromatic and heteroaromatic rings and the core scaffold may be present to allow for flexibility and the ability to adopt multiple conformations within the NNIBP. The NNRTIs are largely hydrophobic and include polar substitutions to improve pharmacokinetic profiles and provide an optimal balance of hydrophilicity and hydrophobicity for an oral route of administration. The currently available NNRTI drugs fall within the drug-like chemical space. The calculated physicochemical properties of the approved NNRTI drugs are provided in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Calculated Physicochemical Properties of Approved NNRTI Drugs<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">properties</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">generic</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center" char=".">PSA</th><th class="colsep0 rowsep0" align="center" char=".">cLogP</th><th class="colsep0 rowsep0" align="center">HBA</th><th class="colsep0 rowsep0" align="center">HBD</th><th class="colsep0 rowsep0" align="center">NrotB</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nevirapine</td><td class="colsep0 rowsep0" align="char" char=".">266.30</td><td class="colsep0 rowsep0" align="char" char=".">58.12</td><td class="colsep0 rowsep0" align="char" char=".">2.05</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">delavirdine</td><td class="colsep0 rowsep0" align="char" char=".">456.56</td><td class="colsep0 rowsep0" align="char" char=".">118.81</td><td class="colsep0 rowsep0" align="char" char=".">–0.06</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">efavirenz</td><td class="colsep0 rowsep0" align="char" char=".">315.67</td><td class="colsep0 rowsep0" align="char" char=".">38.33</td><td class="colsep0 rowsep0" align="char" char=".">3.68</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">etravirine</td><td class="colsep0 rowsep0" align="char" char=".">435.28</td><td class="colsep0 rowsep0" align="char" char=".">120.64</td><td class="colsep0 rowsep0" align="char" char=".">6.11</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rilpivirine</td><td class="colsep0 rowsep0" align="char" char=".">366.42</td><td class="colsep0 rowsep0" align="char" char=".">97.42</td><td class="colsep0 rowsep0" align="char" char=".">5.64</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">doravirine</td><td class="colsep0 rowsep0" align="char" char=".">425.74</td><td class="colsep0 rowsep0" align="char" char=".">104.42</td><td class="colsep0 rowsep0" align="char" char=".">3.47</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The calculated physicochemical properties of the approved drugs are provided. The values were calculated from the Canvas tool (Canvas, Schrödinger, LLC, New York, NY, 2016).</p></div></div></div><div class="NLM_p last">Although approved NNRTIs share several common structural features as outlined above, they also display important differences.<a onclick="showRef(event, 'ref123 ref124 ref125'); return false;" href="javascript:void(0);" class="ref ref123 ref124 ref125">(123−125)</a> The NNRTIs differ in their size and flexibility (cf. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and also in the conformation they adopt within NNIBP and preference for binding to small or large NNIBP. These differences translate to varied potency and resistance profiles.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64">7.2.  Non-nucleoside RT Inhibitors (NNRTIs)</h3><div class="NLM_p">The NNRTIs are classified into three generations depending on their discovery and resistance profile. A greater barrier to the development of resistance is observed for the third-generation NNRTIs compared to earlier generations, although the efficacy of all approved NNRTIs can be compromised by 1–2 mutations.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> First-generation NNRTIs relied on π-stacking interactions to Y181 and Y188. The replacement of the tyrosine residue by a nonaromatic cysteine residue prevented this interaction and resistance developed to these molecules.<a onclick="showRef(event, 'ref85 ref124 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref85 ref124 ref167 ref168">(85,124,167,168)</a> New NNRTIs reduced interactions with Y181 and Y188 and expanded to incorporate interactions with W229, which is less prone to mutation. The newer NNRTIs also incorporated a central hydrogen bond to the backbone carbonyl of K101.</div><div class="NLM_p">Resistance to first-generation NNRTIs has also developed rapidly due to the rigidity of their structures that prevent them from adapting to mutations in the NNIBP. The newer generation is more flexible and may be accommodated within a mutated NNIBP based on drug molecule movements within the NNIBP and slight side chain rearrangements. Thus, newer generation NNRTIs are less prone to the development of resistance.</div><div class="NLM_p">The first-generation NNRTI include NVP and DLV that possess rigid structures and adopt a “butterfly-like” conformation in NNIBP.<a onclick="showRef(event, 'ref68 ref169'); return false;" href="javascript:void(0);" class="ref ref68 ref169">(68,169)</a> EFV is a second-generation NNRTI and is more flexible compared to first-generation NNRTIs with a slightly improved resistance profile.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Third-generation NNRTIs include the diarylpyrimidine derivatives, ETR and RPV that are more flexible, and adopt a horseshoe conformation within NNIBP.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> The horseshoe conformation allows them to reposition themselves within NNIBP despite small changes within the NNIPB due to point mutations. The third-generation NNRTIs, ETR, RPV, and DOR, are effective in wild-type and K103N HIV-1 RT. Repositioning within the NNIBP allows for the accommodation of third-generation NNRTIs within mutation-modified NNIBP.<a onclick="showRef(event, 'ref85 ref124 ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref85 ref124 ref167 ref168">(85,124,167,168)</a></div><div class="NLM_p last">The NNRTIs are well absorbed orally and are available as tablets and as suspensions for oral use as immediate-release or extended-release formulations.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Because resistance develops rapidly to monotherapy, they are typically used in combination with other antiretroviral agents, for instance, cART.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Additionally, EFV, RPV, and DOR are available in single tablet combination regimens with two NRTIs, TDF/FTC, as Atripla, Complera, and Delstrigo, respectively.<a onclick="showRef(event, 'ref171 ref172'); return false;" href="javascript:void(0);" class="ref ref171 ref172">(171,172)</a> Single tablet combination regimens provide the advantages of cART such as lowered dose due to additive or synergistic inhibition among the individual drugs and a greater barrier to the development of resistance.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Additionally, single tablet combination regimens improve patient adherence and reduce pill burden.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65">7.3.  NNRTIs as Preexposure Prophylaxis (PrEP) Agent</h3><div class="NLM_p">NNRTIs can be used to prevent HIV infection in a number of situations. Single-dose NVP can prevent mother-to-child transmission when administered to both mother and baby.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> This approach has been adopted in low-income countries as a cost-efficient and simple way to reduce the incidence of mother-to-child transmission.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><div class="NLM_p">DPV has been studied as pre-exposure prophylaxis (PREP) specifically for women as part of an intravaginal ring. This DPV gel-containing ring was studied in 2 phase III, randomized, placebo, double-blind trials, MTM-020/ASPIRE and RING.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a> These studies evaluated the efficacy of monthly intravaginal rings in African women. Both studies demonstrated marked reductions in HIV incidence, ranging from 27 to 37%. Interestingly, the studies differed over the effect of participant age on rate of protection. Baeten et al. showed that women older than 21 years of age had a higher protection rate compared to those 21 and younger (56% vs −21%).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Nel et al. reported no significant differences between age groups (hazard ratio 0.63 over 21 vs 0.85 21 and younger).<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> These studies are ongoing with open-label extensions; full results are expected in 2019.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><div class="NLM_p">RPV, in a long-acting (LA) formulation, has been studied as a PrEP agent. This formulation is a nanosuspension of RPV-containing nanoparticles that is administered as an intramuscular (IM) injection.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The phase I study MWRI-01 showed that the majority of study participants reported injection site reactions, although no severe (grade 3 or 4) adverse events were attributed to RPV.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></div><div class="NLM_p">HPTN 076, a phase II, double-blind, randomized clinical trial enrolled 136 sexually active HIV-negative women to assess the safety of the RPV LA IM injection vs placebo.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a> The participants were started on QD oral pills for 4 weeks to determine tolerability before moving to the IM phase. There was no difference in safety outcomes between placebo and RPV arms, with 79% and 84% of participants reporting side effects, respectively. Weight loss was the most commonly reported side effect. All but 2% of participants who received all six scheduled injections had RPV concentrations above protein-adjusted IC<sub>90</sub> concentrations after week 4, indicating optimal adherence led to consistent therapeutic levels of drug over the course of the study.</div><div class="NLM_p last">The NNRTI class has a number of potential candidates for PREP in various stages of development. Although the HIV armamentarium is vast, there is currently only one approved regimen for PrEP, tenofovir disproxil fumarate/emtricitabine as an oral pill, once-daily. The NNRTI candidates represent new PrEP modalities that warrant further research in an effort to increase preventative options for individuals at high risk of contracting HIV.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">8.  Medicinal Chemistry Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67">a.  Conformational Flexibility</h3><div class="NLM_p">From several biochemical studies, it was revealed that various domains in the RT structure are flexible including NNRTI and RNase H, but the flexibility of RT is reduced when a ligand binds at the pocket. This is primarily due to the fact that inhibitors restrict the movement of the “thumb” region.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Flexibility is a key for not only stronger binding but also sufficiently flexible for confronting the mutations in the NNIPB. There is an excellent correlation between the number of rotatable bonds (nRotB) with binding affinity and ability to retain activity against possible mutations among these drugs (excluding DLV).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It is evident that compounds having more freedom of rotation in the binding site are able to show better activity versus RT mutants, for instance, NVP, a fairly rigid molecule (nRotB = 1), has shown low activity against V106A, Y188C, Y1991I, Y188 V, <b>L100I</b>, <b>K101P</b>, <b>Y181I</b>, and <b>Y181C</b> mutations (bold letters refers residues that show mutations by all NNRTI drugs) (cf. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">On the other hand, RPV (nRotB = 5) showed significantly improved activity profile to various mutants due to the rotatable dihedral angle around the cyanovinyl group and NH-linked aniline (central ring). Particularly, the cyanovinyl group showed a favorable binding to the hydrophobic tunnel which is formed by Y188, F227, W229, and L234 residues, and nitrogen atoms of a diarylpyrimidine ring form a hydrogen bond with both wild-type and mutants, e.g., K101P and K103N (cf. <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div><figure id="fig15" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0016.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Overlay of X-ray crystal conformations and binding mode of NVP (A) and RPV (B) is shown. Important residues are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68">b.  Physicochemical Properties</h3><div class="NLM_p last">The NNRTI drugs are mostly lipophilic and predominantly un-ionized at physiologic pH.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> They are highly plasma protein bound with >95% plasma protein binding for DLV, EFV, ETR, and RPV (cf. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref39 ref97 ref129 ref137 ref184'); return false;" href="javascript:void(0);" class="ref ref39 ref97 ref129 ref137 ref184">(39,97,129,137,184)</a> NVP is approximately 60% plasma protein bound and has a long half-life. The NNRTIs primarily undergo metabolism via cytochrome P450 oxidative metabolism, primarily via CYP3A4 and CYP2B6. Most NNRTIs are also inhibitors of CYP2C9 and inducers of CYP3A4. The metabolic profile, the half-life of NNRTI and adverse effect profile are important considerations when considering NNRTIs as part of antiretroviral regimens.</div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">c.  Fluorine: A Privileged Atom in NNRTI Design</h3><div class="NLM_p">Fluorine is a key atom in drug designing strategies due to its impact in improving metabolic stability, modulating physicochemical properties, and binding affinity toward targets.<a onclick="showRef(event, 'ref185 ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref185 ref186 ref187">(185−187)</a> Fluorine also highly influences antiviral activity, evidenced in the design of DAPY analogues. The effect of the presence of fluorine substitution has been well explained in the DAPY series, e.g., nonfluorinated (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A, EC<sub>50</sub> = 5.5 nM) showed five times less activity as compared to fluorinated compounds (EC<sub>50</sub> = 1.0 nM) in both wild-type and mutants.<a onclick="showRef(event, 'ref188 ref189'); return false;" href="javascript:void(0);" class="ref ref188 ref189">(188,189)</a></div><figure id="fig16" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0017.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Inhibition of DAPY series in wild-type and (B) inhibition of indolylarylsulfone derivatives influenced by the introduction of halogen atom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In general, several fluorinated NNRTIs compounds have been reported, and this includes the approved drug EFV. A representative fluorinated-NNRTI binding interaction is shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>. In many of X-ray crystal structures of NNRTI-bound to RT complex, fluorinated compounds did not directly interact with residues but mainly modulate the conformational preference of the whole molecule due to high electronegativity (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Moreover, the fluorine atom showed nonbonded hydrophobic interactions, particularly with V106, V179, L234, and W229 residues. It was also observed that because of its strong electron-withdrawing nature, introduction of the fluorine atom in the aromatic ring significantly increases the binding affinity.</div><figure id="fig17" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0018.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. X-ray crystal structures of HIV-1 RT in complex with fluorine-containing NNRTIs doravirine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NCG">4NCG</a>, IC<sub>50</sub> = 0.011 μM, colored green); and KRV-2110 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LAK">3LAK</a>, IC<sub>50</sub> = 0.0034 μM, colored pink).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to fluorine, the other halogens including bromine in ETR contribute to the electrostatic-type interactions. This was also proven with another halogen, i.e., the chlorine atom in indolylarylsulfone derivatives influences the antiviral activity (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B).<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Thus, in modern drug design, introduction of halogens has to be taken into account.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70">d.  Clinical Prospectives</h3><div class="NLM_p">NNRTI development and clinical evaluation has continued in a number of areas, including, but not limited to, prevention as part of cART and as part of dual-therapy regimens.<a onclick="showRef(event, 'ref168 ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref168 ref191 ref192">(168,191,192)</a> DPV has been evaluated for use in HIV prevention in phase III clinical trials in Africa.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a> These trials evaluated DPV as part of a monthly vaginal ring that provided controlled release of the compound at the site of viral transmission. Adherence to oral therapy and vaginal gels was low in this population, necessitating an alternative prevention methodology that did not rely on daily oral adherence or dosing around coital situations.<a onclick="showRef(event, 'ref193 ref194'); return false;" href="javascript:void(0);" class="ref ref193 ref194">(193,194)</a> DPV reduced HIV incidence by 27% and 31% compared to placebo groups in two separate trials.<a onclick="showRef(event, 'ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref176 ref177">(176,177)</a> The efficacy showed in these trials warrants further studies in alternative prevention strategies.</div><div class="NLM_p last">The use of NNRTIs in conjunction with two NRTIs as cART has and is still being studied clinically. Current clinical trials evaluating cART regimens that include DOR or elsulfavirine have shown efficacy in suppressing HIV below the limit of detection in treatment-naïve patients. Clinical trials examining the efficacy and safety of two-drug regimens have also been performed with the aim of reducing overall patient exposure to NRTIs. The combination of the integrase inhibitor DTG and RPV represents the first FDA-approved two-drug treatment for the maintenance of HIV suppression.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> This regimen was shown to be noninferior to a three-drug regimen in maintaining suppression of viral load at 48 weeks. All patients in the study had undetectable viral loads for 6 months prior to enrolment in the study. At 48 weeks, both groups exhibited a viral suppression rate of 95% in the intent-to-treat analysis.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> The results from these studies demonstrate the value of continuing research into the NNRTI class, with potential benefits to a number of treatment modalities.</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">9.  Lessons Learned from NNRTI Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><ul class="NLM_list-list_type-bullet"><li><p class="inline">Two classical approaches for the lead optimization, i.e., molecular hybridization and bioisosteric replacement, are the key for NNRTI drug development.</p></li><li><p class="inline"><i>N</i>-Alkyl substituents create the sterically hindered region, which reduces the rate of <i>N</i>-dealkylation metabolic conversion (cf. NVP lead optimization).</p></li><li><p class="inline">When the molecule is rigid and focuses more on positional adaptability, the molecule cannot adapt to point mutations within the NNIBP and resistance develops rapidly to the molecule.</p></li><li><p class="inline">Introduction of a flexible linker increases the solubility but is also prone to compound promiscuity (cf. DLV lead optimization).</p></li><li><p class="inline">Substitution with a CF<sub>3</sub> group reduces the p<i>K</i><sub>a</sub> value of the drug and improves the potency against HIV-1 inhibitory activity (cf. lead optimization of EFV).</p></li><li><p class="inline">The presence of triple bond in a molecule was expected to be a potential risk for reactive metabolism and found inactive against HIV-1 (cf. lead optimization of EFV).</p></li><li><p class="inline">Introduction of a cyanovinyl group makes the compound highly active against both wildtype and mutated HIV-1 RTs (cf. lead optimization of ETR and RPV).</p></li><li><p class="inline">Introduction of fluorine or halogen atoms in the aromatic ring significantly increases the binding affinity (cf. lead optimization of ETR and EFV).</p></li><li><p class="inline">Most of NNRTI drugs were synthesized by efficient synthetic procedures, which provided an excellent opportunity to explore as many derivatives as needed in developing the lead molecule for improved inhibitory activity.</p></li><li><p class="inline">HIV-1 can develop resistance mutations to all currently available NNRTIs. Further development of newer compounds with unique and better resistance profiles remains a priority.</p></li></ul></div><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Future Design Perspective</h3><div class="NLM_p last">As discussed above, there are various factors to be considered for next-generation NNRTI development.<a onclick="showRef(event, 'ref2 ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref2 ref196 ref197">(2,196,197)</a> From a medicinal chemistry point of view, these can be summarized as (a) improving conformational flexibility of the compound by maintaining its positional adaptability,<a onclick="showRef(event, 'ref2 ref72 ref198 ref199'); return false;" href="javascript:void(0);" class="ref ref2 ref72 ref198 ref199">(2,72,198,199)</a> (b) forming extensive hydrogen bond interactions with the main chain of the protein to avoid resistance toward mutations,<a onclick="showRef(event, 'ref200 ref201'); return false;" href="javascript:void(0);" class="ref ref200 ref201">(200,201)</a> (c) targeting the highly conserved residues such as W229 for stronger interactions or with the adjacent binding site,<a onclick="showRef(event, 'ref202 ref203 ref204'); return false;" href="javascript:void(0);" class="ref ref202 ref203 ref204">(202−204)</a> (d) involving additional interaction with other atoms, including halogen or nitrile groups,<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> and (e) improving physiochemical properties by introducing solubilizing groups into entrance of the NNIBP or utilizing prodrug approaches.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> For development of novel NNRTIs, new technologies with orthogonal HTS methods will provide a strong basis for rapid screening of large chemical libraries.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Additionally, computational approaches, including QSAR,<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> virtual screening,<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> prediction of pharmacologically important properties, and the estimation of binding affinities,<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> will certainly contribute to the rapid development of future antiviral drugs against HIV infection.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00843" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54348" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54348" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00843" class="ext-link">10.1021/acs.jmedchem.8b00843</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Published X-ray crystal structures of HIV-1 reverse transcriptase (RT) with the approved NNRTI drugs; metabolic pathway of DLV and various key metabolic sites are highlighted are in yellow and cyan colors; metabolic pathway of EFV and various key metabolic sites are highlighted are in yellow and cyan colors; metabolic pathway of ETR and various key metabolic sites are highlighted are in yellow and cyan colors; metabolic pathways of RPV and key metabolic sites are highlighted are in yellow and cyan colors (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf">jm8b00843_si_001.pdf (231.79 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00843" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vigneshwaran Namasivayam</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Institute, Pharmaceutical Chemistry II, University of Bonn, 53121 Bonn, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3031-3377" title="Orcid link">http://orcid.org/0000-0003-3031-3377</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ee98808f838f9d8798ae9b8087c38c818080c08a8b"><span class="__cf_email__" data-cfemail="64120a050905170d1224110a0d49060b0a0a4a0001">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Murugesan Vanangamudi</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal and Pharmaceutical Chemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi, Andhra Pradesh 517102, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor G. Kramer</span> - <span class="hlFld-Affiliation affiliation">Merck
Canada Inc., Kirkland, Quebec H9H 4M7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonali Kurup</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Roosevelt University, Schaumburg, Illinois 60173, United States</span>; 
    <span>Present Address:
                        For S.K.: Ferris State University, 220 Ferris Drive, Big Rapids, Michigan 49307, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4722-7862" title="Orcid link">http://orcid.org/0000-0003-4722-7862</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Zhan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9675-6026" title="Orcid link">http://orcid.org/0000-0002-9675-6026</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinyong Liu</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry
of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob Kongsted</span> - <span class="hlFld-Affiliation affiliation">Department
of Physics, Chemistry and Pharmacy, University
of Southern Denmark, DK-5230, Odense M, Denmark</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7725-2164" title="Orcid link">http://orcid.org/0000-0002-7725-2164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siddappa N. Byrareddy</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha 68198-5880, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6889-4640" title="Orcid link">http://orcid.org/0000-0002-6889-4640</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Victor Kramer is an employee in the medical affairs department of Merck Canada Inc. Kirkland, QC, Canada and previously worked at the McGill AIDS Center/Lady Davis Institute from 2009-2015.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85265" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85265" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Vigneshwaran Namasivayam</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3569-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Vigneshwaran Namasivayam</b> is a senior research scientist at Pharmaceutical Institute, University of Bonn, Germany (since 2010), and involved in the field of cheminformatics, computational chemistry, data analysis, and molecular modeling. He gained his doctoral degree under the supervision of Prof. Dr. Hans-Jörg Hofmann from Leipzig University, Germany (2009). He carried out his postdoctoral research at the Technical University of Munich, Germany (2010). Prior to his doctoral studies in Germany, he worked as a Research Executive (2004–2006) at Orchid Chemical and Pharmaceutical Limited, Chennai, India.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Murugesan Vanangamudi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3574-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Murugesan Vanangamudi</b> received his Ph.D. (2013) from CSIR—Central Drug Research Institute (CDRI), Lucknow. Since 2013, he has been working as Associate Professor at the Department of Medicinal and Pharmaceutical Chemistry, Sree Vidyanikethan College of Pharmacy, Tirupathi, India. His research work included rational drug design and synthesis of novel small molecules against HIV-1 reverse transcriptase.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Victor G. Kramer</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3579-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Victor G. Kramer</b> obtained an M.S. degree in Applied Immunology and Molecular Biology under the mentorship of Drs. Ah-kau Ng and Trebor Lawton at the University of Southern Maine. He then spent four years in the SHIV laboratory of Dr. Ruth Ruprecht at the Dana-Farber Cancer Institute in Boston, Massachusetts. He obtained his Ph.D. in Experimental Medicine under the mentorship of Dr. Mark Wainberg at the McGill University AIDS Center and Lady Davis Institute in Montreal, Quebec, Canada. In 2014, he joined Abbvie and worked for their HIV franchise. He now works for Merck Canada Inc. in the Medical Affairs Department and focuses on HIV and hepatitis C therapeutics.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Sonali Kurup</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3584-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sonali Kurup</b> secured a Ph.D. in medicinal chemistry from Duquesne University in 2009 and completed her postdoctoral training at the University of Michigan in 2011. Following her training, Dr. Kurup worked at the College of Pharmacy at Roosevelt University as Assistant Professor of Medicinal Chemistry (2011–2017) and Associate Professor of Medicinal Chemistry (2017–2018). She has recently joined the College of Pharmacy at Ferris State University as Associate Professor of Medicinal Chemistry. Her research focuses on developing novel molecules against resistant pathways for nonsmall cell lung cancer.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Peng Zhan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3589-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Peng Zhan</b> obtained his B.S. degree from Shandong University, China, in 2005. Then he earned his M.S. and Ph.D. degrees in Medicinal Chemistry from Shandong University in 2008 and 2010, respectively. He subsequently joined the research group of Professor Xinyong Liu as a Lecturer (2010–2012). From 2012 to 2014, he worked as a Postdoctoral Fellow funded by JSPS (Japan Society for the Promotion of Science) in the Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. He is now working as an Associate Professor in the laboratory of Professor Xinyong Liu. His research interests involve the discovery of novel antiviral, anticancer, and neurodegenerative disease-related agents based on rational drug design and combinatorial chemistry approaches.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Xinyong Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3594-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xinyong Liu</b> received his B.S. and M.S. degrees from School of Pharmaceutical Sciences, Shandong University, China, in 1984 and in 1991, respectively. From 1997 to 1999 he worked at Instituto de Quimica Medica (CSIC) in Spain as a Senior Visiting Scholar. He obtained his Ph.D. from Shandong University in 2004. He is currently a Full Professor of the Institute of Medicinal Chemistry, Shandong University. His research interests include rational drug design and synthesis and antiviral activity evaluation of a variety of molecules that interact with specific enzymes and receptors in the viral life cycle (HIV, HBV, HCV, and FluV). Other ongoing programs include molecular modification and structure–activity relationships study of natural products used to treat cardiovascular diseases and drug delivery research using PEGylated small-molecular agents.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Jacob Kongsted</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3599-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jacob Kongsted</b> completed his Ph.D. in Theoretical and Computational Chemistry at the University of Copenhagen in 2005, followed by postdoctoral training at Lund University (Sweden) and University of Aarhus (Denmark). In 2009, he moved to University of Southern Denmark as an Assistant Professor, and from 2015 he is Full Professor of computational quantum chemistry at the University of Southern Denmark. Kongsted has a broad research interest in theoretical and computational chemistry and has especially contributed to this field by development of novel quantum chemistry embedding methods as well as application of these computational models to systems of biophysical and biochemical interest. Recent research uses quantum chemistry methods for rational design of light-induced biological functional materials and advanced drug design.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Siddappa N. Byrareddy</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=BIO-d7e3604-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Siddappa N. Byrareddy</b> is an Associate Professor in the Department of Pharmacology and Experimental Neurosciences, University of Nebraska Medical Center, Omaha. He obtained a Ph.D. from the National Institute of Mental Health and Neurosciences, Bangalore, India, and completed postdoctoral training at the Dana-Farber Cancer Institute/Harvard Medical School, Boston, USA. Dr. Byrareddy has a strong background in molecular retrovirology, lentiviral evolution, drugs of abuse, and mucosal virus transmission studies with 12 years of research experience, with over 80 peer-reviewed publications in the field. His laboratory research focuses on the development of effective AIDS vaccine/HIV Cure strategies and therapeutics to control HIV infections.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">V.M acknowledges SERB-DST (Science & Engineering Research Board, Government of India) for a Young Scientist Awards (YSS/2015/001938). S.N.B. thanks NIH R01-AI129745 and MH062261 for financial support. Z.P. acknowledges the Young Scholars Program of Shandong University (YSPSDU no. 2016WLJH32) and the Fundamental Research Funds of Shandong University (no. 2017JC006). L.X. thanks the Key Project of NSFC for International Cooperation (no. 81420108027) and the Key Research and Development Project of Shandong Province (no. 2017CXGC1401). We thank the European Molecular Biology Laboratory (EMBL) for providing the evaluation license of LigPlot<sup>+</sup>. We are indebted to Dr. Vasanthanathan Poongavanam for his valuable discussion during the design of this manuscript and preparation of figures, and we are also thankful to Dr. Mohit Tyagi, Uppsala University, Sweden, for his rigorous proofreading of synthetic schemes for the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">2D</td><td class="NLM_def"><p class="first last">two-dimensional</p></td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">acquired immune deficiency syndrome</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immuno deficiency virus</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">reverse transcriptase</p></td></tr><tr><td class="NLM_term">IN</td><td class="NLM_def"><p class="first last">integrase</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">protease</p></td></tr><tr><td class="NLM_term">NNIBP</td><td class="NLM_def"><p class="first last">non-nucleoside inhibitor-binding pocket</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">protease inhibitor</p></td></tr><tr><td class="NLM_term">INSTI</td><td class="NLM_def"><p class="first last">integrase inhibitor</p></td></tr><tr><td class="NLM_term">NNRTIs</td><td class="NLM_def"><p class="first last">non-nucleoside reverse transcriptase inhibitors</p></td></tr><tr><td class="NLM_term">NRTIs</td><td class="NLM_def"><p class="first last">nucleoside reverse transcriptase inhibitors</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">food and drug administration</p></td></tr><tr><td class="NLM_term">AZT</td><td class="NLM_def"><p class="first last">zidovudine</p></td></tr><tr><td class="NLM_term">NVP</td><td class="NLM_def"><p class="first last">nevirapine</p></td></tr><tr><td class="NLM_term">DLV</td><td class="NLM_def"><p class="first last">delavirdine</p></td></tr><tr><td class="NLM_term">EFV</td><td class="NLM_def"><p class="first last">efavirenz</p></td></tr><tr><td class="NLM_term">ETR</td><td class="NLM_def"><p class="first last">etravirine</p></td></tr><tr><td class="NLM_term">RPV</td><td class="NLM_def"><p class="first last">rilpivirine</p></td></tr><tr><td class="NLM_term">DPV</td><td class="NLM_def"><p class="first last">dapivirine</p></td></tr><tr><td class="NLM_term">UNAIDS</td><td class="NLM_def"><p class="first last">the joint united nations program on HIV/AIDS</p></td></tr><tr><td class="NLM_term">cART</td><td class="NLM_def"><p class="first last">combination antiretroviral therapy</p></td></tr><tr><td class="NLM_term">gp</td><td class="NLM_def"><p class="first last">glycoproteins</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">AI</td><td class="NLM_def"><p class="first last">artificial intelligence</p></td></tr><tr><td class="NLM_term">NN</td><td class="NLM_def"><p class="first last">neural network</p></td></tr><tr><td class="NLM_term">qd</td><td class="NLM_def"><p class="first last">once a day</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">two times a day</p></td></tr><tr><td class="NLM_term">TDF</td><td class="NLM_def"><p class="first last">tenofovirdisoproxilfumarate</p></td></tr><tr><td class="NLM_term">FTC</td><td class="NLM_def"><p class="first last">emtricitabine</p></td></tr><tr><td class="NLM_term">TAF</td><td class="NLM_def"><p class="first last">tenofoviralafenamidefumarate</p></td></tr><tr><td class="NLM_term">3TC</td><td class="NLM_def"><p class="first last">lamivudine</p></td></tr><tr><td class="NLM_term">BT</td><td class="NLM_def"><p class="first last">background therapy</p></td></tr><tr><td class="NLM_term">ddI</td><td class="NLM_def"><p class="first last">didanosine</p></td></tr><tr><td class="NLM_term">NaHMDS</td><td class="NLM_def"><p class="first last">sodium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65778" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65778" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 208 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arts, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span> <span> </span><span class="NLM_article-title">HIV-1 antiretroviral drug therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">a007161</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a007161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1101%2Fcshperspect.a007161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22474613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a007161&issue=4&author=E.+J.+Artsauthor=D.+J.+Hazuda&title=HIV-1+antiretroviral+drug+therapy&doi=10.1101%2Fcshperspect.a007161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 antiretroviral drug therapy</span></div><div class="casAuthors">Arts, Eric J.; Hazuda, Daria J.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">a007161/1-a007161/23</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiviral drugs, which can suppress HIV-1 replication to undetectable levels.  The discovery of HIV-1 as the causative agent of AIDS together with an ever increasing understanding of the virus replication cycle have been instrumental in this effort by providing researchers with the knowledge and tools required to prosecute drug discovery efforts focused on targeted inhibition with specific pharmacol. agents.  To date, an arsenal of 24 Food and Drug Administration (FDA)-approved drugs are available for treatment of HIV-1 infections.  These drugs are distributed into six distinct classes based on their mol. mechanism and resistance profiles: (1) nucleoside-analog reverse transcriptase inhibitors (NNRTIs), (2) non-nucleoside reverse transcriptase inhibitors (NNRTIs), (3) integrase inhibitors, (4) protease inhibitors (Pls), (5) fusion inhibitors, and (6) coreceptor antagonists.  In this article, we will review the basic principles of antiretroviral drug therapy, the mode of drug action, and the factors leading to treatment failure (i.e., drug resistance).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptYbCJ-mCnzbVg90H21EOLACvtfcHk0ljuUMdfcgP_2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemsrk%253D&md5=3c7785e1aac3df6da22f84b2b24f0a2e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a007161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a007161%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DE.%2BJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26atitle%3DHIV-1%2520antiretroviral%2520drug%2520therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26issue%3D4%26spage%3Da007161%26doi%3D10.1101%2Fcshperspect.a007161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poongavanam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanangamudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Shamaileh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veedu, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, N. A.</span></span> <span> </span><span class="NLM_article-title">Integrative approaches in HIV-1 non-nucleoside reverse transcriptase inhibitor design</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e1328</span> <span class="refDoi"> DOI: 10.1002/wcms.1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fwcms.1328" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&issue=1&author=V.+Poongavanamauthor=V.+Namasivayamauthor=M.+Vanangamudiauthor=H.+Al+Shamailehauthor=R.+N.+Veeduauthor=J.+Kihlbergauthor=N.+A.+Murugan&title=Integrative+approaches+in+HIV-1+non-nucleoside+reverse+transcriptase+inhibitor+design&doi=10.1002%2Fwcms.1328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fwcms.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.1328%26sid%3Dliteratum%253Aachs%26aulast%3DPoongavanam%26aufirst%3DV.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DVanangamudi%26aufirst%3DM.%26aulast%3DAl%2BShamaileh%26aufirst%3DH.%26aulast%3DVeedu%26aufirst%3DR.%2BN.%26aulast%3DKihlberg%26aufirst%3DJ.%26aulast%3DMurugan%26aufirst%3DN.%2BA.%26atitle%3DIntegrative%2520approaches%2520in%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520design%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D8%26issue%3D1%26doi%3D10.1002%2Fwcms.1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Anti-HIV drug discovery and development: Current innovations and future trends</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2849-78&issue=7&author=P.+Zhanauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=X.+Liu&title=Anti-HIV+drug+discovery+and+development%3A+Current+innovations+and+future+trends&doi=10.1021%2Facs.jmedchem.5b00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends</span></div><div class="casAuthors">Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2849-2878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection has been compromised to some extent by rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities, and so there is a need for alternative strategies of antiretroviral drug discovery and addnl. therapeutic agents with novel action modes or targets.  From this perspective, we first review current strategies of antiretroviral drug discovery and optimization, with the aid of selected examples from the recent literature.  We highlight the development of phosphate ester-based prodrugs as a means to improve the aq. soly. of HIV inhibitors, and the introduction of the substrate envelope hypothesis as a new approach for overcoming HIV drug resistance.  Finally, we discuss future directions for research, including opportunities for exploitation of novel antiretroviral targets, and the strategy of activation of latent HIV reservoirs as a means to eradicate the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sWUJPJgQN7Vg90H21EOLACvtfcHk0lgqnXgE1SmdoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E&md5=de3f5aee273b0dd6f7e84e20410d06d7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00497%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAnti-HIV%2520drug%2520discovery%2520and%2520development%253A%2520Current%2520innovations%2520and%2520future%2520trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D2849%26epage%3D78%26doi%3D10.1021%2Facs.jmedchem.5b00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1021/jm900492g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900492g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=521-538&issue=2&author=Y.+Mehellouauthor=E.+De+Clercq&title=Twenty-six+years+of+anti-HIV+drug+discovery%3A+where+do+we+stand+and+where+do+we+go%3F&doi=10.1021%2Fjm900492g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm900492g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900492g%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DTwenty-six%2520years%2520of%2520anti-HIV%2520drug%2520discovery%253A%2520where%2520do%2520we%2520stand%2520and%2520where%2520do%2520we%2520go%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D2%26spage%3D521%26epage%3D538%26doi%3D10.1021%2Fjm900492g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flexner, C.</span></span> <span> </span><span class="NLM_article-title">HIV drug development: the next 25 years</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/nrd2336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnrd2336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=959-966&issue=12&author=C.+Flexner&title=HIV+drug+development%3A+the+next+25+years&doi=10.1038%2Fnrd2336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2336%26sid%3Dliteratum%253Aachs%26aulast%3DFlexner%26aufirst%3DC.%26atitle%3DHIV%2520drug%2520development%253A%2520the%2520next%252025%2520years%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D12%26spage%3D959%26epage%3D966%26doi%3D10.1038%2Fnrd2336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zdanowicz, M.
M.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of HIV drug resistance</span>. <i>Am. J. Pharm. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.5688/aj7005100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.5688%2Faj7005100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=17149429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD28jhtVegsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=100&issue=5&author=M.%0AM.+Zdanowicz&title=The+pharmacology+of+HIV+drug+resistance&doi=10.5688%2Faj7005100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of HIV drug resistance</span></div><div class="casAuthors">Zdanowicz Martin M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of pharmaceutical education</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug resistance to human immunodeficiency virus (HIV) is a major factor in the failure of antiretroviral therapy.1 In order for practitioners to provide effective pharmaceutical care to their HIV patients, it is essential that they understand the mechanisms of HIV drug resistance as well as the various factors that can contribute to its emergence.  This article is based on didactic content from the infectious disease section of the Integrated Sequence II Course in the PharmD program at South University.  In the course, students are first given an overview that includes key structural components of HIV and a discussion of the HIV life cycle.  A detailed presentation on the pharmacology of the various classes of antiretroviral agents follows.  The clinical impact and prevalence of HIV drug resistance is then discussed along with factors that might contribute to it.  Mechanisms of drug resistance for each class of antiretroviral agents are presented in detail followed by a discussion of the basis and clinical utility of HIV drug resistance testing.  Finally, new targets for HIV pharmacotherapy are presented along with an overview of new antiretroviral agents that are being developed.  Content taught in lecture is reinforced by relevant case studies that students work on in small groups during the recitation period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKCJIO_hBOUEBuFdjgVNKSfW6udTcc2eZ7bTQjIb7Bibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jhtVegsA%253D%253D&md5=07af0b886e76710ce4abcb250d61d143</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.5688%2Faj7005100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5688%252Faj7005100%26sid%3Dliteratum%253Aachs%26aulast%3DZdanowicz%26aufirst%3DM.%2BM.%26atitle%3DThe%2520pharmacology%2520of%2520HIV%2520drug%2520resistance%26jtitle%3DAm.%2520J.%2520Pharm.%2520Educ.%26date%3D2006%26volume%3D70%26issue%3D5%26spage%3D100%26doi%3D10.5688%2Faj7005100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span> <i>UNAIDS
Data</i>; <span class="NLM_publisher-name">UNAIDS</span>, <span class="NLM_year">2017</span>; <a href="http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf" class="extLink">http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf</a> (accessed Feb 10, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+UNAIDS%0AData%3B+UNAIDS%2C+2017%3B+http%3A%2F%2Fwww.unaids.org%2Fsites%2Fdefault%2Ffiles%2Fmedia_asset%2F20170720_Data_book_2017_en.pdf+%28accessed+Feb+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DUNAIDS%250AData%26pub%3DUNAIDS%26date%3D2017%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">The
Antiretroviral Therapy Cohort Collaboration</span> <span> </span><span class="NLM_article-title">Life expectancy of individuals on combination antiretroviral
therapy in high-income countries: a collaborative analysis of 14 cohort
studies</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">9635</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61113-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2808%2961113-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=293-299&issue=9635&author=The%0AAntiretroviral+Therapy+Cohort+Collaboration&title=Life+expectancy+of+individuals+on+combination+antiretroviral%0Atherapy+in+high-income+countries%3A+a+collaborative+analysis+of+14+cohort%0Astudies&doi=10.1016%2FS0140-6736%2808%2961113-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961113-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961113-7%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DLife%2520expectancy%2520of%2520individuals%2520on%2520combination%2520antiretroviral%250Atherapy%2520in%2520high-income%2520countries%253A%2520a%2520collaborative%2520analysis%2520of%252014%2520cohort%250Astudies%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26issue%3D9635%26spage%3D293%26epage%3D299%26doi%3D10.1016%2FS0140-6736%2808%2961113-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuitton, D. A.</span></span> <span> </span><span class="NLM_article-title">Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/S0753-3322(99)80063-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0753-3322%2899%2980063-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10337461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1ejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1999&pages=73-86&issue=2&author=R.+W.+Shaferauthor=D.+A.+Vuitton&title=Highly+active+antiretroviral+therapy+%28HAART%29+for+the+treatment+of+infection+with+human+immunodeficiency+virus+type+1&doi=10.1016%2FS0753-3322%2899%2980063-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1</span></div><div class="casAuthors">Shafer, R. W.; Vuitton, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-86</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review with 105 refs.  Highly active antiretroviral therapy (HAART) refers to a broad category of treatment regimens usually comprised of three or more antiretroviral drugs that, in previously untreated HIV-1-infected patients, are expected to reduce plasma virus levels below the limits of detection.  Most HAART regimens include drugs from at least two of the three classes of antiretroviral therapy (nucleoside analog reverse transcriptase (RT) inhibitors, non-nucleoside analog RT inhibitors, and protease inhibitors).  In deciding when to initiate antiretroviral therapy, physicians and their patients must balance the virol. and immunol. benefits of early treatment with the costs of drug therapy, the risk of drug side effects, and the risk of drug resistance if adherence is suboptimal.  In previously untreated patients, HIV-1 replication can be suppressed indefinitely with certain HAART regimens.  In previously treated patients, the benefits of HAART are often significantly diminished.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq5rvmmkQDGbVg90H21EOLACvtfcHk0lhJ9CDThUGarw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1ejt74%253D&md5=cbc1580766e4f9a684cd77ad0a269c8c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0753-3322%2899%2980063-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0753-3322%252899%252980063-8%26sid%3Dliteratum%253Aachs%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DVuitton%26aufirst%3DD.%2BA.%26atitle%3DHighly%2520active%2520antiretroviral%2520therapy%2520%2528HAART%2529%2520for%2520the%2520treatment%2520of%2520infection%2520with%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D1999%26volume%3D53%26issue%3D2%26spage%3D73%26epage%3D86%26doi%3D10.1016%2FS0753-3322%2899%2980063-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brechtl, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitbart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, B.</span></span> <span> </span><span class="NLM_article-title">The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection</span>. <i>J. Pain Symptom Manage.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/S0885-3924(00)00245-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0885-3924%2800%2900245-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=11223313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD3M3osV2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=41-51&author=J.+R.+Brechtlauthor=W.+Breitbartauthor=M.+Galiettaauthor=S.+Krivoauthor=B.+Rosenfeld&title=The+use+of+highly+active+antiretroviral+therapy+%28HAART%29+in+patients+with+advanced+HIV+infection&doi=10.1016%2FS0885-3924%2800%2900245-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes</span></div><div class="casAuthors">Brechtl J R; Breitbart W; Galietta M; Krivo S; Rosenfeld B</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain and symptom management</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>
        ISSN:<span class="NLM_cas:issn">0885-3924</span>.
    </div><div class="casAbstract">The effect of highly active antiretroviral therapy (HAART) in the treatment of HIV infection is usually measured by survival, CD4 lymphocyte counts, HIV-1 RNA viral load testing, and the occurrence of opportunistic infections.  This pilot study sought to measure the impact of HAART treatments on a wide range of clinical outcomes and psychological variables in a sample of patients with advanced HIV infection.  Seventy patients with advanced AIDS who were protease inhibitor naive were started on HAART regimens.  Patients were admitted to an AIDS inpatient unit of a long-term care facility that provides treatment and palliative care.  All patients were diagnosed with AIDS, had CD4 cell counts below 300/cc(3), and had a projected survival of greater than one month.  Patients were started on triple-drug HAART regimens with daily medical supervision and observation.  In addition to standard clinical and laboratory markers, a series of observer-rated and self-report instruments were used to measure various physical and psychological factors (e.g., pain and symptom distress, psychological well-being, depression).  Data were collected at baseline and after 1 and 3 months of HAART therapy.  As expected, the CD4 count increased and viral load levels decreased significantly over the 3-month study period.  In addition, patients improved significantly in body weight, and serum albumin and ferritin levels.  The only psychosocial measure that improved significantly with treatment was depression.  Ratings of pain intensity, physical and psychological symptom distress, and overall quality of life did not change.  Of the 70 patients studied, 84.3% were still alive after the 3-month study period.  Of these, 6 (8.6%) were discharged to community.  However, 17 surviving patients (24.3%) had HAART regimens discontinued due to drug intolerance and 11 patients (15.7%) expired during the study period.  While these data are preliminary, HAART regimens appear to have positive effects on CD4 count, HIV viral load, and several other measures of physical well-being in patients with advanced AIDS.  Despite these improvements, the benefits of treatment on pain and symptom distress, and psychological well-being were less clear.  In addition, treatment failure (mortality and intolerance) were not uncommon in this sample (40%).  Further research is clearly necessary to better understand the benefits of HAART therapy in patients with advanced HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRnvbHq_JovMkU0YCbOU3EfW6udTcc2eY-WsSGwCiLrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3osV2nuw%253D%253D&md5=d6247d9fa89f98c5471920bab410281a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0885-3924%2800%2900245-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0885-3924%252800%252900245-1%26sid%3Dliteratum%253Aachs%26aulast%3DBrechtl%26aufirst%3DJ.%2BR.%26aulast%3DBreitbart%26aufirst%3DW.%26aulast%3DGalietta%26aufirst%3DM.%26aulast%3DKrivo%26aufirst%3DS.%26aulast%3DRosenfeld%26aufirst%3DB.%26atitle%3DThe%2520use%2520of%2520highly%2520active%2520antiretroviral%2520therapy%2520%2528HAART%2529%2520in%2520patients%2520with%2520advanced%2520HIV%2520infection%26jtitle%3DJ.%2520Pain%2520Symptom%2520Manage.%26date%3D2001%26volume%3D21%26spage%3D41%26epage%3D51%26doi%3D10.1016%2FS0885-3924%2800%2900245-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastgate, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWnt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=62-80&issue=1&author=N.+A.+Meanwellauthor=M.+R.+Krystalauthor=B.+Nowicka-Sansauthor=D.+R.+Langleyauthor=D.+A.+Conlonauthor=M.+D.+Eastgateauthor=D.+M.+Graselaauthor=P.+Timminsauthor=T.+Wangauthor=J.+F.+Kadow&title=Inhibitors+of+HIV-1+attachment%3A+the+discovery+and+development+of+temsavir+and+its+prodrug+fostemsavir&doi=10.1021%2Facs.jmedchem.7b01337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir</span></div><div class="casAuthors">Meanwell, Nicholas A.; Krystal, Mark R.; Nowicka-Sans, Beata; Langley, David R.; Conlon, David A.; Eastgate, Martin D.; Grasela, Dennis M.; Timmins, Peter; Wang, Tao; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-80</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Human immunodeficiency virus-1 (HIV-1) infection currently requires lifelong therapy with drugs that are used in combination to control viremia.  The indole-3-glyoxamide 6 was discovered as an inhibitor of HIV-1 infectivity using a phenotypic screen and derivs. of this compd. were found to interfere with the HIV-1 entry process by stabilizing a conformation of the virus gp120 protein not recognized by the host cell CD4 receptor.  An extensive optimization program led to the identification of temsavir (31), which exhibited an improved antiviral and pharmacokinetic profile compared to 6 and was explored in phase 3 clin. trials as the phosphonooxymethyl deriv. fostemsavir (35), a prodrug designed to address dissoln.- and soly.-limited absorption issues.  In this drug annotation, the authors summarize the structure-activity and structure-liability studies leading to the discovery of 31 and the clin. studies conducted with 35 that entailed the development of an extended release formulation suitable for phase 3 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOcSXTLXS7p7Vg90H21EOLACvtfcHk0lhJ9CDThUGarw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWnt7fP&md5=e36e5e0ac4ec79860c757a3bce6d0837</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01337%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DConlon%26aufirst%3DD.%2BA.%26aulast%3DEastgate%26aufirst%3DM.%2BD.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DTimmins%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DInhibitors%2520of%2520HIV-1%2520attachment%253A%2520the%2520discovery%2520and%2520development%2520of%2520temsavir%2520and%2520its%2520prodrug%2520fostemsavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D1%26spage%3D62%26epage%3D80%26doi%3D10.1021%2Facs.jmedchem.7b01337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Strategies in the design of antiviral drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1038/nrd703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnrd703" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=13-25&issue=1&author=E.+De%0AClercq&title=Strategies+in+the+design+of+antiviral+drugs&doi=10.1038%2Fnrd703"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd703%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DStrategies%2520in%2520the%2520design%2520of%2520antiviral%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D1%26spage%3D13%26epage%3D25%26doi%3D10.1038%2Fnrd703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/S0166-3542(98)00025-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0166-3542%2898%2900025-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9754886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXksVyrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1998&pages=153-179&issue=3&author=E.+De%0AClercq&title=The+role+of+non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29+in+the+therapy+of+HIV-1+infection&doi=10.1016%2FS0166-3542%2898%2900025-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-179</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with many refs.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have, in addn. to the nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), gained a definitive place in the treatment of HIV-1 infections.  Starting from the HEPT and TIBO derivs., more than 30 structurally different classes of compds. have been identified as NNRTIs, that is compds. that are specifically inhibitory to HIV-1 replication and targeted at the HIV-1 reverse transcriptase (RT).  Two NNRTIs (nevirapine and delavirdine) have been formally licensed for clin. use and several others are in preclin. or clin. development [thiocarboxanilide UC-781, HEPT deriv. MKC-442, quinoxaline HBY 097 and DMP 266 (efavirenz)].  The NNRTIs interact with a specific 'pocket' site of HIV-1 RT that is closely assocd. with, but distinct from, the NRTI binding site.  NNRTIs are notorious for rapidly eliciting resistance due to mutations of the amino acids surrounding the NNRTI-binding site.  However, the emergence of resistant HIV strains can be circumvented if the NNRTIs, alone or in combination, are used from the start at sufficiently high concns.  In vitro, this procedure has proved to 'knock-out' virus replication and to prevent resistance from arising.  In vivo, various triple-drug combinations of NNRTIs (nevirapine, delavirdine or efavirenz) with NRTIs (AZT, 3TC, ddI or d4T) and/or PIs (indinavir or nelfinavir) have been shown to afford a durable anti-HIV activity, as reflected by both a decrease in plasma HIV-1 RNA levels and increased CD4 T-lymphocyte counts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKnF3altW97Vg90H21EOLACvtfcHk0lj1fbFiP_7cAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksVyrsr4%253D&md5=fabfc13b6fa9fdacae68668dd6fbd80a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2898%2900025-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252898%252900025-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520role%2520of%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%2520in%2520the%2520therapy%2520of%2520HIV-1%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D1998%26volume%3D38%26issue%3D3%26spage%3D153%26epage%3D179%26doi%3D10.1016%2FS0166-3542%2898%2900025-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1002/cbdv.200490012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fcbdv.200490012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=17191775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=44-64&issue=1&author=E.+De%0AClercq&title=Non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29%3A+past%2C+present%2C+and+future&doi=10.1002%2Fcbdv.200490012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biodiversity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-64</span>CODEN:
                <span class="NLM_cas:coden">CBHIAM</span>;
        ISSN:<span class="NLM_cas:issn">1612-1872</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta AG</span>)
        </div><div class="casAbstract">A review with refs.  Non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) have become an inherent ingredient of the drug combination schemes that are currently used in the treatment of human immunodeficiency virus type 1 (HIV-1) infections.  Starting from the 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine (HEPT) and 4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivs., numerous classes of compds. have been described as NNRTIs.  Only three compds. have so far been approved for clin. use: nevirapine, delavirdine, and efavirenz.  NNRTIs are notorious for rapidly leading to virus-drug resistance development, primarily based on the emergence of the K103N and Y181C mutations in the HIV-1 RT.  Newer NNRTIs, such as capravirine, dapivirine (TMC 125), and DPC 083, are resilient to these "NNRTI" mutations, and, therefore, offer considerable promise as future anti-HIV-1 drugs.  NNRTIs are targeted at a specific "pocket" binding site within the HIV-1 RT, that is distinct from, but both spatially and functionally related to, the catalytic site, where the nucleoside RT inhibitors (NRTIs) and nucleotide RT inhibitors (NtRTIs) interact.  NNRTIs have acquired a definitive position, as part of a combination regimen with NRTIs and NtRTIs, in the first-line treatment of HIV-1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjIKlSEqbUHLVg90H21EOLACvtfcHk0lj1fbFiP_7cAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D&md5=4e681cc76745c156d8494e57136fd777</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.200490012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.200490012%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DChem.%2520Biodiversity%26date%3D2004%26volume%3D1%26issue%3D1%26spage%3D44%26epage%3D64%26doi%3D10.1002%2Fcbdv.200490012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Approved antiviral drugs over the past 50 years</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1128/CMR.00102-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FCMR.00102-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=27281742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=695-747&issue=3&author=E.+De%0AClercqauthor=G.+Li&title=Approved+antiviral+drugs+over+the+past+50+years&doi=10.1128%2FCMR.00102-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Approved Antiviral Drugs over the Past 50 Years</span></div><div class="casAuthors">De Clercq Erik; Li Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">695-747</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox).  Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbPpNpCY_qYTEC-75aqa5AfW6udTcc2eab5lRQ0A2OObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D&md5=1d25d961c1c6a72d6bc4634041bbb6fe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FCMR.00102-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00102-15%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DApproved%2520antiviral%2520drugs%2520over%2520the%2520past%252050%2520years%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2016%26volume%3D29%26issue%3D3%26spage%3D695%26epage%3D747%26doi%3D10.1128%2FCMR.00102-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friebe, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leinert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poll, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Saal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, M. L.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1021/jm00058a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00058a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=726-732&issue=6&author=W.+Schaferauthor=W.+G.+Friebeauthor=H.+Leinertauthor=A.+Mertensauthor=T.+Pollauthor=W.+von+der+Saalauthor=H.+Zilchauthor=B.+Nuberauthor=M.+L.+Ziegler&title=Non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase%3A+molecular+modeling+and+X-ray+structure+investigations&doi=10.1021%2Fjm00058a009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm00058a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00058a009%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DW.%26aulast%3DFriebe%26aufirst%3DW.%2BG.%26aulast%3DLeinert%26aufirst%3DH.%26aulast%3DMertens%26aufirst%3DA.%26aulast%3DPoll%26aufirst%3DT.%26aulast%3Dvon%2Bder%2BSaal%26aufirst%3DW.%26aulast%3DZilch%26aufirst%3DH.%26aulast%3DNuber%26aufirst%3DB.%26aulast%3DZiegler%26aufirst%3DM.%2BL.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%253A%2520molecular%2520modeling%2520and%2520X-ray%2520structure%2520investigations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26issue%3D6%26spage%3D726%26epage%3D732%26doi%3D10.1021%2Fjm00058a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(96)00091-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0969-2126%2896%2900091-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1996&pages=853-860&issue=7&author=Y.+Hsiouauthor=J.+Dingauthor=K.+Dasauthor=A.+D.+Clarkauthor=S.+H.+Hughesauthor=E.+Arnold&title=Structure+of+unliganded+HIV-1+reverse+transcriptase+at+2.7+A+resolution%3A+implications+of+conformational+changes+for+polymerization+and+inhibition+mechanisms&doi=10.1016%2FS0969-2126%2896%2900091-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2896%2900091-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252896%252900091-3%26sid%3Dliteratum%253Aachs%26aulast%3DHsiou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520unliganded%2520HIV-1%2520reverse%2520transcriptase%2520at%25202.7%2520A%2520resolution%253A%2520implications%2520of%2520conformational%2520changes%2520for%2520polymerization%2520and%2520inhibition%2520mechanisms%26jtitle%3DStructure%26date%3D1996%26volume%3D4%26issue%3D7%26spage%3D853%26epage%3D860%26doi%3D10.1016%2FS0969-2126%2896%2900091-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohlstaedt, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>256</i></span> (<span class="NLM_issue">5065</span>),  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1790</span>, <span class="refDoi"> DOI: 10.1126/science.1377403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1126%2Fscience.1377403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1377403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK38Xls1Kmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1992&pages=1783-1790&issue=5065&author=L.+A.+Kohlstaedtauthor=J.+Wangauthor=J.+M.+Friedmanauthor=P.+A.+Riceauthor=T.+A.+Steitz&title=Crystal+structure+at+3.5+A+resolution+of+HIV-1+reverse+transcriptase+complexed+with+an+inhibitor&doi=10.1126%2Fscience.1377403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor</span></div><div class="casAuthors">Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5065</span>),
    <span class="NLM_cas:pages">1783-90</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A 3.5 angstrom resoln. electron d. map of the HIV-1 reverse transcriptase heterodimer complexed with nevirapine, a drug with potential for treatment of AIDS, reveals an asym. dimer.  The polymerase (pol) domain of the 66-kilodalton subunit has a large cleft analogous to that of the Klenow fragment of Escherichia coli DNA polymerase I.  However, the 51-kilodalton subunit of identical sequence has no such cleft because the four subdomains of the pol domain occupy completely different relative positions.  Two of the four pol subdomains appear to be structurally related to subdomains of the Klenow fragment, including one contg. the catalytic site.  The subdomain that appears likely to bind the template strand at the pol active site has a different structure in the two polymerases.  Duplex A-form RNA-DNA hybrid can be model-built into the cleft that runs between the RNase H and pol active sites.  Nevirapine is almost completely buried in a pocket near but not overlapping with the pol active site.  Residues whose mutation results in drug resistance have been approx. located.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph5VLISXIsPbVg90H21EOLACvtfcHk0lhGSwXMLeFZWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1Kmur8%253D&md5=16b48fc345c2366a078fbdaf1ba71cc8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscience.1377403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1377403%26sid%3Dliteratum%253Aachs%26aulast%3DKohlstaedt%26aufirst%3DL.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DP.%2BA.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26atitle%3DCrystal%2520structure%2520at%25203.5%2520A%2520resolution%2520of%2520HIV-1%2520reverse%2520transcriptase%2520complexed%2520with%2520an%2520inhibitor%26jtitle%3DScience%26date%3D1992%26volume%3D256%26issue%3D5065%26spage%3D1783%26epage%3D1790%26doi%3D10.1126%2Fscience.1377403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baweja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmel, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oren, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatkin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5083</span>– <span class="NLM_lpage">5092</span>, <span class="refDoi"> DOI: 10.1093/nar/gkn464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1093%2Fnar%2Fgkn464" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=5083-5092&issue=15&author=J.+D.+Baumanauthor=K.+Dasauthor=W.+C.+Hoauthor=M.+Bawejaauthor=D.+M.+Himmelauthor=A.+D.+Clarkauthor=D.+A.+Orenauthor=P.+L.+Boyerauthor=S.+H.+Hughesauthor=A.+J.+Shatkinauthor=E.+Arnold&title=Crystal+engineering+of+HIV-1+reverse+transcriptase+for+structure-based+drug+design&doi=10.1093%2Fnar%2Fgkn464"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkn464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkn464%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BD.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DW.%2BC.%26aulast%3DBaweja%26aufirst%3DM.%26aulast%3DHimmel%26aufirst%3DD.%2BM.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DOren%26aufirst%3DD.%2BA.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DShatkin%26aufirst%3DA.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DCrystal%2520engineering%2520of%2520HIV-1%2520reverse%2520transcriptase%2520for%2520structure-based%2520drug%2520design%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2008%26volume%3D36%26issue%3D15%26spage%3D5083%26epage%3D5092%26doi%3D10.1093%2Fnar%2Fgkn464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">HIV-1 reverse transcriptase and antiviral drug resistance. Part 2</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2013.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.coviro.2013.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23602470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFagsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=119-128&issue=2&author=K.+Dasauthor=E.+Arnold&title=HIV-1+reverse+transcriptase+and+antiviral+drug+resistance.+Part+2&doi=10.1016%2Fj.coviro.2013.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 reverse transcriptase and antiviral drug resistance. Part 2</span></div><div class="casAuthors">Das, Kalyan; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-128</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Structures of RT and its complexes combined with biochem. and clin. data help in illuminating the mol. mechanisms of different drug-resistance mutations.  The NRTI drugs that are used in combinations have different primary mutation sites.  RT mutations that confer resistance to one drug can be hypersensitive to another RT drug.  Structure of an RT-DNA-nevirapine complex revealed how NNRTI binding forbids RT from forming a polymerase competent complex.  Collective knowledge about various mechanisms of drug resistance by RT has broader implications for understanding and targeting drug resistance in general.  In Part 1, we discussed the role of RT in developing HIV-1 drug resistance, structural and functional states of RT, and the nucleoside/nucleotide analog (NRTI) and non-nucleoside (NNRTI) drugs used in treating HIV-1 infections.  In this part, we discuss structural understanding of various mechanisms by which RT confers antiviral drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7WuVfmF5aU7Vg90H21EOLACvtfcHk0lhGSwXMLeFZWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFagsbg%253D&md5=ae4501656b7ccbcd86a96df04e08598f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2013.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2013.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DHIV-1%2520reverse%2520transcriptase%2520and%2520antiviral%2520drug%2520resistance.%2520Part%25202%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2013%26volume%3D3%26issue%3D2%26spage%3D119%26epage%3D128%26doi%3D10.1016%2Fj.coviro.2013.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">HIV-1 reverse transcriptase and antiviral drug resistance. Part 1</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2013.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.coviro.2013.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23602471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFanur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=111-118&issue=2&author=K.+Dasauthor=E.+Arnold&title=HIV-1+reverse+transcriptase+and+antiviral+drug+resistance.+Part+1&doi=10.1016%2Fj.coviro.2013.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 reverse transcriptase and antiviral drug resistance. Part 1</span></div><div class="casAuthors">Das, Kalyan; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  HIV-1 reverse transcriptase (RT) contributes to the development of resistance to all anti-AIDS drugs by introducing mutations into the viral genome.  At the mol. level, mutations in RT result in resistance to RT inhibitors.  Eight nucleoside/nucleotide analogs (NRTIs) and five non-nucleoside inhibitors (NNRTIs) are approved HIV-1 drugs.  Structures of RT have been detd. in complexes with substrates and/or inhibitors, and the structures have illuminated different conformational and functional states of the enzyme.  Understanding the mol. mechanisms of resistance to NRTIs and NNRTIs, and their complex relationships, may help in designing new drugs that are periodically required to overcome existing as well as emerging trends of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKm2E0DCBa77Vg90H21EOLACvtfcHk0lg2pkfHg-E7Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFanur0%253D&md5=7c1049b8cdad61bdd7d73c0aefbe496e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2013.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2013.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DHIV-1%2520reverse%2520transcriptase%2520and%2520antiviral%2520drug%2520resistance.%2520Part%25201%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2013%26volume%3D3%26issue%3D2%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.coviro.2013.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapiro, J. M.</span></span> <span> </span><span class="NLM_article-title">HIV-1 drug resistance mutations: an updated framework for the second decade of HAART</span>. <i>AIDS Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18615118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD1cvktFCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=67-84&issue=2&author=R.+W.+Shaferauthor=J.+M.+Schapiro&title=HIV-1+drug+resistance+mutations%3A+an+updated+framework+for+the+second+decade+of+HAART"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 drug resistance mutations: an updated framework for the second decade of HAART</span></div><div class="casAuthors">Shafer Robert W; Schapiro Jonathan M</div><div class="citationInfo"><span class="NLM_cas:title">AIDS reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-84</span>
        ISSN:<span class="NLM_cas:issn">1139-6121</span>.
    </div><div class="casAbstract">More than 200 mutations are associated with antiretroviral resistance to drugs belonging to six licensed antiretroviral classes.  More than 50 reverse transcriptase mutations are associated with nucleoside reverse transcriptase inhibitor resistance including M184V, thymidine analog mutations, mutations associated with non-thymidine analog containing regimens, multi-nucleoside resistance mutations, and several recently identified accessory mutations.  More than 40 reverse transcriptase mutations are associated with nonnucleoside reverse transcriptase inhibitor resistance including major primary and secondary mutations, non-polymorphic minor mutations, and polymorphic accessory mutations.  More than 60 mutations are associated with protease inhibitor resistance including major protease, accessory protease, and protease cleavage site mutations.  More than 30 integrase mutations are associated with the licensed integrase inhibitor raltegravir and the investigational inhibitor elvitegravir.  More than 15 gp41 mutations are associated with the fusion inhibitor enfuvirtide.  CCR5 inhibitor resistance results from mutations that promote gp120 binding to an inhibitor-bound CCR5 receptor or CXCR4 tropism; however, the genotypic correlates of these processes are not yet well characterized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCQ2rBuoWz4GlSCSgBhwJFfW6udTcc2eYlrf2_QiHhZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvktFCktA%253D%253D&md5=7cdf92dda8a1e4576af642f4ead1c523</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DSchapiro%26aufirst%3DJ.%2BM.%26atitle%3DHIV-1%2520drug%2520resistance%2520mutations%253A%2520an%2520updated%2520framework%2520for%2520the%2520second%2520decade%2520of%2520HAART%26jtitle%3DAIDS%2520Rev.%26date%3D2008%26volume%3D10%26issue%3D2%26spage%3D67%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span> <i>Clinical Guidelines</i>, <span class="NLM_publisher-name">U.S. National Library
of Medicine</span>, <span class="NLM_year">2018</span>;<a href="https://aidsinfo.nih.gov/guidelines" class="extLink">https://aidsinfo.nih.gov/guidelines</a> (accessed February 22, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Clinical+Guidelines%2C+U.S.+National+Library%0Aof+Medicine%2C+2018%3Bhttps%3A%2F%2Faidsinfo.nih.gov%2Fguidelines+%28accessed+February+22%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Guidelines%26pub%3DU.S.%2520National%2520Library%250Aof%2520Medicine%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sluis-Cremer, N.</span></span> <span> </span><span class="NLM_article-title">The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2960</span>– <span class="NLM_lpage">2973</span>, <span class="refDoi"> DOI: 10.3390/v6082960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.3390%2Fv6082960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25089538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2qu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=2960-2973&issue=8&author=N.+Sluis-Cremer&title=The+emerging+profile+of+cross-resistance+among+the+nonnucleoside+HIV-1+reverse+transcriptase+inhibitors&doi=10.3390%2Fv6082960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitor</span></div><div class="casAuthors">Sluis-Cremer, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2960-2973</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs.  In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure.  NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection.  For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring contg. dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation contg. the urea-PETT deriv. MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis.  Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs.  Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcoZWVaWI7bVg90H21EOLACvtfcHk0lg2pkfHg-E7Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2qu7zE&md5=cfab3601f81042b54cbfe1a2e0be8a08</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3390%2Fv6082960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv6082960%26sid%3Dliteratum%253Aachs%26aulast%3DSluis-Cremer%26aufirst%3DN.%26atitle%3DThe%2520emerging%2520profile%2520of%2520cross-resistance%2520among%2520the%2520nonnucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DViruses%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D2960%26epage%3D2973%26doi%3D10.3390%2Fv6082960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wensing, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunthard, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, D. D.</span></span> <span> </span><span class="NLM_article-title">2014 Update of the drug resistance mutations in HIV-1</span>. <i>Top. Antivir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25101529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpslyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=642-650&author=A.+M.+Wensingauthor=V.+Calvezauthor=H.+F.+Gunthardauthor=V.+A.+Johnsonauthor=R.+Paredesauthor=D.+Pillayauthor=R.+W.+Shaferauthor=D.+D.+Richman&title=2014+Update+of+the+drug+resistance+mutations+in+HIV-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">2014 Update of the drug resistance mutations in HIV-1</span></div><div class="casAuthors">Wensing Annemarie M; Calvez Vincent; Gunthard Huldrych F; Johnson Victoria A; Paredes Roger; Pillay Deenan; Shafer Robert W; Richman Douglas D</div><div class="citationInfo"><span class="NLM_cas:title">Topics in antiviral medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">642-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013.  The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir.  With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfGd8CCEOs1JagfuraLLzSfW6udTcc2eYlrf2_QiHhZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpslyqtQ%253D%253D&md5=f2df041240b12acaa476c6f2a16be2b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWensing%26aufirst%3DA.%2BM.%26aulast%3DCalvez%26aufirst%3DV.%26aulast%3DGunthard%26aufirst%3DH.%2BF.%26aulast%3DJohnson%26aufirst%3DV.%2BA.%26aulast%3DParedes%26aufirst%3DR.%26aulast%3DPillay%26aufirst%3DD.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DRichman%26aufirst%3DD.%2BD.%26atitle%3D2014%2520Update%2520of%2520the%2520drug%2520resistance%2520mutations%2520in%2520HIV-1%26jtitle%3DTop.%2520Antivir.%2520Med.%26date%3D2014%26volume%3D22%26spage%3D642%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melikian, G.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejesus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razzeca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israelski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1093/jac/dkt316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1093%2Fjac%2Fdkt316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23934770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=12-20&issue=1&author=G.%0AL.+Melikianauthor=S.+Y.+Rheeauthor=V.+Vargheseauthor=D.+Porterauthor=K.+Whiteauthor=J.+Taylorauthor=W.+Townerauthor=P.+Troiaauthor=J.+Burackauthor=E.+Dejesusauthor=G.+K.+Robbinsauthor=K.+Razzecaauthor=R.+Kaganauthor=T.+F.+Liuauthor=W.+J.+Fesselauthor=D.+Israelskiauthor=R.+W.+Shafer&title=Non-nucleoside+reverse+transcriptase+inhibitor+%28NNRTI%29+cross-resistance%3A+implications+for+preclinical+evaluation+of+novel+NNRTIs+and+clinical+genotypic+resistance+testing&doi=10.1093%2Fjac%2Fdkt316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing</span></div><div class="casAuthors">Melikian, George L.; Rhee, Soo-Yon; Varghese, Vici; Porter, Danielle; White, Kirsten; Taylor, Jonathan; Towner, William; Troia, Paolo; Burack, Jeffrey; DeJesus, Edwin; Robbins, Gregory K.; Razzeca, Kristin; Kagan, Ron; Liu, Tommy F.; Fessel, W. Jeffrey; Israelski, Dennis; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-20</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The introduction of two new non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the past 5 years and the identification of novel NNRTI-assocd. mutations have made it necessary to reassess the extent of phenotypic NNRTI cross-resistance.  We analyzed a dataset contg. 1975, 1967, 519 and 187 genotype-phenotype correlations for nevirapine, efavirenz, etravirine and rilpivirine, resp.  We used linear regression to est. the effects of RT mutations on susceptibility to each of these NNRTIs.  Sixteen mutations at 10 positions were significantly assocd. with the greatest contribution to reduced phenotypic susceptibility (≥10-fold) to one or more NNRTIs, including: 14 mutations at six positions for nevirapine (K101P, K103N/S, V106A/M, Y181C/I/V, Y188C/L and G190A/E/Q/S); 10 mutations at six positions for efavirenz (L100I, K101P, K103N, V106M, Y188C/L and G190A/E/Q/S); 5 mutations at four positions for etravirine (K101P, Y181I/V, G190E and F227C); and 6 mutations at five positions for rilpivirine (L100I, K101P, Y181I/V, G190E and F227C).  G190E, a mutation that causes high-level nevirapine and efavirenz resistance, also markedly reduced susceptibility to etravirine and rilpivirine.  K101H, E138G, V179F and M230L mutations, assocd. with reduced susceptibility to etravirine and rilpivirine, were also assocd. with reduced susceptibility to nevirapine and/or efavirenz.  The identification of novel cross-resistance patterns among approved NNRTIs illustrates the need for a systematic approach for testing novel NNRTIs against clin. virus isolates with major NNRTI-resistance mutations and for testing older NNRTIs against virus isolates with mutations identified during the evaluation of a novel NNRTI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWaJg5gfAEMbVg90H21EOLACvtfcHk0liujOsIqMw1KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegt77I&md5=7f54153593f8c5ba5ec1820a663c00bc</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkt316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkt316%26sid%3Dliteratum%253Aachs%26aulast%3DMelikian%26aufirst%3DG.%2BL.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DTowner%26aufirst%3DW.%26aulast%3DTroia%26aufirst%3DP.%26aulast%3DBurack%26aufirst%3DJ.%26aulast%3DDejesus%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DG.%2BK.%26aulast%3DRazzeca%26aufirst%3DK.%26aulast%3DKagan%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DT.%2BF.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DIsraelski%26aufirst%3DD.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520%2528NNRTI%2529%2520cross-resistance%253A%2520implications%2520for%2520preclinical%2520evaluation%2520of%2520novel%2520NNRTIs%2520and%2520clinical%2520genotypic%2520resistance%2520testing%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26issue%3D1%26spage%3D12%26epage%3D20%26doi%3D10.1093%2Fjac%2Fdkt316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span> </span><span class="NLM_article-title">Major Non-Nucleoside RT Inhibitor (NNRTI)
Resistance Mutations</span>.  <i>HIV Drug Resistance
Database</i>; <span class="NLM_publisher-name">Stanford University</span>, <span class="NLM_year">2018</span>; <a href="https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/" class="extLink">https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/</a> (accessed April 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Major+Non-Nucleoside+RT+Inhibitor+%28NNRTI%29%0AResistance+Mutations.+HIV+Drug+Resistance%0ADatabase%3B+Stanford+University%2C+2018%3B+https%3A%2F%2Fhivdb.stanford.edu%2Fdr-summary%2Fresistance-notes%2FNNRTI%2F+%28accessed+April+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DMajor%2520Non-Nucleoside%2520RT%2520Inhibitor%2520%2528NNRTI%2529%250AResistance%2520Mutations%26jtitle%3DHIV%2520Drug%2520Resistance%250ADatabase%26pub%3DStanford%2520University%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michejda, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeger
Smith, M. B.</span></span> <span> </span><span class="NLM_article-title">Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using monte carlo simulations in a linear response method</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">5272</span>– <span class="NLM_lpage">5286</span>, <span class="refDoi"> DOI: 10.1021/jm9804174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9804174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=5272-5286&issue=26&author=R.+H.+Smithauthor=W.+L.+Jorgensenauthor=J.+Tirado-Rivesauthor=M.+L.+Lambauthor=P.+A.+Janssenauthor=C.+J.+Michejdaauthor=M.+B.+Kroeger%0ASmith&title=Prediction+of+binding+affinities+for+TIBO+inhibitors+of+HIV-1+reverse+transcriptase+using+monte+carlo+simulations+in+a+linear+response+method&doi=10.1021%2Fjm9804174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm9804174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9804174%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%2BH.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DMichejda%26aufirst%3DC.%2BJ.%26aulast%3DKroeger%2BSmith%26aufirst%3DM.%2BB.%26atitle%3DPrediction%2520of%2520binding%2520affinities%2520for%2520TIBO%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%2520using%2520monte%2520carlo%2520simulations%2520in%2520a%2520linear%2520response%2520method%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26issue%3D26%26spage%3D5272%26epage%3D5286%26doi%3D10.1021%2Fjm9804174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Caro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavapathruni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A. D.</span></span> <span> </span><span class="NLM_article-title">Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2005.10.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=663-667&issue=3&author=W.+L.+Jorgensenauthor=J.+Ruiz-Caroauthor=J.+Tirado-Rivesauthor=A.+Basavapathruniauthor=K.+S.+Andersonauthor=A.+D.+Hamilton&title=Computer-aided+design+of+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.bmcl.2005.10.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DRuiz-Caro%26aufirst%3DJ.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DBasavapathruni%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26atitle%3DComputer-aided%2520design%2520of%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D3%26spage%3D663%26epage%3D667%26doi%3D10.1016%2Fj.bmcl.2005.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbardella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marturana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadeddu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Colla, P.</span></span> <span> </span><span class="NLM_article-title">Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1021/jm0309856</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309856" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=928-934&issue=4&author=R.+Ragnoauthor=A.+Maiauthor=G.+Sbardellaauthor=M.+Articoauthor=S.+Massaauthor=C.+Musiuauthor=M.+Muraauthor=F.+Marturanaauthor=A.+Cadedduauthor=P.+La+Colla&title=Computer-aided+design%2C+synthesis%2C+and+anti-HIV-1+activity+in+vitro+of+2-alkylamino-6-%5B1-%282%2C6-difluorophenyl%29alkyl%5D-3%2C4-dihydro-5-alkylpyrimidin-4%283H%29-ones+as+novel+potent+non-nucleoside+reverse+transcriptase+inhibitors%2C+also+active+against+the+Y181C+variant&doi=10.1021%2Fjm0309856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0309856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309856%26sid%3Dliteratum%253Aachs%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DSbardella%26aufirst%3DG.%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DMusiu%26aufirst%3DC.%26aulast%3DMura%26aufirst%3DM.%26aulast%3DMarturana%26aufirst%3DF.%26aulast%3DCadeddu%26aufirst%3DA.%26aulast%3DLa%2BColla%26aufirst%3DP.%26atitle%3DComputer-aided%2520design%252C%2520synthesis%252C%2520and%2520anti-HIV-1%2520activity%2520in%2520vitro%2520of%25202-alkylamino-6-%255B1-%25282%252C6-difluorophenyl%2529alkyl%255D-3%252C4-dihydro-5-alkylpyrimidin-4%25283H%2529-ones%2520as%2520novel%2520potent%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%252C%2520also%2520active%2520against%2520the%2520Y181C%2520variant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D4%26spage%3D928%26epage%3D934%26doi%3D10.1021%2Fjm0309856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Special issue: Cheminformatics in drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fcmdc.201800123" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=467-469&issue=6&author=A.+Benderauthor=N.+Brown&title=Special+issue%3A+Cheminformatics+in+drug+discovery&doi=10.1002%2Fcmdc.201800123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800123%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DSpecial%2520issue%253A%2520Cheminformatics%2520in%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D467%26epage%3D469%26doi%3D10.1002%2Fcmdc.201800123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carmine, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span> <span> </span><span class="NLM_article-title">Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.2165/00003495-198530020-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F00003495-198530020-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1985&pages=85-126&issue=2&author=A.+A.+Carmineauthor=R.+N.+Brogden&title=Pirenzepine.+A+review+of+its+pharmacodynamic+and+pharmacokinetic+properties+and+therapeutic+efficacy+in+peptic+ulcer+disease+and+other+allied+diseases&doi=10.2165%2F00003495-198530020-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2165%2F00003495-198530020-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198530020-00001%26sid%3Dliteratum%253Aachs%26aulast%3DCarmine%26aufirst%3DA.%2BA.%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26atitle%3DPirenzepine.%2520A%2520review%2520of%2520its%2520pharmacodynamic%2520and%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%2520in%2520peptic%2520ulcer%2520disease%2520and%2520other%2520allied%2520diseases%26jtitle%3DDrugs%26date%3D1985%26volume%3D30%26issue%3D2%26spage%3D85%26epage%3D126%26doi%3D10.2165%2F00003495-198530020-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proudfoot, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, V. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauldin, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnke, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunder, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiles, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoog, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saboe, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1021/jm00111a045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00111a045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK3MXksV2ltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=2231-2241&issue=7&author=K.+D.+Hargraveauthor=J.+R.+Proudfootauthor=K.+G.+Grozingerauthor=E.+Cullenauthor=S.+R.+Kapadiaauthor=U.+R.+Patelauthor=V.+U.+Fuchsauthor=S.+C.+Mauldinauthor=J.+Vitousauthor=M.+L.+Behnkeauthor=J.+M.+Klunderauthor=K.+Palauthor=J.+W.+Skilesauthor=D.+W.+McNeilauthor=J.+M.+Roseauthor=G.+C.+Chowauthor=M.+T.+Skoogauthor=J.+C.+Wuauthor=G.+Schmidtauthor=W.+W.+Engelauthor=W.+G.+Eberleinauthor=T.+D.+Saboeauthor=S.+J.+Campbellauthor=A.+S.+Rosenthalauthor=J.+Adams&title=Novel+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase.+1.+Tricyclic+pyridobenzo-+and+dipyridodiazepinones&doi=10.1021%2Fjm00111a045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase.  1.  Tricyclic pyridobenzo- and dipyridodiazepinones</span></div><div class="casAuthors">Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen, Ernest; Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.; Vitous, Jana; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2231-41</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human immunodeficiency virus type 1 reverse transcriptase in vitro at concns. as low as 35 nM.  In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.  In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring.  Max. potency is achieved with Me substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.  Addnl. substituents on the A ring can be readily tolerated.  II (BI-RG-587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for preclin. development.  II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT-resistant.  It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1hxlznaETGrVg90H21EOLACvtfcHk0lgSkwCIz2crJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksV2ltrw%253D&md5=8430acdc51ecffc0d3a374f2a978be28</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm00111a045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00111a045%26sid%3Dliteratum%253Aachs%26aulast%3DHargrave%26aufirst%3DK.%2BD.%26aulast%3DProudfoot%26aufirst%3DJ.%2BR.%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26aulast%3DCullen%26aufirst%3DE.%26aulast%3DKapadia%26aufirst%3DS.%2BR.%26aulast%3DPatel%26aufirst%3DU.%2BR.%26aulast%3DFuchs%26aufirst%3DV.%2BU.%26aulast%3DMauldin%26aufirst%3DS.%2BC.%26aulast%3DVitous%26aufirst%3DJ.%26aulast%3DBehnke%26aufirst%3DM.%2BL.%26aulast%3DKlunder%26aufirst%3DJ.%2BM.%26aulast%3DPal%26aufirst%3DK.%26aulast%3DSkiles%26aufirst%3DJ.%2BW.%26aulast%3DMcNeil%26aufirst%3DD.%2BW.%26aulast%3DRose%26aufirst%3DJ.%2BM.%26aulast%3DChow%26aufirst%3DG.%2BC.%26aulast%3DSkoog%26aufirst%3DM.%2BT.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DEngel%26aufirst%3DW.%2BW.%26aulast%3DEberlein%26aufirst%3DW.%2BG.%26aulast%3DSaboe%26aufirst%3DT.%2BD.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DRosenthal%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DNovel%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase.%25201.%2520Tricyclic%2520pyridobenzo-%2520and%2520dipyridodiazepinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26issue%3D7%26spage%3D2231%26epage%3D2241%26doi%3D10.1021%2Fjm00111a045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K.</span>; <span class="NLM_string-name">Proudfoot, J.</span>; <span class="NLM_string-name">Hargrave, K.</span></span>, <span> </span><span class="NLM_article-title">Discovery and development of nevirapine</span>. In  <i>Drug Discovery Development</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">363</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2F0471780103.ch13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=353-363&author=K.+Grozinger&author=J.+Proudfoot&author=K.+Hargrave&title=Drug+Discovery+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2F0471780103.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471780103.ch13%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520development%2520of%2520nevirapine%26btitle%3DDrug%2520Discovery%2520Development%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2006%26spage%3D353%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan-Havard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrail-Tran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taburet, A.-M.</span></span> <span> </span><span class="NLM_article-title">the A. S. G. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2154</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1128/AAC.02294-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.02294-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2154-2160&issue=5&author=P.+Fan-Havardauthor=Z.+Liuauthor=M.+Chouauthor=Y.+Lingauthor=A.+Barrail-Tranauthor=D.+W.+Haasauthor=A.-M.+Taburet&title=the+A.+S.+G.+Pharmacokinetics+of+phase+I+nevirapine+metabolites+following+a+single+dose+and+at+steady+state&doi=10.1128%2FAAC.02294-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FAAC.02294-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02294-12%26sid%3Dliteratum%253Aachs%26aulast%3DFan-Havard%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChou%26aufirst%3DM.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DBarrail-Tran%26aufirst%3DA.%26aulast%3DHaas%26aufirst%3DD.%2BW.%26aulast%3DTaburet%26aufirst%3DA.-M.%26atitle%3Dthe%2520A.%2520S.%2520G.%2520Pharmacokinetics%2520of%2520phase%2520I%2520nevirapine%2520metabolites%2520following%2520a%2520single%2520dose%2520and%2520at%2520steady%2520state%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D5%26spage%3D2154%26epage%3D2160%26doi%3D10.1128%2FAAC.02294-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nummy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridges, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvagno, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of five nevirapine metabolites</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570370203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fjhet.5570370203" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2000&pages=229-239&issue=2&author=K.+G.+Grozingerauthor=D.+P.+Byrneauthor=L.+J.+Nummyauthor=M.+D.+Ridgesauthor=A.+Salvagno&title=Synthesis+of+five+nevirapine+metabolites&doi=10.1002%2Fjhet.5570370203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570370203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570370203%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26aulast%3DByrne%26aufirst%3DD.%2BP.%26aulast%3DNummy%26aufirst%3DL.%2BJ.%26aulast%3DRidges%26aufirst%3DM.%2BD.%26aulast%3DSalvagno%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520five%2520nevirapine%2520metabolites%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2000%26volume%3D37%26issue%3D2%26spage%3D229%26epage%3D239%26doi%3D10.1002%2Fjhet.5570370203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauldin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of nevirapine and its major metabolite</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570320144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fjhet.5570320144" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1995&pages=259-263&issue=1&author=K.+G.+Grozingerauthor=V.+Fuchsauthor=K.+D.+Hargraveauthor=S.+Mauldinauthor=J.+Vitousauthor=S.+Campbellauthor=J.+Adams&title=Synthesis+of+nevirapine+and+its+major+metabolite&doi=10.1002%2Fjhet.5570320144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570320144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570320144%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26aulast%3DFuchs%26aufirst%3DV.%26aulast%3DHargrave%26aufirst%3DK.%2BD.%26aulast%3DMauldin%26aufirst%3DS.%26aulast%3DVitous%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%2520nevirapine%2520and%2520its%2520major%2520metabolite%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1995%26volume%3D32%26issue%3D1%26spage%3D259%26epage%3D263%26doi%3D10.1002%2Fjhet.5570320144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattox, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keirns, J.</span></span> <span> </span><span class="NLM_article-title">Disposition and biotransformation of the antiretroviral drug nevirapine in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">901</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10421616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFCgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=895-901&issue=8&author=P.+Riskaauthor=M.+Lamsonauthor=T.+MacGregorauthor=J.+Saboauthor=S.+Hattoxauthor=J.+Pavauthor=J.+Keirns&title=Disposition+and+biotransformation+of+the+antiretroviral+drug+nevirapine+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and biotransformation of the antiretroviral drug nevirapine in humans</span></div><div class="casAuthors">Riska, Paul; Lamson, Michael; Macgregor, Thomas; Sabo, John; Hattox, Susan; Pav, Joseph; Keirns, James</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacokinetics and biotransformation of the antiretroviral agent nevirapine (NVP) after autoinduction were characterized in eight healthy male volunteers.  Subjects received 200-mg NVP tablets once daily for 2 wk, followed by 200 mg twice daily for 2 wk.  Then they received a single oral dose (soln.) of 50 mg contg. 100 μCi of [14C]NVP.  Biol. fluids were analyzed for total radioactivity, parent compd. (HPLC/UV), and metabolites (electrospray liq. chromatog./mass spectroscopy and liq. chromatog./tandem mass spectroscopy).  Mean recovery of radioactivity was 91.4%, with 81.3% excreted in urine and 10.1% recovered in the feces over a period of 10 days.  Circulating radioactivity was evenly distributed between whole blood and plasma.  At max. plasma concn., parent compd. accounted for ∼75% of the circulating radioactivity.  Mean plasma elimination half-lives for total radioactivity and NVP were 21.3 and 20.0 h, resp.  Several metabolites were identified in urine including 2-hydroxynevirapine glucuronide (18.6%), 3-hydroxynevirapine glucuronide (25.7%), 12-hydroxynevirapine glucuronide (23.7%), 8-hydroxynevirapine glucuronide (1.3%), 3-hydroxynevirapine (1.2%), 12-hydroxynevirapine (0.6%), and 4-carboxynevirapine (2.4%).  Greater than 80% of the radioactivity in urine was made up of glucuronidated conjugates of hydroxylated metabolites of NVP.  Thus, cytochrome P 450 metab., glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of NVP biotransformation and elimination in humans.  Only a small fraction of the dose (2.7%) was excreted in urine as parent compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZI7168xc8kbVg90H21EOLACvtfcHk0lhqbZHpVMBWkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFCgt7g%253D&md5=17459b5f6e76dbf51e0f3753f84f1668</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiska%26aufirst%3DP.%26aulast%3DLamson%26aufirst%3DM.%26aulast%3DMacGregor%26aufirst%3DT.%26aulast%3DSabo%26aufirst%3DJ.%26aulast%3DHattox%26aufirst%3DS.%26aulast%3DPav%26aufirst%3DJ.%26aulast%3DKeirns%26aufirst%3DJ.%26atitle%3DDisposition%2520and%2520biotransformation%2520of%2520the%2520antiretroviral%2520drug%2520nevirapine%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26issue%3D8%26spage%3D895%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span> <i>Nevirapine, FDA Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug
Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Nevirapine%2C+FDA+Package%3B+U.S.+Food+and+Drug%0AAdministration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNevirapine%252C%2520FDA%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span> <span> </span><span class="NLM_article-title">The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.1186/1742-6405-11-36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1186%2F1742-6405-11-36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25926857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=36&author=Y.+Wangauthor=H.+Xingauthor=L.+Liaoauthor=Z.+Wangauthor=B.+Suauthor=Q.+Zhaoauthor=Y.+Fengauthor=P.+Maauthor=J.+Liuauthor=J.+Wuauthor=Y.+Ruanauthor=Y.+Shao&title=The+development+of+drug+resistance+mutations+K103N+Y181C+and+G190A+in+long+term+Nevirapine-containing+antiviral+therapy&doi=10.1186%2F1742-6405-11-36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy</span></div><div class="casAuthors">Wang, Yuncong; Xing, Hui; Liao, Lingjie; Wang, Zhe; Su, Bin; Zhao, Quanbi; Feng, Yi; Ma, Pengfei; Liu, Jia; Wu, Jianjun; Ruan, Yuhua; Shao, Yiming</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36/1-36/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">ARTIC4</span>;
        ISSN:<span class="NLM_cas:issn">1742-6405</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Objective We built a cohort study of HIV patients taking long-term first-line Antiretroviral Therapy in 2003.  In this assay, we focused on the development of primary drug resistance mutations against Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), K103N, Y181C and G190A.  Method The cohort study was built in Henan province, China.  We used Single Genome Amplification (SGA) to analyze the frequency of K103N, Y181C and G190A in serial plasma samples of three individual patients.  We also performed std. genotype HIV drug resistance assay in 204 patients of this cohort study to analyze the frequency of these mutations.  Result In the SGA sequences, the K103N decreased and vanished, while the frequency of Y181C and G190A increased in individual patient receiving long-term Antiretroviral Therapy (ART).  In the sequences of std. genotype HIV drug resistance assay, the frequency of K103N, Y181C and G190A had the similar pattern with that in SGA sequences.  Among these patients, the viral suppression were still sufficient after receiving ART for 72 mo, and 78.6% (160/204) patients could have their CD4 count over than 200cells/ul.  Conclusion In some patients, first-line ART had the possibility to provide sufficient treatment effect for over than 72 mo, but in long-term treatment, the dominant NNRTI drug resistance mutation K103N could reduced, while the proportion of variants with mutation Y181C or G190A may increased.  This result was not similar with that in vitro study, which state that variant with K103N or Y181C had an equal viral fitness with wild type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_zj0ueMuiobVg90H21EOLACvtfcHk0lhqbZHpVMBWkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWjt7c%253D&md5=c3bf6b032d086d79b5a6eca7d0bd6088</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-11-36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-11-36%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DH.%26aulast%3DLiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRuan%26aufirst%3DY.%26aulast%3DShao%26aufirst%3DY.%26atitle%3DThe%2520development%2520of%2520drug%2520resistance%2520mutations%2520K103N%2520Y181C%2520and%2520G190A%2520in%2520long%2520term%2520Nevirapine-containing%2520antiviral%2520therapy%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2014%26volume%3D11%26spage%3D36%26doi%3D10.1186%2F1742-6405-11-36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>312</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">805</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2001.4988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Fjmbi.2001.4988" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2001&pages=795-805&issue=4&author=J.+Renauthor=C.+Nicholsauthor=L.+Birdauthor=P.+Chamberlainauthor=K.+Weaverauthor=S.+Shortauthor=D.+I.+Stuartauthor=D.+K.+Stammers&title=Structural+mechanisms+of+drug+resistance+for+mutations+at+codons+181+and+188+in+HIV-1+reverse+transcriptase+and+the+improved+resilience+of+second+generation+non-nucleoside+inhibitors&doi=10.1006%2Fjmbi.2001.4988"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.4988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.4988%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DC.%26aulast%3DBird%26aufirst%3DL.%26aulast%3DChamberlain%26aufirst%3DP.%26aulast%3DWeaver%26aufirst%3DK.%26aulast%3DShort%26aufirst%3DS.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520mechanisms%2520of%2520drug%2520resistance%2520for%2520mutations%2520at%2520codons%2520181%2520and%2520188%2520in%2520HIV-1%2520reverse%2520transcriptase%2520and%2520the%2520improved%2520resilience%2520of%2520second%2520generation%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D312%26issue%3D4%26spage%3D795%26epage%3D805%26doi%3D10.1006%2Fjmbi.2001.4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meichsner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paessens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, G.</span></span> <span> </span><span class="NLM_article-title">Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>200</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1006/viro.1994.1233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Fviro.1994.1233" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=1994&pages=696-701&issue=2&author=J.+P.+Kleimauthor=R.+Benderauthor=R.+Kirschauthor=C.+Meichsnerauthor=A.+Paessensauthor=G.+Riess&title=Mutational+analysis+of+residue+190+of+human+immunodeficiency+virus+type+1+reverse+transcriptase&doi=10.1006%2Fviro.1994.1233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fviro.1994.1233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1994.1233%26sid%3Dliteratum%253Aachs%26aulast%3DKleim%26aufirst%3DJ.%2BP.%26aulast%3DBender%26aufirst%3DR.%26aulast%3DKirsch%26aufirst%3DR.%26aulast%3DMeichsner%26aufirst%3DC.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DRiess%26aufirst%3DG.%26atitle%3DMutational%2520analysis%2520of%2520residue%2520190%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520reverse%2520transcriptase%26jtitle%3DVirology%26date%3D1994%26volume%3D200%26issue%3D2%26spage%3D696%26epage%3D701%26doi%3D10.1006%2Fviro.1994.1233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>336</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2003.12.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.jmb.2003.12.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2004&pages=569-578&issue=3&author=J.+Renauthor=C.+E.+Nicholsauthor=P.+P.+Chamberlainauthor=K.+L.+Weaverauthor=S.+A.+Shortauthor=D.+K.+Stammers&title=Crystal+structures+of+HIV-1+reverse+transcriptases+mutated+at+codons+100%2C+106+and+108+and+mechanisms+of+resistance+to+non-nucleoside+inhibitors&doi=10.1016%2Fj.jmb.2003.12.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2003.12.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2003.12.055%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DC.%2BE.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DCrystal%2520structures%2520of%2520HIV-1%2520reverse%2520transcriptases%2520mutated%2520at%2520codons%2520100%252C%2520106%2520and%2520108%2520and%2520mechanisms%2520of%2520resistance%2520to%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D336%26issue%3D3%26spage%3D569%26epage%3D578%26doi%3D10.1016%2Fj.jmb.2003.12.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1089</span>– <span class="NLM_lpage">1094</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(00)00513-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0969-2126%2800%2900513-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=1089-1094&issue=10&author=J.+Renauthor=J.+Miltonauthor=K.+L.+Weaverauthor=S.+A.+Shortauthor=D.+I.+Stuartauthor=D.+K.+Stammers&title=Structural+basis+for+the+resilience+of+efavirenz+%28DMP-266%29+to+drug+resistance+mutations+in+HIV-1+reverse+transcriptase&doi=10.1016%2FS0969-2126%2800%2900513-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2800%2900513-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252800%252900513-X%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520resilience%2520of%2520efavirenz%2520%2528DMP-266%2529%2520to%2520drug%2520resistance%2520mutations%2520in%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DStructure%26date%3D2000%26volume%3D8%26issue%3D10%26spage%3D1089%26epage%3D1094%26doi%3D10.1016%2FS0969-2126%2800%2900513-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and durability of nevirapine in antiretroviral drug naive patients</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">S40</span>– <span class="NLM_lpage">S52</span>, <span class="refDoi"> DOI: 10.1097/00126334-200309011-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-200309011-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=14562857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=S40-S52&author=J.+M.+Lange&title=Efficacy+and+durability+of+nevirapine+in+antiretroviral+drug+naive+patients&doi=10.1097%2F00126334-200309011-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and durability of nevirapine in antiretroviral drug naive patients</span></div><div class="casAuthors">Lange, Joep M. A.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S40-S52</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was first reported in the scientific literature in 1990.  Varying doses of nevirapine (NVP) and a no. of regimens contg. this NNRTI have been studied in antiretroviral (ARV) naive patients.  Four key studies have compared the efficacy and safety of triple drug regimens contg. NVP in ARV naive, HIV-1 infected patients.  The INCAS study was the first demonstration of how to use NVP in an effective and durable manner: as a component of a triple drug regimen.  The COMBINE Study was a comparison of protease inhibitor (PI)-based and NVP-based triple regimens.  The Atlantic Study is comparing the safety and efficacy of three triple drug regimens in ARV naive patients.  In this study, treatment consists of a divergent drug regimen (PI and nucleoside reverse transcriptase inhibitors, NRTIs) targeting both HIV-1 protease and reverse transcriptase or a convergent regimen targeting reverse transcriptase alone (three NRTIs or two NRTIs plus a NNRTI).  A clin. endpoint study (BI 1090) compared the efficacy and durability of multi-drug regimens in ARV naive patients with high baseline plasma HIV-1 RNA levels (pVLs) and low peripheral blood CD4+ lymphocyte counts.  Data from these studies confirm that triple regimens contg. NVP suppressed viral replication for up to one year, even when the ARV naive patients had low CD4+ cell counts at baseline.  Nevirapine-contg. regimens suppressed pVLs to <50 copies/mL in approx. 50% of patients in the studies discussed (Intent to Treat analyses).  Data from 96 wk of follow up in the Atlantic Study demonstrates that the regimens contg. didanosine and stavudine plus indinavir or NVP were significantly more successful in suppressing pVLs to <50 copies/mL during this period than a regimen composed of these NRTIs and lamivudine (p ≤ 0.001).  As with other ARV drugs, NVP should always be used as part of a fully suppressive ARV regimen.  When used in this way, it is an effective ARV drug, which contributes to durable virol. and immunol. responses in approx. half of all treated patients.  Nevirapine-contg. regimens are effective in patients with advanced HIV-1 infection, i.e., low CD4+ cell counts.  Data will soon be available from the 2NN Study that compares the efficacy and safety of four different regimens using NVP once daily, NVP twice daily, efavirenz once daily or a combination of NVP and efavirenz.  All four arms of the study include a backbone of stavudine and lamivudine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHicpp_x2tPLVg90H21EOLACvtfcHk0lhSkELZFTLpPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCrt7o%253D&md5=128a3a8437196c515722e6ab1e617bf4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1097%2F00126334-200309011-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-200309011-00007%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520durability%2520of%2520nevirapine%2520in%2520antiretroviral%2520drug%2520naive%2520patients%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2003%26volume%3D34%26spage%3DS40%26epage%3DS52%26doi%3D10.1097%2F00126334-200309011-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montaner, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. M.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study</span>. <i>Jama</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1001/jama.279.12.930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1001%2Fjama.279.12.930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9544767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXitlyisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=930-937&issue=12&author=J.+S.+Montanerauthor=P.+Reissauthor=D.+Cooperauthor=S.+Vellaauthor=M.+Harrisauthor=B.+Conwayauthor=M.+A.+Wainbergauthor=D.+Smithauthor=P.+Robinsonauthor=D.+Hallauthor=M.+Myersauthor=J.+M.+Lange&title=A+randomized%2C+double-blind+trial+comparing+combinations+of+nevirapine%2C+didanosine%2C+and+zidovudine+for+HIV-infected+patients%3A+the+INCAS+Trial.+Italy%2C+The+Netherlands%2C+Canada+and+Australia+Study&doi=10.1001%2Fjama.279.12.930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial</span></div><div class="casAuthors">Montaner, Julio S. G.; Reiss, Peter; Cooper, David; Vella, Stefano; Harris, Marianne; Conway, Brian; Wainberg, Mark A.; Smith, D.; Robinson, Patrick; Hall, David; Myers, Maureen; Lange, Joep M. A.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">930-937</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of anti-retroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease.  However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA.  Of the 153 enrolled patients, 151 were evaluable.  At week 8, plasma HIV-1 RNA levels had decreased by log 2.18, 1.55, and 0.90 in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, resp. (P<.05).  The proportions of patients with plasma HIV-1 RNA levels below 20 copies per mL at week 52 were 51%, 12%, and 0% in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, resp. (P<.001).  Viral amplification was attempted in 59 patients at 6 mo.  Viral isolation was unsuccessful in 19 (79%) of 24, 10 (53%) of 19, and 5 (31%) of 16 patients in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, resp.  Among patients from whom virus could be amplified, resistance to nevirapine was found in all 11 patients receiving zidovudine plus nevirapine and in all 5 patients receiving triple drug therapy.  Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, resp. (P=.08).  Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied.  Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9GorH2fhxjLVg90H21EOLACvtfcHk0lhSkELZFTLpPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlyisr4%253D&md5=1d062ad4a092ba4d94b0b49beffd12f1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1001%2Fjama.279.12.930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.279.12.930%26sid%3Dliteratum%253Aachs%26aulast%3DMontaner%26aufirst%3DJ.%2BS.%26aulast%3DReiss%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DD.%26aulast%3DVella%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DMyers%26aufirst%3DM.%26aulast%3DLange%26aufirst%3DJ.%2BM.%26atitle%3DA%2520randomized%252C%2520double-blind%2520trial%2520comparing%2520combinations%2520of%2520nevirapine%252C%2520didanosine%252C%2520and%2520zidovudine%2520for%2520HIV-infected%2520patients%253A%2520the%2520INCAS%2520Trial.%2520Italy%252C%2520The%2520Netherlands%252C%2520Canada%2520and%2520Australia%2520Study%26jtitle%3DJama%26date%3D1998%26volume%3D279%26issue%3D12%26spage%3D930%26epage%3D937%26doi%3D10.1001%2Fjama.279.12.930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baylor, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johann-Liang, R.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity associated with nevirapine use</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1097/00126334-200404150-00014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-200404150-00014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15021321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD2c7ivVGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2004&pages=538-539&issue=5&author=M.+S.+Baylorauthor=R.+Johann-Liang&title=Hepatotoxicity+associated+with+nevirapine+use&doi=10.1097%2F00126334-200404150-00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity associated with nevirapine use</span></div><div class="casAuthors">Baylor Melisse Sloas; Johann-Liang Rosemary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of acquired immune deficiency syndromes (1999)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">538-9</span>
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-beckN323PZWtyewyzkyLfW6udTcc2eb40SKVyLgED7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7ivVGiug%253D%253D&md5=17d61e7562eced5eee59c64a4d49dbbe</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1097%2F00126334-200404150-00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-200404150-00014%26sid%3Dliteratum%253Aachs%26aulast%3DBaylor%26aufirst%3DM.%2BS.%26aulast%3DJohann-Liang%26aufirst%3DR.%26atitle%3DHepatotoxicity%2520associated%2520with%2520nevirapine%2520use%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2004%26volume%3D35%26issue%3D5%26spage%3D538%26epage%3D539%26doi%3D10.1097%2F00126334-200404150-00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mommeja-Marin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gish, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, F.</span></span> <span> </span><span class="NLM_article-title">Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">829</span>, <span class="refDoi"> DOI: 10.1086/428093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1086%2F428093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15717255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVyhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2005&pages=825-829&issue=6&author=I.+Sanneauthor=H.+Mommeja-Marinauthor=J.+Hinkleauthor=J.+A.+Bartlettauthor=M.+M.+Ledermanauthor=G.+Maartensauthor=C.+Wakefordauthor=A.+Shawauthor=J.+Quinnauthor=R.+G.+Gishauthor=F.+Rousseau&title=Severe+hepatotoxicity+associated+with+nevirapine+use+in+HIV-infected+subjects&doi=10.1086%2F428093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects</span></div><div class="casAuthors">Sanne, Ian; Mommeja-Marin, Herve; Hinkle, John; Bartlett, John A.; Lederman, Michael M.; Maartens, Gary; Wakeford, Charles; Shaw, Audrey; Quinn, Joseph; Gish, Robert G.; Rousseau, Franck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-829</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Human immunodeficiency virus (HIV)-infected South African patients (n = 468) received blinded lamivudine or emtricitabine, stavudine, and either nevirapine or efavirenz (based on screening viral load).  Baseline characteristics were analyzed in univariate and multivariate regression, to identify risk factors for hepatotoxicity (grade 3 or greater increase in serum aminotransferase levels).  The occurrence of early hepatotoxicity was 17% in the nevirapine group and 0% in the efavirenz group and was balanced between the lamivudine and emtricitabine arms.  Two subjects died of hepatic failure.  Independent risk factors were body-mass index (BMI) <18.5, female sex, serum albumin level <35 g/L, mean corpuscular vol. >85 fL, plasma HIV-1 RNA load <20,000 copies/mL, aspartate aminotransferase level <75 IU/L, and lactate dehydrogenase level <164 IU/L.  The use of nevirapine in female patients with a low BMI should be discouraged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoakc1s3TvQ7LVg90H21EOLACvtfcHk0ljkx9OEOli4iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVyhu7k%253D&md5=3d04abf1ab1a893425ad8e2cc625ab93</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1086%2F428093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F428093%26sid%3Dliteratum%253Aachs%26aulast%3DSanne%26aufirst%3DI.%26aulast%3DMommeja-Marin%26aufirst%3DH.%26aulast%3DHinkle%26aufirst%3DJ.%26aulast%3DBartlett%26aufirst%3DJ.%2BA.%26aulast%3DLederman%26aufirst%3DM.%2BM.%26aulast%3DMaartens%26aufirst%3DG.%26aulast%3DWakeford%26aufirst%3DC.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DQuinn%26aufirst%3DJ.%26aulast%3DGish%26aufirst%3DR.%2BG.%26aulast%3DRousseau%26aufirst%3DF.%26atitle%3DSevere%2520hepatotoxicity%2520associated%2520with%2520nevirapine%2520use%2520in%2520HIV-infected%2520subjects%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D191%26issue%3D6%26spage%3D825%26epage%3D829%26doi%3D10.1086%2F428093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bethune, M. P.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009)</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2009.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.antiviral.2009.09.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2010&pages=75-90&issue=1&author=M.+P.+de%0ABethune&title=Non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29%2C+their+discovery%2C+development%2C+and+use+in+the+treatment+of+HIV-1+infection%3A+a+review+of+the+last+20+years+%281989%E2%80%932009%29&doi=10.1016%2Fj.antiviral.2009.09.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2009.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2009.09.008%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%252C%2520their%2520discovery%252C%2520development%252C%2520and%2520use%2520in%2520the%2520treatment%2520of%2520HIV-1%2520infection%253A%2520a%2520review%2520of%2520the%2520last%252020%2520years%2520%25281989%25E2%2580%25932009%2529%26jtitle%3DAntiviral%2520Res.%26date%3D2010%26volume%3D85%26issue%3D1%26spage%3D75%26epage%3D90%26doi%3D10.1016%2Fj.antiviral.2009.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merluzzi, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattox, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>250</i></span> (<span class="NLM_issue">4986</span>),  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1126/science.1701568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1126%2Fscience.1701568" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=1990&pages=1411-1413&issue=4986&author=V.+J.+Merluzziauthor=K.+D.+Hargraveauthor=M.+Labadiaauthor=K.+Grozingerauthor=M.+Skoogauthor=J.+C.+Wuauthor=C.+K.+Shihauthor=K.+Ecknerauthor=S.+Hattoxauthor=J.+Adams&title=Inhibition+of+HIV-1+replication+by+a+nonnucleoside+reverse+transcriptase+inhibitor&doi=10.1126%2Fscience.1701568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.1701568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1701568%26sid%3Dliteratum%253Aachs%26aulast%3DMerluzzi%26aufirst%3DV.%2BJ.%26aulast%3DHargrave%26aufirst%3DK.%2BD.%26aulast%3DLabadia%26aufirst%3DM.%26aulast%3DGrozinger%26aufirst%3DK.%26aulast%3DSkoog%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DShih%26aufirst%3DC.%2BK.%26aulast%3DEckner%26aufirst%3DK.%26aulast%3DHattox%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520HIV-1%2520replication%2520by%2520a%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DScience%26date%3D1990%26volume%3D250%26issue%3D4986%26spage%3D1411%26epage%3D1413%26doi%3D10.1126%2Fscience.1701568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burton, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritzky, A. R.</span></span> <span> </span><span class="NLM_article-title">The selective 3- and 5-nitration of 2-pyridones</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2211</span>– <span class="NLM_lpage">2212</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)96822-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0040-4039%2801%2996822-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1971&pages=2211-2212&issue=24&author=A.+G.+Burtonauthor=P.+J.+Hallsauthor=A.+R.+Katritzky&title=The+selective+3-+and+5-nitration+of+2-pyridones&doi=10.1016%2FS0040-4039%2801%2996822-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2996822-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252996822-4%26sid%3Dliteratum%253Aachs%26aulast%3DBurton%26aufirst%3DA.%2BG.%26aulast%3DHalls%26aufirst%3DP.%2BJ.%26aulast%3DKatritzky%26aufirst%3DA.%2BR.%26atitle%3DThe%2520selective%25203-%2520and%25205-nitration%2520of%25202-pyridones%26jtitle%3DTetrahedron%2520Lett.%26date%3D1971%26volume%3D12%26issue%3D24%26spage%3D2211%26epage%3D2212%26doi%3D10.1016%2FS0040-4039%2801%2996822-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bobbitt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scola, D. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of isoquinoline alkaloids. II. The synthesis and reactions of 4-methyl-3-pyridinecarboxaldehyde and other 4-methyl-3-substituted pyridines1,2</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1021/jo01074a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01074a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1960&pages=560-564&issue=4&author=J.+M.+Bobbittauthor=D.+A.+Scola&title=Synthesis+of+isoquinoline+alkaloids.+II.+The+synthesis+and+reactions+of+4-methyl-3-pyridinecarboxaldehyde+and+other+4-methyl-3-substituted+pyridines1%2C2&doi=10.1021%2Fjo01074a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjo01074a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01074a018%26sid%3Dliteratum%253Aachs%26aulast%3DBobbitt%26aufirst%3DJ.%2BM.%26aulast%3DScola%26aufirst%3DD.%2BA.%26atitle%3DSynthesis%2520of%2520isoquinoline%2520alkaloids.%2520II.%2520The%2520synthesis%2520and%2520reactions%2520of%25204-methyl-3-pyridinecarboxaldehyde%2520and%2520other%25204-methyl-3-substituted%2520pyridines1%252C2%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1960%26volume%3D25%26issue%3D4%26spage%3D560%26epage%3D564%26doi%3D10.1021%2Fjo01074a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span>; <span class="NLM_string-name">Hargrave, K. D.</span>; <span class="NLM_string-name">Adams, J.</span></span> US Patent <span> </span><span class="NLM_article-title">Method for the Preparation of 3-amino-2-chloro-4-methylpyridines</span>. <span class="NLM_patent">US5668287A</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=K.+G.+Grozinger&author=K.+D.+Hargrave&author=J.+Adams&title=Method+for+the+Preparation+of+3-amino-2-chloro-4-methylpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%25203-amino-2-chloro-4-methylpyridines%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span>; <span class="NLM_string-name">Lie, J. J.</span></span> <i>The Art of Drug Synthesis</i>; <span class="NLM_publisher-name">Wiley-Interscience</span>: <span class="NLM_publisher-loc">Ljubljana</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2F9780470134979" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+S.+Johnson&author=J.+J.+Lie&title=The+Art+of+Drug+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2F9780470134979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470134979%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26btitle%3DThe%2520Art%2520of%2520Drug%2520Synthesis%26pub%3DWiley-Interscience%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span>; <span class="NLM_string-name">Hargrave, K. D.</span>; <span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of 5,11-dihydro-6<i>H</i>-dipyrido [3,2-<i>b</i>:2′,3′-<i>e</i>][1,4]diazepines</span>. US Patent <span class="NLM_patent">US5571912</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=K.+G.+Grozinger&author=K.+D.+Hargrave&author=J.+Adams&title=Method+for+the+Preparation+of+5%2C11-dihydro-6H-dipyrido+%5B3%2C2-b%3A2%E2%80%B2%2C3%E2%80%B2-e%5D%5B1%2C4%5Ddiazepines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%25205%252C11-dihydro-6H-dipyrido%2520%255B3%252C2-b%253A2%25E2%2580%25B2%252C3%25E2%2580%25B2-e%255D%255B1%252C4%255Ddiazepines%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boswell, R. F.</span>; <span class="NLM_string-name">Gupton, B. F.</span>; <span class="NLM_string-name">Lo, Y.
S.</span></span> <span> </span><span class="NLM_article-title">Improved Method for Making Nevirapine</span>. China Patent <span class="NLM_patent">CN1280293C</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+F.+Boswell&author=B.+F.+Gupton&author=Y.%0AS.+Lo&title=Improved+Method+for+Making+Nevirapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DR.%2BF.%26atitle%3DImproved%2520Method%2520for%2520Making%2520Nevirapine%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhiquan, Z.</span>; <span class="NLM_string-name">Laisheng, Z.</span>; <span class="NLM_string-name">Xiujuan, W.</span>; <span class="NLM_string-name">Fei, X.</span></span> <span> </span><span class="NLM_article-title">Methods for preparation of nevirapine and intermediate thereof</span>. China Patent <span class="NLM_patent">CN104774204A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Zhiquan&author=Z.+Laisheng&author=W.+Xiujuan&author=X.+Fei&title=Methods+for+preparation+of+nevirapine+and+intermediate+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhiquan%26aufirst%3DZ.%26atitle%3DMethods%2520for%2520preparation%2520of%2520nevirapine%2520and%2520intermediate%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Delavirdine</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1444</span>, <span class="refDoi"> DOI: 10.2165/00003495-200060060-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F00003495-200060060-00013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1411-1444&issue=6&author=L.+J.+Scottauthor=C.+M.+Perry&title=Delavirdine&doi=10.2165%2F00003495-200060060-00013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2165%2F00003495-200060060-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200060060-00013%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DDelavirdine%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26issue%3D6%26spage%3D1411%26epage%3D1444%26doi%3D10.2165%2F00003495-200060060-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dueweke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span> <span> </span><span class="NLM_article-title">U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1127</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.5.1127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.37.5.1127" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=1127-1131&issue=5&author=T.+J.+Duewekeauthor=S.+M.+Poppeauthor=D.+L.+Romeroauthor=S.+M.+Swaneyauthor=A.+G.+Soauthor=K.+M.+Downeyauthor=I.+W.+Althausauthor=F.+Reusserauthor=M.+Bussoauthor=L.+Resnick&title=U-90152%2C+a+potent+inhibitor+of+human+immunodeficiency+virus+type+1+replication&doi=10.1128%2FAAC.37.5.1127"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.5.1127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.5.1127%26sid%3Dliteratum%253Aachs%26aulast%3DDueweke%26aufirst%3DT.%2BJ.%26aulast%3DPoppe%26aufirst%3DS.%2BM.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DSwaney%26aufirst%3DS.%2BM.%26aulast%3DSo%26aufirst%3DA.%2BG.%26aulast%3DDowney%26aufirst%3DK.%2BM.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DResnick%26aufirst%3DL.%26atitle%3DU-90152%252C%2520a%2520potent%2520inhibitor%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520replication%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26issue%3D5%26spage%3D1127%26epage%3D1131%26doi%3D10.1128%2FAAC.37.5.1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span> <span> </span><span class="NLM_article-title">Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8806</span>– <span class="NLM_lpage">8810</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.19.8806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.88.19.8806" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=8806-8810&issue=19&author=D.+L.+Romeroauthor=M.+Bussoauthor=C.+K.+Tanauthor=F.+Reusserauthor=J.+R.+Palmerauthor=S.+M.+Poppeauthor=P.+A.+Aristoffauthor=K.+M.+Downeyauthor=A.+G.+Soauthor=L.+Resnick&title=Nonnucleoside+reverse+transcriptase+inhibitors+that+potently+and+specifically+block+human+immunodeficiency+virus+type+1+replication&doi=10.1073%2Fpnas.88.19.8806"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.19.8806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.19.8806%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DC.%2BK.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DPalmer%26aufirst%3DJ.%2BR.%26aulast%3DPoppe%26aufirst%3DS.%2BM.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26aulast%3DDowney%26aufirst%3DK.%2BM.%26aulast%3DSo%26aufirst%3DA.%2BG.%26aulast%3DResnick%26aufirst%3DL.%26atitle%3DNonnucleoside%2520reverse%2520transcriptase%2520inhibitors%2520that%2520potently%2520and%2520specifically%2520block%2520human%2520immunodeficiency%2520virus%2520type%25201%2520replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26issue%3D19%26spage%3D8806%26epage%3D8810%26doi%3D10.1073%2Fpnas.88.19.8806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmsted, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopta, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosley, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishka, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehle, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span> <span> </span><span class="NLM_article-title">Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3769</span>– <span class="NLM_lpage">3789</span>, <span class="refDoi"> DOI: 10.1021/jm960158n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960158n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3769-3789&issue=19&author=D.+L.+Romeroauthor=R.+A.+Olmstedauthor=T.+J.+Poelauthor=R.+A.+Morgeauthor=C.+Bilesauthor=B.+J.+Keiserauthor=L.+A.+Koptaauthor=J.+M.+Friisauthor=J.+D.+Hosleyauthor=K.+J.+Stefanskiauthor=D.+G.+Wishkaauthor=D.+B.+Evansauthor=J.+Morrisauthor=R.+G.+Stehleauthor=S.+K.+Sharmaauthor=Y.+Yagiauthor=R.+L.+Voormanauthor=W.+J.+Adamsauthor=W.+G.+Tarpleyauthor=R.+C.+Thomas&title=Targeting+delavirdine%2Fatevirdine+resistant+HIV-1%3A+identification+of+%28alkylamino%29piperidine-containing+bis%28heteroaryl%29piperazines+as+broad+spectrum+HIV-1+reverse+transcriptase+inhibitors&doi=10.1021%2Fjm960158n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm960158n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960158n%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DOlmsted%26aufirst%3DR.%2BA.%26aulast%3DPoel%26aufirst%3DT.%2BJ.%26aulast%3DMorge%26aufirst%3DR.%2BA.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DKeiser%26aufirst%3DB.%2BJ.%26aulast%3DKopta%26aufirst%3DL.%2BA.%26aulast%3DFriis%26aufirst%3DJ.%2BM.%26aulast%3DHosley%26aufirst%3DJ.%2BD.%26aulast%3DStefanski%26aufirst%3DK.%2BJ.%26aulast%3DWishka%26aufirst%3DD.%2BG.%26aulast%3DEvans%26aufirst%3DD.%2BB.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DStehle%26aufirst%3DR.%2BG.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DYagi%26aufirst%3DY.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520delavirdine%252Fatevirdine%2520resistant%2520HIV-1%253A%2520identification%2520of%2520%2528alkylamino%2529piperidine-containing%2520bis%2528heteroaryl%2529piperazines%2520as%2520broad%2520spectrum%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D19%26spage%3D3769%26epage%3D3789%26doi%3D10.1021%2Fjm960158n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span>; <span class="NLM_string-name">Aristoff, P. A.</span>; <span class="NLM_string-name">Jensen, R. K.</span>; <span class="NLM_string-name">Morozowich, W.</span>; <span class="NLM_string-name">Romero, D. L.</span>; <span class="NLM_string-name">Schinzer, W. C.</span>; <span class="NLM_string-name">Tarpley, W. G.</span>; <span class="NLM_string-name">Thomas, R. C.</span></span>, <span> </span><span class="NLM_article-title">Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate</span>. In  <i>Integration of Pharmaceutical Discovery and Development: Case Histories</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Borchardt, R. T.</span>, <span class="NLM_string-name">Freidinger, R. M.</span>, <span class="NLM_string-name">Sawyer, T. K.</span>, <span class="NLM_string-name">Smith, P. L.</span></span>, Eds.; <span class="NLM_publisher-name">Springer US</span>: <span class="NLM_publisher-loc">Boston, MA</span>, <span class="NLM_year">1998</span>; pp  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">312</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=285-312&author=W.+J.+Adams&author=P.+A.+Aristoff&author=R.+K.+Jensen&author=W.+Morozowich&author=D.+L.+Romero&author=W.+C.+Schinzer&author=W.+G.+Tarpley&author=R.+C.+Thomasauthor=R.+T.+Borchardt&author=R.+M.+Freidinger&author=T.+K.+Sawyer&author=P.+L.+Smith&title=Integration+of+Pharmaceutical+Discovery+and+Development%3A+Case+Histories"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520and%2520development%2520of%2520the%2520BHAP%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520delavirdine%2520mesylate%26btitle%3DIntegration%2520of%2520Pharmaceutical%2520Discovery%2520and%2520Development%253A%2520Case%2520Histories%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26pub%3DSpringer%2520US%26date%3D1998%26spage%3D285%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrios-Pena, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">W, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1021/jm00033a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00033a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=999-1014&issue=7&author=D.+L.+Romeroauthor=R.+A.+Morgeauthor=C.+Bilesauthor=N.+Berrios-Penaauthor=P.+D.+Mayauthor=J.+R.+Palmerauthor=P.+D.+Johnsonauthor=H.+W.+Smithauthor=M.+Bussoauthor=C.+K.+Tanauthor=R.+L.+Voormanauthor=F.+Reusserauthor=A.+I.+Wauthor=K.+W.+Downeyauthor=A.+G.+Soauthor=L.+Resnikauthor=W.+G.+Tarpleyauthor=P.+A.+Aristoff&title=Discovery%2C+synthesis%2C+and+bioactivity+of+bis%28heteroaryl%29piperazines.+1.+A+novel+class+of+non-nucleoside+HIV-1+reverse+transcriptase+inhibitors&doi=10.1021%2Fjm00033a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm00033a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00033a018%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DMorge%26aufirst%3DR.%2BA.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DBerrios-Pena%26aufirst%3DN.%26aulast%3DMay%26aufirst%3DP.%2BD.%26aulast%3DPalmer%26aufirst%3DJ.%2BR.%26aulast%3DJohnson%26aufirst%3DP.%2BD.%26aulast%3DSmith%26aufirst%3DH.%2BW.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DC.%2BK.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DW%26aufirst%3DA.%2BI.%26aulast%3DDowney%26aufirst%3DK.%2BW.%26aulast%3DSo%26aufirst%3DA.%2BG.%26aulast%3DResnik%26aufirst%3DL.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%252C%2520synthesis%252C%2520and%2520bioactivity%2520of%2520bis%2528heteroaryl%2529piperazines.%25201.%2520A%2520novel%2520class%2520of%2520non-nucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D7%26spage%3D999%26epage%3D1014%26doi%3D10.1021%2Fjm00033a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span> <span> </span><span class="NLM_article-title">Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1021/jm00062a027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00062a027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1505-1508&issue=10&author=D.+L.+Romeroauthor=R.+A.+Morgeauthor=M.+J.+Geninauthor=C.+Bilesauthor=M.+Bussoauthor=L.+Resnickauthor=I.+W.+Althausauthor=F.+Reusserauthor=R.+C.+Thomasauthor=W.+G.+Tarpley&title=Bis%28heteroaryl%29piperazine+%28BHAP%29+reverse+transcriptase+inhibitors%3A+structure-activity+relationships+of+novel+substituted+indole+analogues+and+the+identification+of+1-%5B%285-methanesulfonamido-1H-indol-2-yl%29-carbonyl%5D-4-%5B3-+%5B%281-methylethyl%29amino%5D-pyridinyl%5Dpiperazine+monomethanesulfonate+%28U-90152S%29%2C+a+second-generation+clinical+candidate&doi=10.1021%2Fjm00062a027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm00062a027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00062a027%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DMorge%26aufirst%3DR.%2BA.%26aulast%3DGenin%26aufirst%3DM.%2BJ.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DResnick%26aufirst%3DL.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26atitle%3DBis%2528heteroaryl%2529piperazine%2520%2528BHAP%2529%2520reverse%2520transcriptase%2520inhibitors%253A%2520structure-activity%2520relationships%2520of%2520novel%2520substituted%2520indole%2520analogues%2520and%2520the%2520identification%2520of%25201-%255B%25285-methanesulfonamido-1H-indol-2-yl%2529-carbonyl%255D-4-%255B3-%2520%255B%25281-methylethyl%2529amino%255D-pyridinyl%255Dpiperazine%2520monomethanesulfonate%2520%2528U-90152S%2529%252C%2520a%2520second-generation%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26issue%3D10%26spage%3D1505%26epage%3D1508%26doi%3D10.1021%2Fjm00062a027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozowich, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzer, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate</span>. <i>Pharm. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1007/0-306-47384-4_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1007%2F0-306-47384-4_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9760685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXmvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=285-312&author=W.+J.+Adamsauthor=P.+A.+Aristoffauthor=R.+K.+Jensenauthor=W.+Morozowichauthor=D.+L.+Romeroauthor=W.+C.+Schinzerauthor=W.+G.+Tarpleyauthor=R.+C.+Thomas&title=Discovery+and+development+of+the+BHAP+nonnucleoside+reverse+transcriptase+inhibitor+delavirdine+mesylate&doi=10.1007%2F0-306-47384-4_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate</span></div><div class="casAuthors">Adams, Wade J.; Aristoff, Paul A.; Jensen, Richard K.; Morozowich, Walter; Romero, Donna L.; Schinzer, William C.; Tarpley, W. Gary; Thomas, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">Integration of Pharmaceutical Discovery and Development</span>),
    <span class="NLM_cas:pages">285-312</span>CODEN:
                <span class="NLM_cas:coden">PHBIEB</span>;
        ISSN:<span class="NLM_cas:issn">1078-0467</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">A review with refs.  Discovery and development of the bis(heteroaryl)piperazine (BHAP) nonnucleoside reverse transcriptase inhibitor, delavirdine mesylate, the drug stability in water, its crystal forms, absorption, distribution, metab., and excretion, single-dose pharmacokinetics, safety toxicokinetics, etc., are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplO9BR_91IY7Vg90H21EOLACvtfcHk0lgZVBvUKiSjeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvFyrtr4%253D&md5=92201e7ef2d580791b6bdf53b84c2a79</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2F0-306-47384-4_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-306-47384-4_13%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26aulast%3DJensen%26aufirst%3DR.%2BK.%26aulast%3DMorozowich%26aufirst%3DW.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DSchinzer%26aufirst%3DW.%2BC.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26atitle%3DDiscovery%2520and%2520development%2520of%2520the%2520BHAP%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520delavirdine%2520mesylate%26jtitle%3DPharm.%2520Biotechnol.%26date%3D1998%26volume%3D11%26spage%3D285%26epage%3D312%26doi%3D10.1007%2F0-306-47384-4_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackland, M. J.</span></span> <span> </span><span class="NLM_article-title">Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">639</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=631-639&issue=7&author=R.+L.+Voormanauthor=S.+M.+Maioauthor=M.+J.+Hauerauthor=P.+E.+Sandersauthor=N.+A.+Payneauthor=M.+J.+Ackland&title=Metabolism+of+delavirdine%2C+a+human+immunodeficiency+virus+type-1+reverse+transcriptase+inhibitor%2C+by+microsomal+cytochrome+P450+in+humans%2C+rats%2C+and+other+species%3A+probable+involvement+of+CYP2D6+and+CYP3A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DMaio%26aufirst%3DS.%2BM.%26aulast%3DHauer%26aufirst%3DM.%2BJ.%26aulast%3DSanders%26aufirst%3DP.%2BE.%26aulast%3DPayne%26aufirst%3DN.%2BA.%26aulast%3DAckland%26aufirst%3DM.%2BJ.%26atitle%3DMetabolism%2520of%2520delavirdine%252C%2520a%2520human%2520immunodeficiency%2520virus%2520type-1%2520reverse%2520transcriptase%2520inhibitor%252C%2520by%2520microsomal%2520cytochrome%2520P450%2520in%2520humans%252C%2520rats%252C%2520and%2520other%2520species%253A%2520probable%2520involvement%2520of%2520CYP2D6%2520and%2520CYP3A%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26issue%3D7%26spage%3D631%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeplinger, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>287</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9765359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXmvVWjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1998&pages=381-388&issue=1&author=R.+L.+Voormanauthor=S.+M.+Maioauthor=N.+A.+Payneauthor=Z.+Zhaoauthor=K.+A.+Koeplingerauthor=X.+Wang&title=Microsomal+metabolism+of+delavirdine%3A+evidence+for+mechanism-based+inactivation+of+human+cytochrome+P450+3A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A</span></div><div class="casAuthors">Voorman, Richard L.; Maio, Stephen M.; Payne, N. Ann; Zhao, Zhiyang; Koeplinger, Kenneth A.; Wang, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Administration of delavirdine, an HIV-1 reverse transcriptase inhibitor, to rats or monkeys resulted in apparent loss of hepatic microsomal CYP3A and delavirdine desalkylation activity.  Human CYP3A catalyzes the formation of desalkyl delavirdine and 6'-hydroxy delavirdine, an unstable metabolite, while CYP2D6 catalyzes only desalkyl delavirdine.  CYP2D6 catalyzed desalkyl delavirdine formation was linear with time (up to 30 min) but when catalyzed by cDNA expressed CYP3A4 or human liver microsomes the reaction rate declined progressively with time.  Coincubation with triazolam showed that delavirdine caused a time- and NADPH-dependent loss of CYP3A4 activity in human liver microsomes as measured by triazolam 1'-hydroxylation.  The catalytic activity loss was saturable and was characterized by a Ki of 21.6 ± 8.9 μM and a kinact of 0.59 ± 0.08 min-1.  An apparent partition ratio of 41 was detd. with cDNA expressed CYP3A4, based on the substrate depletion method.  Incubation of [14C]delavirdine with microsomes from several species resulted in irreversible assocn. with an approx. 50 kDa protein, as demonstrated by SDS-PAGE/autoradiog.  Binding to the protein was NADPH dependent, glutathione insensitive, proportional to the level of CYP3A expression and was inhibited by ketoconazole, a specific CYP3A inhibitor.  NADPH-dependent irreversible binding to human and rat total microsomal protein was demonstrated following exhaustive extn. of microsomal protein.  Binding was decreased in the presence of glutathione and appeared to be related to expression level of CYP3A.  These results suggest that delavirdine can inactivate CYP3A and has the potential to slow the metab. of coadministered CYP3A substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVcNMcMAupVrVg90H21EOLACvtfcHk0lgZVBvUKiSjeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvVWjsrw%253D&md5=983063cb9537f05935b728d0add5246e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DMaio%26aufirst%3DS.%2BM.%26aulast%3DPayne%26aufirst%3DN.%2BA.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DKoeplinger%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DMicrosomal%2520metabolism%2520of%2520delavirdine%253A%2520evidence%2520for%2520mechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P450%25203A%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D287%26issue%3D1%26spage%3D381%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3984</span>– <span class="NLM_lpage">3989</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.8.3984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.94.8.3984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9108091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=3984-3989&issue=8&author=R.+M.+Esnoufauthor=J.+Renauthor=A.+L.+Hopkinsauthor=C.+K.+Rossauthor=E.+Y.+Jonesauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Unique+features+in+the+structure+of+the+complex+between+HIV-1+reverse+transcriptase+and+the+bis%28heteroaryl%29piperazine+%28BHAP%29+U-90152+explain+resistance+mutations+for+this+nonnucleoside+inhibitor&doi=10.1073%2Fpnas.94.8.3984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span></div><div class="casAuthors">Esnouf, Robert M.; Ren, Jingshan; Hopkins, Andrew L.; Ross, Carl K.; Jones, E. Yvonne; Stammers, David K.; Stuart, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3984-3989</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The viral reverse transcriptase (RT) provides an attractive target in the search for anti-HIV therapies.  The nonnucleoside inhibitors (NNIs) are a diverse set of compds. (usually HIV-1 specific) that function by distorting the polymerase active site upon binding in a nearby pocket.  Despite being potent and of generally low toxicity, their clin. use has been limited by rapid selection for resistant viral populations.  The 2.65-Å resoln. structure of the complex between HIV-1 RT and the bis(heteroaryl)piperazine (BHAP) NNI, 1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl-ethylamino)pyridinyl] piperazine (U-90152), reveals the inhibitor conformation and bound water mols.  The bulky U-90152 mol. occupies the same pocket as other NNIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236.  These interactions rationalize obsd. resistance mutations, notably Pro-236-Leu, which occurs characteristically for BHAPs.  When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225-226 and 105-106, giving the first clear evidence of the entry mode for NNIs.  The structure allows prediction of binding modes for related inhibitors [(altrylamino)piperidine-BHAPs] and suggests changes to U-90152, such as the addn. of a 6 amino group to the pyridine ring, which may make binding more resilient to mutations in the RT.  The observation of novel hydrogen bonding to the protein main chain may provide lessons for the improvement of quite different inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQuIdPkm-oLVg90H21EOLACvtfcHk0lhRBU2ziRP0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D&md5=d9027e0d3dc8ad612fb84d9e98b7f30e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.8.3984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.8.3984%26sid%3Dliteratum%253Aachs%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRoss%26aufirst%3DC.%2BK.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DUnique%2520features%2520in%2520the%2520structure%2520of%2520the%2520complex%2520between%2520HIV-1%2520reverse%2520transcriptase%2520and%2520the%2520bis%2528heteroaryl%2529piperazine%2520%2528BHAP%2529%2520U-90152%2520explain%2520resistance%2520mutations%2520for%2520this%2520nonnucleoside%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26issue%3D8%26spage%3D3984%26epage%3D3989%26doi%3D10.1073%2Fpnas.94.8.3984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopta, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmsted, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">5267</span>– <span class="NLM_lpage">5275</span>, <span class="refDoi"> DOI: 10.1021/jm960269m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960269m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=5267-5275&issue=26&author=M.+J.+Geninauthor=T.+J.+Poelauthor=Y.+Yagiauthor=C.+Bilesauthor=I.+Althausauthor=B.+J.+Keiserauthor=L.+A.+Koptaauthor=J.+M.+Friisauthor=F.+Reusserauthor=W.+J.+Adamsauthor=R.+A.+Olmstedauthor=R.+L.+Voormanauthor=R.+C.+Thomasauthor=D.+L.+Romero&title=Synthesis+and+bioactivity+of+novel+bis%28heteroaryl%29piperazine+%28BHAP%29+reverse+transcriptase+inhibitors%3A+structure-activity+relationships+and+increased+metabolic+stability+of+novel+substituted+pyridine+analogs&doi=10.1021%2Fjm960269m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm960269m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960269m%26sid%3Dliteratum%253Aachs%26aulast%3DGenin%26aufirst%3DM.%2BJ.%26aulast%3DPoel%26aufirst%3DT.%2BJ.%26aulast%3DYagi%26aufirst%3DY.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DAlthaus%26aufirst%3DI.%26aulast%3DKeiser%26aufirst%3DB.%2BJ.%26aulast%3DKopta%26aufirst%3DL.%2BA.%26aulast%3DFriis%26aufirst%3DJ.%2BM.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DOlmsted%26aufirst%3DR.%2BA.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DSynthesis%2520and%2520bioactivity%2520of%2520novel%2520bis%2528heteroaryl%2529piperazine%2520%2528BHAP%2529%2520reverse%2520transcriptase%2520inhibitors%253A%2520structure-activity%2520relationships%2520and%2520increased%2520metabolic%2520stability%2520of%2520novel%2520substituted%2520pyridine%2520analogs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D26%26spage%3D5267%26epage%3D5275%26doi%3D10.1021%2Fjm960269m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meehan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden-Wiltse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischl, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimuth, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Para, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichman, R. C.</span></span> <span> </span><span class="NLM_article-title">Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">794</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.3.794-797.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.44.3.794-797.2000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=794-797&issue=3&author=L.+M.+Demeterauthor=R.+W.+Shaferauthor=P.+M.+Meehanauthor=J.+Holden-Wiltseauthor=M.+A.+Fischlauthor=W.+W.+Freimuthauthor=M.+F.+Paraauthor=R.+C.+Reichman&title=Delavirdine+susceptibilities+and+associated+reverse+transcriptase+mutations+in+human+immunodeficiency+virus+type+1+isolates+from+patients+in+a+phase+I%2FII+trial+of+delavirdine+monotherapy+%28ACTG+260%29&doi=10.1128%2FAAC.44.3.794-797.2000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.3.794-797.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.3.794-797.2000%26sid%3Dliteratum%253Aachs%26aulast%3DDemeter%26aufirst%3DL.%2BM.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DMeehan%26aufirst%3DP.%2BM.%26aulast%3DHolden-Wiltse%26aufirst%3DJ.%26aulast%3DFischl%26aufirst%3DM.%2BA.%26aulast%3DFreimuth%26aufirst%3DW.%2BW.%26aulast%3DPara%26aufirst%3DM.%2BF.%26aulast%3DReichman%26aufirst%3DR.%2BC.%26atitle%3DDelavirdine%2520susceptibilities%2520and%2520associated%2520reverse%2520transcriptase%2520mutations%2520in%2520human%2520immunodeficiency%2520virus%2520type%25201%2520isolates%2520from%2520patients%2520in%2520a%2520phase%2520I%252FII%2520trial%2520of%2520delavirdine%2520monotherapy%2520%2528ACTG%2520260%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26issue%3D3%26spage%3D794%26epage%3D797%26doi%3D10.1128%2FAAC.44.3.794-797.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerondelis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniappan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambara, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, L. M.</span></span> <span> </span><span class="NLM_article-title">The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">5803</span>– <span class="NLM_lpage">5813</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10364332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFyktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1999&pages=5803-5813&issue=7&author=P.+Gerondelisauthor=R.+H.+Archerauthor=C.+Palaniappanauthor=R.+C.+Reichmanauthor=P.+J.+Fayauthor=R.+A.+Bambaraauthor=L.+M.+Demeter&title=The+P236L+delavirdine-resistant+human+immunodeficiency+virus+type+1+mutant+is+replication+defective+and+demonstrates+alterations+in+both+RNA+5%E2%80%B2-end-+and+DNA+3%E2%80%B2-end-directed+RNase+H+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities</span></div><div class="casAuthors">Gerondelis, Peter; Archer, Richard H.; Palaniappan, Chockalingam; Reichman, Richard C.; Fay, Philip J.; Bambara, Robert A.; Demeter, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5803-5813</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) delavirdine (DLV) selects in vitro for the human immunodeficiency virus type 1 (HIV-1) RT mutation P236L, which confers high-level resistance to DLV but not other NNRTIs.  Unexpectedly, P236L has developed infrequently in HIV-1 isolates obtained from patients receiving DLV; K103N is the predominant resistance mutation obsd. in that setting.  We characterized the replication fitness of viruses derived from pNL4-3 contg. P236L or K103N in both H9 and primary human peripheral blood mononuclear cell cultures infected in parallel with the two mutants.  In the absence of DLV, p24 prodn. by wild-type virus occurred more rapidly and to higher levels than with either mutant; P236L consistently demonstrated a two- to threefold decrease in p24 relative to K103N.  At low levels of DLV, growth of wild-type virus was severely inhibited, and K103N replicated two- to threefold more efficiently than P236L.  At high concns. of DLV, P236L replication and K103N replication were both inhibited.  Recombinant RTs contg. K103N or P236L were analyzed for DNA polymn. on heteropolymeric RNA templates and RNase H degrdn. of RNA-DNA hybrids.  Neither mutant demonstrated defects in polymn.  K103N demonstrated normal RNA 5'-end-directed RNase H cleavage and slowed DNA 3'-end-directed RNase H cleavage compared to wild-type RT.  P236L demonstrated slowing of both DNA 3'-end- and RNA 5'-end-directed RNase H cleavage, consistent with its reduced replication efficiency relative to K103N.  These data suggest that NNRTI resistance mutations can lead to redns. in the efficiency of RNase H cleavage, which may contribute to a redn. in the replication fitness of HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCEI3Ul0ZvFLVg90H21EOLACvtfcHk0lhRBU2ziRP0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFyktrg%253D&md5=d5590756f7d2cd380830b836a02b743e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerondelis%26aufirst%3DP.%26aulast%3DArcher%26aufirst%3DR.%2BH.%26aulast%3DPalaniappan%26aufirst%3DC.%26aulast%3DReichman%26aufirst%3DR.%2BC.%26aulast%3DFay%26aufirst%3DP.%2BJ.%26aulast%3DBambara%26aufirst%3DR.%2BA.%26aulast%3DDemeter%26aufirst%3DL.%2BM.%26atitle%3DThe%2520P236L%2520delavirdine-resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%2520mutant%2520is%2520replication%2520defective%2520and%2520demonstrates%2520alterations%2520in%2520both%2520RNA%25205%25E2%2580%25B2-end-%2520and%2520DNA%25203%25E2%2580%25B2-end-directed%2520RNase%2520H%2520activities%26jtitle%3DJ.%2520Virol.%26date%3D1999%26volume%3D73%26issue%3D7%26spage%3D5803%26epage%3D5813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavash, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenstein, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2550</span>– <span class="NLM_lpage">2560</span>, <span class="refDoi"> DOI: 10.1021/jm030558s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030558s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisl2it70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2550-2560&issue=10&author=K.+Dasauthor=A.+D.+Clarkauthor=P.+J.+Lewiauthor=J.+Heeresauthor=M.+R.+De+Jongeauthor=L.+M.+Koymansauthor=H.+M.+Vinkersauthor=F.+Daeyaertauthor=D.+W.+Ludoviciauthor=M.+J.+Kuklaauthor=B.+De+Corteauthor=R.+W.+Kavashauthor=C.+Y.+Hoauthor=H.+Yeauthor=M.+A.+Lichtensteinauthor=K.+Andriesauthor=R.+Pauwelsauthor=M.+P.+De+Bethuneauthor=P.+L.+Boyerauthor=P.+Clarkauthor=S.+H.+Hughesauthor=P.+A.+Janssenauthor=E.+Arnold&title=Roles+of+conformational+and+positional+adaptability+in+structure-based+design+of+TMC125-R165335+%28etravirine%29+and+related+non-nucleoside+reverse+transcriptase+inhibitors+that+are+highly+potent+and+effective+against+wild-type+and+drug-resistant+HIV-1+variants&doi=10.1021%2Fjm030558s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants</span></div><div class="casAuthors">Das, Kalyan; Clark, Arthur D., Jr.; Lewi, Paul J.; Heeres, Jan; De Jonge, Marc R.; Koymans, Lucien M. H.; Vinkers, H. Maarten; Daeyaert, Frederik; Ludovici, Donald W.; Kukla, Michael J.; De Corte, Bart; Kavash, Robert W.; Ho, Chih Y.; Ye, Hong; Lichtenstein, Mark. A.; Andries, Koen; Pauwels, Rudi; De Bethune, Marie-Pierre; Boyer, Paul L.; Clark, Patrick; Hughes, Stephen H.; Janssen, Paul A. J.; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2550-2560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anti-AIDS drug candidate and non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125-R165335 (etravirine) caused an initial drop in viral load similar to that obsd. with a five-drug combination in naive patients and retains potency in patients infected with NNRTI-resistant HIV-1 variants.  TMC125-R165335 and related anti-AIDS drug candidates can bind the enzyme RT in multiple conformations and thereby escape the effects of drug-resistance mutations.  Structural studies showed that this inhibitor and other diarylpyrimidine (DAPY) analogs can adapt to changes in the NNRTI-binding pocket in several ways: (1) DAPY analogs can bind in at least two conformationally distinct modes; (2) within a given binding mode, torsional flexibility ("wiggling") of DAPY analogs permits access to numerous conformational variants; and (3) the compact design of the DAPY analogs permits significant repositioning and reorientation (translation and rotation) within the pocket ("jiggling").  Such adaptations appear to be crit. for potency against wild-type and a wide range of drug-resistant mutant HIV-1 RTs.  Exploitation of favorable components of inhibitor conformational flexibility (such as torsional flexibility about strategically located chem. bonds) can be a powerful drug design concept, esp. for designing drugs that will be effective against rapidly mutating targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNFqXwggOSMLVg90H21EOLACvtfcHk0ljbwnUG9ymm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisl2it70%253D&md5=56c2fce83bead1990e138ee7486a373d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm030558s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030558s%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3DVinkers%26aufirst%3DH.%2BM.%26aulast%3DDaeyaert%26aufirst%3DF.%26aulast%3DLudovici%26aufirst%3DD.%2BW.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BCorte%26aufirst%3DB.%26aulast%3DKavash%26aufirst%3DR.%2BW.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DLichtenstein%26aufirst%3DM.%2BA.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DDe%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DClark%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DRoles%2520of%2520conformational%2520and%2520positional%2520adaptability%2520in%2520structure-based%2520design%2520of%2520TMC125-R165335%2520%2528etravirine%2529%2520and%2520related%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520that%2520are%2520highly%2520potent%2520and%2520effective%2520against%2520wild-type%2520and%2520drug-resistant%2520HIV-1%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D10%26spage%3D2550%26epage%3D2560%26doi%3D10.1021%2Fjm030558s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlmann, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storch, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lie, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcomb, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arens, M. Q.</span></span> <span> </span><span class="NLM_article-title">Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine</span>. <i>J. Clin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.jcv.2004.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.jcv.2004.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15465412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFCksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2004&pages=198-203&issue=3&author=E.+J.+Uhlmannauthor=P.+Tebasauthor=G.+A.+Storchauthor=W.+G.+Powderlyauthor=Y.+S.+Lieauthor=J.+M.+Whitcombauthor=N.+S.+Hellmannauthor=M.+Q.+Arens&title=Effects+of+the+G190A+substitution+of+HIV+reverse+transcriptase+on+phenotypic+susceptibility+of+patient+isolates+to+delavirdine&doi=10.1016%2Fj.jcv.2004.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine</span></div><div class="casAuthors">Uhlmann, Erik J.; Tebas, Pablo; Storch, Gregory A.; Powderly, William G.; Lie, Yolanda S.; Whitcomb, Jeannette M.; Hellmann, Nicholas S.; Arens, Max Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">JCVIFB</span>;
        ISSN:<span class="NLM_cas:issn">1386-6532</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: Cross resistance is common among the non-nucleoside reverse transcriptase inhibitors (NNRTIs).  G190A appears in 5-15% of the patients treated with nevirapine or efavirenz who develop clin. resistance.  Objectives: In this study we investigated the effect of G190A and other NNRTI substitutions on the phenotypic susceptibility to this class of drugs.  Study design: We identified 15 individuals, who after treatment with NNRTIs (nevirapine or efavirenz; median exposure of 20 mo), developed isolated G190A, G190A in combination with K103N, or K103N alone.  Phenotypic and genotypic analyses of stored plasma specimens were performed before and after the mutations occurred to assess NNRTI susceptibility.  Results: All isolates that developed only G190A substitution became less susceptible to nevirapine (median: 125-fold) and efavirenz (median: 10-fold) but were 2.5-fold more sensitive to delavirdine (Wilcoxon P=0.06).  In the group with only K103N substitution, acquisition of resistance to all NNRTIs was obsd.  In the group with the double substitutions, G190A and K103N, delavirdine susceptibility decreased 13-fold, while resistance to nevirapine and efavirenz decreased by 239- and 154-folds, resp. (Kruskal-Wallis H P=0.009).  Conclusions: The data suggest that the presence of a G190A substitution attenuates the phenotypic resistance assocd. with a K103N substitution, although resistance is still present.  The in vivo significance of the increased phenotypic susceptibility to delavirdine is not known but could be evaluated in a clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo3wqcU6Uc-bVg90H21EOLACvtfcHk0ljbwnUG9ymm8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFCksLs%253D&md5=b1bef723a89d73d3d78c49f17fc5d40e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jcv.2004.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcv.2004.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DUhlmann%26aufirst%3DE.%2BJ.%26aulast%3DTebas%26aufirst%3DP.%26aulast%3DStorch%26aufirst%3DG.%2BA.%26aulast%3DPowderly%26aufirst%3DW.%2BG.%26aulast%3DLie%26aufirst%3DY.%2BS.%26aulast%3DWhitcomb%26aufirst%3DJ.%2BM.%26aulast%3DHellmann%26aufirst%3DN.%2BS.%26aulast%3DArens%26aufirst%3DM.%2BQ.%26atitle%3DEffects%2520of%2520the%2520G190A%2520substitution%2520of%2520HIV%2520reverse%2520transcriptase%2520on%2520phenotypic%2520susceptibility%2520of%2520patient%2520isolates%2520to%2520delavirdine%26jtitle%3DJ.%2520Clin.%2520Virol.%26date%3D2004%26volume%3D31%26issue%3D3%26spage%3D198%26epage%3D203%26doi%3D10.1016%2Fj.jcv.2004.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Delavirdine: a review of its use in HIV infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1444</span>, <span class="refDoi"> DOI: 10.2165/00003495-200060060-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F00003495-200060060-00013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1411-1444&issue=6&author=L.+J.+Scottauthor=C.+M.+Perry&title=Delavirdine%3A+a+review+of+its+use+in+HIV+infection&doi=10.2165%2F00003495-200060060-00013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2165%2F00003495-200060060-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200060060-00013%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DDelavirdine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520HIV%2520infection%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26issue%3D6%26spage%3D1411%26epage%3D1444%26doi%3D10.2165%2F00003495-200060060-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. T.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaitt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimuth, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falloon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wathen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daenzer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. C.</span></span> <span> </span><span class="NLM_article-title">Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1657</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.7.1657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.40.7.1657" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=1657-1664&issue=7&author=R.+T.+Daveyauthor=D.+G.+Chaittauthor=G.+F.+Reedauthor=W.+W.+Freimuthauthor=B.+R.+Herpinauthor=J.+A.+Metcalfauthor=P.+S.+Eastmanauthor=J.+Falloonauthor=J.+A.+Kovacsauthor=M.+A.+Polisauthor=R.+E.+Walkerauthor=H.+Masurauthor=J.+Boyleauthor=S.+Colemanauthor=S.+R.+Coxauthor=L.+Wathenauthor=C.+L.+Daenzerauthor=H.+C.+Lane&title=Randomized%2C+controlled+phase+I%2FII%2C+trial+of+combination+therapy+with+delavirdine+%28U-90152S%29+and+conventional+nucleosides+in+human+immunodeficiency+virus+type+1-infected+patients&doi=10.1128%2FAAC.40.7.1657"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.7.1657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.7.1657%26sid%3Dliteratum%253Aachs%26aulast%3DDavey%26aufirst%3DR.%2BT.%26aulast%3DChaitt%26aufirst%3DD.%2BG.%26aulast%3DReed%26aufirst%3DG.%2BF.%26aulast%3DFreimuth%26aufirst%3DW.%2BW.%26aulast%3DHerpin%26aufirst%3DB.%2BR.%26aulast%3DMetcalf%26aufirst%3DJ.%2BA.%26aulast%3DEastman%26aufirst%3DP.%2BS.%26aulast%3DFalloon%26aufirst%3DJ.%26aulast%3DKovacs%26aufirst%3DJ.%2BA.%26aulast%3DPolis%26aufirst%3DM.%2BA.%26aulast%3DWalker%26aufirst%3DR.%2BE.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DBoyle%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DS.%2BR.%26aulast%3DWathen%26aufirst%3DL.%26aulast%3DDaenzer%26aufirst%3DC.%2BL.%26aulast%3DLane%26aufirst%3DH.%2BC.%26atitle%3DRandomized%252C%2520controlled%2520phase%2520I%252FII%252C%2520trial%2520of%2520combination%2520therapy%2520with%2520delavirdine%2520%2528U-90152S%2529%2520and%2520conventional%2520nucleosides%2520in%2520human%2520immunodeficiency%2520virus%2520type%25201-infected%2520patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26issue%3D7%26spage%3D1657%26epage%3D1664%26doi%3D10.1128%2FAAC.40.7.1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Been-Tiktak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun-Vezinet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staszewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colebunders, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borleffs, J. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/S0924-8579(98)00082-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0924-8579%2898%2900082-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10075273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=13-21&issue=1&author=A.+M.+Been-Tiktakauthor=C.+A.+Boucherauthor=F.+Brun-Vezinetauthor=V.+Jolyauthor=J.+W.+Mulderauthor=J.+Jostauthor=D.+A.+Cooperauthor=M.+Moroniauthor=J.+M.+Gatellauthor=S.+Staszewskiauthor=R.+Colebundersauthor=G.+J.+Stewartauthor=D.+A.+Hawkinsauthor=M.+A.+Johnsonauthor=J.+M.+Parkinauthor=D.+H.+Kennedyauthor=J.+F.+Hoyauthor=J.+C.+Borleffs&title=Efficacy+and+safety+of+combination+therapy+with+delavirdine+and+zidovudine%3A+a+European%2FAustralian+phase+II+trial&doi=10.1016%2FS0924-8579%2898%2900082-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial</span></div><div class="casAuthors">Been-Tiktak, Anne M. M.; Boucher, Charles A. B.; Brun-Vezinet, Francoise; Joly, Veronique; Mulder, Jan W.; Jost, J.; Cooper, David A.; Moroni, Mauro; Gatell, Jose M.; Staszewski, Schlomo; Colebunders, Robert; Stewart, Graeme J.; Hawkins, David A.; Johnson, Margaret A.; Parkin, Jacqueline M.; Kennedy, Dermot H.; Hoy, Jennifer F.; Borleffs, Jan C. C.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-21</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">This study investigated the safety and antiviral effect of 3 delavirdine dose regimens or placebo in combination with zidovudine in patients who were already taking zidovudine.  Eighty-nine symptomatic HIV-1 seropos. individuals with CD4+ cell counts between 50 and 350 cells/μL were included. The influence of combination therapy on viral susceptibility to both zidovudine and delavirdine was investigated.  Death or the occurrence, or recurrence, of an AIDS-defining illness was considered as a clin. endpoint.  The addn. of delavirdine to the antiretroviral treatment regimen resulted in a significant, but transient, redn. in virus load, as detd. by quant. RNA measurements.  CD4+ cell count did not change significantly.  Susceptibility to zidovudine remained unchanged after 12 wk of combination therapy, whereas 70% of the patients demonstrated a substantial decrease in sensitivity to delavirdine.  Two patients suffered from an AIDS-defining disease during the study.  No deaths occurred.  Generally, the drug appeared to be safe.  Skin rash was the most frequently obsd. event (52%).  In most patients the rash either resolved spontaneously or was treated successfully with a short course of antihistamines.  The definite place of delavirdine in the management of HIV disease, in particular when given in combination with other antiretroviral agents, remains to be further explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUnITOBIUTbVg90H21EOLACvtfcHk0ljDFNOlZq9ocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFSltb8%253D&md5=ddd83610ba03a6d38ceecd06627c948a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS0924-8579%2898%2900082-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-8579%252898%252900082-X%26sid%3Dliteratum%253Aachs%26aulast%3DBeen-Tiktak%26aufirst%3DA.%2BM.%26aulast%3DBoucher%26aufirst%3DC.%2BA.%26aulast%3DBrun-Vezinet%26aufirst%3DF.%26aulast%3DJoly%26aufirst%3DV.%26aulast%3DMulder%26aufirst%3DJ.%2BW.%26aulast%3DJost%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DD.%2BA.%26aulast%3DMoroni%26aufirst%3DM.%26aulast%3DGatell%26aufirst%3DJ.%2BM.%26aulast%3DStaszewski%26aufirst%3DS.%26aulast%3DColebunders%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DHawkins%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DParkin%26aufirst%3DJ.%2BM.%26aulast%3DKennedy%26aufirst%3DD.%2BH.%26aulast%3DHoy%26aufirst%3DJ.%2BF.%26aulast%3DBorleffs%26aufirst%3DJ.%2BC.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520combination%2520therapy%2520with%2520delavirdine%2520and%2520zidovudine%253A%2520a%2520European%252FAustralian%2520phase%2520II%2520trial%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D1999%26volume%3D11%26issue%3D1%26spage%3D13%26epage%3D21%26doi%3D10.1016%2FS0924-8579%2898%2900082-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimuth, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischl, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1097/00126334-199908010-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-199908010-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10428106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtl2ktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=281-292&issue=4&author=G.+H.+Friedlandauthor=R.+Pollardauthor=B.+Griffithauthor=M.+Hughesauthor=G.+Morseauthor=R.+Bassettauthor=W.+Freimuthauthor=L.+Demeterauthor=E.+Connickauthor=T.+Nevinauthor=M.+Hirschauthor=M.+Fischl&title=Efficacy+and+safety+of+delavirdine+mesylate+with+zidovudine+and+didanosine+compared+with+two-drug+combinations+of+these+agents+in+persons+with+HIV+disease+with+CD4+counts+of+100+to+500+cells%2Fmm3+%28ACTG+261%29.+ACTG+261+Team&doi=10.1097%2F00126334-199908010-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)</span></div><div class="casAuthors">Friedland, Gerald H.; Pollard, Richard; Griffith, Brigitte; Hughes, Michael; Morse, Gene; Bassett, Roland; Freimuth, William; Demeter, Lisa; Connick, Elizabeth; Nevin, Thomas; Hirsch, Martin</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">281-292</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">To evaluate the antiretroviral activity of delavirdine mesylate, a non-nucleoside reverse transcriptase inhibitor of HIV-1, we performed a phase II, randomized, double-blind, multicenter trial comparing the three-drug combination of delavirdine with zidovudine and didanosine to two-drug combinations of these drugs.  Patients with CD4 cell counts between 100 and 500 cells/mm3 without prior or <6 mo of monotherapy with zidovudine or didanosine were randomized to one of four arms and obsd. on a follow-up basis for 48 wk.  In total, 544 patients were evaluated.  In those assigned to the three-drug regimen, mean short-term (weeks 4-12) and long-term (weeks 40-48) change in CD4 cells from baseline were 49.3 ± 8.1 and 65.4 ± 13.4 cells/mm3, resp.; mean short-term and long-term HIV-1 RNA changes from baseline were -1.13 log10 ± 0.12 and -0.73 ± 0.12 copies/mL, resp.  These responses in CD4 cell counts and HIV-1 RNA levels were better in comparisons with each of the two-drug arms at all study points; however, differences were not consistently significant.  Gastrointestinal side effects were experienced by 33% of patients (178 of 544), and 30% (121 of 407) receiving delavirdine experienced rash, only one case of which was severe.  In this study, therapy with delavirdine + zidovudine + didanosine was safe and showed modest, but not always significant, antiviral activity and CD4 cell count benefit compared with two-drug regimens with these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtB-x7g_IH17Vg90H21EOLACvtfcHk0lgqg6gDoQhRcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtl2ktLs%253D&md5=18f178c4c1119c0411d3e1cd04b09259</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1097%2F00126334-199908010-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-199908010-00005%26sid%3Dliteratum%253Aachs%26aulast%3DFriedland%26aufirst%3DG.%2BH.%26aulast%3DPollard%26aufirst%3DR.%26aulast%3DGriffith%26aufirst%3DB.%26aulast%3DHughes%26aufirst%3DM.%26aulast%3DMorse%26aufirst%3DG.%26aulast%3DBassett%26aufirst%3DR.%26aulast%3DFreimuth%26aufirst%3DW.%26aulast%3DDemeter%26aufirst%3DL.%26aulast%3DConnick%26aufirst%3DE.%26aulast%3DNevin%26aufirst%3DT.%26aulast%3DHirsch%26aufirst%3DM.%26aulast%3DFischl%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520delavirdine%2520mesylate%2520with%2520zidovudine%2520and%2520didanosine%2520compared%2520with%2520two-drug%2520combinations%2520of%2520these%2520agents%2520in%2520persons%2520with%2520HIV%2520disease%2520with%2520CD4%2520counts%2520of%2520100%2520to%2520500%2520cells%252Fmm3%2520%2528ACTG%2520261%2529.%2520ACTG%2520261%2520Team%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D1999%26volume%3D21%26issue%3D4%26spage%3D281%26epage%3D292%26doi%3D10.1097%2F00126334-199908010-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span> <i>Current and Resolved Drug Shortages and Discontinuations
Reported
to FDA</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Delavirdine%20Mesylate%20(RESCRIPTOR)%20Tablets&amp;st=d" class="extLink">https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Delavirdine%20Mesylate%20(RESCRIPTOR)%20Tablets&st=d</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Current+and+Resolved+Drug+Shortages+and+Discontinuations%0AReported%0Ato+FDA%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fdrugshortages%2Fdsp_ActiveIngredientDetails.cfm%3FAI%3DDelavirdine%2520Mesylate%2520%28RESCRIPTOR%29%2520Tablets%26st%3Dd+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520and%2520Resolved%2520Drug%2520Shortages%2520and%2520Discontinuations%250AReported%250Ato%2520FDA%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt Huffman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korthuis, P. T.</span></span> <span> </span><span class="NLM_article-title">Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span> (<span class="NLM_issue">9546</span>),  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69638-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2806%2969638-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1503-1515&issue=9546&author=R.+Chouauthor=R.+Fuauthor=L.+H.+Hoyt+Huffmanauthor=P.+T.+Korthuis&title=Initial+highly-active+antiretroviral+therapy+with+a+protease+inhibitor+versus+a+non-nucleoside+reverse+transcriptase+inhibitor%3A+discrepancies+between+direct+and+indirect+meta-analyses&doi=10.1016%2FS0140-6736%2806%2969638-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969638-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969638-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DR.%26aulast%3DHoyt%2BHuffman%26aufirst%3DL.%2BH.%26aulast%3DKorthuis%26aufirst%3DP.%2BT.%26atitle%3DInitial%2520highly-active%2520antiretroviral%2520therapy%2520with%2520a%2520protease%2520inhibitor%2520versus%2520a%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%253A%2520discrepancies%2520between%2520direct%2520and%2520indirect%2520meta-analyses%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26issue%3D9546%26spage%3D1503%26epage%3D1515%26doi%3D10.1016%2FS0140-6736%2806%2969638-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenjie, S.</span>; <span class="NLM_string-name">Xuhua, X.</span>; <span class="NLM_string-name">Weiyong, M.</span></span> <span> </span><span class="NLM_article-title">Preparing Method of 1-(5-nitro-1<i>H</i>-indole-2-carbonyl)-4-{3-[(1-methylethyl)amino]-2-pyridine}</span>. China Patent <span class="NLM_patent">CN101016295A</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Wenjie&author=X.+Xuhua&author=M.+Weiyong&title=Preparing+Method+of+1-%285-nitro-1H-indole-2-carbonyl%29-4-%7B3-%5B%281-methylethyl%29amino%5D-2-pyridine%7D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWenjie%26aufirst%3DS.%26atitle%3DPreparing%2520Method%2520of%25201-%25285-nitro-1H-indole-2-carbonyl%2529-4-%257B3-%255B%25281-methylethyl%2529amino%255D-2-pyridine%257D%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ensi, W.</span>; <span class="NLM_string-name">Jing, G.</span>; <span class="NLM_string-name">Shengxiu, N.</span>; <span class="NLM_string-name">Nan, Z.</span>; <span class="NLM_string-name">Liping, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of Delavirdine</span>. China Patent <span class="NLM_patent">CN102675284A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+Ensi&author=G.+Jing&author=N.+Shengxiu&author=Z.+Nan&author=J.+Liping&title=Synthesis+Method+of+Delavirdine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEnsi%26aufirst%3DW.%26atitle%3DSynthesis%2520Method%2520of%2520Delavirdine%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of anti-AIDS Medicine Delavirdine</span>. China Patent <span class="NLM_patent">CN102633778A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=G.+Min&title=Synthesis+Method+of+anti-AIDS+Medicine+Delavirdine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DG.%26atitle%3DSynthesis%2520Method%2520of%2520anti-AIDS%2520Medicine%2520Delavirdine%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britcher, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumma, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span> <span> </span><span class="NLM_article-title">L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2602</span>– <span class="NLM_lpage">2605</span>, <span class="refDoi"> DOI: 10.1128/AAC.39.12.2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.39.12.2602" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1995&pages=2602-2605&issue=12&author=S.+D.+Youngauthor=S.+F.+Britcherauthor=L.+O.+Tranauthor=L.+S.+Payneauthor=W.+C.+Lummaauthor=T.+A.+Lyleauthor=J.+R.+Huffauthor=P.+S.+Andersonauthor=D.+B.+Olsenauthor=S.+S.+Carroll&title=L-743%2C+726+%28DMP-266%29%3A+a+novel%2C+highly+potent+nonnucleoside+inhibitor+of+the+human+immunodeficiency+virus+type+1+reverse+transcriptase&doi=10.1128%2FAAC.39.12.2602"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FAAC.39.12.2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.39.12.2602%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DBritcher%26aufirst%3DS.%2BF.%26aulast%3DTran%26aufirst%3DL.%2BO.%26aulast%3DPayne%26aufirst%3DL.%2BS.%26aulast%3DLumma%26aufirst%3DW.%2BC.%26aulast%3DLyle%26aufirst%3DT.%2BA.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DAnderson%26aufirst%3DP.%2BS.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DL-743%252C%2520726%2520%2528DMP-266%2529%253A%2520a%2520novel%252C%2520highly%2520potent%2520nonnucleoside%2520inhibitor%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520type%25201%2520reverse%2520transcriptase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1995%26volume%3D39%26issue%3D12%26spage%3D2602%26epage%3D2605%26doi%3D10.1128%2FAAC.39.12.2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckheit, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliakas-Boltz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowdon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonucci, T. K.</span></span> <span> </span><span class="NLM_article-title">Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/0166-3542(94)90092-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2F0166-3542%2894%2990092-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1994&pages=43-56&issue=1&author=R.+W.+Buckheitauthor=V.+Fliakas-Boltzauthor=W.+D.+Deckerauthor=J.+L.+Robersonauthor=C.+A.+Pyleauthor=E.+L.+Whiteauthor=B.+J.+Bowdonauthor=J.+B.+McMahonauthor=M.+R.+Boydauthor=J.+P.+Baderauthor=D.+G.+Nickellauthor=H.+Barthauthor=T.+K.+Antonucci&title=Biological+and+biochemical+anti-HIV+activity+of+the+benzothiadiazine+class+of+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1016%2F0166-3542%2894%2990092-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0166-3542%2894%2990092-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-3542%252894%252990092-2%26sid%3Dliteratum%253Aachs%26aulast%3DBuckheit%26aufirst%3DR.%2BW.%26aulast%3DFliakas-Boltz%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DW.%2BD.%26aulast%3DRoberson%26aufirst%3DJ.%2BL.%26aulast%3DPyle%26aufirst%3DC.%2BA.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DBowdon%26aufirst%3DB.%2BJ.%26aulast%3DMcMahon%26aufirst%3DJ.%2BB.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DBader%26aufirst%3DJ.%2BP.%26aulast%3DNickell%26aufirst%3DD.%2BG.%26aulast%3DBarth%26aufirst%3DH.%26aulast%3DAntonucci%26aufirst%3DT.%2BK.%26atitle%3DBiological%2520and%2520biochemical%2520anti-HIV%2520activity%2520of%2520the%2520benzothiadiazine%2520class%2520of%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntiviral%2520Res.%26date%3D1994%26volume%3D25%26issue%3D1%26spage%3D43%26epage%3D56%26doi%3D10.1016%2F0166-3542%2894%2990092-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">E1</span>– <span class="NLM_lpage">E72</span>, <span class="refDoi"> DOI: 10.1002/med.20241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fmed.20241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=21523792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=E1-E72&author=P.+Zhanauthor=X.+Chenauthor=D.+Liauthor=Z.+Fangauthor=E.+De+Clercqauthor=X.+Liu&title=HIV-1+NNRTIs%3A+structural+diversity%2C+pharmacophore+similarity%2C+and+implications+for+drug+design&doi=10.1002%2Fmed.20241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design</span></div><div class="casAuthors">Zhan, Peng; Chen, Xuwang; Li, Dongyue; Fang, Zengjun; De Clercq, Erik; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">E1-E72</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) nowadays represent very potent and most promising anti-AIDS agents that specifically target the HIV-1 reverse transcriptase (RT).  However, the effectiveness of NNRTI drugs can be hampered by rapid emergence of drug-resistant viruses and severe side effects upon long-term use.  Therefore, there is an urgent need to develop novel, highly potent NNRTIs with broad spectrum antiviral activity and improved pharmacokinetic properties, and more efficient strategies that facilitate and shorten the drug discovery process would be extremely beneficial.  Fortunately, the structural diversity of NNRTIs provided a wide space for novel lead discovery, and the pharmacophore similarity of NNRTIs gave valuable hints for lead discovery and optimization.  More importantly, with the continued efforts in the development of computational tools and increased crystallog. information on RT/NNRTI complexes, structure-based approaches using a combination of traditional medicinal chem., structural biol., and computational chem. are being used increasingly in the design of NNRTIs.  First, this review covers two decades of research and development for various NNRTI families based on their chem. scaffolds, and then describes the structural similarity of NNRTIs.  We have attempted to assemble a comprehensive overview of the general approaches in NNRTI lead discovery and optimization reported in the literature during the last decade.  The successful applications of medicinal chem. strategies, crystallog., and computational tools for designing novel NNRTIs are highlighted.  Future directions for research are also outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA7jjFerOFrbVg90H21EOLACvtfcHk0lgvBazra_foxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbo%253D&md5=08cc3f8e0815f70ee052ccda81d75dfb</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fmed.20241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20241%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DHIV-1%2520NNRTIs%253A%2520structural%2520diversity%252C%2520pharmacophore%2520similarity%252C%2520and%2520implications%2520for%2520drug%2520design%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26spage%3DE1%26epage%3DE72%26doi%3D10.1002%2Fmed.20241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britcher, S. F.</span>; <span class="NLM_string-name">Goldman, M. E.</span>; <span class="NLM_string-name">Huff, J. R.</span>; <span class="NLM_string-name">Lumma, W. C.</span>; <span class="NLM_string-name">Lyle, T. A.</span>; <span class="NLM_string-name">Payne, L. S.</span>; <span class="NLM_string-name">Quesada, M. L.</span>; <span class="NLM_string-name">Sanders, W. M.</span>; <span class="NLM_string-name">Tucker, T. J.</span>; <span class="NLM_string-name">Young, S. D.</span></span> <span> </span><span class="NLM_article-title">Quinazoline Derivatives as Inhibitors of HIV Reverse Transcriptase</span>. World Patent <span class="NLM_patent">WO1993004047A1</span>, <span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=S.+F.+Britcher&author=M.+E.+Goldman&author=J.+R.+Huff&author=W.+C.+Lumma&author=T.+A.+Lyle&author=L.+S.+Payne&author=M.+L.+Quesada&author=W.+M.+Sanders&author=T.+J.+Tucker&author=S.+D.+Young&title=Quinazoline+Derivatives+as+Inhibitors+of+HIV+Reverse+Transcriptase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBritcher%26aufirst%3DS.%2BF.%26atitle%3DQuinazoline%2520Derivatives%2520as%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houpis, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volante, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a new generation reverse transcriptase inhibitor via the BCl3/GaCl3-induced condensation of anilines with nitriles (sugasawa reaction)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">6811</span>– <span class="NLM_lpage">6814</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(94)85011-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2F0040-4039%2894%2985011-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=6811-6814&issue=37&author=I.+N.+Houpisauthor=A.+Molinaauthor=A.+W.+Douglasauthor=L.+Xavierauthor=J.+Lynchauthor=R.+P.+Volanteauthor=P.+J.+Reider&title=Synthesis+of+a+new+generation+reverse+transcriptase+inhibitor+via+the+BCl3%2FGaCl3-induced+condensation+of+anilines+with+nitriles+%28sugasawa+reaction%29&doi=10.1016%2F0040-4039%2894%2985011-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2894%2985011-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252894%252985011-9%26sid%3Dliteratum%253Aachs%26aulast%3DHoupis%26aufirst%3DI.%2BN.%26aulast%3DMolina%26aufirst%3DA.%26aulast%3DDouglas%26aufirst%3DA.%2BW.%26aulast%3DXavier%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DJ.%26aulast%3DVolante%26aufirst%3DR.%2BP.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26atitle%3DSynthesis%2520of%2520a%2520new%2520generation%2520reverse%2520transcriptase%2520inhibitor%2520via%2520the%2520BCl3%252FGaCl3-induced%2520condensation%2520of%2520anilines%2520with%2520nitriles%2520%2528sugasawa%2520reaction%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D1994%26volume%3D35%26issue%3D37%26spage%3D6811%26epage%3D6814%26doi%3D10.1016%2F0040-4039%2894%2985011-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiscount, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britcher, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumma, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 Reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2437</span>– <span class="NLM_lpage">2444</span>, <span class="refDoi"> DOI: 10.1021/jm00041a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00041a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2437-2444&issue=15&author=T.+J.+Tuckerauthor=T.+A.+Lyleauthor=C.+M.+Wiscountauthor=S.+F.+Britcherauthor=S.+D.+Youngauthor=W.+M.+Sandersauthor=W.+C.+Lummaauthor=M.+E.+Goldmanauthor=J.+A.+O%E2%80%99Brien&title=Synthesis+of+a+series+of+4-%28Arylethynyl%29-6-chloro-4-cyclopropyl-3%2C4-dihydroquinazolin-2%281H%29-ones+as+novel+non-nucleoside+HIV-1+Reverse+transcriptase+inhibitors&doi=10.1021%2Fjm00041a023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm00041a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00041a023%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DLyle%26aufirst%3DT.%2BA.%26aulast%3DWiscount%26aufirst%3DC.%2BM.%26aulast%3DBritcher%26aufirst%3DS.%2BF.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DSanders%26aufirst%3DW.%2BM.%26aulast%3DLumma%26aufirst%3DW.%2BC.%26aulast%3DGoldman%26aufirst%3DM.%2BE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520a%2520series%2520of%25204-%2528Arylethynyl%2529-6-chloro-4-cyclopropyl-3%252C4-dihydroquinazolin-2%25281H%2529-ones%2520as%2520novel%2520non-nucleoside%2520HIV-1%2520Reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D15%26spage%3D2437%26epage%3D2444%26doi%3D10.1021%2Fjm00041a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCamp, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span> <span> </span><span class="NLM_article-title">Lithium alkoxides of cinchona alkaloids as chiral controllers for enantioselective acetylide addition to cyclic N-acyl ketimines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.1021/jo00111a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00111a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=1590-1594&issue=6&author=M.+A.+Huffmanauthor=N.+Yasudaauthor=A.+E.+DeCampauthor=E.+J.+J.+Grabowski&title=Lithium+alkoxides+of+cinchona+alkaloids+as+chiral+controllers+for+enantioselective+acetylide+addition+to+cyclic+N-acyl+ketimines&doi=10.1021%2Fjo00111a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjo00111a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00111a016%26sid%3Dliteratum%253Aachs%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DDeCamp%26aufirst%3DA.%2BE.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26atitle%3DLithium%2520alkoxides%2520of%2520cinchona%2520alkaloids%2520as%2520chiral%2520controllers%2520for%2520enantioselective%2520acetylide%2520addition%2520to%2520cyclic%2520N-acyl%2520ketimines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26issue%3D6%26spage%3D1590%26epage%3D1594%26doi%3D10.1021%2Fjo00111a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouverneur, V.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1039/B610213C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1039%2FB610213C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18197348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=320-330&issue=2&author=S.+Purserauthor=P.+R.+Mooreauthor=S.+Swallowauthor=V.+Gouverneur&title=Fluorine+in+medicinal+chemistry&doi=10.1039%2FB610213C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Purser, Sophie; Moore, Peter R.; Swallow, Steve; Gouverneur, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">320-330</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  It has become evident that fluorinated compds. have a remarkable record in medicinal chem. and will play a continuing role in providing lead compds. for therapeutic applications.  This tutorial review provides a sampling of renowned fluorinated drugs and their mode of action with a discussion clarifying the role and impact of fluorine substitution on drug potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFKAqJ3UbgGbVg90H21EOLACvtfcHk0ljCDtImUtLNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsw%253D%253D&md5=e6c9e3084e454c44a4ba245b98f7f1d7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1039%2FB610213C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB610213C%26sid%3Dliteratum%253Aachs%26aulast%3DPurser%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DP.%2BR.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DGouverneur%26aufirst%3DV.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26issue%3D2%26spage%3D320%26epage%3D330%26doi%3D10.1039%2FB610213C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boechat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kover, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongertz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeiro, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, M. L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollinger, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-Ones</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.2174/157340607782360326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2174%2F157340607782360326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18045202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSisb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=533-542&issue=6&author=N.+Boechatauthor=W.+B.+Koverauthor=V.+Bongertzauthor=M.+M.+Bastosauthor=N.+C.+Romeiroauthor=M.+L.+G.+Azevedoauthor=W.+Wollinger&title=Design%2C+synthesis+and+pharmacological+evaluation+of+HIV-1+reverse+transcriptase+inhibition+of+new+indolin-2-Ones&doi=10.2174%2F157340607782360326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones</span></div><div class="casAuthors">Boechat, Nubia; Kover, W. Bruce; Bongertz, Vera; Bastos, Monica M.; Romeiro, Nelilma C.; Azevedo, Maria L. G.; Wollinger, Wagner</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">533-542</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The design, synthesis and anti HIV-1 replication inhibition of 3-(cyclopropylethynyl)-3-hydroxy-indolin-2-ones, e.g., I, analogs of efavirenz (Sustiva), are described.  Different substituted isatins were used to generate final products that contain pharmacophoric features for RT inhibition, such as the oxoindole and cyclopropylethynyl groups.  The suitability of the indolin-2-one ring in the planned compds. in replacement to the benzoxazinone ring of efavirenz was proven, since I presented a greater activity than efavirenz against HIV-1 replication and was not significantly cytotoxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcenY7PrTUHrVg90H21EOLACvtfcHk0ljCDtImUtLNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSisb7M&md5=c39eeda2e338305f5b2977d269971bd8</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2174%2F157340607782360326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157340607782360326%26sid%3Dliteratum%253Aachs%26aulast%3DBoechat%26aufirst%3DN.%26aulast%3DKover%26aufirst%3DW.%2BB.%26aulast%3DBongertz%26aufirst%3DV.%26aulast%3DBastos%26aufirst%3DM.%2BM.%26aulast%3DRomeiro%26aufirst%3DN.%2BC.%26aulast%3DAzevedo%26aufirst%3DM.%2BL.%2BG.%26aulast%3DWollinger%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520pharmacological%2520evaluation%2520of%2520HIV-1%2520reverse%2520transcriptase%2520inhibition%2520of%2520new%2520indolin-2-Ones%26jtitle%3DMed.%2520Chem.%26date%3D2007%26volume%3D3%26issue%3D6%26spage%3D533%26epage%3D542%26doi%3D10.2174%2F157340607782360326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogburn, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, Z.</span></span> <span> </span><span class="NLM_article-title">Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1218</span>– <span class="NLM_lpage">1229</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.031393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1124%2Fdmd.109.031393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1218-1229&issue=7&author=E.+T.+Ogburnauthor=D.+R.+Jonesauthor=A.+R.+Mastersauthor=C.+Xuauthor=Y.+Guoauthor=Z.+Desta&title=Efavirenz+primary+and+secondary+metabolism+in+vitro+and+in+vivo%3A+identification+of+novel+metabolic+pathways+and+cytochrome+P450+2A6+as+the+principal+catalyst+of+efavirenz+7-hydroxylation&doi=10.1124%2Fdmd.109.031393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.031393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.031393%26sid%3Dliteratum%253Aachs%26aulast%3DOgburn%26aufirst%3DE.%2BT.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DMasters%26aufirst%3DA.%2BR.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DDesta%26aufirst%3DZ.%26atitle%3DEfavirenz%2520primary%2520and%2520secondary%2520metabolism%2520in%2520vitro%2520and%2520in%2520vivo%253A%2520identification%2520of%2520novel%2520metabolic%2520pathways%2520and%2520cytochrome%2520P450%25202A6%2520as%2520the%2520principal%2520catalyst%2520of%2520efavirenz%25207-hydroxylation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D7%26spage%3D1218%26epage%3D1229%26doi%3D10.1124%2Fdmd.109.031393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flockhart, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, Z.</span></span> <span> </span><span class="NLM_article-title">The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.049601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1124%2Fjpet.103.049601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=12676886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=287-300&author=B.+A.+Wardauthor=J.+C.+Gorskiauthor=D.+R.+Jonesauthor=S.+D.+Hallauthor=D.+A.+Flockhartauthor=Z.+Desta&title=The+cytochrome+P450+2B6+%28CYP2B6%29+is+the+main+catalyst+of+efavirenz+primary+and+secondary+metabolism%3A+implication+for+HIV%2FAIDS+therapy+and+utility+of+efavirenz+as+a+substrate+marker+of+CYP2B6+catalytic+activity&doi=10.1124%2Fjpet.103.049601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity</span></div><div class="casAuthors">Ward, Bryan A.; Gorski, J. Christopher; Jones, David R.; Hall, Stephen D.; Flockhart, David A.; Desta, Zeruesenay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">287-300</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We used human liver microsomes (HLMs) and recombinant cytochromes P 450 (P450s) to identify the routes of efavirenz metab. and the P450s involved.  In HLMs, efavirenz undergoes primary oxidative hydroxylation to 8-hydroxyefavirenz (major) and 7-hydroxyefavirenz (minor) and secondary metab. to 8,14-dihydroxyefavirenz.  The formation of 8-hydroxyefavirenz in two HLMs showed sigmoidal kinetics (av. apparent Km, 20.2 μM; Vmax, 140 pmol/min/mg protein; and Hill coeff., 1.5), whereas that of 7-hydroxyefavirenz formation was characterized by hyperbolic kinetics (Km, 40.1 μM and Vmax, 20.5 pmol/min/mg protein).  In a panel of 10 P450s, CYP2B6 formed 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz from efavirenz (10 μM) at the highest rate.  The Km value for the formation of 8-hydroxyefavirenz in CYP2B6 derived from hyperbolic Eq. 12.4 μM was close to that obtained in HLMs (Km, 20.2 μM).  None of the P450s tested showed activity toward 7-hydroxylation of efavirenz.  When 8-hydroxyefavirenz (2.5 μM) was used as a substrate, 8,14-dihydroxyefavirenz was formed by CYP2B6 at the highest rate, and its kinetics showed substrate inhibition (Ksi, ∼94 μM in HLMs and ∼234 μM in CYP2B6).  In a panel of 11 HLMs, 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz formation rates from efavirenz (10 μM) correlated significantly with the activity of CYP2B6 and CYP3A.  N,N',N''-Triethylenethiophosphoramide (thioTEPA; 50 μM) inhibited the formation rates of 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz from efavirenz (10 μM) by ≥60% in HLMs and CYP2B6, with Ki values < 4 μM.  In conclusion, CYP2B6 is the principal catalyst of efavirenz sequential hydroxylation.  Efavirenz systemic exposure is likely to be subject to interindividual variability in CYP2B6 activity and to drug interactions involving this isoform.  Efavirenz may be a valuable phenotyping tool to study the role of CYP2B6 in human drug metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdxH6M1qc21bVg90H21EOLACvtfcHk0ljCDtImUtLNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksr8%253D&md5=b08295185f3dd7c339a7744309002233</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.049601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.049601%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DB.%2BA.%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26aulast%3DFlockhart%26aufirst%3DD.%2BA.%26aulast%3DDesta%26aufirst%3DZ.%26atitle%3DThe%2520cytochrome%2520P450%25202B6%2520%2528CYP2B6%2529%2520is%2520the%2520main%2520catalyst%2520of%2520efavirenz%2520primary%2520and%2520secondary%2520metabolism%253A%2520implication%2520for%2520HIV%252FAIDS%2520therapy%2520and%2520utility%2520of%2520efavirenz%2520as%2520a%2520substrate%2520marker%2520of%2520CYP2B6%2520catalytic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D287%26epage%3D300%26doi%3D10.1124%2Fjpet.103.049601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemzik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krahn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, G. T.</span></span> <span> </span><span class="NLM_article-title">The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1006/taap.2000.9055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Ftaap.2000.9055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=11076702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2000&pages=102-113&issue=1&author=A.+E.+Mutlibauthor=R.+J.+Gersonauthor=P.+C.+Meunierauthor=P.+J.+Haleyauthor=H.+Chenauthor=L.+S.+Ganauthor=M.+H.+Daviesauthor=B.+Gemzikauthor=D.+D.+Christauthor=D.+F.+Krahnauthor=J.+A.+Markwalderauthor=S.+P.+Seitzauthor=R.+T.+Robertsonauthor=G.+T.+Miwa&title=The+species-dependent+metabolism+of+efavirenz+produces+a+nephrotoxic+glutathione+conjugate+in+rats&doi=10.1006%2Ftaap.2000.9055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">The Species-Dependent Metabolism of Efavirenz Produces a Nephrotoxic Glutathione Conjugate in Rats</span></div><div class="casAuthors">Mutlib, Abdul E.; Gerson, Ronald J.; Meunier, Paul C.; Haley, Patrick J.; Chen, Hao; Gan, Lawrence S.; Davies, Marc H.; Gemzik, Brian; Christ, David D.; Krahn, David F.; Markwalder, Jay A.; Seitz, Steven P.; Robertson, Richard T.; Miwa, Gerald T.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Efavirenz, a potent nonnucleoside reverse transcriptase inhibitor widely prescribed for the treatment of HIV infection, produces renal tubular epithelial cell necrosis in rats but not in cynomolgus monkeys or humans.  This species selectivity in nephrotoxicity could result from differences in the prodn. or processing of reactive metabolites, or both.  A detailed comparison of the metabolites produced by rats, monkeys, and humans revealed that rats produce a unique glutathione adduct.  The mechanism of formation and role of this glutathione adduct in the renal toxicity were investigated using both chem. and biochem. probes.  Efavirenz was labeled at the methine position on the cyclopropyl ring with the stable isotope deuterium, effectively reducing the formation of the cyclopropanol metabolite, an obligate precursor to the glutathione adduct.  This substitution markedly reduced both the incidence and severity of nephrotoxicity as measured histol.  Further processing of this glutathione adduct was also important in producing the lesion and was demonstrated by inhibiting γ-glutamyltranspeptidase with acivicin pretreatment (10 mg/kg, IV) prior to dosing with efavirenz.  Again, both the incidence and severity of the nephrotoxicity were reduced, such that four of nine rats given acivicin were without detectable lesions.  These studies provide compelling evidence that a species-specific formation of glutathione conjugate(s) from efavirenz is involved in producing nephrotoxicity in rats.  Mechanisms are proposed for the formation of reactive metabolites that could be responsible for the renal toxicity obsd. in rats.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtZ2yUYxMePrVg90H21EOLACvtfcHk0lgqLfWQKqaLLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D&md5=13f8d2f66902fef25d827b2f492f88ce</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1006%2Ftaap.2000.9055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Ftaap.2000.9055%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DGerson%26aufirst%3DR.%2BJ.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DDavies%26aufirst%3DM.%2BH.%26aulast%3DGemzik%26aufirst%3DB.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26aulast%3DKrahn%26aufirst%3DD.%2BF.%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DRobertson%26aufirst%3DR.%2BT.%26aulast%3DMiwa%26aufirst%3DG.%2BT.%26atitle%3DThe%2520species-dependent%2520metabolism%2520of%2520efavirenz%2520produces%2520a%2520nephrotoxic%2520glutathione%2520conjugate%2520in%2520rats%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2000%26volume%3D169%26issue%3D1%26spage%3D102%26epage%3D113%26doi%3D10.1006%2Ftaap.2000.9055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowgren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noreen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridborg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unge, T.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1677</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2002.02811.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1046%2Fj.1432-1327.2002.02811.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=11895437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD38XisVKitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2002&pages=1670-1677&author=J.+Lindbergauthor=S.+Sigurdssonauthor=S.+Lowgrenauthor=H.+O.+Anderssonauthor=C.+Sahlbergauthor=R.+Noreenauthor=K.+Fridborgauthor=H.+Zhangauthor=T.+Unge&title=Structural+basis+for+the+inhibitory+efficacy+of+efavirenz+%28DMP-266%29%2C+MSC194+and+PNU142721+towards+the+HIV-1+RT+K103N+mutant&doi=10.1046%2Fj.1432-1327.2002.02811.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant</span></div><div class="casAuthors">Lindberg, Jimmy; Sigurosson, Snaevar; Lowgren, Seved; Andersson, Hans O.; Sahlberg, Christer; Noreen, Rolf; Fridborg, Kerstin; Zhang, Hong; Unge, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1670-1677</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The K103N substitution is a frequently obsd. HIV-1 RT mutation in patients who do not respond to combination-therapy.  The drugs Efavirenz, MSC194 and PNU142721 belong to the recent generation of NNRTIs characterized by an improved resistance profile to the most common single point mutations within HIV-1 RT, including the K103N mutation.  In the present study we present structural observations from Efavirenz in complex with wild-type protein and the K103N mutant and PNU142721 and MSC194 in complex with the K103N mutant.  The structures unanimously indicate that the K103N substitution induces only minor positional adjustments of the three inhibitors and the residues lining the binding pocket.  Thus, compared to the corresponding wild-type structures, these inhibitors bind to the mutant in a conservative mode rather than through major rearrangements.  The structures implicate that the reduced inhibitory efficacy should be attributed to the changes in the chem. environment in the vicinity of the substituted N103 residue.  This is supported by changes in hydrophobic and electrostatic interactions to the inhibitors between wild-type and K103N mutant complexes.  These potent inhibitors accommodate to the K103N mutation by forming new interactions to the N103 side chain.  Our results are consistent with the proposal by Hsiou et al. that inhibitors with good activity against the K103N mutant would be expected to have favorable interactions with the mutant asparagines side chain, thereby compensating for resistance caused by stabilization of the mutant enzyme due to a hydrogen-bond network involving the N103 and Y188 side chains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM844LYh-y9rVg90H21EOLACvtfcHk0lgqLfWQKqaLLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisVKitr8%253D&md5=1cb2d0df1f8c6c1cb6fd37d0424361ad</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2002.02811.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2002.02811.x%26sid%3Dliteratum%253Aachs%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DSigurdsson%26aufirst%3DS.%26aulast%3DLowgren%26aufirst%3DS.%26aulast%3DAndersson%26aufirst%3DH.%2BO.%26aulast%3DSahlberg%26aufirst%3DC.%26aulast%3DNoreen%26aufirst%3DR.%26aulast%3DFridborg%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DUnge%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520for%2520the%2520inhibitory%2520efficacy%2520of%2520efavirenz%2520%2528DMP-266%2529%252C%2520MSC194%2520and%2520PNU142721%2520towards%2520the%2520HIV-1%2520RT%2520K103N%2520mutant%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2002%26volume%3D269%26spage%3D1670%26epage%3D1677%26doi%3D10.1046%2Fj.1432-1327.2002.02811.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>309</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2001.4648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Fjmbi.2001.4648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2001&pages=437-445&issue=2&author=Y.+Hsiouauthor=J.+Dingauthor=K.+Dasauthor=A.+D.+Clarkauthor=P.+L.+Boyerauthor=P.+Lewiauthor=P.+A.+Janssenauthor=J.+P.+Kleimauthor=M.+Rosnerauthor=S.+H.+Hughesauthor=E.+Arnold&title=The+Lys103Asn+mutation+of+HIV-1+RT%3A+a+novel+mechanism+of+drug+resistance&doi=10.1006%2Fjmbi.2001.4648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.4648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.4648%26sid%3Dliteratum%253Aachs%26aulast%3DHsiou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DLewi%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DKleim%26aufirst%3DJ.%2BP.%26aulast%3DRosner%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DThe%2520Lys103Asn%2520mutation%2520of%2520HIV-1%2520RT%253A%2520a%2520novel%2520mechanism%2520of%2520drug%2520resistance%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D309%26issue%3D2%26spage%3D437%26epage%3D445%26doi%3D10.1006%2Fjmbi.2001.4648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span> <i>Efavirenz Package</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver
Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Efavirenz+Package%3B+U.S.%0AFood+and+Drug+Administration%3A+Silver%0ASpring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEfavirenz%2520Package%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staszewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashima, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachlis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiest, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labriola, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manion, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, N. M.</span></span> <span> </span><span class="NLM_article-title">Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">1865</span>– <span class="NLM_lpage">1873</span>, <span class="refDoi"> DOI: 10.1056/NEJM199912163412501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJM199912163412501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10601505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=1865-1873&issue=25&author=S.+Staszewskiauthor=J.+Morales-Ramirezauthor=K.+T.+Tashimaauthor=A.+Rachlisauthor=D.+Skiestauthor=J.+Stanfordauthor=R.+Strykerauthor=P.+Johnsonauthor=D.+F.+Labriolaauthor=D.+Farinaauthor=D.+J.+Manionauthor=N.+M.+Ruiz&title=Efavirenz+plus+zidovudine+and+lamivudine%2C+efavirenz+plus+indinavir%2C+and+indinavir+plus+zidovudine+and+lamivudine+in+the+treatment+of+HIV-1+infection+in+adults.+Study+006+Team&doi=10.1056%2FNEJM199912163412501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults</span></div><div class="casAuthors">Staszewski, Schlomo; Morales-Ramirez, Javier; Tashima, Karen T.; Rachlis, Anita; Skiest, Daniel; Stanford, James; Stryker, Richard; Johnson, Philip; Labriola, Dominic F.; Farina, Dianne; Manion, Douglas J.; Ruiz, Nancy M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1865-1873</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Efavirenz is a nonnucleoside reverse-transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1).  We compared two regimens contg. efavirenz, one with a protease inhibitor and the other with two nucleoside reverse-transcriptase inhibitors, with a std. three-drug regimen.  Methods: The study subjects were 450 patients who had not previously been treated with lamivudine or any nonnucleoside reverse-transcriptase inhibitor or protease inhibitor.  In this open-label study, patients were randomly assigned to one of three regimens: efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily); the protease inhibitor indinavir (800 mg every eight hours) plus zidovudine and lamivudine; or efavirenz plus indinavir (1000 mg every eight hours).  Results: Suppression of plasma HIV-1 RNA to undetectable levels was achieved in more patients in the group given efavirenz plus nucleoside reverse-transcriptase inhibitors than in the group given indinavir plus nucleoside reverse-transcriptase inhibitors (70 % vs. 48 %, P<0.001).  The efficacy of the regimen of efavirenz plus indinavir was similar (53 %) to that of the regimen of indinavir, zidovudine, and lamivudine.  CD4 cell counts increased significantly with all combinations (range of increases, 180 to 201 cells per cubic millimeter).  More patients discontinued treatment because of adverse events in the group given indinavir and two nucleoside reverse-transcriptase inhibitors than in the group given efavirenz and two nucleoside reverse-transcriptase inhibitors (43 % vs. 27 %, P=0.005).  Conclusions: As antiretroviral therapy in HIV-1-infected adults, the combination of efavirenz, zidovudine, and lamivudine has greater antiviral activity and is better tolerated than the combination of indinavir, zidovudine, and lamivudine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmnBhI-LNWbVg90H21EOLACvtfcHk0lggja3s2hFAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVCmtw%253D%253D&md5=19c08c44aa950e70073d6ef00b4faa10</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1056%2FNEJM199912163412501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199912163412501%26sid%3Dliteratum%253Aachs%26aulast%3DStaszewski%26aufirst%3DS.%26aulast%3DMorales-Ramirez%26aufirst%3DJ.%26aulast%3DTashima%26aufirst%3DK.%2BT.%26aulast%3DRachlis%26aufirst%3DA.%26aulast%3DSkiest%26aufirst%3DD.%26aulast%3DStanford%26aufirst%3DJ.%26aulast%3DStryker%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DLabriola%26aufirst%3DD.%2BF.%26aulast%3DFarina%26aufirst%3DD.%26aulast%3DManion%26aufirst%3DD.%2BJ.%26aulast%3DRuiz%26aufirst%3DN.%2BM.%26atitle%3DEfavirenz%2520plus%2520zidovudine%2520and%2520lamivudine%252C%2520efavirenz%2520plus%2520indinavir%252C%2520and%2520indinavir%2520plus%2520zidovudine%2520and%2520lamivudine%2520in%2520the%2520treatment%2520of%2520HIV-1%2520infection%2520in%2520adults.%2520Study%2520006%2520Team%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26issue%3D25%26spage%3D1865%26epage%3D1873%26doi%3D10.1056%2FNEJM199912163412501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span> <i>Guidelines for the Use of Antiretroviral Agents
in HIV-1-Infected
Adults and Adolescents</i>; <span class="NLM_publisher-name">AIDSinfo</span>, <span class="NLM_year">2018</span>; <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf" class="extLink">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</a> (accessed May 14, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Guidelines+for+the+Use+of+Antiretroviral+Agents%0Ain+HIV-1-Infected%0AAdults+and+Adolescents%3B+AIDSinfo%2C+2018%3B+https%3A%2F%2Faidsinfo.nih.gov%2Fcontentfiles%2Flvguidelines%2Fadultandadolescentgl.pdf+%28accessed+May+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGuidelines%2520for%2520the%2520Use%2520of%2520Antiretroviral%2520Agents%250Ain%2520HIV-1-Infected%250AAdults%2520and%2520Adolescents%26pub%3DAIDSinfo%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span>; <span class="NLM_string-name">Britcher, S. F.</span>; <span class="NLM_string-name">Payne, L. S.</span>; <span class="NLM_string-name">Tran, L. O.</span>; <span class="NLM_string-name">Lumma, W. C.</span></span> U.S. Patent <span> </span><span class="NLM_article-title">Benzoxazinones as Inhibitors of HIV Reverse Transcriptase</span>. <span class="NLM_patent">US5519021A</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=S.+D.+Young&author=S.+F.+Britcher&author=L.+S.+Payne&author=L.+O.+Tran&author=W.+C.+Lumma&title=Benzoxazinones+as+Inhibitors+of+HIV+Reverse+Transcriptase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DS.%2BD.%26atitle%3DBenzoxazinones%2520as%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, M. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of HIV-1 reverse transcriptase inhibitor DMP 266</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4373</span>– <span class="NLM_lpage">4384</span>, <span class="refDoi"> DOI: 10.1080/00397919708005064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1080%2F00397919708005064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXht1alug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=4373-4384&author=L.%0AA.+Radescaauthor=Y.+S.+Loauthor=J.+R.+Mooreauthor=M.+E.+Pierce&title=Synthesis+of+HIV-1+reverse+transcriptase+inhibitor+DMP+266&doi=10.1080%2F00397919708005064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of HIV-1 reverse transcriptase inhibitor DMP 266</span></div><div class="casAuthors">Radesca, Lilian A.; Lo, Young S.; Moore, James R.; Pierce, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4373-4384</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">DMP 266, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor was prepd. in six steps starting from com. available 4-chlorophenyl isocyanate.  The racemic compd. was formed very efficiently from N-tert-butoxycarbonyl-4-chloroaniline and resoln. was accomplished via the (-)-camphanates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNwZ2z4QpbrVg90H21EOLACvtfcHk0lggja3s2hFAgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXht1alug%253D%253D&md5=f508104aa182d46c1f44c0bf071ca9b2</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1080%2F00397919708005064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919708005064%26sid%3Dliteratum%253Aachs%26aulast%3DRadesca%26aufirst%3DL.%2BA.%26aulast%3DLo%26aufirst%3DY.%2BS.%26aulast%3DMoore%26aufirst%3DJ.%2BR.%26aulast%3DPierce%26aufirst%3DM.%2BE.%26atitle%3DSynthesis%2520of%2520HIV-1%2520reverse%2520transcriptase%2520inhibitor%2520DMP%2520266%26jtitle%3DSynth.%2520Commun.%26date%3D1997%26volume%3D27%26spage%3D4373%26epage%3D4384%26doi%3D10.1080%2F00397919708005064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corley, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntington, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remenar, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collum, D. B.</span></span> <span> </span><span class="NLM_article-title">Lithium ephedrate-mediated addition of a lithium acetylide to a ketone: Solution structures and relative reactivities of mixed aggregates underlying the high enantioselectivities</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2038</span>, <span class="refDoi"> DOI: 10.1021/ja9713791</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9713791" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=2028-2038&issue=9&author=A.+Thompsonauthor=E.+G.+Corleyauthor=M.+F.+Huntingtonauthor=E.+J.+J.+Grabowskiauthor=J.+F.+Remenarauthor=D.+B.+Collum&title=Lithium+ephedrate-mediated+addition+of+a+lithium+acetylide+to+a+ketone%3A+Solution+structures+and+relative+reactivities+of+mixed+aggregates+underlying+the+high+enantioselectivities&doi=10.1021%2Fja9713791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fja9713791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9713791%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DCorley%26aufirst%3DE.%2BG.%26aulast%3DHuntington%26aufirst%3DM.%2BF.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26aulast%3DRemenar%26aufirst%3DJ.%2BF.%26aulast%3DCollum%26aufirst%3DD.%2BB.%26atitle%3DLithium%2520ephedrate-mediated%2520addition%2520of%2520a%2520lithium%2520acetylide%2520to%2520a%2520ketone%253A%2520Solution%2520structures%2520and%2520relative%2520reactivities%2520of%2520mixed%2520aggregates%2520underlying%2520the%2520high%2520enantioselectivities%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26issue%3D9%26spage%3D2028%26epage%3D2038%26doi%3D10.1021%2Fja9713791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corley, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntington, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span> <span> </span><span class="NLM_article-title">Use of an ephedrine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone: asymmetric synthesis of the reverse transcriptase inhibitor L-743,726</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">8937</span>– <span class="NLM_lpage">8940</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(95)01955-H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2F0040-4039%2895%2901955-H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=8937-8940&issue=49&author=A.+S.+Thompsonauthor=E.+G.+Corleyauthor=M.+F.+Huntingtonauthor=E.+J.+J.+Grabowski&title=Use+of+an+ephedrine+alkoxide+to+mediate+enantioselective+addition+of+an+acetylide+to+a+prochiral+ketone%3A+asymmetric+synthesis+of+the+reverse+transcriptase+inhibitor+L-743%2C726&doi=10.1016%2F0040-4039%2895%2901955-H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2901955-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252901955-H%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DCorley%26aufirst%3DE.%2BG.%26aulast%3DHuntington%26aufirst%3DM.%2BF.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26atitle%3DUse%2520of%2520an%2520ephedrine%2520alkoxide%2520to%2520mediate%2520enantioselective%2520addition%2520of%2520an%2520acetylide%2520to%2520a%2520prochiral%2520ketone%253A%2520asymmetric%2520synthesis%2520of%2520the%2520reverse%2520transcriptase%2520inhibitor%2520L-743%252C726%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26issue%3D49%26spage%3D8937%26epage%3D8940%26doi%3D10.1016%2F0040-4039%2895%2901955-H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortunak, J. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Confalone, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corley, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span> <span> </span><span class="NLM_article-title">Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">8536</span>– <span class="NLM_lpage">8543</span>, <span class="refDoi"> DOI: 10.1021/jo981170l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo981170l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=8536-8543&issue=23&author=M.+E.+Pierceauthor=R.+L.+Parsonsauthor=L.+A.+Radescaauthor=Y.+S.+Loauthor=S.+Silvermanauthor=J.+R.+Mooreauthor=Q.+Islamauthor=A.+Choudhuryauthor=J.+M.+D.+Fortunakauthor=D.+Nguyenauthor=C.+Luoauthor=S.+J.+Morganauthor=W.+P.+Davisauthor=P.+N.+Confaloneauthor=C.-y.+Chenauthor=R.+D.+Tillyerauthor=L.+Freyauthor=L.+Tanauthor=F.+Xuauthor=D.+Zhaoauthor=A.+S.+Thompsonauthor=E.+G.+Corleyauthor=E.+J.+J.+Grabowskiauthor=R.+Reamerauthor=P.+J.+Reider&title=Practical+asymmetric+synthesis+of+efavirenz+%28DMP+266%29%2C+an+HIV-1+reverse+transcriptase+inhibitor&doi=10.1021%2Fjo981170l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fjo981170l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo981170l%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DM.%2BE.%26aulast%3DParsons%26aufirst%3DR.%2BL.%26aulast%3DRadesca%26aufirst%3DL.%2BA.%26aulast%3DLo%26aufirst%3DY.%2BS.%26aulast%3DSilverman%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DJ.%2BR.%26aulast%3DIslam%26aufirst%3DQ.%26aulast%3DChoudhury%26aufirst%3DA.%26aulast%3DFortunak%26aufirst%3DJ.%2BM.%2BD.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DMorgan%26aufirst%3DS.%2BJ.%26aulast%3DDavis%26aufirst%3DW.%2BP.%26aulast%3DConfalone%26aufirst%3DP.%2BN.%26aulast%3DChen%26aufirst%3DC.-y.%26aulast%3DTillyer%26aufirst%3DR.%2BD.%26aulast%3DFrey%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DCorley%26aufirst%3DE.%2BG.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26aulast%3DReamer%26aufirst%3DR.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26atitle%3DPractical%2520asymmetric%2520synthesis%2520of%2520efavirenz%2520%2528DMP%2520266%2529%252C%2520an%2520HIV-1%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1998%26volume%3D63%26issue%3D23%26spage%3D8536%26epage%3D8543%26doi%3D10.1021%2Fjo981170l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span>; <span class="NLM_string-name">Long, X.</span>; <span class="NLM_string-name">Luo, B.</span>; <span class="NLM_string-name">Kulesza, A.</span>; <span class="NLM_string-name">Reichwagen, J.</span>; <span class="NLM_string-name">Guo, Y.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Efavirenz by Cyclisation</span>. World Patent <span class="NLM_patent">WO2012097510A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Dai&author=X.+Long&author=B.+Luo&author=A.+Kulesza&author=J.+Reichwagen&author=Y.+Guo&title=Process+for+Preparation+of+Efavirenz+by+Cyclisation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Efavirenz%2520by%2520Cyclisation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Correia, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeberger, P. H.</span></span> <span> </span><span class="NLM_article-title">A concise flow synthesis of efavirenz</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4945</span>– <span class="NLM_lpage">4948</span>, <span class="refDoi"> DOI: 10.1002/anie.201411728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fanie.201411728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=4945-4948&issue=16&author=C.%0AA.+Correiaauthor=K.+Gilmoreauthor=D.+T.+McQuadeauthor=P.+H.+Seeberger&title=A+concise+flow+synthesis+of+efavirenz&doi=10.1002%2Fanie.201411728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A Concise Flow Synthesis of Efavirenz</span></div><div class="casAuthors">Correia, Camille A.; Gilmore, Kerry; McQuade, D. Tyler; Seeberger, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4945-4948</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Efavirenz is an essential medicine for the treatment of HIV, which is still inaccessible to millions of people worldwide.  A novel, semi-continuous process provides rac-Efavirenz with an overall yield of 45% from 1,4-dichlorobenzene.  This streamlined proof-of-principle synthesis relies on the efficient copper-catalyzed formation of an aryl isocyanate and a subsequent intramol. cyclization to install the carbamate core of Efavirenz in one step.  This three-step method represents the shortest synthesis of the racemic analog of this life-saving drug to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkfsgAKAjCELVg90H21EOLACvtfcHk0li9YiSKGQnkow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu7s%253D&md5=4811f0b57f4b876bdda5107d569a69d1</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411728%26sid%3Dliteratum%253Aachs%26aulast%3DCorreia%26aufirst%3DC.%2BA.%26aulast%3DGilmore%26aufirst%3DK.%26aulast%3DMcQuade%26aufirst%3DD.%2BT.%26aulast%3DSeeberger%26aufirst%3DP.%2BH.%26atitle%3DA%2520concise%2520flow%2520synthesis%2520of%2520efavirenz%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26issue%3D16%26spage%3D4945%26epage%3D4948%26doi%3D10.1002%2Fanie.201411728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span>; <span class="NLM_string-name">Tillyer, R. D.</span>; <span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">Efficient Enantioselective Addition Reaction using an Organozinc Reagent</span>. World Patent <span class="NLM_patent">WO1998051676A1</span>, <span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=C.+Y.+Chen&author=R.+D.+Tillyer&author=L.+Tan&title=Efficient+Enantioselective+Addition+Reaction+using+an+Organozinc+Reagent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BY.%26atitle%3DEfficient%2520Enantioselective%2520Addition%2520Reaction%2520using%2520an%2520Organozinc%2520Reagent%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/nsb0595-407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnsb0595-407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=407-415&issue=5&author=J.+Dingauthor=K.+Dasauthor=H.+Moereelsauthor=L.+Koymansauthor=K.+Andriesauthor=P.+A.+Janssenauthor=S.+H.+Hughesauthor=E.+Arnold&title=Structure+of+HIV-1+RT%2FTIBO+R+86183+complex+reveals+similarity+in+the+binding+of+diverse+nonnucleoside+inhibitors&doi=10.1038%2Fnsb0595-407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fnsb0595-407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0595-407%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DMoereels%26aufirst%3DH.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520HIV-1%2520RT%252FTIBO%2520R%252086183%2520complex%2520reveals%2520similarity%2520in%2520the%2520binding%2520of%2520diverse%2520nonnucleoside%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D2%26issue%3D5%26spage%3D407%26epage%3D415%26doi%3D10.1038%2Fnsb0595-407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raeymaeckers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelder, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woestenborghs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heykants, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clercq, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1038/343470a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2F343470a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1689015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=1990&pages=470-474&author=R.+Pauwelsauthor=K.+Andriesauthor=J.+Desmyterauthor=D.+Scholsauthor=M.+J.+Kuklaauthor=H.+J.+Breslinauthor=A.+Raeymaeckersauthor=J.+V.+Gelderauthor=R.+Woestenborghsauthor=J.+Heykantsauthor=K.+Schellekensauthor=M.+A.+C.+Janssenauthor=E.+D.+Clercqauthor=P.+A.+J.+Janssen&title=Potent+and+selective+inhibition+of+HIV-1+replication+in+vitro+by+a+novel+series+of+TIBO+derivatives&doi=10.1038%2F343470a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span></div><div class="casAuthors">Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Van Gelder, Jozef; Woestenborghs, Robert; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6257</span>),
    <span class="NLM_cas:pages">470-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">In the search for compds. active against human immunodeficiency virus (HIV), it was found that members of a novel series of tetrahydro-imidazol[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivs. inhibit the replication of HIV-1, the main etiol. agent of AIDS, but not of HIV-2 or of any other DNA or RNA viruses.  In five cell systems, HIV-1 is inhibited by TIBO derivs. in nanomolar amts., which are 104-105 times lower that the cytotoxic concn.  The unprecedented specificity of these compds. may be due to an interaction with a reverse transcriptase-assocd. process.  By contrast, AZT (3'-azido-2',3'-dideoxythymidine), which is used for the treatment of AIDS, and DDC (2',3'-dideoxycytidine) and DDI (2',3'-dideoxyinosine), whose clin. application is being assessed, inhibit both HIV-1 and HIV-2 at concns. that, depending on the cell systems, are 2 to 4 orders of magnitude below their cytotoxic concn.  TIBO-derivs. are new chems. unrelated to any other antiviral agents.  They may be the most specific and potent inhibitors of HIV-1 replication studied so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodXWsMmazOdrVg90H21EOLACvtfcHk0li9YiSKGQnkow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D&md5=c303b47ff312a49dded6132ebbaa4ca1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2F343470a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F343470a0%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DRaeymaeckers%26aufirst%3DA.%26aulast%3DGelder%26aufirst%3DJ.%2BV.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DHeykants%26aufirst%3DJ.%26aulast%3DSchellekens%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DM.%2BA.%2BC.%26aulast%3DClercq%26aufirst%3DE.%2BD.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520HIV-1%2520replication%2520in%2520vitro%2520by%2520a%2520novel%2520series%2520of%2520TIBO%2520derivatives%26jtitle%3DNature%26date%3D1990%26volume%3D343%26spage%3D470%26epage%3D474%26doi%3D10.1038%2F343470a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobo-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koepke, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michejda, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(01)00168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0969-2126%2801%2900168-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1995&pages=365-379&author=J.+Dingauthor=K.+Dasauthor=C.+Tantilloauthor=W.+Zhangauthor=A.+D.+Clarkauthor=S.+Jessenauthor=X.+Luauthor=Y.+Hsiouauthor=A.+Jacobo-Molinaauthor=K.+Andriesauthor=R.+Pauwelsauthor=H.+Moereelsauthor=L.+Koymansauthor=P.+A.+J.+Janssenauthor=R.+H.+Smithauthor=M.+K.+Koepkeauthor=C.+J.+Michejdaauthor=S.+H.+Hughesauthor=E.+Arnold&title=Structure+of+HIV-1+reverse+transcriptase+in+a+complex+with+the+non-nucleoside+inhibitor+%CE%B1-APA+R+95845+at+2.8+%C3%85+resolution&doi=10.1016%2FS0969-2126%2801%2900168-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2801%2900168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252801%252900168-X%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DTantillo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DJessen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHsiou%26aufirst%3DY.%26aulast%3DJacobo-Molina%26aufirst%3DA.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DMoereels%26aufirst%3DH.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DSmith%26aufirst%3DR.%2BH.%26aulast%3DKoepke%26aufirst%3DM.%2BK.%26aulast%3DMichejda%26aufirst%3DC.%2BJ.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520HIV-1%2520reverse%2520transcriptase%2520in%2520a%2520complex%2520with%2520the%2520non-nucleoside%2520inhibitor%2520%25CE%25B1-APA%2520R%252095845%2520at%25202.8%2520%25C3%2585%2520resolution%26jtitle%3DStructure%26date%3D1995%26volume%3D3%26spage%3D365%26epage%3D379%26doi%3D10.1016%2FS0969-2126%2801%2900168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Daele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffels, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vreese, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woestenborghs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandamme, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, C. G.</span></span> <span> </span><span class="NLM_article-title">Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1715</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.5.1711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.90.5.1711" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=1711-1715&issue=5&author=R.+Pauwelsauthor=K.+Andriesauthor=Z.+Debyserauthor=P.+Van+Daeleauthor=D.+Scholsauthor=P.+Stoffelsauthor=K.+De+Vreeseauthor=R.+Woestenborghsauthor=A.+M.+Vandammeauthor=C.+G.+Janssen&title=Potent+and+highly+selective+human+immunodeficiency+virus+type+1+%28HIV-1%29+inhibition+by+a+series+of+alpha-anilinophenylacetamide+derivatives+targeted+at+HIV-1+reverse+transcriptase&doi=10.1073%2Fpnas.90.5.1711"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.5.1711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.5.1711%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DVan%2BDaele%26aufirst%3DP.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DStoffels%26aufirst%3DP.%26aulast%3DDe%2BVreese%26aufirst%3DK.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DVandamme%26aufirst%3DA.%2BM.%26aulast%3DJanssen%26aufirst%3DC.%2BG.%26atitle%3DPotent%2520and%2520highly%2520selective%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520inhibition%2520by%2520a%2520series%2520of%2520alpha-anilinophenylacetamide%2520derivatives%2520targeted%2520at%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26issue%3D5%26spage%3D1711%26epage%3D1715%26doi%3D10.1073%2Fpnas.90.5.1711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavash, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azijn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aken, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00411-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0960-894X%2801%2900411-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2229-2234&author=D.+W.+Ludoviciauthor=R.+W.+Kavashauthor=M.+J.+Kuklaauthor=C.+Y.+Hoauthor=H.+Yeauthor=B.+L.+De+Corteauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=H.+Azijnauthor=R.+Pauwelsauthor=H.+E.+Moereelsauthor=J.+Heeresauthor=L.+M.+Koymansauthor=M.+R.+de+Jongeauthor=K.+J.+Van+Akenauthor=F.+F.+Daeyaertauthor=P.+J.+Lewiauthor=K.+Dasauthor=E.+Arnoldauthor=P.+A.+Janssen&title=Evolution+of+anti-HIV+drug+candidates.+Part+2%3A+Diaryltriazine+%28DATA%29+analogues&doi=10.1016%2FS0960-894X%2801%2900411-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900411-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900411-5%26sid%3Dliteratum%253Aachs%26aulast%3DLudovici%26aufirst%3DD.%2BW.%26aulast%3DKavash%26aufirst%3DR.%2BW.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DDe%2BCorte%26aufirst%3DB.%2BL.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DMoereels%26aufirst%3DH.%2BE.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DVan%2BAken%26aufirst%3DK.%2BJ.%26aulast%3DDaeyaert%26aufirst%3DF.%2BF.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DEvolution%2520of%2520anti-HIV%2520drug%2520candidates.%2520Part%25202%253A%2520Diaryltriazine%2520%2528DATA%2529%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D2229%26epage%3D2234%26doi%3D10.1016%2FS0960-894X%2801%2900411-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenstein, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavash, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azijn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aken, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2235</span>– <span class="NLM_lpage">2239</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00412-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0960-894X%2801%2900412-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2235-2239&issue=17&author=D.+W.+Ludoviciauthor=B.+L.+De+Corteauthor=M.+J.+Kuklaauthor=H.+Yeauthor=C.+Y.+Hoauthor=M.+A.+Lichtensteinauthor=R.+W.+Kavashauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=H.+Azijnauthor=R.+Pauwelsauthor=P.+J.+Lewiauthor=J.+Heeresauthor=L.+M.+Koymansauthor=M.+R.+de+Jongeauthor=K.+J.+Van+Akenauthor=F.+F.+Daeyaertauthor=K.+Dasauthor=E.+Arnoldauthor=P.+A.+Janssen&title=Evolution+of+anti-HIV+drug+candidates.+Part+3%3A+Diarylpyrimidine+%28DAPY%29+analogues&doi=10.1016%2FS0960-894X%2801%2900412-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900412-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900412-7%26sid%3Dliteratum%253Aachs%26aulast%3DLudovici%26aufirst%3DD.%2BW.%26aulast%3DDe%2BCorte%26aufirst%3DB.%2BL.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DLichtenstein%26aufirst%3DM.%2BA.%26aulast%3DKavash%26aufirst%3DR.%2BW.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DVan%2BAken%26aufirst%3DK.%2BJ.%26aulast%3DDaeyaert%26aufirst%3DF.%2BF.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DEvolution%2520of%2520anti-HIV%2520drug%2520candidates.%2520Part%25203%253A%2520Diarylpyrimidine%2520%2528DAPY%2529%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D17%26spage%3D2235%26epage%3D2239%26doi%3D10.1016%2FS0960-894X%2801%2900412-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azijn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thielemans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span> <span> </span><span class="NLM_article-title">TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4680</span>– <span class="NLM_lpage">4686</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.12.4680-4686.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.48.12.4680-4686.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15561844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=4680-4686&issue=12&author=K.+Andriesauthor=H.+Azijnauthor=T.+Thielemansauthor=D.+Ludoviciauthor=M.+Kuklaauthor=J.+Heeresauthor=P.+Janssenauthor=B.+De+Corteauthor=J.+Vingerhoetsauthor=R.+Pauwelsauthor=M.+P.+de+Bethune&title=TMC125%2C+a+novel+next-generation+nonnucleoside+reverse+transcriptase+inhibitor+active+against+nonnucleoside+reverse+transcriptase+inhibitor-resistant+human+immunodeficiency+virus+type+1&doi=10.1128%2FAAC.48.12.4680-4686.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1</span></div><div class="casAuthors">Andries, Koen; Azijn, Hilde; Thielemans, Theo; Ludovici, Donald; Kukla, Michael; Heeres, Jan; Janssen, Paul; De Corte, Bart; Vingerhoets, Johan; Pauwels, Rudi; de Bethune, Marie-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4680-4686</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1); however, currently marketed NNRTIs rapidly select resistant virus, and cross-resistance within the class is extensive.  A parallel screening strategy was applied to test candidates from a series of diarylpyrimidines against wild-type and resistant HIV strains carrying clin. relevant mutations.  Serum protein binding and metabolic stability were addressed early in the selection process.  The emerging clin. candidate, TMC125, was highly active against wild-type HIV-1 (50% effective concn. [EC50] = 1.4 to 4.8 nM) and showed some activity against HIV-2 (EC50 = 3.5 μM).  TMC125 also inhibited a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus.  Incubation of TMC125 with human liver microsomal fractions suggested good metabolic stability (15% decrease in drug concn. and 7% decrease in antiviral activity after 120 min).  Although TMC125 is highly protein bound, its antiviral effect was not reduced by the presence of 45 mg of human serum albumin/mL, 1 mg of α1-acid glycoprotein/mL, or 50% human serum.  In an initial screen for activity against a panel of 25 viruses carrying single and double reverse transcriptase amino acid substitutions assocd. with NNRTI resistance, the EC50 of TMC125 was <5 nM for 19 viruses, including the double mutants K101E + K103N and K103N + Y181C.  TMC125 also retained activity (EC50 < 100 nM) against 97% of 1,081 recent clin. derived recombinant viruses resistant to at least one of the currently marketed NNRTIs.  TMC125 is a potent next generation NNRTI, with the potential for use in individuals infected with NNRTI-resistant virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHVfHO28azELVg90H21EOLACvtfcHk0ljkRny7X-9hrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmt77I&md5=293f542ebbeb94e283d21070bb17c25f</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.12.4680-4686.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.12.4680-4686.2004%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DThielemans%26aufirst%3DT.%26aulast%3DLudovici%26aufirst%3DD.%26aulast%3DKukla%26aufirst%3DM.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DJanssen%26aufirst%3DP.%26aulast%3DDe%2BCorte%26aufirst%3DB.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26atitle%3DTMC125%252C%2520a%2520novel%2520next-generation%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520active%2520against%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor-resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26issue%3D12%26spage%3D4680%26epage%3D4686%26doi%3D10.1128%2FAAC.48.12.4680-4686.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Etravirine</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2357</span>– <span class="NLM_lpage">2372</span>, <span class="refDoi"> DOI: 10.2165/0003495-200868160-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F0003495-200868160-00007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2357-2372&issue=16&author=E.+D.+Deeksauthor=G.+M.+Keating&title=Etravirine&doi=10.2165%2F0003495-200868160-00007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.2165%2F0003495-200868160-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F0003495-200868160-00007%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DEtravirine%26jtitle%3DDrugs%26date%3D2008%26volume%3D68%26issue%3D16%26spage%3D2357%26epage%3D2372%26doi%3D10.2165%2F0003495-200868160-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, D. J.</span></span> <span> </span><span class="NLM_article-title">Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.2146/ajhp080559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2146%2Fajhp080559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=20101061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVejtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=193-205&issue=3&author=R.+K.+Elsayedauthor=D.+J.+Caldwell&title=Etravirine%3A+a+novel+nonnucleoside+reverse+transcriptase+inhibitor+for+managing+human+immunodeficiency+virus+infection&doi=10.2146%2Fajhp080559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection</span></div><div class="casAuthors">Elsayed, Raghda K.; Caldwell, David J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-205</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">A review.  Purpose. The pharmacol., efficacy, and safety of etravirine and its clin. utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.  Summary. While single mutations confer resistance to earlier nonnucleoside reverse transcriptase inhibitors (NNRTIs), etravirine exhibited an Increased barrier to resistance by requiring multiple mutations for resistance to occur in preclin. studies.  Randomized controlled trials have demonstrated the efficacy of etravirine in achieving HIV RNA viral loads of <50 copies/mL and a significant increase in baseline CD4+ lymphocyte count in treatment-experienced patients.  There has been a trend toward increased rates of death, progression to acquired immunodeficiency syndrome, and opportunistic infections in patients using placebo during Phase III trials.  Baseline patient characteristics that correlate with changes in etravirine efficacy are reported.  Mild-to-moderate rash and nausea are the most common adverse effects of etravirine.  If rash is suspected, etravirine should be discontinued and rechallenge should be avoided due to the risk of severe and possibly fatal skin reactions.  Unlike some antiretrovirals, increased risks of hepatic, lipid, or neuropsychiatric abnormalities are not correlated with its use.  Several drug interactions are expected with etravirine use, and some may require dosage adjustment or substitution of concurrent drugs.  No dosage adjustments are recommended for patients with mild-to-moderate hepatic or renal Impairment.  Conclusion. Etravirine, a second-generation NNRTI, is efficacious in achieving viral suppression and improving the immune function in treatment-experienced HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxKwz022HTkLVg90H21EOLACvtfcHk0li5lWrWSowwkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVejtbc%253D&md5=ff0a9cd401885deb3e5e29f57aef4882</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2146%2Fajhp080559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp080559%26sid%3Dliteratum%253Aachs%26aulast%3DElsayed%26aufirst%3DR.%2BK.%26aulast%3DCaldwell%26aufirst%3DD.%2BJ.%26atitle%3DEtravirine%253A%2520a%2520novel%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520for%2520managing%2520human%2520immunodeficiency%2520virus%2520infection%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2010%26volume%3D67%26issue%3D3%26spage%3D193%26epage%3D205%26doi%3D10.2146%2Fajhp080559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Béthune, M.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkel, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medaer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Knaep, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohets, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffels, P.</span></span> <span> </span><span class="NLM_article-title">In search of a novel anti-HIV Drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1901</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1021/jm040840e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040840e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1901-1909&issue=6&author=P.+A.+J.+Janssenauthor=P.+J.+Lewiauthor=E.+Arnoldauthor=F.+Daeyaertauthor=M.+de+Jongeauthor=J.+Heeresauthor=L.+Koymansauthor=M.+Vinkersauthor=J.+Guillemontauthor=E.+Pasquierauthor=M.+Kuklaauthor=D.+Ludoviciauthor=K.+Andriesauthor=M.-P.+de+B%C3%A9thuneauthor=R.+Pauwelsauthor=K.+Dasauthor=A.+D.+Clarkauthor=Y.+V.+Frenkelauthor=S.+H.+Hughesauthor=B.+Medaerauthor=F.+De+Knaepauthor=H.+Bohetsauthor=F.+De+Clerckauthor=A.+Lampoauthor=P.+Williamsauthor=P.+Stoffels&title=In+search+of+a+novel+anti-HIV+Drug%3A+multidisciplinary+coordination+in+the+discovery+of+4-%5B%5B4-%5B%5B4-%5B%281E%29-2-Cyanoethenyl%5D-2%2C6-dimethylphenyl%5Damino%5D-2-+pyrimidinyl%5Damino%5Dbenzonitrile+%28R278474%2C+Rilpivirine%29&doi=10.1021%2Fjm040840e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)</span></div><div class="casAuthors">Janssen, Paul A. J.; Lewi, Paul J.; Arnold, Eddy; Daeyaert, Frits; de Jonge, Marc; Heeres, Jan; Koymans, Luc; Vinkers, Maarten; Guillemont, Jerome; Pasquier, Elisabeth; Kukla, Mike; Ludovici, Don; Andries, Koen; de Bethune, Marie-Pierre; Pauwels, Rudi; Das, Kalyan; Clark, Art D., Jr.; Frenkel, Yulia Volovik; Hughes, Stephen H.; Medaer, Bart; De Knaep, Fons; Bohets, Hilde; De Clerck, Fred; Lampo, Ann; Williams, Peter; Stoffels, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1901-1909</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate.  R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet these criteria and to be suitable for high compliance oral treatment of HIV-1 infection.  The discovery of R278474 was the result of a coordinated multidisciplinary effort involving medicinal chemists, virologists, crystallographers, mol. modelers, toxicologists, anal. chemists, pharmacists, and many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8upgC3x1GuLVg90H21EOLACvtfcHk0li5lWrWSowwkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D&md5=d4b650dcaa248d5cdb1dd500135c8f7e</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm040840e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040840e%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DDaeyaert%26aufirst%3DF.%26aulast%3Dde%2BJonge%26aufirst%3DM.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DVinkers%26aufirst%3DM.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DKukla%26aufirst%3DM.%26aulast%3DLudovici%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BB%25C3%25A9thune%26aufirst%3DM.-P.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DFrenkel%26aufirst%3DY.%2BV.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DMedaer%26aufirst%3DB.%26aulast%3DDe%2BKnaep%26aufirst%3DF.%26aulast%3DBohets%26aufirst%3DH.%26aulast%3DDe%2BClerck%26aufirst%3DF.%26aulast%3DLampo%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DStoffels%26aufirst%3DP.%26atitle%3DIn%2520search%2520of%2520a%2520novel%2520anti-HIV%2520Drug%253A%2520multidisciplinary%2520coordination%2520in%2520the%2520discovery%2520of%25204-%255B%255B4-%255B%255B4-%255B%25281E%2529-2-Cyanoethenyl%255D-2%252C6-dimethylphenyl%255Damino%255D-2-%2520pyrimidinyl%255Damino%255Dbenzonitrile%2520%2528R278474%252C%2520Rilpivirine%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D1901%26epage%3D1909%26doi%3D10.1021%2Fjm040840e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lansdon, E.
B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brendza, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4295</span>– <span class="NLM_lpage">4429</span>, <span class="refDoi"> DOI: 10.1021/jm1002233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1002233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFeqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4295-4429&issue=10&author=E.%0AB.+Lansdonauthor=K.+M.+Brendzaauthor=M.+Hungauthor=R.+Wangauthor=S.+Mukundauthor=D.+Jinauthor=G.+Birkusauthor=N.+Kuttyauthor=X.+Liu&title=Crystal+structures+of+HIV-1+reverse+transcriptase+with+etravirine+%28TMC125%29+and+rilpivirine+%28TMC278%29%3A+implications+for+drug+design&doi=10.1021%2Fjm1002233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design</span></div><div class="casAuthors">Lansdon, Eric B.; Brendza, Katherine M.; Hung, Magdeleine; Wang, Ruth; Mukund, Susmith; Jin, Debi; Birkus, Gabriel; Kutty, Nilima; Liu, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4295-4299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent flexibility, helping to maintain activity against a wide range of resistance mutations.  Crystal structures were detd. with wild-type and K103N HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278).  These structures reveal a similar binding mode for TMC125 and TMC278, whether bound to wild-type or K103N RT.  Comparison to previously published structures reveals differences in binding modes for TMC125 and differences in protein conformation for TMC278.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVNZlZQF054rVg90H21EOLACvtfcHk0liq6gPRnh4Y8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFeqsLs%253D&md5=d99b8d74a488eb94da35246c6f141240</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm1002233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1002233%26sid%3Dliteratum%253Aachs%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DBrendza%26aufirst%3DK.%2BM.%26aulast%3DHung%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DD.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DKutty%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DCrystal%2520structures%2520of%2520HIV-1%2520reverse%2520transcriptase%2520with%2520etravirine%2520%2528TMC125%2529%2520and%2520rilpivirine%2520%2528TMC278%2529%253A%2520implications%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D10%26spage%3D4295%26epage%3D4429%26doi%3D10.1021%2Fjm1002233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romines, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">5000</span>– <span class="NLM_lpage">5008</span>, <span class="refDoi"> DOI: 10.1021/jm8004493</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8004493" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5000-5008&issue=16&author=J.+Renauthor=P.+P.+Chamberlainauthor=A.+Stampauthor=S.+A.+Shortauthor=K.+L.+Weaverauthor=K.+R.+Rominesauthor=R.+Hazenauthor=A.+Freemanauthor=R.+G.+Ferrisauthor=C.+W.+Andrewsauthor=L.+Booneauthor=J.+H.+Chanauthor=D.+K.+Stammers&title=Structural+basis+for+the+improved+drug+resistance+profile+of+new+generation+benzophenone+non-nucleoside+HIV-1+reverse+transcriptase+inhibitors&doi=10.1021%2Fjm8004493"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm8004493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004493%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DStamp%26aufirst%3DA.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DRomines%26aufirst%3DK.%2BR.%26aulast%3DHazen%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DA.%26aulast%3DFerris%26aufirst%3DR.%2BG.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DBoone%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DJ.%2BH.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520improved%2520drug%2520resistance%2520profile%2520of%2520new%2520generation%2520benzophenone%2520non-nucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D16%26spage%3D5000%26epage%3D5008%26doi%3D10.1021%2Fjm8004493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholler-Gyure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raoof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Smedt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoetelmans, R. M.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and pharmacodynamics of etravirine</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.2165/10895940-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F10895940-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=19725591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGnsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=561-574&issue=9&author=M.+Scholler-Gyureauthor=T.+N.+Kakudaauthor=A.+Raoofauthor=G.+De+Smedtauthor=R.+M.+Hoetelmans&title=Clinical+pharmacokinetics+and+pharmacodynamics+of+etravirine&doi=10.2165%2F10895940-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics and pharmacodynamics of etravirine</span></div><div class="casAuthors">Scholler-Gyure, Monika; Kakuda, Thomas N.; Raoof, Araz; De Smedt, Goedele; Hoetelmans, Richard M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">561-574</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection.  It has a high genetic barrier to the emergence of viral resistance, and maintains its antiviral activity in the presence of common NNRTI mutations.  The pharmacokinetics of etravirine in HIV-infected patients at the recommended dosage of 200 mg twice daily demonstrates moderate intersubject variability and no time dependency.  Due to substantially lower exposures when taken on an empty stomach, etravirine should be administered following a meal.  The drug is highly protein bound (99.9%) to albumin and α1-acid glycoprotein and shows a relatively long elimination half-life of 30-40 h.  Etravirine is metabolized by cytochrome P 450 (CYP) 3A, 2C9 and 2C19; the metabolites are subsequently glucuronidated by uridine diphosphate glucuronosyltransferase.  Renal elimination of etravirine is negligible.  Etravirine has the potential for interactions by inducing CYP3A and inhibiting CYP2C9 and 2C19; it is a mild inhibitor of P-glycoprotein but not a substrate.  The drug interaction profile of etravirine has been well characterized and is manageable.  No dosage adjustments are needed in patients with renal impairment or mild to moderate hepatic impairment.  Race, sex, bodyweight and age do not affect the pharmacokinetics of etravirine.  In the two phase III trials DUET-1 and DUET-2, no relationship was demonstrated between the pharmacokinetics of etravirine and the primary efficacy endpoint of viral load below 50 copies/mL or the safety profile of etravirine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdy72LoMGX7Vg90H21EOLACvtfcHk0liq6gPRnh4Y8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGnsLbL&md5=8c9bce4045563221d8ac92ec221e36f2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.2165%2F10895940-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F10895940-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DScholler-Gyure%26aufirst%3DM.%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DRaoof%26aufirst%3DA.%26aulast%3DDe%2BSmedt%26aufirst%3DG.%26aulast%3DHoetelmans%26aufirst%3DR.%2BM.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520etravirine%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2009%26volume%3D48%26issue%3D9%26spage%3D561%26epage%3D574%26doi%3D10.2165%2F10895940-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanakakis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumpus, N. N.</span></span> <span> </span><span class="NLM_article-title">Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.044404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1124%2Fdmd.111.044404" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=803-814&issue=4&author=L.+J.+Yanakakisauthor=N.+N.+Bumpus&title=Biotransformation+of+the+antiretroviral+drug+etravirine%3A+metabolite+identification%2C+reaction+phenotyping%2C+and+characterization+of+autoinduction+of+cytochrome+P450-dependent+metabolism&doi=10.1124%2Fdmd.111.044404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.044404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.044404%26sid%3Dliteratum%253Aachs%26aulast%3DYanakakis%26aufirst%3DL.%2BJ.%26aulast%3DBumpus%26aufirst%3DN.%2BN.%26atitle%3DBiotransformation%2520of%2520the%2520antiretroviral%2520drug%2520etravirine%253A%2520metabolite%2520identification%252C%2520reaction%2520phenotyping%252C%2520and%2520characterization%2520of%2520autoinduction%2520of%2520cytochrome%2520P450-dependent%2520metabolism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D4%26spage%3D803%26epage%3D814%26doi%3D10.1124%2Fdmd.111.044404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lade, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumpus, N. N.</span></span> <span> </span><span class="NLM_article-title">Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5067</span>– <span class="NLM_lpage">5079</span>, <span class="refDoi"> DOI: 10.1128/AAC.01401-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.01401-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5067-5079&issue=10&author=J.+M.+Ladeauthor=L.+B.+Averyauthor=N.+N.+Bumpus&title=Human+biotransformation+of+the+nonnucleoside+reverse+transcriptase+inhibitor+rilpivirine+and+a+cross-species+metabolism+comparison&doi=10.1128%2FAAC.01401-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1128%2FAAC.01401-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01401-13%26sid%3Dliteratum%253Aachs%26aulast%3DLade%26aufirst%3DJ.%2BM.%26aulast%3DAvery%26aufirst%3DL.%2BB.%26aulast%3DBumpus%26aufirst%3DN.%2BN.%26atitle%3DHuman%2520biotransformation%2520of%2520the%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520rilpivirine%2520and%2520a%2520cross-species%2520metabolism%2520comparison%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D10%26spage%3D5067%26epage%3D5079%26doi%3D10.1128%2FAAC.01401-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alteri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccherini-Silberstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrotta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perno, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svicher, V.</span></span> <span> </span><span class="NLM_article-title">Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2011.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.drup.2011.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=21295512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlGkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=141-149&issue=3&author=S.+Alcaroauthor=C.+Alteriauthor=A.+Arteseauthor=F.+Ceccherini-Silbersteinauthor=G.+Costaauthor=F.+Ortusoauthor=L.+Parrottaauthor=C.+F.+Pernoauthor=V.+Svicher&title=Molecular+and+structural+aspects+of+clinically+relevant+mutations+related+to+the+approved+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.drup.2011.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase</span></div><div class="casAuthors">Alcaro, Stefano; Alteri, Claudia; Artese, Anna; Ceccherini-Silberstein, Francesca; Costa, Giosue; Ortuso, Francesco; Parrotta, Lucia; Perno, Carlo Federico; Svicher, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years relevant progress has been made in the treatment of HIV-1 with a consequent decrease in mortality.  The availability of potent antiretroviral drugs and the ability of viral load assays that accurately evaluate the true level of viral replication, have led to a better understanding of pathogenesis of the disease and how to obtain improved therapeutic profiles.  The highly active antiretroviral therapy (HAART), based on a combination of three or more antiretroviral drugs, has radically changed the clin. outcome of HIV.  In particular, reverse transcriptase non-nucleoside inhibitors (NNRTIs) play an essential role in most protocols and are often used in first line treatment.  The high specificity of these inhibitors towards HIV-1 has increased the no. of structural and mol. modeling studies of enzyme complexes and that have led to chem. syntheses of more selective second and third-generation NNRTIs.  However, a considerable percentage of new HIV-1 infections are caused by the emergence of drug-resistant mutant viruses that complicate treatment strategies.  In this review we discuss relevant clin. and structural aspects for the management of antiretroviral drug resistance, with detailed explanations of mechanisms and mutation patterns useful to better understand the relation between drug resistance and therapy failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1XVvMaPx3K7Vg90H21EOLACvtfcHk0lguaBYTuiPTwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlGkt7c%253D&md5=e4e75144150c7bfd12bd22d7c5beb040</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2011.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2011.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DAlteri%26aufirst%3DC.%26aulast%3DArtese%26aufirst%3DA.%26aulast%3DCeccherini-Silberstein%26aufirst%3DF.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DParrotta%26aufirst%3DL.%26aulast%3DPerno%26aufirst%3DC.%2BF.%26aulast%3DSvicher%26aufirst%3DV.%26atitle%3DMolecular%2520and%2520structural%2520aspects%2520of%2520clinically%2520relevant%2520mutations%2520related%2520to%2520the%2520approved%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2011%26volume%3D14%26issue%3D3%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.drup.2011.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puleo, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2737</span>– <span class="NLM_lpage">2745</span>, <span class="refDoi"> DOI: 10.1021/jm501908a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501908a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2737-2745&issue=6&author=K.+M.+Freyauthor=D.+E.+Puleoauthor=K.+A.+Spasovauthor=M.+Bolliniauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=Structure-based+evaluation+of+non-nucleoside+inhibitors+with+improved+potency+and+solubility+that+target+HIV+reverse+transcriptase+variants&doi=10.1021%2Fjm501908a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Evaluation of Non-nucleoside Inhibitors with Improved Potency and Solubility That Target HIV Reverse Transcriptase Variants</span></div><div class="casAuthors">Frey, Kathleen M.; Puleo, David E.; Spasov, Krasimir A.; Bollini, Mariella; Jorgensen, William L.; Anderson, Karen S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2737-2745</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of novel non-nucleoside inhibitors (NNRTIs) with activity against variants of HIV reverse transcriptase (RT) is crucial for overcoming treatment failure.  The NNRTIs bind in an allosteric pocket in RT ∼10 Å away from the active site.  Earlier analogs of the catechol diether compd. series have picomolar activity against HIV strains with wild-type RT but lose potency against variants with single Y181C and double K103N/Y181C mutations.  As guided by structure-based and computational studies, removal of the 5-Cl substitution of compd. 1 on the catechol aryl ring system led to a new analog compd. 2 that maintains greater potency against Y181C and K103N/Y181C variants and better soly. (510 μg/mL).  Crystal structures were detd. for wild-type, Y181C, and K103N/Y181C RT in complex with both compds. 1 and 2 to understand the structural basis for these findings.  Comparison of the structures reveals that the Y181C mutation destabilizes the binding mode of compd. 1 and disrupts the interactions with residues in the pocket.  Compd. 2 maintains the same conformation in wild-type and mutant structures, in addn. to several interactions with the NNRTI binding pocket.  Comparison of the six crystal structures will assist in the understanding of compd. binding modes and future optimization of the catechol diether series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp43Id88QK4TbVg90H21EOLACvtfcHk0lguaBYTuiPTwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt7w%253D&md5=13f9ea42933e5b5c4c44942754c5c650</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fjm501908a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501908a%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DK.%2BM.%26aulast%3DPuleo%26aufirst%3DD.%2BE.%26aulast%3DSpasov%26aufirst%3DK.%2BA.%26aulast%3DBollini%26aufirst%3DM.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DStructure-based%2520evaluation%2520of%2520non-nucleoside%2520inhibitors%2520with%2520improved%2520potency%2520and%2520solubility%2520that%2520target%2520HIV%2520reverse%2520transcriptase%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D6%26spage%3D2737%26epage%3D2745%26doi%3D10.1021%2Fjm501908a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paris, K.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haq, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felts, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. M.</span></span> <span> </span><span class="NLM_article-title">Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6413</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/jm900854h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900854h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6413-6420&issue=20&author=K.%0AA.+Parisauthor=O.+Haqauthor=A.+K.+Feltsauthor=K.+Dasauthor=E.+Arnoldauthor=R.+M.+Levy&title=Conformational+landscape+of+the+human+immunodeficiency+virus+type+1+reverse+transcriptase+non-nucleoside+inhibitor+binding+pocket%3A+lessons+for+inhibitor+design+from+a+cluster+analysis+of+many+crystal+structures&doi=10.1021%2Fjm900854h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fjm900854h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900854h%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DK.%2BA.%26aulast%3DHaq%26aufirst%3DO.%26aulast%3DFelts%26aufirst%3DA.%2BK.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DLevy%26aufirst%3DR.%2BM.%26atitle%3DConformational%2520landscape%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520type%25201%2520reverse%2520transcriptase%2520non-nucleoside%2520inhibitor%2520binding%2520pocket%253A%2520lessons%2520for%2520inhibitor%2520design%2520from%2520a%2520cluster%2520analysis%2520of%2520many%2520crystal%2520structures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D20%26spage%3D6413%26epage%3D6420%26doi%3D10.1021%2Fjm900854h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khatib, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charalambous, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Oliveira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span> <span> </span><span class="NLM_article-title">Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">971</span>, <span class="refDoi"> DOI: 10.1128/AAC.04215-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.04215-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=960-971&issue=2&author=A.+E.+Bassonauthor=S.+Y.+Rheeauthor=C.+M.+Parryauthor=Z.+El-Khatibauthor=S.+Charalambousauthor=T.+De+Oliveiraauthor=D.+Pillayauthor=C.+Hoffmannauthor=D.+Katzensteinauthor=R.+W.+Shaferauthor=L.+Morris&title=Impact+of+drug+resistance-associated+amino+acid+changes+in+HIV-1+subtype+C+on+susceptibility+to+newer+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1128%2FAAC.04215-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FAAC.04215-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04215-14%26sid%3Dliteratum%253Aachs%26aulast%3DBasson%26aufirst%3DA.%2BE.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DParry%26aufirst%3DC.%2BM.%26aulast%3DEl-Khatib%26aufirst%3DZ.%26aulast%3DCharalambous%26aufirst%3DS.%26aulast%3DDe%2BOliveira%26aufirst%3DT.%26aulast%3DPillay%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DKatzenstein%26aufirst%3DD.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DMorris%26aufirst%3DL.%26atitle%3DImpact%2520of%2520drug%2520resistance-associated%2520amino%2520acid%2520changes%2520in%2520HIV-1%2520subtype%2520C%2520on%2520susceptibility%2520to%2520newer%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D2%26spage%3D960%26epage%3D971%26doi%3D10.1128%2FAAC.04215-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Magen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schader, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4667</span>– <span class="NLM_lpage">4672</span>, <span class="refDoi"> DOI: 10.1128/AAC.00800-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.00800-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=4667-4672&issue=11&author=H.+Xuauthor=Y.+Quanauthor=B.+G.+Brennerauthor=T.+Bar-Magenauthor=M.+Oliveiraauthor=S.+M.+Schaderauthor=M.+A.+Wainberg&title=Human+immunodeficiency+virus+type+1+recombinant+reverse+transcriptase+enzymes+containing+the+G190A+and+Y181C+resistance+mutations+remain+sensitive+to+etravirine&doi=10.1128%2FAAC.00800-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1128%2FAAC.00800-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00800-09%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DQuan%26aufirst%3DY.%26aulast%3DBrenner%26aufirst%3DB.%2BG.%26aulast%3DBar-Magen%26aufirst%3DT.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DSchader%26aufirst%3DS.%2BM.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520type%25201%2520recombinant%2520reverse%2520transcriptase%2520enzymes%2520containing%2520the%2520G190A%2520and%2520Y181C%2520resistance%2520mutations%2520remain%2520sensitive%2520to%2520etravirine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26issue%3D11%26spage%3D4667%26epage%3D4672%26doi%3D10.1128%2FAAC.00800-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saravolatz, L. D.</span></span> <span> </span><span class="NLM_article-title">Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1093/jac/dks404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1093%2Fjac%2Fdks404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23099850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=250-256&issue=2&author=M.+Sharmaauthor=L.+D.+Saravolatz&title=Rilpivirine%3A+a+new+non-nucleoside+reverse+transcriptase+inhibitor&doi=10.1093%2Fjac%2Fdks404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</span></div><div class="casAuthors">Sharma, Mamta; Saravolatz, Louis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-256</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents.  The recommended dose is a 25 mg tablet once daily taken orally with a meal.  Due to cytochrome P 450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a no. of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort).  Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes.  Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clin. trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates.  Virol. failure occurs more commonly with higher baseline viral loads (>100 000 copies/mL) and lower baseline CD4 counts (<50cells/mm3).  Seventeen NNRTI mutations have been assocd. with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N.  Resistance to rilpivirine largely excludes future use of the NNRTI class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMF-84gVV5t7Vg90H21EOLACvtfcHk0lgcIKI1jdvDTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVCjsA%253D%253D&md5=83d5fe1e2377ec908cc5f7b5e9eb94ab</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdks404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdks404%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DSaravolatz%26aufirst%3DL.%2BD.%26atitle%3DRilpivirine%253A%2520a%2520new%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2013%26volume%3D68%26issue%3D2%26spage%3D250%26epage%3D256%26doi%3D10.1093%2Fjac%2Fdks404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span> <i>Etravirine Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Etravirine+Package%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEtravirine%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauly, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span> <span> </span><span class="NLM_article-title">A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants</span>. <i>Retrovirology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">99</span>, <span class="refDoi"> DOI: 10.1186/1742-4690-9-99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1186%2F1742-4690-9-99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23217210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVeksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=99&author=B.+C.+Johnsonauthor=G.+T.+Paulyauthor=G.+Raiauthor=D.+Patelauthor=J.+D.+Baumanauthor=H.+L.+Bakerauthor=K.+Dasauthor=J.+P.+Schneiderauthor=D.+J.+Maloneyauthor=E.+Arnoldauthor=C.+J.+Thomasauthor=S.+H.+Hughes&title=A+comparison+of+the+ability+of+rilpivirine+%28TMC278%29+and+selected+analogues+to+inhibit+clinically+relevant+HIV-1+reverse+transcriptase+mutants&doi=10.1186%2F1742-4690-9-99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants</span></div><div class="casAuthors">Johnson, Barry C.; Pauly, Gary T.; Rai, Ganesha; Patel, Disha; Bauman, Joseph D.; Baker, Heather L.; Das, Kalyan; Schneider, Joel P.; Maloney, David J.; Arnold, Eddy; Thomas, Craig J.; Hughes, Stephen H.</div><div class="citationInfo"><span class="NLM_cas:title">Retrovirology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99</span>CODEN:
                <span class="NLM_cas:coden">RETRBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-4690</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chem. step of DNA synthesis.  In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clin. relevant RT mutants.  Many structural analogs of rilpivirine are described in the patent literature, but detailed analyses of their antiviral activities have not been published.  This work addresses the ability of several of these analogs to inhibit the replication of wild-type (WT) and drug-resistant HIV-1.  Results: We used a combination of structure activity relationships and X-ray crystallog. to examine NNRTIs that are structurally related to rilpivirine to det. their ability to inhibit WT RT and several clin. relevant RT mutants.  Several analogs showed broad activity with only modest losses of potency when challenged with drug-resistant viruses.  Structural analyses (crystallog. or modeling) of several analogs whose potencies were reduced by RT mutations provide insight into why these compds. were less effective.  Conclusions: Subtle variations between compds. can lead to profound differences in their activities and resistance profiles.  Compds. with larger substitutions replacing the pyrimidine and benzonitrile groups of rilpivirine, which reorient pocket residues, tend to lose more activity against the mutants we tested.  These results provide a deeper understanding of how rilpivirine and related compds. interact with the NNRTI binding pocket and should facilitate development of novel inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEp7L0uk3OsrVg90H21EOLACvtfcHk0lgcIKI1jdvDTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVeksL8%253D&md5=7eadce812488ec262f6e088dc9d3a7ed</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2F1742-4690-9-99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4690-9-99%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BC.%26aulast%3DPauly%26aufirst%3DG.%2BT.%26aulast%3DRai%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DBauman%26aufirst%3DJ.%2BD.%26aulast%3DBaker%26aufirst%3DH.%2BL.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DJ.%2BP.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26atitle%3DA%2520comparison%2520of%2520the%2520ability%2520of%2520rilpivirine%2520%2528TMC278%2529%2520and%2520selected%2520analogues%2520to%2520inhibit%2520clinically%2520relevant%2520HIV-1%2520reverse%2520transcriptase%2520mutants%26jtitle%3DRetrovirology%26date%3D2012%26volume%3D9%26spage%3D99%26doi%3D10.1186%2F1742-4690-9-99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span> <span> </span><span class="NLM_article-title">Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1586/14787210.2014.863708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1586%2F14787210.2014.863708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=24308712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Orsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=13-29&issue=1&author=D.+Ripamontiauthor=E.+Bombanaauthor=M.+Rizzi&title=Rilpivirine%3A+drug+profile+of+a+second-generation+non-nucleoside+reverse+transcriptase+HIV-inhibitor&doi=10.1586%2F14787210.2014.863708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor</span></div><div class="casAuthors">Ripamonti, Diego; Bombana, Enrico; Rizzi, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-29</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Rilpivirine (RPV) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of the diarylpyrimidine family.  RPV can be given once daily, is well absorbed and should be administered with food.  It is eliminated mainly by hepatic metab.  Two phase III noninferiority trials (ECHO and THRIVE), compared RPV 25mg with efavirenz (EFV) 600 mg, both given once daily, and combined with 2NRTI backbone.  At week 48, response rate for pooled data were 84 vs. 82% (difference: 2%; 95% CI: -2.0 to 6.0%).  EFV arms performed better than RPV arms when at higher baseline HIV RNA, so RPV was approved for treatment-naive patients with HIV RNA below 100,000 copies/mL.  Approx. 90% of viruses phenotypically resistant to RPV showed cross-resistance to ETR.  Conversely, phenotypic anal. showed that in EFV arm, none were resistant to the second-generation NNRTIs.  CD4 count increases were similar between groups, but RPV showed a lower rate of discontinuation due to adverse events and lower rates of central nervous system effects, rash and lipid abnormalities.  Potency, tolerability and co-formulation in a single tablet (Eviplera, Complera) make this drug a new and attractive option for the treatment of HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9gmCkqrVcqLVg90H21EOLACvtfcHk0lhxq4ILCdHtzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Orsbk%253D&md5=e2ea563d672ec7d4915dda7894da4811</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1586%2F14787210.2014.863708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14787210.2014.863708%26sid%3Dliteratum%253Aachs%26aulast%3DRipamonti%26aufirst%3DD.%26aulast%3DBombana%26aufirst%3DE.%26aulast%3DRizzi%26aufirst%3DM.%26atitle%3DRilpivirine%253A%2520drug%2520profile%2520of%2520a%2520second-generation%2520non-nucleoside%2520reverse%2520transcriptase%2520HIV-inhibitor%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2014%26volume%3D12%26issue%3D1%26spage%3D13%26epage%3D29%26doi%3D10.1586%2F14787210.2014.863708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskey, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mislak, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1079</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1075-1079&issue=10&author=W.+T.+Grayauthor=K.+M.+Freyauthor=S.+B.+Laskeyauthor=A.+C.+Mislakauthor=K.+A.+Spasovauthor=W.+G.+Leeauthor=M.+Bolliniauthor=R.+F.+Silicianoauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=Potent+inhibitors+active+against+HIV+reverse+transcriptase+with+K101P%2C+a+mutation+conferring+rilpivirine+resistance&doi=10.1021%2Facsmedchemlett.5b00254"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00254%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DW.%2BT.%26aulast%3DFrey%26aufirst%3DK.%2BM.%26aulast%3DLaskey%26aufirst%3DS.%2BB.%26aulast%3DMislak%26aufirst%3DA.%2BC.%26aulast%3DSpasov%26aufirst%3DK.%2BA.%26aulast%3DLee%26aufirst%3DW.%2BG.%26aulast%3DBollini%26aufirst%3DM.%26aulast%3DSiliciano%26aufirst%3DR.%2BF.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520inhibitors%2520active%2520against%2520HIV%2520reverse%2520transcriptase%2520with%2520K101P%252C%2520a%2520mutation%2520conferring%2520rilpivirine%2520resistance%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D10%26spage%3D1075%26epage%3D1079%26doi%3D10.1021%2Facsmedchemlett.5b00254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby-Germinario, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petropoulos, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5649</span>– <span class="NLM_lpage">5657</span>, <span class="refDoi"> DOI: 10.1128/AAC.01536-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.01536-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5649-5657&issue=11&author=H.+T.+Xuauthor=S.+P.+Colby-Germinarioauthor=W.+Huangauthor=M.+Oliveiraauthor=Y.+Hanauthor=Y.+Quanauthor=C.+J.+Petropoulosauthor=M.+A.+Wainberg&title=Role+of+the+K101E+substitution+in+HIV-1+reverse+transcriptase+in+resistance+to+rilpivirine+and+other+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1128%2FAAC.01536-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1128%2FAAC.01536-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01536-13%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%2BT.%26aulast%3DColby-Germinario%26aufirst%3DS.%2BP.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DQuan%26aufirst%3DY.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520the%2520K101E%2520substitution%2520in%2520HIV-1%2520reverse%2520transcriptase%2520in%2520resistance%2520to%2520rilpivirine%2520and%2520other%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D11%26spage%3D5649%26epage%3D5657%26doi%3D10.1128%2FAAC.01536-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michailidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzek, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagedorn, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norden, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parniak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span> <span> </span><span class="NLM_article-title">Biochemical mechanism of HIV-1 resistance to rilpivirine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">38110</span>– <span class="NLM_lpage">38123</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.398180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1074%2Fjbc.M112.398180" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=38110-38123&issue=45&author=K.+Singhauthor=B.+Marchandauthor=D.+K.+Raiauthor=B.+Sharmaauthor=E.+Michailidisauthor=E.+M.+Ryanauthor=K.+B.+Matzekauthor=M.+D.+Leslieauthor=A.+N.+Hagedornauthor=Z.+Liauthor=P.+R.+Nordenauthor=A.+Hachiyaauthor=M.+A.+Parniakauthor=H.+T.+Xuauthor=M.+A.+Wainbergauthor=S.+G.+Sarafianos&title=Biochemical+mechanism+of+HIV-1+resistance+to+rilpivirine&doi=10.1074%2Fjbc.M112.398180"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.398180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.398180%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DMarchand%26aufirst%3DB.%26aulast%3DRai%26aufirst%3DD.%2BK.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DRyan%26aufirst%3DE.%2BM.%26aulast%3DMatzek%26aufirst%3DK.%2BB.%26aulast%3DLeslie%26aufirst%3DM.%2BD.%26aulast%3DHagedorn%26aufirst%3DA.%2BN.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DNorden%26aufirst%3DP.%2BR.%26aulast%3DHachiya%26aufirst%3DA.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DXu%26aufirst%3DH.%2BT.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DBiochemical%2520mechanism%2520of%2520HIV-1%2520resistance%2520to%2520rilpivirine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26issue%3D45%26spage%3D38110%26epage%3D38123%26doi%3D10.1074%2Fjbc.M112.398180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2788</span>– <span class="NLM_lpage">2792</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2017.04.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2788-2792&issue=12&author=L.+Weiauthor=H.+L.+Wangauthor=L.+Huangauthor=C.+H.+Chenauthor=S.+L.+Morris-Natschkeauthor=K.+H.+Leeauthor=L.+Xie&title=Drug-like+property-driven+optimization+of+4-substituted+1%2C5-diarylanilines+as+potent+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors+against+rilpivirine-resistant+mutant+virus&doi=10.1016%2Fj.bmcl.2017.04.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DDrug-like%2520property-driven%2520optimization%2520of%25204-substituted%25201%252C5-diarylanilines%2520as%2520potent%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520against%2520rilpivirine-resistant%2520mutant%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D12%26spage%3D2788%26epage%3D2792%26doi%3D10.1016%2Fj.bmcl.2017.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaoglu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansdon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eygen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picchio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svarovskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span> <span> </span><span class="NLM_article-title">The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1097/QAI.0b013e31823aca74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FQAI.0b013e31823aca74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=21997204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SgtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=47-54&issue=1&author=R.+Kulkarniauthor=K.+Babaogluauthor=E.+B.+Lansdonauthor=L.+Rimskyauthor=V.+Van+Eygenauthor=G.+Picchioauthor=E.+Svarovskaiaauthor=M.+D.+Millerauthor=K.+L.+White&title=The+HIV-1+reverse+transcriptase+M184I+mutation+enhances+the+E138K-associated+resistance+to+rilpivirine+and+decreases+viral+fitness&doi=10.1097%2FQAI.0b013e31823aca74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness</span></div><div class="casAuthors">Kulkarni, Rima; Babaoglu, Kerim; Lansdon, Eric B.; Rimsky, Laurence; Van Eygen, Veerle; Picchio, Gaston; Svarovskaia, Evguenia; Miller, Michael D.; White, Kirsten L.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The registrational phase III clin. trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two nucleoside/nucleotide RT inhibitors (NRTIs) found a unique genotypic resistance pattern involving the NNRTI mutation E138K with the NRTI mutation M184I.  Eighty percent of subjects used emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF); a single tablet regimen of FTC/RPV/TDF is in development.  Methods: HIV-1 with E138K and/or M184V or I mutations were constructed and phenotyped in MT-2 cells and the PhenoSense and Antivirogram assays.  Viral fitness was detd. using growth competitions.  Mol. models of the mutants were constructed from the RT-RPV crystal structure.  Results: The E138K mutant showed low-level reduced susceptibility to RPV (2.4-fold), but full susceptibility to FTC and tenofovir (TFV).  Viruses with M184V or M184I showed high-level resistance to FTC and full susceptibility to RPV and TFV.  Addn. of M184I, but not M184V, to E138K, further decreased susceptibility to RPV and maintained FTC resistance.  The E138K and M184V or I single and double mutants showed decreased replication fitness compared with wild type.  M184V outcompeted M184I when compared directly and in the background of E138K.  E138K + M184I was less fit than either E138K or M184I alone.  Removing a salt bridge between E138/K101 is implicated in resistance to RPV.  Conclusions: The higher frequency of E138K and M184I among RPV + FTC/TDF virol. failures is due to reduced susceptibility of the single mutants to RPV and FTC and the enhanced resistance to RPV for the double mutant at the cost of decreased viral fitness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0f6ss0TwYi7Vg90H21EOLACvtfcHk0ljdWJ77_pde_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SgtbvO&md5=1134d4490bd5e383fe67ab31a39766cf</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e31823aca74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e31823aca74%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DR.%26aulast%3DBabaoglu%26aufirst%3DK.%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DRimsky%26aufirst%3DL.%26aulast%3DVan%2BEygen%26aufirst%3DV.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26atitle%3DThe%2520HIV-1%2520reverse%2520transcriptase%2520M184I%2520mutation%2520enhances%2520the%2520E138K-associated%2520resistance%2520to%2520rilpivirine%2520and%2520decreases%2520viral%2520fitness%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2012%26volume%3D59%26issue%3D1%26spage%3D47%26epage%3D54%26doi%3D10.1097%2FQAI.0b013e31823aca74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span> <i>Rilpivirine Package</i>; <span class="NLM_publisher-name">U.S. Food and
Drug
Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Rilpivirine+Package%3B+U.S.+Food+and%0ADrug%0AAdministration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRilpivirine%2520Package%26pub%3DU.S.%2520Food%2520and%250ADrug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span> <i>Etravirine Prescribing
Information</i>; <span class="NLM_publisher-name">AIDSinfo</span>, <span class="NLM_year">2018</span>; <a href="https://aidsinfo.nih.gov/drugs/398/etravirine/16/professional" class="extLink">https://aidsinfo.nih.gov/drugs/398/etravirine/16/professional</a> (accessed May 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Etravirine+Prescribing%0AInformation%3B+AIDSinfo%2C+2018%3B+https%3A%2F%2Faidsinfo.nih.gov%2Fdrugs%2F398%2Fetravirine%2F16%2Fprofessional+%28accessed+May+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEtravirine%2520Prescribing%250AInformation%26pub%3DAIDSinfo%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katlama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madruga, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picchio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodfall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Smedt, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2289</span>– <span class="NLM_lpage">2300</span>, <span class="refDoi"> DOI: 10.1097/QAD.0b013e3283316a5e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FQAD.0b013e3283316a5e" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=2289-2300&issue=17&author=C.+Katlamaauthor=R.+Haubrichauthor=J.+Lalezariauthor=A.+Lazzarinauthor=J.+V.+Madrugaauthor=J.+M.+Molinaauthor=M.+Schechterauthor=M.+Peetersauthor=G.+Picchioauthor=J.+Vingerhoetsauthor=B.+Woodfallauthor=G.+De+Smedt&title=Efficacy+and+safety+of+etravirine+in+treatment-experienced%2C+HIV-1+patients%3A+pooled+48+week+analysis+of+two+randomized%2C+controlled+trials&doi=10.1097%2FQAD.0b013e3283316a5e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1097%2FQAD.0b013e3283316a5e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0b013e3283316a5e%26sid%3Dliteratum%253Aachs%26aulast%3DKatlama%26aufirst%3DC.%26aulast%3DHaubrich%26aufirst%3DR.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DLazzarin%26aufirst%3DA.%26aulast%3DMadruga%26aufirst%3DJ.%2BV.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DSchechter%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DWoodfall%26aufirst%3DB.%26aulast%3DDe%2BSmedt%26aufirst%3DG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520etravirine%2520in%2520treatment-experienced%252C%2520HIV-1%2520patients%253A%2520pooled%252048%2520week%2520analysis%2520of%2520two%2520randomized%252C%2520controlled%2520trials%26jtitle%3DAIDS%26date%3D2009%26volume%3D23%26issue%3D17%26spage%3D2289%26epage%3D2300%26doi%3D10.1097%2FQAD.0b013e3283316a5e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luber, A. D.</span></span> <span> </span><span class="NLM_article-title">Genetic barriers to resistance and impact on clinical response</span>. <i>MedGenMed: Medscape general medicine</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">69</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=16369295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD2MnotFOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=69&issue=3&author=A.+D.+Luber&title=Genetic+barriers+to+resistance+and+impact+on+clinical+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic barriers to resistance and impact on clinical response</span></div><div class="casAuthors">Luber Andrew D</div><div class="citationInfo"><span class="NLM_cas:title">MedGenMed : Medscape general medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of drug resistance and cross-resistance continues to pose a challenge to successful long-term antiretroviral therapy despite the availability of new antiretroviral agents.  The genetic barrier to resistance of a regimen does not directly correlate with its effectiveness.  For some regimens with a low genetic barrier to resistance, however, the emergence of only 1 or 2 key resistance mutations may confer drug resistance not only to that regimen but also to other agents, thereby limiting subsequent treatment options.  In addition to the genetic barrier to resistance, factors such as efficacy, safety, tolerability, convenience, and adherence must be considered when choosing a regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-5uVX9JSZzmPgL4LrC-0VfW6udTcc2eaeBY6hpCwpQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnotFOitw%253D%253D&md5=0d078402a73680ccd893d5b3272ac047</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuber%26aufirst%3DA.%2BD.%26atitle%3DGenetic%2520barriers%2520to%2520resistance%2520and%2520impact%2520on%2520clinical%2520response%26jtitle%3DMedGenMed%253A%2520Medscape%2520general%2520medicine%26date%3D2005%26volume%3D7%26issue%3D3%26spage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span> <i>Rilpivirine Prescribing Information</i>; <span class="NLM_publisher-name">AIDSinfo</span>, <span class="NLM_year">2018</span>; <a href="https://aidsinfo.nih.gov/drugs/426/rilpivirine/19/professional" class="extLink">https://aidsinfo.nih.gov/drugs/426/rilpivirine/19/professional</a> (accessed May 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Rilpivirine+Prescribing+Information%3B+AIDSinfo%2C+2018%3B+https%3A%2F%2Faidsinfo.nih.gov%2Fdrugs%2F426%2Frilpivirine%2F19%2Fprofessional+%28accessed+May+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRilpivirine%2520Prescribing%2520Information%26pub%3DAIDSinfo%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinsztejn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supparatpinyo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crauwels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsky, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanveggel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1097/QAI.0b013e31824d006e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FQAI.0b013e31824d006e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22343174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFGrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=33-42&issue=1&author=C.%0AJ.+Cohenauthor=J.+M.+Molinaauthor=P.+Cahnauthor=B.+Clotetauthor=J.+Fourieauthor=B.+Grinsztejnauthor=H.+Wuauthor=M.+A.+Johnsonauthor=M.+Saagauthor=K.+Supparatpinyoauthor=H.+Crauwelsauthor=E.+Lefebvreauthor=L.+T.+Rimskyauthor=S.+Vanveggelauthor=P.+Williamsauthor=K.+Boven&title=Efficacy+and+safety+of+rilpivirine+%28TMC278%29+versus+efavirenz+at+48+weeks+in+treatment-naive+HIV-1-infected+patients%3A+pooled+results+from+the+phase+3+double-blind+randomized+ECHO+and+THRIVE+Trials&doi=10.1097%2FQAI.0b013e31824d006e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials</span></div><div class="casAuthors">Cohen, Calvin J.; Molina, Jean-Michel; Cahn, Pedro; Clotet, Bonaventura; Fourie, Jan; Grinsztejn, Beatriz; Wu, Hao; Johnson, Margaret A.; Saag, Michael; Supparatpinyo, Khuanchai; Crauwels, Herta; Lefebvre, Eric; Rimsky, Laurence T.; Vanveggel, Simon; Williams, Peter; Boven, Katia</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Pooled anal. of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz.  Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (ECHO) or TDF/FTC, zidovudine/lamivudine, or abacavir/lamivudine (THRIVE).  The primary endpoint was confirmed response [viral load <50 copies per mL; intent-to-treat time-to-loss-of-virol.-response (ITT-TLOVR) algorithm] at week 48.  The pooled data set enabled analyses of subgroups and predictors of response/virol. failure.  Results: Confirmed responses were 84% (rilpivirine) and 82% (efavirenz).  The difference in response rates (95% confidence interval) was 2.0% (-2.0% to 6.0%).  The incidence of virol. failure was 9% (rilpivirine) vs. 5% (efavirenz).  Responses in ITT-TLOVR and ITT-snapshot analyses were consistent.  Responses were similar for rilpivirine and efavirenz by background regimen, gender, race and clade.  Suboptimal adherence and higher baseline viral load resulted in lower responses, higher virol. failure, and development of resistance in both groups; the effects on virol. failure were more apparent with rilpivirine.  CD4 cell count increased over time in both groups.  Rilpivirine compared with efavirenz gave smaller incidences of adverse events leading to discontinuation (3% vs. 8%, resp.), treatment-related grade 2-4 adverse events (16% vs. 31%), rash (3% vs. 14%), dizziness (8% vs. 26%), abnormal dreams/nightmares (8% vs. 13%), and grade 2-4 lipid abnormalities.  Conclusions: At week 48, rilpivirine 25 mg once daily and efavirenz 600 mg once daily had comparable response rates.  Rilpivirine had more virol. failures and improved tolerability vs. efavirenz.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDdTELL1cP7Vg90H21EOLACvtfcHk0liXs9vqqYMvkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFGrurs%253D&md5=8670bbbaedeb5053b8dd202ea8c10b8c</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e31824d006e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e31824d006e%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DC.%2BJ.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DCahn%26aufirst%3DP.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DFourie%26aufirst%3DJ.%26aulast%3DGrinsztejn%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DSaag%26aufirst%3DM.%26aulast%3DSupparatpinyo%26aufirst%3DK.%26aulast%3DCrauwels%26aufirst%3DH.%26aulast%3DLefebvre%26aufirst%3DE.%26aulast%3DRimsky%26aufirst%3DL.%2BT.%26aulast%3DVanveggel%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DBoven%26aufirst%3DK.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520rilpivirine%2520%2528TMC278%2529%2520versus%2520efavirenz%2520at%252048%2520weeks%2520in%2520treatment-naive%2520HIV-1-infected%2520patients%253A%2520pooled%2520results%2520from%2520the%2520phase%25203%2520double-blind%2520randomized%2520ECHO%2520and%2520THRIVE%2520Trials%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2012%26volume%3D60%26issue%3D1%26spage%3D33%26epage%3D42%26doi%3D10.1097%2FQAI.0b013e31824d006e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corte, D.</span>; <span class="NLM_string-name">De
Jonge, M. R.</span>; <span class="NLM_string-name">Heeres, J.</span>; <span class="NLM_string-name">Ho, C. Y.</span>; <span class="NLM_string-name">Janssen, P. A. J.</span>; <span class="NLM_string-name">Kavash, R. W.</span>; <span class="NLM_string-name">Koymans, L. M. H.</span>; <span class="NLM_string-name">Kukla, M. J.</span>; <span class="NLM_string-name">Ludovici, D. W.</span>; <span class="NLM_string-name">Van Aken, K. J. A.</span></span> <span> </span><span class="NLM_article-title">HIV Replication Inhibiting Pyrimidines</span>. U.S. Patent <span class="NLM_patent">US6878717B2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+Corte&author=M.+R.+De%0AJonge&author=J.+Heeres&author=C.+Y.+Ho&author=P.+A.+J.+Janssen&author=R.+W.+Kavash&author=L.+M.+H.+Koymans&author=M.+J.+Kukla&author=D.+W.+Ludovici&author=K.+J.+A.+Van+Aken&title=HIV+Replication+Inhibiting+Pyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCorte%26aufirst%3DD.%26atitle%3DHIV%2520Replication%2520Inhibiting%2520Pyrimidines%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maikap, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titirmare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurjar, M. K.</span></span> <span> </span><span class="NLM_article-title">An improved synthesis of etravirine</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1021/op9003289</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op9003289" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=657-660&issue=3&author=S.+Joshiauthor=G.+C.+Maikapauthor=S.+Titirmareauthor=A.+Chaudhariauthor=M.+K.+Gurjar&title=An+improved+synthesis+of+etravirine&doi=10.1021%2Fop9003289"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fop9003289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop9003289%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DMaikap%26aufirst%3DG.%2BC.%26aulast%3DTitirmare%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DA.%26aulast%3DGurjar%26aufirst%3DM.%2BK.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520etravirine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2010%26volume%3D14%26issue%3D3%26spage%3D657%26epage%3D660%26doi%3D10.1021%2Fop9003289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fier, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and late-stage functionalization of complex molecules through C–H fluorination and nucleophilic aromatic substitution</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">10139</span>– <span class="NLM_lpage">10147</span>, <span class="refDoi"> DOI: 10.1021/ja5049303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5049303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=10139-10147&issue=28&author=P.+S.+Fierauthor=J.+F.+Hartwig&title=Synthesis+and+late-stage+functionalization+of+complex+molecules+through+C%E2%80%93H+fluorination+and+nucleophilic+aromatic+substitution&doi=10.1021%2Fja5049303"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fja5049303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5049303%26sid%3Dliteratum%253Aachs%26aulast%3DFier%26aufirst%3DP.%2BS.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DSynthesis%2520and%2520late-stage%2520functionalization%2520of%2520complex%2520molecules%2520through%2520C%25E2%2580%2593H%2520fluorination%2520and%2520nucleophilic%2520aromatic%2520substitution%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26issue%3D28%26spage%3D10139%26epage%3D10147%26doi%3D10.1021%2Fja5049303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K. J. L. M.</span>; <span class="NLM_string-name">De, C. B.</span>; <span class="NLM_string-name">DE, J.
M. R.</span>; <span class="NLM_string-name">Heeres, J.</span>; <span class="NLM_string-name">Ho, C. Y.</span>; <span class="NLM_string-name">Janssen, M. A. C.</span>; <span class="NLM_string-name">Janssen, P. A. J.</span>; <span class="NLM_string-name">Koymans, L. M. H.</span>; <span class="NLM_string-name">Kukla, M. J.</span>; <span class="NLM_string-name">Ludovici, D. W.</span></span> <span> </span><span class="NLM_article-title">HIV Inhibiting Pyrimidine Derivatives</span>. World Patent <span class="NLM_patent">WO1999050250A1</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=K.+J.+L.+M.+Andries&author=C.+B.+De&author=J.%0AM.+R.+DE&author=J.+Heeres&author=C.+Y.+Ho&author=M.+A.+C.+Janssen&author=P.+A.+J.+Janssen&author=L.+M.+H.+Koymans&author=M.+J.+Kukla&author=D.+W.+Ludovici&title=HIV+Inhibiting+Pyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%2BJ.%2BL.%2BM.%26atitle%3DHIV%2520Inhibiting%2520Pyrimidine%2520Derivatives%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palandjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaurrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertogs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigerinck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2072</span>– <span class="NLM_lpage">2079</span>, <span class="refDoi"> DOI: 10.1021/jm040838n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040838n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2072-2079&issue=6&author=J.+Guillemontauthor=E.+Pasquierauthor=P.+Palandjianauthor=D.+Vernierauthor=S.+Gaurrandauthor=P.+J.+Lewiauthor=J.+Heeresauthor=M.+R.+de+Jongeauthor=L.+M.+Koymansauthor=F.+F.+Daeyaertauthor=M.+H.+Vinkersauthor=E.+Arnoldauthor=K.+Dasauthor=R.+Pauwelsauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=E.+Bettensauthor=K.+Hertogsauthor=P.+Wigerinckauthor=P.+Timmermanauthor=P.+A.+Janssen&title=Synthesis+of+novel+diarylpyrimidine+analogues+and+their+antiviral+activity+against+human+immunodeficiency+virus+type+1&doi=10.1021%2Fjm040838n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm040838n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040838n%26sid%3Dliteratum%253Aachs%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DPalandjian%26aufirst%3DP.%26aulast%3DVernier%26aufirst%3DD.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3DDaeyaert%26aufirst%3DF.%2BF.%26aulast%3DVinkers%26aufirst%3DM.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DBettens%26aufirst%3DE.%26aulast%3DHertogs%26aufirst%3DK.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DSynthesis%2520of%2520novel%2520diarylpyrimidine%2520analogues%2520and%2520their%2520antiviral%2520activity%2520against%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D2072%26epage%3D2079%26doi%3D10.1021%2Fjm040838n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schils, D. P. R.</span>; <span class="NLM_string-name">Stappers, A. E.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile</span>. U.S. Patent <span class="NLM_patent">US20080171878A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+P.+R.+Schils&author=A.+E.+Stappers&title=Process+for+Preparing+4-%5B%281%2C6-dihydro-6-oxo-2-pyrimidinyl%29amino%5Dbenzonitrile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchils%26aufirst%3DD.%2BP.%2BR.%26atitle%3DProcess%2520for%2520Preparing%25204-%255B%25281%252C6-dihydro-6-oxo-2-pyrimidinyl%2529amino%255Dbenzonitrile%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches to the 2011 new drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&issue=11&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+approaches+to+the+2011+new+drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520approaches%2520to%2520the%25202011%2520new%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffito, M.</span></span> <span> </span><span class="NLM_article-title">Long-acting antiviral agents for HIV treatment</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FCOH.0000000000000169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26049949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=246-252&issue=4&author=D.+A.+Margolisauthor=M.+Boffito&title=Long-acting+antiviral+agents+for+HIV+treatment&doi=10.1097%2FCOH.0000000000000169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting antiviral agents for HIV treatment</span></div><div class="casAuthors">Margolis, David A.; Boffito, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">246-252</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Long-acting antiretroviral (ARV) agents are currently under development for the treatment of chronic HIV infection.  This review focuses on data recently produced on injectable ARVs for patients living with HIV/AIDS and on the patients' perspectives on the use of these agents.  Recent findings: Cryst. nanoparticle formulations of the nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278) and of the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) have progressed into phase II clin. trials as injectable maintenance therapy for patients living with HIV/AIDS with an undetectable viral load.  Summary: Phase II studies evaluating the coadministration of rilpivirine and cabotegravir i.m. to HIV-infected individuals with an undetectable viral load are currently underway.  Rilpivirine and cabotegravir are characterized by different mechanisms of action against HIV and a favorable drug interaction profile, providing a rationale for coadministration.  The high potency and low daily dosing requirements of oral cabotegravir and rilpivirine facilitate long-acting formulation development.  I.m. dosing is preceded by an oral lead-in phase to assess safety and tolerability in individual participants.  In addn. to assessing the safety of injectable therapies in ongoing studies, it will be important to evaluate whether differences in drug adherence between injectable and oral therapies lead to different virol. outcomes, including rates of virol. failure and the emergence of resistance.  Long-acting formulations may be assocd. with challenges, such as the management of adverse effects with persistent drug concns. and the risk of virol. resistance, as drug concns. decline following discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRsw4JuEgenrVg90H21EOLACvtfcHk0lguCkARwA8j_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtLo%253D&md5=b3a24adf1ac01264a07c00b51c10ecfa</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000169%26sid%3Dliteratum%253Aachs%26aulast%3DMargolis%26aufirst%3DD.%2BA.%26aulast%3DBoffito%26aufirst%3DM.%26atitle%3DLong-acting%2520antiviral%2520agents%2520for%2520HIV%2520treatment%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2015%26volume%3D10%26issue%3D4%26spage%3D246%26epage%3D252%26doi%3D10.1097%2FCOH.0000000000000169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Garcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellbrink, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanpanah, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podzamczer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clair, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crauwels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreen, W. R.</span></span> <span> </span><span class="NLM_article-title">Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span> (<span class="NLM_issue">10101</span>),  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1510</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31917-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2817%2931917-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=1499-1510&issue=10101&author=D.+A.+Margolisauthor=J.+Gonzalez-Garciaauthor=H.+J.+Stellbrinkauthor=J.+J.+Eronauthor=Y.+Yazdanpanahauthor=D.+Podzamczerauthor=T.+Lutzauthor=J.+B.+Angelauthor=G.+J.+Richmondauthor=B.+Clotetauthor=F.+Gutierrezauthor=L.+Sloanauthor=M.+S.+Clairauthor=M.+Murrayauthor=S.+L.+Fordauthor=J.+Mrusauthor=P.+Patelauthor=H.+Crauwelsauthor=S.+K.+Griffithauthor=K.+C.+Suttonauthor=D.+Doreyauthor=K.+Y.+Smithauthor=P.+E.+Williamsauthor=W.+R.+Spreen&title=Long-acting+intramuscular+cabotegravir+and+rilpivirine+in+adults+with+HIV-1+infection+%28LATTE-2%29%3A+96-week+results+of+a+randomised%2C+open-label%2C+phase+2b%2C+non-inferiority+trial&doi=10.1016%2FS0140-6736%2817%2931917-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931917-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931917-7%26sid%3Dliteratum%253Aachs%26aulast%3DMargolis%26aufirst%3DD.%2BA.%26aulast%3DGonzalez-Garcia%26aufirst%3DJ.%26aulast%3DStellbrink%26aufirst%3DH.%2BJ.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DYazdanpanah%26aufirst%3DY.%26aulast%3DPodzamczer%26aufirst%3DD.%26aulast%3DLutz%26aufirst%3DT.%26aulast%3DAngel%26aufirst%3DJ.%2BB.%26aulast%3DRichmond%26aufirst%3DG.%2BJ.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DGutierrez%26aufirst%3DF.%26aulast%3DSloan%26aufirst%3DL.%26aulast%3DClair%26aufirst%3DM.%2BS.%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DS.%2BL.%26aulast%3DMrus%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DCrauwels%26aufirst%3DH.%26aulast%3DGriffith%26aufirst%3DS.%2BK.%26aulast%3DSutton%26aufirst%3DK.%2BC.%26aulast%3DDorey%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DK.%2BY.%26aulast%3DWilliams%26aufirst%3DP.%2BE.%26aulast%3DSpreen%26aufirst%3DW.%2BR.%26atitle%3DLong-acting%2520intramuscular%2520cabotegravir%2520and%2520rilpivirine%2520in%2520adults%2520with%2520HIV-1%2520infection%2520%2528LATTE-2%2529%253A%252096-week%2520results%2520of%2520a%2520randomised%252C%2520open-label%252C%2520phase%25202b%252C%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26issue%3D10101%26spage%3D1499%26epage%3D1510%26doi%3D10.1016%2FS0140-6736%2817%2931917-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantsios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deVente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span> <span> </span><span class="NLM_article-title">Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e0190487</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0190487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1371%2Fjournal.pone.0190487" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&issue=1&author=D.+Kerriganauthor=A.+Mantsiosauthor=M.+Gorgolasauthor=M.+L.+Montesauthor=F.+Pulidoauthor=C.+Brinsonauthor=J.+deVenteauthor=G.+J.+Richmondauthor=S.+W.+Beckhamauthor=P.+Hammondauthor=D.+Margolisauthor=M.+Murray&title=Experiences+with+long+acting+injectable+ART%3A+A+qualitative+study+among+PLHIV+participating+in+a+Phase+II+study+of+cabotegravir+%2B+rilpivirine+%28LATTE-2%29+in+the+United+States+and+Spain&doi=10.1371%2Fjournal.pone.0190487"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0190487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0190487%26sid%3Dliteratum%253Aachs%26aulast%3DKerrigan%26aufirst%3DD.%26aulast%3DMantsios%26aufirst%3DA.%26aulast%3DGorgolas%26aufirst%3DM.%26aulast%3DMontes%26aufirst%3DM.%2BL.%26aulast%3DPulido%26aufirst%3DF.%26aulast%3DBrinson%26aufirst%3DC.%26aulast%3DdeVente%26aufirst%3DJ.%26aulast%3DRichmond%26aufirst%3DG.%2BJ.%26aulast%3DBeckham%26aufirst%3DS.%2BW.%26aulast%3DHammond%26aufirst%3DP.%26aulast%3DMargolis%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DExperiences%2520with%2520long%2520acting%2520injectable%2520ART%253A%2520A%2520qualitative%2520study%2520among%2520PLHIV%2520participating%2520in%2520a%2520Phase%2520II%2520study%2520of%2520cabotegravir%2520%252B%2520rilpivirine%2520%2528LATTE-2%2529%2520in%2520the%2520United%2520States%2520and%2520Spain%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D1%26doi%3D10.1371%2Fjournal.pone.0190487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R.</span>; <span class="NLM_string-name">Kravchenko, A. V.</span>; <span class="NLM_string-name">Orlova-Morozova, E.</span>; <span class="NLM_string-name">Nagimova, F.</span>; <span class="NLM_string-name">Kozirev, O.</span>; <span class="NLM_string-name">Shimonava, T.</span>; <span class="NLM_string-name">Deulina, M.</span>; <span class="NLM_string-name">Vostokova, N.</span>; <span class="NLM_string-name">Zozulya, O.</span>; <span class="NLM_string-name">Bichko, V.</span></span>, <span> </span><span class="NLM_article-title">Elsulfavirine as compared to Efavirenz in combination with TDF/FTC: 48-week study</span>. In  <i>Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA</i>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">Poster 452LB</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=Poster+452LB&author=R.+Murphy&author=A.+V.+Kravchenko&author=E.+Orlova-Morozova&author=F.+Nagimova&author=O.+Kozirev&author=T.+Shimonava&author=M.+Deulina&author=N.+Vostokova&author=O.+Zozulya&author=V.+Bichko&title=Elsulfavirine+as+compared+to+Efavirenz+in+combination+with+TDF%2FFTC%3A+48-week+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%26atitle%3DElsulfavirine%2520as%2520compared%2520to%2520Efavirenz%2520in%2520combination%2520with%2520TDF%252FFTC%253A%252048-week%2520study%26jtitle%3DConference%2520on%2520Retroviruses%2520and%2520Opportunistic%2520Infections%2520%2528CROI%2529%252C%2520Seattle%252C%2520WA%26date%3D2017%26spage%3DPoster%2520452LB" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtenbaum, C. J.</span></span> <span> </span><span class="NLM_article-title">Emerging reverse transcriptase inhibitors for HIV-1 infection</span>. <i>Expert Opin. Emerging Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1080/14728214.2018.1474202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1080%2F14728214.2018.1474202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29737220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1eisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=149-157&issue=2&author=M.+A.+Raiauthor=S.+Pannekauthor=C.+J.+Fichtenbaum&title=Emerging+reverse+transcriptase+inhibitors+for+HIV-1+infection&doi=10.1080%2F14728214.2018.1474202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging reverse transcriptase inhibitors for HIV-1 infection</span></div><div class="casAuthors">Rai, Mohammad A.; Pannek, Sam; Fichtenbaum, Carl J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART).  Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART.  However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibitors (NNRTIs) have significant side effects and resistance profiles.  We summarize the mechanisms of resistance and other limitations of the existing NRTIs/NNRTIs.  GS-9131, MK-8591, Elsulfavirine and Doravirine are four new agents that are furthest along in development.  ART development has evolved with several new promising agents.  Longer-acting agents, like MK-8591 are extremely attractive to enhance drug adherence and patient satisfaction.  Doravirine offers an NNRTI effective against common mutations that has fewer side effects, limitations on dosing and drug interactions.  GS-9131 is very potent and active against a variety of NRTI mutants but it is too early in its development to understand its full risks and benefits.  Finally, Elsulfavirine has a long half-life and preliminary data suggests fewer side effects than the most commonly used NNRTI, efavirenz.  Each of these new agents shows promise and potential to improve ART in the future.  The newer generation of reverse transcriptase inhibitors have longer half-lives, more favorable adverse effect profiles, and fewer drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZDrir6egMCbVg90H21EOLACvtfcHk0lguCkARwA8j_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1eisb8%253D&md5=2b77d96da86e14fc691ce8cacf2ea5cc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1080%2F14728214.2018.1474202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728214.2018.1474202%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DM.%2BA.%26aulast%3DPannek%26aufirst%3DS.%26aulast%3DFichtenbaum%26aufirst%3DC.%2BJ.%26atitle%3DEmerging%2520reverse%2520transcriptase%2520inhibitors%2520for%2520HIV-1%2520infection%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2018%26volume%3D23%26issue%3D2%26spage%3D149%26epage%3D157%26doi%3D10.1080%2F14728214.2018.1474202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Elsulfavirine: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1811</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0820-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1007%2Fs40265-017-0820-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1811-1816&issue=16&author=Z.+T.+Al-Salama&title=Elsulfavirine%3A+First+global+approval&doi=10.1007%2Fs40265-017-0820-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0820-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0820-3%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DElsulfavirine%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26issue%3D16%26spage%3D1811%26epage%3D1816%26doi%3D10.1007%2Fs40265-017-0820-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muraglia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orvieto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescatore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span> <span> </span><span class="NLM_article-title">Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2748</span>– <span class="NLM_lpage">2752</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2006.02.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2748-2752&issue=10&author=E.+Muragliaauthor=O.+D.+Kinzelauthor=R.+Lauferauthor=M.+D.+Millerauthor=G.+Moyerauthor=V.+Munshiauthor=F.+Orvietoauthor=M.+C.+Palumbiauthor=G.+Pescatoreauthor=M.+Rowleyauthor=P.+D.+Williamsauthor=V.+Summa&title=Tetrazole+thioacetanilides%3A+potent+non-nucleoside+inhibitors+of+WT+HIV+reverse+transcriptase+and+its+K103N+mutant&doi=10.1016%2Fj.bmcl.2006.02.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DMuraglia%26aufirst%3DE.%26aulast%3DKinzel%26aufirst%3DO.%2BD.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPescatore%26aufirst%3DG.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DP.%2BD.%26aulast%3DSumma%26aufirst%3DV.%26atitle%3DTetrazole%2520thioacetanilides%253A%2520potent%2520non-nucleoside%2520inhibitors%2520of%2520WT%2520HIV%2520reverse%2520transcriptase%2520and%2520its%2520K103N%2520mutant%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D10%26spage%3D2748%26epage%3D2752%26doi%3D10.1016%2Fj.bmcl.2006.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De La Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenket, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korboukh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamatake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, J. L.</span></span> <span> </span><span class="NLM_article-title">Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4444</span>– <span class="NLM_lpage">4449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2006.06.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4444-4449&issue=17&author=M.+De+La+Rosaauthor=H.+W.+Kimauthor=E.+Gunicauthor=C.+Jenketauthor=U.+Boyleauthor=Y.+H.+Kohauthor=I.+Korboukhauthor=M.+Allanauthor=W.+Zhangauthor=H.+Chenauthor=W.+Xuauthor=S.+Nilarauthor=N.+Yaoauthor=R.+Hamatakeauthor=S.+A.+Langauthor=Z.+Hongauthor=Z.+Zhangauthor=J.+L.+Girardet&title=Tri-substituted+triazoles+as+potent+non-nucleoside+inhibitors+of+the+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.bmcl.2006.06.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.048%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DGunic%26aufirst%3DE.%26aulast%3DJenket%26aufirst%3DC.%26aulast%3DBoyle%26aufirst%3DU.%26aulast%3DKoh%26aufirst%3DY.%2BH.%26aulast%3DKorboukh%26aufirst%3DI.%26aulast%3DAllan%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DNilar%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DN.%26aulast%3DHamatake%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DS.%2BA.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGirardet%26aufirst%3DJ.%2BL.%26atitle%3DTri-substituted%2520triazoles%2520as%2520potent%2520non-nucleoside%2520inhibitors%2520of%2520the%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D17%26spage%3D4444%26epage%3D4449%26doi%3D10.1016%2Fj.bmcl.2006.06.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romines, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. W.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazen, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boone, L. R.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1021/jm050670l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050670l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=727-739&issue=2&author=K.+R.+Rominesauthor=G.+A.+Freemanauthor=L.+T.+Schallerauthor=J.+R.+Cowanauthor=S.+S.+Gonzalesauthor=J.+H.+Tidwellauthor=C.+W.+Andrewsauthor=D.+K.+Stammersauthor=R.+J.+Hazenauthor=R.+G.+Ferrisauthor=S.+A.+Shortauthor=J.+H.+Chanauthor=L.+R.+Boone&title=Structure-activity+relationship+studies+of+novel+benzophenones+leading+to+the+discovery+of+a+potent%2C+next+generation+HIV+nonnucleoside+reverse+transcriptase+inhibitor&doi=10.1021%2Fjm050670l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fjm050670l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050670l%26sid%3Dliteratum%253Aachs%26aulast%3DRomines%26aufirst%3DK.%2BR.%26aulast%3DFreeman%26aufirst%3DG.%2BA.%26aulast%3DSchaller%26aufirst%3DL.%2BT.%26aulast%3DCowan%26aufirst%3DJ.%2BR.%26aulast%3DGonzales%26aufirst%3DS.%2BS.%26aulast%3DTidwell%26aufirst%3DJ.%2BH.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DHazen%26aufirst%3DR.%2BJ.%26aulast%3DFerris%26aufirst%3DR.%2BG.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DChan%26aufirst%3DJ.%2BH.%26aulast%3DBoone%26aufirst%3DL.%2BR.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520novel%2520benzophenones%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520potent%252C%2520next%2520generation%2520HIV%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D2%26spage%3D727%26epage%3D739%26doi%3D10.1021%2Fjm050670l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisko, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlow-Poehnelt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span> <span> </span><span class="NLM_article-title">The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2959</span>– <span class="NLM_lpage">2966</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2008.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18396399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2959-2966&issue=9&author=T.+J.+Tuckerauthor=S.+Saggarauthor=J.+T.+Siskoauthor=R.+M.+Tyneborauthor=T.+M.+Williamsauthor=P.+J.+Felockauthor=J.+A.+Flynnauthor=M.+T.+Laiauthor=Y.+Liangauthor=G.+McGaugheyauthor=M.+Liuauthor=M.+Millerauthor=G.+Moyerauthor=V.+Munshiauthor=R.+Perlow-Poehneltauthor=S.+Prasadauthor=R.+Sanchezauthor=M.+Torrentauthor=J.+P.+Vaccaauthor=B.+L.+Wanauthor=Y.+Yan&title=The+design+and+synthesis+of+diaryl+ether+second+generation+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29+with+enhanced+potency+versus+key+clinical+mutations&doi=10.1016%2Fj.bmcl.2008.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations</span></div><div class="casAuthors">Tucker, Thomas J.; Saggar, Sandeep; Sisko, John T.; Tynebor, Robert M.; Williams, Theresa M.; Felock, Peter J.; Flynn, Jessica A.; Lai, Ming-Tain; Liang, Yuexia; McGaughey, Georgia; Liu, Meiquing; Miller, Mike; Moyer, Gregory; Munshi, Vandna; Perlow-Poehnelt, Rebecca; Prasad, Sridhar; Sanchez, Rosa; Torrent, Maricel; Vacca, Joseph P.; Wan, Bang-Lin; Yan, Youwei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2959-2966</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Using a combination of traditional Medicinal Chem./SAR anal., crystallog., and mol. modeling, a series of highly potent NNRTIs that possess broad antiviral activity against a no. of key clin. mutations were synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRQ9ahkVZKDbVg90H21EOLACvtfcHk0lhXQdpWgyYd-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsbk%253D&md5=9ff592bb0542c3b06edfab15865c45b8</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DSaggar%26aufirst%3DS.%26aulast%3DSisko%26aufirst%3DJ.%2BT.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BA.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DPerlow-Poehnelt%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DYan%26aufirst%3DY.%26atitle%3DThe%2520design%2520and%2520synthesis%2520of%2520diaryl%2520ether%2520second%2520generation%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%2520with%2520enhanced%2520potency%2520versus%2520key%2520clinical%2520mutations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D9%26spage%3D2959%26epage%3D2966%26doi%3D10.1016%2Fj.bmcl.2008.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisko, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlow-Poehnelt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chloro benzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6503</span>– <span class="NLM_lpage">6511</span>, <span class="refDoi"> DOI: 10.1021/jm800856c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800856c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6503-6511&issue=20&author=T.+J.+Tuckerauthor=J.+T.+Siskoauthor=R.+M.+Tyneborauthor=T.+M.+Williamsauthor=P.+J.+Felockauthor=J.+A.+Flynnauthor=M.+T.+Laiauthor=Y.+Liangauthor=G.+McGaugheyauthor=M.+Liuauthor=M.+Millerauthor=G.+Moyerauthor=V.+Munshiauthor=R.+Perlow-Poehneltauthor=S.+Prasadauthor=J.+C.+Reidauthor=R.+Sanchezauthor=M.+Torrentauthor=J.+P.+Vaccaauthor=B.+L.+Wanauthor=Y.+Yan&title=Discovery+of+3-%7B5-%5B%286-amino-1H-pyrazolo%5B3%2C4-b%5Dpyridine-3-yl%29methoxy%5D-2-chlorophenoxy%7D-5-chloro+benzonitrile+%28MK-4965%29%3A+a+potent%2C+orally+bioavailable+HIV-1+non-nucleoside+reverse+transcriptase+inhibitor+with+improved+potency+against+key+mutant+viruses&doi=10.1021%2Fjm800856c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fjm800856c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800856c%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DSisko%26aufirst%3DJ.%2BT.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BA.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DPerlow-Poehnelt%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DYan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25203-%257B5-%255B%25286-amino-1H-pyrazolo%255B3%252C4-b%255Dpyridine-3-yl%2529methoxy%255D-2-chlorophenoxy%257D-5-chloro%2520benzonitrile%2520%2528MK-4965%2529%253A%2520a%2520potent%252C%2520orally%2520bioavailable%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520with%2520improved%2520potency%2520against%2520key%2520mutant%2520viruses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D20%26spage%3D6503%26epage%3D6511%26doi%3D10.1021%2Fjm800856c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distefano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">7920</span>– <span class="NLM_lpage">7933</span>, <span class="refDoi"> DOI: 10.1021/jm2010173</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2010173" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7920-7933&issue=22&author=R.+Gomezauthor=S.+J.+Jollyauthor=T.+Williamsauthor=J.+P.+Vaccaauthor=M.+Torrentauthor=G.+McGaugheyauthor=M.+T.+Laiauthor=P.+Felockauthor=V.+Munshiauthor=D.+Distefanoauthor=J.+Flynnauthor=M.+Millerauthor=Y.+Yanauthor=J.+Reidauthor=R.+Sanchezauthor=Y.+Liangauthor=B.+Patonauthor=B.+L.+Wanauthor=N.+Anthony&title=Design+and+synthesis+of+conformationally+constrained+inhibitors+of+non-nucleoside+reverse+transcriptase&doi=10.1021%2Fjm2010173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Conformationally Constrained Non-Nucleoside Inhibitors of Reverse Transcriptase</span></div><div class="casAuthors">Gomez, Robert; Jolly, Samson J.; Williams, Theresa; Vacca, Joseph P.; Torrent, Maricel; McGaughey, Georgia; Lai, Ming-Tain; Felock, Peter; Munshi, Vandna; DiStefano, Daniel; Flynn, Jessica; Miller, Mike; Yan, Youwei; Reid, John; Sanchez, Rosa; Liang, Yuexia; Paton, Brenda; Wan, Bang-Lin; Anthony, Neville</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7920-7933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly active antiretroviral therapy (HAART) significantly reduces human immunodeficiency virus (HIV) viral load and has led to a dramatic decrease in acquired immunodeficiency syndrome (AIDS) related mortality.  Despite this success, there remains a crit. need for new HIV therapies to address the emergence of drug resistant viral strains.  Next generation NNRTIs are sought that are effective against these mutant forms of the HIV virus.  The bound conformations of our lead inhibitors, MK-1107 (1, I) and MK-4965 (2, II), were divergent about the oxymethylene linker, and each of these conformations was rigidified using two isomeric cyclic constraints.  The constraint derived from the bioactive conformation of 2 provided novel, highly potent NNRTIs that possess broad spectrum antiviral activity and good pharmacokinetic profiles.  Systematic SAR led to the identification of indazole as the optimal conformational constraint to provide MK-6186 (3, III) and MK-7445 (6, VI).  Despite their reduced flexibility, these compds. had potency comparable to that of the corresponding acyclic ethers in both recombinant enzyme and cell based assays against both the wild-type and the clin. relevant mutant strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMjl75rEMAbVg90H21EOLACvtfcHk0liUnRU_NE5nEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu7vO&md5=cd6ebeacd7764755e41e715e325f2081</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjm2010173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2010173%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DJolly%26aufirst%3DS.%2BJ.%26aulast%3DWilliams%26aufirst%3DT.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DDistefano%26aufirst%3DD.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DPaton%26aufirst%3DB.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DAnthony%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520conformationally%2520constrained%2520inhibitors%2520of%2520non-nucleoside%2520reverse%2520transcriptase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D22%26spage%3D7920%26epage%3D7933%26doi%3D10.1021%2Fjm2010173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javanbakht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billedeau, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschfeld, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy-Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzadegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villasenor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jernelius, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span> <span> </span><span class="NLM_article-title">Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7449</span>– <span class="NLM_lpage">7458</span>, <span class="refDoi"> DOI: 10.1021/jm800527x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800527x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7449-7458&issue=23&author=Z.+K.+Sweeneyauthor=S.+F.+Harrisauthor=S.+F.+Aroraauthor=H.+Javanbakhtauthor=Y.+Liauthor=J.+Fretlandauthor=J.+P.+Davidsonauthor=J.+R.+Billedeauauthor=S.+K.+Gleasonauthor=D.+Hirschfeldauthor=J.+J.+Kennedy-Smithauthor=T.+Mirzadeganauthor=R.+Roetzauthor=M.+Smithauthor=S.+Sperryauthor=J.+M.+Suhauthor=J.+Wuauthor=S.+Tsingauthor=A.+G.+Villasenorauthor=A.+Paulauthor=G.+Suauthor=G.+Heilekauthor=J.+Q.+Hangauthor=A.+S.+Zhouauthor=J.+A.+Jerneliusauthor=F.+J.+Zhangauthor=K.+Klumpp&title=Design+of+annulated+pyrazoles+as+inhibitors+of+HIV-1+reverse+transcriptase&doi=10.1021%2Fjm800527x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm800527x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800527x%26sid%3Dliteratum%253Aachs%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DArora%26aufirst%3DS.%2BF.%26aulast%3DJavanbakht%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26aulast%3DBilledeau%26aufirst%3DJ.%2BR.%26aulast%3DGleason%26aufirst%3DS.%2BK.%26aulast%3DHirschfeld%26aufirst%3DD.%26aulast%3DKennedy-Smith%26aufirst%3DJ.%2BJ.%26aulast%3DMirzadegan%26aufirst%3DT.%26aulast%3DRoetz%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DSuh%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DHeilek%26aufirst%3DG.%26aulast%3DHang%26aufirst%3DJ.%2BQ.%26aulast%3DZhou%26aufirst%3DA.%2BS.%26aulast%3DJernelius%26aufirst%3DJ.%2BA.%26aulast%3DZhang%26aufirst%3DF.%2BJ.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DDesign%2520of%2520annulated%2520pyrazoles%2520as%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D23%26spage%3D7449%26epage%3D7458%26doi%3D10.1021%2Fjm800527x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeStefano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7344</span>– <span class="NLM_lpage">7350</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2011.10.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7344-7350&issue=24&author=R.+Gomezauthor=S.+Jollyauthor=T.+Williamsauthor=T.+Tuckerauthor=R.+Tyneborauthor=J.+Vaccaauthor=G.+McGaugheyauthor=M.+T.+Laiauthor=P.+Felockauthor=V.+Munshiauthor=D.+DeStefanoauthor=S.+Touchauthor=M.+Millerauthor=Y.+Yanauthor=R.+Sanchezauthor=Y.+Liangauthor=B.+Patonauthor=B.+L.+Wanauthor=N.+Anthony&title=Design+and+synthesis+of+pyridone+inhibitors+of+non-nucleoside+reverse+transcriptase&doi=10.1016%2Fj.bmcl.2011.10.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DJolly%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DT.%26aulast%3DTucker%26aufirst%3DT.%26aulast%3DTynebor%26aufirst%3DR.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DDeStefano%26aufirst%3DD.%26aulast%3DTouch%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DPaton%26aufirst%3DB.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DAnthony%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520pyridone%2520inhibitors%2520of%2520non-nucleoside%2520reverse%2520transcriptase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D24%26spage%3D7344%26epage%3D7350%26doi%3D10.1016%2Fj.bmcl.2011.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cote, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asante-Appiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blouin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chefson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromlish, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschenes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont-Gaudet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forget, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plamondon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seliniotakis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducharme, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2013.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=24412110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=917-922&issue=3&author=B.+Coteauthor=J.+D.+Burchauthor=E.+Asante-Appiahauthor=C.+Baylyauthor=L.+Bedardauthor=M.+Blouinauthor=L.+C.+Campeauauthor=E.+Cauchonauthor=M.+Chanauthor=A.+Chefsonauthor=N.+Coulombeauthor=W.+Cromlishauthor=S.+Debnathauthor=D.+Deschenesauthor=K.+Dupont-Gaudetauthor=J.+P.+Falgueyretauthor=R.+Forgetauthor=S.+Gagneauthor=D.+Gauvreauauthor=M.+Girardinauthor=S.+Guiralauthor=E.+Langloisauthor=C.+S.+Liauthor=N.+Nguyenauthor=R.+Pappauthor=S.+Plamondonauthor=A.+Royauthor=S.+Royauthor=R.+Seliniotakisauthor=M.+St-Ongeauthor=S.+Ouelletauthor=P.+Tawaauthor=J.+F.+Truchonauthor=J.+Vaccaauthor=M.+Wronaauthor=Y.+Yanauthor=Y.+Ducharme&title=Discovery+of+MK-1439%2C+an+orally+bioavailable+non-nucleoside+reverse+transcriptase+inhibitor+potent+against+a+wide+range+of+resistant+mutant+HIV+viruses&doi=10.1016%2Fj.bmcl.2013.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses</span></div><div class="casAuthors">Cote, Bernard; Burch, Jason D.; Asante-Appiah, Ernest; Bayly, Chris; Bedard, Leanne; Blouin, Marc; Campeau, Louis-Charles; Cauchon, Elizabeth; Chan, Manuel; Chefson, Amandine; Coulombe, Nathalie; Cromlish, Wanda; Debnath, Smita; Deschenes, Denis; Dupont-Gaudet, Kristina; Falgueyret, Jean-Pierre; Forget, Robert; Gagne, Sebastien; Gauvreau, Danny; Girardin, Melina; Guiral, Sebastien; Langlois, Eric; Li, Chun Sing; Nguyen, Natalie; Papp, Rob; Plamondon, Serge; Roy, Amelie; Roy, Stephanie; Seliniotakis, Ria; St-Onge, Miguel; Ouellet, Stephane; Tawa, Paul; Truchon, Jean-Francois; Vacca, Joe; Wrona, Marc; Yan, Youwei; Ducharme, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">917-922</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36.  In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clin. relevant, resistant mutant HIV viruses.  The overall favorable preclin. pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human.  NNRTI 36, now known as MK-1439, is currently in clin. development for the treatment of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJff1LINDbQ7Vg90H21EOLACvtfcHk0ljXXhJVeDoQhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D&md5=7d63ec63691d2d21eb29b8dd9c4c5e63</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DB.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DBayly%26aufirst%3DC.%26aulast%3DBedard%26aufirst%3DL.%26aulast%3DBlouin%26aufirst%3DM.%26aulast%3DCampeau%26aufirst%3DL.%2BC.%26aulast%3DCauchon%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DM.%26aulast%3DChefson%26aufirst%3DA.%26aulast%3DCoulombe%26aufirst%3DN.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DDebnath%26aufirst%3DS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDupont-Gaudet%26aufirst%3DK.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DForget%26aufirst%3DR.%26aulast%3DGagne%26aufirst%3DS.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DGirardin%26aufirst%3DM.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DLanglois%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DPapp%26aufirst%3DR.%26aulast%3DPlamondon%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSeliniotakis%26aufirst%3DR.%26aulast%3DSt-Onge%26aufirst%3DM.%26aulast%3DOuellet%26aufirst%3DS.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DWrona%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DDucharme%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520MK-1439%252C%2520an%2520orally%2520bioavailable%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520potent%2520against%2520a%2520wide%2520range%2520of%2520resistant%2520mutant%2520HIV%2520viruses%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D917%26epage%3D922%26doi%3D10.1016%2Fj.bmcl.2013.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sax, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeJesus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupinacci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, C.</span></span>; <span class="NLM_contrib-group">DRIVE-FORWARD Study Group</span> <span> </span><span class="NLM_article-title">Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e211</span>– <span class="NLM_lpage">e220</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(18)30021-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS2352-3018%2818%2930021-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29592840" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=e211-e220&issue=5&author=J.+M.+Molinaauthor=K.+Squiresauthor=P.+E.+Saxauthor=P.+Cahnauthor=J.+Lombaardauthor=E.+DeJesusauthor=M.+T.+Laiauthor=X.+Xuauthor=A.+Rodgersauthor=L.+Lupinacciauthor=S.+Kumarauthor=P.+Sklarauthor=B.+Y.+Nguyenauthor=G.+J.+Hannaauthor=C.+Hwangauthor=DRIVE-FORWARD+Study+Group&title=Doravirine+versus+ritonavir-boosted+darunavir+in+antiretroviral-naive+adults+with+HIV-1+%28DRIVE-FORWARD%29%3A+48-week+results+of+a+randomised%2C+double-blind%2C+phase+3%2C+non-inferiority+trial&doi=10.1016%2FS2352-3018%2818%2930021-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2818%2930021-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252818%252930021-3%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DSquires%26aufirst%3DK.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DCahn%26aufirst%3DP.%26aulast%3DLombaard%26aufirst%3DJ.%26aulast%3DDeJesus%26aufirst%3DE.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DRodgers%26aufirst%3DA.%26aulast%3DLupinacci%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSklar%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DB.%2BY.%26aulast%3DHanna%26aufirst%3DG.%2BJ.%26aulast%3DHwang%26aufirst%3DC.%26aulast%3D%26atitle%3DDoravirine%2520versus%2520ritonavir-boosted%2520darunavir%2520in%2520antiretroviral-naive%2520adults%2520with%2520HIV-1%2520%2528DRIVE-FORWARD%2529%253A%252048-week%2520results%2520of%2520a%2520randomised%252C%2520double-blind%252C%2520phase%25203%252C%2520non-inferiority%2520trial%26jtitle%3DLancet%2520HIV%26date%3D2018%26volume%3D5%26issue%3D5%26spage%3De211%26epage%3De220%26doi%3D10.1016%2FS2352-3018%2818%2930021-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span> </span><span class="NLM_article-title">Fixed
dose combination of doravirine/lamivudine/TDF is non-inferior
to efavirenz/emtricitabine/TDF in treatment-naïve adults with
HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study</span>. In  <i>9th IAS Conference on HIV Science, Paris, France, 23–26
July</i>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Fixed%0Adose+combination+of+doravirine%2Flamivudine%2FTDF+is+non-inferior%0Ato+efavirenz%2Femtricitabine%2FTDF+in+treatment-na%C3%AFve+adults+with%0AHIV-1+infection%3A+week+48+results+of+the+Phase+3+DRIVE-AHEAD+study.+In+9th+IAS+Conference+on+HIV+Science%2C+Paris%2C+France%2C+23%E2%80%9326%0AJuly%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26atitle%3DFixed%250Adose%2520combination%2520of%2520doravirine%252Flamivudine%252FTDF%2520is%2520non-inferior%250Ato%2520efavirenz%252Femtricitabine%252FTDF%2520in%2520treatment-na%25C3%25AFve%2520adults%2520with%250AHIV-1%2520infection%253A%2520week%252048%2520results%2520of%2520the%2520Phase%25203%2520DRIVE-AHEAD%2520study%26jtitle%3D9th%2520IAS%2520Conference%2520on%2520HIV%2520Science%252C%2520Paris%252C%2520France%252C%252023%25E2%2580%259326%250AJuly%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanangamudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poongavanam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span> <span> </span><span class="NLM_article-title">HIV-1 non-nucleoside reverse transcriptase inhibitors: SAR and lead optimization using CoMFA and CoMSIA studies (1995–2016)</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3774</span>– <span class="NLM_lpage">3812</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170705122851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2174%2F0929867324666170705122851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=28685686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFensL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3774-3812&author=M.+Vanangamudiauthor=V.+Poongavanamauthor=V.+Namasivayam&title=HIV-1+non-nucleoside+reverse+transcriptase+inhibitors%3A+SAR+and+lead+optimization+using+CoMFA+and+CoMSIA+studies+%281995%E2%80%932016%29&doi=10.2174%2F0929867324666170705122851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016)</span></div><div class="casAuthors">Vanangamudi, Murugesan; Poongavanam, Vasanthanathan; Namasivayam, Vigneshwaran</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3774-3812</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Design of inhibitors for HIV-1 reverse transcriptase inhibition (HIV-1 RT) is one of the successful chemotherapies for the treatment of HIV infection.  Among the inhibitors available for HIV-1 RT, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have shown to be very promising and clin. approved drugs.  However, the efficiency of many of these drugs has been reduced by the drug-resistant variants of HIV-1 RT.  The aim of the current review is to provide a summary of lead optimization strategies from the 3D-QSARs studies on NNRTI class from the past 21 years (1995 to 2016).  Methods: The conformation dependent-alignment based (CoMFA and CoMSIA) methods have been proven very successful ligand based strategy in the drug design.  Here, CoMFA and CoMSIA studies reported for structurally distinct NNRTIs including thiazolobenzimidazole, dipyridodiazepinone, 1,1,3-trioxo [1,2,4]-thiadiazine, formimidoester disulfides, thiocarbamate, thiazolidinone derivs., etc. have been discussed in detail.  In addn., we explore the position of the functional groups that drive the protein-ligand interaction.  Results: The structure-activity relationship (SAR) revealed from CoMFA and CoMSIA studies of these drug classes is not only in agreement with the structure-based method but also provides an efficient way of lead optimization.  In addn. to mol. docking expts., protein-ligand interaction fingerprints were calcd. in order to understand the common binding mode of NNRTI compds.  Conclusion: Overall, this review enlightens the protein-ligand interactions with a detailed SAR discussion for chemotypes.  Such discussion will help medicinal chemist to gain a better understanding for the design of novel and promising NNRTI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRtbp3XHOx_rVg90H21EOLACvtfcHk0ljXXhJVeDoQhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFensL7N&md5=e90ed864fef7d0eb053f69860c84c437</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170705122851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170705122851%26sid%3Dliteratum%253Aachs%26aulast%3DVanangamudi%26aufirst%3DM.%26aulast%3DPoongavanam%26aufirst%3DV.%26aulast%3DNamasivayam%26aufirst%3DV.%26atitle%3DHIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520SAR%2520and%2520lead%2520optimization%2520using%2520CoMFA%2520and%2520CoMSIA%2520studies%2520%25281995%25E2%2580%25932016%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3774%26epage%3D3812%26doi%3D10.2174%2F0929867324666170705122851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1021/jm200990c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200990c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3595-613&issue=8&author=D.+Liauthor=P.+Zhanauthor=E.+De+Clercqauthor=X.+Liu&title=Strategies+for+the+design+of+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors%3A+lessons+from+the+development+of+seven+representative+paradigms&doi=10.1021%2Fjm200990c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm200990c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200990c%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DStrategies%2520for%2520the%2520design%2520of%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520lessons%2520from%2520the%2520development%2520of%2520seven%2520representative%2520paradigms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D8%26spage%3D3595%26epage%3D613%26doi%3D10.1021%2Fjm200990c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnsmb.2223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22266819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=253-259&issue=2&author=K.+Dasauthor=S.+E.+Martinezauthor=J.+D.+Baumanauthor=E.+Arnold&title=HIV-1+reverse+transcriptase+complex+with+DNA+and+nevirapine+reveals+non-nucleoside+inhibition+mechanism&doi=10.1038%2Fnsmb.2223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism</span></div><div class="casAuthors">Das, Kalyan; Martinez, Sergio E.; Bauman, Joseph D.; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-259</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Combinations of nucleoside and non-nucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT) are widely used in anti-AIDS therapies.  Five NNRTIs, including nevirapine, are clin. drugs; however, the mol. mechanism of inhibition by NNRTIs is not clear.  We detd. the crystal structures of RT-DNA-nevirapine, RT-DNA, and RT-DNA-AZT-triphosphate complexes at 2.85-, 2.70-, and 2.80-Å resoln., resp.  The RT-DNA complex in the crystal could bind nevirapine or AZT-triphosphate but not both.  Binding of nevirapine led to opening of the NNRTI-binding pocket.  The pocket formation caused shifting of the 3' end of the DNA primer by ∼5.5 Å away from its polymerase active site position.  Nucleic acid interactions with fingers and palm subdomains were reduced, the dNTP-binding pocket was distorted and the thumb opened up.  The structures elucidate complementary roles of nucleoside and non-nucleoside inhibitors in inhibiting RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxsRKzSWU5S7Vg90H21EOLACvtfcHk0lg5TXcKX0s_Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtrg%253D&md5=8acb0ebef279d7fe999080d12298792c</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2223%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DMartinez%26aufirst%3DS.%2BE.%26aulast%3DBauman%26aufirst%3DJ.%2BD.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DHIV-1%2520reverse%2520transcriptase%2520complex%2520with%2520DNA%2520and%2520nevirapine%2520reveals%2520non-nucleoside%2520inhibition%2520mechanism%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D2%26spage%3D253%26epage%3D259%26doi%3D10.1038%2Fnsmb.2223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usach, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peris, J. E.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability</span>. <i>J. Int. AIDS Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18567</span>, <span class="refDoi"> DOI: 10.7448/IAS.16.1.18567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.7448%2FIAS.16.1.18567" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=18567&author=I.+Usachauthor=V.+Melisauthor=J.+E.+Peris&title=Non-nucleoside+reverse+transcriptase+inhibitors%3A+a+review+on+pharmacokinetics%2C+pharmacodynamics%2C+safety+and+tolerability&doi=10.7448%2FIAS.16.1.18567"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.7448%2FIAS.16.1.18567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7448%252FIAS.16.1.18567%26sid%3Dliteratum%253Aachs%26aulast%3DUsach%26aufirst%3DI.%26aulast%3DMelis%26aufirst%3DV.%26aulast%3DPeris%26aufirst%3DJ.%2BE.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520a%2520review%2520on%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520safety%2520and%2520tolerability%26jtitle%3DJ.%2520Int.%2520AIDS%2520Soc.%26date%3D2013%26volume%3D16%26spage%3D18567%26doi%3D10.7448%2FIAS.16.1.18567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span> <i>Atripla Package</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver
Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Atripla+Package%3B+U.S.%0AFood+and+Drug+Administration%3A+Silver%0ASpring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAtripla%2520Package%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span> <i>Odefsey Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Odefsey+Package%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DOdefsey%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R.</span></span> <span> </span><span class="NLM_article-title">Reducing the “pill burden</span>. <i>Can. Med. Assoc. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>184</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">E117</span>– <span class="NLM_lpage">E118</span>, <span class="refDoi"> DOI: 10.1503/cmaj.109-4076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1503%2Fcmaj.109-4076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2012&pages=E117-E118&issue=2&author=R.+Collier&title=Reducing+the+%E2%80%9Cpill+burden&doi=10.1503%2Fcmaj.109-4076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1503%2Fcmaj.109-4076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1503%252Fcmaj.109-4076%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DR.%26atitle%3DReducing%2520the%2520%25E2%2580%259Cpill%2520burden%26jtitle%3DCan.%2520Med.%2520Assoc.%2520J.%26date%3D2012%26volume%3D184%26issue%3D2%26spage%3DE117%26epage%3DE118%26doi%3D10.1503%2Fcmaj.109-4076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guay, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musoke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagenda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakaki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deseyve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirochnick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mofenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mmiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. B.</span></span> <span> </span><span class="NLM_article-title">Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>354</i></span> (<span class="NLM_issue">9181</span>),  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(99)80008-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2899%2980008-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=1999&pages=795-802&issue=9181&author=L.+A.+Guayauthor=P.+Musokeauthor=T.+Flemingauthor=D.+Bagendaauthor=M.+Allenauthor=C.+Nakabiitoauthor=J.+Shermanauthor=P.+Bakakiauthor=C.+Ducarauthor=M.+Deseyveauthor=L.+Emelauthor=M.+Mirochnickauthor=M.+G.+Fowlerauthor=L.+Mofensonauthor=P.+Miottiauthor=K.+Dransfieldauthor=D.+Brayauthor=F.+Mmiroauthor=J.+B.+Jackson&title=Intrapartum+and+neonatal+single-dose+nevirapine+compared+with+zidovudine+for+prevention+of+mother-to-child+transmission+of+HIV-1+in+Kampala%2C+Uganda%3A+HIVNET+012+randomised+trial&doi=10.1016%2FS0140-6736%2899%2980008-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2899%2980008-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252899%252980008-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuay%26aufirst%3DL.%2BA.%26aulast%3DMusoke%26aufirst%3DP.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DBagenda%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3DSherman%26aufirst%3DJ.%26aulast%3DBakaki%26aufirst%3DP.%26aulast%3DDucar%26aufirst%3DC.%26aulast%3DDeseyve%26aufirst%3DM.%26aulast%3DEmel%26aufirst%3DL.%26aulast%3DMirochnick%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DM.%2BG.%26aulast%3DMofenson%26aufirst%3DL.%26aulast%3DMiotti%26aufirst%3DP.%26aulast%3DDransfield%26aufirst%3DK.%26aulast%3DBray%26aufirst%3DD.%26aulast%3DMmiro%26aufirst%3DF.%26aulast%3DJackson%26aufirst%3DJ.%2BB.%26atitle%3DIntrapartum%2520and%2520neonatal%2520single-dose%2520nevirapine%2520compared%2520with%2520zidovudine%2520for%2520prevention%2520of%2520mother-to-child%2520transmission%2520of%2520HIV-1%2520in%2520Kampala%252C%2520Uganda%253A%2520HIVNET%2520012%2520randomised%2520trial%26jtitle%3DLancet%26date%3D1999%26volume%3D354%26issue%3D9181%26spage%3D795%26epage%3D802%26doi%3D10.1016%2FS0140-6736%2899%2980008-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayouba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foupouapouognigni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kfutwah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thonnon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monny-Lobe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eteki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouanfack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nlend, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barre-Sinoussi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerrienet, E.</span></span> <span> </span><span class="NLM_article-title">Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1097/00126334-200311010-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-200311010-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=14600571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=274-280&issue=3&author=A.+Ayoubaauthor=G.+Teneauthor=P.+Cuninauthor=Y.+Foupouapouognigniauthor=E.+Menuauthor=A.+Kfutwahauthor=J.+Thonnonauthor=G.+Scarlattiauthor=M.+Monny-Lobeauthor=N.+Etekiauthor=C.+Kouanfackauthor=M.+Tardyauthor=R.+Lekeauthor=M.+Nkamauthor=A.+E.+Nlendauthor=F.+Barre-Sinoussiauthor=P.+M.+Martinauthor=E.+Nerrienet&title=Low+rate+of+mother-to-child+transmission+of+HIV-1+after+nevirapine+intervention+in+a+pilot+public+health+program+in+Yaounde%2C+Cameroon&doi=10.1097%2F00126334-200311010-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaounde, Cameroon</span></div><div class="casAuthors">Ayouba, Ahidjo; Tene, Gilbert; Cunin, Patrick; Foupouapouognigni, Yacouba; Menu, Elisabeth; Kfutwah, Anfumbom; Thonnon, Jocelyn; Scarlatti, Gabriella; Monny-Lobe, Marcel; Eteki, Nicole; Kouanfack, Charles; Tardy, Michele; Leke, Robert; Nkam, Maurice; Nlend, Anne E.; Barre-Sinoussi, Francoise; Martin, Paul M. V.; Nerrienet, Eric</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">274-280</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE: To det. the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaounde, Cameroon.  DESIGN: The study was a prospective Public Health Pilot Program covering a 3-yr period (Jan. 2000-Dec. 2002).  METHODS: Counseled and consenting HIV-1-pos. pregnant women were given a single dose of NVP at the onset of labor.  Babies were given 2 mg/kg NVP syrup within the first 72 h of life.  NVP-treated children were regularly followed up and examd. for HIV-1 infection at 6-8 wk and 5-6 mo through plasma viral load (VL) quantification with the bDNA system.  RESULTS: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 wk and 5-6 mo.  Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL.  Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points.  One hundred seven children (87%) were considered not infected at 6-8 wk of age.  CONCLUSIONS: Our results indicate that the HIV-1 MTCT rate 6-8 wk after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJHeFCAJD2LVg90H21EOLACvtfcHk0lhfC1RFpJsJJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslWltL4%253D&md5=3c210a6c564c2330eb7811c3d57fb6eb</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1097%2F00126334-200311010-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-200311010-00003%26sid%3Dliteratum%253Aachs%26aulast%3DAyouba%26aufirst%3DA.%26aulast%3DTene%26aufirst%3DG.%26aulast%3DCunin%26aufirst%3DP.%26aulast%3DFoupouapouognigni%26aufirst%3DY.%26aulast%3DMenu%26aufirst%3DE.%26aulast%3DKfutwah%26aufirst%3DA.%26aulast%3DThonnon%26aufirst%3DJ.%26aulast%3DScarlatti%26aufirst%3DG.%26aulast%3DMonny-Lobe%26aufirst%3DM.%26aulast%3DEteki%26aufirst%3DN.%26aulast%3DKouanfack%26aufirst%3DC.%26aulast%3DTardy%26aufirst%3DM.%26aulast%3DLeke%26aufirst%3DR.%26aulast%3DNkam%26aufirst%3DM.%26aulast%3DNlend%26aufirst%3DA.%2BE.%26aulast%3DBarre-Sinoussi%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DNerrienet%26aufirst%3DE.%26atitle%3DLow%2520rate%2520of%2520mother-to-child%2520transmission%2520of%2520HIV-1%2520after%2520nevirapine%2520intervention%2520in%2520a%2520pilot%2520public%2520health%2520program%2520in%2520Yaounde%252C%2520Cameroon%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2003%26volume%3D34%26issue%3D3%26spage%3D274%26epage%3D280%26doi%3D10.1097%2F00126334-200311010-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee-Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto-Torres, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matovu
Kiweewa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mhlanga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeenarain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffoor, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pather, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellors, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheckter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthiaume, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndase, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germuga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szydlo, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensch, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torjesen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakhtoura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S.</span></span> <span> </span><span class="NLM_article-title">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2121</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1506110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1506110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26900902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2121-2132&issue=22&author=J.+M.+Baetenauthor=T.+Palanee-Phillipsauthor=E.+R.+Brownauthor=K.+Schwartzauthor=L.+E.+Soto-Torresauthor=V.+Govenderauthor=N.+M.+Mgodiauthor=F.+Matovu%0AKiweewaauthor=G.+Nairauthor=F.+Mhlangaauthor=S.+Sivaauthor=L.+G.+Bekkerauthor=N.+Jeenarainauthor=Z.+Gaffoorauthor=F.+Martinsonauthor=B.+Makananiauthor=A.+Patherauthor=L.+Naidooauthor=M.+Husnikauthor=B.+A.+Richardsonauthor=U.+M.+Parikhauthor=J.+W.+Mellorsauthor=M.+A.+Marzinkeauthor=C.+W.+Hendrixauthor=A.+van+der+Stratenauthor=G.+Ramjeeauthor=Z.+M.+Chirenjeauthor=C.+Nakabiitoauthor=T.+E.+Tahaauthor=J.+Jonesauthor=A.+Mayoauthor=R.+Scheckterauthor=J.+Berthiaumeauthor=E.+Livantauthor=C.+Jacobsonauthor=P.+Ndaseauthor=R.+Whiteauthor=K.+Pattersonauthor=D.+Germugaauthor=B.+Galaskaauthor=K.+Bungeauthor=D.+Singhauthor=D.+W.+Szydloauthor=E.+T.+Montgomeryauthor=B.+S.+Menschauthor=K.+Torjesenauthor=C.+I.+Grossmanauthor=N.+Chakhtouraauthor=A.+Nelauthor=Z.+Rosenbergauthor=I.+McGowanauthor=S.+Hillier&title=Use+of+a+vaginal+ring+containing+dapivirine+for+HIV-1+prevention+in+women&doi=10.1056%2FNEJMoa1506110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span></div><div class="casAuthors">Baeten, J. M.; Palanee-Phillips, T.; Brown, E. R.; Schwartz, K.; Soto-Torres, L. E.; Govender, V.; Mgodi, N. M.; Kiweewa, F. Matovu; Nair, G.; Mhlanga, F.; Siva, S.; Bekker, L.-G.; Jeenarain, N.; Gaffoor, Z.; Martinson, F.; Makanani, B.; Pather, A.; Naidoo, L.; Husnik, M.; Richardson, B. A.; Parikh, U. M.; Mellors, J. W.; Marzinke, M. A.; Hendrix, C. W.; van der Straten, A.; Ramjee, G.; Chirenje, Z. M.; Nakabiito, C.; Taha, T. E.; Jones, J.; Mayo, A.; Scheckter, R.; Berthiaume, J.; Livant, E.; Jacobson, C.; Ndase, P.; White, R.; Patterson, K.; Germuga, D.; Galaska, B.; Bunge, K.; Singh, D.; Szydlo, D. W.; Montgomery, E. T.; Mensch, B. S.; Torjesen, K.; Grossman, C. I.; Chakhtoura, N.; Nel, A.; Rosenberg, Z.; McGowan, I.; Hillier, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2121-2132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  However, in clin. trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence.  Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.  METHODS We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring contg. dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe.  RESULTS Among the 2629 women who were enrolled, 168 HIV-1 infections occurred: 71 in the dapivirine group and 97 in the placebo group (incidence, 3.3 and 4.5 per 100 personyears, resp.).  The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P = 0.046) than that in the placebo group.  In an anal. that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P = 0.007) than that in the placebo group.  In a post hoc anal., higher rates of HIV-1 protection were obsd. among women over the age of 21 years (56%; 95% CI, 31 to 71; P<0.001) but not among those 21 years of age or younger (-27%; 95% CI, -133 to 31; P = 0.45), a difference that was correlated with reduced adherence.  The rates of adverse medical events and antiretroviral resistance among women who acquired HIV-1 infection were similar in the two groups.  CONCLUSIONS A monthly vaginal ring contg. dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohJjDza7DrCrVg90H21EOLACvtfcHk0lhfC1RFpJsJJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN&md5=be3a0c5c5d1a57d7b3343d84b9a28e9c</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1506110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1506110%26sid%3Dliteratum%253Aachs%26aulast%3DBaeten%26aufirst%3DJ.%2BM.%26aulast%3DPalanee-Phillips%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DE.%2BR.%26aulast%3DSchwartz%26aufirst%3DK.%26aulast%3DSoto-Torres%26aufirst%3DL.%2BE.%26aulast%3DGovender%26aufirst%3DV.%26aulast%3DMgodi%26aufirst%3DN.%2BM.%26aulast%3DMatovu%2BKiweewa%26aufirst%3DF.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DMhlanga%26aufirst%3DF.%26aulast%3DSiva%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.%2BG.%26aulast%3DJeenarain%26aufirst%3DN.%26aulast%3DGaffoor%26aufirst%3DZ.%26aulast%3DMartinson%26aufirst%3DF.%26aulast%3DMakanani%26aufirst%3DB.%26aulast%3DPather%26aufirst%3DA.%26aulast%3DNaidoo%26aufirst%3DL.%26aulast%3DHusnik%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3DTaha%26aufirst%3DT.%2BE.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DMayo%26aufirst%3DA.%26aulast%3DScheckter%26aufirst%3DR.%26aulast%3DBerthiaume%26aufirst%3DJ.%26aulast%3DLivant%26aufirst%3DE.%26aulast%3DJacobson%26aufirst%3DC.%26aulast%3DNdase%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DPatterson%26aufirst%3DK.%26aulast%3DGermuga%26aufirst%3DD.%26aulast%3DGalaska%26aufirst%3DB.%26aulast%3DBunge%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSzydlo%26aufirst%3DD.%2BW.%26aulast%3DMontgomery%26aufirst%3DE.%2BT.%26aulast%3DMensch%26aufirst%3DB.%2BS.%26aulast%3DTorjesen%26aufirst%3DK.%26aulast%3DGrossman%26aufirst%3DC.%2BI.%26aulast%3DChakhtoura%26aufirst%3DN.%26aulast%3DNel%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DZ.%26aulast%3DMcGowan%26aufirst%3DI.%26aulast%3DHillier%26aufirst%3DS.%26atitle%3DUse%2520of%2520a%2520vaginal%2520ring%2520containing%2520dapivirine%2520for%2520HIV-1%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D22%26spage%3D2121%26epage%3D2132%26doi%3D10.1056%2FNEJMoa1506110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotze, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabude, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusemererwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malherbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuttall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntshele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steytler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borremans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resseler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Roey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangeneugden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Baelen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2133</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1602046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=27959766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2133-2143&issue=22&author=A.+Nelauthor=N.+van+Niekerkauthor=S.+Kapigaauthor=L.+G.+Bekkerauthor=C.+Gamaauthor=K.+Gillauthor=A.+Kamaliauthor=P.+Kotzeauthor=C.+Louwauthor=Z.+Mabudeauthor=N.+Mitiauthor=S.+Kusemererwaauthor=H.+Tempelmanauthor=H.+Carstensauthor=B.+Devlinauthor=M.+Isaacsauthor=M.+Malherbeauthor=W.+Mansauthor=J.+Nuttallauthor=M.+Russellauthor=S.+Ntsheleauthor=M.+Smitauthor=L.+Solaiauthor=P.+Spenceauthor=J.+Steytlerauthor=K.+Windleauthor=M.+Borremansauthor=S.+Resselerauthor=J.+Van+Roeyauthor=W.+Parysauthor=T.+Vangeneugdenauthor=B.+Van+Baelenauthor=Z.+Rosenberg&title=Safety+and+efficacy+of+a+dapivirine+vaginal+ring+for+HIV+prevention+in+women&doi=10.1056%2FNEJMoa1602046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span></div><div class="casAuthors">Nel, A.; van Niekerk, N.; Kapiga, S.; Bekker, L.-G.; Gama, C.; Gill, K.; Kamali, A.; Kotze, P.; Louw, C.; Mabude, Z.; Miti, N.; Kusemererwa, S.; Tempelman, H.; Carstens, H.; Devlin, B.; Isaacs, M.; Malherbe, M.; Mans, W.; Nuttall, J.; Russell, M.; Ntshele, S.; Smit, M.; Solai, L.; Spence, P.; Steytler, J.; Windle, K.; Borremans, M.; Resseler, S.; Van Roey, J.; Parys, W.; Vangeneugden, T.; Van Baelen, B.; Rosenberg, Z.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2133-2143</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa.  We evaluated the safety and efficacy of extended use of a vaginal ring contg. dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda.  METHODS: In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings contg. either 25 mg of dapivirine or placebo.  Participants inserted the rings themselves every 4 wk for up to 24 mo.  The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion.  RESULTS: A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years).  The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P = 0.04).  There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P = 0.43 for treatment-by-age interaction).  Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group.  Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]).  However, no clear pattern was identified.  CONCLUSIONS: Among women in sub-Saharan Africa, the dapivirine ring was not assocd. with any safety concerns and was assocd. with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_wx1pEUBBCrVg90H21EOLACvtfcHk0lhUayxst6qIFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM&md5=970e69fc1a0fc725671e9e372fba6737</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602046%26sid%3Dliteratum%253Aachs%26aulast%3DNel%26aufirst%3DA.%26aulast%3Dvan%2BNiekerk%26aufirst%3DN.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.%2BG.%26aulast%3DGama%26aufirst%3DC.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DKamali%26aufirst%3DA.%26aulast%3DKotze%26aufirst%3DP.%26aulast%3DLouw%26aufirst%3DC.%26aulast%3DMabude%26aufirst%3DZ.%26aulast%3DMiti%26aufirst%3DN.%26aulast%3DKusemererwa%26aufirst%3DS.%26aulast%3DTempelman%26aufirst%3DH.%26aulast%3DCarstens%26aufirst%3DH.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DIsaacs%26aufirst%3DM.%26aulast%3DMalherbe%26aufirst%3DM.%26aulast%3DMans%26aufirst%3DW.%26aulast%3DNuttall%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DNtshele%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DSolai%26aufirst%3DL.%26aulast%3DSpence%26aufirst%3DP.%26aulast%3DSteytler%26aufirst%3DJ.%26aulast%3DWindle%26aufirst%3DK.%26aulast%3DBorremans%26aufirst%3DM.%26aulast%3DResseler%26aufirst%3DS.%26aulast%3DVan%2BRoey%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3DVangeneugden%26aufirst%3DT.%26aulast%3DVan%2BBaelen%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DZ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520a%2520dapivirine%2520vaginal%2520ring%2520for%2520HIV%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D22%26spage%3D2133%26epage%3D2143%26doi%3D10.1056%2FNEJMoa1602046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchbinder, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A. Y.</span></span> <span> </span><span class="NLM_article-title">CROI 2018: epidemic trends and advances in HIV prevention</span>. <i>Top. Antivir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29727292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BC1MjpvVOquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1-16&author=S.+P.+Buchbinderauthor=A.+Y.+Liu&title=CROI+2018%3A+epidemic+trends+and+advances+in+HIV+prevention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">CROI 2018: Epidemic Trends and Advances in HIV Prevention</span></div><div class="casAuthors">Buchbinder Susan P; Liu Albert Y</div><div class="citationInfo"><span class="NLM_cas:title">Topics in antiviral medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">At the 2018 Conference on Retroviruses and Opportunistic Infections, trends in and risk factors for in HIV infection were highlighted.  In the United States, new HIV diagnoses are highest in the South and among African Americans and are increasing in rural areas.  Youth remain highly vulnerable to HIV infection globally.  The epidemiology of HIV infections among people who inject drugs is changing, with overdose deaths, a major public health concern.  Phylogenetics are being used to identify HIV transmission clusters and hotspots, which can inform prevention efforts.  Vaginal microbial dysbiosis and proteomic alterations are associated with increased risk of HIV acquisition, as are the pregnancy and postpartum periods.  HIV testing is a central first step for the HIV care and treatment continua, and several innovative strategies to expand HIV testing coverage and frequency show promise.  Preexposure prophylaxis (PrEP) uptake is rapidly increasing in some cities, with reductions of new infections at the population level, but use is lower among African Americans and Latinos, youth, cis- and transgender women, and people who inject drugs.  PrEP continuation remains a challenge.  Two open-label extension studies of the dapivirine vaginal ring demonstrated high uptake, adherence, and reduced HIV infections.  Several novel systemic and topical prevention agents show promise in non-human primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtJ_ZqXNoZPTW1zwg2yUK5fW6udTcc2eYRMohHz7QosLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjpvVOquw%253D%253D&md5=6222438378ea63baffd6c702522362d2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchbinder%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DA.%2BY.%26atitle%3DCROI%25202018%253A%2520epidemic%2520trends%2520and%2520advances%2520in%2520HIV%2520prevention%26jtitle%3DTop.%2520Antivir.%2520Med.%26date%3D2018%26volume%3D26%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Council, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belshan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayer, W. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachaud-Durand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Destache, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. V.</span></span> <span> </span><span class="NLM_article-title">Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>), <span class="NLM_elocation-id">e1005075</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1005075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1371%2Fjournal.ppat.1005075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&issue=8&author=M.+Kovarovaauthor=O.+D.+Councilauthor=A.+A.+Dateauthor=J.+M.+Longauthor=T.+Nochiiauthor=M.+Belshanauthor=A.+Shibataauthor=H.+Vincentauthor=C.+E.+Bakerauthor=W.+O.+Thayerauthor=G.+Krausauthor=S.+Lachaud-Durandauthor=P.+Williamsauthor=C.+J.+Destacheauthor=J.+V.+Garcia&title=Nanoformulations+of+rilpivirine+for+topical+pericoital+and+systemic+coitus-independent+administration+efficiently+prevent+HIV+transmission&doi=10.1371%2Fjournal.ppat.1005075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005075%26sid%3Dliteratum%253Aachs%26aulast%3DKovarova%26aufirst%3DM.%26aulast%3DCouncil%26aufirst%3DO.%2BD.%26aulast%3DDate%26aufirst%3DA.%2BA.%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DNochii%26aufirst%3DT.%26aulast%3DBelshan%26aufirst%3DM.%26aulast%3DShibata%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DH.%26aulast%3DBaker%26aufirst%3DC.%2BE.%26aulast%3DThayer%26aufirst%3DW.%2BO.%26aulast%3DKraus%26aufirst%3DG.%26aulast%3DLachaud-Durand%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DDestache%26aufirst%3DC.%2BJ.%26aulast%3DGarcia%26aufirst%3DJ.%2BV.%26atitle%3DNanoformulations%2520of%2520rilpivirine%2520for%2520topical%2520pericoital%2520and%2520systemic%2520coitus-independent%2520administration%2520efficiently%2520prevent%2520HIV%2520transmission%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26issue%3D8%26doi%3D10.1371%2Fjournal.ppat.1005075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezzutti, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson-Harman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Else, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achilles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranston, R. D.</span></span> <span> </span><span class="NLM_article-title">Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e569</span>– <span class="NLM_lpage">e578</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(16)30113-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS2352-3018%2816%2930113-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=27658864" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e569-e578&issue=12&author=I.+McGowanauthor=C.+S.+Dezzuttiauthor=A.+Siegelauthor=J.+Engstromauthor=A.+Nikiforovauthor=K.+Duffillauthor=C.+Shetlerauthor=N.+Richardson-Harmanauthor=K.+Abebeauthor=D.+Backauthor=L.+Elseauthor=D.+Eganauthor=S.+Khooauthor=J.+E.+Eganauthor=R.+Stallauthor=P.+E.+Williamsauthor=K.+K.+Rehmanauthor=A.+Adlerauthor=R.+M.+Brandauthor=B.+Chenauthor=S.+Achillesauthor=R.+D.+Cranston&title=Long-acting+rilpivirine+as+potential+pre-exposure+prophylaxis+for+HIV-1+prevention+%28the+MWRI-01+study%29%3A+an+open-label%2C+phase+1%2C+compartmental%2C+pharmacokinetic+and+pharmacodynamic+assessment&doi=10.1016%2FS2352-3018%2816%2930113-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2816%2930113-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252816%252930113-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DI.%26aulast%3DDezzutti%26aufirst%3DC.%2BS.%26aulast%3DSiegel%26aufirst%3DA.%26aulast%3DEngstrom%26aufirst%3DJ.%26aulast%3DNikiforov%26aufirst%3DA.%26aulast%3DDuffill%26aufirst%3DK.%26aulast%3DShetler%26aufirst%3DC.%26aulast%3DRichardson-Harman%26aufirst%3DN.%26aulast%3DAbebe%26aufirst%3DK.%26aulast%3DBack%26aufirst%3DD.%26aulast%3DElse%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DD.%26aulast%3DKhoo%26aufirst%3DS.%26aulast%3DEgan%26aufirst%3DJ.%2BE.%26aulast%3DStall%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DP.%2BE.%26aulast%3DRehman%26aufirst%3DK.%2BK.%26aulast%3DAdler%26aufirst%3DA.%26aulast%3DBrand%26aufirst%3DR.%2BM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DAchilles%26aufirst%3DS.%26aulast%3DCranston%26aufirst%3DR.%2BD.%26atitle%3DLong-acting%2520rilpivirine%2520as%2520potential%2520pre-exposure%2520prophylaxis%2520for%2520HIV-1%2520prevention%2520%2528the%2520MWRI-01%2520study%2529%253A%2520an%2520open-label%252C%2520phase%25201%252C%2520compartmental%252C%2520pharmacokinetic%2520and%2520pharmacodynamic%2520assessment%26jtitle%3DLancet%2520HIV%26date%3D2016%26volume%3D3%26issue%3D12%26spage%3De569%26epage%3De578%26doi%3D10.1016%2FS2352-3018%2816%2930113-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span> </span><span class="NLM_article-title">HPTN 076: TMC278 LA Safe, Tolerable and
Acceptable for HIV Pre-Exposure
Prophylaxis</span>. In  <i>Conference on Retroviruses
and Opportunistic Infections (CROI), Seattle, Washington, Seattle,
WA</i>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=HPTN+076%3A+TMC278+LA+Safe%2C+Tolerable+and%0AAcceptable+for+HIV+Pre-Exposure%0AProphylaxis.+In+Conference+on+Retroviruses%0Aand+Opportunistic+Infections+%28CROI%29%2C+Seattle%2C+Washington%2C+Seattle%2C%0AWA%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26atitle%3DHPTN%2520076%253A%2520TMC278%2520LA%2520Safe%252C%2520Tolerable%2520and%250AAcceptable%2520for%2520HIV%2520Pre-Exposure%250AProphylaxis%26jtitle%3DConference%2520on%2520Retroviruses%250Aand%2520Opportunistic%2520Infections%2520%2528CROI%2529%252C%2520Seattle%252C%2520Washington%252C%2520Seattle%252C%250AWA%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span> <i>HPTN 076: Phase
II Safety and Acceptability of an Investigational
Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)</i>; <span class="NLM_publisher-name">HIV Prevention Trials Network</span>, <span class="NLM_year">2018</span>; <a href="https://www.hptn.org/research/studies/hptn076" class="extLink">https://www.hptn.org/research/studies/hptn076</a> (accessed August
16, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+HPTN+076%3A+Phase%0AII+Safety+and+Acceptability+of+an+Investigational%0AInjectable+Product%2C+TMC278+LA%2C+for+Pre+Exposure+Prophylaxis+%28PrEP%29%3B+HIV+Prevention+Trials+Network%2C+2018%3B+https%3A%2F%2Fwww.hptn.org%2Fresearch%2Fstudies%2Fhptn076+%28accessed+August%0A16%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DHPTN%2520076%253A%2520Phase%250AII%2520Safety%2520and%2520Acceptability%2520of%2520an%2520Investigational%250AInjectable%2520Product%252C%2520TMC278%2520LA%252C%2520for%2520Pre%2520Exposure%2520Prophylaxis%2520%2528PrEP%2529%26pub%3DHIV%2520Prevention%2520Trials%2520Network%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seckler, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkley, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintrode, P. L.</span></span> <span> </span><span class="NLM_article-title">Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2010.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bpj.2010.11.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=144-153&issue=1&author=J.+M.+Secklerauthor=M.+D.+Barkleyauthor=P.+L.+Wintrode&title=Allosteric+suppression+of+HIV-1+reverse+transcriptase+structural+dynamics+upon+inhibitor+binding&doi=10.1016%2Fj.bpj.2010.11.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2010.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2010.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DSeckler%26aufirst%3DJ.%2BM.%26aulast%3DBarkley%26aufirst%3DM.%2BD.%26aulast%3DWintrode%26aufirst%3DP.%2BL.%26atitle%3DAllosteric%2520suppression%2520of%2520HIV-1%2520reverse%2520transcriptase%2520structural%2520dynamics%2520upon%2520inhibitor%2520binding%26jtitle%3DBiophys.%2520J.%26date%3D2011%26volume%3D100%26issue%3D1%26spage%3D144%26epage%3D153%26doi%3D10.1016%2Fj.bpj.2010.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span> <i>Delavirdine Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug
Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Delavirdine+Package%3B+U.S.+Food+and+Drug%0AAdministration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDelavirdine%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obst-Sander, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/cbic.200301023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+B%C3%B6hmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry&doi=10.1002%2Fcbic.200301023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2eb5rf_QZfxU6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBioChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643%26doi%3D10.1002%2Fcbic.200301023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&issue=14&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0liitRqdNv6_aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishima, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronenborn, A. M.</span></span> <span> </span><span class="NLM_article-title">Conformational plasticity of the NNRTI-binding pocket in HIV-1 reverse transcriptase: A fluorine nuclear magnetic resonance study</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">3864</span>– <span class="NLM_lpage">3873</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.6b00113</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.6b00113" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=3864-3873&issue=28&author=N.+G.+Sharafauthor=R.+Ishimaauthor=A.+M.+Gronenborn&title=Conformational+plasticity+of+the+NNRTI-binding+pocket+in+HIV-1+reverse+transcriptase%3A+A+fluorine+nuclear+magnetic+resonance+study&doi=10.1021%2Facs.biochem.6b00113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.6b00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.6b00113%26sid%3Dliteratum%253Aachs%26aulast%3DSharaf%26aufirst%3DN.%2BG.%26aulast%3DIshima%26aufirst%3DR.%26aulast%3DGronenborn%26aufirst%3DA.%2BM.%26atitle%3DConformational%2520plasticity%2520of%2520the%2520NNRTI-binding%2520pocket%2520in%2520HIV-1%2520reverse%2520transcriptase%253A%2520A%2520fluorine%2520nuclear%2520magnetic%2520resonance%2520study%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26issue%3D28%26spage%3D3864%26epage%3D3873%26doi%3D10.1021%2Facs.biochem.6b00113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1113256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1517%2F13543776.2016.1113256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26559996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWmurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=281-289&issue=2&author=B.+Huangauthor=D.+Kangauthor=J.+Yangauthor=P.+Zhanauthor=X.+Liu&title=Novel+diarylpyrimidines+and+diaryltriazines+as+potent+HIV-1+NNRTIs+with+dramatically+improved+solubility%3A+a+patent+evaluation+of+US20140378443A1&doi=10.1517%2F13543776.2016.1113256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1</span></div><div class="casAuthors">Huang, Boshi; Kang, Dongwei; Yang, Jiapei; Zhan, Peng; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">281-289</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Diarylpyrimidine and diaryltriazine derivs., two representative structurally related classes of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with robust potencies against wild-type and several mutant strains of HIV-1, have attracted more and more attention in the last decade.  However, they have been suffering from poor aq. soly.  A series of novel diarylpyrimidines and diaryltriazines with solubilizing substituents attached to the central rings were reported as potent NNRTIs in the patent US20140378443A1.  Some compds. exhibited potencies against wild-type HIV-1 which were comparable or even superior to those of dapivirine, etravirine and rilpivirine.  In addn., dramatically enhanced solubilities were obsd. for these new compds.  Moreover, some structure optimization strategies for improving aq. soly. are detailed in this review, providing new insights into development of next-generation NNRTIs endowed with favorable soly.  We anticipate that application of these strategies will ultimately lead to discovery of new anti-HIV drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1dLeivplI8LVg90H21EOLACvtfcHk0lgySScTj4Dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWmurvF&md5=612a5aaa157bd2c1e6e2c066a4c4581f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1113256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1113256%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DNovel%2520diarylpyrimidines%2520and%2520diaryltriazines%2520as%2520potent%2520HIV-1%2520NNRTIs%2520with%2520dramatically%2520improved%2520solubility%253A%2520a%2520patent%2520evaluation%2520of%2520US20140378443A1%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D281%26epage%3D289%26doi%3D10.1517%2F13543776.2016.1113256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1088832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1517%2F13543776.2016.1088832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26415039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVajsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1477-1486&issue=12&author=Q.+Mengauthor=N.+Liuauthor=B.+Huangauthor=P.+Zhanauthor=X.+Liu&title=Novel+fluorine-containing+DAPY+derivatives+as+potent+HIV-1+NNRTIs%3A+a+patent+evaluation+of+WO2014072419&doi=10.1517%2F13543776.2016.1088832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419</span></div><div class="casAuthors">Meng, Qing; Liu, Na; Huang, Boshi; Zhan, Peng; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1486</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Diarylpyrimidine (DAPY) derivs., one family of HIV non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) with superior activities against wild-type (WT) HIV-1 and NNRTI-resistant strains, have attracted much attention in the past decade.  A series of DAPY derivs. featuring a fluorine atom on the central ring were reported as novel NNRTIs in the patent WO2014072419.  Some compds. exhibited robust potency against both WT and mutant strains, which were approx. equal to or higher than those of the ref. drug TMC120.  Moreover, it has become evident that fluorinated mols. have a remarkable record in many other potent NNRTIs.  Thus, this survey provides a sampling of renowned fluorinated NNRTIs and their mode of action, with an anal. clarifying the functional roles and impact of fluorine substitution on antiviral potency.  We envision that fluorinated NNRTIs will play a continuing role in affording anti-HIV drug candidates for therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl1Ku91OQ-srVg90H21EOLACvtfcHk0lgySScTj4Dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVajsrfN&md5=9c96ffb29cebdfc0dfb29f7b08d61a91</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1088832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1088832%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DNovel%2520fluorine-containing%2520DAPY%2520derivatives%2520as%2520potent%2520HIV-1%2520NNRTIs%253A%2520a%2520patent%2520evaluation%2520of%2520WO2014072419%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26issue%3D12%26spage%3D1477%26epage%3D1486%26doi%3D10.1517%2F13543776.2016.1088832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piscitelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinistro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5034</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm070488f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070488f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5034-5038&issue=20&author=G.+La+Reginaauthor=A.+Colucciaauthor=F.+Piscitelliauthor=A.+Bergaminiauthor=A.+Sinistroauthor=A.+Cavazzaauthor=G.+Magaauthor=A.+Samueleauthor=S.+Zanoliauthor=E.+Novellinoauthor=M.+Articoauthor=R.+Silvestri&title=Indolyl+aryl+sulfones+as+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors%3A+role+of+two+halogen+atoms+at+the+indole+ring+in+developing+new+analogues+with+improved+antiviral+activity&doi=10.1021%2Fjm070488f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Fjm070488f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070488f%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DPiscitelli%26aufirst%3DF.%26aulast%3DBergamini%26aufirst%3DA.%26aulast%3DSinistro%26aufirst%3DA.%26aulast%3DCavazza%26aufirst%3DA.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DSamuele%26aufirst%3DA.%26aulast%3DZanoli%26aufirst%3DS.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DIndolyl%2520aryl%2520sulfones%2520as%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520role%2520of%2520two%2520halogen%2520atoms%2520at%2520the%2520indole%2520ring%2520in%2520developing%2520new%2520analogues%2520with%2520improved%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D20%26spage%3D5034%26epage%3D5038%26doi%3D10.1021%2Fjm070488f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Chapter Nine - The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)</span>. In  <i>Advances in Pharmacology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2013</span>; Vol. 67, pp  <span class="NLM_fpage">317</span>− <span class="NLM_lpage">358</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=317-358&author=E.+De+Clercq&title=Advances+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DChapter%2520Nine%2520-%2520The%2520Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%252C%2520Nonnucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%252C%2520and%2520Protease%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520HIV%2520Infections%2520%2528AIDS%2529%26btitle%3DAdvances%2520in%2520Pharmacology%26aulast%3DDe%2BClercq%26aufirst%3DE.%26pub%3DAcademic%2520Press%26date%3D2013%26spage%3D317%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span> <span> </span><span class="NLM_article-title">Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014−2017)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1438410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1080%2F13543776.2018.1438410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29411697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=299-316&issue=4&author=X.+Zuoauthor=Z.+Huoauthor=D.+Kangauthor=G.+Wuauthor=Z.+Zhouauthor=X.+Liuauthor=P.+Zhan&title=Current+insights+into+anti-HIV+drug+discovery+and+development%3A+a+review+of+recent+patent+literature+%282014%E2%88%922017%29&doi=10.1080%2F13543776.2018.1438410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)</span></div><div class="casAuthors">Zuo, Xiaofang; Huo, Zhipeng; Kang, Dongwei; Wu, Gaochan; Zhou, Zhongxia; Liu, Xinyong; Zhan, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-316</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: To deal with the rapid emergence of drug resistance challenges, together with the difficulty to eradicate the virus, off-target effects and significant cumulative drug toxicities, it is still imperative to develop next-generation anti-HIV agents with novel chem. classes or new mechanisms of action.: We primarily focused on current strategies to discover novel anti-HIV agents.  Moreover, examples of anti-HIV lead compds. were mainly selected from recently patented publications (reported between 2014 and 2017).  In particular, 'privileged structure'-focused substituents decorating approach, scaffold hopping, natural-product diversification and prodrug are focused on.  Furthermore, exploitation of new compds. with unexplored mechanisms of action and medicinal chem. strategies to deplete the HIV reservoir were also described.  Perspectives that could inspire future anti-HIV drug discovery are delineated.: Even if a large no. of patents have been disclosed recently, addnl. HIV inhibitors are still required, esp. novel chem. skeletons displaying a unexploited mechanism of action.  Current medicinal chem. strategies are inadequate, and appropriate and new methodologies and technologies should be exploited to identify novel anti-HIV drug candidates in a time- and cost- effective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsNhCVIx9ytLVg90H21EOLACvtfcHk0lgySScTj4Dthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyitb4%253D&md5=079363fcb726677dea5ea2fda2e11ba0</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1438410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1438410%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DX.%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DP.%26atitle%3DCurrent%2520insights%2520into%2520anti-HIV%2520drug%2520discovery%2520and%2520development%253A%2520a%2520review%2520of%2520recent%2520patent%2520literature%2520%25282014%25E2%2588%25922017%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26issue%3D4%26spage%3D299%26epage%3D316%26doi%3D10.1080%2F13543776.2018.1438410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mkhize, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taljaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span> <span> </span><span class="NLM_article-title">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1402269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1402269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25651245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=509-518&issue=6&author=J.+M.+Marrazzoauthor=G.+Ramjeeauthor=B.+A.+Richardsonauthor=K.+Gomezauthor=N.+Mgodiauthor=G.+Nairauthor=T.+Palaneeauthor=C.+Nakabiitoauthor=A.+van+der+Stratenauthor=L.+Noguchiauthor=C.+W.+Hendrixauthor=J.+Y.+Daiauthor=S.+Ganeshauthor=B.+Mkhizeauthor=M.+Taljaardauthor=U.+M.+Parikhauthor=J.+Piperauthor=B.+Masseauthor=C.+Grossmanauthor=J.+Rooneyauthor=J.+L.+Schwartzauthor=H.+Wattsauthor=M.+A.+Marzinkeauthor=S.+L.+Hillierauthor=I.+M.+McGowanauthor=Z.+M.+Chirenje&title=Tenofovir-based+preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1402269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Marrazzo, Jeanne M.; Ramjee, Gita; Richardson, Barbra A.; Gomez, Kailazarid; Mgodi, Nyaradzo; Nair, Gonasagrie; Palanee, Thesla; Nakabiito, Clemensia; van der Straten, Ariane; Noguchi, Lisa; Hendrix, Craig W.; Dai, James Y.; Ganesh, Shayhana; Mkhize, Baningi; Taljaard, Marthinette; Parikh, Urvi M.; Piper, Jeanna; Masse, Benoit; Grossman, Cynthia; Rooney, James; Schwartz, Jill L.; Watts, Heather; Marzinke, Mark A.; Hillier, Sharon L.; McGowan, Ian M.; Chirenje, Z. Mike</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">509-518/1-509-518/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe.  HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly.  Of 12,320 women who were screened, 5029 were enrolled in the study.  The rate of retention in the study was 91% during 5509 person-years of follow-up.  A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years.  In the modified intention-to-treat anal., the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21).  In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, resp.  Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous.  Detection of TFV in plasma was neg. assocd. with characteristics predictive of HIV-1 acquisition.  Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P = 0.004).  We obsd. no significant differences in the frequencies of other adverse events.  None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat anal.  Adherence to study drugs was low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwMI6Bbu9d7Vg90H21EOLACvtfcHk0liMxx6gAY2zkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D&md5=dfa4a90697a305320dc82815b0d60a1f</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402269%26sid%3Dliteratum%253Aachs%26aulast%3DMarrazzo%26aufirst%3DJ.%2BM.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DGomez%26aufirst%3DK.%26aulast%3DMgodi%26aufirst%3DN.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DPalanee%26aufirst%3DT.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DNoguchi%26aufirst%3DL.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3DDai%26aufirst%3DJ.%2BY.%26aulast%3DGanesh%26aufirst%3DS.%26aulast%3DMkhize%26aufirst%3DB.%26aulast%3DTaljaard%26aufirst%3DM.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DPiper%26aufirst%3DJ.%26aulast%3DMasse%26aufirst%3DB.%26aulast%3DGrossman%26aufirst%3DC.%26aulast%3DRooney%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DJ.%2BL.%26aulast%3DWatts%26aufirst%3DH.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHillier%26aufirst%3DS.%2BL.%26aulast%3DMcGowan%26aufirst%3DI.%2BM.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26atitle%3DTenofovir-based%2520preexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D6%26spage%3D509%26epage%3D518%26doi%3D10.1056%2FNEJMoa1402269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malahleha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manongi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyango, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monedi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak’Oketch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reblin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makatu, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiernan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkendale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastro, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span> <span> </span><span class="NLM_article-title">Preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1202614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22784040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=411-422&issue=5&author=L.+Van+Dammeauthor=A.+Corneliauthor=K.+Ahmedauthor=K.+Agotauthor=J.+Lombaardauthor=S.+Kapigaauthor=M.+Malahlehaauthor=F.+Owinoauthor=R.+Manongiauthor=J.+Onyangoauthor=L.+Temuauthor=M.+C.+Monediauthor=P.+Mak%E2%80%99Oketchauthor=M.+Makandaauthor=I.+Reblinauthor=S.+E.+Makatuauthor=L.+Saylorauthor=H.+Kiernanauthor=S.+Kirkendaleauthor=C.+Wongauthor=R.+Grantauthor=A.+Kashubaauthor=K.+Nandaauthor=J.+Mandalaauthor=K.+Fransenauthor=J.+Deeseauthor=T.+Crucittiauthor=T.+D.+Mastroauthor=D.+Taylor&title=Preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1202614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Van Damme, Lut; Corneli, Amy; Ahmed, Khatija; Agot, Kawango; Lombaard, Johan; Kapiga, Saidi; Malahleha, Mookho; Owino, Fredrick; Manongi, Rachel; Onyango, Jacob; Temu, Lucky; Monedi, Modie Constance; Mak'Oketch, Paul; Makanda, Mankalimeng; Reblin, Ilse; Makatu, Shumani Elsie; Saylor, Lisa; Kiernan, Haddie; Kirkendale, Stella; Wong, Christina; Grant, Robert; Kashuba, Angela; Nanda, Kavita; Mandala, Justin; Fransen, Katrien; Deese, Jennifer; Crucitti, Tania; Mastro, Timothy D.; Taylor, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others.  Methods: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-neg. women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily.  The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety.  Results: HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estd. hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P = 0.81).  The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P = 0.04, P<0.001, and P = 0.03, resp.).  Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P = 0.051).  Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion.  The study was stopped early, on Apr. 18, 2011, because of lack of efficacy.  Conclusions: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was assocd. with increased rates of side effects, as compared with placebo.  Despite substantial counseling efforts, drug adherence appeared to be low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-zDy6lkjhp7Vg90H21EOLACvtfcHk0liMxx6gAY2zkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL&md5=b570dd1c89c2fe20667ddd92f2f1cba0</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202614%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDamme%26aufirst%3DL.%26aulast%3DCorneli%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DK.%26aulast%3DAgot%26aufirst%3DK.%26aulast%3DLombaard%26aufirst%3DJ.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DMalahleha%26aufirst%3DM.%26aulast%3DOwino%26aufirst%3DF.%26aulast%3DManongi%26aufirst%3DR.%26aulast%3DOnyango%26aufirst%3DJ.%26aulast%3DTemu%26aufirst%3DL.%26aulast%3DMonedi%26aufirst%3DM.%2BC.%26aulast%3DMak%25E2%2580%2599Oketch%26aufirst%3DP.%26aulast%3DMakanda%26aufirst%3DM.%26aulast%3DReblin%26aufirst%3DI.%26aulast%3DMakatu%26aufirst%3DS.%2BE.%26aulast%3DSaylor%26aufirst%3DL.%26aulast%3DKiernan%26aufirst%3DH.%26aulast%3DKirkendale%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DGrant%26aufirst%3DR.%26aulast%3DKashuba%26aufirst%3DA.%26aulast%3DNanda%26aufirst%3DK.%26aulast%3DMandala%26aufirst%3DJ.%26aulast%3DFransen%26aufirst%3DK.%26aulast%3DDeese%26aufirst%3DJ.%26aulast%3DCrucitti%26aufirst%3DT.%26aulast%3DMastro%26aufirst%3DT.%2BD.%26aulast%3DTaylor%26aufirst%3DD.%26atitle%3DPreexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D5%26spage%3D411%26epage%3D422%26doi%3D10.1056%2FNEJMoa1202614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llibre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeulen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboud, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span> (<span class="NLM_issue">10123</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)33095-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2817%2933095-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=839-849&issue=10123&author=J.+M.+Llibreauthor=C.+C.+Hungauthor=C.+Brinsonauthor=F.+Castelliauthor=P.+M.+Girardauthor=L.+P.+Kahlauthor=E.+A.+Blairauthor=K.+Angelisauthor=B.+Wynneauthor=K.+Vandermeulenauthor=M.+Underwoodauthor=K.+Smithauthor=M.+Gartlandauthor=M.+Aboud&title=Efficacy%2C+safety%2C+and+tolerability+of+dolutegravir-rilpivirine+for+the+maintenance+of+virological+suppression+in+adults+with+HIV-1%3A+phase+3%2C+randomised%2C+non-inferiority+SWORD-1+and+SWORD-2+studies&doi=10.1016%2FS0140-6736%2817%2933095-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2933095-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252933095-7%26sid%3Dliteratum%253Aachs%26aulast%3DLlibre%26aufirst%3DJ.%2BM.%26aulast%3DHung%26aufirst%3DC.%2BC.%26aulast%3DBrinson%26aufirst%3DC.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DP.%2BM.%26aulast%3DKahl%26aufirst%3DL.%2BP.%26aulast%3DBlair%26aufirst%3DE.%2BA.%26aulast%3DAngelis%26aufirst%3DK.%26aulast%3DWynne%26aufirst%3DB.%26aulast%3DVandermeulen%26aufirst%3DK.%26aulast%3DUnderwood%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DGartland%26aufirst%3DM.%26aulast%3DAboud%26aufirst%3DM.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520dolutegravir-rilpivirine%2520for%2520the%2520maintenance%2520of%2520virological%2520suppression%2520in%2520adults%2520with%2520HIV-1%253A%2520phase%25203%252C%2520randomised%252C%2520non-inferiority%2520SWORD-1%2520and%2520SWORD-2%2520studies%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26issue%3D10123%26spage%3D839%26epage%3D849%26doi%3D10.1016%2FS0140-6736%2817%2933095-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sluis-Cremer, N.</span></span> <span> </span><span class="NLM_article-title">Future of nonnucleoside reverse transcriptase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.1073/pnas.1720975115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.1720975115" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=637-638&issue=4&author=N.+Sluis-Cremer&title=Future+of+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1073%2Fpnas.1720975115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1720975115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1720975115%26sid%3Dliteratum%253Aachs%26aulast%3DSluis-Cremer%26aufirst%3DN.%26atitle%3DFuture%2520of%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D4%26spage%3D637%26epage%3D638%26doi%3D10.1073%2Fpnas.1720975115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calmy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, P. E.</span></span> <span> </span><span class="NLM_article-title">Will NNRTIs be driving forward again?</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e200</span>– <span class="NLM_lpage">e201</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(18)30037-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS2352-3018%2818%2930037-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29592841" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=e200-e201&issue=5&author=A.+Calmyauthor=P.+E.+Tarr&title=Will+NNRTIs+be+driving+forward+again%3F&doi=10.1016%2FS2352-3018%2818%2930037-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2818%2930037-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252818%252930037-7%26sid%3Dliteratum%253Aachs%26aulast%3DCalmy%26aufirst%3DA.%26aulast%3DTarr%26aufirst%3DP.%2BE.%26atitle%3DWill%2520NNRTIs%2520be%2520driving%2520forward%2520again%253F%26jtitle%3DLancet%2520HIV%26date%3D2018%26volume%3D5%26issue%3D5%26spage%3De200%26epage%3De201%26doi%3D10.1016%2FS2352-3018%2818%2930037-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mislak, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1840</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2203</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2014.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bbagen.2014.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=24726448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVSlsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=2203-2211&issue=7&author=A.+C.+Mislakauthor=K.+M.+Freyauthor=M.+Bolliniauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=A+mechanistic+and+structural+investigation+of+modified+derivatives+of+the+diaryltriazine+class+of+NNRTIs+targeting+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.bbagen.2014.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase</span></div><div class="casAuthors">Mislak, Andrea C.; Frey, Kathleen M.; Bollini, Mariela; Jorgensen, William L.; Anderson, Karen S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2203-2211</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are vital in treating HIV-1 infection by inhibiting reverse transcriptase (RT).  Drug toxicity and resistance drive the need for effective new inhibitors with improved physiochem. properties and potent antiviral activity.  Computer-aided and structure-based drug design have guided the addn. of solubilizing substituents to the diaryltriazine scaffold.  These derivs. have markedly improved soly. and maintain low nanomolar antiviral activity against RT.  The mol. and structural basis of inhibition for this series was detd. to facilitate future inhibitor development with improved pharmacol. profiles.  The mol. mechanism of inhibition was investigated using transient-state kinetic anal.  Crystal structures of RT in complex with each inhibitor were obtained to investigate the structural basis of inhibition.  The diaryltriazine and its morpholine deriv. have RT inhibition consts. of 9±2 nM and 14±4 nM, resp.  They adopt differential binding modes within the non-nucleoside inhibitor binding pocket to distort the catalytic site geometry and primer grip regions.  The novel morpholinopropoxy substituent extends into the RT/solvent interface of the NNIBP.  Kinetic and structural analyses show that these inhibitors behave as conventional NNRTIs and inhibit the polymn. step.  This study confirms that appending solubilizing substituents on the azine ring of diaryltriazine class of NNRTIs that extend into the RT/solvent interface effectively maintains low nanomolar potency and improves physiochem. properties.  The modification of NNRTI scaffolds with solubilizing substituents, which extend into the RT/solvent interface, yields potent antivirals and is an effective strategy for developing novel inhibitors with improved pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmiKVZSjLTf7Vg90H21EOLACvtfcHk0lhLhO79Jx5tCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVSlsLfJ&md5=0e3ce9b5013ab5b36d24f32b5302c3d3</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2014.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2014.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DMislak%26aufirst%3DA.%2BC.%26aulast%3DFrey%26aufirst%3DK.%2BM.%26aulast%3DBollini%26aufirst%3DM.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DA%2520mechanistic%2520and%2520structural%2520investigation%2520of%2520modified%2520derivatives%2520of%2520the%2520diaryltriazine%2520class%2520of%2520NNRTIs%2520targeting%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26issue%3D7%26spage%3D2203%26epage%3D2211%26doi%3D10.1016%2Fj.bbagen.2014.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruccoleri, A.</span></span> <span> </span><span class="NLM_article-title">Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1089/aid.2012.0141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1089%2Faid.2012.0141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=4-12&issue=1&author=A.+Bruccoleri&title=Positional+adaptability+in+the+design+of+mutation-resistant+nonnucleoside+HIV-1+reverse+transcriptase+inhibitors%3A+a+supramolecular+perspective&doi=10.1089%2Faid.2012.0141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1089%2Faid.2012.0141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Faid.2012.0141%26sid%3Dliteratum%253Aachs%26aulast%3DBruccoleri%26aufirst%3DA.%26atitle%3DPositional%2520adaptability%2520in%2520the%2520design%2520of%2520mutation-resistant%2520nonnucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%253A%2520a%2520supramolecular%2520perspective%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2013%26volume%3D29%26issue%3D1%26spage%3D4%26epage%3D12%26doi%3D10.1089%2Faid.2012.0141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Design strategies of novel NNRTIs to overcome drug resistance</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">3903</span>– <span class="NLM_lpage">3917</span>, <span class="refDoi"> DOI: 10.2174/092986709789178019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2174%2F092986709789178019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=19747133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCktbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=3903-3917&issue=29&author=P.+Zhanauthor=X.+Liuauthor=Z.+Liauthor=C.+Pannecouqueauthor=E.+De+Clercq&title=Design+strategies+of+novel+NNRTIs+to+overcome+drug+resistance&doi=10.2174%2F092986709789178019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Design strategies of novel NNRTIs to overcome drug resistance</span></div><div class="casAuthors">Zhan, Peng; Liu, Xinyong; Li, Zhenyu; Pannecouque, Christophe; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3903-3917</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT).  However, to a great extent, the efficacy of NNRTI drugs is impaired by rapid emergence of drug-resistance mutations.  Fortunately, detailed anal. of a wide range of crystal structures of HIV-1 RT/NNRTI complexes together with data on drug resistance mutations has identified factors important for design of inhibitors and resilience to mutations, such as, exhibiting conformational flexibility and positional adaptability of NNRTIs, forming extensive main chain hydrogen bonding, targeting highly conserved residues in HIV-1 RT and possessing unconventional mechanisms for NNRTI-mediated inhibition of RT.  Besides, the plasticity of NNRTIs binding pocket (NNIBP) also provides a broad space for the discovery of new generations of NNRTIs.  For instance, the composite binding pocket, integrating all available crystal structure information about the NNRTI binding site of HIV RT, was demonstrated to be an effective tool to better understand the flexible nature of the binding pocket and to identify specific inhibitors.  The RT/solvent interface proved to be an attractive site for incorporating a moiety to improve water soly. and pharmacokinetics or introducing a second pharmacophore to construct multifunctional ligand.  Totally, the characterization of NNRTIs and NNIBP may help in the design of more effective drugs that are potent toward wild type and drug-resistant strains of RT.  In this paper we attempt to translate the general knowledge gained from a large no. of related literature into a set of medicinal chem. strategies to improve the drug resistance profile of NNRTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfBY0F4M_eN7Vg90H21EOLACvtfcHk0lgpZRLLR6YJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCktbvM&md5=4834066bfce8ae018df14be7e84d5a90</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.2174%2F092986709789178019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709789178019%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDesign%2520strategies%2520of%2520novel%2520NNRTIs%2520to%2520overcome%2520drug%2520resistance%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26issue%3D29%26spage%3D3903%26epage%3D3917%26doi%3D10.2174%2F092986709789178019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrin-Solt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span> <span> </span><span class="NLM_article-title">Mechanistic study of common non-nucleoside reverse transcriptase inhibitor-resistant mutations with K103N and Y181C substitutions</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">263</span>, <span class="refDoi"> DOI: 10.3390/v8100263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.3390%2Fv8100263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=263&issue=10&author=M.-T.+Laiauthor=V.+Munshiauthor=M.+Luauthor=M.+Fengauthor=R.+Hrin-Soltauthor=P.+M.+McKennaauthor=D.+J.+Hazudaauthor=M.+D.+Miller&title=Mechanistic+study+of+common+non-nucleoside+reverse+transcriptase+inhibitor-resistant+mutations+with+K103N+and+Y181C+substitutions&doi=10.3390%2Fv8100263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic study of common non-nucleoside reverse transcriptase inhibitor-resistant mutations with K103N and Y181C substitutions</span></div><div class="casAuthors">Lai, Ming-Tain; Munshi, Vandna; Lu, Meiqing; Feng, Mei Zhen; Hrin-Solt, Renee; McKenna, Philip M.; Hazuda, Daria J.; Miller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">263/1-263/12</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a mainstay of therapy for human immunodeficiency type 1 virus (HIV-1) infections.  However, their effectiveness can be hampered by the emergence of resistant mutations.  To aid in designing effective NNRTIs against the resistant mutants, it is important to understand the resistance mechanism of the mutations.  Here, we investigate the mechanism of the two most prevalent NNRTI-assocd. mutations with K103N or Y181C substitution.  Virus and reverse transcriptase (RT) with K103N/Y188F, K103A, or K103E substitutions and with Y181F, Y188F, or Y181F/Y188F substitutions were employed to study the resistance mechanism of the K103N and Y181C mutants, resp.  Results showed that the virus and RT with K103N/Y188F substitutions displayed similar resistance levels to the virus and RT with K103N substitution vs. NNRTIs.  Virus and RT contg. Y181F, Y188F, or Y181F/Y188F substitution exhibited either enhanced or similar susceptibility to NNRTIs compared with the wild type (WT) virus.  These results suggest that the hydrogen bond between N103 and Y188 may not play an important role in the resistance of the K103N variant to NNRTIs.  Furthermore, the results from the studies with the Y181 or Y188 variant provide the direct evidence that arom. π-π stacking plays a crucial role in the binding of NNRTIs to RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH_YDeVk0EtLVg90H21EOLACvtfcHk0lgpZRLLR6YJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlajsQ%253D%253D&md5=c594e11bc9851b548d4d1c4abe64d86d</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.3390%2Fv8100263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv8100263%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DM.-T.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DHrin-Solt%26aufirst%3DR.%26aulast%3DMcKenna%26aufirst%3DP.%2BM.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DMechanistic%2520study%2520of%2520common%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor-resistant%2520mutations%2520with%2520K103N%2520and%2520Y181C%2520substitutions%26jtitle%3DViruses%26date%3D2016%26volume%3D8%26issue%3D10%26spage%3D263%26doi%3D10.3390%2Fv8100263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daelemans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel diarylpyrimidine derivatives as potent HIV-1 NNRTIs targeting the ″NNRTI adjacent″ binding site</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=334-338&issue=4&author=Z.+Huoauthor=H.+Zhangauthor=D.+Kangauthor=Z.+Zhouauthor=G.+Wuauthor=S.+Destaauthor=X.+Zuoauthor=Z.+Wangauthor=L.+Jingauthor=X.+Dingauthor=D.+Daelemansauthor=E.+De+Clercqauthor=C.+Pannecouqueauthor=P.+Zhanauthor=X.+Liu&title=Discovery+of+novel+diarylpyrimidine+derivatives+as+potent+HIV-1+NNRTIs+targeting+the+%E2%80%B3NNRTI+adjacent%E2%80%B3+binding+site&doi=10.1021%2Facsmedchemlett.7b00524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00524%26sid%3Dliteratum%253Aachs%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDesta%26aufirst%3DS.%26aulast%3DZuo%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DDaelemans%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520diarylpyrimidine%2520derivatives%2520as%2520potent%2520HIV-1%2520NNRTIs%2520targeting%2520the%2520%25E2%2580%25B3NNRTI%2520adjacent%25E2%2580%25B3%2520binding%2520site%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D334%26epage%3D338%26doi%3D10.1021%2Facsmedchemlett.7b00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daelemans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs targeting the tolerant region I of NNIBP</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1193</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1188-1193&issue=11&author=D.+Kangauthor=X.+Dingauthor=G.+Wuauthor=Z.+Huoauthor=Z.+Zhouauthor=T.+Zhaoauthor=D.+Fengauthor=Z.+Wangauthor=Y.+Tianauthor=D.+Daelemansauthor=E.+De+Clercqauthor=C.+Pannecouqueauthor=P.+Zhanauthor=X.+Liu&title=Discovery+of+thiophene%5B3%2C2-d%5Dpyrimidine+derivatives+as+potent+HIV-1+NNRTIs+targeting+the+tolerant+region+I+of+NNIBP&doi=10.1021%2Facsmedchemlett.7b00361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00361%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DDaelemans%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520thiophene%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520as%2520potent%2520HIV-1%2520NNRTIs%2520targeting%2520the%2520tolerant%2520region%2520I%2520of%2520NNIBP%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D11%26spage%3D1188%26epage%3D1193%26doi%3D10.1021%2Facsmedchemlett.7b00361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.3851/IMP1607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.3851%2FIMP1607" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=213-237&issue=6&author=G.+La+Reginaauthor=A.+Colucciaauthor=R.+Silvestri&title=Looking+for+an+active+conformation+of+the+future+HIV+type-1+non-nucleoside+reverse+transcriptase+inhibitors&doi=10.3851%2FIMP1607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.3851%2FIMP1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP1607%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DLooking%2520for%2520an%2520active%2520conformation%2520of%2520the%2520future%2520HIV%2520type-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2010%26volume%3D20%26issue%3D6%26spage%3D213%26epage%3D237%26doi%3D10.3851%2FIMP1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daelemans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Further exploring solvent-exposed tolerant regions of allosteric binding pocket for novel HIV-1 NNRTIs discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=370-375&issue=4&author=D.+Kangauthor=Z.+Wangauthor=H.+Zhangauthor=G.+Wuauthor=T.+Zhaoauthor=Z.+Zhouauthor=Z.+Huoauthor=B.+Huangauthor=D.+Fengauthor=X.+Dingauthor=J.+Zhangauthor=X.+Zuoauthor=L.+Jingauthor=W.+Luoauthor=S.+Gumaauthor=D.+Daelemansauthor=E.+Clercqauthor=C.+Pannecouqueauthor=P.+Zhanauthor=X.+Liu&title=Further+exploring+solvent-exposed+tolerant+regions+of+allosteric+binding+pocket+for+novel+HIV-1+NNRTIs+discovery&doi=10.1021%2Facsmedchemlett.8b00054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00054%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZuo%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DGuma%26aufirst%3DS.%26aulast%3DDaelemans%26aufirst%3DD.%26aulast%3DClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DFurther%2520exploring%2520solvent-exposed%2520tolerant%2520regions%2520of%2520allosteric%2520binding%2520pocket%2520for%2520novel%2520HIV-1%2520NNRTIs%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D370%26epage%3D375%26doi%3D10.1021%2Facsmedchemlett.8b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kudalkar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quijano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisneros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">E802</span>– <span class="NLM_lpage">E811</span>, <span class="refDoi"> DOI: 10.1073/pnas.1717932115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.1717932115" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E802-E811&issue=4&author=S.+N.+Kudalkarauthor=J.+Beloorauthor=E.+Quijanoauthor=K.+A.+Spasovauthor=W.-G.+Leeauthor=J.+A.+Cisnerosauthor=W.+M.+Saltzmanauthor=P.+Kumarauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=From+in+silico+hit+to+long-acting+late-stage+preclinical+candidate+to+combat+HIV-1+infection&doi=10.1073%2Fpnas.1717932115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1717932115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1717932115%26sid%3Dliteratum%253Aachs%26aulast%3DKudalkar%26aufirst%3DS.%2BN.%26aulast%3DBeloor%26aufirst%3DJ.%26aulast%3DQuijano%26aufirst%3DE.%26aulast%3DSpasov%26aufirst%3DK.%2BA.%26aulast%3DLee%26aufirst%3DW.-G.%26aulast%3DCisneros%26aufirst%3DJ.%2BA.%26aulast%3DSaltzman%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DFrom%2520in%2520silico%2520hit%2520to%2520long-acting%2520late-stage%2520preclinical%2520candidate%2520to%2520combat%2520HIV-1%2520infection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D4%26spage%3DE802%26epage%3DE811%26doi%3D10.1073%2Fpnas.1717932115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poongavanam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scipione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandolfi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Santo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tramontano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kongsted, J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1039/C7MD00600D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1039%2FC7MD00600D" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=562-575&issue=3&author=V.+Poongavanamauthor=A.+Coronaauthor=C.+Steinmannauthor=L.+Scipioneauthor=N.+Grandiauthor=F.+Pandolfiauthor=R.+Di+Santoauthor=R.+Costiauthor=F.+Espositoauthor=E.+Tramontanoauthor=J.+Kongsted&title=Structure-guided+approach+identifies+a+novel+class+of+HIV-1+ribonuclease+H+inhibitors%3A+binding+mode+insights+through+magnesium+complexation+and+site-directed+mutagenesis+studies&doi=10.1039%2FC7MD00600D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1039%2FC7MD00600D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00600D%26sid%3Dliteratum%253Aachs%26aulast%3DPoongavanam%26aufirst%3DV.%26aulast%3DCorona%26aufirst%3DA.%26aulast%3DSteinmann%26aufirst%3DC.%26aulast%3DScipione%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DN.%26aulast%3DPandolfi%26aufirst%3DF.%26aulast%3DDi%2BSanto%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DR.%26aulast%3DEsposito%26aufirst%3DF.%26aulast%3DTramontano%26aufirst%3DE.%26aulast%3DKongsted%26aufirst%3DJ.%26atitle%3DStructure-guided%2520approach%2520identifies%2520a%2520novel%2520class%2520of%2520HIV-1%2520ribonuclease%2520H%2520inhibitors%253A%2520binding%2520mode%2520insights%2520through%2520magnesium%2520complexation%2520and%2520site-directed%2520mutagenesis%2520studies%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D562%26epage%3D575%26doi%3D10.1039%2FC7MD00600D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimarães, C. R.
W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1021/ci700271z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci700271z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2gsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2416-2428&author=G.+Barreiroauthor=C.+R.%0AW.+Guimar%C3%A3esauthor=I.+Tubert-Brohmanauthor=T.+M.+Lyonsauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Search+for+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase+using+chemical+similarity%2C+molecular+docking%2C+and+MM-GB%2FSA+scoring&doi=10.1021%2Fci700271z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Search for Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase Using Chemical Similarity, Molecular Docking, and MM-GB/SA Scoring</span></div><div class="casAuthors">Barreiro, Gabriela; Guimaraes, Cristiano R. W.; Tubert-Brohman, Ivan; Lyons, Theresa M.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2416-2428</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A virtual screening protocol has been applied to seek nonnucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) and its K103N mutant.  First, a chem. similarity search on the Maybridge library was performed using known NNRTIs as ref. structures.  The top-ranked mols. obtained from this procedure plus 26 known NNRTIs were then docked into the binding sites of the wild-type reverse transcriptase (HIV-RT) and its K103N variant (K103N-RT) using Glide 3.5.  The top-ranked 100 compds. from the docking for both proteins were postscored with a procedure using mol. mechanics and continuum solvation (MM-GB/SA).  The validity of the virtual screening protocol was supported by (i) testing of the MM-GB/SA procedure, (ii) agreement between predicted and crystallog. binding poses, (iii) recovery of known potent NNRTIs at the top of both rankings, and (iv) identification of top-scoring library compds. that are close in structure to recently reported NNRTI HTS hits.  However, purchase and assaying of selected top-scoring compds. from the library failed to yield active anti-HIV agents.  Nevertheless, the highest-ranked database compd., S10087, was pursued as contg. a potentially viable core.  Subsequent synthesis and assaying of S10087 analogs proposed by further computational anal. yielded anti-HIV agents with EC50 values as low as 310 nM.  Thus, with the aid of computational tools, it was possible to evolve a false pos. into a true active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GtNhGutd4rVg90H21EOLACvtfcHk0lhFv_1-TuEKuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2gsrjP&md5=b9e58fd3889a55cdbca3f973210c2c17</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fci700271z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700271z%26sid%3Dliteratum%253Aachs%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DGuimar%25C3%25A3es%26aufirst%3DC.%2BR.%2BW.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DLyons%26aufirst%3DT.%2BM.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DSearch%2520for%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%2520using%2520chemical%2520similarity%252C%2520molecular%2520docking%252C%2520and%2520MM-GB%252FSA%2520scoring%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2416%26epage%3D2428%26doi%3D10.1021%2Fci700271z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 53 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Li Ding, Christophe Pannecouque, Erik De Clercq, Chunlin Zhuang, <span class="NLM_string-name hlFld-ContribAuthor">Fen-Er Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 5067-5081. <a href="https://doi.org/10.1021/acs.jmedchem.1c00128" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00128</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00128%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydrophobic%252BPocket%252BOccupation%252BDesign%252Bof%252BDifluoro-Biphenyl-Diarylpyrimidines%252Bas%252BNon-Nucleoside%252BHIV-1%252BReverse%252BTranscriptase%252BInhibitors%25253A%252Bfrom%252BN-Alkylation%252Bto%252BMethyl%252BHopping%252Bon%252Bthe%252BPyrimidine%252BRing%26aulast%3DDing%26aufirst%3DLi%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23012021%26date%3D14042021%26volume%3D64%26issue%3D8%26spage%3D5067%26epage%3D5081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dongwei Kang, Francesc X. Ruiz, Yanying Sun, Da Feng, Lanlan Jing, Zhao Wang, Tao Zhang, Shenghua Gao, Lin Sun, Erik De Clercq, Christophe Pannecouque, Eddy Arnold, Peng Zhan, <span class="NLM_string-name hlFld-ContribAuthor">Xinyong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 4239-4256. <a href="https://doi.org/10.1021/acs.jmedchem.1c00268" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00268</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00268%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2%25252C4%25252C5-Trisubstituted%252BPyrimidines%252Bas%252BPotent%252BHIV-1%252BNNRTIs%25253A%252BRational%252BDesign%25252C%252BSynthesis%25252C%252BActivity%252BEvaluation%25252C%252Band%252BCrystallographic%252BStudies%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10022021%26date%3D18032021%26volume%3D64%26issue%3D7%26spage%3D4239%26epage%3D4256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria E. Cilento, Karen A. Kirby, <span class="NLM_string-name hlFld-ContribAuthor">Stefan G. Sarafianos</span>. </span><span class="cited-content_cbyCitation_article-title">Avoiding Drug Resistance in HIV Reverse Transcriptase. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3271-3296. <a href="https://doi.org/10.1021/acs.chemrev.0c00967" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00967%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DAvoiding%252BDrug%252BResistance%252Bin%252BHIV%252BReverse%252BTranscriptase%26aulast%3DCilento%26aufirst%3DMaria%2BE.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06092020%26date%3D28012021%26volume%3D121%26issue%3D6%26spage%3D3271%26epage%3D3296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaofeng Liu, Ying Shao, <span class="NLM_string-name hlFld-ContribAuthor">Jiangtao Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium-Catalyzed Chemoselective N–H Bond Insertion Reactions of 2-Pyridones/7-Azaindoles with Sulfoxonium Ylides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     , 1038-1043. <a href="https://doi.org/10.1021/acs.orglett.0c04229" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c04229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c04229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c04229%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRuthenium-Catalyzed%252BChemoselective%252BN%2525E2%252580%252593H%252BBond%252BInsertion%252BReactions%252Bof%252B2-Pyridones%25252F7-Azaindoles%252Bwith%252BSulfoxonium%252BYlides%26aulast%3DLiu%26aufirst%3DXiaofeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22122020%26date%3D21012021%26volume%3D23%26issue%3D3%26spage%3D1038%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dongwei Kang, Yanying Sun, N. Arul Murugan, Da Feng, Fenju Wei, Jing Li, Xiangyi Jiang, Erik De Clercq, Christophe Pannecouque, Peng Zhan, <span class="NLM_string-name hlFld-ContribAuthor">Xinyong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (8)
                                     , 2225-2234. <a href="https://doi.org/10.1021/acsinfecdis.0c00327" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00327</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00327%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252BExploration%252Bof%252BNNIBP%252BTolerant%252BRegion%252BI%252BLeads%252Bto%252BPotent%252BHIV-1%252BNNRTIs%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D18052020%26date%3D17072020%26date%3D03072020%26volume%3D6%26issue%3D8%26spage%3D2225%26epage%3D2234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dongwei Kang, Da Feng, Yanying Sun, Zengjun Fang, Fenju Wei, Erik De Clercq, Christophe Pannecouque, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4837-4848. <a href="https://doi.org/10.1021/acs.jmedchem.0c00117" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00117%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BBioisosterism%252BYields%252BHIV-1%252BNNRTIs%252Bwith%252BImproved%252BDrug-Resistance%252BProfiles%252Band%252BFavorable%252BPharmacokinetic%252BProperties%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22012020%26date%3D22042020%26date%3D15042020%26volume%3D63%26issue%3D9%26spage%3D4837%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sheng Han, Yali Sang, Yan Wu, Yuan Tao, Christophe Pannecouque, Erik De Clercq, Chunlin Zhuang, <span class="NLM_string-name hlFld-ContribAuthor">Fen-Er Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2020,</strong> <em>6 </em>
                                    (5)
                                     , 787-801. <a href="https://doi.org/10.1021/acsinfecdis.9b00229" title="DOI URL">https://doi.org/10.1021/acsinfecdis.9b00229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.9b00229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.9b00229%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DMolecular%252BHybridization-Inspired%252BOptimization%252Bof%252BDiarylbenzopyrimidines%252Bas%252BHIV-1%252BNonnucleoside%252BReverse%252BTranscriptase%252BInhibitors%252Bwith%252BImproved%252BActivity%252Bagainst%252BK103N%252Band%252BE138K%252BMutants%252Band%252BPharmacokinetic%252BProfiles%26aulast%3DHan%26aufirst%3DSheng%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D19062019%26date%3D24102019%26date%3D10102019%26volume%3D6%26issue%3D5%26spage%3D787%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dongwei Kang, F. Xavier Ruiz, Da Feng, Alyssa Pilch, Tong Zhao, Fenju Wei, Zhao Wang, Yanying Sun, Zengjun Fang, Erik De Clercq, Christophe Pannecouque, Eddy Arnold, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1298-1312. <a href="https://doi.org/10.1021/acs.jmedchem.9b01769" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01769</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01769%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252BFluorine-Substituted%252BDiarylpyrimidine%252BDerivatives%252Bas%252BNovel%252BHIV-1%252BNNRTIs%252Bwith%252BHighly%252BImproved%252BResistance%252BProfiles%252Band%252BLow%252BActivity%252Bfor%252Bthe%252BhERG%252BIon%252BChannel%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24102019%26date%3D24012020%26date%3D14012020%26volume%3D63%26issue%3D3%26spage%3D1298%26epage%3D1312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhipeng  Fu</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Shenghua  Gao</span>, <span class="hlFld-ContribAuthor ">Srinivasulu  Cherukupalli</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>42 </em>, 116239. <a href="https://doi.org/10.1016/j.bmc.2021.116239" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116239%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DExploiting%252Bthe%252Bhydrophobic%252Bchannel%252Bof%252Bthe%252BNNIBP%25253A%252BDiscovery%252Bof%252Bnovel%252Bdiarylpyrimidines%252Bas%252BHIV-1%252BNNRTIs%252Bagainst%252Bwild-type%252Band%252BK103N%252Bmutant%252Bviruses%26aulast%3DFu%26aufirst%3DZhipeng%26date%3D2021%26volume%3D42%26spage%3D116239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexios  Chatzigoulas</span>, <span class="hlFld-ContribAuthor ">Zoe  Cournia</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of allosteric modulators: Challenges and successes. </span><span class="cited-content_cbyCitation_journal-name">WIREs Computational Molecular Science</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1002/wcms.1529" title="DOI URL">https://doi.org/10.1002/wcms.1529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/wcms.1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fwcms.1529%26sid%3Dliteratum%253Aachs%26jtitle%3DWIREs%2520Computational%2520Molecular%2520Science%26atitle%3DRational%252Bdesign%252Bof%252Ballosteric%252Bmodulators%25253A%252BChallenges%252Band%252Bsuccesses%26aulast%3DChatzigoulas%26aufirst%3DAlexios%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Richardson</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>3 </em>, 1-26. <a href="https://doi.org/10.1080/17460441.2021.1933427" title="DOI URL">https://doi.org/10.1080/17460441.2021.1933427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1933427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1933427%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApplications%252Bof%252Bfluorine%252Bto%252Bthe%252Bconstruction%252Bof%252Bbioisosteric%252Belements%252Bfor%252Bthe%252Bpurposes%252Bof%252Bnovel%252Bdrug%252Bdiscovery%26aulast%3DRichardson%26aufirst%3DPaul%26date%3D2021%26date%3D2021%26volume%3D3%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104905. <a href="https://doi.org/10.1016/j.bioorg.2021.104905" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104905</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104905%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DChemical%252Bspace%252Bexploration%252Bof%252Bnovel%252Bnaphthyl-carboxamide-diarylpyrimidine%252Bderivatives%252Bwith%252Bpotent%252Banti-HIV-1%252Bactivity%26aulast%3DSang%26aufirst%3DYali%26date%3D2021%26volume%3D111%26spage%3D104905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Shu  Song</span>, <span class="hlFld-ContribAuthor ">Zhao  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116195. <a href="https://doi.org/10.1016/j.bmc.2021.116195" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116195%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banti-HIV%252Bevaluation%252Bof%252Bnovel%252B5-substituted%252Bdiarylpyrimidine%252Bderivatives%252Bas%252Bpotent%252BHIV-1%252BNNRTIs%26aulast%3DGao%26aufirst%3DPing%26date%3D2021%26volume%3D40%26spage%3D116195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masamitsu  Tsukamoto</span>, <span class="hlFld-ContribAuthor ">Tadashi  Nakamura</span>, <span class="hlFld-ContribAuthor ">Hirohiko  Kimura</span>, <span class="hlFld-ContribAuthor ">Hitoshi  Nakayama</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and application of trifluoromethylpyridines as a key structural motif in active agrochemical and pharmaceutical ingredients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pesticide Science</span><span> <strong>2021,</strong> <em>46 </em>
                                    (2)
                                     , 125-142. <a href="https://doi.org/10.1584/jpestics.D21-012" title="DOI URL">https://doi.org/10.1584/jpestics.D21-012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1584/jpestics.D21-012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1584%2Fjpestics.D21-012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pesticide%2520Science%26atitle%3DSynthesis%252Band%252Bapplication%252Bof%252Btrifluoromethylpyridines%252Bas%252Ba%252Bkey%252Bstructural%252Bmotif%252Bin%252Bactive%252Bagrochemical%252Band%252Bpharmaceutical%252Bingredients%26aulast%3DTsukamoto%26aufirst%3DMasamitsu%26date%3D2021%26volume%3D46%26issue%3D2%26spage%3D125%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lanfei  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongmei  Cui</span>, <span class="hlFld-ContribAuthor ">Chunhao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Approach to 3-Fluoroindoles and 3,3-Difluoroindolines from 2,2-Difluoro-2-phenylethan-1-amines via C–H/N–H Coupling. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>16 </em><a href="https://doi.org/10.1055/a-1509-8624" title="DOI URL">https://doi.org/10.1055/a-1509-8624</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1509-8624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1509-8624%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DDirect%252BApproach%252Bto%252B3-Fluoroindoles%252Band%252B3%25252C3-Difluoroindolines%252Bfrom%252B2%25252C2-Difluoro-2-phenylethan-1-amines%252Bvia%252BC%2525E2%252580%252593H%25252FN%2525E2%252580%252593H%252BCoupling%26aulast%3DZhang%26aufirst%3DLanfei%26date%3D2021%26date%3D2021%26volume%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Ding</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>41 </em>
                                    (3)
                                     , 1255-1290. <a href="https://doi.org/10.1002/med.21760" title="DOI URL">https://doi.org/10.1002/med.21760</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21760%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DDruggability%252Bmodification%252Bstrategies%252Bof%252Bthe%252Bdiarylpyrimidine%2525E2%252580%252590type%252Bnon%2525E2%252580%252590nucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DDing%26aufirst%3DLi%26date%3D2021%26date%3D2021%26volume%3D41%26issue%3D3%26spage%3D1255%26epage%3D1290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Zhao  Wang</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Mahmoud E.S.  Soliman</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113051. <a href="https://doi.org/10.1016/j.ejmech.2020.113051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploiting%252Bthe%252Btolerant%252Bregion%252BI%252Bof%252Bthe%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitor%252B%252528NNRTI%252529%252Bbinding%252Bpocket.%252BPart%252B2%25253A%252BDiscovery%252Bof%252Bdiarylpyrimidine%252Bderivatives%252Bas%252Bpotent%252BHIV-1%252BNNRTIs%252Bwith%252Bhigh%252BFsp3%252Bvalues%252Band%252Bfavorable%252Bdrug-like%252Bproperties%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2021%26volume%3D213%26spage%3D113051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanying  Sun</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Feng  Da</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Pei  Li</span>, <span class="hlFld-ContribAuthor ">Baodan  Zhang</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113204. <a href="https://doi.org/10.1016/j.ejmech.2021.113204" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113204%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnovel%252Bpotent%252BHIV-1%252Binhibitors%252Bby%252Bexploiting%252Bthe%252Btolerant%252Bregions%252Bof%252Bthe%252BNNRTIs%252Bbinding%252Bpocket%26aulast%3DSun%26aufirst%3DYanying%26date%3D2021%26volume%3D214%26spage%3D113204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Da  Feng</span>, <span class="hlFld-ContribAuthor ">Fenju  Wei</span>, <span class="hlFld-ContribAuthor ">Yanying  Sun</span>, <span class="hlFld-ContribAuthor ">Prem Prakash  Sharma</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hao  Lin</span>, <span class="hlFld-ContribAuthor ">Brijesh  Rathi</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>59 </em><a href="https://doi.org/10.1016/j.cclet.2021.02.033" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.02.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.02.033%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DBoronic%252Bacid-containing%252Bdiarylpyrimidine%252Bderivatives%252Bas%252Bnovel%252BHIV-1%252BNNRTIs%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DFeng%26aufirst%3DDa%26date%3D2021%26volume%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleksandra  Gruevska</span>, <span class="hlFld-ContribAuthor ">Ángela B.  Moragrega</span>, <span class="hlFld-ContribAuthor ">Andrea  Cossarizza</span>, <span class="hlFld-ContribAuthor ">Juan V.  Esplugues</span>, <span class="hlFld-ContribAuthor ">Ana  Blas-García</span>, <span class="hlFld-ContribAuthor ">Nadezda  Apostolova</span>. </span><span class="cited-content_cbyCitation_article-title">Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 410. <a href="https://doi.org/10.3390/cells10020410" title="DOI URL">https://doi.org/10.3390/cells10020410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10020410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10020410%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DApoptosis%252Bof%252BHepatocytes%25253A%252BRelevance%252Bfor%252BHIV-Infected%252BPatients%252Bunder%252BTreatment%26aulast%3DGruevska%26aufirst%3DAleksandra%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D2%26spage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Da  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Zuo</span>, <span class="hlFld-ContribAuthor ">Lanlan  Jing</span>, <span class="hlFld-ContribAuthor ">Chin-Ho  Chen</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Hao  Lin</span>, <span class="hlFld-ContribAuthor ">Mahmoud  Soliman</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiung  Lee</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and evaluation of “dual-site”-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113063. <a href="https://doi.org/10.1016/j.ejmech.2020.113063" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113063%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252B%2525E2%252580%25259Cdual-site%2525E2%252580%25259D-binding%252Bdiarylpyrimidines%252Btargeting%252Bboth%252BNNIBP%252Band%252Bthe%252BNNRTI%252Badjacent%252Bsite%252Bof%252Bthe%252BHIV-1%252Breverse%252Btranscriptase%26aulast%3DFeng%26aufirst%3DDa%26date%3D2021%26volume%3D211%26spage%3D113063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. A.  Kirichenko</span>, <span class="hlFld-ContribAuthor ">D. E.  Kireev</span>, <span class="hlFld-ContribAuthor ">A. V.  Kravchenko</span>, <span class="hlFld-ContribAuthor ">A. V.  Pokrovskaya</span>, <span class="hlFld-ContribAuthor ">U. A.  Kuimova</span>, <span class="hlFld-ContribAuthor ">N. V.  Sizova</span>, <span class="hlFld-ContribAuthor ">S. O.  Mayorova</span>, <span class="hlFld-ContribAuthor ">D. A.  Gusev</span>, <span class="hlFld-ContribAuthor ">V. V.  Pokrovsky</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of the HIV-1 drug resistance to elsulfavirine and the effectiveness of it among Russian treatment-naïve patients. </span><span class="cited-content_cbyCitation_journal-name">Journal Infectology</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 29-39. <a href="https://doi.org/10.22625/2072-6732-2020-12-5-29-39" title="DOI URL">https://doi.org/10.22625/2072-6732-2020-12-5-29-39</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.22625/2072-6732-2020-12-5-29-39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.22625%2F2072-6732-2020-12-5-29-39%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520Infectology%26atitle%3DEvaluation%252Bof%252Bthe%252BHIV-1%252Bdrug%252Bresistance%252Bto%252Belsulfavirine%252Band%252Bthe%252Beffectiveness%252Bof%252Bit%252Bamong%252BRussian%252Btreatment-na%2525C3%2525AFve%252Bpatients%26aulast%3DKirichenko%26aufirst%3DA.%2BA.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D5%26spage%3D29%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven J.  Smith</span>, <span class="hlFld-ContribAuthor ">Gary T.  Pauly</span>, <span class="hlFld-ContribAuthor ">Katharine  Hewlett</span>, <span class="hlFld-ContribAuthor ">Joel P.  Schneider</span>, <span class="hlFld-ContribAuthor ">Stephen H.  Hughes</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐based non‐nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (1)
                                     , 4-17. <a href="https://doi.org/10.1111/cbdd.13766" title="DOI URL">https://doi.org/10.1111/cbdd.13766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13766%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DStructure%2525E2%252580%252590based%252Bnon%2525E2%252580%252590nucleoside%252Binhibitor%252Bdesign%25253A%252BDeveloping%252Binhibitors%252Bthat%252Bare%252Beffective%252Bagainst%252Bresistant%252Bmutants%26aulast%3DSmith%26aufirst%3DSteven%2BJ.%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D1%26spage%3D4%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepak  Pradhan</span>, <span class="hlFld-ContribAuthor ">Prativa  Biswasroy</span>, <span class="hlFld-ContribAuthor ">Amit  Goyal</span>, <span class="hlFld-ContribAuthor ">Goutam  Ghosh</span>, <span class="hlFld-ContribAuthor ">Goutam  Rath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections. </span><span class="cited-content_cbyCitation_journal-name">AAPS PharmSciTech</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     <a href="https://doi.org/10.1208/s12249-020-01908-5" title="DOI URL">https://doi.org/10.1208/s12249-020-01908-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12249-020-01908-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12249-020-01908-5%26sid%3Dliteratum%253Aachs%26jtitle%3DAAPS%2520PharmSciTech%26atitle%3DRecent%252BAdvancement%252Bin%252BNanotechnology-Based%252BDrug%252BDelivery%252BSystem%252BAgainst%252BViral%252BInfections%26aulast%3DPradhan%26aufirst%3DDeepak%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Young Hyun  Shin</span>, <span class="hlFld-ContribAuthor ">Chul Min  Park</span>, <span class="hlFld-ContribAuthor ">Cheol-Hee  Yoon</span>. </span><span class="cited-content_cbyCitation_article-title">An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs: General Principles and Current Status. </span><span class="cited-content_cbyCitation_journal-name">Infection & Chemotherapy</span><span> <strong>2021,</strong> <em>53 </em>
                                    (1)
                                     , 29. <a href="https://doi.org/10.3947/ic.2020.0100" title="DOI URL">https://doi.org/10.3947/ic.2020.0100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3947/ic.2020.0100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3947%2Fic.2020.0100%26sid%3Dliteratum%253Aachs%26jtitle%3DInfection%2520%2526%2520Chemotherapy%26atitle%3DAn%252BOverview%252Bof%252BHuman%252BImmunodeficiency%252BVirus-1%252BAntiretroviral%252BDrugs%25253A%252BGeneral%252BPrinciples%252Band%252BCurrent%252BStatus%26aulast%3DShin%26aufirst%3DYoung%2BHyun%26date%3D2021%26volume%3D53%26issue%3D1%26spage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murugesan  Vanangamudi</span>, <span class="hlFld-ContribAuthor ">Pramod C.  Nair</span>, <span class="hlFld-ContribAuthor ">S. E. Maida  Engels</span>, <span class="hlFld-ContribAuthor ">Senthilkumar  Palaniappan</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 63-95. <a href="https://doi.org/10.1007/978-981-16-0267-2_3" title="DOI URL">https://doi.org/10.1007/978-981-16-0267-2_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0267-2_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0267-2_3%26sid%3Dliteratum%253Aachs%26atitle%3DStructural%252BInsights%252Bto%252BHuman%252BImmunodeficiency%252BVirus%252B%252528HIV-1%252529%252BTargets%252Band%252BTheir%252BInhibition%26aulast%3DVanangamudi%26aufirst%3DMurugesan%26date%3D2021%26date%3D2021%26spage%3D63%26epage%3D95%26pub%3DSpringer%2520Singapore%26atitle%3DAntiviral%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DLiu%26aufirst%3DXinyong%26date%3D2021%26volume%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria E.  Cilento</span>, <span class="hlFld-ContribAuthor ">Karen A.  Kirby</span>, <span class="hlFld-ContribAuthor ">Philip R.  Tedbury</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Sarafianos</span>. </span><span class="cited-content_cbyCitation_article-title">Proteins and Disease | Structural Basis of HIV Reverse Transcription, Inhibition, and Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 92-104. <a href="https://doi.org/10.1016/B978-0-12-809633-8.21570-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-809633-8.21570-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809633-8.21570-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809633-8.21570-7%26sid%3Dliteratum%253Aachs%26atitle%3DProteins%252Band%252BDisease%252B%25257C%252BStructural%252BBasis%252Bof%252BHIV%252BReverse%252BTranscription%25252C%252BInhibition%25252C%252Band%252BDrug%252BResistance%26aulast%3DCilento%26aufirst%3DMaria%2BE.%26date%3D2021%26spage%3D92%26epage%3D104%26pub%3DElsevier%26atitle%3DEncyclopedia%252Bof%252BBiological%252BChemistry%252BIII%26date%3D2021%26volume%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marianna  Nalli</span>, <span class="hlFld-ContribAuthor ">Jorge I.  Armijos Rivera</span>, <span class="hlFld-ContribAuthor ">Domiziana  Masci</span>, <span class="hlFld-ContribAuthor ">Antonio  Coluccia</span>, <span class="hlFld-ContribAuthor ">Roger  Badia</span>, <span class="hlFld-ContribAuthor ">Eva  Riveira-Muñoz</span>, <span class="hlFld-ContribAuthor ">Alessandro  Brambilla</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Cinquina</span>, <span class="hlFld-ContribAuthor ">Ombretta  Turriziani</span>, <span class="hlFld-ContribAuthor ">Francesca  Falasca</span>, <span class="hlFld-ContribAuthor ">Myriam  Catalano</span>, <span class="hlFld-ContribAuthor ">Cristina  Limatola</span>, <span class="hlFld-ContribAuthor ">José A.  Esté</span>, <span class="hlFld-ContribAuthor ">Giovanni  Maga</span>, <span class="hlFld-ContribAuthor ">Romano  Silvestri</span>, <span class="hlFld-ContribAuthor ">Emmanuele  Crespan</span>, <span class="hlFld-ContribAuthor ">Giuseppe  La Regina</span>. </span><span class="cited-content_cbyCitation_article-title">New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112696. <a href="https://doi.org/10.1016/j.ejmech.2020.112696" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112696%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bindolylarylsulfone%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252Bshow%252Blow%252Bnanomolar%252Binhibition%252Bof%252Bsingle%252Band%252Bdouble%252BHIV-1%252Bmutant%252Bstrains%26aulast%3DNalli%26aufirst%3DMarianna%26date%3D2020%26volume%3D208%26spage%3D112696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhao  Wang</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Da  Feng</span>, <span class="hlFld-ContribAuthor ">Srinivasulu  Cherukupalli</span>, <span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Fu</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112811. <a href="https://doi.org/10.1016/j.ejmech.2020.112811" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112811%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bdual%252Btolerant%252Bregions%252Bof%252Bbinding%252Bpocket%25253A%252BDiscovery%252Bof%252Bnovel%252Bmorpholine-substituted%252Bdiarylpyrimidines%252Bas%252Bpotent%252BHIV-1%252BNNRTIs%252Bwith%252Bsignificantly%252Bimproved%252Bwater%252Bsolubility%26aulast%3DWang%26aufirst%3DZhao%26date%3D2020%26volume%3D206%26spage%3D112811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuang-Xi  Gu</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Hai-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Gen-Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Shuang  Cao</span>, <span class="hlFld-ContribAuthor ">Lu  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent discoveries in HIV-1 reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>54 </em>, 166-172. <a href="https://doi.org/10.1016/j.coph.2020.09.017" title="DOI URL">https://doi.org/10.1016/j.coph.2020.09.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.09.017%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DRecent%252Bdiscoveries%252Bin%252BHIV-1%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DGu%26aufirst%3DShuang-Xi%26date%3D2020%26volume%3D54%26spage%3D166%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murugesan  Vanangamudi</span>, <span class="hlFld-ContribAuthor ">Sonali  Kurup</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>. </span><span class="cited-content_cbyCitation_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>54 </em>, 179-187. <a href="https://doi.org/10.1016/j.coph.2020.10.009" title="DOI URL">https://doi.org/10.1016/j.coph.2020.10.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.10.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DNon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252B%252528NNRTIs%252529%25253A%252Ba%252Bbrief%252Boverview%252Bof%252Bclinically%252Bapproved%252Bdrugs%252Band%252Bcombination%252Bregimens%26aulast%3DVanangamudi%26aufirst%3DMurugesan%26date%3D2020%26volume%3D54%26spage%3D179%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Ming  Li</span>, <span class="hlFld-ContribAuthor ">Rong-Hua  Luo</span>, <span class="hlFld-ContribAuthor ">Liu-Meng  Yang</span>, <span class="hlFld-ContribAuthor ">Si-Ming  Huang</span>, <span class="hlFld-ContribAuthor ">Sui-Yuan  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Gui  Zheng</span>, <span class="hlFld-ContribAuthor ">Dong-Xuan  Ni</span>, <span class="hlFld-ContribAuthor ">Yi-Man  Cui</span>, <span class="hlFld-ContribAuthor ">Xing-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Li  Li</span>, <span class="hlFld-ContribAuthor ">Rui-Han  Zhang</span>, <span class="hlFld-ContribAuthor ">E  Tang</span>, <span class="hlFld-ContribAuthor ">Hong-Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong-Tang  Zheng</span>, <span class="hlFld-ContribAuthor ">Yan-Ping  He</span>, <span class="hlFld-ContribAuthor ">Wei-Lie  Xiao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anti-HIV evaluation of 5-alkyl- 6-(benzo[d][1,3]dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>102 </em>, 104041. <a href="https://doi.org/10.1016/j.bioorg.2020.104041" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104041%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banti-HIV%252Bevaluation%252Bof%252B5-alkyl-%252B6-%252528benzo%25255Bd%25255D%25255B1%25252C3%25255Ddioxol-5-alkyl%252529-2-mercaptopyrimidin-4%2525283H%252529-ones%252Bas%252Bpotent%252BHIV-1%252BNNRTIs%26aulast%3DLi%26aufirst%3DYi-Ming%26date%3D2020%26volume%3D102%26spage%3D104041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaomei  Chen</span>, <span class="hlFld-ContribAuthor ">Li  Ding</span>, <span class="hlFld-ContribAuthor ">Yuan  Tao</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>202 </em>, 112549. <a href="https://doi.org/10.1016/j.ejmech.2020.112549" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112549%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBioisosterism-based%252Bdesign%252Band%252Benantiomeric%252Bprofiling%252Bof%252Bchiral%252Bhydroxyl-substituted%252Bbiphenyl-diarylpyrimidine%252Bnonnucleoside%252BHIV-1%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DChen%26aufirst%3DXiaomei%26date%3D2020%26volume%3D202%26spage%3D112549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pretisha Flora  Cutinho</span>, <span class="hlFld-ContribAuthor ">Ravi C.  Shankar</span>, <span class="hlFld-ContribAuthor ">Avinash  Anand</span>, <span class="hlFld-ContribAuthor ">Jaydeep  Roy</span>, <span class="hlFld-ContribAuthor ">Chetan H.  Mehta</span>, <span class="hlFld-ContribAuthor ">Usha Y.  Nayak</span>, <span class="hlFld-ContribAuthor ">Manikanta  Murahari</span>. </span><span class="cited-content_cbyCitation_article-title">Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II). </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (13)
                                     , 3772-3789. <a href="https://doi.org/10.1080/07391102.2019.1663263" title="DOI URL">https://doi.org/10.1080/07391102.2019.1663263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1663263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1663263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DHit%252Bidentification%252Band%252Bdrug%252Brepositioning%252Bof%252Bpotential%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252Bby%252Bstructure-based%252Bapproach%252Busing%252Bcomputational%252Btools%252B%252528part%252BII%252529%26aulast%3DCutinho%26aufirst%3DPretisha%2BFlora%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D13%26spage%3D3772%26epage%3D3789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanjing  Wang</span>, <span class="hlFld-ContribAuthor ">Xiangeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Xiong</span>, <span class="hlFld-ContribAuthor ">Aman Chandra  Kaushik</span>, <span class="hlFld-ContribAuthor ">Junaid  Muhammad</span>, <span class="hlFld-ContribAuthor ">Abbas  Khan</span>, <span class="hlFld-ContribAuthor ">Hao  Dai</span>, <span class="hlFld-ContribAuthor ">Dong-Qing  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an
              in silico
              study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>38 </em>
                                    (11)
                                     , 3327-3341. <a href="https://doi.org/10.1080/07391102.2019.1656673" title="DOI URL">https://doi.org/10.1080/07391102.2019.1656673</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1656673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1656673%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DNew%252Bstrategy%252Bfor%252Bidentifying%252Bpotential%252Bnatural%252BHIV-1%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252Bagainst%252Bdrug-resistance%25253A%252Ban%252Bin%252Bsilico%252Bstudy%26aulast%3DWang%26aufirst%3DYanjing%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D11%26spage%3D3327%26epage%3D3341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Drug Targets. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-96. <a href="https://doi.org/10.1002/9781119607311.ch1" title="DOI URL">https://doi.org/10.1002/9781119607311.ch1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119607311.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119607311.ch1%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BTargets%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D96%26pub%3DWiley%26atitle%3DMedicinal%252BChemistry%252Bfor%252BPractitioners%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2020%26date%3D2020%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (6)
                                     , 961-978. <a href="https://doi.org/10.1016/j.apsb.2019.11.010" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.11.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.11.010%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDevelopment%252Bof%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252B%252528NNRTIs%252529%25253A%252Bour%252Bpast%252Btwenty%252Byears%26aulast%3DZhuang%26aufirst%3DChunlin%26date%3D2020%26volume%3D10%26issue%3D6%26spage%3D961%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jay  Trivedi</span>, <span class="hlFld-ContribAuthor ">Payel  Ghosh</span>, <span class="hlFld-ContribAuthor ">Debashis  Mitra</span>. </span><span class="cited-content_cbyCitation_article-title">N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK) inhibits HIV-1 by suppressing the activity of viral protease. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2020,</strong> <em>527 </em>
                                    (1)
                                     , 167-172. <a href="https://doi.org/10.1016/j.bbrc.2020.04.096" title="DOI URL">https://doi.org/10.1016/j.bbrc.2020.04.096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2020.04.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2020.04.096%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DN-p-Tosyl-L-phenylalanine%252Bchloromethyl%252Bketone%252B%252528TPCK%252529%252Binhibits%252BHIV-1%252Bby%252Bsuppressing%252Bthe%252Bactivity%252Bof%252Bviral%252Bprotease%26aulast%3DTrivedi%26aufirst%3DJay%26date%3D2020%26volume%3D527%26issue%3D1%26spage%3D167%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Da  Feng</span>, <span class="hlFld-ContribAuthor ">Tiziana  Ginex</span>, <span class="hlFld-ContribAuthor ">Jinmi  Zou</span>, <span class="hlFld-ContribAuthor ">Fenju  Wei</span>, <span class="hlFld-ContribAuthor ">Tong  Zhao</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Yanying  Sun</span>, <span class="hlFld-ContribAuthor ">Samuel  Desta</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (5)
                                     , 878-894. <a href="https://doi.org/10.1016/j.apsb.2019.08.013" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.08.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.08.013%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DExploring%252Bthe%252Bhydrophobic%252Bchannel%252Bof%252BNNIBP%252Bleads%252Bto%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Bpiperidine-substituted%252Bthiophene%25255B3%25252C2-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotent%252BHIV-1%252BNNRTIs%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2020%26volume%3D10%26issue%3D5%26spage%3D878%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Da  Feng</span>, <span class="hlFld-ContribAuthor ">Lanlan  Jing</span>, <span class="hlFld-ContribAuthor ">Yanying  Sun</span>, <span class="hlFld-ContribAuthor ">Fenju  Wei</span>, <span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Gaochan  Wu</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>193 </em>, 112237. <a href="https://doi.org/10.1016/j.ejmech.2020.112237" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112237%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIn%252Bsitu%252Bclick%252Bchemistry-based%252Brapid%252Bdiscovery%252Bof%252Bnovel%252BHIV-1%252BNNRTIs%252Bby%252Bexploiting%252Bthe%252Bhydrophobic%252Bchannel%252Band%252Btolerant%252Bregions%252Bof%252BNNIBP%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2020%26volume%3D193%26spage%3D112237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting-Ting  Li</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chun-Lin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (7)
                                     , 1581. <a href="https://doi.org/10.3390/molecules25071581" title="DOI URL">https://doi.org/10.3390/molecules25071581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25071581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25071581%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DScaffold%252BHopping%252Bin%252BDiscovery%252Bof%252BHIV-1%252BNon-Nucleoside%252BReverse%252BTranscriptase%252BInhibitors%25253A%252BFrom%252BCH%252528CN%252529-DABOs%252Bto%252BCH%252528CN%252529-DAPYs%26aulast%3DLi%26aufirst%3DTing-Ting%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D7%26spage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanming  Chen</span>, <span class="hlFld-ContribAuthor ">Yafeng  Tian</span>, <span class="hlFld-ContribAuthor ">Ya  Gao</span>, <span class="hlFld-ContribAuthor ">Fengshou  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaogang  Luo</span>, <span class="hlFld-ContribAuthor ">Xiulian  Ju</span>, <span class="hlFld-ContribAuthor ">Genyan  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">In silico Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00164" title="DOI URL">https://doi.org/10.3389/fchem.2020.00164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00164%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DIn%252Bsilico%252BDesign%252Bof%252BNovel%252BHIV-1%252BNNRTIs%252BBased%252Bon%252BCombined%252BModeling%252BStudies%252Bof%252BDihydrofuro%25255B3%25252C4-d%25255Dpyrimidines%26aulast%3DChen%26aufirst%3DYanming%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>96 </em>, 103595. <a href="https://doi.org/10.1016/j.bioorg.2020.103595" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103595%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore-fusing%252Bdesign%252Bof%252Bpyrimidine%252Bsulfonylacetanilides%252Bas%252Bpotent%252Bnon-nucleoside%252Binhibitors%252Bof%252BHIV-1%252Breverse%252Btranscriptase%26aulast%3DSang%26aufirst%3DYali%26date%3D2020%26volume%3D96%26spage%3D103595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng  Han</span>, <span class="hlFld-ContribAuthor ">Yuan  Lei</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (3)
                                     , 764-768. <a href="https://doi.org/10.1016/j.cclet.2019.11.020" title="DOI URL">https://doi.org/10.1016/j.cclet.2019.11.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2019.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2019.11.020%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DFragment-based%252Bdiscovery%252Bof%252Bsulfur-containing%252Bdiarylbenzopyrimidines%252Bas%252Bnovel%252Bnonnucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DHan%26aufirst%3DSheng%26date%3D2020%26volume%3D31%26issue%3D3%26spage%3D764%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengbo  Xu</span>, <span class="hlFld-ContribAuthor ">Yijing  Xin</span>, <span class="hlFld-ContribAuthor ">Minghua  Chen</span>, <span class="hlFld-ContribAuthor ">Mingyu  Ba</span>, <span class="hlFld-ContribAuthor ">Qinglan  Guo</span>, <span class="hlFld-ContribAuthor ">Chenggen  Zhu</span>, <span class="hlFld-ContribAuthor ">Ying  Guo</span>, <span class="hlFld-ContribAuthor ">Jiangong  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112071. <a href="https://doi.org/10.1016/j.ejmech.2020.112071" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Bsynthesis%25252C%252Band%252Boptimization%252Bof%252Ban%252BN-alkoxy%252Bindolylacetamide%252Bagainst%252BHIV-1%252Bcarrying%252BNNRTI-resistant%252Bmutations%252Bfrom%252Bthe%252BIsatis%252Bindigotica%252Broot%26aulast%3DXu%26aufirst%3DChengbo%26date%3D2020%26volume%3D189%26spage%3D112071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Lei</span>, <span class="hlFld-ContribAuthor ">Sheng  Han</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (5)
                                     , 1050. <a href="https://doi.org/10.3390/molecules25051050" title="DOI URL">https://doi.org/10.3390/molecules25051050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25051050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25051050%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDesign%252Bof%252BBiphenyl-Substituted%252BDiarylpyrimidines%252Bwith%252Ba%252BCyanomethyl%252BLinker%252Bas%252BHIV-1%252BNNRTIs%252Bvia%252Ba%252BMolecular%252BHybridization%252BStrategy%26aulast%3DLei%26aufirst%3DYuan%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D5%26spage%3D1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaijun  Jin</span>, <span class="hlFld-ContribAuthor ">Minjie  Liu</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Ge  Meng</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (2)
                                     , 344-357. <a href="https://doi.org/10.1016/j.apsb.2019.09.007" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.09.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.09.007%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DImproving%252Bthe%252Bpositional%252Badaptability%25253A%252Bstructure-based%252Bdesign%252Bof%252Bbiphenyl-substituted%252Bdiaryltriazines%252Bas%252Bnovel%252Bnon-nucleoside%252BHIV-1%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DJin%26aufirst%3DKaijun%26date%3D2020%26volume%3D10%26issue%3D2%26spage%3D344%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Xiao</span>, <span class="hlFld-ContribAuthor ">Jia-Fan  Tang</span>, <span class="hlFld-ContribAuthor ">Ge  Meng</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Gen-Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Qiang  Xu</span>, <span class="hlFld-ContribAuthor ">Feng-Shou  Wu</span>, <span class="hlFld-ContribAuthor ">Shuang-Xi  Gu</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111864. <a href="https://doi.org/10.1016/j.ejmech.2019.111864" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111864</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111864%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndazolyl-substituted%252Bpiperidin-4-yl-aminopyrimidines%252Bas%252BHIV-1%252BNNRTIs%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivities%26aulast%3DXiao%26aufirst%3DTing%26date%3D2020%26volume%3D186%26spage%3D111864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng  Han</span>, <span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Yan  Wu</span>, <span class="hlFld-ContribAuthor ">Yuan  Tao</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111874. <a href="https://doi.org/10.1016/j.ejmech.2019.111874" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111874%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment%252Bhopping-based%252Bdiscovery%252Bof%252Bnovel%252Bsulfinylacetamide-diarylpyrimidines%252B%252528DAPYs%252529%252Bas%252BHIV-1%252Bnonnucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DHan%26aufirst%3DSheng%26date%3D2020%26volume%3D185%26spage%3D111874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Tong  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhao  Wang</span>, <span class="hlFld-ContribAuthor ">Da  Feng</span>, <span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Gaochan  Wu</span>, <span class="hlFld-ContribAuthor ">Fenju  Wei</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Lanlan  Jing</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Zuo</span>, <span class="hlFld-ContribAuthor ">Ye  Tian</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Communications Chemistry</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42004-019-0174-8" title="DOI URL">https://doi.org/10.1038/s42004-019-0174-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42004-019-0174-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42004-019-0174-8%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpiperidine-substituted%252Bthiazolo%25255B5%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotent%252Band%252Borally%252Bbioavailable%252BHIV-1%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DKang%26aufirst%3DDongwei%26date%3D2019%26date%3D2019%26volume%3D2%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Wang</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Guangdi  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (10)
                                     , 813-829. <a href="https://doi.org/10.1080/17425255.2019.1673367" title="DOI URL">https://doi.org/10.1080/17425255.2019.1673367</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2019.1673367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2019.1673367%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DCurrent%252Band%252Bemerging%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252B%252528NNRTIs%252529%252Bfor%252BHIV-1%252Btreatment%26aulast%3DWang%26aufirst%3DYali%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D10%26spage%3D813%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kathleen M  Frey</span>, <span class="hlFld-ContribAuthor ">Tasnim  Tabassum</span>. </span><span class="cited-content_cbyCitation_article-title">Current structure-based methods for designing non-nucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Virology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (8)
                                     , 537-544. <a href="https://doi.org/10.2217/fvl-2019-0055" title="DOI URL">https://doi.org/10.2217/fvl-2019-0055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fvl-2019-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffvl-2019-0055%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Virology%26atitle%3DCurrent%252Bstructure-based%252Bmethods%252Bfor%252Bdesigning%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DFrey%26aufirst%3DKathleen%2BM%26date%3D2019%26volume%3D14%26issue%3D8%26spage%3D537%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamal  Singh</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Sarafianos</span>, <span class="hlFld-ContribAuthor ">Anders  Sönnerborg</span>. </span><span class="cited-content_cbyCitation_article-title">Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2019,</strong> <em>12 </em>
                                    (2)
                                     , 62. <a href="https://doi.org/10.3390/ph12020062" title="DOI URL">https://doi.org/10.3390/ph12020062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph12020062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph12020062%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DLong-Acting%252BAnti-HIV%252BDrugs%252BTargeting%252BHIV-1%252BReverse%252BTranscriptase%252Band%252BIntegrase%26aulast%3DSingh%26aufirst%3DKamal%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D2%26spage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) The overall architecture of HIV-1 is shown and (B) three-dimensional structure of HIV-1 RT (p66/p51) in complex with nucleic acids is highlighted in different colors. (C) A brief timeline of HIV-1 drug development and in particular the drugs identified for RT are highlighted. The two-dimensional (2D) representation of approved NNRTI drugs is depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Ligand binding pockets of HIV-1 RT are shown with nevirapine (gray) and zidovudine (green), and the key structural domains are highlighted including the non-nucleoside inhibitor-binding pocket (NNIBP) (see text for details). (B) NNIBP of HIV-1 RT including important secondary structural domains and amino acid residues in the pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Venn diagram showing the most common clinically significant NNRTI-resistance mutations published for NNRTI approved drugs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Key steps and intermediate compounds in the lead optimization process of NVP. The possible sites of CYP450 metabolism are indicated with yellow spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Binding mode of NVP (green) with important amino acid residues in the binding pocket of HIV-1 RT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V81">3V81</a>) and hydrophobic pockets are encircled in red and (B) schematic representation of ligand pharmacophore models are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0019.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of NVP (<b>8</b>) by Merluzzi et al.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and Grozinger et al.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0020.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Key Building Blocks Required for NVP (<b>8</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0021.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of NVP (<b>8</b>) Proposed by Grozinger et al.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0022.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Recent Synthetic Procedure Developed for NVP (<b>8</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Key steps, techniques, and intermediate compounds in the lead optimization process of DLV. The possible sites of CYP450 metabolism are indicated with a yellow and cyan spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) The 2D ligand interaction diagram of RT and DLV (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM">1KLM</a>). The important amino acids residues in the binding pocket are shown. (B) The 3D representation of DLV indicating the conformational flexibility by specifying the number of rotatable bonds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0023.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of DLV by Romero et al.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0024.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Modified Synthetic Procedure of DLV (<b>34</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0025.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Recent Synthetic Procedure Developed for DLV (<b>34</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0009.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lead compounds and important compounds synthesized and tested in the process of EFV lead optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0010.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) The binding mode of EFV in the binding pocket of HIV-1 RT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JKH">1JKH</a>) with important amino acids in the pocket and (B) the 2D ligand interaction diagram of EFV is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0026.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis Steps of EFV Developed by Pierce et al.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0027.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Advancements in the Synthesis of EFV by Chen et al.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0011.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Key lead optimization process of ETR and RPV</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0012.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. 2D protein–ligand interaction diagram for (A) ETR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MEC">3MEC</a>) and (B) RPV (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZD1">2ZD1</a>) and the important amino acids in the NNIBP of RT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0013.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Schematic representation of (A) ETR bound to K103N mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MED">3MED</a>) and (B) RPV bound to K103N/L100I double mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZE2">2ZE2</a>) in the NNIBP of RT.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0028.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Initial Synthetic Procedure for ETR Proposed by De Corte et al.<a onclick="showRef(event, 'ref113 ref143'); return false;" href="javascript:void(0);" class="ref ref113 ref143">(113,143)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0029.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Modified Synthesis of ETR (<b>64</b>) by Joshi et al.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0030.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Modified Synthesis Scheme of ETR (<b>64</b>) by Fier et al.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0031.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthetic Procedure Developed for RPV (<b>84</b>) by Janssen Pharmaceuticals</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0032.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Modified Synthetic Process of RPV (<b>84</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0033.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Alternative Synthetic Procedure Developed for RPV (<b>84</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0034.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of RPV (<b>84</b>) by Heck Reaction<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0035.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Block <b>83</b> by Heck Reaction</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0014.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. 2D chemical structures of NNRTIs in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0015.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Schematic representation of doravirine design and lead optimization process.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0016.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Overlay of X-ray crystal conformations and binding mode of NVP (A) and RPV (B) is shown. Important residues are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0017.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Inhibition of DAPY series in wild-type and (B) inhibition of indolylarylsulfone derivatives influenced by the introduction of halogen atom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/medium/jm-2018-00843t_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0018.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. X-ray crystal structures of HIV-1 RT in complex with fluorine-containing NNRTIs doravirine (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NCG">4NCG</a>, IC<sub>50</sub> = 0.011 μM, colored green); and KRV-2110 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LAK">3LAK</a>, IC<sub>50</sub> = 0.0034 μM, colored pink).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b00843/20190516/images/large/jm-2018-00843t_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00843&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 208 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arts, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span> <span> </span><span class="NLM_article-title">HIV-1 antiretroviral drug therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">a007161</span>, <span class="refDoi"> DOI: 10.1101/cshperspect.a007161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1101%2Fcshperspect.a007161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22474613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlemsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=a007161&issue=4&author=E.+J.+Artsauthor=D.+J.+Hazuda&title=HIV-1+antiretroviral+drug+therapy&doi=10.1101%2Fcshperspect.a007161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 antiretroviral drug therapy</span></div><div class="casAuthors">Arts, Eric J.; Hazuda, Daria J.</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">a007161/1-a007161/23</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  The most significant advance in the medical management of HIV-1 infection has been the treatment of patients with antiviral drugs, which can suppress HIV-1 replication to undetectable levels.  The discovery of HIV-1 as the causative agent of AIDS together with an ever increasing understanding of the virus replication cycle have been instrumental in this effort by providing researchers with the knowledge and tools required to prosecute drug discovery efforts focused on targeted inhibition with specific pharmacol. agents.  To date, an arsenal of 24 Food and Drug Administration (FDA)-approved drugs are available for treatment of HIV-1 infections.  These drugs are distributed into six distinct classes based on their mol. mechanism and resistance profiles: (1) nucleoside-analog reverse transcriptase inhibitors (NNRTIs), (2) non-nucleoside reverse transcriptase inhibitors (NNRTIs), (3) integrase inhibitors, (4) protease inhibitors (Pls), (5) fusion inhibitors, and (6) coreceptor antagonists.  In this article, we will review the basic principles of antiretroviral drug therapy, the mode of drug action, and the factors leading to treatment failure (i.e., drug resistance).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptYbCJ-mCnzbVg90H21EOLACvtfcHk0lj6pUrUDE7ALQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlemsrk%253D&md5=3c7785e1aac3df6da22f84b2b24f0a2e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a007161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a007161%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DE.%2BJ.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26atitle%3DHIV-1%2520antiretroviral%2520drug%2520therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2012%26volume%3D2%26issue%3D4%26spage%3Da007161%26doi%3D10.1101%2Fcshperspect.a007161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poongavanam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanangamudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Shamaileh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veedu, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugan, N. A.</span></span> <span> </span><span class="NLM_article-title">Integrative approaches in HIV-1 non-nucleoside reverse transcriptase inhibitor design</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e1328</span> <span class="refDoi"> DOI: 10.1002/wcms.1328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fwcms.1328" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&issue=1&author=V.+Poongavanamauthor=V.+Namasivayamauthor=M.+Vanangamudiauthor=H.+Al+Shamailehauthor=R.+N.+Veeduauthor=J.+Kihlbergauthor=N.+A.+Murugan&title=Integrative+approaches+in+HIV-1+non-nucleoside+reverse+transcriptase+inhibitor+design&doi=10.1002%2Fwcms.1328"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fwcms.1328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.1328%26sid%3Dliteratum%253Aachs%26aulast%3DPoongavanam%26aufirst%3DV.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DVanangamudi%26aufirst%3DM.%26aulast%3DAl%2BShamaileh%26aufirst%3DH.%26aulast%3DVeedu%26aufirst%3DR.%2BN.%26aulast%3DKihlberg%26aufirst%3DJ.%26aulast%3DMurugan%26aufirst%3DN.%2BA.%26atitle%3DIntegrative%2520approaches%2520in%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520design%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D8%26issue%3D1%26doi%3D10.1002%2Fwcms.1328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Anti-HIV drug discovery and development: Current innovations and future trends</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2849-78&issue=7&author=P.+Zhanauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=X.+Liu&title=Anti-HIV+drug+discovery+and+development%3A+Current+innovations+and+future+trends&doi=10.1021%2Facs.jmedchem.5b00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends</span></div><div class="casAuthors">Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2849-2878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection has been compromised to some extent by rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities, and so there is a need for alternative strategies of antiretroviral drug discovery and addnl. therapeutic agents with novel action modes or targets.  From this perspective, we first review current strategies of antiretroviral drug discovery and optimization, with the aid of selected examples from the recent literature.  We highlight the development of phosphate ester-based prodrugs as a means to improve the aq. soly. of HIV inhibitors, and the introduction of the substrate envelope hypothesis as a new approach for overcoming HIV drug resistance.  Finally, we discuss future directions for research, including opportunities for exploitation of novel antiretroviral targets, and the strategy of activation of latent HIV reservoirs as a means to eradicate the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sWUJPJgQN7Vg90H21EOLACvtfcHk0lj6pUrUDE7ALQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E&md5=de3f5aee273b0dd6f7e84e20410d06d7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00497%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAnti-HIV%2520drug%2520discovery%2520and%2520development%253A%2520Current%2520innovations%2520and%2520future%2520trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D7%26spage%3D2849%26epage%3D78%26doi%3D10.1021%2Facs.jmedchem.5b00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1021/jm900492g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900492g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=521-538&issue=2&author=Y.+Mehellouauthor=E.+De+Clercq&title=Twenty-six+years+of+anti-HIV+drug+discovery%3A+where+do+we+stand+and+where+do+we+go%3F&doi=10.1021%2Fjm900492g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm900492g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900492g%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DTwenty-six%2520years%2520of%2520anti-HIV%2520drug%2520discovery%253A%2520where%2520do%2520we%2520stand%2520and%2520where%2520do%2520we%2520go%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D2%26spage%3D521%26epage%3D538%26doi%3D10.1021%2Fjm900492g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flexner, C.</span></span> <span> </span><span class="NLM_article-title">HIV drug development: the next 25 years</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/nrd2336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnrd2336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=959-966&issue=12&author=C.+Flexner&title=HIV+drug+development%3A+the+next+25+years&doi=10.1038%2Fnrd2336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd2336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2336%26sid%3Dliteratum%253Aachs%26aulast%3DFlexner%26aufirst%3DC.%26atitle%3DHIV%2520drug%2520development%253A%2520the%2520next%252025%2520years%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D12%26spage%3D959%26epage%3D966%26doi%3D10.1038%2Fnrd2336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zdanowicz, M.
M.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of HIV drug resistance</span>. <i>Am. J. Pharm. Educ.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">100</span>, <span class="refDoi"> DOI: 10.5688/aj7005100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.5688%2Faj7005100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=17149429" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD28jhtVegsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=100&issue=5&author=M.%0AM.+Zdanowicz&title=The+pharmacology+of+HIV+drug+resistance&doi=10.5688%2Faj7005100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of HIV drug resistance</span></div><div class="casAuthors">Zdanowicz Martin M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of pharmaceutical education</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug resistance to human immunodeficiency virus (HIV) is a major factor in the failure of antiretroviral therapy.1 In order for practitioners to provide effective pharmaceutical care to their HIV patients, it is essential that they understand the mechanisms of HIV drug resistance as well as the various factors that can contribute to its emergence.  This article is based on didactic content from the infectious disease section of the Integrated Sequence II Course in the PharmD program at South University.  In the course, students are first given an overview that includes key structural components of HIV and a discussion of the HIV life cycle.  A detailed presentation on the pharmacology of the various classes of antiretroviral agents follows.  The clinical impact and prevalence of HIV drug resistance is then discussed along with factors that might contribute to it.  Mechanisms of drug resistance for each class of antiretroviral agents are presented in detail followed by a discussion of the basis and clinical utility of HIV drug resistance testing.  Finally, new targets for HIV pharmacotherapy are presented along with an overview of new antiretroviral agents that are being developed.  Content taught in lecture is reinforced by relevant case studies that students work on in small groups during the recitation period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKCJIO_hBOUEBuFdjgVNKSfW6udTcc2eZtCyOs0pOg_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jhtVegsA%253D%253D&md5=07af0b886e76710ce4abcb250d61d143</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.5688%2Faj7005100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5688%252Faj7005100%26sid%3Dliteratum%253Aachs%26aulast%3DZdanowicz%26aufirst%3DM.%2BM.%26atitle%3DThe%2520pharmacology%2520of%2520HIV%2520drug%2520resistance%26jtitle%3DAm.%2520J.%2520Pharm.%2520Educ.%26date%3D2006%26volume%3D70%26issue%3D5%26spage%3D100%26doi%3D10.5688%2Faj7005100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span> <i>UNAIDS
Data</i>; <span class="NLM_publisher-name">UNAIDS</span>, <span class="NLM_year">2017</span>; <a href="http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf" class="extLink">http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf</a> (accessed Feb 10, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+UNAIDS%0AData%3B+UNAIDS%2C+2017%3B+http%3A%2F%2Fwww.unaids.org%2Fsites%2Fdefault%2Ffiles%2Fmedia_asset%2F20170720_Data_book_2017_en.pdf+%28accessed+Feb+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DUNAIDS%250AData%26pub%3DUNAIDS%26date%3D2017%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">The
Antiretroviral Therapy Cohort Collaboration</span> <span> </span><span class="NLM_article-title">Life expectancy of individuals on combination antiretroviral
therapy in high-income countries: a collaborative analysis of 14 cohort
studies</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">9635</span>),  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61113-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2808%2961113-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=293-299&issue=9635&author=The%0AAntiretroviral+Therapy+Cohort+Collaboration&title=Life+expectancy+of+individuals+on+combination+antiretroviral%0Atherapy+in+high-income+countries%3A+a+collaborative+analysis+of+14+cohort%0Astudies&doi=10.1016%2FS0140-6736%2808%2961113-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961113-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961113-7%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DLife%2520expectancy%2520of%2520individuals%2520on%2520combination%2520antiretroviral%250Atherapy%2520in%2520high-income%2520countries%253A%2520a%2520collaborative%2520analysis%2520of%252014%2520cohort%250Astudies%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26issue%3D9635%26spage%3D293%26epage%3D299%26doi%3D10.1016%2FS0140-6736%2808%2961113-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuitton, D. A.</span></span> <span> </span><span class="NLM_article-title">Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/S0753-3322(99)80063-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0753-3322%2899%2980063-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10337461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1ejt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1999&pages=73-86&issue=2&author=R.+W.+Shaferauthor=D.+A.+Vuitton&title=Highly+active+antiretroviral+therapy+%28HAART%29+for+the+treatment+of+infection+with+human+immunodeficiency+virus+type+1&doi=10.1016%2FS0753-3322%2899%2980063-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1</span></div><div class="casAuthors">Shafer, R. W.; Vuitton, D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-86</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review with 105 refs.  Highly active antiretroviral therapy (HAART) refers to a broad category of treatment regimens usually comprised of three or more antiretroviral drugs that, in previously untreated HIV-1-infected patients, are expected to reduce plasma virus levels below the limits of detection.  Most HAART regimens include drugs from at least two of the three classes of antiretroviral therapy (nucleoside analog reverse transcriptase (RT) inhibitors, non-nucleoside analog RT inhibitors, and protease inhibitors).  In deciding when to initiate antiretroviral therapy, physicians and their patients must balance the virol. and immunol. benefits of early treatment with the costs of drug therapy, the risk of drug side effects, and the risk of drug resistance if adherence is suboptimal.  In previously untreated patients, HIV-1 replication can be suppressed indefinitely with certain HAART regimens.  In previously treated patients, the benefits of HAART are often significantly diminished.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoq5rvmmkQDGbVg90H21EOLACvtfcHk0liqhXdWwAtqaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1ejt74%253D&md5=cbc1580766e4f9a684cd77ad0a269c8c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0753-3322%2899%2980063-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0753-3322%252899%252980063-8%26sid%3Dliteratum%253Aachs%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DVuitton%26aufirst%3DD.%2BA.%26atitle%3DHighly%2520active%2520antiretroviral%2520therapy%2520%2528HAART%2529%2520for%2520the%2520treatment%2520of%2520infection%2520with%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D1999%26volume%3D53%26issue%3D2%26spage%3D73%26epage%3D86%26doi%3D10.1016%2FS0753-3322%2899%2980063-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brechtl, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitbart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galietta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, B.</span></span> <span> </span><span class="NLM_article-title">The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection</span>. <i>J. Pain Symptom Manage.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/S0885-3924(00)00245-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0885-3924%2800%2900245-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=11223313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD3M3osV2nuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=41-51&author=J.+R.+Brechtlauthor=W.+Breitbartauthor=M.+Galiettaauthor=S.+Krivoauthor=B.+Rosenfeld&title=The+use+of+highly+active+antiretroviral+therapy+%28HAART%29+in+patients+with+advanced+HIV+infection&doi=10.1016%2FS0885-3924%2800%2900245-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes</span></div><div class="casAuthors">Brechtl J R; Breitbart W; Galietta M; Krivo S; Rosenfeld B</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pain and symptom management</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>
        ISSN:<span class="NLM_cas:issn">0885-3924</span>.
    </div><div class="casAbstract">The effect of highly active antiretroviral therapy (HAART) in the treatment of HIV infection is usually measured by survival, CD4 lymphocyte counts, HIV-1 RNA viral load testing, and the occurrence of opportunistic infections.  This pilot study sought to measure the impact of HAART treatments on a wide range of clinical outcomes and psychological variables in a sample of patients with advanced HIV infection.  Seventy patients with advanced AIDS who were protease inhibitor naive were started on HAART regimens.  Patients were admitted to an AIDS inpatient unit of a long-term care facility that provides treatment and palliative care.  All patients were diagnosed with AIDS, had CD4 cell counts below 300/cc(3), and had a projected survival of greater than one month.  Patients were started on triple-drug HAART regimens with daily medical supervision and observation.  In addition to standard clinical and laboratory markers, a series of observer-rated and self-report instruments were used to measure various physical and psychological factors (e.g., pain and symptom distress, psychological well-being, depression).  Data were collected at baseline and after 1 and 3 months of HAART therapy.  As expected, the CD4 count increased and viral load levels decreased significantly over the 3-month study period.  In addition, patients improved significantly in body weight, and serum albumin and ferritin levels.  The only psychosocial measure that improved significantly with treatment was depression.  Ratings of pain intensity, physical and psychological symptom distress, and overall quality of life did not change.  Of the 70 patients studied, 84.3% were still alive after the 3-month study period.  Of these, 6 (8.6%) were discharged to community.  However, 17 surviving patients (24.3%) had HAART regimens discontinued due to drug intolerance and 11 patients (15.7%) expired during the study period.  While these data are preliminary, HAART regimens appear to have positive effects on CD4 count, HIV viral load, and several other measures of physical well-being in patients with advanced AIDS.  Despite these improvements, the benefits of treatment on pain and symptom distress, and psychological well-being were less clear.  In addition, treatment failure (mortality and intolerance) were not uncommon in this sample (40%).  Further research is clearly necessary to better understand the benefits of HAART therapy in patients with advanced HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRnvbHq_JovMkU0YCbOU3EfW6udTcc2eZJQf2XPCDcQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3osV2nuw%253D%253D&md5=d6247d9fa89f98c5471920bab410281a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0885-3924%2800%2900245-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0885-3924%252800%252900245-1%26sid%3Dliteratum%253Aachs%26aulast%3DBrechtl%26aufirst%3DJ.%2BR.%26aulast%3DBreitbart%26aufirst%3DW.%26aulast%3DGalietta%26aufirst%3DM.%26aulast%3DKrivo%26aufirst%3DS.%26aulast%3DRosenfeld%26aufirst%3DB.%26atitle%3DThe%2520use%2520of%2520highly%2520active%2520antiretroviral%2520therapy%2520%2528HAART%2529%2520in%2520patients%2520with%2520advanced%2520HIV%2520infection%26jtitle%3DJ.%2520Pain%2520Symptom%2520Manage.%26date%3D2001%26volume%3D21%26spage%3D41%26epage%3D51%26doi%3D10.1016%2FS0885-3924%2800%2900245-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicka-Sans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastgate, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWnt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=62-80&issue=1&author=N.+A.+Meanwellauthor=M.+R.+Krystalauthor=B.+Nowicka-Sansauthor=D.+R.+Langleyauthor=D.+A.+Conlonauthor=M.+D.+Eastgateauthor=D.+M.+Graselaauthor=P.+Timminsauthor=T.+Wangauthor=J.+F.+Kadow&title=Inhibitors+of+HIV-1+attachment%3A+the+discovery+and+development+of+temsavir+and+its+prodrug+fostemsavir&doi=10.1021%2Facs.jmedchem.7b01337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir</span></div><div class="casAuthors">Meanwell, Nicholas A.; Krystal, Mark R.; Nowicka-Sans, Beata; Langley, David R.; Conlon, David A.; Eastgate, Martin D.; Grasela, Dennis M.; Timmins, Peter; Wang, Tao; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-80</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Human immunodeficiency virus-1 (HIV-1) infection currently requires lifelong therapy with drugs that are used in combination to control viremia.  The indole-3-glyoxamide 6 was discovered as an inhibitor of HIV-1 infectivity using a phenotypic screen and derivs. of this compd. were found to interfere with the HIV-1 entry process by stabilizing a conformation of the virus gp120 protein not recognized by the host cell CD4 receptor.  An extensive optimization program led to the identification of temsavir (31), which exhibited an improved antiviral and pharmacokinetic profile compared to 6 and was explored in phase 3 clin. trials as the phosphonooxymethyl deriv. fostemsavir (35), a prodrug designed to address dissoln.- and soly.-limited absorption issues.  In this drug annotation, the authors summarize the structure-activity and structure-liability studies leading to the discovery of 31 and the clin. studies conducted with 35 that entailed the development of an extended release formulation suitable for phase 3 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOcSXTLXS7p7Vg90H21EOLACvtfcHk0lgctOYUK5YNtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWnt7fP&md5=e36e5e0ac4ec79860c757a3bce6d0837</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01337%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DNowicka-Sans%26aufirst%3DB.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DConlon%26aufirst%3DD.%2BA.%26aulast%3DEastgate%26aufirst%3DM.%2BD.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DTimmins%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DInhibitors%2520of%2520HIV-1%2520attachment%253A%2520the%2520discovery%2520and%2520development%2520of%2520temsavir%2520and%2520its%2520prodrug%2520fostemsavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D1%26spage%3D62%26epage%3D80%26doi%3D10.1021%2Facs.jmedchem.7b01337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Strategies in the design of antiviral drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1038/nrd703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnrd703" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=13-25&issue=1&author=E.+De%0AClercq&title=Strategies+in+the+design+of+antiviral+drugs&doi=10.1038%2Fnrd703"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd703%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DStrategies%2520in%2520the%2520design%2520of%2520antiviral%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D1%26spage%3D13%26epage%3D25%26doi%3D10.1038%2Fnrd703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/S0166-3542(98)00025-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0166-3542%2898%2900025-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9754886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXksVyrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1998&pages=153-179&issue=3&author=E.+De%0AClercq&title=The+role+of+non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29+in+the+therapy+of+HIV-1+infection&doi=10.1016%2FS0166-3542%2898%2900025-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-179</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with many refs.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have, in addn. to the nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs), gained a definitive place in the treatment of HIV-1 infections.  Starting from the HEPT and TIBO derivs., more than 30 structurally different classes of compds. have been identified as NNRTIs, that is compds. that are specifically inhibitory to HIV-1 replication and targeted at the HIV-1 reverse transcriptase (RT).  Two NNRTIs (nevirapine and delavirdine) have been formally licensed for clin. use and several others are in preclin. or clin. development [thiocarboxanilide UC-781, HEPT deriv. MKC-442, quinoxaline HBY 097 and DMP 266 (efavirenz)].  The NNRTIs interact with a specific 'pocket' site of HIV-1 RT that is closely assocd. with, but distinct from, the NRTI binding site.  NNRTIs are notorious for rapidly eliciting resistance due to mutations of the amino acids surrounding the NNRTI-binding site.  However, the emergence of resistant HIV strains can be circumvented if the NNRTIs, alone or in combination, are used from the start at sufficiently high concns.  In vitro, this procedure has proved to 'knock-out' virus replication and to prevent resistance from arising.  In vivo, various triple-drug combinations of NNRTIs (nevirapine, delavirdine or efavirenz) with NRTIs (AZT, 3TC, ddI or d4T) and/or PIs (indinavir or nelfinavir) have been shown to afford a durable anti-HIV activity, as reflected by both a decrease in plasma HIV-1 RNA levels and increased CD4 T-lymphocyte counts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNKnF3altW97Vg90H21EOLACvtfcHk0ljUA-mtcir3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksVyrsr4%253D&md5=fabfc13b6fa9fdacae68668dd6fbd80a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2898%2900025-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252898%252900025-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520role%2520of%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%2520in%2520the%2520therapy%2520of%2520HIV-1%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D1998%26volume%3D38%26issue%3D3%26spage%3D153%26epage%3D179%26doi%3D10.1016%2FS0166-3542%2898%2900025-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1002/cbdv.200490012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fcbdv.200490012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=17191775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=44-64&issue=1&author=E.+De%0AClercq&title=Non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29%3A+past%2C+present%2C+and+future&doi=10.1002%2Fcbdv.200490012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biodiversity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-64</span>CODEN:
                <span class="NLM_cas:coden">CBHIAM</span>;
        ISSN:<span class="NLM_cas:issn">1612-1872</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta AG</span>)
        </div><div class="casAbstract">A review with refs.  Non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) have become an inherent ingredient of the drug combination schemes that are currently used in the treatment of human immunodeficiency virus type 1 (HIV-1) infections.  Starting from the 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine (HEPT) and 4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivs., numerous classes of compds. have been described as NNRTIs.  Only three compds. have so far been approved for clin. use: nevirapine, delavirdine, and efavirenz.  NNRTIs are notorious for rapidly leading to virus-drug resistance development, primarily based on the emergence of the K103N and Y181C mutations in the HIV-1 RT.  Newer NNRTIs, such as capravirine, dapivirine (TMC 125), and DPC 083, are resilient to these "NNRTI" mutations, and, therefore, offer considerable promise as future anti-HIV-1 drugs.  NNRTIs are targeted at a specific "pocket" binding site within the HIV-1 RT, that is distinct from, but both spatially and functionally related to, the catalytic site, where the nucleoside RT inhibitors (NRTIs) and nucleotide RT inhibitors (NtRTIs) interact.  NNRTIs have acquired a definitive position, as part of a combination regimen with NRTIs and NtRTIs, in the first-line treatment of HIV-1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjIKlSEqbUHLVg90H21EOLACvtfcHk0ljUA-mtcir3GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D&md5=4e681cc76745c156d8494e57136fd777</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.200490012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.200490012%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DChem.%2520Biodiversity%26date%3D2004%26volume%3D1%26issue%3D1%26spage%3D44%26epage%3D64%26doi%3D10.1002%2Fcbdv.200490012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Approved antiviral drugs over the past 50 years</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1128/CMR.00102-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FCMR.00102-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=27281742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=695-747&issue=3&author=E.+De%0AClercqauthor=G.+Li&title=Approved+antiviral+drugs+over+the+past+50+years&doi=10.1128%2FCMR.00102-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Approved Antiviral Drugs over the Past 50 Years</span></div><div class="casAuthors">De Clercq Erik; Li Guangdi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical microbiology reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">695-747</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox).  Here, we present for the first time a comprehensive overview of antiviral drugs approved over the past 50 years, shedding light on the development of effective antiviral treatments against current and emerging infectious diseases worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbPpNpCY_qYTEC-75aqa5AfW6udTcc2eZtOrB5mzD5Qrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fos12htA%253D%253D&md5=1d25d961c1c6a72d6bc4634041bbb6fe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FCMR.00102-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00102-15%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DApproved%2520antiviral%2520drugs%2520over%2520the%2520past%252050%2520years%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2016%26volume%3D29%26issue%3D3%26spage%3D695%26epage%3D747%26doi%3D10.1128%2FCMR.00102-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friebe, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leinert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poll, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von der Saal, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, M. L.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">726</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1021/jm00058a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00058a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=726-732&issue=6&author=W.+Schaferauthor=W.+G.+Friebeauthor=H.+Leinertauthor=A.+Mertensauthor=T.+Pollauthor=W.+von+der+Saalauthor=H.+Zilchauthor=B.+Nuberauthor=M.+L.+Ziegler&title=Non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase%3A+molecular+modeling+and+X-ray+structure+investigations&doi=10.1021%2Fjm00058a009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm00058a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00058a009%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DW.%26aulast%3DFriebe%26aufirst%3DW.%2BG.%26aulast%3DLeinert%26aufirst%3DH.%26aulast%3DMertens%26aufirst%3DA.%26aulast%3DPoll%26aufirst%3DT.%26aulast%3Dvon%2Bder%2BSaal%26aufirst%3DW.%26aulast%3DZilch%26aufirst%3DH.%26aulast%3DNuber%26aufirst%3DB.%26aulast%3DZiegler%26aufirst%3DM.%2BL.%26atitle%3DNon-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%253A%2520molecular%2520modeling%2520and%2520X-ray%2520structure%2520investigations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26issue%3D6%26spage%3D726%26epage%3D732%26doi%3D10.1021%2Fjm00058a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(96)00091-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0969-2126%2896%2900091-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1996&pages=853-860&issue=7&author=Y.+Hsiouauthor=J.+Dingauthor=K.+Dasauthor=A.+D.+Clarkauthor=S.+H.+Hughesauthor=E.+Arnold&title=Structure+of+unliganded+HIV-1+reverse+transcriptase+at+2.7+A+resolution%3A+implications+of+conformational+changes+for+polymerization+and+inhibition+mechanisms&doi=10.1016%2FS0969-2126%2896%2900091-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2896%2900091-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252896%252900091-3%26sid%3Dliteratum%253Aachs%26aulast%3DHsiou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520unliganded%2520HIV-1%2520reverse%2520transcriptase%2520at%25202.7%2520A%2520resolution%253A%2520implications%2520of%2520conformational%2520changes%2520for%2520polymerization%2520and%2520inhibition%2520mechanisms%26jtitle%3DStructure%26date%3D1996%26volume%3D4%26issue%3D7%26spage%3D853%26epage%3D860%26doi%3D10.1016%2FS0969-2126%2896%2900091-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kohlstaedt, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span> <span> </span><span class="NLM_article-title">Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>256</i></span> (<span class="NLM_issue">5065</span>),  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1790</span>, <span class="refDoi"> DOI: 10.1126/science.1377403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1126%2Fscience.1377403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1377403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK38Xls1Kmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=256&publication_year=1992&pages=1783-1790&issue=5065&author=L.+A.+Kohlstaedtauthor=J.+Wangauthor=J.+M.+Friedmanauthor=P.+A.+Riceauthor=T.+A.+Steitz&title=Crystal+structure+at+3.5+A+resolution+of+HIV-1+reverse+transcriptase+complexed+with+an+inhibitor&doi=10.1126%2Fscience.1377403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor</span></div><div class="casAuthors">Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">256</span>
        (<span class="NLM_cas:issue">5065</span>),
    <span class="NLM_cas:pages">1783-90</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A 3.5 angstrom resoln. electron d. map of the HIV-1 reverse transcriptase heterodimer complexed with nevirapine, a drug with potential for treatment of AIDS, reveals an asym. dimer.  The polymerase (pol) domain of the 66-kilodalton subunit has a large cleft analogous to that of the Klenow fragment of Escherichia coli DNA polymerase I.  However, the 51-kilodalton subunit of identical sequence has no such cleft because the four subdomains of the pol domain occupy completely different relative positions.  Two of the four pol subdomains appear to be structurally related to subdomains of the Klenow fragment, including one contg. the catalytic site.  The subdomain that appears likely to bind the template strand at the pol active site has a different structure in the two polymerases.  Duplex A-form RNA-DNA hybrid can be model-built into the cleft that runs between the RNase H and pol active sites.  Nevirapine is almost completely buried in a pocket near but not overlapping with the pol active site.  Residues whose mutation results in drug resistance have been approx. located.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph5VLISXIsPbVg90H21EOLACvtfcHk0lj85TlHV5k9Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xls1Kmur8%253D&md5=16b48fc345c2366a078fbdaf1ba71cc8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscience.1377403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1377403%26sid%3Dliteratum%253Aachs%26aulast%3DKohlstaedt%26aufirst%3DL.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFriedman%26aufirst%3DJ.%2BM.%26aulast%3DRice%26aufirst%3DP.%2BA.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26atitle%3DCrystal%2520structure%2520at%25203.5%2520A%2520resolution%2520of%2520HIV-1%2520reverse%2520transcriptase%2520complexed%2520with%2520an%2520inhibitor%26jtitle%3DScience%26date%3D1992%26volume%3D256%26issue%3D5065%26spage%3D1783%26epage%3D1790%26doi%3D10.1126%2Fscience.1377403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baweja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmel, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oren, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shatkin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5083</span>– <span class="NLM_lpage">5092</span>, <span class="refDoi"> DOI: 10.1093/nar/gkn464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1093%2Fnar%2Fgkn464" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=5083-5092&issue=15&author=J.+D.+Baumanauthor=K.+Dasauthor=W.+C.+Hoauthor=M.+Bawejaauthor=D.+M.+Himmelauthor=A.+D.+Clarkauthor=D.+A.+Orenauthor=P.+L.+Boyerauthor=S.+H.+Hughesauthor=A.+J.+Shatkinauthor=E.+Arnold&title=Crystal+engineering+of+HIV-1+reverse+transcriptase+for+structure-based+drug+design&doi=10.1093%2Fnar%2Fgkn464"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkn464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkn464%26sid%3Dliteratum%253Aachs%26aulast%3DBauman%26aufirst%3DJ.%2BD.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DW.%2BC.%26aulast%3DBaweja%26aufirst%3DM.%26aulast%3DHimmel%26aufirst%3DD.%2BM.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DOren%26aufirst%3DD.%2BA.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DShatkin%26aufirst%3DA.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DCrystal%2520engineering%2520of%2520HIV-1%2520reverse%2520transcriptase%2520for%2520structure-based%2520drug%2520design%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2008%26volume%3D36%26issue%3D15%26spage%3D5083%26epage%3D5092%26doi%3D10.1093%2Fnar%2Fgkn464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">HIV-1 reverse transcriptase and antiviral drug resistance. Part 2</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2013.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.coviro.2013.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23602470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFagsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=119-128&issue=2&author=K.+Dasauthor=E.+Arnold&title=HIV-1+reverse+transcriptase+and+antiviral+drug+resistance.+Part+2&doi=10.1016%2Fj.coviro.2013.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 reverse transcriptase and antiviral drug resistance. Part 2</span></div><div class="casAuthors">Das, Kalyan; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-128</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Structures of RT and its complexes combined with biochem. and clin. data help in illuminating the mol. mechanisms of different drug-resistance mutations.  The NRTI drugs that are used in combinations have different primary mutation sites.  RT mutations that confer resistance to one drug can be hypersensitive to another RT drug.  Structure of an RT-DNA-nevirapine complex revealed how NNRTI binding forbids RT from forming a polymerase competent complex.  Collective knowledge about various mechanisms of drug resistance by RT has broader implications for understanding and targeting drug resistance in general.  In Part 1, we discussed the role of RT in developing HIV-1 drug resistance, structural and functional states of RT, and the nucleoside/nucleotide analog (NRTI) and non-nucleoside (NNRTI) drugs used in treating HIV-1 infections.  In this part, we discuss structural understanding of various mechanisms by which RT confers antiviral drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7WuVfmF5aU7Vg90H21EOLACvtfcHk0lj85TlHV5k9Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFagsbg%253D&md5=ae4501656b7ccbcd86a96df04e08598f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2013.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2013.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DHIV-1%2520reverse%2520transcriptase%2520and%2520antiviral%2520drug%2520resistance.%2520Part%25202%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2013%26volume%3D3%26issue%3D2%26spage%3D119%26epage%3D128%26doi%3D10.1016%2Fj.coviro.2013.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">HIV-1 reverse transcriptase and antiviral drug resistance. Part 1</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2013.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.coviro.2013.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23602471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsFanur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=111-118&issue=2&author=K.+Dasauthor=E.+Arnold&title=HIV-1+reverse+transcriptase+and+antiviral+drug+resistance.+Part+1&doi=10.1016%2Fj.coviro.2013.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 reverse transcriptase and antiviral drug resistance. Part 1</span></div><div class="casAuthors">Das, Kalyan; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-118</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  HIV-1 reverse transcriptase (RT) contributes to the development of resistance to all anti-AIDS drugs by introducing mutations into the viral genome.  At the mol. level, mutations in RT result in resistance to RT inhibitors.  Eight nucleoside/nucleotide analogs (NRTIs) and five non-nucleoside inhibitors (NNRTIs) are approved HIV-1 drugs.  Structures of RT have been detd. in complexes with substrates and/or inhibitors, and the structures have illuminated different conformational and functional states of the enzyme.  Understanding the mol. mechanisms of resistance to NRTIs and NNRTIs, and their complex relationships, may help in designing new drugs that are periodically required to overcome existing as well as emerging trends of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKm2E0DCBa77Vg90H21EOLACvtfcHk0lh1lNBgoUyMmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsFanur0%253D&md5=7c1049b8cdad61bdd7d73c0aefbe496e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2013.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2013.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DHIV-1%2520reverse%2520transcriptase%2520and%2520antiviral%2520drug%2520resistance.%2520Part%25201%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2013%26volume%3D3%26issue%3D2%26spage%3D111%26epage%3D118%26doi%3D10.1016%2Fj.coviro.2013.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapiro, J. M.</span></span> <span> </span><span class="NLM_article-title">HIV-1 drug resistance mutations: an updated framework for the second decade of HAART</span>. <i>AIDS Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18615118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD1cvktFCktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=67-84&issue=2&author=R.+W.+Shaferauthor=J.+M.+Schapiro&title=HIV-1+drug+resistance+mutations%3A+an+updated+framework+for+the+second+decade+of+HAART"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 drug resistance mutations: an updated framework for the second decade of HAART</span></div><div class="casAuthors">Shafer Robert W; Schapiro Jonathan M</div><div class="citationInfo"><span class="NLM_cas:title">AIDS reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">67-84</span>
        ISSN:<span class="NLM_cas:issn">1139-6121</span>.
    </div><div class="casAbstract">More than 200 mutations are associated with antiretroviral resistance to drugs belonging to six licensed antiretroviral classes.  More than 50 reverse transcriptase mutations are associated with nucleoside reverse transcriptase inhibitor resistance including M184V, thymidine analog mutations, mutations associated with non-thymidine analog containing regimens, multi-nucleoside resistance mutations, and several recently identified accessory mutations.  More than 40 reverse transcriptase mutations are associated with nonnucleoside reverse transcriptase inhibitor resistance including major primary and secondary mutations, non-polymorphic minor mutations, and polymorphic accessory mutations.  More than 60 mutations are associated with protease inhibitor resistance including major protease, accessory protease, and protease cleavage site mutations.  More than 30 integrase mutations are associated with the licensed integrase inhibitor raltegravir and the investigational inhibitor elvitegravir.  More than 15 gp41 mutations are associated with the fusion inhibitor enfuvirtide.  CCR5 inhibitor resistance results from mutations that promote gp120 binding to an inhibitor-bound CCR5 receptor or CXCR4 tropism; however, the genotypic correlates of these processes are not yet well characterized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCQ2rBuoWz4GlSCSgBhwJFfW6udTcc2eatby9Cm5WkyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvktFCktA%253D%253D&md5=7cdf92dda8a1e4576af642f4ead1c523</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DSchapiro%26aufirst%3DJ.%2BM.%26atitle%3DHIV-1%2520drug%2520resistance%2520mutations%253A%2520an%2520updated%2520framework%2520for%2520the%2520second%2520decade%2520of%2520HAART%26jtitle%3DAIDS%2520Rev.%26date%3D2008%26volume%3D10%26issue%3D2%26spage%3D67%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span> <i>Clinical Guidelines</i>, <span class="NLM_publisher-name">U.S. National Library
of Medicine</span>, <span class="NLM_year">2018</span>;<a href="https://aidsinfo.nih.gov/guidelines" class="extLink">https://aidsinfo.nih.gov/guidelines</a> (accessed February 22, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Clinical+Guidelines%2C+U.S.+National+Library%0Aof+Medicine%2C+2018%3Bhttps%3A%2F%2Faidsinfo.nih.gov%2Fguidelines+%28accessed+February+22%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Guidelines%26pub%3DU.S.%2520National%2520Library%250Aof%2520Medicine%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sluis-Cremer, N.</span></span> <span> </span><span class="NLM_article-title">The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2960</span>– <span class="NLM_lpage">2973</span>, <span class="refDoi"> DOI: 10.3390/v6082960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.3390%2Fv6082960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25089538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2qu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=2960-2973&issue=8&author=N.+Sluis-Cremer&title=The+emerging+profile+of+cross-resistance+among+the+nonnucleoside+HIV-1+reverse+transcriptase+inhibitors&doi=10.3390%2Fv6082960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitor</span></div><div class="casAuthors">Sluis-Cremer, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2960-2973</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs.  In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure.  NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection.  For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring contg. dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation contg. the urea-PETT deriv. MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis.  Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs.  Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcoZWVaWI7bVg90H21EOLACvtfcHk0lh1lNBgoUyMmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2qu7zE&md5=cfab3601f81042b54cbfe1a2e0be8a08</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3390%2Fv6082960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv6082960%26sid%3Dliteratum%253Aachs%26aulast%3DSluis-Cremer%26aufirst%3DN.%26atitle%3DThe%2520emerging%2520profile%2520of%2520cross-resistance%2520among%2520the%2520nonnucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DViruses%26date%3D2014%26volume%3D6%26issue%3D8%26spage%3D2960%26epage%3D2973%26doi%3D10.3390%2Fv6082960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wensing, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunthard, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richman, D. D.</span></span> <span> </span><span class="NLM_article-title">2014 Update of the drug resistance mutations in HIV-1</span>. <i>Top. Antivir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">650</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25101529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BC2cbpslyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=642-650&author=A.+M.+Wensingauthor=V.+Calvezauthor=H.+F.+Gunthardauthor=V.+A.+Johnsonauthor=R.+Paredesauthor=D.+Pillayauthor=R.+W.+Shaferauthor=D.+D.+Richman&title=2014+Update+of+the+drug+resistance+mutations+in+HIV-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">2014 Update of the drug resistance mutations in HIV-1</span></div><div class="casAuthors">Wensing Annemarie M; Calvez Vincent; Gunthard Huldrych F; Johnson Victoria A; Paredes Roger; Pillay Deenan; Shafer Robert W; Richman Douglas D</div><div class="citationInfo"><span class="NLM_cas:title">Topics in antiviral medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">642-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013.  The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir.  With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfGd8CCEOs1JagfuraLLzSfW6udTcc2eatby9Cm5WkyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbpslyqtQ%253D%253D&md5=f2df041240b12acaa476c6f2a16be2b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWensing%26aufirst%3DA.%2BM.%26aulast%3DCalvez%26aufirst%3DV.%26aulast%3DGunthard%26aufirst%3DH.%2BF.%26aulast%3DJohnson%26aufirst%3DV.%2BA.%26aulast%3DParedes%26aufirst%3DR.%26aulast%3DPillay%26aufirst%3DD.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DRichman%26aufirst%3DD.%2BD.%26atitle%3D2014%2520Update%2520of%2520the%2520drug%2520resistance%2520mutations%2520in%2520HIV-1%26jtitle%3DTop.%2520Antivir.%2520Med.%26date%3D2014%26volume%3D22%26spage%3D642%26epage%3D650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melikian, G.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varghese, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejesus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razzeca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israelski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1093/jac/dkt316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1093%2Fjac%2Fdkt316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23934770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=12-20&issue=1&author=G.%0AL.+Melikianauthor=S.+Y.+Rheeauthor=V.+Vargheseauthor=D.+Porterauthor=K.+Whiteauthor=J.+Taylorauthor=W.+Townerauthor=P.+Troiaauthor=J.+Burackauthor=E.+Dejesusauthor=G.+K.+Robbinsauthor=K.+Razzecaauthor=R.+Kaganauthor=T.+F.+Liuauthor=W.+J.+Fesselauthor=D.+Israelskiauthor=R.+W.+Shafer&title=Non-nucleoside+reverse+transcriptase+inhibitor+%28NNRTI%29+cross-resistance%3A+implications+for+preclinical+evaluation+of+novel+NNRTIs+and+clinical+genotypic+resistance+testing&doi=10.1093%2Fjac%2Fdkt316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing</span></div><div class="casAuthors">Melikian, George L.; Rhee, Soo-Yon; Varghese, Vici; Porter, Danielle; White, Kirsten; Taylor, Jonathan; Towner, William; Troia, Paolo; Burack, Jeffrey; DeJesus, Edwin; Robbins, Gregory K.; Razzeca, Kristin; Kagan, Ron; Liu, Tommy F.; Fessel, W. Jeffrey; Israelski, Dennis; Shafer, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-20</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The introduction of two new non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the past 5 years and the identification of novel NNRTI-assocd. mutations have made it necessary to reassess the extent of phenotypic NNRTI cross-resistance.  We analyzed a dataset contg. 1975, 1967, 519 and 187 genotype-phenotype correlations for nevirapine, efavirenz, etravirine and rilpivirine, resp.  We used linear regression to est. the effects of RT mutations on susceptibility to each of these NNRTIs.  Sixteen mutations at 10 positions were significantly assocd. with the greatest contribution to reduced phenotypic susceptibility (≥10-fold) to one or more NNRTIs, including: 14 mutations at six positions for nevirapine (K101P, K103N/S, V106A/M, Y181C/I/V, Y188C/L and G190A/E/Q/S); 10 mutations at six positions for efavirenz (L100I, K101P, K103N, V106M, Y188C/L and G190A/E/Q/S); 5 mutations at four positions for etravirine (K101P, Y181I/V, G190E and F227C); and 6 mutations at five positions for rilpivirine (L100I, K101P, Y181I/V, G190E and F227C).  G190E, a mutation that causes high-level nevirapine and efavirenz resistance, also markedly reduced susceptibility to etravirine and rilpivirine.  K101H, E138G, V179F and M230L mutations, assocd. with reduced susceptibility to etravirine and rilpivirine, were also assocd. with reduced susceptibility to nevirapine and/or efavirenz.  The identification of novel cross-resistance patterns among approved NNRTIs illustrates the need for a systematic approach for testing novel NNRTIs against clin. virus isolates with major NNRTI-resistance mutations and for testing older NNRTIs against virus isolates with mutations identified during the evaluation of a novel NNRTI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWaJg5gfAEMbVg90H21EOLACvtfcHk0lgZRBV9oIZGAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegt77I&md5=7f54153593f8c5ba5ec1820a663c00bc</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkt316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkt316%26sid%3Dliteratum%253Aachs%26aulast%3DMelikian%26aufirst%3DG.%2BL.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DVarghese%26aufirst%3DV.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DJ.%26aulast%3DTowner%26aufirst%3DW.%26aulast%3DTroia%26aufirst%3DP.%26aulast%3DBurack%26aufirst%3DJ.%26aulast%3DDejesus%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DG.%2BK.%26aulast%3DRazzeca%26aufirst%3DK.%26aulast%3DKagan%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DT.%2BF.%26aulast%3DFessel%26aufirst%3DW.%2BJ.%26aulast%3DIsraelski%26aufirst%3DD.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520%2528NNRTI%2529%2520cross-resistance%253A%2520implications%2520for%2520preclinical%2520evaluation%2520of%2520novel%2520NNRTIs%2520and%2520clinical%2520genotypic%2520resistance%2520testing%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26issue%3D1%26spage%3D12%26epage%3D20%26doi%3D10.1093%2Fjac%2Fdkt316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span> </span><span class="NLM_article-title">Major Non-Nucleoside RT Inhibitor (NNRTI)
Resistance Mutations</span>.  <i>HIV Drug Resistance
Database</i>; <span class="NLM_publisher-name">Stanford University</span>, <span class="NLM_year">2018</span>; <a href="https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/" class="extLink">https://hivdb.stanford.edu/dr-summary/resistance-notes/NNRTI/</a> (accessed April 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Major+Non-Nucleoside+RT+Inhibitor+%28NNRTI%29%0AResistance+Mutations.+HIV+Drug+Resistance%0ADatabase%3B+Stanford+University%2C+2018%3B+https%3A%2F%2Fhivdb.stanford.edu%2Fdr-summary%2Fresistance-notes%2FNNRTI%2F+%28accessed+April+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DMajor%2520Non-Nucleoside%2520RT%2520Inhibitor%2520%2528NNRTI%2529%250AResistance%2520Mutations%26jtitle%3DHIV%2520Drug%2520Resistance%250ADatabase%26pub%3DStanford%2520University%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michejda, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeger
Smith, M. B.</span></span> <span> </span><span class="NLM_article-title">Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using monte carlo simulations in a linear response method</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">5272</span>– <span class="NLM_lpage">5286</span>, <span class="refDoi"> DOI: 10.1021/jm9804174</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9804174" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=5272-5286&issue=26&author=R.+H.+Smithauthor=W.+L.+Jorgensenauthor=J.+Tirado-Rivesauthor=M.+L.+Lambauthor=P.+A.+Janssenauthor=C.+J.+Michejdaauthor=M.+B.+Kroeger%0ASmith&title=Prediction+of+binding+affinities+for+TIBO+inhibitors+of+HIV-1+reverse+transcriptase+using+monte+carlo+simulations+in+a+linear+response+method&doi=10.1021%2Fjm9804174"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm9804174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9804174%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%2BH.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DMichejda%26aufirst%3DC.%2BJ.%26aulast%3DKroeger%2BSmith%26aufirst%3DM.%2BB.%26atitle%3DPrediction%2520of%2520binding%2520affinities%2520for%2520TIBO%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%2520using%2520monte%2520carlo%2520simulations%2520in%2520a%2520linear%2520response%2520method%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26issue%3D26%26spage%3D5272%26epage%3D5286%26doi%3D10.1021%2Fjm9804174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Caro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavapathruni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A. D.</span></span> <span> </span><span class="NLM_article-title">Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2005.10.038" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=663-667&issue=3&author=W.+L.+Jorgensenauthor=J.+Ruiz-Caroauthor=J.+Tirado-Rivesauthor=A.+Basavapathruniauthor=K.+S.+Andersonauthor=A.+D.+Hamilton&title=Computer-aided+design+of+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.bmcl.2005.10.038"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DRuiz-Caro%26aufirst%3DJ.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DBasavapathruni%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26aulast%3DHamilton%26aufirst%3DA.%2BD.%26atitle%3DComputer-aided%2520design%2520of%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D3%26spage%3D663%26epage%3D667%26doi%3D10.1016%2Fj.bmcl.2005.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbardella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marturana, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadeddu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Colla, P.</span></span> <span> </span><span class="NLM_article-title">Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1021/jm0309856</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309856" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=928-934&issue=4&author=R.+Ragnoauthor=A.+Maiauthor=G.+Sbardellaauthor=M.+Articoauthor=S.+Massaauthor=C.+Musiuauthor=M.+Muraauthor=F.+Marturanaauthor=A.+Cadedduauthor=P.+La+Colla&title=Computer-aided+design%2C+synthesis%2C+and+anti-HIV-1+activity+in+vitro+of+2-alkylamino-6-%5B1-%282%2C6-difluorophenyl%29alkyl%5D-3%2C4-dihydro-5-alkylpyrimidin-4%283H%29-ones+as+novel+potent+non-nucleoside+reverse+transcriptase+inhibitors%2C+also+active+against+the+Y181C+variant&doi=10.1021%2Fjm0309856"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0309856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309856%26sid%3Dliteratum%253Aachs%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DSbardella%26aufirst%3DG.%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DMassa%26aufirst%3DS.%26aulast%3DMusiu%26aufirst%3DC.%26aulast%3DMura%26aufirst%3DM.%26aulast%3DMarturana%26aufirst%3DF.%26aulast%3DCadeddu%26aufirst%3DA.%26aulast%3DLa%2BColla%26aufirst%3DP.%26atitle%3DComputer-aided%2520design%252C%2520synthesis%252C%2520and%2520anti-HIV-1%2520activity%2520in%2520vitro%2520of%25202-alkylamino-6-%255B1-%25282%252C6-difluorophenyl%2529alkyl%255D-3%252C4-dihydro-5-alkylpyrimidin-4%25283H%2529-ones%2520as%2520novel%2520potent%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%252C%2520also%2520active%2520against%2520the%2520Y181C%2520variant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D4%26spage%3D928%26epage%3D934%26doi%3D10.1021%2Fjm0309856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span> <span> </span><span class="NLM_article-title">Special issue: Cheminformatics in drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fcmdc.201800123" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=467-469&issue=6&author=A.+Benderauthor=N.+Brown&title=Special+issue%3A+Cheminformatics+in+drug+discovery&doi=10.1002%2Fcmdc.201800123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800123%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%26atitle%3DSpecial%2520issue%253A%2520Cheminformatics%2520in%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D467%26epage%3D469%26doi%3D10.1002%2Fcmdc.201800123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carmine, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogden, R. N.</span></span> <span> </span><span class="NLM_article-title">Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.2165/00003495-198530020-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F00003495-198530020-00001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1985&pages=85-126&issue=2&author=A.+A.+Carmineauthor=R.+N.+Brogden&title=Pirenzepine.+A+review+of+its+pharmacodynamic+and+pharmacokinetic+properties+and+therapeutic+efficacy+in+peptic+ulcer+disease+and+other+allied+diseases&doi=10.2165%2F00003495-198530020-00001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2165%2F00003495-198530020-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-198530020-00001%26sid%3Dliteratum%253Aachs%26aulast%3DCarmine%26aufirst%3DA.%2BA.%26aulast%3DBrogden%26aufirst%3DR.%2BN.%26atitle%3DPirenzepine.%2520A%2520review%2520of%2520its%2520pharmacodynamic%2520and%2520pharmacokinetic%2520properties%2520and%2520therapeutic%2520efficacy%2520in%2520peptic%2520ulcer%2520disease%2520and%2520other%2520allied%2520diseases%26jtitle%3DDrugs%26date%3D1985%26volume%3D30%26issue%3D2%26spage%3D85%26epage%3D126%26doi%3D10.2165%2F00003495-198530020-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proudfoot, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, V. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauldin, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnke, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunder, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiles, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoog, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saboe, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1021/jm00111a045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00111a045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK3MXksV2ltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=2231-2241&issue=7&author=K.+D.+Hargraveauthor=J.+R.+Proudfootauthor=K.+G.+Grozingerauthor=E.+Cullenauthor=S.+R.+Kapadiaauthor=U.+R.+Patelauthor=V.+U.+Fuchsauthor=S.+C.+Mauldinauthor=J.+Vitousauthor=M.+L.+Behnkeauthor=J.+M.+Klunderauthor=K.+Palauthor=J.+W.+Skilesauthor=D.+W.+McNeilauthor=J.+M.+Roseauthor=G.+C.+Chowauthor=M.+T.+Skoogauthor=J.+C.+Wuauthor=G.+Schmidtauthor=W.+W.+Engelauthor=W.+G.+Eberleinauthor=T.+D.+Saboeauthor=S.+J.+Campbellauthor=A.+S.+Rosenthalauthor=J.+Adams&title=Novel+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase.+1.+Tricyclic+pyridobenzo-+and+dipyridodiazepinones&doi=10.1021%2Fjm00111a045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase.  1.  Tricyclic pyridobenzo- and dipyridodiazepinones</span></div><div class="casAuthors">Hargrave, Karl D.; Proudfoot, John R.; Grozinger, Karl G.; Cullen, Ernest; Kapadia, Suresh R.; Patel, Usha R.; Fuchs, Victor U.; Mauldin, Scott C.; Vitous, Jana; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2231-41</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Novel pyrido[2,3-b][1,4]benzodiazepinones, pyrido[2,3-b][1,5]benzodiazepinones, and dipyrido[3,2-b:2',3'-e][1,4]diazepinones e.g., I (X = N, X1 = CH; X = CH; X1 = N) and II inhibited human immunodeficiency virus type 1 reverse transcriptase in vitro at concns. as low as 35 nM.  In all three series, small substituents (e.g., Me, Et, Ac) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., Et, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.  In general, lipophilic substituents are preferred on the A ring, whereas substitution on the C ring generally reduces potency relative to the corresponding compds. with no substituents on the arom. ring.  Max. potency is achieved with Me substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.  Addnl. substituents on the A ring can be readily tolerated.  II (BI-RG-587) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for preclin. development.  II is noncytotoxic except at high doses and effective against all clin. isolates of HIV-1, including those which are AZT-resistant.  It is specific for HIV-1, ineffective against HIV-2, inactive against simian and feline reverse transcriptase, and does not inhibit DNA polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1hxlznaETGrVg90H21EOLACvtfcHk0lgduWntDErtjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksV2ltrw%253D&md5=8430acdc51ecffc0d3a374f2a978be28</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm00111a045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00111a045%26sid%3Dliteratum%253Aachs%26aulast%3DHargrave%26aufirst%3DK.%2BD.%26aulast%3DProudfoot%26aufirst%3DJ.%2BR.%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26aulast%3DCullen%26aufirst%3DE.%26aulast%3DKapadia%26aufirst%3DS.%2BR.%26aulast%3DPatel%26aufirst%3DU.%2BR.%26aulast%3DFuchs%26aufirst%3DV.%2BU.%26aulast%3DMauldin%26aufirst%3DS.%2BC.%26aulast%3DVitous%26aufirst%3DJ.%26aulast%3DBehnke%26aufirst%3DM.%2BL.%26aulast%3DKlunder%26aufirst%3DJ.%2BM.%26aulast%3DPal%26aufirst%3DK.%26aulast%3DSkiles%26aufirst%3DJ.%2BW.%26aulast%3DMcNeil%26aufirst%3DD.%2BW.%26aulast%3DRose%26aufirst%3DJ.%2BM.%26aulast%3DChow%26aufirst%3DG.%2BC.%26aulast%3DSkoog%26aufirst%3DM.%2BT.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DEngel%26aufirst%3DW.%2BW.%26aulast%3DEberlein%26aufirst%3DW.%2BG.%26aulast%3DSaboe%26aufirst%3DT.%2BD.%26aulast%3DCampbell%26aufirst%3DS.%2BJ.%26aulast%3DRosenthal%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DNovel%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase.%25201.%2520Tricyclic%2520pyridobenzo-%2520and%2520dipyridodiazepinones%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26issue%3D7%26spage%3D2231%26epage%3D2241%26doi%3D10.1021%2Fjm00111a045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K.</span>; <span class="NLM_string-name">Proudfoot, J.</span>; <span class="NLM_string-name">Hargrave, K.</span></span>, <span> </span><span class="NLM_article-title">Discovery and development of nevirapine</span>. In  <i>Drug Discovery Development</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">363</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2F0471780103.ch13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=353-363&author=K.+Grozinger&author=J.+Proudfoot&author=K.+Hargrave&title=Drug+Discovery+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2F0471780103.ch13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471780103.ch13%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520development%2520of%2520nevirapine%26btitle%3DDrug%2520Discovery%2520Development%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2006%26spage%3D353%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan-Havard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrail-Tran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taburet, A.-M.</span></span> <span> </span><span class="NLM_article-title">the A. S. G. Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2154</span>– <span class="NLM_lpage">2160</span>, <span class="refDoi"> DOI: 10.1128/AAC.02294-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.02294-12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2154-2160&issue=5&author=P.+Fan-Havardauthor=Z.+Liuauthor=M.+Chouauthor=Y.+Lingauthor=A.+Barrail-Tranauthor=D.+W.+Haasauthor=A.-M.+Taburet&title=the+A.+S.+G.+Pharmacokinetics+of+phase+I+nevirapine+metabolites+following+a+single+dose+and+at+steady+state&doi=10.1128%2FAAC.02294-12"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FAAC.02294-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02294-12%26sid%3Dliteratum%253Aachs%26aulast%3DFan-Havard%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChou%26aufirst%3DM.%26aulast%3DLing%26aufirst%3DY.%26aulast%3DBarrail-Tran%26aufirst%3DA.%26aulast%3DHaas%26aufirst%3DD.%2BW.%26aulast%3DTaburet%26aufirst%3DA.-M.%26atitle%3Dthe%2520A.%2520S.%2520G.%2520Pharmacokinetics%2520of%2520phase%2520I%2520nevirapine%2520metabolites%2520following%2520a%2520single%2520dose%2520and%2520at%2520steady%2520state%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D5%26spage%3D2154%26epage%3D2160%26doi%3D10.1128%2FAAC.02294-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nummy, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridges, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvagno, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of five nevirapine metabolites</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570370203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fjhet.5570370203" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2000&pages=229-239&issue=2&author=K.+G.+Grozingerauthor=D.+P.+Byrneauthor=L.+J.+Nummyauthor=M.+D.+Ridgesauthor=A.+Salvagno&title=Synthesis+of+five+nevirapine+metabolites&doi=10.1002%2Fjhet.5570370203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570370203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570370203%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26aulast%3DByrne%26aufirst%3DD.%2BP.%26aulast%3DNummy%26aufirst%3DL.%2BJ.%26aulast%3DRidges%26aufirst%3DM.%2BD.%26aulast%3DSalvagno%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520five%2520nevirapine%2520metabolites%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2000%26volume%3D37%26issue%3D2%26spage%3D229%26epage%3D239%26doi%3D10.1002%2Fjhet.5570370203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauldin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of nevirapine and its major metabolite</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570320144</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fjhet.5570320144" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1995&pages=259-263&issue=1&author=K.+G.+Grozingerauthor=V.+Fuchsauthor=K.+D.+Hargraveauthor=S.+Mauldinauthor=J.+Vitousauthor=S.+Campbellauthor=J.+Adams&title=Synthesis+of+nevirapine+and+its+major+metabolite&doi=10.1002%2Fjhet.5570320144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570320144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570320144%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26aulast%3DFuchs%26aufirst%3DV.%26aulast%3DHargrave%26aufirst%3DK.%2BD.%26aulast%3DMauldin%26aufirst%3DS.%26aulast%3DVitous%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DSynthesis%2520of%2520nevirapine%2520and%2520its%2520major%2520metabolite%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1995%26volume%3D32%26issue%3D1%26spage%3D259%26epage%3D263%26doi%3D10.1002%2Fjhet.5570320144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattox, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keirns, J.</span></span> <span> </span><span class="NLM_article-title">Disposition and biotransformation of the antiretroviral drug nevirapine in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">901</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10421616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXkvFCgt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=895-901&issue=8&author=P.+Riskaauthor=M.+Lamsonauthor=T.+MacGregorauthor=J.+Saboauthor=S.+Hattoxauthor=J.+Pavauthor=J.+Keirns&title=Disposition+and+biotransformation+of+the+antiretroviral+drug+nevirapine+in+humans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Disposition and biotransformation of the antiretroviral drug nevirapine in humans</span></div><div class="casAuthors">Riska, Paul; Lamson, Michael; Macgregor, Thomas; Sabo, John; Hattox, Susan; Pav, Joseph; Keirns, James</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">895-901</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The pharmacokinetics and biotransformation of the antiretroviral agent nevirapine (NVP) after autoinduction were characterized in eight healthy male volunteers.  Subjects received 200-mg NVP tablets once daily for 2 wk, followed by 200 mg twice daily for 2 wk.  Then they received a single oral dose (soln.) of 50 mg contg. 100 μCi of [14C]NVP.  Biol. fluids were analyzed for total radioactivity, parent compd. (HPLC/UV), and metabolites (electrospray liq. chromatog./mass spectroscopy and liq. chromatog./tandem mass spectroscopy).  Mean recovery of radioactivity was 91.4%, with 81.3% excreted in urine and 10.1% recovered in the feces over a period of 10 days.  Circulating radioactivity was evenly distributed between whole blood and plasma.  At max. plasma concn., parent compd. accounted for ∼75% of the circulating radioactivity.  Mean plasma elimination half-lives for total radioactivity and NVP were 21.3 and 20.0 h, resp.  Several metabolites were identified in urine including 2-hydroxynevirapine glucuronide (18.6%), 3-hydroxynevirapine glucuronide (25.7%), 12-hydroxynevirapine glucuronide (23.7%), 8-hydroxynevirapine glucuronide (1.3%), 3-hydroxynevirapine (1.2%), 12-hydroxynevirapine (0.6%), and 4-carboxynevirapine (2.4%).  Greater than 80% of the radioactivity in urine was made up of glucuronidated conjugates of hydroxylated metabolites of NVP.  Thus, cytochrome P 450 metab., glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of NVP biotransformation and elimination in humans.  Only a small fraction of the dose (2.7%) was excreted in urine as parent compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZI7168xc8kbVg90H21EOLACvtfcHk0lg-zfFwXrv6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXkvFCgt7g%253D&md5=17459b5f6e76dbf51e0f3753f84f1668</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRiska%26aufirst%3DP.%26aulast%3DLamson%26aufirst%3DM.%26aulast%3DMacGregor%26aufirst%3DT.%26aulast%3DSabo%26aufirst%3DJ.%26aulast%3DHattox%26aufirst%3DS.%26aulast%3DPav%26aufirst%3DJ.%26aulast%3DKeirns%26aufirst%3DJ.%26atitle%3DDisposition%2520and%2520biotransformation%2520of%2520the%2520antiretroviral%2520drug%2520nevirapine%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26issue%3D8%26spage%3D895%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span> <i>Nevirapine, FDA Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug
Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Nevirapine%2C+FDA+Package%3B+U.S.+Food+and+Drug%0AAdministration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNevirapine%252C%2520FDA%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span> <span> </span><span class="NLM_article-title">The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.1186/1742-6405-11-36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1186%2F1742-6405-11-36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25926857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVWjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=36&author=Y.+Wangauthor=H.+Xingauthor=L.+Liaoauthor=Z.+Wangauthor=B.+Suauthor=Q.+Zhaoauthor=Y.+Fengauthor=P.+Maauthor=J.+Liuauthor=J.+Wuauthor=Y.+Ruanauthor=Y.+Shao&title=The+development+of+drug+resistance+mutations+K103N+Y181C+and+G190A+in+long+term+Nevirapine-containing+antiviral+therapy&doi=10.1186%2F1742-6405-11-36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy</span></div><div class="casAuthors">Wang, Yuncong; Xing, Hui; Liao, Lingjie; Wang, Zhe; Su, Bin; Zhao, Quanbi; Feng, Yi; Ma, Pengfei; Liu, Jia; Wu, Jianjun; Ruan, Yuhua; Shao, Yiming</div><div class="citationInfo"><span class="NLM_cas:title">AIDS Research and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36/1-36/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">ARTIC4</span>;
        ISSN:<span class="NLM_cas:issn">1742-6405</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Objective We built a cohort study of HIV patients taking long-term first-line Antiretroviral Therapy in 2003.  In this assay, we focused on the development of primary drug resistance mutations against Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), K103N, Y181C and G190A.  Method The cohort study was built in Henan province, China.  We used Single Genome Amplification (SGA) to analyze the frequency of K103N, Y181C and G190A in serial plasma samples of three individual patients.  We also performed std. genotype HIV drug resistance assay in 204 patients of this cohort study to analyze the frequency of these mutations.  Result In the SGA sequences, the K103N decreased and vanished, while the frequency of Y181C and G190A increased in individual patient receiving long-term Antiretroviral Therapy (ART).  In the sequences of std. genotype HIV drug resistance assay, the frequency of K103N, Y181C and G190A had the similar pattern with that in SGA sequences.  Among these patients, the viral suppression were still sufficient after receiving ART for 72 mo, and 78.6% (160/204) patients could have their CD4 count over than 200cells/ul.  Conclusion In some patients, first-line ART had the possibility to provide sufficient treatment effect for over than 72 mo, but in long-term treatment, the dominant NNRTI drug resistance mutation K103N could reduced, while the proportion of variants with mutation Y181C or G190A may increased.  This result was not similar with that in vitro study, which state that variant with K103N or Y181C had an equal viral fitness with wild type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_zj0ueMuiobVg90H21EOLACvtfcHk0lg-zfFwXrv6yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVWjt7c%253D&md5=c3bf6b032d086d79b5a6eca7d0bd6088</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-11-36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-11-36%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DH.%26aulast%3DLiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRuan%26aufirst%3DY.%26aulast%3DShao%26aufirst%3DY.%26atitle%3DThe%2520development%2520of%2520drug%2520resistance%2520mutations%2520K103N%2520Y181C%2520and%2520G190A%2520in%2520long%2520term%2520Nevirapine-containing%2520antiviral%2520therapy%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2014%26volume%3D11%26spage%3D36%26doi%3D10.1186%2F1742-6405-11-36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bird, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>312</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">805</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2001.4988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Fjmbi.2001.4988" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2001&pages=795-805&issue=4&author=J.+Renauthor=C.+Nicholsauthor=L.+Birdauthor=P.+Chamberlainauthor=K.+Weaverauthor=S.+Shortauthor=D.+I.+Stuartauthor=D.+K.+Stammers&title=Structural+mechanisms+of+drug+resistance+for+mutations+at+codons+181+and+188+in+HIV-1+reverse+transcriptase+and+the+improved+resilience+of+second+generation+non-nucleoside+inhibitors&doi=10.1006%2Fjmbi.2001.4988"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.4988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.4988%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DC.%26aulast%3DBird%26aufirst%3DL.%26aulast%3DChamberlain%26aufirst%3DP.%26aulast%3DWeaver%26aufirst%3DK.%26aulast%3DShort%26aufirst%3DS.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520mechanisms%2520of%2520drug%2520resistance%2520for%2520mutations%2520at%2520codons%2520181%2520and%2520188%2520in%2520HIV-1%2520reverse%2520transcriptase%2520and%2520the%2520improved%2520resilience%2520of%2520second%2520generation%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D312%26issue%3D4%26spage%3D795%26epage%3D805%26doi%3D10.1006%2Fjmbi.2001.4988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meichsner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paessens, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, G.</span></span> <span> </span><span class="NLM_article-title">Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>200</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1006/viro.1994.1233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Fviro.1994.1233" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=1994&pages=696-701&issue=2&author=J.+P.+Kleimauthor=R.+Benderauthor=R.+Kirschauthor=C.+Meichsnerauthor=A.+Paessensauthor=G.+Riess&title=Mutational+analysis+of+residue+190+of+human+immunodeficiency+virus+type+1+reverse+transcriptase&doi=10.1006%2Fviro.1994.1233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1006%2Fviro.1994.1233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1994.1233%26sid%3Dliteratum%253Aachs%26aulast%3DKleim%26aufirst%3DJ.%2BP.%26aulast%3DBender%26aufirst%3DR.%26aulast%3DKirsch%26aufirst%3DR.%26aulast%3DMeichsner%26aufirst%3DC.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DRiess%26aufirst%3DG.%26atitle%3DMutational%2520analysis%2520of%2520residue%2520190%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520reverse%2520transcriptase%26jtitle%3DVirology%26date%3D1994%26volume%3D200%26issue%3D2%26spage%3D696%26epage%3D701%26doi%3D10.1006%2Fviro.1994.1233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>336</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2003.12.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.jmb.2003.12.055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2004&pages=569-578&issue=3&author=J.+Renauthor=C.+E.+Nicholsauthor=P.+P.+Chamberlainauthor=K.+L.+Weaverauthor=S.+A.+Shortauthor=D.+K.+Stammers&title=Crystal+structures+of+HIV-1+reverse+transcriptases+mutated+at+codons+100%2C+106+and+108+and+mechanisms+of+resistance+to+non-nucleoside+inhibitors&doi=10.1016%2Fj.jmb.2003.12.055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2003.12.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2003.12.055%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DNichols%26aufirst%3DC.%2BE.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DCrystal%2520structures%2520of%2520HIV-1%2520reverse%2520transcriptases%2520mutated%2520at%2520codons%2520100%252C%2520106%2520and%2520108%2520and%2520mechanisms%2520of%2520resistance%2520to%2520non-nucleoside%2520inhibitors%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D336%26issue%3D3%26spage%3D569%26epage%3D578%26doi%3D10.1016%2Fj.jmb.2003.12.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1089</span>– <span class="NLM_lpage">1094</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(00)00513-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0969-2126%2800%2900513-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=1089-1094&issue=10&author=J.+Renauthor=J.+Miltonauthor=K.+L.+Weaverauthor=S.+A.+Shortauthor=D.+I.+Stuartauthor=D.+K.+Stammers&title=Structural+basis+for+the+resilience+of+efavirenz+%28DMP-266%29+to+drug+resistance+mutations+in+HIV-1+reverse+transcriptase&doi=10.1016%2FS0969-2126%2800%2900513-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2800%2900513-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252800%252900513-X%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520resilience%2520of%2520efavirenz%2520%2528DMP-266%2529%2520to%2520drug%2520resistance%2520mutations%2520in%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DStructure%26date%3D2000%26volume%3D8%26issue%3D10%26spage%3D1089%26epage%3D1094%26doi%3D10.1016%2FS0969-2126%2800%2900513-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and durability of nevirapine in antiretroviral drug naive patients</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">S40</span>– <span class="NLM_lpage">S52</span>, <span class="refDoi"> DOI: 10.1097/00126334-200309011-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-200309011-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=14562857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFCrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=S40-S52&author=J.+M.+Lange&title=Efficacy+and+durability+of+nevirapine+in+antiretroviral+drug+naive+patients&doi=10.1097%2F00126334-200309011-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and durability of nevirapine in antiretroviral drug naive patients</span></div><div class="casAuthors">Lange, Joep M. A.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S40-S52</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was first reported in the scientific literature in 1990.  Varying doses of nevirapine (NVP) and a no. of regimens contg. this NNRTI have been studied in antiretroviral (ARV) naive patients.  Four key studies have compared the efficacy and safety of triple drug regimens contg. NVP in ARV naive, HIV-1 infected patients.  The INCAS study was the first demonstration of how to use NVP in an effective and durable manner: as a component of a triple drug regimen.  The COMBINE Study was a comparison of protease inhibitor (PI)-based and NVP-based triple regimens.  The Atlantic Study is comparing the safety and efficacy of three triple drug regimens in ARV naive patients.  In this study, treatment consists of a divergent drug regimen (PI and nucleoside reverse transcriptase inhibitors, NRTIs) targeting both HIV-1 protease and reverse transcriptase or a convergent regimen targeting reverse transcriptase alone (three NRTIs or two NRTIs plus a NNRTI).  A clin. endpoint study (BI 1090) compared the efficacy and durability of multi-drug regimens in ARV naive patients with high baseline plasma HIV-1 RNA levels (pVLs) and low peripheral blood CD4+ lymphocyte counts.  Data from these studies confirm that triple regimens contg. NVP suppressed viral replication for up to one year, even when the ARV naive patients had low CD4+ cell counts at baseline.  Nevirapine-contg. regimens suppressed pVLs to <50 copies/mL in approx. 50% of patients in the studies discussed (Intent to Treat analyses).  Data from 96 wk of follow up in the Atlantic Study demonstrates that the regimens contg. didanosine and stavudine plus indinavir or NVP were significantly more successful in suppressing pVLs to <50 copies/mL during this period than a regimen composed of these NRTIs and lamivudine (p ≤ 0.001).  As with other ARV drugs, NVP should always be used as part of a fully suppressive ARV regimen.  When used in this way, it is an effective ARV drug, which contributes to durable virol. and immunol. responses in approx. half of all treated patients.  Nevirapine-contg. regimens are effective in patients with advanced HIV-1 infection, i.e., low CD4+ cell counts.  Data will soon be available from the 2NN Study that compares the efficacy and safety of four different regimens using NVP once daily, NVP twice daily, efavirenz once daily or a combination of NVP and efavirenz.  All four arms of the study include a backbone of stavudine and lamivudine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHicpp_x2tPLVg90H21EOLACvtfcHk0ljg5EMiTFRxqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFCrt7o%253D&md5=128a3a8437196c515722e6ab1e617bf4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1097%2F00126334-200309011-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-200309011-00007%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520durability%2520of%2520nevirapine%2520in%2520antiretroviral%2520drug%2520naive%2520patients%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2003%26volume%3D34%26spage%3DS40%26epage%3DS52%26doi%3D10.1097%2F00126334-200309011-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montaner, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. M.</span></span> <span> </span><span class="NLM_article-title">A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study</span>. <i>Jama</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1001/jama.279.12.930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1001%2Fjama.279.12.930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9544767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXitlyisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=930-937&issue=12&author=J.+S.+Montanerauthor=P.+Reissauthor=D.+Cooperauthor=S.+Vellaauthor=M.+Harrisauthor=B.+Conwayauthor=M.+A.+Wainbergauthor=D.+Smithauthor=P.+Robinsonauthor=D.+Hallauthor=M.+Myersauthor=J.+M.+Lange&title=A+randomized%2C+double-blind+trial+comparing+combinations+of+nevirapine%2C+didanosine%2C+and+zidovudine+for+HIV-infected+patients%3A+the+INCAS+Trial.+Italy%2C+The+Netherlands%2C+Canada+and+Australia+Study&doi=10.1001%2Fjama.279.12.930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial</span></div><div class="casAuthors">Montaner, Julio S. G.; Reiss, Peter; Cooper, David; Vella, Stefano; Harris, Marianne; Conway, Brian; Wainberg, Mark A.; Smith, D.; Robinson, Patrick; Hall, David; Myers, Maureen; Lange, Joep M. A.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">930-937</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Current guidelines recommend that individuals infected with the human immunodeficiency virus type 1 (HIV-1) be treated using combinations of anti-retroviral agents to achieve sustained suppression of viral replication as measured by the plasma HIV-1 RNA assay, in the hopes of achieving prolonged remission of the disease.  However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA.  Of the 153 enrolled patients, 151 were evaluable.  At week 8, plasma HIV-1 RNA levels had decreased by log 2.18, 1.55, and 0.90 in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, resp. (P<.05).  The proportions of patients with plasma HIV-1 RNA levels below 20 copies per mL at week 52 were 51%, 12%, and 0% in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, resp. (P<.001).  Viral amplification was attempted in 59 patients at 6 mo.  Viral isolation was unsuccessful in 19 (79%) of 24, 10 (53%) of 19, and 5 (31%) of 16 patients in the triple drug therapy, zidovudine plus didanosine, and zidovudine plus nevirapine groups, resp.  Among patients from whom virus could be amplified, resistance to nevirapine was found in all 11 patients receiving zidovudine plus nevirapine and in all 5 patients receiving triple drug therapy.  Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, resp. (P=.08).  Triple drug therapy with zidovudine, didanosine, and nevirapine led to a substantially greater and sustained decrease in plasma viral load than the 2-drug regimens studied.  Our results also suggest that suppression of viral replication, as demonstrated by a decrease in the plasma HIV-1 RNA load below the level of quantitation of the most sensitive test available, may at least forestall the development of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9GorH2fhxjLVg90H21EOLACvtfcHk0ljg5EMiTFRxqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitlyisr4%253D&md5=1d062ad4a092ba4d94b0b49beffd12f1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1001%2Fjama.279.12.930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.279.12.930%26sid%3Dliteratum%253Aachs%26aulast%3DMontaner%26aufirst%3DJ.%2BS.%26aulast%3DReiss%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DD.%26aulast%3DVella%26aufirst%3DS.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DConway%26aufirst%3DB.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DMyers%26aufirst%3DM.%26aulast%3DLange%26aufirst%3DJ.%2BM.%26atitle%3DA%2520randomized%252C%2520double-blind%2520trial%2520comparing%2520combinations%2520of%2520nevirapine%252C%2520didanosine%252C%2520and%2520zidovudine%2520for%2520HIV-infected%2520patients%253A%2520the%2520INCAS%2520Trial.%2520Italy%252C%2520The%2520Netherlands%252C%2520Canada%2520and%2520Australia%2520Study%26jtitle%3DJama%26date%3D1998%26volume%3D279%26issue%3D12%26spage%3D930%26epage%3D937%26doi%3D10.1001%2Fjama.279.12.930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baylor, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johann-Liang, R.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity associated with nevirapine use</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1097/00126334-200404150-00014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-200404150-00014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15021321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD2c7ivVGiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2004&pages=538-539&issue=5&author=M.+S.+Baylorauthor=R.+Johann-Liang&title=Hepatotoxicity+associated+with+nevirapine+use&doi=10.1097%2F00126334-200404150-00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity associated with nevirapine use</span></div><div class="casAuthors">Baylor Melisse Sloas; Johann-Liang Rosemary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of acquired immune deficiency syndromes (1999)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">538-9</span>
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-beckN323PZWtyewyzkyLfW6udTcc2ebpGdgNR9X5u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7ivVGiug%253D%253D&md5=17d61e7562eced5eee59c64a4d49dbbe</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1097%2F00126334-200404150-00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-200404150-00014%26sid%3Dliteratum%253Aachs%26aulast%3DBaylor%26aufirst%3DM.%2BS.%26aulast%3DJohann-Liang%26aufirst%3DR.%26atitle%3DHepatotoxicity%2520associated%2520with%2520nevirapine%2520use%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2004%26volume%3D35%26issue%3D5%26spage%3D538%26epage%3D539%26doi%3D10.1097%2F00126334-200404150-00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanne, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mommeja-Marin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gish, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, F.</span></span> <span> </span><span class="NLM_article-title">Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">829</span>, <span class="refDoi"> DOI: 10.1086/428093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1086%2F428093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15717255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVyhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2005&pages=825-829&issue=6&author=I.+Sanneauthor=H.+Mommeja-Marinauthor=J.+Hinkleauthor=J.+A.+Bartlettauthor=M.+M.+Ledermanauthor=G.+Maartensauthor=C.+Wakefordauthor=A.+Shawauthor=J.+Quinnauthor=R.+G.+Gishauthor=F.+Rousseau&title=Severe+hepatotoxicity+associated+with+nevirapine+use+in+HIV-infected+subjects&doi=10.1086%2F428093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects</span></div><div class="casAuthors">Sanne, Ian; Mommeja-Marin, Herve; Hinkle, John; Bartlett, John A.; Lederman, Michael M.; Maartens, Gary; Wakeford, Charles; Shaw, Audrey; Quinn, Joseph; Gish, Robert G.; Rousseau, Franck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-829</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Human immunodeficiency virus (HIV)-infected South African patients (n = 468) received blinded lamivudine or emtricitabine, stavudine, and either nevirapine or efavirenz (based on screening viral load).  Baseline characteristics were analyzed in univariate and multivariate regression, to identify risk factors for hepatotoxicity (grade 3 or greater increase in serum aminotransferase levels).  The occurrence of early hepatotoxicity was 17% in the nevirapine group and 0% in the efavirenz group and was balanced between the lamivudine and emtricitabine arms.  Two subjects died of hepatic failure.  Independent risk factors were body-mass index (BMI) <18.5, female sex, serum albumin level <35 g/L, mean corpuscular vol. >85 fL, plasma HIV-1 RNA load <20,000 copies/mL, aspartate aminotransferase level <75 IU/L, and lactate dehydrogenase level <164 IU/L.  The use of nevirapine in female patients with a low BMI should be discouraged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoakc1s3TvQ7LVg90H21EOLACvtfcHk0ljI-9xgu6ik5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVyhu7k%253D&md5=3d04abf1ab1a893425ad8e2cc625ab93</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1086%2F428093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F428093%26sid%3Dliteratum%253Aachs%26aulast%3DSanne%26aufirst%3DI.%26aulast%3DMommeja-Marin%26aufirst%3DH.%26aulast%3DHinkle%26aufirst%3DJ.%26aulast%3DBartlett%26aufirst%3DJ.%2BA.%26aulast%3DLederman%26aufirst%3DM.%2BM.%26aulast%3DMaartens%26aufirst%3DG.%26aulast%3DWakeford%26aufirst%3DC.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DQuinn%26aufirst%3DJ.%26aulast%3DGish%26aufirst%3DR.%2BG.%26aulast%3DRousseau%26aufirst%3DF.%26atitle%3DSevere%2520hepatotoxicity%2520associated%2520with%2520nevirapine%2520use%2520in%2520HIV-infected%2520subjects%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2005%26volume%3D191%26issue%3D6%26spage%3D825%26epage%3D829%26doi%3D10.1086%2F428093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bethune, M. P.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009)</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2009.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.antiviral.2009.09.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2010&pages=75-90&issue=1&author=M.+P.+de%0ABethune&title=Non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29%2C+their+discovery%2C+development%2C+and+use+in+the+treatment+of+HIV-1+infection%3A+a+review+of+the+last+20+years+%281989%E2%80%932009%29&doi=10.1016%2Fj.antiviral.2009.09.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2009.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2009.09.008%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%252C%2520their%2520discovery%252C%2520development%252C%2520and%2520use%2520in%2520the%2520treatment%2520of%2520HIV-1%2520infection%253A%2520a%2520review%2520of%2520the%2520last%252020%2520years%2520%25281989%25E2%2580%25932009%2529%26jtitle%3DAntiviral%2520Res.%26date%3D2010%26volume%3D85%26issue%3D1%26spage%3D75%26epage%3D90%26doi%3D10.1016%2Fj.antiviral.2009.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merluzzi, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labadia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoog, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattox, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>250</i></span> (<span class="NLM_issue">4986</span>),  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1126/science.1701568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1126%2Fscience.1701568" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=1990&pages=1411-1413&issue=4986&author=V.+J.+Merluzziauthor=K.+D.+Hargraveauthor=M.+Labadiaauthor=K.+Grozingerauthor=M.+Skoogauthor=J.+C.+Wuauthor=C.+K.+Shihauthor=K.+Ecknerauthor=S.+Hattoxauthor=J.+Adams&title=Inhibition+of+HIV-1+replication+by+a+nonnucleoside+reverse+transcriptase+inhibitor&doi=10.1126%2Fscience.1701568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.1701568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1701568%26sid%3Dliteratum%253Aachs%26aulast%3DMerluzzi%26aufirst%3DV.%2BJ.%26aulast%3DHargrave%26aufirst%3DK.%2BD.%26aulast%3DLabadia%26aufirst%3DM.%26aulast%3DGrozinger%26aufirst%3DK.%26aulast%3DSkoog%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DShih%26aufirst%3DC.%2BK.%26aulast%3DEckner%26aufirst%3DK.%26aulast%3DHattox%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520HIV-1%2520replication%2520by%2520a%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DScience%26date%3D1990%26volume%3D250%26issue%3D4986%26spage%3D1411%26epage%3D1413%26doi%3D10.1126%2Fscience.1701568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burton, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritzky, A. R.</span></span> <span> </span><span class="NLM_article-title">The selective 3- and 5-nitration of 2-pyridones</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">2211</span>– <span class="NLM_lpage">2212</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)96822-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0040-4039%2801%2996822-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1971&pages=2211-2212&issue=24&author=A.+G.+Burtonauthor=P.+J.+Hallsauthor=A.+R.+Katritzky&title=The+selective+3-+and+5-nitration+of+2-pyridones&doi=10.1016%2FS0040-4039%2801%2996822-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2996822-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252996822-4%26sid%3Dliteratum%253Aachs%26aulast%3DBurton%26aufirst%3DA.%2BG.%26aulast%3DHalls%26aufirst%3DP.%2BJ.%26aulast%3DKatritzky%26aufirst%3DA.%2BR.%26atitle%3DThe%2520selective%25203-%2520and%25205-nitration%2520of%25202-pyridones%26jtitle%3DTetrahedron%2520Lett.%26date%3D1971%26volume%3D12%26issue%3D24%26spage%3D2211%26epage%3D2212%26doi%3D10.1016%2FS0040-4039%2801%2996822-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bobbitt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scola, D. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of isoquinoline alkaloids. II. The synthesis and reactions of 4-methyl-3-pyridinecarboxaldehyde and other 4-methyl-3-substituted pyridines1,2</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">564</span>, <span class="refDoi"> DOI: 10.1021/jo01074a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01074a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1960&pages=560-564&issue=4&author=J.+M.+Bobbittauthor=D.+A.+Scola&title=Synthesis+of+isoquinoline+alkaloids.+II.+The+synthesis+and+reactions+of+4-methyl-3-pyridinecarboxaldehyde+and+other+4-methyl-3-substituted+pyridines1%2C2&doi=10.1021%2Fjo01074a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjo01074a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01074a018%26sid%3Dliteratum%253Aachs%26aulast%3DBobbitt%26aufirst%3DJ.%2BM.%26aulast%3DScola%26aufirst%3DD.%2BA.%26atitle%3DSynthesis%2520of%2520isoquinoline%2520alkaloids.%2520II.%2520The%2520synthesis%2520and%2520reactions%2520of%25204-methyl-3-pyridinecarboxaldehyde%2520and%2520other%25204-methyl-3-substituted%2520pyridines1%252C2%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1960%26volume%3D25%26issue%3D4%26spage%3D560%26epage%3D564%26doi%3D10.1021%2Fjo01074a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span>; <span class="NLM_string-name">Hargrave, K. D.</span>; <span class="NLM_string-name">Adams, J.</span></span> US Patent <span> </span><span class="NLM_article-title">Method for the Preparation of 3-amino-2-chloro-4-methylpyridines</span>. <span class="NLM_patent">US5668287A</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=K.+G.+Grozinger&author=K.+D.+Hargrave&author=J.+Adams&title=Method+for+the+Preparation+of+3-amino-2-chloro-4-methylpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%25203-amino-2-chloro-4-methylpyridines%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span>; <span class="NLM_string-name">Lie, J. J.</span></span> <i>The Art of Drug Synthesis</i>; <span class="NLM_publisher-name">Wiley-Interscience</span>: <span class="NLM_publisher-loc">Ljubljana</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2F9780470134979" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+S.+Johnson&author=J.+J.+Lie&title=The+Art+of+Drug+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2F9780470134979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470134979%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26btitle%3DThe%2520Art%2520of%2520Drug%2520Synthesis%26pub%3DWiley-Interscience%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, K. G.</span>; <span class="NLM_string-name">Hargrave, K. D.</span>; <span class="NLM_string-name">Adams, J.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of 5,11-dihydro-6<i>H</i>-dipyrido [3,2-<i>b</i>:2′,3′-<i>e</i>][1,4]diazepines</span>. US Patent <span class="NLM_patent">US5571912</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=K.+G.+Grozinger&author=K.+D.+Hargrave&author=J.+Adams&title=Method+for+the+Preparation+of+5%2C11-dihydro-6H-dipyrido+%5B3%2C2-b%3A2%E2%80%B2%2C3%E2%80%B2-e%5D%5B1%2C4%5Ddiazepines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DK.%2BG.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%25205%252C11-dihydro-6H-dipyrido%2520%255B3%252C2-b%253A2%25E2%2580%25B2%252C3%25E2%2580%25B2-e%255D%255B1%252C4%255Ddiazepines%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boswell, R. F.</span>; <span class="NLM_string-name">Gupton, B. F.</span>; <span class="NLM_string-name">Lo, Y.
S.</span></span> <span> </span><span class="NLM_article-title">Improved Method for Making Nevirapine</span>. China Patent <span class="NLM_patent">CN1280293C</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+F.+Boswell&author=B.+F.+Gupton&author=Y.%0AS.+Lo&title=Improved+Method+for+Making+Nevirapine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoswell%26aufirst%3DR.%2BF.%26atitle%3DImproved%2520Method%2520for%2520Making%2520Nevirapine%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhiquan, Z.</span>; <span class="NLM_string-name">Laisheng, Z.</span>; <span class="NLM_string-name">Xiujuan, W.</span>; <span class="NLM_string-name">Fei, X.</span></span> <span> </span><span class="NLM_article-title">Methods for preparation of nevirapine and intermediate thereof</span>. China Patent <span class="NLM_patent">CN104774204A</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Z.+Zhiquan&author=Z.+Laisheng&author=W.+Xiujuan&author=X.+Fei&title=Methods+for+preparation+of+nevirapine+and+intermediate+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhiquan%26aufirst%3DZ.%26atitle%3DMethods%2520for%2520preparation%2520of%2520nevirapine%2520and%2520intermediate%2520thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Delavirdine</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1444</span>, <span class="refDoi"> DOI: 10.2165/00003495-200060060-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F00003495-200060060-00013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1411-1444&issue=6&author=L.+J.+Scottauthor=C.+M.+Perry&title=Delavirdine&doi=10.2165%2F00003495-200060060-00013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2165%2F00003495-200060060-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200060060-00013%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DDelavirdine%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26issue%3D6%26spage%3D1411%26epage%3D1444%26doi%3D10.2165%2F00003495-200060060-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dueweke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span> <span> </span><span class="NLM_article-title">U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1127</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.5.1127</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.37.5.1127" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=1127-1131&issue=5&author=T.+J.+Duewekeauthor=S.+M.+Poppeauthor=D.+L.+Romeroauthor=S.+M.+Swaneyauthor=A.+G.+Soauthor=K.+M.+Downeyauthor=I.+W.+Althausauthor=F.+Reusserauthor=M.+Bussoauthor=L.+Resnick&title=U-90152%2C+a+potent+inhibitor+of+human+immunodeficiency+virus+type+1+replication&doi=10.1128%2FAAC.37.5.1127"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.5.1127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.5.1127%26sid%3Dliteratum%253Aachs%26aulast%3DDueweke%26aufirst%3DT.%2BJ.%26aulast%3DPoppe%26aufirst%3DS.%2BM.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DSwaney%26aufirst%3DS.%2BM.%26aulast%3DSo%26aufirst%3DA.%2BG.%26aulast%3DDowney%26aufirst%3DK.%2BM.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DResnick%26aufirst%3DL.%26atitle%3DU-90152%252C%2520a%2520potent%2520inhibitor%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520replication%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26issue%3D5%26spage%3D1127%26epage%3D1131%26doi%3D10.1128%2FAAC.37.5.1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poppe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span> <span> </span><span class="NLM_article-title">Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">8806</span>– <span class="NLM_lpage">8810</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.19.8806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.88.19.8806" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=8806-8810&issue=19&author=D.+L.+Romeroauthor=M.+Bussoauthor=C.+K.+Tanauthor=F.+Reusserauthor=J.+R.+Palmerauthor=S.+M.+Poppeauthor=P.+A.+Aristoffauthor=K.+M.+Downeyauthor=A.+G.+Soauthor=L.+Resnick&title=Nonnucleoside+reverse+transcriptase+inhibitors+that+potently+and+specifically+block+human+immunodeficiency+virus+type+1+replication&doi=10.1073%2Fpnas.88.19.8806"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.19.8806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.19.8806%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DC.%2BK.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DPalmer%26aufirst%3DJ.%2BR.%26aulast%3DPoppe%26aufirst%3DS.%2BM.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26aulast%3DDowney%26aufirst%3DK.%2BM.%26aulast%3DSo%26aufirst%3DA.%2BG.%26aulast%3DResnick%26aufirst%3DL.%26atitle%3DNonnucleoside%2520reverse%2520transcriptase%2520inhibitors%2520that%2520potently%2520and%2520specifically%2520block%2520human%2520immunodeficiency%2520virus%2520type%25201%2520replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26issue%3D19%26spage%3D8806%26epage%3D8810%26doi%3D10.1073%2Fpnas.88.19.8806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmsted, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopta, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosley, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanski, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishka, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stehle, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span> <span> </span><span class="NLM_article-title">Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3769</span>– <span class="NLM_lpage">3789</span>, <span class="refDoi"> DOI: 10.1021/jm960158n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960158n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3769-3789&issue=19&author=D.+L.+Romeroauthor=R.+A.+Olmstedauthor=T.+J.+Poelauthor=R.+A.+Morgeauthor=C.+Bilesauthor=B.+J.+Keiserauthor=L.+A.+Koptaauthor=J.+M.+Friisauthor=J.+D.+Hosleyauthor=K.+J.+Stefanskiauthor=D.+G.+Wishkaauthor=D.+B.+Evansauthor=J.+Morrisauthor=R.+G.+Stehleauthor=S.+K.+Sharmaauthor=Y.+Yagiauthor=R.+L.+Voormanauthor=W.+J.+Adamsauthor=W.+G.+Tarpleyauthor=R.+C.+Thomas&title=Targeting+delavirdine%2Fatevirdine+resistant+HIV-1%3A+identification+of+%28alkylamino%29piperidine-containing+bis%28heteroaryl%29piperazines+as+broad+spectrum+HIV-1+reverse+transcriptase+inhibitors&doi=10.1021%2Fjm960158n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm960158n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960158n%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DOlmsted%26aufirst%3DR.%2BA.%26aulast%3DPoel%26aufirst%3DT.%2BJ.%26aulast%3DMorge%26aufirst%3DR.%2BA.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DKeiser%26aufirst%3DB.%2BJ.%26aulast%3DKopta%26aufirst%3DL.%2BA.%26aulast%3DFriis%26aufirst%3DJ.%2BM.%26aulast%3DHosley%26aufirst%3DJ.%2BD.%26aulast%3DStefanski%26aufirst%3DK.%2BJ.%26aulast%3DWishka%26aufirst%3DD.%2BG.%26aulast%3DEvans%26aufirst%3DD.%2BB.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DStehle%26aufirst%3DR.%2BG.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DYagi%26aufirst%3DY.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520delavirdine%252Fatevirdine%2520resistant%2520HIV-1%253A%2520identification%2520of%2520%2528alkylamino%2529piperidine-containing%2520bis%2528heteroaryl%2529piperazines%2520as%2520broad%2520spectrum%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D19%26spage%3D3769%26epage%3D3789%26doi%3D10.1021%2Fjm960158n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span>; <span class="NLM_string-name">Aristoff, P. A.</span>; <span class="NLM_string-name">Jensen, R. K.</span>; <span class="NLM_string-name">Morozowich, W.</span>; <span class="NLM_string-name">Romero, D. L.</span>; <span class="NLM_string-name">Schinzer, W. C.</span>; <span class="NLM_string-name">Tarpley, W. G.</span>; <span class="NLM_string-name">Thomas, R. C.</span></span>, <span> </span><span class="NLM_article-title">Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate</span>. In  <i>Integration of Pharmaceutical Discovery and Development: Case Histories</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Borchardt, R. T.</span>, <span class="NLM_string-name">Freidinger, R. M.</span>, <span class="NLM_string-name">Sawyer, T. K.</span>, <span class="NLM_string-name">Smith, P. L.</span></span>, Eds.; <span class="NLM_publisher-name">Springer US</span>: <span class="NLM_publisher-loc">Boston, MA</span>, <span class="NLM_year">1998</span>; pp  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">312</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=285-312&author=W.+J.+Adams&author=P.+A.+Aristoff&author=R.+K.+Jensen&author=W.+Morozowich&author=D.+L.+Romero&author=W.+C.+Schinzer&author=W.+G.+Tarpley&author=R.+C.+Thomasauthor=R.+T.+Borchardt&author=R.+M.+Freidinger&author=T.+K.+Sawyer&author=P.+L.+Smith&title=Integration+of+Pharmaceutical+Discovery+and+Development%3A+Case+Histories"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520and%2520development%2520of%2520the%2520BHAP%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520delavirdine%2520mesylate%26btitle%3DIntegration%2520of%2520Pharmaceutical%2520Discovery%2520and%2520Development%253A%2520Case%2520Histories%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26pub%3DSpringer%2520US%26date%3D1998%26spage%3D285%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berrios-Pena, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">W, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">So, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">999</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1021/jm00033a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00033a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=999-1014&issue=7&author=D.+L.+Romeroauthor=R.+A.+Morgeauthor=C.+Bilesauthor=N.+Berrios-Penaauthor=P.+D.+Mayauthor=J.+R.+Palmerauthor=P.+D.+Johnsonauthor=H.+W.+Smithauthor=M.+Bussoauthor=C.+K.+Tanauthor=R.+L.+Voormanauthor=F.+Reusserauthor=A.+I.+Wauthor=K.+W.+Downeyauthor=A.+G.+Soauthor=L.+Resnikauthor=W.+G.+Tarpleyauthor=P.+A.+Aristoff&title=Discovery%2C+synthesis%2C+and+bioactivity+of+bis%28heteroaryl%29piperazines.+1.+A+novel+class+of+non-nucleoside+HIV-1+reverse+transcriptase+inhibitors&doi=10.1021%2Fjm00033a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm00033a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00033a018%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DMorge%26aufirst%3DR.%2BA.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DBerrios-Pena%26aufirst%3DN.%26aulast%3DMay%26aufirst%3DP.%2BD.%26aulast%3DPalmer%26aufirst%3DJ.%2BR.%26aulast%3DJohnson%26aufirst%3DP.%2BD.%26aulast%3DSmith%26aufirst%3DH.%2BW.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DC.%2BK.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DW%26aufirst%3DA.%2BI.%26aulast%3DDowney%26aufirst%3DK.%2BW.%26aulast%3DSo%26aufirst%3DA.%2BG.%26aulast%3DResnik%26aufirst%3DL.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%252C%2520synthesis%252C%2520and%2520bioactivity%2520of%2520bis%2528heteroaryl%2529piperazines.%25201.%2520A%2520novel%2520class%2520of%2520non-nucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D7%26spage%3D999%26epage%3D1014%26doi%3D10.1021%2Fjm00033a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span> <span> </span><span class="NLM_article-title">Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1021/jm00062a027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00062a027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1505-1508&issue=10&author=D.+L.+Romeroauthor=R.+A.+Morgeauthor=M.+J.+Geninauthor=C.+Bilesauthor=M.+Bussoauthor=L.+Resnickauthor=I.+W.+Althausauthor=F.+Reusserauthor=R.+C.+Thomasauthor=W.+G.+Tarpley&title=Bis%28heteroaryl%29piperazine+%28BHAP%29+reverse+transcriptase+inhibitors%3A+structure-activity+relationships+of+novel+substituted+indole+analogues+and+the+identification+of+1-%5B%285-methanesulfonamido-1H-indol-2-yl%29-carbonyl%5D-4-%5B3-+%5B%281-methylethyl%29amino%5D-pyridinyl%5Dpiperazine+monomethanesulfonate+%28U-90152S%29%2C+a+second-generation+clinical+candidate&doi=10.1021%2Fjm00062a027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm00062a027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00062a027%26sid%3Dliteratum%253Aachs%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DMorge%26aufirst%3DR.%2BA.%26aulast%3DGenin%26aufirst%3DM.%2BJ.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DBusso%26aufirst%3DM.%26aulast%3DResnick%26aufirst%3DL.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26atitle%3DBis%2528heteroaryl%2529piperazine%2520%2528BHAP%2529%2520reverse%2520transcriptase%2520inhibitors%253A%2520structure-activity%2520relationships%2520of%2520novel%2520substituted%2520indole%2520analogues%2520and%2520the%2520identification%2520of%25201-%255B%25285-methanesulfonamido-1H-indol-2-yl%2529-carbonyl%255D-4-%255B3-%2520%255B%25281-methylethyl%2529amino%255D-pyridinyl%255Dpiperazine%2520monomethanesulfonate%2520%2528U-90152S%2529%252C%2520a%2520second-generation%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26issue%3D10%26spage%3D1505%26epage%3D1508%26doi%3D10.1021%2Fjm00062a027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aristoff, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morozowich, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinzer, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarpley, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate</span>. <i>Pharm. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1007/0-306-47384-4_13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1007%2F0-306-47384-4_13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9760685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXmvFyrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=285-312&author=W.+J.+Adamsauthor=P.+A.+Aristoffauthor=R.+K.+Jensenauthor=W.+Morozowichauthor=D.+L.+Romeroauthor=W.+C.+Schinzerauthor=W.+G.+Tarpleyauthor=R.+C.+Thomas&title=Discovery+and+development+of+the+BHAP+nonnucleoside+reverse+transcriptase+inhibitor+delavirdine+mesylate&doi=10.1007%2F0-306-47384-4_13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate</span></div><div class="casAuthors">Adams, Wade J.; Aristoff, Paul A.; Jensen, Richard K.; Morozowich, Walter; Romero, Donna L.; Schinzer, William C.; Tarpley, W. Gary; Thomas, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">Integration of Pharmaceutical Discovery and Development</span>),
    <span class="NLM_cas:pages">285-312</span>CODEN:
                <span class="NLM_cas:coden">PHBIEB</span>;
        ISSN:<span class="NLM_cas:issn">1078-0467</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">A review with refs.  Discovery and development of the bis(heteroaryl)piperazine (BHAP) nonnucleoside reverse transcriptase inhibitor, delavirdine mesylate, the drug stability in water, its crystal forms, absorption, distribution, metab., and excretion, single-dose pharmacokinetics, safety toxicokinetics, etc., are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplO9BR_91IY7Vg90H21EOLACvtfcHk0liWLxOueULtzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvFyrtr4%253D&md5=92201e7ef2d580791b6bdf53b84c2a79</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2F0-306-47384-4_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F0-306-47384-4_13%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DAristoff%26aufirst%3DP.%2BA.%26aulast%3DJensen%26aufirst%3DR.%2BK.%26aulast%3DMorozowich%26aufirst%3DW.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26aulast%3DSchinzer%26aufirst%3DW.%2BC.%26aulast%3DTarpley%26aufirst%3DW.%2BG.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26atitle%3DDiscovery%2520and%2520development%2520of%2520the%2520BHAP%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520delavirdine%2520mesylate%26jtitle%3DPharm.%2520Biotechnol.%26date%3D1998%26volume%3D11%26spage%3D285%26epage%3D312%26doi%3D10.1007%2F0-306-47384-4_13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackland, M. J.</span></span> <span> </span><span class="NLM_article-title">Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">631</span>– <span class="NLM_lpage">639</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=631-639&issue=7&author=R.+L.+Voormanauthor=S.+M.+Maioauthor=M.+J.+Hauerauthor=P.+E.+Sandersauthor=N.+A.+Payneauthor=M.+J.+Ackland&title=Metabolism+of+delavirdine%2C+a+human+immunodeficiency+virus+type-1+reverse+transcriptase+inhibitor%2C+by+microsomal+cytochrome+P450+in+humans%2C+rats%2C+and+other+species%3A+probable+involvement+of+CYP2D6+and+CYP3A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DMaio%26aufirst%3DS.%2BM.%26aulast%3DHauer%26aufirst%3DM.%2BJ.%26aulast%3DSanders%26aufirst%3DP.%2BE.%26aulast%3DPayne%26aufirst%3DN.%2BA.%26aulast%3DAckland%26aufirst%3DM.%2BJ.%26atitle%3DMetabolism%2520of%2520delavirdine%252C%2520a%2520human%2520immunodeficiency%2520virus%2520type-1%2520reverse%2520transcriptase%2520inhibitor%252C%2520by%2520microsomal%2520cytochrome%2520P450%2520in%2520humans%252C%2520rats%252C%2520and%2520other%2520species%253A%2520probable%2520involvement%2520of%2520CYP2D6%2520and%2520CYP3A%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1998%26volume%3D26%26issue%3D7%26spage%3D631%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeplinger, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>287</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9765359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXmvVWjsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1998&pages=381-388&issue=1&author=R.+L.+Voormanauthor=S.+M.+Maioauthor=N.+A.+Payneauthor=Z.+Zhaoauthor=K.+A.+Koeplingerauthor=X.+Wang&title=Microsomal+metabolism+of+delavirdine%3A+evidence+for+mechanism-based+inactivation+of+human+cytochrome+P450+3A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A</span></div><div class="casAuthors">Voorman, Richard L.; Maio, Stephen M.; Payne, N. Ann; Zhao, Zhiyang; Koeplinger, Kenneth A.; Wang, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">381-388</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Administration of delavirdine, an HIV-1 reverse transcriptase inhibitor, to rats or monkeys resulted in apparent loss of hepatic microsomal CYP3A and delavirdine desalkylation activity.  Human CYP3A catalyzes the formation of desalkyl delavirdine and 6'-hydroxy delavirdine, an unstable metabolite, while CYP2D6 catalyzes only desalkyl delavirdine.  CYP2D6 catalyzed desalkyl delavirdine formation was linear with time (up to 30 min) but when catalyzed by cDNA expressed CYP3A4 or human liver microsomes the reaction rate declined progressively with time.  Coincubation with triazolam showed that delavirdine caused a time- and NADPH-dependent loss of CYP3A4 activity in human liver microsomes as measured by triazolam 1'-hydroxylation.  The catalytic activity loss was saturable and was characterized by a Ki of 21.6 ± 8.9 μM and a kinact of 0.59 ± 0.08 min-1.  An apparent partition ratio of 41 was detd. with cDNA expressed CYP3A4, based on the substrate depletion method.  Incubation of [14C]delavirdine with microsomes from several species resulted in irreversible assocn. with an approx. 50 kDa protein, as demonstrated by SDS-PAGE/autoradiog.  Binding to the protein was NADPH dependent, glutathione insensitive, proportional to the level of CYP3A expression and was inhibited by ketoconazole, a specific CYP3A inhibitor.  NADPH-dependent irreversible binding to human and rat total microsomal protein was demonstrated following exhaustive extn. of microsomal protein.  Binding was decreased in the presence of glutathione and appeared to be related to expression level of CYP3A.  These results suggest that delavirdine can inactivate CYP3A and has the potential to slow the metab. of coadministered CYP3A substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVcNMcMAupVrVg90H21EOLACvtfcHk0lgkw2-TrDlTEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvVWjsrw%253D&md5=983063cb9537f05935b728d0add5246e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DMaio%26aufirst%3DS.%2BM.%26aulast%3DPayne%26aufirst%3DN.%2BA.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DKoeplinger%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DMicrosomal%2520metabolism%2520of%2520delavirdine%253A%2520evidence%2520for%2520mechanism-based%2520inactivation%2520of%2520human%2520cytochrome%2520P450%25203A%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D287%26issue%3D1%26spage%3D381%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esnouf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. I.</span></span> <span> </span><span class="NLM_article-title">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3984</span>– <span class="NLM_lpage">3989</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.8.3984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.94.8.3984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=9108091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=3984-3989&issue=8&author=R.+M.+Esnoufauthor=J.+Renauthor=A.+L.+Hopkinsauthor=C.+K.+Rossauthor=E.+Y.+Jonesauthor=D.+K.+Stammersauthor=D.+I.+Stuart&title=Unique+features+in+the+structure+of+the+complex+between+HIV-1+reverse+transcriptase+and+the+bis%28heteroaryl%29piperazine+%28BHAP%29+U-90152+explain+resistance+mutations+for+this+nonnucleoside+inhibitor&doi=10.1073%2Fpnas.94.8.3984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor</span></div><div class="casAuthors">Esnouf, Robert M.; Ren, Jingshan; Hopkins, Andrew L.; Ross, Carl K.; Jones, E. Yvonne; Stammers, David K.; Stuart, David I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3984-3989</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The viral reverse transcriptase (RT) provides an attractive target in the search for anti-HIV therapies.  The nonnucleoside inhibitors (NNIs) are a diverse set of compds. (usually HIV-1 specific) that function by distorting the polymerase active site upon binding in a nearby pocket.  Despite being potent and of generally low toxicity, their clin. use has been limited by rapid selection for resistant viral populations.  The 2.65-Å resoln. structure of the complex between HIV-1 RT and the bis(heteroaryl)piperazine (BHAP) NNI, 1-(5-methanesulfonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methyl-ethylamino)pyridinyl] piperazine (U-90152), reveals the inhibitor conformation and bound water mols.  The bulky U-90152 mol. occupies the same pocket as other NNIs, but the complex is stabilized quite differently, in particular by hydrogen bonding to the main chain of Lys-103 and extensive hydrophobic contacts with Pro-236.  These interactions rationalize obsd. resistance mutations, notably Pro-236-Leu, which occurs characteristically for BHAPs.  When bound, part of U-90152 protrudes into the solvent creating a channel between Pro-236 and the polypeptide segments 225-226 and 105-106, giving the first clear evidence of the entry mode for NNIs.  The structure allows prediction of binding modes for related inhibitors [(altrylamino)piperidine-BHAPs] and suggests changes to U-90152, such as the addn. of a 6 amino group to the pyridine ring, which may make binding more resilient to mutations in the RT.  The observation of novel hydrogen bonding to the protein main chain may provide lessons for the improvement of quite different inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQuIdPkm-oLVg90H21EOLACvtfcHk0lgkw2-TrDlTEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ehuro%253D&md5=d9027e0d3dc8ad612fb84d9e98b7f30e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.8.3984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.8.3984%26sid%3Dliteratum%253Aachs%26aulast%3DEsnouf%26aufirst%3DR.%2BM.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DRoss%26aufirst%3DC.%2BK.%26aulast%3DJones%26aufirst%3DE.%2BY.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DStuart%26aufirst%3DD.%2BI.%26atitle%3DUnique%2520features%2520in%2520the%2520structure%2520of%2520the%2520complex%2520between%2520HIV-1%2520reverse%2520transcriptase%2520and%2520the%2520bis%2528heteroaryl%2529piperazine%2520%2528BHAP%2529%2520U-90152%2520explain%2520resistance%2520mutations%2520for%2520this%2520nonnucleoside%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26issue%3D8%26spage%3D3984%26epage%3D3989%26doi%3D10.1073%2Fpnas.94.8.3984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biles, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopta, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reusser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmsted, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, D. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">5267</span>– <span class="NLM_lpage">5275</span>, <span class="refDoi"> DOI: 10.1021/jm960269m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960269m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=5267-5275&issue=26&author=M.+J.+Geninauthor=T.+J.+Poelauthor=Y.+Yagiauthor=C.+Bilesauthor=I.+Althausauthor=B.+J.+Keiserauthor=L.+A.+Koptaauthor=J.+M.+Friisauthor=F.+Reusserauthor=W.+J.+Adamsauthor=R.+A.+Olmstedauthor=R.+L.+Voormanauthor=R.+C.+Thomasauthor=D.+L.+Romero&title=Synthesis+and+bioactivity+of+novel+bis%28heteroaryl%29piperazine+%28BHAP%29+reverse+transcriptase+inhibitors%3A+structure-activity+relationships+and+increased+metabolic+stability+of+novel+substituted+pyridine+analogs&doi=10.1021%2Fjm960269m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm960269m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960269m%26sid%3Dliteratum%253Aachs%26aulast%3DGenin%26aufirst%3DM.%2BJ.%26aulast%3DPoel%26aufirst%3DT.%2BJ.%26aulast%3DYagi%26aufirst%3DY.%26aulast%3DBiles%26aufirst%3DC.%26aulast%3DAlthaus%26aufirst%3DI.%26aulast%3DKeiser%26aufirst%3DB.%2BJ.%26aulast%3DKopta%26aufirst%3DL.%2BA.%26aulast%3DFriis%26aufirst%3DJ.%2BM.%26aulast%3DReusser%26aufirst%3DF.%26aulast%3DAdams%26aufirst%3DW.%2BJ.%26aulast%3DOlmsted%26aufirst%3DR.%2BA.%26aulast%3DVoorman%26aufirst%3DR.%2BL.%26aulast%3DThomas%26aufirst%3DR.%2BC.%26aulast%3DRomero%26aufirst%3DD.%2BL.%26atitle%3DSynthesis%2520and%2520bioactivity%2520of%2520novel%2520bis%2528heteroaryl%2529piperazine%2520%2528BHAP%2529%2520reverse%2520transcriptase%2520inhibitors%253A%2520structure-activity%2520relationships%2520and%2520increased%2520metabolic%2520stability%2520of%2520novel%2520substituted%2520pyridine%2520analogs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26issue%3D26%26spage%3D5267%26epage%3D5275%26doi%3D10.1021%2Fjm960269m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meehan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holden-Wiltse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischl, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimuth, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Para, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichman, R. C.</span></span> <span> </span><span class="NLM_article-title">Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">794</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.3.794-797.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.44.3.794-797.2000" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=794-797&issue=3&author=L.+M.+Demeterauthor=R.+W.+Shaferauthor=P.+M.+Meehanauthor=J.+Holden-Wiltseauthor=M.+A.+Fischlauthor=W.+W.+Freimuthauthor=M.+F.+Paraauthor=R.+C.+Reichman&title=Delavirdine+susceptibilities+and+associated+reverse+transcriptase+mutations+in+human+immunodeficiency+virus+type+1+isolates+from+patients+in+a+phase+I%2FII+trial+of+delavirdine+monotherapy+%28ACTG+260%29&doi=10.1128%2FAAC.44.3.794-797.2000"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.3.794-797.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.3.794-797.2000%26sid%3Dliteratum%253Aachs%26aulast%3DDemeter%26aufirst%3DL.%2BM.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DMeehan%26aufirst%3DP.%2BM.%26aulast%3DHolden-Wiltse%26aufirst%3DJ.%26aulast%3DFischl%26aufirst%3DM.%2BA.%26aulast%3DFreimuth%26aufirst%3DW.%2BW.%26aulast%3DPara%26aufirst%3DM.%2BF.%26aulast%3DReichman%26aufirst%3DR.%2BC.%26atitle%3DDelavirdine%2520susceptibilities%2520and%2520associated%2520reverse%2520transcriptase%2520mutations%2520in%2520human%2520immunodeficiency%2520virus%2520type%25201%2520isolates%2520from%2520patients%2520in%2520a%2520phase%2520I%252FII%2520trial%2520of%2520delavirdine%2520monotherapy%2520%2528ACTG%2520260%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26issue%3D3%26spage%3D794%26epage%3D797%26doi%3D10.1128%2FAAC.44.3.794-797.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerondelis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palaniappan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bambara, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, L. M.</span></span> <span> </span><span class="NLM_article-title">The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">5803</span>– <span class="NLM_lpage">5813</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10364332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFyktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1999&pages=5803-5813&issue=7&author=P.+Gerondelisauthor=R.+H.+Archerauthor=C.+Palaniappanauthor=R.+C.+Reichmanauthor=P.+J.+Fayauthor=R.+A.+Bambaraauthor=L.+M.+Demeter&title=The+P236L+delavirdine-resistant+human+immunodeficiency+virus+type+1+mutant+is+replication+defective+and+demonstrates+alterations+in+both+RNA+5%E2%80%B2-end-+and+DNA+3%E2%80%B2-end-directed+RNase+H+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities</span></div><div class="casAuthors">Gerondelis, Peter; Archer, Richard H.; Palaniappan, Chockalingam; Reichman, Richard C.; Fay, Philip J.; Bambara, Robert A.; Demeter, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">5803-5813</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) delavirdine (DLV) selects in vitro for the human immunodeficiency virus type 1 (HIV-1) RT mutation P236L, which confers high-level resistance to DLV but not other NNRTIs.  Unexpectedly, P236L has developed infrequently in HIV-1 isolates obtained from patients receiving DLV; K103N is the predominant resistance mutation obsd. in that setting.  We characterized the replication fitness of viruses derived from pNL4-3 contg. P236L or K103N in both H9 and primary human peripheral blood mononuclear cell cultures infected in parallel with the two mutants.  In the absence of DLV, p24 prodn. by wild-type virus occurred more rapidly and to higher levels than with either mutant; P236L consistently demonstrated a two- to threefold decrease in p24 relative to K103N.  At low levels of DLV, growth of wild-type virus was severely inhibited, and K103N replicated two- to threefold more efficiently than P236L.  At high concns. of DLV, P236L replication and K103N replication were both inhibited.  Recombinant RTs contg. K103N or P236L were analyzed for DNA polymn. on heteropolymeric RNA templates and RNase H degrdn. of RNA-DNA hybrids.  Neither mutant demonstrated defects in polymn.  K103N demonstrated normal RNA 5'-end-directed RNase H cleavage and slowed DNA 3'-end-directed RNase H cleavage compared to wild-type RT.  P236L demonstrated slowing of both DNA 3'-end- and RNA 5'-end-directed RNase H cleavage, consistent with its reduced replication efficiency relative to K103N.  These data suggest that NNRTI resistance mutations can lead to redns. in the efficiency of RNase H cleavage, which may contribute to a redn. in the replication fitness of HIV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCEI3Ul0ZvFLVg90H21EOLACvtfcHk0lgA5TZc_n4i1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFyktrg%253D&md5=d5590756f7d2cd380830b836a02b743e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerondelis%26aufirst%3DP.%26aulast%3DArcher%26aufirst%3DR.%2BH.%26aulast%3DPalaniappan%26aufirst%3DC.%26aulast%3DReichman%26aufirst%3DR.%2BC.%26aulast%3DFay%26aufirst%3DP.%2BJ.%26aulast%3DBambara%26aufirst%3DR.%2BA.%26aulast%3DDemeter%26aufirst%3DL.%2BM.%26atitle%3DThe%2520P236L%2520delavirdine-resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%2520mutant%2520is%2520replication%2520defective%2520and%2520demonstrates%2520alterations%2520in%2520both%2520RNA%25205%25E2%2580%25B2-end-%2520and%2520DNA%25203%25E2%2580%25B2-end-directed%2520RNase%2520H%2520activities%26jtitle%3DJ.%2520Virol.%26date%3D1999%26volume%3D73%26issue%3D7%26spage%3D5803%26epage%3D5813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavash, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenstein, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2550</span>– <span class="NLM_lpage">2560</span>, <span class="refDoi"> DOI: 10.1021/jm030558s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030558s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisl2it70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2550-2560&issue=10&author=K.+Dasauthor=A.+D.+Clarkauthor=P.+J.+Lewiauthor=J.+Heeresauthor=M.+R.+De+Jongeauthor=L.+M.+Koymansauthor=H.+M.+Vinkersauthor=F.+Daeyaertauthor=D.+W.+Ludoviciauthor=M.+J.+Kuklaauthor=B.+De+Corteauthor=R.+W.+Kavashauthor=C.+Y.+Hoauthor=H.+Yeauthor=M.+A.+Lichtensteinauthor=K.+Andriesauthor=R.+Pauwelsauthor=M.+P.+De+Bethuneauthor=P.+L.+Boyerauthor=P.+Clarkauthor=S.+H.+Hughesauthor=P.+A.+Janssenauthor=E.+Arnold&title=Roles+of+conformational+and+positional+adaptability+in+structure-based+design+of+TMC125-R165335+%28etravirine%29+and+related+non-nucleoside+reverse+transcriptase+inhibitors+that+are+highly+potent+and+effective+against+wild-type+and+drug-resistant+HIV-1+variants&doi=10.1021%2Fjm030558s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants</span></div><div class="casAuthors">Das, Kalyan; Clark, Arthur D., Jr.; Lewi, Paul J.; Heeres, Jan; De Jonge, Marc R.; Koymans, Lucien M. H.; Vinkers, H. Maarten; Daeyaert, Frederik; Ludovici, Donald W.; Kukla, Michael J.; De Corte, Bart; Kavash, Robert W.; Ho, Chih Y.; Ye, Hong; Lichtenstein, Mark. A.; Andries, Koen; Pauwels, Rudi; De Bethune, Marie-Pierre; Boyer, Paul L.; Clark, Patrick; Hughes, Stephen H.; Janssen, Paul A. J.; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2550-2560</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anti-AIDS drug candidate and non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125-R165335 (etravirine) caused an initial drop in viral load similar to that obsd. with a five-drug combination in naive patients and retains potency in patients infected with NNRTI-resistant HIV-1 variants.  TMC125-R165335 and related anti-AIDS drug candidates can bind the enzyme RT in multiple conformations and thereby escape the effects of drug-resistance mutations.  Structural studies showed that this inhibitor and other diarylpyrimidine (DAPY) analogs can adapt to changes in the NNRTI-binding pocket in several ways: (1) DAPY analogs can bind in at least two conformationally distinct modes; (2) within a given binding mode, torsional flexibility ("wiggling") of DAPY analogs permits access to numerous conformational variants; and (3) the compact design of the DAPY analogs permits significant repositioning and reorientation (translation and rotation) within the pocket ("jiggling").  Such adaptations appear to be crit. for potency against wild-type and a wide range of drug-resistant mutant HIV-1 RTs.  Exploitation of favorable components of inhibitor conformational flexibility (such as torsional flexibility about strategically located chem. bonds) can be a powerful drug design concept, esp. for designing drugs that will be effective against rapidly mutating targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNFqXwggOSMLVg90H21EOLACvtfcHk0lgA5TZc_n4i1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisl2it70%253D&md5=56c2fce83bead1990e138ee7486a373d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm030558s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030558s%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DDe%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3DVinkers%26aufirst%3DH.%2BM.%26aulast%3DDaeyaert%26aufirst%3DF.%26aulast%3DLudovici%26aufirst%3DD.%2BW.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BCorte%26aufirst%3DB.%26aulast%3DKavash%26aufirst%3DR.%2BW.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DLichtenstein%26aufirst%3DM.%2BA.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DDe%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DClark%26aufirst%3DP.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DRoles%2520of%2520conformational%2520and%2520positional%2520adaptability%2520in%2520structure-based%2520design%2520of%2520TMC125-R165335%2520%2528etravirine%2529%2520and%2520related%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520that%2520are%2520highly%2520potent%2520and%2520effective%2520against%2520wild-type%2520and%2520drug-resistant%2520HIV-1%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D10%26spage%3D2550%26epage%3D2560%26doi%3D10.1021%2Fjm030558s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uhlmann, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storch, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lie, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcomb, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arens, M. Q.</span></span> <span> </span><span class="NLM_article-title">Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine</span>. <i>J. Clin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.jcv.2004.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.jcv.2004.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15465412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFCksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2004&pages=198-203&issue=3&author=E.+J.+Uhlmannauthor=P.+Tebasauthor=G.+A.+Storchauthor=W.+G.+Powderlyauthor=Y.+S.+Lieauthor=J.+M.+Whitcombauthor=N.+S.+Hellmannauthor=M.+Q.+Arens&title=Effects+of+the+G190A+substitution+of+HIV+reverse+transcriptase+on+phenotypic+susceptibility+of+patient+isolates+to+delavirdine&doi=10.1016%2Fj.jcv.2004.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine</span></div><div class="casAuthors">Uhlmann, Erik J.; Tebas, Pablo; Storch, Gregory A.; Powderly, William G.; Lie, Yolanda S.; Whitcomb, Jeannette M.; Hellmann, Nicholas S.; Arens, Max Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">JCVIFB</span>;
        ISSN:<span class="NLM_cas:issn">1386-6532</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background: Cross resistance is common among the non-nucleoside reverse transcriptase inhibitors (NNRTIs).  G190A appears in 5-15% of the patients treated with nevirapine or efavirenz who develop clin. resistance.  Objectives: In this study we investigated the effect of G190A and other NNRTI substitutions on the phenotypic susceptibility to this class of drugs.  Study design: We identified 15 individuals, who after treatment with NNRTIs (nevirapine or efavirenz; median exposure of 20 mo), developed isolated G190A, G190A in combination with K103N, or K103N alone.  Phenotypic and genotypic analyses of stored plasma specimens were performed before and after the mutations occurred to assess NNRTI susceptibility.  Results: All isolates that developed only G190A substitution became less susceptible to nevirapine (median: 125-fold) and efavirenz (median: 10-fold) but were 2.5-fold more sensitive to delavirdine (Wilcoxon P=0.06).  In the group with only K103N substitution, acquisition of resistance to all NNRTIs was obsd.  In the group with the double substitutions, G190A and K103N, delavirdine susceptibility decreased 13-fold, while resistance to nevirapine and efavirenz decreased by 239- and 154-folds, resp. (Kruskal-Wallis H P=0.009).  Conclusions: The data suggest that the presence of a G190A substitution attenuates the phenotypic resistance assocd. with a K103N substitution, although resistance is still present.  The in vivo significance of the increased phenotypic susceptibility to delavirdine is not known but could be evaluated in a clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo3wqcU6Uc-bVg90H21EOLACvtfcHk0lgbUU2Tx-bXkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFCksLs%253D&md5=b1bef723a89d73d3d78c49f17fc5d40e</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.jcv.2004.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcv.2004.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DUhlmann%26aufirst%3DE.%2BJ.%26aulast%3DTebas%26aufirst%3DP.%26aulast%3DStorch%26aufirst%3DG.%2BA.%26aulast%3DPowderly%26aufirst%3DW.%2BG.%26aulast%3DLie%26aufirst%3DY.%2BS.%26aulast%3DWhitcomb%26aufirst%3DJ.%2BM.%26aulast%3DHellmann%26aufirst%3DN.%2BS.%26aulast%3DArens%26aufirst%3DM.%2BQ.%26atitle%3DEffects%2520of%2520the%2520G190A%2520substitution%2520of%2520HIV%2520reverse%2520transcriptase%2520on%2520phenotypic%2520susceptibility%2520of%2520patient%2520isolates%2520to%2520delavirdine%26jtitle%3DJ.%2520Clin.%2520Virol.%26date%3D2004%26volume%3D31%26issue%3D3%26spage%3D198%26epage%3D203%26doi%3D10.1016%2Fj.jcv.2004.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Delavirdine: a review of its use in HIV infection</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1411</span>– <span class="NLM_lpage">1444</span>, <span class="refDoi"> DOI: 10.2165/00003495-200060060-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F00003495-200060060-00013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1411-1444&issue=6&author=L.+J.+Scottauthor=C.+M.+Perry&title=Delavirdine%3A+a+review+of+its+use+in+HIV+infection&doi=10.2165%2F00003495-200060060-00013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2165%2F00003495-200060060-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200060060-00013%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DDelavirdine%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520HIV%2520infection%26jtitle%3DDrugs%26date%3D2000%26volume%3D60%26issue%3D6%26spage%3D1411%26epage%3D1444%26doi%3D10.2165%2F00003495-200060060-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. T.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaitt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimuth, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falloon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wathen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daenzer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. C.</span></span> <span> </span><span class="NLM_article-title">Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1657</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.1128/AAC.40.7.1657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.40.7.1657" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1996&pages=1657-1664&issue=7&author=R.+T.+Daveyauthor=D.+G.+Chaittauthor=G.+F.+Reedauthor=W.+W.+Freimuthauthor=B.+R.+Herpinauthor=J.+A.+Metcalfauthor=P.+S.+Eastmanauthor=J.+Falloonauthor=J.+A.+Kovacsauthor=M.+A.+Polisauthor=R.+E.+Walkerauthor=H.+Masurauthor=J.+Boyleauthor=S.+Colemanauthor=S.+R.+Coxauthor=L.+Wathenauthor=C.+L.+Daenzerauthor=H.+C.+Lane&title=Randomized%2C+controlled+phase+I%2FII%2C+trial+of+combination+therapy+with+delavirdine+%28U-90152S%29+and+conventional+nucleosides+in+human+immunodeficiency+virus+type+1-infected+patients&doi=10.1128%2FAAC.40.7.1657"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.40.7.1657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.40.7.1657%26sid%3Dliteratum%253Aachs%26aulast%3DDavey%26aufirst%3DR.%2BT.%26aulast%3DChaitt%26aufirst%3DD.%2BG.%26aulast%3DReed%26aufirst%3DG.%2BF.%26aulast%3DFreimuth%26aufirst%3DW.%2BW.%26aulast%3DHerpin%26aufirst%3DB.%2BR.%26aulast%3DMetcalf%26aufirst%3DJ.%2BA.%26aulast%3DEastman%26aufirst%3DP.%2BS.%26aulast%3DFalloon%26aufirst%3DJ.%26aulast%3DKovacs%26aufirst%3DJ.%2BA.%26aulast%3DPolis%26aufirst%3DM.%2BA.%26aulast%3DWalker%26aufirst%3DR.%2BE.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DBoyle%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DS.%26aulast%3DCox%26aufirst%3DS.%2BR.%26aulast%3DWathen%26aufirst%3DL.%26aulast%3DDaenzer%26aufirst%3DC.%2BL.%26aulast%3DLane%26aufirst%3DH.%2BC.%26atitle%3DRandomized%252C%2520controlled%2520phase%2520I%252FII%252C%2520trial%2520of%2520combination%2520therapy%2520with%2520delavirdine%2520%2528U-90152S%2529%2520and%2520conventional%2520nucleosides%2520in%2520human%2520immunodeficiency%2520virus%2520type%25201-infected%2520patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1996%26volume%3D40%26issue%3D7%26spage%3D1657%26epage%3D1664%26doi%3D10.1128%2FAAC.40.7.1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Been-Tiktak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun-Vezinet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatell, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staszewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colebunders, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borleffs, J. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/S0924-8579(98)00082-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0924-8579%2898%2900082-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10075273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFSltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=13-21&issue=1&author=A.+M.+Been-Tiktakauthor=C.+A.+Boucherauthor=F.+Brun-Vezinetauthor=V.+Jolyauthor=J.+W.+Mulderauthor=J.+Jostauthor=D.+A.+Cooperauthor=M.+Moroniauthor=J.+M.+Gatellauthor=S.+Staszewskiauthor=R.+Colebundersauthor=G.+J.+Stewartauthor=D.+A.+Hawkinsauthor=M.+A.+Johnsonauthor=J.+M.+Parkinauthor=D.+H.+Kennedyauthor=J.+F.+Hoyauthor=J.+C.+Borleffs&title=Efficacy+and+safety+of+combination+therapy+with+delavirdine+and+zidovudine%3A+a+European%2FAustralian+phase+II+trial&doi=10.1016%2FS0924-8579%2898%2900082-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial</span></div><div class="casAuthors">Been-Tiktak, Anne M. M.; Boucher, Charles A. B.; Brun-Vezinet, Francoise; Joly, Veronique; Mulder, Jan W.; Jost, J.; Cooper, David A.; Moroni, Mauro; Gatell, Jose M.; Staszewski, Schlomo; Colebunders, Robert; Stewart, Graeme J.; Hawkins, David A.; Johnson, Margaret A.; Parkin, Jacqueline M.; Kennedy, Dermot H.; Hoy, Jennifer F.; Borleffs, Jan C. C.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-21</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">This study investigated the safety and antiviral effect of 3 delavirdine dose regimens or placebo in combination with zidovudine in patients who were already taking zidovudine.  Eighty-nine symptomatic HIV-1 seropos. individuals with CD4+ cell counts between 50 and 350 cells/μL were included. The influence of combination therapy on viral susceptibility to both zidovudine and delavirdine was investigated.  Death or the occurrence, or recurrence, of an AIDS-defining illness was considered as a clin. endpoint.  The addn. of delavirdine to the antiretroviral treatment regimen resulted in a significant, but transient, redn. in virus load, as detd. by quant. RNA measurements.  CD4+ cell count did not change significantly.  Susceptibility to zidovudine remained unchanged after 12 wk of combination therapy, whereas 70% of the patients demonstrated a substantial decrease in sensitivity to delavirdine.  Two patients suffered from an AIDS-defining disease during the study.  No deaths occurred.  Generally, the drug appeared to be safe.  Skin rash was the most frequently obsd. event (52%).  In most patients the rash either resolved spontaneously or was treated successfully with a short course of antihistamines.  The definite place of delavirdine in the management of HIV disease, in particular when given in combination with other antiretroviral agents, remains to be further explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUnITOBIUTbVg90H21EOLACvtfcHk0lgbUU2Tx-bXkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFSltb8%253D&md5=ddd83610ba03a6d38ceecd06627c948a</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS0924-8579%2898%2900082-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-8579%252898%252900082-X%26sid%3Dliteratum%253Aachs%26aulast%3DBeen-Tiktak%26aufirst%3DA.%2BM.%26aulast%3DBoucher%26aufirst%3DC.%2BA.%26aulast%3DBrun-Vezinet%26aufirst%3DF.%26aulast%3DJoly%26aufirst%3DV.%26aulast%3DMulder%26aufirst%3DJ.%2BW.%26aulast%3DJost%26aufirst%3DJ.%26aulast%3DCooper%26aufirst%3DD.%2BA.%26aulast%3DMoroni%26aufirst%3DM.%26aulast%3DGatell%26aufirst%3DJ.%2BM.%26aulast%3DStaszewski%26aufirst%3DS.%26aulast%3DColebunders%26aufirst%3DR.%26aulast%3DStewart%26aufirst%3DG.%2BJ.%26aulast%3DHawkins%26aufirst%3DD.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DParkin%26aufirst%3DJ.%2BM.%26aulast%3DKennedy%26aufirst%3DD.%2BH.%26aulast%3DHoy%26aufirst%3DJ.%2BF.%26aulast%3DBorleffs%26aufirst%3DJ.%2BC.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520combination%2520therapy%2520with%2520delavirdine%2520and%2520zidovudine%253A%2520a%2520European%252FAustralian%2520phase%2520II%2520trial%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D1999%26volume%3D11%26issue%3D1%26spage%3D13%26epage%3D21%26doi%3D10.1016%2FS0924-8579%2898%2900082-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freimuth, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischl, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1097/00126334-199908010-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-199908010-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10428106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjtl2ktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=281-292&issue=4&author=G.+H.+Friedlandauthor=R.+Pollardauthor=B.+Griffithauthor=M.+Hughesauthor=G.+Morseauthor=R.+Bassettauthor=W.+Freimuthauthor=L.+Demeterauthor=E.+Connickauthor=T.+Nevinauthor=M.+Hirschauthor=M.+Fischl&title=Efficacy+and+safety+of+delavirdine+mesylate+with+zidovudine+and+didanosine+compared+with+two-drug+combinations+of+these+agents+in+persons+with+HIV+disease+with+CD4+counts+of+100+to+500+cells%2Fmm3+%28ACTG+261%29.+ACTG+261+Team&doi=10.1097%2F00126334-199908010-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)</span></div><div class="casAuthors">Friedland, Gerald H.; Pollard, Richard; Griffith, Brigitte; Hughes, Michael; Morse, Gene; Bassett, Roland; Freimuth, William; Demeter, Lisa; Connick, Elizabeth; Nevin, Thomas; Hirsch, Martin</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">281-292</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">To evaluate the antiretroviral activity of delavirdine mesylate, a non-nucleoside reverse transcriptase inhibitor of HIV-1, we performed a phase II, randomized, double-blind, multicenter trial comparing the three-drug combination of delavirdine with zidovudine and didanosine to two-drug combinations of these drugs.  Patients with CD4 cell counts between 100 and 500 cells/mm3 without prior or <6 mo of monotherapy with zidovudine or didanosine were randomized to one of four arms and obsd. on a follow-up basis for 48 wk.  In total, 544 patients were evaluated.  In those assigned to the three-drug regimen, mean short-term (weeks 4-12) and long-term (weeks 40-48) change in CD4 cells from baseline were 49.3 ± 8.1 and 65.4 ± 13.4 cells/mm3, resp.; mean short-term and long-term HIV-1 RNA changes from baseline were -1.13 log10 ± 0.12 and -0.73 ± 0.12 copies/mL, resp.  These responses in CD4 cell counts and HIV-1 RNA levels were better in comparisons with each of the two-drug arms at all study points; however, differences were not consistently significant.  Gastrointestinal side effects were experienced by 33% of patients (178 of 544), and 30% (121 of 407) receiving delavirdine experienced rash, only one case of which was severe.  In this study, therapy with delavirdine + zidovudine + didanosine was safe and showed modest, but not always significant, antiviral activity and CD4 cell count benefit compared with two-drug regimens with these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtB-x7g_IH17Vg90H21EOLACvtfcHk0lgZZiEA7QPF8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjtl2ktLs%253D&md5=18f178c4c1119c0411d3e1cd04b09259</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1097%2F00126334-199908010-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-199908010-00005%26sid%3Dliteratum%253Aachs%26aulast%3DFriedland%26aufirst%3DG.%2BH.%26aulast%3DPollard%26aufirst%3DR.%26aulast%3DGriffith%26aufirst%3DB.%26aulast%3DHughes%26aufirst%3DM.%26aulast%3DMorse%26aufirst%3DG.%26aulast%3DBassett%26aufirst%3DR.%26aulast%3DFreimuth%26aufirst%3DW.%26aulast%3DDemeter%26aufirst%3DL.%26aulast%3DConnick%26aufirst%3DE.%26aulast%3DNevin%26aufirst%3DT.%26aulast%3DHirsch%26aufirst%3DM.%26aulast%3DFischl%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520delavirdine%2520mesylate%2520with%2520zidovudine%2520and%2520didanosine%2520compared%2520with%2520two-drug%2520combinations%2520of%2520these%2520agents%2520in%2520persons%2520with%2520HIV%2520disease%2520with%2520CD4%2520counts%2520of%2520100%2520to%2520500%2520cells%252Fmm3%2520%2528ACTG%2520261%2529.%2520ACTG%2520261%2520Team%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D1999%26volume%3D21%26issue%3D4%26spage%3D281%26epage%3D292%26doi%3D10.1097%2F00126334-199908010-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span> <i>Current and Resolved Drug Shortages and Discontinuations
Reported
to FDA</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Delavirdine%20Mesylate%20(RESCRIPTOR)%20Tablets&amp;st=d" class="extLink">https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Delavirdine%20Mesylate%20(RESCRIPTOR)%20Tablets&st=d</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Current+and+Resolved+Drug+Shortages+and+Discontinuations%0AReported%0Ato+FDA%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fdrugshortages%2Fdsp_ActiveIngredientDetails.cfm%3FAI%3DDelavirdine%2520Mesylate%2520%28RESCRIPTOR%29%2520Tablets%26st%3Dd+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520and%2520Resolved%2520Drug%2520Shortages%2520and%2520Discontinuations%250AReported%250Ato%2520FDA%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt Huffman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korthuis, P. T.</span></span> <span> </span><span class="NLM_article-title">Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>368</i></span> (<span class="NLM_issue">9546</span>),  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(06)69638-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2806%2969638-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1503-1515&issue=9546&author=R.+Chouauthor=R.+Fuauthor=L.+H.+Hoyt+Huffmanauthor=P.+T.+Korthuis&title=Initial+highly-active+antiretroviral+therapy+with+a+protease+inhibitor+versus+a+non-nucleoside+reverse+transcriptase+inhibitor%3A+discrepancies+between+direct+and+indirect+meta-analyses&doi=10.1016%2FS0140-6736%2806%2969638-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969638-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969638-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DR.%26aulast%3DHoyt%2BHuffman%26aufirst%3DL.%2BH.%26aulast%3DKorthuis%26aufirst%3DP.%2BT.%26atitle%3DInitial%2520highly-active%2520antiretroviral%2520therapy%2520with%2520a%2520protease%2520inhibitor%2520versus%2520a%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%253A%2520discrepancies%2520between%2520direct%2520and%2520indirect%2520meta-analyses%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26issue%3D9546%26spage%3D1503%26epage%3D1515%26doi%3D10.1016%2FS0140-6736%2806%2969638-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenjie, S.</span>; <span class="NLM_string-name">Xuhua, X.</span>; <span class="NLM_string-name">Weiyong, M.</span></span> <span> </span><span class="NLM_article-title">Preparing Method of 1-(5-nitro-1<i>H</i>-indole-2-carbonyl)-4-{3-[(1-methylethyl)amino]-2-pyridine}</span>. China Patent <span class="NLM_patent">CN101016295A</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Wenjie&author=X.+Xuhua&author=M.+Weiyong&title=Preparing+Method+of+1-%285-nitro-1H-indole-2-carbonyl%29-4-%7B3-%5B%281-methylethyl%29amino%5D-2-pyridine%7D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWenjie%26aufirst%3DS.%26atitle%3DPreparing%2520Method%2520of%25201-%25285-nitro-1H-indole-2-carbonyl%2529-4-%257B3-%255B%25281-methylethyl%2529amino%255D-2-pyridine%257D%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ensi, W.</span>; <span class="NLM_string-name">Jing, G.</span>; <span class="NLM_string-name">Shengxiu, N.</span>; <span class="NLM_string-name">Nan, Z.</span>; <span class="NLM_string-name">Liping, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of Delavirdine</span>. China Patent <span class="NLM_patent">CN102675284A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=W.+Ensi&author=G.+Jing&author=N.+Shengxiu&author=Z.+Nan&author=J.+Liping&title=Synthesis+Method+of+Delavirdine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEnsi%26aufirst%3DW.%26atitle%3DSynthesis%2520Method%2520of%2520Delavirdine%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of anti-AIDS Medicine Delavirdine</span>. China Patent <span class="NLM_patent">CN102633778A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=G.+Min&title=Synthesis+Method+of+anti-AIDS+Medicine+Delavirdine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DG.%26atitle%3DSynthesis%2520Method%2520of%2520anti-AIDS%2520Medicine%2520Delavirdine%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britcher, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumma, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span> <span> </span><span class="NLM_article-title">L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2602</span>– <span class="NLM_lpage">2605</span>, <span class="refDoi"> DOI: 10.1128/AAC.39.12.2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.39.12.2602" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1995&pages=2602-2605&issue=12&author=S.+D.+Youngauthor=S.+F.+Britcherauthor=L.+O.+Tranauthor=L.+S.+Payneauthor=W.+C.+Lummaauthor=T.+A.+Lyleauthor=J.+R.+Huffauthor=P.+S.+Andersonauthor=D.+B.+Olsenauthor=S.+S.+Carroll&title=L-743%2C+726+%28DMP-266%29%3A+a+novel%2C+highly+potent+nonnucleoside+inhibitor+of+the+human+immunodeficiency+virus+type+1+reverse+transcriptase&doi=10.1128%2FAAC.39.12.2602"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FAAC.39.12.2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.39.12.2602%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DBritcher%26aufirst%3DS.%2BF.%26aulast%3DTran%26aufirst%3DL.%2BO.%26aulast%3DPayne%26aufirst%3DL.%2BS.%26aulast%3DLumma%26aufirst%3DW.%2BC.%26aulast%3DLyle%26aufirst%3DT.%2BA.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DAnderson%26aufirst%3DP.%2BS.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DL-743%252C%2520726%2520%2528DMP-266%2529%253A%2520a%2520novel%252C%2520highly%2520potent%2520nonnucleoside%2520inhibitor%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520type%25201%2520reverse%2520transcriptase%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1995%26volume%3D39%26issue%3D12%26spage%3D2602%26epage%3D2605%26doi%3D10.1128%2FAAC.39.12.2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckheit, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliakas-Boltz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowdon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonucci, T. K.</span></span> <span> </span><span class="NLM_article-title">Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/0166-3542(94)90092-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2F0166-3542%2894%2990092-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1994&pages=43-56&issue=1&author=R.+W.+Buckheitauthor=V.+Fliakas-Boltzauthor=W.+D.+Deckerauthor=J.+L.+Robersonauthor=C.+A.+Pyleauthor=E.+L.+Whiteauthor=B.+J.+Bowdonauthor=J.+B.+McMahonauthor=M.+R.+Boydauthor=J.+P.+Baderauthor=D.+G.+Nickellauthor=H.+Barthauthor=T.+K.+Antonucci&title=Biological+and+biochemical+anti-HIV+activity+of+the+benzothiadiazine+class+of+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1016%2F0166-3542%2894%2990092-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0166-3542%2894%2990092-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-3542%252894%252990092-2%26sid%3Dliteratum%253Aachs%26aulast%3DBuckheit%26aufirst%3DR.%2BW.%26aulast%3DFliakas-Boltz%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DW.%2BD.%26aulast%3DRoberson%26aufirst%3DJ.%2BL.%26aulast%3DPyle%26aufirst%3DC.%2BA.%26aulast%3DWhite%26aufirst%3DE.%2BL.%26aulast%3DBowdon%26aufirst%3DB.%2BJ.%26aulast%3DMcMahon%26aufirst%3DJ.%2BB.%26aulast%3DBoyd%26aufirst%3DM.%2BR.%26aulast%3DBader%26aufirst%3DJ.%2BP.%26aulast%3DNickell%26aufirst%3DD.%2BG.%26aulast%3DBarth%26aufirst%3DH.%26aulast%3DAntonucci%26aufirst%3DT.%2BK.%26atitle%3DBiological%2520and%2520biochemical%2520anti-HIV%2520activity%2520of%2520the%2520benzothiadiazine%2520class%2520of%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntiviral%2520Res.%26date%3D1994%26volume%3D25%26issue%3D1%26spage%3D43%26epage%3D56%26doi%3D10.1016%2F0166-3542%2894%2990092-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">E1</span>– <span class="NLM_lpage">E72</span>, <span class="refDoi"> DOI: 10.1002/med.20241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fmed.20241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=21523792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=E1-E72&author=P.+Zhanauthor=X.+Chenauthor=D.+Liauthor=Z.+Fangauthor=E.+De+Clercqauthor=X.+Liu&title=HIV-1+NNRTIs%3A+structural+diversity%2C+pharmacophore+similarity%2C+and+implications+for+drug+design&doi=10.1002%2Fmed.20241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design</span></div><div class="casAuthors">Zhan, Peng; Chen, Xuwang; Li, Dongyue; Fang, Zengjun; De Clercq, Erik; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">E1-E72</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) nowadays represent very potent and most promising anti-AIDS agents that specifically target the HIV-1 reverse transcriptase (RT).  However, the effectiveness of NNRTI drugs can be hampered by rapid emergence of drug-resistant viruses and severe side effects upon long-term use.  Therefore, there is an urgent need to develop novel, highly potent NNRTIs with broad spectrum antiviral activity and improved pharmacokinetic properties, and more efficient strategies that facilitate and shorten the drug discovery process would be extremely beneficial.  Fortunately, the structural diversity of NNRTIs provided a wide space for novel lead discovery, and the pharmacophore similarity of NNRTIs gave valuable hints for lead discovery and optimization.  More importantly, with the continued efforts in the development of computational tools and increased crystallog. information on RT/NNRTI complexes, structure-based approaches using a combination of traditional medicinal chem., structural biol., and computational chem. are being used increasingly in the design of NNRTIs.  First, this review covers two decades of research and development for various NNRTI families based on their chem. scaffolds, and then describes the structural similarity of NNRTIs.  We have attempted to assemble a comprehensive overview of the general approaches in NNRTI lead discovery and optimization reported in the literature during the last decade.  The successful applications of medicinal chem. strategies, crystallog., and computational tools for designing novel NNRTIs are highlighted.  Future directions for research are also outlined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA7jjFerOFrbVg90H21EOLACvtfcHk0lj_pZuKMnYbHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWmsbo%253D&md5=08cc3f8e0815f70ee052ccda81d75dfb</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fmed.20241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20241%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DHIV-1%2520NNRTIs%253A%2520structural%2520diversity%252C%2520pharmacophore%2520similarity%252C%2520and%2520implications%2520for%2520drug%2520design%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2013%26volume%3D33%26spage%3DE1%26epage%3DE72%26doi%3D10.1002%2Fmed.20241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britcher, S. F.</span>; <span class="NLM_string-name">Goldman, M. E.</span>; <span class="NLM_string-name">Huff, J. R.</span>; <span class="NLM_string-name">Lumma, W. C.</span>; <span class="NLM_string-name">Lyle, T. A.</span>; <span class="NLM_string-name">Payne, L. S.</span>; <span class="NLM_string-name">Quesada, M. L.</span>; <span class="NLM_string-name">Sanders, W. M.</span>; <span class="NLM_string-name">Tucker, T. J.</span>; <span class="NLM_string-name">Young, S. D.</span></span> <span> </span><span class="NLM_article-title">Quinazoline Derivatives as Inhibitors of HIV Reverse Transcriptase</span>. World Patent <span class="NLM_patent">WO1993004047A1</span>, <span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=S.+F.+Britcher&author=M.+E.+Goldman&author=J.+R.+Huff&author=W.+C.+Lumma&author=T.+A.+Lyle&author=L.+S.+Payne&author=M.+L.+Quesada&author=W.+M.+Sanders&author=T.+J.+Tucker&author=S.+D.+Young&title=Quinazoline+Derivatives+as+Inhibitors+of+HIV+Reverse+Transcriptase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBritcher%26aufirst%3DS.%2BF.%26atitle%3DQuinazoline%2520Derivatives%2520as%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houpis, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volante, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a new generation reverse transcriptase inhibitor via the BCl3/GaCl3-induced condensation of anilines with nitriles (sugasawa reaction)</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">6811</span>– <span class="NLM_lpage">6814</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(94)85011-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2F0040-4039%2894%2985011-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1994&pages=6811-6814&issue=37&author=I.+N.+Houpisauthor=A.+Molinaauthor=A.+W.+Douglasauthor=L.+Xavierauthor=J.+Lynchauthor=R.+P.+Volanteauthor=P.+J.+Reider&title=Synthesis+of+a+new+generation+reverse+transcriptase+inhibitor+via+the+BCl3%2FGaCl3-induced+condensation+of+anilines+with+nitriles+%28sugasawa+reaction%29&doi=10.1016%2F0040-4039%2894%2985011-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2894%2985011-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252894%252985011-9%26sid%3Dliteratum%253Aachs%26aulast%3DHoupis%26aufirst%3DI.%2BN.%26aulast%3DMolina%26aufirst%3DA.%26aulast%3DDouglas%26aufirst%3DA.%2BW.%26aulast%3DXavier%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DJ.%26aulast%3DVolante%26aufirst%3DR.%2BP.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26atitle%3DSynthesis%2520of%2520a%2520new%2520generation%2520reverse%2520transcriptase%2520inhibitor%2520via%2520the%2520BCl3%252FGaCl3-induced%2520condensation%2520of%2520anilines%2520with%2520nitriles%2520%2528sugasawa%2520reaction%2529%26jtitle%3DTetrahedron%2520Lett.%26date%3D1994%26volume%3D35%26issue%3D37%26spage%3D6811%26epage%3D6814%26doi%3D10.1016%2F0040-4039%2894%2985011-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiscount, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britcher, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumma, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of a series of 4-(Arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 Reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2437</span>– <span class="NLM_lpage">2444</span>, <span class="refDoi"> DOI: 10.1021/jm00041a023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00041a023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2437-2444&issue=15&author=T.+J.+Tuckerauthor=T.+A.+Lyleauthor=C.+M.+Wiscountauthor=S.+F.+Britcherauthor=S.+D.+Youngauthor=W.+M.+Sandersauthor=W.+C.+Lummaauthor=M.+E.+Goldmanauthor=J.+A.+O%E2%80%99Brien&title=Synthesis+of+a+series+of+4-%28Arylethynyl%29-6-chloro-4-cyclopropyl-3%2C4-dihydroquinazolin-2%281H%29-ones+as+novel+non-nucleoside+HIV-1+Reverse+transcriptase+inhibitors&doi=10.1021%2Fjm00041a023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm00041a023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00041a023%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DLyle%26aufirst%3DT.%2BA.%26aulast%3DWiscount%26aufirst%3DC.%2BM.%26aulast%3DBritcher%26aufirst%3DS.%2BF.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DSanders%26aufirst%3DW.%2BM.%26aulast%3DLumma%26aufirst%3DW.%2BC.%26aulast%3DGoldman%26aufirst%3DM.%2BE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520a%2520series%2520of%25204-%2528Arylethynyl%2529-6-chloro-4-cyclopropyl-3%252C4-dihydroquinazolin-2%25281H%2529-ones%2520as%2520novel%2520non-nucleoside%2520HIV-1%2520Reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26issue%3D15%26spage%3D2437%26epage%3D2444%26doi%3D10.1021%2Fjm00041a023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeCamp, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span> <span> </span><span class="NLM_article-title">Lithium alkoxides of cinchona alkaloids as chiral controllers for enantioselective acetylide addition to cyclic N-acyl ketimines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1590</span>– <span class="NLM_lpage">1594</span>, <span class="refDoi"> DOI: 10.1021/jo00111a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00111a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=1590-1594&issue=6&author=M.+A.+Huffmanauthor=N.+Yasudaauthor=A.+E.+DeCampauthor=E.+J.+J.+Grabowski&title=Lithium+alkoxides+of+cinchona+alkaloids+as+chiral+controllers+for+enantioselective+acetylide+addition+to+cyclic+N-acyl+ketimines&doi=10.1021%2Fjo00111a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjo00111a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00111a016%26sid%3Dliteratum%253Aachs%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DDeCamp%26aufirst%3DA.%2BE.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26atitle%3DLithium%2520alkoxides%2520of%2520cinchona%2520alkaloids%2520as%2520chiral%2520controllers%2520for%2520enantioselective%2520acetylide%2520addition%2520to%2520cyclic%2520N-acyl%2520ketimines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26issue%3D6%26spage%3D1590%26epage%3D1594%26doi%3D10.1021%2Fjo00111a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouverneur, V.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1039/B610213C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1039%2FB610213C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18197348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2008&pages=320-330&issue=2&author=S.+Purserauthor=P.+R.+Mooreauthor=S.+Swallowauthor=V.+Gouverneur&title=Fluorine+in+medicinal+chemistry&doi=10.1039%2FB610213C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Purser, Sophie; Moore, Peter R.; Swallow, Steve; Gouverneur, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">320-330</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  It has become evident that fluorinated compds. have a remarkable record in medicinal chem. and will play a continuing role in providing lead compds. for therapeutic applications.  This tutorial review provides a sampling of renowned fluorinated drugs and their mode of action with a discussion clarifying the role and impact of fluorine substitution on drug potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFKAqJ3UbgGbVg90H21EOLACvtfcHk0lhOsVt67jXofQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVGgsw%253D%253D&md5=e6c9e3084e454c44a4ba245b98f7f1d7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1039%2FB610213C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB610213C%26sid%3Dliteratum%253Aachs%26aulast%3DPurser%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DP.%2BR.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DGouverneur%26aufirst%3DV.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2008%26volume%3D37%26issue%3D2%26spage%3D320%26epage%3D330%26doi%3D10.1039%2FB610213C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boechat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kover, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bongertz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastos, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeiro, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, M. L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollinger, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-Ones</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.2174/157340607782360326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2174%2F157340607782360326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18045202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSisb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=533-542&issue=6&author=N.+Boechatauthor=W.+B.+Koverauthor=V.+Bongertzauthor=M.+M.+Bastosauthor=N.+C.+Romeiroauthor=M.+L.+G.+Azevedoauthor=W.+Wollinger&title=Design%2C+synthesis+and+pharmacological+evaluation+of+HIV-1+reverse+transcriptase+inhibition+of+new+indolin-2-Ones&doi=10.2174%2F157340607782360326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones</span></div><div class="casAuthors">Boechat, Nubia; Kover, W. Bruce; Bongertz, Vera; Bastos, Monica M.; Romeiro, Nelilma C.; Azevedo, Maria L. G.; Wollinger, Wagner</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">533-542</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The design, synthesis and anti HIV-1 replication inhibition of 3-(cyclopropylethynyl)-3-hydroxy-indolin-2-ones, e.g., I, analogs of efavirenz (Sustiva), are described.  Different substituted isatins were used to generate final products that contain pharmacophoric features for RT inhibition, such as the oxoindole and cyclopropylethynyl groups.  The suitability of the indolin-2-one ring in the planned compds. in replacement to the benzoxazinone ring of efavirenz was proven, since I presented a greater activity than efavirenz against HIV-1 replication and was not significantly cytotoxic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcenY7PrTUHrVg90H21EOLACvtfcHk0lhOsVt67jXofQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSisb7M&md5=c39eeda2e338305f5b2977d269971bd8</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2174%2F157340607782360326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157340607782360326%26sid%3Dliteratum%253Aachs%26aulast%3DBoechat%26aufirst%3DN.%26aulast%3DKover%26aufirst%3DW.%2BB.%26aulast%3DBongertz%26aufirst%3DV.%26aulast%3DBastos%26aufirst%3DM.%2BM.%26aulast%3DRomeiro%26aufirst%3DN.%2BC.%26aulast%3DAzevedo%26aufirst%3DM.%2BL.%2BG.%26aulast%3DWollinger%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520pharmacological%2520evaluation%2520of%2520HIV-1%2520reverse%2520transcriptase%2520inhibition%2520of%2520new%2520indolin-2-Ones%26jtitle%3DMed.%2520Chem.%26date%3D2007%26volume%3D3%26issue%3D6%26spage%3D533%26epage%3D542%26doi%3D10.2174%2F157340607782360326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogburn, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, Z.</span></span> <span> </span><span class="NLM_article-title">Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1218</span>– <span class="NLM_lpage">1229</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.031393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1124%2Fdmd.109.031393" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1218-1229&issue=7&author=E.+T.+Ogburnauthor=D.+R.+Jonesauthor=A.+R.+Mastersauthor=C.+Xuauthor=Y.+Guoauthor=Z.+Desta&title=Efavirenz+primary+and+secondary+metabolism+in+vitro+and+in+vivo%3A+identification+of+novel+metabolic+pathways+and+cytochrome+P450+2A6+as+the+principal+catalyst+of+efavirenz+7-hydroxylation&doi=10.1124%2Fdmd.109.031393"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.031393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.031393%26sid%3Dliteratum%253Aachs%26aulast%3DOgburn%26aufirst%3DE.%2BT.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DMasters%26aufirst%3DA.%2BR.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DDesta%26aufirst%3DZ.%26atitle%3DEfavirenz%2520primary%2520and%2520secondary%2520metabolism%2520in%2520vitro%2520and%2520in%2520vivo%253A%2520identification%2520of%2520novel%2520metabolic%2520pathways%2520and%2520cytochrome%2520P450%25202A6%2520as%2520the%2520principal%2520catalyst%2520of%2520efavirenz%25207-hydroxylation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26issue%3D7%26spage%3D1218%26epage%3D1229%26doi%3D10.1124%2Fdmd.109.031393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorski, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flockhart, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, Z.</span></span> <span> </span><span class="NLM_article-title">The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">300</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.049601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1124%2Fjpet.103.049601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=12676886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=287-300&author=B.+A.+Wardauthor=J.+C.+Gorskiauthor=D.+R.+Jonesauthor=S.+D.+Hallauthor=D.+A.+Flockhartauthor=Z.+Desta&title=The+cytochrome+P450+2B6+%28CYP2B6%29+is+the+main+catalyst+of+efavirenz+primary+and+secondary+metabolism%3A+implication+for+HIV%2FAIDS+therapy+and+utility+of+efavirenz+as+a+substrate+marker+of+CYP2B6+catalytic+activity&doi=10.1124%2Fjpet.103.049601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity</span></div><div class="casAuthors">Ward, Bryan A.; Gorski, J. Christopher; Jones, David R.; Hall, Stephen D.; Flockhart, David A.; Desta, Zeruesenay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">287-300</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We used human liver microsomes (HLMs) and recombinant cytochromes P 450 (P450s) to identify the routes of efavirenz metab. and the P450s involved.  In HLMs, efavirenz undergoes primary oxidative hydroxylation to 8-hydroxyefavirenz (major) and 7-hydroxyefavirenz (minor) and secondary metab. to 8,14-dihydroxyefavirenz.  The formation of 8-hydroxyefavirenz in two HLMs showed sigmoidal kinetics (av. apparent Km, 20.2 μM; Vmax, 140 pmol/min/mg protein; and Hill coeff., 1.5), whereas that of 7-hydroxyefavirenz formation was characterized by hyperbolic kinetics (Km, 40.1 μM and Vmax, 20.5 pmol/min/mg protein).  In a panel of 10 P450s, CYP2B6 formed 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz from efavirenz (10 μM) at the highest rate.  The Km value for the formation of 8-hydroxyefavirenz in CYP2B6 derived from hyperbolic Eq. 12.4 μM was close to that obtained in HLMs (Km, 20.2 μM).  None of the P450s tested showed activity toward 7-hydroxylation of efavirenz.  When 8-hydroxyefavirenz (2.5 μM) was used as a substrate, 8,14-dihydroxyefavirenz was formed by CYP2B6 at the highest rate, and its kinetics showed substrate inhibition (Ksi, ∼94 μM in HLMs and ∼234 μM in CYP2B6).  In a panel of 11 HLMs, 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz formation rates from efavirenz (10 μM) correlated significantly with the activity of CYP2B6 and CYP3A.  N,N',N''-Triethylenethiophosphoramide (thioTEPA; 50 μM) inhibited the formation rates of 8-hydroxyefavirenz and 8,14-dihydroxyefavirenz from efavirenz (10 μM) by ≥60% in HLMs and CYP2B6, with Ki values < 4 μM.  In conclusion, CYP2B6 is the principal catalyst of efavirenz sequential hydroxylation.  Efavirenz systemic exposure is likely to be subject to interindividual variability in CYP2B6 activity and to drug interactions involving this isoform.  Efavirenz may be a valuable phenotyping tool to study the role of CYP2B6 in human drug metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdxH6M1qc21bVg90H21EOLACvtfcHk0lhOsVt67jXofQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvF2ksr8%253D&md5=b08295185f3dd7c339a7744309002233</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.049601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.049601%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DB.%2BA.%26aulast%3DGorski%26aufirst%3DJ.%2BC.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26aulast%3DFlockhart%26aufirst%3DD.%2BA.%26aulast%3DDesta%26aufirst%3DZ.%26atitle%3DThe%2520cytochrome%2520P450%25202B6%2520%2528CYP2B6%2529%2520is%2520the%2520main%2520catalyst%2520of%2520efavirenz%2520primary%2520and%2520secondary%2520metabolism%253A%2520implication%2520for%2520HIV%252FAIDS%2520therapy%2520and%2520utility%2520of%2520efavirenz%2520as%2520a%2520substrate%2520marker%2520of%2520CYP2B6%2520catalytic%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D287%26epage%3D300%26doi%3D10.1124%2Fjpet.103.049601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemzik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krahn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, G. T.</span></span> <span> </span><span class="NLM_article-title">The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>169</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1006/taap.2000.9055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Ftaap.2000.9055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=11076702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2000&pages=102-113&issue=1&author=A.+E.+Mutlibauthor=R.+J.+Gersonauthor=P.+C.+Meunierauthor=P.+J.+Haleyauthor=H.+Chenauthor=L.+S.+Ganauthor=M.+H.+Daviesauthor=B.+Gemzikauthor=D.+D.+Christauthor=D.+F.+Krahnauthor=J.+A.+Markwalderauthor=S.+P.+Seitzauthor=R.+T.+Robertsonauthor=G.+T.+Miwa&title=The+species-dependent+metabolism+of+efavirenz+produces+a+nephrotoxic+glutathione+conjugate+in+rats&doi=10.1006%2Ftaap.2000.9055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">The Species-Dependent Metabolism of Efavirenz Produces a Nephrotoxic Glutathione Conjugate in Rats</span></div><div class="casAuthors">Mutlib, Abdul E.; Gerson, Ronald J.; Meunier, Paul C.; Haley, Patrick J.; Chen, Hao; Gan, Lawrence S.; Davies, Marc H.; Gemzik, Brian; Christ, David D.; Krahn, David F.; Markwalder, Jay A.; Seitz, Steven P.; Robertson, Richard T.; Miwa, Gerald T.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Efavirenz, a potent nonnucleoside reverse transcriptase inhibitor widely prescribed for the treatment of HIV infection, produces renal tubular epithelial cell necrosis in rats but not in cynomolgus monkeys or humans.  This species selectivity in nephrotoxicity could result from differences in the prodn. or processing of reactive metabolites, or both.  A detailed comparison of the metabolites produced by rats, monkeys, and humans revealed that rats produce a unique glutathione adduct.  The mechanism of formation and role of this glutathione adduct in the renal toxicity were investigated using both chem. and biochem. probes.  Efavirenz was labeled at the methine position on the cyclopropyl ring with the stable isotope deuterium, effectively reducing the formation of the cyclopropanol metabolite, an obligate precursor to the glutathione adduct.  This substitution markedly reduced both the incidence and severity of nephrotoxicity as measured histol.  Further processing of this glutathione adduct was also important in producing the lesion and was demonstrated by inhibiting γ-glutamyltranspeptidase with acivicin pretreatment (10 mg/kg, IV) prior to dosing with efavirenz.  Again, both the incidence and severity of the nephrotoxicity were reduced, such that four of nine rats given acivicin were without detectable lesions.  These studies provide compelling evidence that a species-specific formation of glutathione conjugate(s) from efavirenz is involved in producing nephrotoxicity in rats.  Mechanisms are proposed for the formation of reactive metabolites that could be responsible for the renal toxicity obsd. in rats.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtZ2yUYxMePrVg90H21EOLACvtfcHk0ljWK0yeAgDqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D&md5=13f8d2f66902fef25d827b2f492f88ce</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1006%2Ftaap.2000.9055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Ftaap.2000.9055%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DGerson%26aufirst%3DR.%2BJ.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DDavies%26aufirst%3DM.%2BH.%26aulast%3DGemzik%26aufirst%3DB.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26aulast%3DKrahn%26aufirst%3DD.%2BF.%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DRobertson%26aufirst%3DR.%2BT.%26aulast%3DMiwa%26aufirst%3DG.%2BT.%26atitle%3DThe%2520species-dependent%2520metabolism%2520of%2520efavirenz%2520produces%2520a%2520nephrotoxic%2520glutathione%2520conjugate%2520in%2520rats%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2000%26volume%3D169%26issue%3D1%26spage%3D102%26epage%3D113%26doi%3D10.1006%2Ftaap.2000.9055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigurdsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowgren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noreen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridborg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unge, T.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant</span>. <i>Eur. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">1670</span>– <span class="NLM_lpage">1677</span>, <span class="refDoi"> DOI: 10.1046/j.1432-1327.2002.02811.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1046%2Fj.1432-1327.2002.02811.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=11895437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD38XisVKitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2002&pages=1670-1677&author=J.+Lindbergauthor=S.+Sigurdssonauthor=S.+Lowgrenauthor=H.+O.+Anderssonauthor=C.+Sahlbergauthor=R.+Noreenauthor=K.+Fridborgauthor=H.+Zhangauthor=T.+Unge&title=Structural+basis+for+the+inhibitory+efficacy+of+efavirenz+%28DMP-266%29%2C+MSC194+and+PNU142721+towards+the+HIV-1+RT+K103N+mutant&doi=10.1046%2Fj.1432-1327.2002.02811.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant</span></div><div class="casAuthors">Lindberg, Jimmy; Sigurosson, Snaevar; Lowgren, Seved; Andersson, Hans O.; Sahlberg, Christer; Noreen, Rolf; Fridborg, Kerstin; Zhang, Hong; Unge, Torsten</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1670-1677</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The K103N substitution is a frequently obsd. HIV-1 RT mutation in patients who do not respond to combination-therapy.  The drugs Efavirenz, MSC194 and PNU142721 belong to the recent generation of NNRTIs characterized by an improved resistance profile to the most common single point mutations within HIV-1 RT, including the K103N mutation.  In the present study we present structural observations from Efavirenz in complex with wild-type protein and the K103N mutant and PNU142721 and MSC194 in complex with the K103N mutant.  The structures unanimously indicate that the K103N substitution induces only minor positional adjustments of the three inhibitors and the residues lining the binding pocket.  Thus, compared to the corresponding wild-type structures, these inhibitors bind to the mutant in a conservative mode rather than through major rearrangements.  The structures implicate that the reduced inhibitory efficacy should be attributed to the changes in the chem. environment in the vicinity of the substituted N103 residue.  This is supported by changes in hydrophobic and electrostatic interactions to the inhibitors between wild-type and K103N mutant complexes.  These potent inhibitors accommodate to the K103N mutation by forming new interactions to the N103 side chain.  Our results are consistent with the proposal by Hsiou et al. that inhibitors with good activity against the K103N mutant would be expected to have favorable interactions with the mutant asparagines side chain, thereby compensating for resistance caused by stabilization of the mutant enzyme due to a hydrogen-bond network involving the N103 and Y188 side chains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM844LYh-y9rVg90H21EOLACvtfcHk0ljWK0yeAgDqBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisVKitr8%253D&md5=1cb2d0df1f8c6c1cb6fd37d0424361ad</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1046%2Fj.1432-1327.2002.02811.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1432-1327.2002.02811.x%26sid%3Dliteratum%253Aachs%26aulast%3DLindberg%26aufirst%3DJ.%26aulast%3DSigurdsson%26aufirst%3DS.%26aulast%3DLowgren%26aufirst%3DS.%26aulast%3DAndersson%26aufirst%3DH.%2BO.%26aulast%3DSahlberg%26aufirst%3DC.%26aulast%3DNoreen%26aufirst%3DR.%26aulast%3DFridborg%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DUnge%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520for%2520the%2520inhibitory%2520efficacy%2520of%2520efavirenz%2520%2528DMP-266%2529%252C%2520MSC194%2520and%2520PNU142721%2520towards%2520the%2520HIV-1%2520RT%2520K103N%2520mutant%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2002%26volume%3D269%26spage%3D1670%26epage%3D1677%26doi%3D10.1046%2Fj.1432-1327.2002.02811.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleim, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>309</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2001.4648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1006%2Fjmbi.2001.4648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2001&pages=437-445&issue=2&author=Y.+Hsiouauthor=J.+Dingauthor=K.+Dasauthor=A.+D.+Clarkauthor=P.+L.+Boyerauthor=P.+Lewiauthor=P.+A.+Janssenauthor=J.+P.+Kleimauthor=M.+Rosnerauthor=S.+H.+Hughesauthor=E.+Arnold&title=The+Lys103Asn+mutation+of+HIV-1+RT%3A+a+novel+mechanism+of+drug+resistance&doi=10.1006%2Fjmbi.2001.4648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.4648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.4648%26sid%3Dliteratum%253Aachs%26aulast%3DHsiou%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DLewi%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DKleim%26aufirst%3DJ.%2BP.%26aulast%3DRosner%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DThe%2520Lys103Asn%2520mutation%2520of%2520HIV-1%2520RT%253A%2520a%2520novel%2520mechanism%2520of%2520drug%2520resistance%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D309%26issue%3D2%26spage%3D437%26epage%3D445%26doi%3D10.1006%2Fjmbi.2001.4648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span> <i>Efavirenz Package</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver
Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Efavirenz+Package%3B+U.S.%0AFood+and+Drug+Administration%3A+Silver%0ASpring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEfavirenz%2520Package%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Staszewski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashima, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachlis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiest, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labriola, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manion, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, N. M.</span></span> <span> </span><span class="NLM_article-title">Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>341</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">1865</span>– <span class="NLM_lpage">1873</span>, <span class="refDoi"> DOI: 10.1056/NEJM199912163412501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJM199912163412501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10601505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVCmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=1865-1873&issue=25&author=S.+Staszewskiauthor=J.+Morales-Ramirezauthor=K.+T.+Tashimaauthor=A.+Rachlisauthor=D.+Skiestauthor=J.+Stanfordauthor=R.+Strykerauthor=P.+Johnsonauthor=D.+F.+Labriolaauthor=D.+Farinaauthor=D.+J.+Manionauthor=N.+M.+Ruiz&title=Efavirenz+plus+zidovudine+and+lamivudine%2C+efavirenz+plus+indinavir%2C+and+indinavir+plus+zidovudine+and+lamivudine+in+the+treatment+of+HIV-1+infection+in+adults.+Study+006+Team&doi=10.1056%2FNEJM199912163412501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults</span></div><div class="casAuthors">Staszewski, Schlomo; Morales-Ramirez, Javier; Tashima, Karen T.; Rachlis, Anita; Skiest, Daniel; Stanford, James; Stryker, Richard; Johnson, Philip; Labriola, Dominic F.; Farina, Dianne; Manion, Douglas J.; Ruiz, Nancy M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">1865-1873</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Efavirenz is a nonnucleoside reverse-transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1).  We compared two regimens contg. efavirenz, one with a protease inhibitor and the other with two nucleoside reverse-transcriptase inhibitors, with a std. three-drug regimen.  Methods: The study subjects were 450 patients who had not previously been treated with lamivudine or any nonnucleoside reverse-transcriptase inhibitor or protease inhibitor.  In this open-label study, patients were randomly assigned to one of three regimens: efavirenz (600 mg daily) plus zidovudine (300 mg twice daily) and lamivudine (150 mg twice daily); the protease inhibitor indinavir (800 mg every eight hours) plus zidovudine and lamivudine; or efavirenz plus indinavir (1000 mg every eight hours).  Results: Suppression of plasma HIV-1 RNA to undetectable levels was achieved in more patients in the group given efavirenz plus nucleoside reverse-transcriptase inhibitors than in the group given indinavir plus nucleoside reverse-transcriptase inhibitors (70 % vs. 48 %, P<0.001).  The efficacy of the regimen of efavirenz plus indinavir was similar (53 %) to that of the regimen of indinavir, zidovudine, and lamivudine.  CD4 cell counts increased significantly with all combinations (range of increases, 180 to 201 cells per cubic millimeter).  More patients discontinued treatment because of adverse events in the group given indinavir and two nucleoside reverse-transcriptase inhibitors than in the group given efavirenz and two nucleoside reverse-transcriptase inhibitors (43 % vs. 27 %, P=0.005).  Conclusions: As antiretroviral therapy in HIV-1-infected adults, the combination of efavirenz, zidovudine, and lamivudine has greater antiviral activity and is better tolerated than the combination of indinavir, zidovudine, and lamivudine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmnBhI-LNWbVg90H21EOLACvtfcHk0lje9lv0mxdEXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVCmtw%253D%253D&md5=19c08c44aa950e70073d6ef00b4faa10</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1056%2FNEJM199912163412501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199912163412501%26sid%3Dliteratum%253Aachs%26aulast%3DStaszewski%26aufirst%3DS.%26aulast%3DMorales-Ramirez%26aufirst%3DJ.%26aulast%3DTashima%26aufirst%3DK.%2BT.%26aulast%3DRachlis%26aufirst%3DA.%26aulast%3DSkiest%26aufirst%3DD.%26aulast%3DStanford%26aufirst%3DJ.%26aulast%3DStryker%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DLabriola%26aufirst%3DD.%2BF.%26aulast%3DFarina%26aufirst%3DD.%26aulast%3DManion%26aufirst%3DD.%2BJ.%26aulast%3DRuiz%26aufirst%3DN.%2BM.%26atitle%3DEfavirenz%2520plus%2520zidovudine%2520and%2520lamivudine%252C%2520efavirenz%2520plus%2520indinavir%252C%2520and%2520indinavir%2520plus%2520zidovudine%2520and%2520lamivudine%2520in%2520the%2520treatment%2520of%2520HIV-1%2520infection%2520in%2520adults.%2520Study%2520006%2520Team%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26issue%3D25%26spage%3D1865%26epage%3D1873%26doi%3D10.1056%2FNEJM199912163412501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span> <i>Guidelines for the Use of Antiretroviral Agents
in HIV-1-Infected
Adults and Adolescents</i>; <span class="NLM_publisher-name">AIDSinfo</span>, <span class="NLM_year">2018</span>; <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf" class="extLink">https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</a> (accessed May 14, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Guidelines+for+the+Use+of+Antiretroviral+Agents%0Ain+HIV-1-Infected%0AAdults+and+Adolescents%3B+AIDSinfo%2C+2018%3B+https%3A%2F%2Faidsinfo.nih.gov%2Fcontentfiles%2Flvguidelines%2Fadultandadolescentgl.pdf+%28accessed+May+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGuidelines%2520for%2520the%2520Use%2520of%2520Antiretroviral%2520Agents%250Ain%2520HIV-1-Infected%250AAdults%2520and%2520Adolescents%26pub%3DAIDSinfo%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span>; <span class="NLM_string-name">Britcher, S. F.</span>; <span class="NLM_string-name">Payne, L. S.</span>; <span class="NLM_string-name">Tran, L. O.</span>; <span class="NLM_string-name">Lumma, W. C.</span></span> U.S. Patent <span> </span><span class="NLM_article-title">Benzoxazinones as Inhibitors of HIV Reverse Transcriptase</span>. <span class="NLM_patent">US5519021A</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=S.+D.+Young&author=S.+F.+Britcher&author=L.+S.+Payne&author=L.+O.+Tran&author=W.+C.+Lumma&title=Benzoxazinones+as+Inhibitors+of+HIV+Reverse+Transcriptase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DS.%2BD.%26atitle%3DBenzoxazinones%2520as%2520Inhibitors%2520of%2520HIV%2520Reverse%2520Transcriptase%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, M. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis of HIV-1 reverse transcriptase inhibitor DMP 266</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4373</span>– <span class="NLM_lpage">4384</span>, <span class="refDoi"> DOI: 10.1080/00397919708005064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1080%2F00397919708005064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK1cXht1alug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=4373-4384&author=L.%0AA.+Radescaauthor=Y.+S.+Loauthor=J.+R.+Mooreauthor=M.+E.+Pierce&title=Synthesis+of+HIV-1+reverse+transcriptase+inhibitor+DMP+266&doi=10.1080%2F00397919708005064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of HIV-1 reverse transcriptase inhibitor DMP 266</span></div><div class="casAuthors">Radesca, Lilian A.; Lo, Young S.; Moore, James R.; Pierce, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4373-4384</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">DMP 266, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor was prepd. in six steps starting from com. available 4-chlorophenyl isocyanate.  The racemic compd. was formed very efficiently from N-tert-butoxycarbonyl-4-chloroaniline and resoln. was accomplished via the (-)-camphanates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNwZ2z4QpbrVg90H21EOLACvtfcHk0lje9lv0mxdEXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXht1alug%253D%253D&md5=f508104aa182d46c1f44c0bf071ca9b2</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1080%2F00397919708005064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919708005064%26sid%3Dliteratum%253Aachs%26aulast%3DRadesca%26aufirst%3DL.%2BA.%26aulast%3DLo%26aufirst%3DY.%2BS.%26aulast%3DMoore%26aufirst%3DJ.%2BR.%26aulast%3DPierce%26aufirst%3DM.%2BE.%26atitle%3DSynthesis%2520of%2520HIV-1%2520reverse%2520transcriptase%2520inhibitor%2520DMP%2520266%26jtitle%3DSynth.%2520Commun.%26date%3D1997%26volume%3D27%26spage%3D4373%26epage%3D4384%26doi%3D10.1080%2F00397919708005064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corley, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntington, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remenar, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collum, D. B.</span></span> <span> </span><span class="NLM_article-title">Lithium ephedrate-mediated addition of a lithium acetylide to a ketone: Solution structures and relative reactivities of mixed aggregates underlying the high enantioselectivities</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>120</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2028</span>– <span class="NLM_lpage">2038</span>, <span class="refDoi"> DOI: 10.1021/ja9713791</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9713791" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=2028-2038&issue=9&author=A.+Thompsonauthor=E.+G.+Corleyauthor=M.+F.+Huntingtonauthor=E.+J.+J.+Grabowskiauthor=J.+F.+Remenarauthor=D.+B.+Collum&title=Lithium+ephedrate-mediated+addition+of+a+lithium+acetylide+to+a+ketone%3A+Solution+structures+and+relative+reactivities+of+mixed+aggregates+underlying+the+high+enantioselectivities&doi=10.1021%2Fja9713791"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fja9713791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9713791%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DCorley%26aufirst%3DE.%2BG.%26aulast%3DHuntington%26aufirst%3DM.%2BF.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26aulast%3DRemenar%26aufirst%3DJ.%2BF.%26aulast%3DCollum%26aufirst%3DD.%2BB.%26atitle%3DLithium%2520ephedrate-mediated%2520addition%2520of%2520a%2520lithium%2520acetylide%2520to%2520a%2520ketone%253A%2520Solution%2520structures%2520and%2520relative%2520reactivities%2520of%2520mixed%2520aggregates%2520underlying%2520the%2520high%2520enantioselectivities%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26issue%3D9%26spage%3D2028%26epage%3D2038%26doi%3D10.1021%2Fja9713791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corley, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntington, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span> <span> </span><span class="NLM_article-title">Use of an ephedrine alkoxide to mediate enantioselective addition of an acetylide to a prochiral ketone: asymmetric synthesis of the reverse transcriptase inhibitor L-743,726</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">49</span>),  <span class="NLM_fpage">8937</span>– <span class="NLM_lpage">8940</span>, <span class="refDoi"> DOI: 10.1016/0040-4039(95)01955-H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2F0040-4039%2895%2901955-H" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1995&pages=8937-8940&issue=49&author=A.+S.+Thompsonauthor=E.+G.+Corleyauthor=M.+F.+Huntingtonauthor=E.+J.+J.+Grabowski&title=Use+of+an+ephedrine+alkoxide+to+mediate+enantioselective+addition+of+an+acetylide+to+a+prochiral+ketone%3A+asymmetric+synthesis+of+the+reverse+transcriptase+inhibitor+L-743%2C726&doi=10.1016%2F0040-4039%2895%2901955-H"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2F0040-4039%2895%2901955-H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4039%252895%252901955-H%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DCorley%26aufirst%3DE.%2BG.%26aulast%3DHuntington%26aufirst%3DM.%2BF.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26atitle%3DUse%2520of%2520an%2520ephedrine%2520alkoxide%2520to%2520mediate%2520enantioselective%2520addition%2520of%2520an%2520acetylide%2520to%2520a%2520prochiral%2520ketone%253A%2520asymmetric%2520synthesis%2520of%2520the%2520reverse%2520transcriptase%2520inhibitor%2520L-743%252C726%26jtitle%3DTetrahedron%2520Lett.%26date%3D1995%26volume%3D36%26issue%3D49%26spage%3D8937%26epage%3D8940%26doi%3D10.1016%2F0040-4039%2895%2901955-H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortunak, J. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Confalone, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corley, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span> <span> </span><span class="NLM_article-title">Practical asymmetric synthesis of efavirenz (DMP 266), an HIV-1 reverse transcriptase inhibitor</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">8536</span>– <span class="NLM_lpage">8543</span>, <span class="refDoi"> DOI: 10.1021/jo981170l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo981170l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1998&pages=8536-8543&issue=23&author=M.+E.+Pierceauthor=R.+L.+Parsonsauthor=L.+A.+Radescaauthor=Y.+S.+Loauthor=S.+Silvermanauthor=J.+R.+Mooreauthor=Q.+Islamauthor=A.+Choudhuryauthor=J.+M.+D.+Fortunakauthor=D.+Nguyenauthor=C.+Luoauthor=S.+J.+Morganauthor=W.+P.+Davisauthor=P.+N.+Confaloneauthor=C.-y.+Chenauthor=R.+D.+Tillyerauthor=L.+Freyauthor=L.+Tanauthor=F.+Xuauthor=D.+Zhaoauthor=A.+S.+Thompsonauthor=E.+G.+Corleyauthor=E.+J.+J.+Grabowskiauthor=R.+Reamerauthor=P.+J.+Reider&title=Practical+asymmetric+synthesis+of+efavirenz+%28DMP+266%29%2C+an+HIV-1+reverse+transcriptase+inhibitor&doi=10.1021%2Fjo981170l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fjo981170l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo981170l%26sid%3Dliteratum%253Aachs%26aulast%3DPierce%26aufirst%3DM.%2BE.%26aulast%3DParsons%26aufirst%3DR.%2BL.%26aulast%3DRadesca%26aufirst%3DL.%2BA.%26aulast%3DLo%26aufirst%3DY.%2BS.%26aulast%3DSilverman%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DJ.%2BR.%26aulast%3DIslam%26aufirst%3DQ.%26aulast%3DChoudhury%26aufirst%3DA.%26aulast%3DFortunak%26aufirst%3DJ.%2BM.%2BD.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DMorgan%26aufirst%3DS.%2BJ.%26aulast%3DDavis%26aufirst%3DW.%2BP.%26aulast%3DConfalone%26aufirst%3DP.%2BN.%26aulast%3DChen%26aufirst%3DC.-y.%26aulast%3DTillyer%26aufirst%3DR.%2BD.%26aulast%3DFrey%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DA.%2BS.%26aulast%3DCorley%26aufirst%3DE.%2BG.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26aulast%3DReamer%26aufirst%3DR.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26atitle%3DPractical%2520asymmetric%2520synthesis%2520of%2520efavirenz%2520%2528DMP%2520266%2529%252C%2520an%2520HIV-1%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1998%26volume%3D63%26issue%3D23%26spage%3D8536%26epage%3D8543%26doi%3D10.1021%2Fjo981170l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, D.</span>; <span class="NLM_string-name">Long, X.</span>; <span class="NLM_string-name">Luo, B.</span>; <span class="NLM_string-name">Kulesza, A.</span>; <span class="NLM_string-name">Reichwagen, J.</span>; <span class="NLM_string-name">Guo, Y.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Efavirenz by Cyclisation</span>. World Patent <span class="NLM_patent">WO2012097510A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Dai&author=X.+Long&author=B.+Luo&author=A.+Kulesza&author=J.+Reichwagen&author=Y.+Guo&title=Process+for+Preparation+of+Efavirenz+by+Cyclisation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Efavirenz%2520by%2520Cyclisation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Correia, C.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuade, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeberger, P. H.</span></span> <span> </span><span class="NLM_article-title">A concise flow synthesis of efavirenz</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4945</span>– <span class="NLM_lpage">4948</span>, <span class="refDoi"> DOI: 10.1002/anie.201411728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fanie.201411728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=4945-4948&issue=16&author=C.%0AA.+Correiaauthor=K.+Gilmoreauthor=D.+T.+McQuadeauthor=P.+H.+Seeberger&title=A+concise+flow+synthesis+of+efavirenz&doi=10.1002%2Fanie.201411728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">A Concise Flow Synthesis of Efavirenz</span></div><div class="casAuthors">Correia, Camille A.; Gilmore, Kerry; McQuade, D. Tyler; Seeberger, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4945-4948</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Efavirenz is an essential medicine for the treatment of HIV, which is still inaccessible to millions of people worldwide.  A novel, semi-continuous process provides rac-Efavirenz with an overall yield of 45% from 1,4-dichlorobenzene.  This streamlined proof-of-principle synthesis relies on the efficient copper-catalyzed formation of an aryl isocyanate and a subsequent intramol. cyclization to install the carbamate core of Efavirenz in one step.  This three-step method represents the shortest synthesis of the racemic analog of this life-saving drug to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkfsgAKAjCELVg90H21EOLACvtfcHk0ljniP_zXuwTBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu7s%253D&md5=4811f0b57f4b876bdda5107d569a69d1</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411728%26sid%3Dliteratum%253Aachs%26aulast%3DCorreia%26aufirst%3DC.%2BA.%26aulast%3DGilmore%26aufirst%3DK.%26aulast%3DMcQuade%26aufirst%3DD.%2BT.%26aulast%3DSeeberger%26aufirst%3DP.%2BH.%26atitle%3DA%2520concise%2520flow%2520synthesis%2520of%2520efavirenz%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26issue%3D16%26spage%3D4945%26epage%3D4948%26doi%3D10.1002%2Fanie.201411728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span>; <span class="NLM_string-name">Tillyer, R. D.</span>; <span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">Efficient Enantioselective Addition Reaction using an Organozinc Reagent</span>. World Patent <span class="NLM_patent">WO1998051676A1</span>, <span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=C.+Y.+Chen&author=R.+D.+Tillyer&author=L.+Tan&title=Efficient+Enantioselective+Addition+Reaction+using+an+Organozinc+Reagent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BY.%26atitle%3DEfficient%2520Enantioselective%2520Addition%2520Reaction%2520using%2520an%2520Organozinc%2520Reagent%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/nsb0595-407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnsb0595-407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=407-415&issue=5&author=J.+Dingauthor=K.+Dasauthor=H.+Moereelsauthor=L.+Koymansauthor=K.+Andriesauthor=P.+A.+Janssenauthor=S.+H.+Hughesauthor=E.+Arnold&title=Structure+of+HIV-1+RT%2FTIBO+R+86183+complex+reveals+similarity+in+the+binding+of+diverse+nonnucleoside+inhibitors&doi=10.1038%2Fnsb0595-407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fnsb0595-407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0595-407%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DMoereels%26aufirst%3DH.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520HIV-1%2520RT%252FTIBO%2520R%252086183%2520complex%2520reveals%2520similarity%2520in%2520the%2520binding%2520of%2520diverse%2520nonnucleoside%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D2%26issue%3D5%26spage%3D407%26epage%3D415%26doi%3D10.1038%2Fnsb0595-407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raeymaeckers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelder, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woestenborghs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heykants, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clercq, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1038/343470a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2F343470a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1689015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=1990&pages=470-474&author=R.+Pauwelsauthor=K.+Andriesauthor=J.+Desmyterauthor=D.+Scholsauthor=M.+J.+Kuklaauthor=H.+J.+Breslinauthor=A.+Raeymaeckersauthor=J.+V.+Gelderauthor=R.+Woestenborghsauthor=J.+Heykantsauthor=K.+Schellekensauthor=M.+A.+C.+Janssenauthor=E.+D.+Clercqauthor=P.+A.+J.+Janssen&title=Potent+and+selective+inhibition+of+HIV-1+replication+in+vitro+by+a+novel+series+of+TIBO+derivatives&doi=10.1038%2F343470a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span></div><div class="casAuthors">Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Van Gelder, Jozef; Woestenborghs, Robert; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6257</span>),
    <span class="NLM_cas:pages">470-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">In the search for compds. active against human immunodeficiency virus (HIV), it was found that members of a novel series of tetrahydro-imidazol[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivs. inhibit the replication of HIV-1, the main etiol. agent of AIDS, but not of HIV-2 or of any other DNA or RNA viruses.  In five cell systems, HIV-1 is inhibited by TIBO derivs. in nanomolar amts., which are 104-105 times lower that the cytotoxic concn.  The unprecedented specificity of these compds. may be due to an interaction with a reverse transcriptase-assocd. process.  By contrast, AZT (3'-azido-2',3'-dideoxythymidine), which is used for the treatment of AIDS, and DDC (2',3'-dideoxycytidine) and DDI (2',3'-dideoxyinosine), whose clin. application is being assessed, inhibit both HIV-1 and HIV-2 at concns. that, depending on the cell systems, are 2 to 4 orders of magnitude below their cytotoxic concn.  TIBO-derivs. are new chems. unrelated to any other antiviral agents.  They may be the most specific and potent inhibitors of HIV-1 replication studied so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodXWsMmazOdrVg90H21EOLACvtfcHk0lhLpSrZqWmGCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D&md5=c303b47ff312a49dded6132ebbaa4ca1</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2F343470a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F343470a0%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DRaeymaeckers%26aufirst%3DA.%26aulast%3DGelder%26aufirst%3DJ.%2BV.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DHeykants%26aufirst%3DJ.%26aulast%3DSchellekens%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DM.%2BA.%2BC.%26aulast%3DClercq%26aufirst%3DE.%2BD.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520HIV-1%2520replication%2520in%2520vitro%2520by%2520a%2520novel%2520series%2520of%2520TIBO%2520derivatives%26jtitle%3DNature%26date%3D1990%26volume%3D343%26spage%3D470%26epage%3D474%26doi%3D10.1038%2F343470a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobo-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koepke, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michejda, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(01)00168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0969-2126%2801%2900168-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1995&pages=365-379&author=J.+Dingauthor=K.+Dasauthor=C.+Tantilloauthor=W.+Zhangauthor=A.+D.+Clarkauthor=S.+Jessenauthor=X.+Luauthor=Y.+Hsiouauthor=A.+Jacobo-Molinaauthor=K.+Andriesauthor=R.+Pauwelsauthor=H.+Moereelsauthor=L.+Koymansauthor=P.+A.+J.+Janssenauthor=R.+H.+Smithauthor=M.+K.+Koepkeauthor=C.+J.+Michejdaauthor=S.+H.+Hughesauthor=E.+Arnold&title=Structure+of+HIV-1+reverse+transcriptase+in+a+complex+with+the+non-nucleoside+inhibitor+%CE%B1-APA+R+95845+at+2.8+%C3%85+resolution&doi=10.1016%2FS0969-2126%2801%2900168-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2801%2900168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252801%252900168-X%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DTantillo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DJessen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHsiou%26aufirst%3DY.%26aulast%3DJacobo-Molina%26aufirst%3DA.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DMoereels%26aufirst%3DH.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DSmith%26aufirst%3DR.%2BH.%26aulast%3DKoepke%26aufirst%3DM.%2BK.%26aulast%3DMichejda%26aufirst%3DC.%2BJ.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520HIV-1%2520reverse%2520transcriptase%2520in%2520a%2520complex%2520with%2520the%2520non-nucleoside%2520inhibitor%2520%25CE%25B1-APA%2520R%252095845%2520at%25202.8%2520%25C3%2585%2520resolution%26jtitle%3DStructure%26date%3D1995%26volume%3D3%26spage%3D365%26epage%3D379%26doi%3D10.1016%2FS0969-2126%2801%2900168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Daele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffels, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vreese, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woestenborghs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandamme, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, C. G.</span></span> <span> </span><span class="NLM_article-title">Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1715</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.5.1711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.90.5.1711" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=1711-1715&issue=5&author=R.+Pauwelsauthor=K.+Andriesauthor=Z.+Debyserauthor=P.+Van+Daeleauthor=D.+Scholsauthor=P.+Stoffelsauthor=K.+De+Vreeseauthor=R.+Woestenborghsauthor=A.+M.+Vandammeauthor=C.+G.+Janssen&title=Potent+and+highly+selective+human+immunodeficiency+virus+type+1+%28HIV-1%29+inhibition+by+a+series+of+alpha-anilinophenylacetamide+derivatives+targeted+at+HIV-1+reverse+transcriptase&doi=10.1073%2Fpnas.90.5.1711"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.5.1711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.5.1711%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DVan%2BDaele%26aufirst%3DP.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DStoffels%26aufirst%3DP.%26aulast%3DDe%2BVreese%26aufirst%3DK.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DVandamme%26aufirst%3DA.%2BM.%26aulast%3DJanssen%26aufirst%3DC.%2BG.%26atitle%3DPotent%2520and%2520highly%2520selective%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520inhibition%2520by%2520a%2520series%2520of%2520alpha-anilinophenylacetamide%2520derivatives%2520targeted%2520at%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26issue%3D5%26spage%3D1711%26epage%3D1715%26doi%3D10.1073%2Fpnas.90.5.1711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavash, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azijn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aken, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2234</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00411-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0960-894X%2801%2900411-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2229-2234&author=D.+W.+Ludoviciauthor=R.+W.+Kavashauthor=M.+J.+Kuklaauthor=C.+Y.+Hoauthor=H.+Yeauthor=B.+L.+De+Corteauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=H.+Azijnauthor=R.+Pauwelsauthor=H.+E.+Moereelsauthor=J.+Heeresauthor=L.+M.+Koymansauthor=M.+R.+de+Jongeauthor=K.+J.+Van+Akenauthor=F.+F.+Daeyaertauthor=P.+J.+Lewiauthor=K.+Dasauthor=E.+Arnoldauthor=P.+A.+Janssen&title=Evolution+of+anti-HIV+drug+candidates.+Part+2%3A+Diaryltriazine+%28DATA%29+analogues&doi=10.1016%2FS0960-894X%2801%2900411-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900411-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900411-5%26sid%3Dliteratum%253Aachs%26aulast%3DLudovici%26aufirst%3DD.%2BW.%26aulast%3DKavash%26aufirst%3DR.%2BW.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DDe%2BCorte%26aufirst%3DB.%2BL.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DMoereels%26aufirst%3DH.%2BE.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DVan%2BAken%26aufirst%3DK.%2BJ.%26aulast%3DDaeyaert%26aufirst%3DF.%2BF.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DEvolution%2520of%2520anti-HIV%2520drug%2520candidates.%2520Part%25202%253A%2520Diaryltriazine%2520%2528DATA%2529%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D2229%26epage%3D2234%26doi%3D10.1016%2FS0960-894X%2801%2900411-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenstein, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavash, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azijn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Aken, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2235</span>– <span class="NLM_lpage">2239</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00412-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0960-894X%2801%2900412-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2235-2239&issue=17&author=D.+W.+Ludoviciauthor=B.+L.+De+Corteauthor=M.+J.+Kuklaauthor=H.+Yeauthor=C.+Y.+Hoauthor=M.+A.+Lichtensteinauthor=R.+W.+Kavashauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=H.+Azijnauthor=R.+Pauwelsauthor=P.+J.+Lewiauthor=J.+Heeresauthor=L.+M.+Koymansauthor=M.+R.+de+Jongeauthor=K.+J.+Van+Akenauthor=F.+F.+Daeyaertauthor=K.+Dasauthor=E.+Arnoldauthor=P.+A.+Janssen&title=Evolution+of+anti-HIV+drug+candidates.+Part+3%3A+Diarylpyrimidine+%28DAPY%29+analogues&doi=10.1016%2FS0960-894X%2801%2900412-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900412-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900412-7%26sid%3Dliteratum%253Aachs%26aulast%3DLudovici%26aufirst%3DD.%2BW.%26aulast%3DDe%2BCorte%26aufirst%3DB.%2BL.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHo%26aufirst%3DC.%2BY.%26aulast%3DLichtenstein%26aufirst%3DM.%2BA.%26aulast%3DKavash%26aufirst%3DR.%2BW.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DVan%2BAken%26aufirst%3DK.%2BJ.%26aulast%3DDaeyaert%26aufirst%3DF.%2BF.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DEvolution%2520of%2520anti-HIV%2520drug%2520candidates.%2520Part%25203%253A%2520Diarylpyrimidine%2520%2528DAPY%2529%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D17%26spage%3D2235%26epage%3D2239%26doi%3D10.1016%2FS0960-894X%2801%2900412-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azijn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thielemans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Corte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span> <span> </span><span class="NLM_article-title">TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4680</span>– <span class="NLM_lpage">4686</span>, <span class="refDoi"> DOI: 10.1128/AAC.48.12.4680-4686.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.48.12.4680-4686.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15561844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKmt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=4680-4686&issue=12&author=K.+Andriesauthor=H.+Azijnauthor=T.+Thielemansauthor=D.+Ludoviciauthor=M.+Kuklaauthor=J.+Heeresauthor=P.+Janssenauthor=B.+De+Corteauthor=J.+Vingerhoetsauthor=R.+Pauwelsauthor=M.+P.+de+Bethune&title=TMC125%2C+a+novel+next-generation+nonnucleoside+reverse+transcriptase+inhibitor+active+against+nonnucleoside+reverse+transcriptase+inhibitor-resistant+human+immunodeficiency+virus+type+1&doi=10.1128%2FAAC.48.12.4680-4686.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1</span></div><div class="casAuthors">Andries, Koen; Azijn, Hilde; Thielemans, Theo; Ludovici, Donald; Kukla, Michael; Heeres, Jan; Janssen, Paul; De Corte, Bart; Vingerhoets, Johan; Pauwels, Rudi; de Bethune, Marie-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4680-4686</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1); however, currently marketed NNRTIs rapidly select resistant virus, and cross-resistance within the class is extensive.  A parallel screening strategy was applied to test candidates from a series of diarylpyrimidines against wild-type and resistant HIV strains carrying clin. relevant mutations.  Serum protein binding and metabolic stability were addressed early in the selection process.  The emerging clin. candidate, TMC125, was highly active against wild-type HIV-1 (50% effective concn. [EC50] = 1.4 to 4.8 nM) and showed some activity against HIV-2 (EC50 = 3.5 μM).  TMC125 also inhibited a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus.  Incubation of TMC125 with human liver microsomal fractions suggested good metabolic stability (15% decrease in drug concn. and 7% decrease in antiviral activity after 120 min).  Although TMC125 is highly protein bound, its antiviral effect was not reduced by the presence of 45 mg of human serum albumin/mL, 1 mg of α1-acid glycoprotein/mL, or 50% human serum.  In an initial screen for activity against a panel of 25 viruses carrying single and double reverse transcriptase amino acid substitutions assocd. with NNRTI resistance, the EC50 of TMC125 was <5 nM for 19 viruses, including the double mutants K101E + K103N and K103N + Y181C.  TMC125 also retained activity (EC50 < 100 nM) against 97% of 1,081 recent clin. derived recombinant viruses resistant to at least one of the currently marketed NNRTIs.  TMC125 is a potent next generation NNRTI, with the potential for use in individuals infected with NNRTI-resistant virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHVfHO28azELVg90H21EOLACvtfcHk0lj2Jocf7OrSFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKmt77I&md5=293f542ebbeb94e283d21070bb17c25f</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1128%2FAAC.48.12.4680-4686.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.48.12.4680-4686.2004%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DAzijn%26aufirst%3DH.%26aulast%3DThielemans%26aufirst%3DT.%26aulast%3DLudovici%26aufirst%3DD.%26aulast%3DKukla%26aufirst%3DM.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DJanssen%26aufirst%3DP.%26aulast%3DDe%2BCorte%26aufirst%3DB.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26atitle%3DTMC125%252C%2520a%2520novel%2520next-generation%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520active%2520against%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor-resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26issue%3D12%26spage%3D4680%26epage%3D4686%26doi%3D10.1128%2FAAC.48.12.4680-4686.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Etravirine</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">2357</span>– <span class="NLM_lpage">2372</span>, <span class="refDoi"> DOI: 10.2165/0003495-200868160-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F0003495-200868160-00007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=2357-2372&issue=16&author=E.+D.+Deeksauthor=G.+M.+Keating&title=Etravirine&doi=10.2165%2F0003495-200868160-00007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.2165%2F0003495-200868160-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F0003495-200868160-00007%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DEtravirine%26jtitle%3DDrugs%26date%3D2008%26volume%3D68%26issue%3D16%26spage%3D2357%26epage%3D2372%26doi%3D10.2165%2F0003495-200868160-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elsayed, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, D. J.</span></span> <span> </span><span class="NLM_article-title">Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection</span>. <i>Am. J. Health-Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.2146/ajhp080559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2146%2Fajhp080559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=20101061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVejtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=193-205&issue=3&author=R.+K.+Elsayedauthor=D.+J.+Caldwell&title=Etravirine%3A+a+novel+nonnucleoside+reverse+transcriptase+inhibitor+for+managing+human+immunodeficiency+virus+infection&doi=10.2146%2Fajhp080559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection</span></div><div class="casAuthors">Elsayed, Raghda K.; Caldwell, David J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Health-System Pharmacy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-205</span>CODEN:
                <span class="NLM_cas:coden">AHSPEK</span>;
        ISSN:<span class="NLM_cas:issn">1079-2082</span>.
    
            (<span class="NLM_cas:orgname">American Society of Health-System Pharmacists</span>)
        </div><div class="casAbstract">A review.  Purpose. The pharmacol., efficacy, and safety of etravirine and its clin. utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.  Summary. While single mutations confer resistance to earlier nonnucleoside reverse transcriptase inhibitors (NNRTIs), etravirine exhibited an Increased barrier to resistance by requiring multiple mutations for resistance to occur in preclin. studies.  Randomized controlled trials have demonstrated the efficacy of etravirine in achieving HIV RNA viral loads of <50 copies/mL and a significant increase in baseline CD4+ lymphocyte count in treatment-experienced patients.  There has been a trend toward increased rates of death, progression to acquired immunodeficiency syndrome, and opportunistic infections in patients using placebo during Phase III trials.  Baseline patient characteristics that correlate with changes in etravirine efficacy are reported.  Mild-to-moderate rash and nausea are the most common adverse effects of etravirine.  If rash is suspected, etravirine should be discontinued and rechallenge should be avoided due to the risk of severe and possibly fatal skin reactions.  Unlike some antiretrovirals, increased risks of hepatic, lipid, or neuropsychiatric abnormalities are not correlated with its use.  Several drug interactions are expected with etravirine use, and some may require dosage adjustment or substitution of concurrent drugs.  No dosage adjustments are recommended for patients with mild-to-moderate hepatic or renal Impairment.  Conclusion. Etravirine, a second-generation NNRTI, is efficacious in achieving viral suppression and improving the immune function in treatment-experienced HIV-infected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxKwz022HTkLVg90H21EOLACvtfcHk0lj2Jocf7OrSFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVejtbc%253D&md5=ff0a9cd401885deb3e5e29f57aef4882</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2146%2Fajhp080559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fajhp080559%26sid%3Dliteratum%253Aachs%26aulast%3DElsayed%26aufirst%3DR.%2BK.%26aulast%3DCaldwell%26aufirst%3DD.%2BJ.%26atitle%3DEtravirine%253A%2520a%2520novel%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520for%2520managing%2520human%2520immunodeficiency%2520virus%2520infection%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2010%26volume%3D67%26issue%3D3%26spage%3D193%26epage%3D205%26doi%3D10.2146%2Fajhp080559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Béthune, M.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkel, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medaer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Knaep, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohets, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffels, P.</span></span> <span> </span><span class="NLM_article-title">In search of a novel anti-HIV Drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1901</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1021/jm040840e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040840e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1901-1909&issue=6&author=P.+A.+J.+Janssenauthor=P.+J.+Lewiauthor=E.+Arnoldauthor=F.+Daeyaertauthor=M.+de+Jongeauthor=J.+Heeresauthor=L.+Koymansauthor=M.+Vinkersauthor=J.+Guillemontauthor=E.+Pasquierauthor=M.+Kuklaauthor=D.+Ludoviciauthor=K.+Andriesauthor=M.-P.+de+B%C3%A9thuneauthor=R.+Pauwelsauthor=K.+Dasauthor=A.+D.+Clarkauthor=Y.+V.+Frenkelauthor=S.+H.+Hughesauthor=B.+Medaerauthor=F.+De+Knaepauthor=H.+Bohetsauthor=F.+De+Clerckauthor=A.+Lampoauthor=P.+Williamsauthor=P.+Stoffels&title=In+search+of+a+novel+anti-HIV+Drug%3A+multidisciplinary+coordination+in+the+discovery+of+4-%5B%5B4-%5B%5B4-%5B%281E%29-2-Cyanoethenyl%5D-2%2C6-dimethylphenyl%5Damino%5D-2-+pyrimidinyl%5Damino%5Dbenzonitrile+%28R278474%2C+Rilpivirine%29&doi=10.1021%2Fjm040840e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)</span></div><div class="casAuthors">Janssen, Paul A. J.; Lewi, Paul J.; Arnold, Eddy; Daeyaert, Frits; de Jonge, Marc; Heeres, Jan; Koymans, Luc; Vinkers, Maarten; Guillemont, Jerome; Pasquier, Elisabeth; Kukla, Mike; Ludovici, Don; Andries, Koen; de Bethune, Marie-Pierre; Pauwels, Rudi; Das, Kalyan; Clark, Art D., Jr.; Frenkel, Yulia Volovik; Hughes, Stephen H.; Medaer, Bart; De Knaep, Fons; Bohets, Hilde; De Clerck, Fred; Lampo, Ann; Williams, Peter; Stoffels, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1901-1909</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate.  R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet these criteria and to be suitable for high compliance oral treatment of HIV-1 infection.  The discovery of R278474 was the result of a coordinated multidisciplinary effort involving medicinal chemists, virologists, crystallographers, mol. modelers, toxicologists, anal. chemists, pharmacists, and many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8upgC3x1GuLVg90H21EOLACvtfcHk0lin7rQEUgOvSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D&md5=d4b650dcaa248d5cdb1dd500135c8f7e</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm040840e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040840e%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DDaeyaert%26aufirst%3DF.%26aulast%3Dde%2BJonge%26aufirst%3DM.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DVinkers%26aufirst%3DM.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DKukla%26aufirst%3DM.%26aulast%3DLudovici%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BB%25C3%25A9thune%26aufirst%3DM.-P.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DFrenkel%26aufirst%3DY.%2BV.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DMedaer%26aufirst%3DB.%26aulast%3DDe%2BKnaep%26aufirst%3DF.%26aulast%3DBohets%26aufirst%3DH.%26aulast%3DDe%2BClerck%26aufirst%3DF.%26aulast%3DLampo%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DStoffels%26aufirst%3DP.%26atitle%3DIn%2520search%2520of%2520a%2520novel%2520anti-HIV%2520Drug%253A%2520multidisciplinary%2520coordination%2520in%2520the%2520discovery%2520of%25204-%255B%255B4-%255B%255B4-%255B%25281E%2529-2-Cyanoethenyl%255D-2%252C6-dimethylphenyl%255Damino%255D-2-%2520pyrimidinyl%255Damino%255Dbenzonitrile%2520%2528R278474%252C%2520Rilpivirine%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D1901%26epage%3D1909%26doi%3D10.1021%2Fjm040840e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lansdon, E.
B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brendza, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4295</span>– <span class="NLM_lpage">4429</span>, <span class="refDoi"> DOI: 10.1021/jm1002233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1002233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFeqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4295-4429&issue=10&author=E.%0AB.+Lansdonauthor=K.+M.+Brendzaauthor=M.+Hungauthor=R.+Wangauthor=S.+Mukundauthor=D.+Jinauthor=G.+Birkusauthor=N.+Kuttyauthor=X.+Liu&title=Crystal+structures+of+HIV-1+reverse+transcriptase+with+etravirine+%28TMC125%29+and+rilpivirine+%28TMC278%29%3A+implications+for+drug+design&doi=10.1021%2Fjm1002233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design</span></div><div class="casAuthors">Lansdon, Eric B.; Brendza, Katherine M.; Hung, Magdeleine; Wang, Ruth; Mukund, Susmith; Jin, Debi; Birkus, Gabriel; Kutty, Nilima; Liu, Xiaohong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4295-4299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent flexibility, helping to maintain activity against a wide range of resistance mutations.  Crystal structures were detd. with wild-type and K103N HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278).  These structures reveal a similar binding mode for TMC125 and TMC278, whether bound to wild-type or K103N RT.  Comparison to previously published structures reveals differences in binding modes for TMC125 and differences in protein conformation for TMC278.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVNZlZQF054rVg90H21EOLACvtfcHk0lin7rQEUgOvSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFeqsLs%253D&md5=d99b8d74a488eb94da35246c6f141240</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm1002233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1002233%26sid%3Dliteratum%253Aachs%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DBrendza%26aufirst%3DK.%2BM.%26aulast%3DHung%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DD.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DKutty%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DCrystal%2520structures%2520of%2520HIV-1%2520reverse%2520transcriptase%2520with%2520etravirine%2520%2528TMC125%2529%2520and%2520rilpivirine%2520%2528TMC278%2529%253A%2520implications%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D10%26spage%3D4295%26epage%3D4429%26doi%3D10.1021%2Fjm1002233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romines, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">5000</span>– <span class="NLM_lpage">5008</span>, <span class="refDoi"> DOI: 10.1021/jm8004493</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8004493" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5000-5008&issue=16&author=J.+Renauthor=P.+P.+Chamberlainauthor=A.+Stampauthor=S.+A.+Shortauthor=K.+L.+Weaverauthor=K.+R.+Rominesauthor=R.+Hazenauthor=A.+Freemanauthor=R.+G.+Ferrisauthor=C.+W.+Andrewsauthor=L.+Booneauthor=J.+H.+Chanauthor=D.+K.+Stammers&title=Structural+basis+for+the+improved+drug+resistance+profile+of+new+generation+benzophenone+non-nucleoside+HIV-1+reverse+transcriptase+inhibitors&doi=10.1021%2Fjm8004493"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm8004493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004493%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DStamp%26aufirst%3DA.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DWeaver%26aufirst%3DK.%2BL.%26aulast%3DRomines%26aufirst%3DK.%2BR.%26aulast%3DHazen%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DA.%26aulast%3DFerris%26aufirst%3DR.%2BG.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DBoone%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DJ.%2BH.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26atitle%3DStructural%2520basis%2520for%2520the%2520improved%2520drug%2520resistance%2520profile%2520of%2520new%2520generation%2520benzophenone%2520non-nucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D16%26spage%3D5000%26epage%3D5008%26doi%3D10.1021%2Fjm8004493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scholler-Gyure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakuda, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raoof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Smedt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoetelmans, R. M.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics and pharmacodynamics of etravirine</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.2165/10895940-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2165%2F10895940-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=19725591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGnsLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=561-574&issue=9&author=M.+Scholler-Gyureauthor=T.+N.+Kakudaauthor=A.+Raoofauthor=G.+De+Smedtauthor=R.+M.+Hoetelmans&title=Clinical+pharmacokinetics+and+pharmacodynamics+of+etravirine&doi=10.2165%2F10895940-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics and pharmacodynamics of etravirine</span></div><div class="casAuthors">Scholler-Gyure, Monika; Kakuda, Thomas N.; Raoof, Araz; De Smedt, Goedele; Hoetelmans, Richard M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">561-574</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection.  It has a high genetic barrier to the emergence of viral resistance, and maintains its antiviral activity in the presence of common NNRTI mutations.  The pharmacokinetics of etravirine in HIV-infected patients at the recommended dosage of 200 mg twice daily demonstrates moderate intersubject variability and no time dependency.  Due to substantially lower exposures when taken on an empty stomach, etravirine should be administered following a meal.  The drug is highly protein bound (99.9%) to albumin and α1-acid glycoprotein and shows a relatively long elimination half-life of 30-40 h.  Etravirine is metabolized by cytochrome P 450 (CYP) 3A, 2C9 and 2C19; the metabolites are subsequently glucuronidated by uridine diphosphate glucuronosyltransferase.  Renal elimination of etravirine is negligible.  Etravirine has the potential for interactions by inducing CYP3A and inhibiting CYP2C9 and 2C19; it is a mild inhibitor of P-glycoprotein but not a substrate.  The drug interaction profile of etravirine has been well characterized and is manageable.  No dosage adjustments are needed in patients with renal impairment or mild to moderate hepatic impairment.  Race, sex, bodyweight and age do not affect the pharmacokinetics of etravirine.  In the two phase III trials DUET-1 and DUET-2, no relationship was demonstrated between the pharmacokinetics of etravirine and the primary efficacy endpoint of viral load below 50 copies/mL or the safety profile of etravirine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdy72LoMGX7Vg90H21EOLACvtfcHk0lj3vcFj_1cxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGnsLbL&md5=8c9bce4045563221d8ac92ec221e36f2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.2165%2F10895940-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F10895940-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DScholler-Gyure%26aufirst%3DM.%26aulast%3DKakuda%26aufirst%3DT.%2BN.%26aulast%3DRaoof%26aufirst%3DA.%26aulast%3DDe%2BSmedt%26aufirst%3DG.%26aulast%3DHoetelmans%26aufirst%3DR.%2BM.%26atitle%3DClinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520etravirine%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2009%26volume%3D48%26issue%3D9%26spage%3D561%26epage%3D574%26doi%3D10.2165%2F10895940-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanakakis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumpus, N. N.</span></span> <span> </span><span class="NLM_article-title">Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.044404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1124%2Fdmd.111.044404" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=803-814&issue=4&author=L.+J.+Yanakakisauthor=N.+N.+Bumpus&title=Biotransformation+of+the+antiretroviral+drug+etravirine%3A+metabolite+identification%2C+reaction+phenotyping%2C+and+characterization+of+autoinduction+of+cytochrome+P450-dependent+metabolism&doi=10.1124%2Fdmd.111.044404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.044404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.044404%26sid%3Dliteratum%253Aachs%26aulast%3DYanakakis%26aufirst%3DL.%2BJ.%26aulast%3DBumpus%26aufirst%3DN.%2BN.%26atitle%3DBiotransformation%2520of%2520the%2520antiretroviral%2520drug%2520etravirine%253A%2520metabolite%2520identification%252C%2520reaction%2520phenotyping%252C%2520and%2520characterization%2520of%2520autoinduction%2520of%2520cytochrome%2520P450-dependent%2520metabolism%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D4%26spage%3D803%26epage%3D814%26doi%3D10.1124%2Fdmd.111.044404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lade, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumpus, N. N.</span></span> <span> </span><span class="NLM_article-title">Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">5067</span>– <span class="NLM_lpage">5079</span>, <span class="refDoi"> DOI: 10.1128/AAC.01401-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.01401-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5067-5079&issue=10&author=J.+M.+Ladeauthor=L.+B.+Averyauthor=N.+N.+Bumpus&title=Human+biotransformation+of+the+nonnucleoside+reverse+transcriptase+inhibitor+rilpivirine+and+a+cross-species+metabolism+comparison&doi=10.1128%2FAAC.01401-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1128%2FAAC.01401-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01401-13%26sid%3Dliteratum%253Aachs%26aulast%3DLade%26aufirst%3DJ.%2BM.%26aulast%3DAvery%26aufirst%3DL.%2BB.%26aulast%3DBumpus%26aufirst%3DN.%2BN.%26atitle%3DHuman%2520biotransformation%2520of%2520the%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%2520rilpivirine%2520and%2520a%2520cross-species%2520metabolism%2520comparison%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D10%26spage%3D5067%26epage%3D5079%26doi%3D10.1128%2FAAC.01401-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alcaro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alteri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccherini-Silberstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortuso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrotta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perno, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svicher, V.</span></span> <span> </span><span class="NLM_article-title">Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2011.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.drup.2011.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=21295512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntlGkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=141-149&issue=3&author=S.+Alcaroauthor=C.+Alteriauthor=A.+Arteseauthor=F.+Ceccherini-Silbersteinauthor=G.+Costaauthor=F.+Ortusoauthor=L.+Parrottaauthor=C.+F.+Pernoauthor=V.+Svicher&title=Molecular+and+structural+aspects+of+clinically+relevant+mutations+related+to+the+approved+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.drup.2011.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase</span></div><div class="casAuthors">Alcaro, Stefano; Alteri, Claudia; Artese, Anna; Ceccherini-Silberstein, Francesca; Costa, Giosue; Ortuso, Francesco; Parrotta, Lucia; Perno, Carlo Federico; Svicher, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years relevant progress has been made in the treatment of HIV-1 with a consequent decrease in mortality.  The availability of potent antiretroviral drugs and the ability of viral load assays that accurately evaluate the true level of viral replication, have led to a better understanding of pathogenesis of the disease and how to obtain improved therapeutic profiles.  The highly active antiretroviral therapy (HAART), based on a combination of three or more antiretroviral drugs, has radically changed the clin. outcome of HIV.  In particular, reverse transcriptase non-nucleoside inhibitors (NNRTIs) play an essential role in most protocols and are often used in first line treatment.  The high specificity of these inhibitors towards HIV-1 has increased the no. of structural and mol. modeling studies of enzyme complexes and that have led to chem. syntheses of more selective second and third-generation NNRTIs.  However, a considerable percentage of new HIV-1 infections are caused by the emergence of drug-resistant mutant viruses that complicate treatment strategies.  In this review we discuss relevant clin. and structural aspects for the management of antiretroviral drug resistance, with detailed explanations of mechanisms and mutation patterns useful to better understand the relation between drug resistance and therapy failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1XVvMaPx3K7Vg90H21EOLACvtfcHk0lj3vcFj_1cxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntlGkt7c%253D&md5=e4e75144150c7bfd12bd22d7c5beb040</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2011.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2011.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DAlteri%26aufirst%3DC.%26aulast%3DArtese%26aufirst%3DA.%26aulast%3DCeccherini-Silberstein%26aufirst%3DF.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DParrotta%26aufirst%3DL.%26aulast%3DPerno%26aufirst%3DC.%2BF.%26aulast%3DSvicher%26aufirst%3DV.%26atitle%3DMolecular%2520and%2520structural%2520aspects%2520of%2520clinically%2520relevant%2520mutations%2520related%2520to%2520the%2520approved%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2011%26volume%3D14%26issue%3D3%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.drup.2011.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puleo, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2737</span>– <span class="NLM_lpage">2745</span>, <span class="refDoi"> DOI: 10.1021/jm501908a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501908a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2737-2745&issue=6&author=K.+M.+Freyauthor=D.+E.+Puleoauthor=K.+A.+Spasovauthor=M.+Bolliniauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=Structure-based+evaluation+of+non-nucleoside+inhibitors+with+improved+potency+and+solubility+that+target+HIV+reverse+transcriptase+variants&doi=10.1021%2Fjm501908a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Evaluation of Non-nucleoside Inhibitors with Improved Potency and Solubility That Target HIV Reverse Transcriptase Variants</span></div><div class="casAuthors">Frey, Kathleen M.; Puleo, David E.; Spasov, Krasimir A.; Bollini, Mariella; Jorgensen, William L.; Anderson, Karen S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2737-2745</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of novel non-nucleoside inhibitors (NNRTIs) with activity against variants of HIV reverse transcriptase (RT) is crucial for overcoming treatment failure.  The NNRTIs bind in an allosteric pocket in RT ∼10 Å away from the active site.  Earlier analogs of the catechol diether compd. series have picomolar activity against HIV strains with wild-type RT but lose potency against variants with single Y181C and double K103N/Y181C mutations.  As guided by structure-based and computational studies, removal of the 5-Cl substitution of compd. 1 on the catechol aryl ring system led to a new analog compd. 2 that maintains greater potency against Y181C and K103N/Y181C variants and better soly. (510 μg/mL).  Crystal structures were detd. for wild-type, Y181C, and K103N/Y181C RT in complex with both compds. 1 and 2 to understand the structural basis for these findings.  Comparison of the structures reveals that the Y181C mutation destabilizes the binding mode of compd. 1 and disrupts the interactions with residues in the pocket.  Compd. 2 maintains the same conformation in wild-type and mutant structures, in addn. to several interactions with the NNRTI binding pocket.  Comparison of the six crystal structures will assist in the understanding of compd. binding modes and future optimization of the catechol diether series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp43Id88QK4TbVg90H21EOLACvtfcHk0lj3vcFj_1cxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtV2nt7w%253D&md5=13f9ea42933e5b5c4c44942754c5c650</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fjm501908a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501908a%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DK.%2BM.%26aulast%3DPuleo%26aufirst%3DD.%2BE.%26aulast%3DSpasov%26aufirst%3DK.%2BA.%26aulast%3DBollini%26aufirst%3DM.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DStructure-based%2520evaluation%2520of%2520non-nucleoside%2520inhibitors%2520with%2520improved%2520potency%2520and%2520solubility%2520that%2520target%2520HIV%2520reverse%2520transcriptase%2520variants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D6%26spage%3D2737%26epage%3D2745%26doi%3D10.1021%2Fjm501908a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paris, K.
A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haq, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felts, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. M.</span></span> <span> </span><span class="NLM_article-title">Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6413</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/jm900854h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900854h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6413-6420&issue=20&author=K.%0AA.+Parisauthor=O.+Haqauthor=A.+K.+Feltsauthor=K.+Dasauthor=E.+Arnoldauthor=R.+M.+Levy&title=Conformational+landscape+of+the+human+immunodeficiency+virus+type+1+reverse+transcriptase+non-nucleoside+inhibitor+binding+pocket%3A+lessons+for+inhibitor+design+from+a+cluster+analysis+of+many+crystal+structures&doi=10.1021%2Fjm900854h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1021%2Fjm900854h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900854h%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DK.%2BA.%26aulast%3DHaq%26aufirst%3DO.%26aulast%3DFelts%26aufirst%3DA.%2BK.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DLevy%26aufirst%3DR.%2BM.%26atitle%3DConformational%2520landscape%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520type%25201%2520reverse%2520transcriptase%2520non-nucleoside%2520inhibitor%2520binding%2520pocket%253A%2520lessons%2520for%2520inhibitor%2520design%2520from%2520a%2520cluster%2520analysis%2520of%2520many%2520crystal%2520structures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D20%26spage%3D6413%26epage%3D6420%26doi%3D10.1021%2Fjm900854h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parry, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khatib, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charalambous, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Oliveira, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span> <span> </span><span class="NLM_article-title">Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">971</span>, <span class="refDoi"> DOI: 10.1128/AAC.04215-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.04215-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=960-971&issue=2&author=A.+E.+Bassonauthor=S.+Y.+Rheeauthor=C.+M.+Parryauthor=Z.+El-Khatibauthor=S.+Charalambousauthor=T.+De+Oliveiraauthor=D.+Pillayauthor=C.+Hoffmannauthor=D.+Katzensteinauthor=R.+W.+Shaferauthor=L.+Morris&title=Impact+of+drug+resistance-associated+amino+acid+changes+in+HIV-1+subtype+C+on+susceptibility+to+newer+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1128%2FAAC.04215-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1128%2FAAC.04215-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04215-14%26sid%3Dliteratum%253Aachs%26aulast%3DBasson%26aufirst%3DA.%2BE.%26aulast%3DRhee%26aufirst%3DS.%2BY.%26aulast%3DParry%26aufirst%3DC.%2BM.%26aulast%3DEl-Khatib%26aufirst%3DZ.%26aulast%3DCharalambous%26aufirst%3DS.%26aulast%3DDe%2BOliveira%26aufirst%3DT.%26aulast%3DPillay%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DC.%26aulast%3DKatzenstein%26aufirst%3DD.%26aulast%3DShafer%26aufirst%3DR.%2BW.%26aulast%3DMorris%26aufirst%3DL.%26atitle%3DImpact%2520of%2520drug%2520resistance-associated%2520amino%2520acid%2520changes%2520in%2520HIV-1%2520subtype%2520C%2520on%2520susceptibility%2520to%2520newer%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D2%26spage%3D960%26epage%3D971%26doi%3D10.1128%2FAAC.04215-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Magen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schader, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span> <span> </span><span class="NLM_article-title">Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4667</span>– <span class="NLM_lpage">4672</span>, <span class="refDoi"> DOI: 10.1128/AAC.00800-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.00800-09" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=4667-4672&issue=11&author=H.+Xuauthor=Y.+Quanauthor=B.+G.+Brennerauthor=T.+Bar-Magenauthor=M.+Oliveiraauthor=S.+M.+Schaderauthor=M.+A.+Wainberg&title=Human+immunodeficiency+virus+type+1+recombinant+reverse+transcriptase+enzymes+containing+the+G190A+and+Y181C+resistance+mutations+remain+sensitive+to+etravirine&doi=10.1128%2FAAC.00800-09"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1128%2FAAC.00800-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00800-09%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DQuan%26aufirst%3DY.%26aulast%3DBrenner%26aufirst%3DB.%2BG.%26aulast%3DBar-Magen%26aufirst%3DT.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DSchader%26aufirst%3DS.%2BM.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26atitle%3DHuman%2520immunodeficiency%2520virus%2520type%25201%2520recombinant%2520reverse%2520transcriptase%2520enzymes%2520containing%2520the%2520G190A%2520and%2520Y181C%2520resistance%2520mutations%2520remain%2520sensitive%2520to%2520etravirine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26issue%3D11%26spage%3D4667%26epage%3D4672%26doi%3D10.1128%2FAAC.00800-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saravolatz, L. D.</span></span> <span> </span><span class="NLM_article-title">Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1093/jac/dks404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1093%2Fjac%2Fdks404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23099850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=250-256&issue=2&author=M.+Sharmaauthor=L.+D.+Saravolatz&title=Rilpivirine%3A+a+new+non-nucleoside+reverse+transcriptase+inhibitor&doi=10.1093%2Fjac%2Fdks404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor</span></div><div class="casAuthors">Sharma, Mamta; Saravolatz, Louis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-256</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult patients in combination with other antiretroviral agents.  The recommended dose is a 25 mg tablet once daily taken orally with a meal.  Due to cytochrome P 450 3A4 enzyme induction or gastric pH increase, rilpivirine cannot be coadministered with a no. of other drugs (anticonvulsants, rifabutin, rifampicin, rifapentine, proton pump inhibitors, systemic dexamethasone and St John's wort).  Rilpivirine should be used with caution when coadministered with a drug with a known risk for torsade de pointes.  Rilpivirine has a better tolerability than a comparative NNRTI, efavirenz, in clin. trials, with fewer central nervous system adverse effects, rashes, lipid abnormalities and discontinuation rates.  Virol. failure occurs more commonly with higher baseline viral loads (>100 000 copies/mL) and lower baseline CD4 counts (<50cells/mm3).  Seventeen NNRTI mutations have been assocd. with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N.  Resistance to rilpivirine largely excludes future use of the NNRTI class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMF-84gVV5t7Vg90H21EOLACvtfcHk0liHiZ8rrcs0ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVCjsA%253D%253D&md5=83d5fe1e2377ec908cc5f7b5e9eb94ab</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdks404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdks404%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DSaravolatz%26aufirst%3DL.%2BD.%26atitle%3DRilpivirine%253A%2520a%2520new%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2013%26volume%3D68%26issue%3D2%26spage%3D250%26epage%3D256%26doi%3D10.1093%2Fjac%2Fdks404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span> <i>Etravirine Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Etravirine+Package%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEtravirine%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauly, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span> <span> </span><span class="NLM_article-title">A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants</span>. <i>Retrovirology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">99</span>, <span class="refDoi"> DOI: 10.1186/1742-4690-9-99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1186%2F1742-4690-9-99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=23217210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisVeksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=99&author=B.+C.+Johnsonauthor=G.+T.+Paulyauthor=G.+Raiauthor=D.+Patelauthor=J.+D.+Baumanauthor=H.+L.+Bakerauthor=K.+Dasauthor=J.+P.+Schneiderauthor=D.+J.+Maloneyauthor=E.+Arnoldauthor=C.+J.+Thomasauthor=S.+H.+Hughes&title=A+comparison+of+the+ability+of+rilpivirine+%28TMC278%29+and+selected+analogues+to+inhibit+clinically+relevant+HIV-1+reverse+transcriptase+mutants&doi=10.1186%2F1742-4690-9-99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants</span></div><div class="casAuthors">Johnson, Barry C.; Pauly, Gary T.; Rai, Ganesha; Patel, Disha; Bauman, Joseph D.; Baker, Heather L.; Das, Kalyan; Schneider, Joel P.; Maloney, David J.; Arnold, Eddy; Thomas, Craig J.; Hughes, Stephen H.</div><div class="citationInfo"><span class="NLM_cas:title">Retrovirology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99</span>CODEN:
                <span class="NLM_cas:coden">RETRBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-4690</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chem. step of DNA synthesis.  In contrast to earlier NNRTIs, rilpivirine retains potency against well-characterized, clin. relevant RT mutants.  Many structural analogs of rilpivirine are described in the patent literature, but detailed analyses of their antiviral activities have not been published.  This work addresses the ability of several of these analogs to inhibit the replication of wild-type (WT) and drug-resistant HIV-1.  Results: We used a combination of structure activity relationships and X-ray crystallog. to examine NNRTIs that are structurally related to rilpivirine to det. their ability to inhibit WT RT and several clin. relevant RT mutants.  Several analogs showed broad activity with only modest losses of potency when challenged with drug-resistant viruses.  Structural analyses (crystallog. or modeling) of several analogs whose potencies were reduced by RT mutations provide insight into why these compds. were less effective.  Conclusions: Subtle variations between compds. can lead to profound differences in their activities and resistance profiles.  Compds. with larger substitutions replacing the pyrimidine and benzonitrile groups of rilpivirine, which reorient pocket residues, tend to lose more activity against the mutants we tested.  These results provide a deeper understanding of how rilpivirine and related compds. interact with the NNRTI binding pocket and should facilitate development of novel inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEp7L0uk3OsrVg90H21EOLACvtfcHk0liGfN2wdHlwxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisVeksL8%253D&md5=7eadce812488ec262f6e088dc9d3a7ed</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2F1742-4690-9-99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-4690-9-99%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BC.%26aulast%3DPauly%26aufirst%3DG.%2BT.%26aulast%3DRai%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DBauman%26aufirst%3DJ.%2BD.%26aulast%3DBaker%26aufirst%3DH.%2BL.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DJ.%2BP.%26aulast%3DMaloney%26aufirst%3DD.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26atitle%3DA%2520comparison%2520of%2520the%2520ability%2520of%2520rilpivirine%2520%2528TMC278%2529%2520and%2520selected%2520analogues%2520to%2520inhibit%2520clinically%2520relevant%2520HIV-1%2520reverse%2520transcriptase%2520mutants%26jtitle%3DRetrovirology%26date%3D2012%26volume%3D9%26spage%3D99%26doi%3D10.1186%2F1742-4690-9-99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ripamonti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, M.</span></span> <span> </span><span class="NLM_article-title">Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1586/14787210.2014.863708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1586%2F14787210.2014.863708" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=24308712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Orsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=13-29&issue=1&author=D.+Ripamontiauthor=E.+Bombanaauthor=M.+Rizzi&title=Rilpivirine%3A+drug+profile+of+a+second-generation+non-nucleoside+reverse+transcriptase+HIV-inhibitor&doi=10.1586%2F14787210.2014.863708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor</span></div><div class="casAuthors">Ripamonti, Diego; Bombana, Enrico; Rizzi, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-29</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Rilpivirine (RPV) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of the diarylpyrimidine family.  RPV can be given once daily, is well absorbed and should be administered with food.  It is eliminated mainly by hepatic metab.  Two phase III noninferiority trials (ECHO and THRIVE), compared RPV 25mg with efavirenz (EFV) 600 mg, both given once daily, and combined with 2NRTI backbone.  At week 48, response rate for pooled data were 84 vs. 82% (difference: 2%; 95% CI: -2.0 to 6.0%).  EFV arms performed better than RPV arms when at higher baseline HIV RNA, so RPV was approved for treatment-naive patients with HIV RNA below 100,000 copies/mL.  Approx. 90% of viruses phenotypically resistant to RPV showed cross-resistance to ETR.  Conversely, phenotypic anal. showed that in EFV arm, none were resistant to the second-generation NNRTIs.  CD4 count increases were similar between groups, but RPV showed a lower rate of discontinuation due to adverse events and lower rates of central nervous system effects, rash and lipid abnormalities.  Potency, tolerability and co-formulation in a single tablet (Eviplera, Complera) make this drug a new and attractive option for the treatment of HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9gmCkqrVcqLVg90H21EOLACvtfcHk0liGfN2wdHlwxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Orsbk%253D&md5=e2ea563d672ec7d4915dda7894da4811</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1586%2F14787210.2014.863708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14787210.2014.863708%26sid%3Dliteratum%253Aachs%26aulast%3DRipamonti%26aufirst%3DD.%26aulast%3DBombana%26aufirst%3DE.%26aulast%3DRizzi%26aufirst%3DM.%26atitle%3DRilpivirine%253A%2520drug%2520profile%2520of%2520a%2520second-generation%2520non-nucleoside%2520reverse%2520transcriptase%2520HIV-inhibitor%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2014%26volume%3D12%26issue%3D1%26spage%3D13%26epage%3D29%26doi%3D10.1586%2F14787210.2014.863708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskey, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mislak, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliciano, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1079</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1075-1079&issue=10&author=W.+T.+Grayauthor=K.+M.+Freyauthor=S.+B.+Laskeyauthor=A.+C.+Mislakauthor=K.+A.+Spasovauthor=W.+G.+Leeauthor=M.+Bolliniauthor=R.+F.+Silicianoauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=Potent+inhibitors+active+against+HIV+reverse+transcriptase+with+K101P%2C+a+mutation+conferring+rilpivirine+resistance&doi=10.1021%2Facsmedchemlett.5b00254"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00254%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DW.%2BT.%26aulast%3DFrey%26aufirst%3DK.%2BM.%26aulast%3DLaskey%26aufirst%3DS.%2BB.%26aulast%3DMislak%26aufirst%3DA.%2BC.%26aulast%3DSpasov%26aufirst%3DK.%2BA.%26aulast%3DLee%26aufirst%3DW.%2BG.%26aulast%3DBollini%26aufirst%3DM.%26aulast%3DSiliciano%26aufirst%3DR.%2BF.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520inhibitors%2520active%2520against%2520HIV%2520reverse%2520transcriptase%2520with%2520K101P%252C%2520a%2520mutation%2520conferring%2520rilpivirine%2520resistance%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D10%26spage%3D1075%26epage%3D1079%26doi%3D10.1021%2Facsmedchemlett.5b00254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby-Germinario, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petropoulos, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span> <span> </span><span class="NLM_article-title">Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">5649</span>– <span class="NLM_lpage">5657</span>, <span class="refDoi"> DOI: 10.1128/AAC.01536-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1128%2FAAC.01536-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5649-5657&issue=11&author=H.+T.+Xuauthor=S.+P.+Colby-Germinarioauthor=W.+Huangauthor=M.+Oliveiraauthor=Y.+Hanauthor=Y.+Quanauthor=C.+J.+Petropoulosauthor=M.+A.+Wainberg&title=Role+of+the+K101E+substitution+in+HIV-1+reverse+transcriptase+in+resistance+to+rilpivirine+and+other+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1128%2FAAC.01536-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1128%2FAAC.01536-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01536-13%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%2BT.%26aulast%3DColby-Germinario%26aufirst%3DS.%2BP.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DQuan%26aufirst%3DY.%26aulast%3DPetropoulos%26aufirst%3DC.%2BJ.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26atitle%3DRole%2520of%2520the%2520K101E%2520substitution%2520in%2520HIV-1%2520reverse%2520transcriptase%2520in%2520resistance%2520to%2520rilpivirine%2520and%2520other%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D11%26spage%3D5649%26epage%3D5657%26doi%3D10.1128%2FAAC.01536-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michailidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzek, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagedorn, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norden, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parniak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span> <span> </span><span class="NLM_article-title">Biochemical mechanism of HIV-1 resistance to rilpivirine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">38110</span>– <span class="NLM_lpage">38123</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.398180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1074%2Fjbc.M112.398180" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=38110-38123&issue=45&author=K.+Singhauthor=B.+Marchandauthor=D.+K.+Raiauthor=B.+Sharmaauthor=E.+Michailidisauthor=E.+M.+Ryanauthor=K.+B.+Matzekauthor=M.+D.+Leslieauthor=A.+N.+Hagedornauthor=Z.+Liauthor=P.+R.+Nordenauthor=A.+Hachiyaauthor=M.+A.+Parniakauthor=H.+T.+Xuauthor=M.+A.+Wainbergauthor=S.+G.+Sarafianos&title=Biochemical+mechanism+of+HIV-1+resistance+to+rilpivirine&doi=10.1074%2Fjbc.M112.398180"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.398180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.398180%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DMarchand%26aufirst%3DB.%26aulast%3DRai%26aufirst%3DD.%2BK.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DRyan%26aufirst%3DE.%2BM.%26aulast%3DMatzek%26aufirst%3DK.%2BB.%26aulast%3DLeslie%26aufirst%3DM.%2BD.%26aulast%3DHagedorn%26aufirst%3DA.%2BN.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DNorden%26aufirst%3DP.%2BR.%26aulast%3DHachiya%26aufirst%3DA.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DXu%26aufirst%3DH.%2BT.%26aulast%3DWainberg%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DBiochemical%2520mechanism%2520of%2520HIV-1%2520resistance%2520to%2520rilpivirine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26issue%3D45%26spage%3D38110%26epage%3D38123%26doi%3D10.1074%2Fjbc.M112.398180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris-Natschke, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span> <span> </span><span class="NLM_article-title">Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">2788</span>– <span class="NLM_lpage">2792</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2017.04.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2788-2792&issue=12&author=L.+Weiauthor=H.+L.+Wangauthor=L.+Huangauthor=C.+H.+Chenauthor=S.+L.+Morris-Natschkeauthor=K.+H.+Leeauthor=L.+Xie&title=Drug-like+property-driven+optimization+of+4-substituted+1%2C5-diarylanilines+as+potent+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors+against+rilpivirine-resistant+mutant+virus&doi=10.1016%2Fj.bmcl.2017.04.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.068%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DMorris-Natschke%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DXie%26aufirst%3DL.%26atitle%3DDrug-like%2520property-driven%2520optimization%2520of%25204-substituted%25201%252C5-diarylanilines%2520as%2520potent%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520against%2520rilpivirine-resistant%2520mutant%2520virus%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D12%26spage%3D2788%26epage%3D2792%26doi%3D10.1016%2Fj.bmcl.2017.04.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babaoglu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansdon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Eygen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picchio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svarovskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. L.</span></span> <span> </span><span class="NLM_article-title">The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1097/QAI.0b013e31823aca74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FQAI.0b013e31823aca74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=21997204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SgtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=47-54&issue=1&author=R.+Kulkarniauthor=K.+Babaogluauthor=E.+B.+Lansdonauthor=L.+Rimskyauthor=V.+Van+Eygenauthor=G.+Picchioauthor=E.+Svarovskaiaauthor=M.+D.+Millerauthor=K.+L.+White&title=The+HIV-1+reverse+transcriptase+M184I+mutation+enhances+the+E138K-associated+resistance+to+rilpivirine+and+decreases+viral+fitness&doi=10.1097%2FQAI.0b013e31823aca74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness</span></div><div class="casAuthors">Kulkarni, Rima; Babaoglu, Kerim; Lansdon, Eric B.; Rimsky, Laurence; Van Eygen, Veerle; Picchio, Gaston; Svarovskaia, Evguenia; Miller, Michael D.; White, Kirsten L.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The registrational phase III clin. trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two nucleoside/nucleotide RT inhibitors (NRTIs) found a unique genotypic resistance pattern involving the NNRTI mutation E138K with the NRTI mutation M184I.  Eighty percent of subjects used emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF); a single tablet regimen of FTC/RPV/TDF is in development.  Methods: HIV-1 with E138K and/or M184V or I mutations were constructed and phenotyped in MT-2 cells and the PhenoSense and Antivirogram assays.  Viral fitness was detd. using growth competitions.  Mol. models of the mutants were constructed from the RT-RPV crystal structure.  Results: The E138K mutant showed low-level reduced susceptibility to RPV (2.4-fold), but full susceptibility to FTC and tenofovir (TFV).  Viruses with M184V or M184I showed high-level resistance to FTC and full susceptibility to RPV and TFV.  Addn. of M184I, but not M184V, to E138K, further decreased susceptibility to RPV and maintained FTC resistance.  The E138K and M184V or I single and double mutants showed decreased replication fitness compared with wild type.  M184V outcompeted M184I when compared directly and in the background of E138K.  E138K + M184I was less fit than either E138K or M184I alone.  Removing a salt bridge between E138/K101 is implicated in resistance to RPV.  Conclusions: The higher frequency of E138K and M184I among RPV + FTC/TDF virol. failures is due to reduced susceptibility of the single mutants to RPV and FTC and the enhanced resistance to RPV for the double mutant at the cost of decreased viral fitness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0f6ss0TwYi7Vg90H21EOLACvtfcHk0lhLedn_B5-dZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SgtbvO&md5=1134d4490bd5e383fe67ab31a39766cf</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e31823aca74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e31823aca74%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DR.%26aulast%3DBabaoglu%26aufirst%3DK.%26aulast%3DLansdon%26aufirst%3DE.%2BB.%26aulast%3DRimsky%26aufirst%3DL.%26aulast%3DVan%2BEygen%26aufirst%3DV.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DSvarovskaia%26aufirst%3DE.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DWhite%26aufirst%3DK.%2BL.%26atitle%3DThe%2520HIV-1%2520reverse%2520transcriptase%2520M184I%2520mutation%2520enhances%2520the%2520E138K-associated%2520resistance%2520to%2520rilpivirine%2520and%2520decreases%2520viral%2520fitness%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2012%26volume%3D59%26issue%3D1%26spage%3D47%26epage%3D54%26doi%3D10.1097%2FQAI.0b013e31823aca74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span> <i>Rilpivirine Package</i>; <span class="NLM_publisher-name">U.S. Food and
Drug
Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Rilpivirine+Package%3B+U.S.+Food+and%0ADrug%0AAdministration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRilpivirine%2520Package%26pub%3DU.S.%2520Food%2520and%250ADrug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span> <i>Etravirine Prescribing
Information</i>; <span class="NLM_publisher-name">AIDSinfo</span>, <span class="NLM_year">2018</span>; <a href="https://aidsinfo.nih.gov/drugs/398/etravirine/16/professional" class="extLink">https://aidsinfo.nih.gov/drugs/398/etravirine/16/professional</a> (accessed May 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Etravirine+Prescribing%0AInformation%3B+AIDSinfo%2C+2018%3B+https%3A%2F%2Faidsinfo.nih.gov%2Fdrugs%2F398%2Fetravirine%2F16%2Fprofessional+%28accessed+May+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DEtravirine%2520Prescribing%250AInformation%26pub%3DAIDSinfo%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katlama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madruga, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picchio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingerhoets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodfall, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Smedt, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2289</span>– <span class="NLM_lpage">2300</span>, <span class="refDoi"> DOI: 10.1097/QAD.0b013e3283316a5e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FQAD.0b013e3283316a5e" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=2289-2300&issue=17&author=C.+Katlamaauthor=R.+Haubrichauthor=J.+Lalezariauthor=A.+Lazzarinauthor=J.+V.+Madrugaauthor=J.+M.+Molinaauthor=M.+Schechterauthor=M.+Peetersauthor=G.+Picchioauthor=J.+Vingerhoetsauthor=B.+Woodfallauthor=G.+De+Smedt&title=Efficacy+and+safety+of+etravirine+in+treatment-experienced%2C+HIV-1+patients%3A+pooled+48+week+analysis+of+two+randomized%2C+controlled+trials&doi=10.1097%2FQAD.0b013e3283316a5e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1097%2FQAD.0b013e3283316a5e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0b013e3283316a5e%26sid%3Dliteratum%253Aachs%26aulast%3DKatlama%26aufirst%3DC.%26aulast%3DHaubrich%26aufirst%3DR.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DLazzarin%26aufirst%3DA.%26aulast%3DMadruga%26aufirst%3DJ.%2BV.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DSchechter%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DPicchio%26aufirst%3DG.%26aulast%3DVingerhoets%26aufirst%3DJ.%26aulast%3DWoodfall%26aufirst%3DB.%26aulast%3DDe%2BSmedt%26aufirst%3DG.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520etravirine%2520in%2520treatment-experienced%252C%2520HIV-1%2520patients%253A%2520pooled%252048%2520week%2520analysis%2520of%2520two%2520randomized%252C%2520controlled%2520trials%26jtitle%3DAIDS%26date%3D2009%26volume%3D23%26issue%3D17%26spage%3D2289%26epage%3D2300%26doi%3D10.1097%2FQAD.0b013e3283316a5e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luber, A. D.</span></span> <span> </span><span class="NLM_article-title">Genetic barriers to resistance and impact on clinical response</span>. <i>MedGenMed: Medscape general medicine</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">69</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=16369295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD2MnotFOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=69&issue=3&author=A.+D.+Luber&title=Genetic+barriers+to+resistance+and+impact+on+clinical+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic barriers to resistance and impact on clinical response</span></div><div class="casAuthors">Luber Andrew D</div><div class="citationInfo"><span class="NLM_cas:title">MedGenMed : Medscape general medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">69</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of drug resistance and cross-resistance continues to pose a challenge to successful long-term antiretroviral therapy despite the availability of new antiretroviral agents.  The genetic barrier to resistance of a regimen does not directly correlate with its effectiveness.  For some regimens with a low genetic barrier to resistance, however, the emergence of only 1 or 2 key resistance mutations may confer drug resistance not only to that regimen but also to other agents, thereby limiting subsequent treatment options.  In addition to the genetic barrier to resistance, factors such as efficacy, safety, tolerability, convenience, and adherence must be considered when choosing a regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-5uVX9JSZzmPgL4LrC-0VfW6udTcc2ebbKwQNmGUsbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MnotFOitw%253D%253D&md5=0d078402a73680ccd893d5b3272ac047</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuber%26aufirst%3DA.%2BD.%26atitle%3DGenetic%2520barriers%2520to%2520resistance%2520and%2520impact%2520on%2520clinical%2520response%26jtitle%3DMedGenMed%253A%2520Medscape%2520general%2520medicine%26date%3D2005%26volume%3D7%26issue%3D3%26spage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span> <i>Rilpivirine Prescribing Information</i>; <span class="NLM_publisher-name">AIDSinfo</span>, <span class="NLM_year">2018</span>; <a href="https://aidsinfo.nih.gov/drugs/426/rilpivirine/19/professional" class="extLink">https://aidsinfo.nih.gov/drugs/426/rilpivirine/19/professional</a> (accessed May 14, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Rilpivirine+Prescribing+Information%3B+AIDSinfo%2C+2018%3B+https%3A%2F%2Faidsinfo.nih.gov%2Fdrugs%2F426%2Frilpivirine%2F19%2Fprofessional+%28accessed+May+14%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRilpivirine%2520Prescribing%2520Information%26pub%3DAIDSinfo%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinsztejn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supparatpinyo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crauwels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimsky, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanveggel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1097/QAI.0b013e31824d006e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FQAI.0b013e31824d006e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22343174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFGrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=33-42&issue=1&author=C.%0AJ.+Cohenauthor=J.+M.+Molinaauthor=P.+Cahnauthor=B.+Clotetauthor=J.+Fourieauthor=B.+Grinsztejnauthor=H.+Wuauthor=M.+A.+Johnsonauthor=M.+Saagauthor=K.+Supparatpinyoauthor=H.+Crauwelsauthor=E.+Lefebvreauthor=L.+T.+Rimskyauthor=S.+Vanveggelauthor=P.+Williamsauthor=K.+Boven&title=Efficacy+and+safety+of+rilpivirine+%28TMC278%29+versus+efavirenz+at+48+weeks+in+treatment-naive+HIV-1-infected+patients%3A+pooled+results+from+the+phase+3+double-blind+randomized+ECHO+and+THRIVE+Trials&doi=10.1097%2FQAI.0b013e31824d006e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials</span></div><div class="casAuthors">Cohen, Calvin J.; Molina, Jean-Michel; Cahn, Pedro; Clotet, Bonaventura; Fourie, Jan; Grinsztejn, Beatriz; Wu, Hao; Johnson, Margaret A.; Saag, Michael; Supparatpinyo, Khuanchai; Crauwels, Herta; Lefebvre, Eric; Rimsky, Laurence T.; Vanveggel, Simon; Williams, Peter; Boven, Katia</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Pooled anal. of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz.  Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (ECHO) or TDF/FTC, zidovudine/lamivudine, or abacavir/lamivudine (THRIVE).  The primary endpoint was confirmed response [viral load <50 copies per mL; intent-to-treat time-to-loss-of-virol.-response (ITT-TLOVR) algorithm] at week 48.  The pooled data set enabled analyses of subgroups and predictors of response/virol. failure.  Results: Confirmed responses were 84% (rilpivirine) and 82% (efavirenz).  The difference in response rates (95% confidence interval) was 2.0% (-2.0% to 6.0%).  The incidence of virol. failure was 9% (rilpivirine) vs. 5% (efavirenz).  Responses in ITT-TLOVR and ITT-snapshot analyses were consistent.  Responses were similar for rilpivirine and efavirenz by background regimen, gender, race and clade.  Suboptimal adherence and higher baseline viral load resulted in lower responses, higher virol. failure, and development of resistance in both groups; the effects on virol. failure were more apparent with rilpivirine.  CD4 cell count increased over time in both groups.  Rilpivirine compared with efavirenz gave smaller incidences of adverse events leading to discontinuation (3% vs. 8%, resp.), treatment-related grade 2-4 adverse events (16% vs. 31%), rash (3% vs. 14%), dizziness (8% vs. 26%), abnormal dreams/nightmares (8% vs. 13%), and grade 2-4 lipid abnormalities.  Conclusions: At week 48, rilpivirine 25 mg once daily and efavirenz 600 mg once daily had comparable response rates.  Rilpivirine had more virol. failures and improved tolerability vs. efavirenz.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTDdTELL1cP7Vg90H21EOLACvtfcHk0lhbq1Dmd74oXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFGrurs%253D&md5=8670bbbaedeb5053b8dd202ea8c10b8c</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e31824d006e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e31824d006e%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DC.%2BJ.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DCahn%26aufirst%3DP.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DFourie%26aufirst%3DJ.%26aulast%3DGrinsztejn%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DSaag%26aufirst%3DM.%26aulast%3DSupparatpinyo%26aufirst%3DK.%26aulast%3DCrauwels%26aufirst%3DH.%26aulast%3DLefebvre%26aufirst%3DE.%26aulast%3DRimsky%26aufirst%3DL.%2BT.%26aulast%3DVanveggel%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DBoven%26aufirst%3DK.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520rilpivirine%2520%2528TMC278%2529%2520versus%2520efavirenz%2520at%252048%2520weeks%2520in%2520treatment-naive%2520HIV-1-infected%2520patients%253A%2520pooled%2520results%2520from%2520the%2520phase%25203%2520double-blind%2520randomized%2520ECHO%2520and%2520THRIVE%2520Trials%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2012%26volume%3D60%26issue%3D1%26spage%3D33%26epage%3D42%26doi%3D10.1097%2FQAI.0b013e31824d006e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corte, D.</span>; <span class="NLM_string-name">De
Jonge, M. R.</span>; <span class="NLM_string-name">Heeres, J.</span>; <span class="NLM_string-name">Ho, C. Y.</span>; <span class="NLM_string-name">Janssen, P. A. J.</span>; <span class="NLM_string-name">Kavash, R. W.</span>; <span class="NLM_string-name">Koymans, L. M. H.</span>; <span class="NLM_string-name">Kukla, M. J.</span>; <span class="NLM_string-name">Ludovici, D. W.</span>; <span class="NLM_string-name">Van Aken, K. J. A.</span></span> <span> </span><span class="NLM_article-title">HIV Replication Inhibiting Pyrimidines</span>. U.S. Patent <span class="NLM_patent">US6878717B2</span>, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+Corte&author=M.+R.+De%0AJonge&author=J.+Heeres&author=C.+Y.+Ho&author=P.+A.+J.+Janssen&author=R.+W.+Kavash&author=L.+M.+H.+Koymans&author=M.+J.+Kukla&author=D.+W.+Ludovici&author=K.+J.+A.+Van+Aken&title=HIV+Replication+Inhibiting+Pyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCorte%26aufirst%3DD.%26atitle%3DHIV%2520Replication%2520Inhibiting%2520Pyrimidines%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maikap, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titirmare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurjar, M. K.</span></span> <span> </span><span class="NLM_article-title">An improved synthesis of etravirine</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1021/op9003289</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op9003289" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=657-660&issue=3&author=S.+Joshiauthor=G.+C.+Maikapauthor=S.+Titirmareauthor=A.+Chaudhariauthor=M.+K.+Gurjar&title=An+improved+synthesis+of+etravirine&doi=10.1021%2Fop9003289"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fop9003289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop9003289%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DMaikap%26aufirst%3DG.%2BC.%26aulast%3DTitirmare%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DA.%26aulast%3DGurjar%26aufirst%3DM.%2BK.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520etravirine%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2010%26volume%3D14%26issue%3D3%26spage%3D657%26epage%3D660%26doi%3D10.1021%2Fop9003289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fier, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and late-stage functionalization of complex molecules through C–H fluorination and nucleophilic aromatic substitution</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">10139</span>– <span class="NLM_lpage">10147</span>, <span class="refDoi"> DOI: 10.1021/ja5049303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5049303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=10139-10147&issue=28&author=P.+S.+Fierauthor=J.+F.+Hartwig&title=Synthesis+and+late-stage+functionalization+of+complex+molecules+through+C%E2%80%93H+fluorination+and+nucleophilic+aromatic+substitution&doi=10.1021%2Fja5049303"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fja5049303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5049303%26sid%3Dliteratum%253Aachs%26aulast%3DFier%26aufirst%3DP.%2BS.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DSynthesis%2520and%2520late-stage%2520functionalization%2520of%2520complex%2520molecules%2520through%2520C%25E2%2580%2593H%2520fluorination%2520and%2520nucleophilic%2520aromatic%2520substitution%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26issue%3D28%26spage%3D10139%26epage%3D10147%26doi%3D10.1021%2Fja5049303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K. J. L. M.</span>; <span class="NLM_string-name">De, C. B.</span>; <span class="NLM_string-name">DE, J.
M. R.</span>; <span class="NLM_string-name">Heeres, J.</span>; <span class="NLM_string-name">Ho, C. Y.</span>; <span class="NLM_string-name">Janssen, M. A. C.</span>; <span class="NLM_string-name">Janssen, P. A. J.</span>; <span class="NLM_string-name">Koymans, L. M. H.</span>; <span class="NLM_string-name">Kukla, M. J.</span>; <span class="NLM_string-name">Ludovici, D. W.</span></span> <span> </span><span class="NLM_article-title">HIV Inhibiting Pyrimidine Derivatives</span>. World Patent <span class="NLM_patent">WO1999050250A1</span>, <span class="NLM_year">1999</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&author=K.+J.+L.+M.+Andries&author=C.+B.+De&author=J.%0AM.+R.+DE&author=J.+Heeres&author=C.+Y.+Ho&author=M.+A.+C.+Janssen&author=P.+A.+J.+Janssen&author=L.+M.+H.+Koymans&author=M.+J.+Kukla&author=D.+W.+Ludovici&title=HIV+Inhibiting+Pyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndries%26aufirst%3DK.%2BJ.%2BL.%2BM.%26atitle%3DHIV%2520Inhibiting%2520Pyrimidine%2520Derivatives%26date%3D1999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palandjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaurrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertogs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigerinck, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmerman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2072</span>– <span class="NLM_lpage">2079</span>, <span class="refDoi"> DOI: 10.1021/jm040838n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040838n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2072-2079&issue=6&author=J.+Guillemontauthor=E.+Pasquierauthor=P.+Palandjianauthor=D.+Vernierauthor=S.+Gaurrandauthor=P.+J.+Lewiauthor=J.+Heeresauthor=M.+R.+de+Jongeauthor=L.+M.+Koymansauthor=F.+F.+Daeyaertauthor=M.+H.+Vinkersauthor=E.+Arnoldauthor=K.+Dasauthor=R.+Pauwelsauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=E.+Bettensauthor=K.+Hertogsauthor=P.+Wigerinckauthor=P.+Timmermanauthor=P.+A.+Janssen&title=Synthesis+of+novel+diarylpyrimidine+analogues+and+their+antiviral+activity+against+human+immunodeficiency+virus+type+1&doi=10.1021%2Fjm040838n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm040838n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040838n%26sid%3Dliteratum%253Aachs%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DPalandjian%26aufirst%3DP.%26aulast%3DVernier%26aufirst%3DD.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3Dde%2BJonge%26aufirst%3DM.%2BR.%26aulast%3DKoymans%26aufirst%3DL.%2BM.%26aulast%3DDaeyaert%26aufirst%3DF.%2BF.%26aulast%3DVinkers%26aufirst%3DM.%2BH.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DBettens%26aufirst%3DE.%26aulast%3DHertogs%26aufirst%3DK.%26aulast%3DWigerinck%26aufirst%3DP.%26aulast%3DTimmerman%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DSynthesis%2520of%2520novel%2520diarylpyrimidine%2520analogues%2520and%2520their%2520antiviral%2520activity%2520against%2520human%2520immunodeficiency%2520virus%2520type%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D6%26spage%3D2072%26epage%3D2079%26doi%3D10.1021%2Fjm040838n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schils, D. P. R.</span>; <span class="NLM_string-name">Stappers, A. E.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino]benzonitrile</span>. U.S. Patent <span class="NLM_patent">US20080171878A1</span>, <span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+P.+R.+Schils&author=A.+E.+Stappers&title=Process+for+Preparing+4-%5B%281%2C6-dihydro-6-oxo-2-pyrimidinyl%29amino%5Dbenzonitrile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSchils%26aufirst%3DD.%2BP.%2BR.%26atitle%3DProcess%2520for%2520Preparing%25204-%255B%25281%252C6-dihydro-6-oxo-2-pyrimidinyl%2529amino%255Dbenzonitrile%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches to the 2011 new drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&issue=11&author=H.+X.+Dingauthor=K.+K.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+approaches+to+the+2011+new+drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520approaches%2520to%2520the%25202011%2520new%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boffito, M.</span></span> <span> </span><span class="NLM_article-title">Long-acting antiviral agents for HIV treatment</span>. <i>Curr. Opin. HIV AIDS</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1097/COH.0000000000000169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2FCOH.0000000000000169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26049949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=246-252&issue=4&author=D.+A.+Margolisauthor=M.+Boffito&title=Long-acting+antiviral+agents+for+HIV+treatment&doi=10.1097%2FCOH.0000000000000169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting antiviral agents for HIV treatment</span></div><div class="casAuthors">Margolis, David A.; Boffito, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in HIV & AIDS</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">246-252</span>CODEN:
                <span class="NLM_cas:coden">COHABM</span>;
        ISSN:<span class="NLM_cas:issn">1746-630X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Long-acting antiretroviral (ARV) agents are currently under development for the treatment of chronic HIV infection.  This review focuses on data recently produced on injectable ARVs for patients living with HIV/AIDS and on the patients' perspectives on the use of these agents.  Recent findings: Cryst. nanoparticle formulations of the nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278) and of the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) have progressed into phase II clin. trials as injectable maintenance therapy for patients living with HIV/AIDS with an undetectable viral load.  Summary: Phase II studies evaluating the coadministration of rilpivirine and cabotegravir i.m. to HIV-infected individuals with an undetectable viral load are currently underway.  Rilpivirine and cabotegravir are characterized by different mechanisms of action against HIV and a favorable drug interaction profile, providing a rationale for coadministration.  The high potency and low daily dosing requirements of oral cabotegravir and rilpivirine facilitate long-acting formulation development.  I.m. dosing is preceded by an oral lead-in phase to assess safety and tolerability in individual participants.  In addn. to assessing the safety of injectable therapies in ongoing studies, it will be important to evaluate whether differences in drug adherence between injectable and oral therapies lead to different virol. outcomes, including rates of virol. failure and the emergence of resistance.  Long-acting formulations may be assocd. with challenges, such as the management of adverse effects with persistent drug concns. and the risk of virol. resistance, as drug concns. decline following discontinuation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRsw4JuEgenrVg90H21EOLACvtfcHk0lhSvltnUzIWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFSjtLo%253D&md5=b3a24adf1ac01264a07c00b51c10ecfa</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1097%2FCOH.0000000000000169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOH.0000000000000169%26sid%3Dliteratum%253Aachs%26aulast%3DMargolis%26aufirst%3DD.%2BA.%26aulast%3DBoffito%26aufirst%3DM.%26atitle%3DLong-acting%2520antiviral%2520agents%2520for%2520HIV%2520treatment%26jtitle%3DCurr.%2520Opin.%2520HIV%2520AIDS%26date%3D2015%26volume%3D10%26issue%3D4%26spage%3D246%26epage%3D252%26doi%3D10.1097%2FCOH.0000000000000169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Garcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellbrink, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanpanah, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podzamczer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clair, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crauwels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreen, W. R.</span></span> <span> </span><span class="NLM_article-title">Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span> (<span class="NLM_issue">10101</span>),  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1510</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31917-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2817%2931917-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=1499-1510&issue=10101&author=D.+A.+Margolisauthor=J.+Gonzalez-Garciaauthor=H.+J.+Stellbrinkauthor=J.+J.+Eronauthor=Y.+Yazdanpanahauthor=D.+Podzamczerauthor=T.+Lutzauthor=J.+B.+Angelauthor=G.+J.+Richmondauthor=B.+Clotetauthor=F.+Gutierrezauthor=L.+Sloanauthor=M.+S.+Clairauthor=M.+Murrayauthor=S.+L.+Fordauthor=J.+Mrusauthor=P.+Patelauthor=H.+Crauwelsauthor=S.+K.+Griffithauthor=K.+C.+Suttonauthor=D.+Doreyauthor=K.+Y.+Smithauthor=P.+E.+Williamsauthor=W.+R.+Spreen&title=Long-acting+intramuscular+cabotegravir+and+rilpivirine+in+adults+with+HIV-1+infection+%28LATTE-2%29%3A+96-week+results+of+a+randomised%2C+open-label%2C+phase+2b%2C+non-inferiority+trial&doi=10.1016%2FS0140-6736%2817%2931917-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931917-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931917-7%26sid%3Dliteratum%253Aachs%26aulast%3DMargolis%26aufirst%3DD.%2BA.%26aulast%3DGonzalez-Garcia%26aufirst%3DJ.%26aulast%3DStellbrink%26aufirst%3DH.%2BJ.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DYazdanpanah%26aufirst%3DY.%26aulast%3DPodzamczer%26aufirst%3DD.%26aulast%3DLutz%26aufirst%3DT.%26aulast%3DAngel%26aufirst%3DJ.%2BB.%26aulast%3DRichmond%26aufirst%3DG.%2BJ.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DGutierrez%26aufirst%3DF.%26aulast%3DSloan%26aufirst%3DL.%26aulast%3DClair%26aufirst%3DM.%2BS.%26aulast%3DMurray%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DS.%2BL.%26aulast%3DMrus%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DCrauwels%26aufirst%3DH.%26aulast%3DGriffith%26aufirst%3DS.%2BK.%26aulast%3DSutton%26aufirst%3DK.%2BC.%26aulast%3DDorey%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DK.%2BY.%26aulast%3DWilliams%26aufirst%3DP.%2BE.%26aulast%3DSpreen%26aufirst%3DW.%2BR.%26atitle%3DLong-acting%2520intramuscular%2520cabotegravir%2520and%2520rilpivirine%2520in%2520adults%2520with%2520HIV-1%2520infection%2520%2528LATTE-2%2529%253A%252096-week%2520results%2520of%2520a%2520randomised%252C%2520open-label%252C%2520phase%25202b%252C%2520non-inferiority%2520trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26issue%3D10101%26spage%3D1499%26epage%3D1510%26doi%3D10.1016%2FS0140-6736%2817%2931917-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantsios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montes, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deVente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckham, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, M.</span></span> <span> </span><span class="NLM_article-title">Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>), <span class="NLM_elocation-id">e0190487</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0190487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1371%2Fjournal.pone.0190487" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&issue=1&author=D.+Kerriganauthor=A.+Mantsiosauthor=M.+Gorgolasauthor=M.+L.+Montesauthor=F.+Pulidoauthor=C.+Brinsonauthor=J.+deVenteauthor=G.+J.+Richmondauthor=S.+W.+Beckhamauthor=P.+Hammondauthor=D.+Margolisauthor=M.+Murray&title=Experiences+with+long+acting+injectable+ART%3A+A+qualitative+study+among+PLHIV+participating+in+a+Phase+II+study+of+cabotegravir+%2B+rilpivirine+%28LATTE-2%29+in+the+United+States+and+Spain&doi=10.1371%2Fjournal.pone.0190487"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0190487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0190487%26sid%3Dliteratum%253Aachs%26aulast%3DKerrigan%26aufirst%3DD.%26aulast%3DMantsios%26aufirst%3DA.%26aulast%3DGorgolas%26aufirst%3DM.%26aulast%3DMontes%26aufirst%3DM.%2BL.%26aulast%3DPulido%26aufirst%3DF.%26aulast%3DBrinson%26aufirst%3DC.%26aulast%3DdeVente%26aufirst%3DJ.%26aulast%3DRichmond%26aufirst%3DG.%2BJ.%26aulast%3DBeckham%26aufirst%3DS.%2BW.%26aulast%3DHammond%26aufirst%3DP.%26aulast%3DMargolis%26aufirst%3DD.%26aulast%3DMurray%26aufirst%3DM.%26atitle%3DExperiences%2520with%2520long%2520acting%2520injectable%2520ART%253A%2520A%2520qualitative%2520study%2520among%2520PLHIV%2520participating%2520in%2520a%2520Phase%2520II%2520study%2520of%2520cabotegravir%2520%252B%2520rilpivirine%2520%2528LATTE-2%2529%2520in%2520the%2520United%2520States%2520and%2520Spain%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26issue%3D1%26doi%3D10.1371%2Fjournal.pone.0190487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R.</span>; <span class="NLM_string-name">Kravchenko, A. V.</span>; <span class="NLM_string-name">Orlova-Morozova, E.</span>; <span class="NLM_string-name">Nagimova, F.</span>; <span class="NLM_string-name">Kozirev, O.</span>; <span class="NLM_string-name">Shimonava, T.</span>; <span class="NLM_string-name">Deulina, M.</span>; <span class="NLM_string-name">Vostokova, N.</span>; <span class="NLM_string-name">Zozulya, O.</span>; <span class="NLM_string-name">Bichko, V.</span></span>, <span> </span><span class="NLM_article-title">Elsulfavirine as compared to Efavirenz in combination with TDF/FTC: 48-week study</span>. In  <i>Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA</i>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">Poster 452LB</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=Poster+452LB&author=R.+Murphy&author=A.+V.+Kravchenko&author=E.+Orlova-Morozova&author=F.+Nagimova&author=O.+Kozirev&author=T.+Shimonava&author=M.+Deulina&author=N.+Vostokova&author=O.+Zozulya&author=V.+Bichko&title=Elsulfavirine+as+compared+to+Efavirenz+in+combination+with+TDF%2FFTC%3A+48-week+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%26atitle%3DElsulfavirine%2520as%2520compared%2520to%2520Efavirenz%2520in%2520combination%2520with%2520TDF%252FFTC%253A%252048-week%2520study%26jtitle%3DConference%2520on%2520Retroviruses%2520and%2520Opportunistic%2520Infections%2520%2528CROI%2529%252C%2520Seattle%252C%2520WA%26date%3D2017%26spage%3DPoster%2520452LB" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rai, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichtenbaum, C. J.</span></span> <span> </span><span class="NLM_article-title">Emerging reverse transcriptase inhibitors for HIV-1 infection</span>. <i>Expert Opin. Emerging Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1080/14728214.2018.1474202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1080%2F14728214.2018.1474202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29737220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1eisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=149-157&issue=2&author=M.+A.+Raiauthor=S.+Pannekauthor=C.+J.+Fichtenbaum&title=Emerging+reverse+transcriptase+inhibitors+for+HIV-1+infection&doi=10.1080%2F14728214.2018.1474202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging reverse transcriptase inhibitors for HIV-1 infection</span></div><div class="casAuthors">Rai, Mohammad A.; Pannek, Sam; Fichtenbaum, Carl J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART).  Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART.  However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibitors (NNRTIs) have significant side effects and resistance profiles.  We summarize the mechanisms of resistance and other limitations of the existing NRTIs/NNRTIs.  GS-9131, MK-8591, Elsulfavirine and Doravirine are four new agents that are furthest along in development.  ART development has evolved with several new promising agents.  Longer-acting agents, like MK-8591 are extremely attractive to enhance drug adherence and patient satisfaction.  Doravirine offers an NNRTI effective against common mutations that has fewer side effects, limitations on dosing and drug interactions.  GS-9131 is very potent and active against a variety of NRTI mutants but it is too early in its development to understand its full risks and benefits.  Finally, Elsulfavirine has a long half-life and preliminary data suggests fewer side effects than the most commonly used NNRTI, efavirenz.  Each of these new agents shows promise and potential to improve ART in the future.  The newer generation of reverse transcriptase inhibitors have longer half-lives, more favorable adverse effect profiles, and fewer drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZDrir6egMCbVg90H21EOLACvtfcHk0liADUOhekLUhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1eisb8%253D&md5=2b77d96da86e14fc691ce8cacf2ea5cc</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1080%2F14728214.2018.1474202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728214.2018.1474202%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DM.%2BA.%26aulast%3DPannek%26aufirst%3DS.%26aulast%3DFichtenbaum%26aufirst%3DC.%2BJ.%26atitle%3DEmerging%2520reverse%2520transcriptase%2520inhibitors%2520for%2520HIV-1%2520infection%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2018%26volume%3D23%26issue%3D2%26spage%3D149%26epage%3D157%26doi%3D10.1080%2F14728214.2018.1474202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span> <span> </span><span class="NLM_article-title">Elsulfavirine: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1811</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0820-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1007%2Fs40265-017-0820-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=1811-1816&issue=16&author=Z.+T.+Al-Salama&title=Elsulfavirine%3A+First+global+approval&doi=10.1007%2Fs40265-017-0820-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0820-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0820-3%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26atitle%3DElsulfavirine%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26issue%3D16%26spage%3D1811%26epage%3D1816%26doi%3D10.1007%2Fs40265-017-0820-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muraglia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orvieto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescatore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span> <span> </span><span class="NLM_article-title">Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2748</span>– <span class="NLM_lpage">2752</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2006.02.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2748-2752&issue=10&author=E.+Muragliaauthor=O.+D.+Kinzelauthor=R.+Lauferauthor=M.+D.+Millerauthor=G.+Moyerauthor=V.+Munshiauthor=F.+Orvietoauthor=M.+C.+Palumbiauthor=G.+Pescatoreauthor=M.+Rowleyauthor=P.+D.+Williamsauthor=V.+Summa&title=Tetrazole+thioacetanilides%3A+potent+non-nucleoside+inhibitors+of+WT+HIV+reverse+transcriptase+and+its+K103N+mutant&doi=10.1016%2Fj.bmcl.2006.02.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DMuraglia%26aufirst%3DE.%26aulast%3DKinzel%26aufirst%3DO.%2BD.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DOrvieto%26aufirst%3DF.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPescatore%26aufirst%3DG.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DP.%2BD.%26aulast%3DSumma%26aufirst%3DV.%26atitle%3DTetrazole%2520thioacetanilides%253A%2520potent%2520non-nucleoside%2520inhibitors%2520of%2520WT%2520HIV%2520reverse%2520transcriptase%2520and%2520its%2520K103N%2520mutant%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D10%26spage%3D2748%26epage%3D2752%26doi%3D10.1016%2Fj.bmcl.2006.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De La Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenket, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korboukh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamatake, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, J. L.</span></span> <span> </span><span class="NLM_article-title">Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4444</span>– <span class="NLM_lpage">4449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2006.06.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4444-4449&issue=17&author=M.+De+La+Rosaauthor=H.+W.+Kimauthor=E.+Gunicauthor=C.+Jenketauthor=U.+Boyleauthor=Y.+H.+Kohauthor=I.+Korboukhauthor=M.+Allanauthor=W.+Zhangauthor=H.+Chenauthor=W.+Xuauthor=S.+Nilarauthor=N.+Yaoauthor=R.+Hamatakeauthor=S.+A.+Langauthor=Z.+Hongauthor=Z.+Zhangauthor=J.+L.+Girardet&title=Tri-substituted+triazoles+as+potent+non-nucleoside+inhibitors+of+the+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.bmcl.2006.06.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.048%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DGunic%26aufirst%3DE.%26aulast%3DJenket%26aufirst%3DC.%26aulast%3DBoyle%26aufirst%3DU.%26aulast%3DKoh%26aufirst%3DY.%2BH.%26aulast%3DKorboukh%26aufirst%3DI.%26aulast%3DAllan%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DNilar%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DN.%26aulast%3DHamatake%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DS.%2BA.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DGirardet%26aufirst%3DJ.%2BL.%26atitle%3DTri-substituted%2520triazoles%2520as%2520potent%2520non-nucleoside%2520inhibitors%2520of%2520the%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26issue%3D17%26spage%3D4444%26epage%3D4449%26doi%3D10.1016%2Fj.bmcl.2006.06.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romines, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaller, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, C. W.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammers, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazen, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boone, L. R.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1021/jm050670l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050670l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=727-739&issue=2&author=K.+R.+Rominesauthor=G.+A.+Freemanauthor=L.+T.+Schallerauthor=J.+R.+Cowanauthor=S.+S.+Gonzalesauthor=J.+H.+Tidwellauthor=C.+W.+Andrewsauthor=D.+K.+Stammersauthor=R.+J.+Hazenauthor=R.+G.+Ferrisauthor=S.+A.+Shortauthor=J.+H.+Chanauthor=L.+R.+Boone&title=Structure-activity+relationship+studies+of+novel+benzophenones+leading+to+the+discovery+of+a+potent%2C+next+generation+HIV+nonnucleoside+reverse+transcriptase+inhibitor&doi=10.1021%2Fjm050670l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Fjm050670l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050670l%26sid%3Dliteratum%253Aachs%26aulast%3DRomines%26aufirst%3DK.%2BR.%26aulast%3DFreeman%26aufirst%3DG.%2BA.%26aulast%3DSchaller%26aufirst%3DL.%2BT.%26aulast%3DCowan%26aufirst%3DJ.%2BR.%26aulast%3DGonzales%26aufirst%3DS.%2BS.%26aulast%3DTidwell%26aufirst%3DJ.%2BH.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DStammers%26aufirst%3DD.%2BK.%26aulast%3DHazen%26aufirst%3DR.%2BJ.%26aulast%3DFerris%26aufirst%3DR.%2BG.%26aulast%3DShort%26aufirst%3DS.%2BA.%26aulast%3DChan%26aufirst%3DJ.%2BH.%26aulast%3DBoone%26aufirst%3DL.%2BR.%26atitle%3DStructure-activity%2520relationship%2520studies%2520of%2520novel%2520benzophenones%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520potent%252C%2520next%2520generation%2520HIV%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D2%26spage%3D727%26epage%3D739%26doi%3D10.1021%2Fjm050670l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisko, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlow-Poehnelt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span> <span> </span><span class="NLM_article-title">The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2959</span>– <span class="NLM_lpage">2966</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.03.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2008.03.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=18396399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2959-2966&issue=9&author=T.+J.+Tuckerauthor=S.+Saggarauthor=J.+T.+Siskoauthor=R.+M.+Tyneborauthor=T.+M.+Williamsauthor=P.+J.+Felockauthor=J.+A.+Flynnauthor=M.+T.+Laiauthor=Y.+Liangauthor=G.+McGaugheyauthor=M.+Liuauthor=M.+Millerauthor=G.+Moyerauthor=V.+Munshiauthor=R.+Perlow-Poehneltauthor=S.+Prasadauthor=R.+Sanchezauthor=M.+Torrentauthor=J.+P.+Vaccaauthor=B.+L.+Wanauthor=Y.+Yan&title=The+design+and+synthesis+of+diaryl+ether+second+generation+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29+with+enhanced+potency+versus+key+clinical+mutations&doi=10.1016%2Fj.bmcl.2008.03.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations</span></div><div class="casAuthors">Tucker, Thomas J.; Saggar, Sandeep; Sisko, John T.; Tynebor, Robert M.; Williams, Theresa M.; Felock, Peter J.; Flynn, Jessica A.; Lai, Ming-Tain; Liang, Yuexia; McGaughey, Georgia; Liu, Meiquing; Miller, Mike; Moyer, Gregory; Munshi, Vandna; Perlow-Poehnelt, Rebecca; Prasad, Sridhar; Sanchez, Rosa; Torrent, Maricel; Vacca, Joseph P.; Wan, Bang-Lin; Yan, Youwei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2959-2966</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Using a combination of traditional Medicinal Chem./SAR anal., crystallog., and mol. modeling, a series of highly potent NNRTIs that possess broad antiviral activity against a no. of key clin. mutations were synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRQ9ahkVZKDbVg90H21EOLACvtfcHk0ljOa00rryyZkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsbk%253D&md5=9ff592bb0542c3b06edfab15865c45b8</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.03.064%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DSaggar%26aufirst%3DS.%26aulast%3DSisko%26aufirst%3DJ.%2BT.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BA.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DPerlow-Poehnelt%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DYan%26aufirst%3DY.%26atitle%3DThe%2520design%2520and%2520synthesis%2520of%2520diaryl%2520ether%2520second%2520generation%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%2520with%2520enhanced%2520potency%2520versus%2520key%2520clinical%2520mutations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D9%26spage%3D2959%26epage%3D2966%26doi%3D10.1016%2Fj.bmcl.2008.03.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisko, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlow-Poehnelt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chloro benzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6503</span>– <span class="NLM_lpage">6511</span>, <span class="refDoi"> DOI: 10.1021/jm800856c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800856c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6503-6511&issue=20&author=T.+J.+Tuckerauthor=J.+T.+Siskoauthor=R.+M.+Tyneborauthor=T.+M.+Williamsauthor=P.+J.+Felockauthor=J.+A.+Flynnauthor=M.+T.+Laiauthor=Y.+Liangauthor=G.+McGaugheyauthor=M.+Liuauthor=M.+Millerauthor=G.+Moyerauthor=V.+Munshiauthor=R.+Perlow-Poehneltauthor=S.+Prasadauthor=J.+C.+Reidauthor=R.+Sanchezauthor=M.+Torrentauthor=J.+P.+Vaccaauthor=B.+L.+Wanauthor=Y.+Yan&title=Discovery+of+3-%7B5-%5B%286-amino-1H-pyrazolo%5B3%2C4-b%5Dpyridine-3-yl%29methoxy%5D-2-chlorophenoxy%7D-5-chloro+benzonitrile+%28MK-4965%29%3A+a+potent%2C+orally+bioavailable+HIV-1+non-nucleoside+reverse+transcriptase+inhibitor+with+improved+potency+against+key+mutant+viruses&doi=10.1021%2Fjm800856c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Fjm800856c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800856c%26sid%3Dliteratum%253Aachs%26aulast%3DTucker%26aufirst%3DT.%2BJ.%26aulast%3DSisko%26aufirst%3DJ.%2BT.%26aulast%3DTynebor%26aufirst%3DR.%2BM.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BA.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DPerlow-Poehnelt%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DJ.%2BC.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DYan%26aufirst%3DY.%26atitle%3DDiscovery%2520of%25203-%257B5-%255B%25286-amino-1H-pyrazolo%255B3%252C4-b%255Dpyridine-3-yl%2529methoxy%255D-2-chlorophenoxy%257D-5-chloro%2520benzonitrile%2520%2528MK-4965%2529%253A%2520a%2520potent%252C%2520orally%2520bioavailable%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520with%2520improved%2520potency%2520against%2520key%2520mutant%2520viruses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D20%26spage%3D6503%26epage%3D6511%26doi%3D10.1021%2Fjm800856c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distefano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">7920</span>– <span class="NLM_lpage">7933</span>, <span class="refDoi"> DOI: 10.1021/jm2010173</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2010173" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7920-7933&issue=22&author=R.+Gomezauthor=S.+J.+Jollyauthor=T.+Williamsauthor=J.+P.+Vaccaauthor=M.+Torrentauthor=G.+McGaugheyauthor=M.+T.+Laiauthor=P.+Felockauthor=V.+Munshiauthor=D.+Distefanoauthor=J.+Flynnauthor=M.+Millerauthor=Y.+Yanauthor=J.+Reidauthor=R.+Sanchezauthor=Y.+Liangauthor=B.+Patonauthor=B.+L.+Wanauthor=N.+Anthony&title=Design+and+synthesis+of+conformationally+constrained+inhibitors+of+non-nucleoside+reverse+transcriptase&doi=10.1021%2Fjm2010173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Conformationally Constrained Non-Nucleoside Inhibitors of Reverse Transcriptase</span></div><div class="casAuthors">Gomez, Robert; Jolly, Samson J.; Williams, Theresa; Vacca, Joseph P.; Torrent, Maricel; McGaughey, Georgia; Lai, Ming-Tain; Felock, Peter; Munshi, Vandna; DiStefano, Daniel; Flynn, Jessica; Miller, Mike; Yan, Youwei; Reid, John; Sanchez, Rosa; Liang, Yuexia; Paton, Brenda; Wan, Bang-Lin; Anthony, Neville</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7920-7933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly active antiretroviral therapy (HAART) significantly reduces human immunodeficiency virus (HIV) viral load and has led to a dramatic decrease in acquired immunodeficiency syndrome (AIDS) related mortality.  Despite this success, there remains a crit. need for new HIV therapies to address the emergence of drug resistant viral strains.  Next generation NNRTIs are sought that are effective against these mutant forms of the HIV virus.  The bound conformations of our lead inhibitors, MK-1107 (1, I) and MK-4965 (2, II), were divergent about the oxymethylene linker, and each of these conformations was rigidified using two isomeric cyclic constraints.  The constraint derived from the bioactive conformation of 2 provided novel, highly potent NNRTIs that possess broad spectrum antiviral activity and good pharmacokinetic profiles.  Systematic SAR led to the identification of indazole as the optimal conformational constraint to provide MK-6186 (3, III) and MK-7445 (6, VI).  Despite their reduced flexibility, these compds. had potency comparable to that of the corresponding acyclic ethers in both recombinant enzyme and cell based assays against both the wild-type and the clin. relevant mutant strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogMjl75rEMAbVg90H21EOLACvtfcHk0liKEhZJMdemow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOqu7vO&md5=cd6ebeacd7764755e41e715e325f2081</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Fjm2010173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2010173%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DJolly%26aufirst%3DS.%2BJ.%26aulast%3DWilliams%26aufirst%3DT.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DDistefano%26aufirst%3DD.%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DPaton%26aufirst%3DB.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DAnthony%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520conformationally%2520constrained%2520inhibitors%2520of%2520non-nucleoside%2520reverse%2520transcriptase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D22%26spage%3D7920%26epage%3D7933%26doi%3D10.1021%2Fjm2010173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javanbakht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fretland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billedeau, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleason, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschfeld, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy-Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzadegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roetz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villasenor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jernelius, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span> <span> </span><span class="NLM_article-title">Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">7449</span>– <span class="NLM_lpage">7458</span>, <span class="refDoi"> DOI: 10.1021/jm800527x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800527x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7449-7458&issue=23&author=Z.+K.+Sweeneyauthor=S.+F.+Harrisauthor=S.+F.+Aroraauthor=H.+Javanbakhtauthor=Y.+Liauthor=J.+Fretlandauthor=J.+P.+Davidsonauthor=J.+R.+Billedeauauthor=S.+K.+Gleasonauthor=D.+Hirschfeldauthor=J.+J.+Kennedy-Smithauthor=T.+Mirzadeganauthor=R.+Roetzauthor=M.+Smithauthor=S.+Sperryauthor=J.+M.+Suhauthor=J.+Wuauthor=S.+Tsingauthor=A.+G.+Villasenorauthor=A.+Paulauthor=G.+Suauthor=G.+Heilekauthor=J.+Q.+Hangauthor=A.+S.+Zhouauthor=J.+A.+Jerneliusauthor=F.+J.+Zhangauthor=K.+Klumpp&title=Design+of+annulated+pyrazoles+as+inhibitors+of+HIV-1+reverse+transcriptase&doi=10.1021%2Fjm800527x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Fjm800527x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800527x%26sid%3Dliteratum%253Aachs%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DHarris%26aufirst%3DS.%2BF.%26aulast%3DArora%26aufirst%3DS.%2BF.%26aulast%3DJavanbakht%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFretland%26aufirst%3DJ.%26aulast%3DDavidson%26aufirst%3DJ.%2BP.%26aulast%3DBilledeau%26aufirst%3DJ.%2BR.%26aulast%3DGleason%26aufirst%3DS.%2BK.%26aulast%3DHirschfeld%26aufirst%3DD.%26aulast%3DKennedy-Smith%26aufirst%3DJ.%2BJ.%26aulast%3DMirzadegan%26aufirst%3DT.%26aulast%3DRoetz%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DSuh%26aufirst%3DJ.%2BM.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DPaul%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DG.%26aulast%3DHeilek%26aufirst%3DG.%26aulast%3DHang%26aufirst%3DJ.%2BQ.%26aulast%3DZhou%26aufirst%3DA.%2BS.%26aulast%3DJernelius%26aufirst%3DJ.%2BA.%26aulast%3DZhang%26aufirst%3DF.%2BJ.%26aulast%3DKlumpp%26aufirst%3DK.%26atitle%3DDesign%2520of%2520annulated%2520pyrazoles%2520as%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26issue%3D23%26spage%3D7449%26epage%3D7458%26doi%3D10.1021%2Fjm800527x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynebor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeStefano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">7344</span>– <span class="NLM_lpage">7350</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2011.10.027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7344-7350&issue=24&author=R.+Gomezauthor=S.+Jollyauthor=T.+Williamsauthor=T.+Tuckerauthor=R.+Tyneborauthor=J.+Vaccaauthor=G.+McGaugheyauthor=M.+T.+Laiauthor=P.+Felockauthor=V.+Munshiauthor=D.+DeStefanoauthor=S.+Touchauthor=M.+Millerauthor=Y.+Yanauthor=R.+Sanchezauthor=Y.+Liangauthor=B.+Patonauthor=B.+L.+Wanauthor=N.+Anthony&title=Design+and+synthesis+of+pyridone+inhibitors+of+non-nucleoside+reverse+transcriptase&doi=10.1016%2Fj.bmcl.2011.10.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DR.%26aulast%3DJolly%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DT.%26aulast%3DTucker%26aufirst%3DT.%26aulast%3DTynebor%26aufirst%3DR.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DMcGaughey%26aufirst%3DG.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DFelock%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DDeStefano%26aufirst%3DD.%26aulast%3DTouch%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSanchez%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DPaton%26aufirst%3DB.%26aulast%3DWan%26aufirst%3DB.%2BL.%26aulast%3DAnthony%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520pyridone%2520inhibitors%2520of%2520non-nucleoside%2520reverse%2520transcriptase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D24%26spage%3D7344%26epage%3D7350%26doi%3D10.1016%2Fj.bmcl.2011.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cote, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burch, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asante-Appiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blouin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauchon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chefson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromlish, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschenes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont-Gaudet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falgueyret, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forget, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plamondon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seliniotakis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truchon, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducharme, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bmcl.2013.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=24412110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=917-922&issue=3&author=B.+Coteauthor=J.+D.+Burchauthor=E.+Asante-Appiahauthor=C.+Baylyauthor=L.+Bedardauthor=M.+Blouinauthor=L.+C.+Campeauauthor=E.+Cauchonauthor=M.+Chanauthor=A.+Chefsonauthor=N.+Coulombeauthor=W.+Cromlishauthor=S.+Debnathauthor=D.+Deschenesauthor=K.+Dupont-Gaudetauthor=J.+P.+Falgueyretauthor=R.+Forgetauthor=S.+Gagneauthor=D.+Gauvreauauthor=M.+Girardinauthor=S.+Guiralauthor=E.+Langloisauthor=C.+S.+Liauthor=N.+Nguyenauthor=R.+Pappauthor=S.+Plamondonauthor=A.+Royauthor=S.+Royauthor=R.+Seliniotakisauthor=M.+St-Ongeauthor=S.+Ouelletauthor=P.+Tawaauthor=J.+F.+Truchonauthor=J.+Vaccaauthor=M.+Wronaauthor=Y.+Yanauthor=Y.+Ducharme&title=Discovery+of+MK-1439%2C+an+orally+bioavailable+non-nucleoside+reverse+transcriptase+inhibitor+potent+against+a+wide+range+of+resistant+mutant+HIV+viruses&doi=10.1016%2Fj.bmcl.2013.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses</span></div><div class="casAuthors">Cote, Bernard; Burch, Jason D.; Asante-Appiah, Ernest; Bayly, Chris; Bedard, Leanne; Blouin, Marc; Campeau, Louis-Charles; Cauchon, Elizabeth; Chan, Manuel; Chefson, Amandine; Coulombe, Nathalie; Cromlish, Wanda; Debnath, Smita; Deschenes, Denis; Dupont-Gaudet, Kristina; Falgueyret, Jean-Pierre; Forget, Robert; Gagne, Sebastien; Gauvreau, Danny; Girardin, Melina; Guiral, Sebastien; Langlois, Eric; Li, Chun Sing; Nguyen, Natalie; Papp, Rob; Plamondon, Serge; Roy, Amelie; Roy, Stephanie; Seliniotakis, Ria; St-Onge, Miguel; Ouellet, Stephane; Tawa, Paul; Truchon, Jean-Francois; Vacca, Joe; Wrona, Marc; Yan, Youwei; Ducharme, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">917-922</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a novel series of non-nucleoside reverse transcriptase inhibitors (NNRTI) led to the identification of pyridone 36.  In cell cultures, this new NNRTI shows a superior potency profile against a range of wild type and clin. relevant, resistant mutant HIV viruses.  The overall favorable preclin. pharmacokinetic profile of 36 led to the prediction of a once daily low dose regimen in human.  NNRTI 36, now known as MK-1439, is currently in clin. development for the treatment of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJff1LINDbQ7Vg90H21EOLACvtfcHk0lgu9bbKzobxqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1yisw%253D%253D&md5=7d63ec63691d2d21eb29b8dd9c4c5e63</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DB.%26aulast%3DBurch%26aufirst%3DJ.%2BD.%26aulast%3DAsante-Appiah%26aufirst%3DE.%26aulast%3DBayly%26aufirst%3DC.%26aulast%3DBedard%26aufirst%3DL.%26aulast%3DBlouin%26aufirst%3DM.%26aulast%3DCampeau%26aufirst%3DL.%2BC.%26aulast%3DCauchon%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DM.%26aulast%3DChefson%26aufirst%3DA.%26aulast%3DCoulombe%26aufirst%3DN.%26aulast%3DCromlish%26aufirst%3DW.%26aulast%3DDebnath%26aufirst%3DS.%26aulast%3DDeschenes%26aufirst%3DD.%26aulast%3DDupont-Gaudet%26aufirst%3DK.%26aulast%3DFalgueyret%26aufirst%3DJ.%2BP.%26aulast%3DForget%26aufirst%3DR.%26aulast%3DGagne%26aufirst%3DS.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DGirardin%26aufirst%3DM.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DLanglois%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DC.%2BS.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DPapp%26aufirst%3DR.%26aulast%3DPlamondon%26aufirst%3DS.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DSeliniotakis%26aufirst%3DR.%26aulast%3DSt-Onge%26aufirst%3DM.%26aulast%3DOuellet%26aufirst%3DS.%26aulast%3DTawa%26aufirst%3DP.%26aulast%3DTruchon%26aufirst%3DJ.%2BF.%26aulast%3DVacca%26aufirst%3DJ.%26aulast%3DWrona%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DDucharme%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520MK-1439%252C%2520an%2520orally%2520bioavailable%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor%2520potent%2520against%2520a%2520wide%2520range%2520of%2520resistant%2520mutant%2520HIV%2520viruses%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D917%26epage%3D922%26doi%3D10.1016%2Fj.bmcl.2013.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sax, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeJesus, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupinacci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, C.</span></span>; <span class="NLM_contrib-group">DRIVE-FORWARD Study Group</span> <span> </span><span class="NLM_article-title">Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e211</span>– <span class="NLM_lpage">e220</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(18)30021-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS2352-3018%2818%2930021-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29592840" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=e211-e220&issue=5&author=J.+M.+Molinaauthor=K.+Squiresauthor=P.+E.+Saxauthor=P.+Cahnauthor=J.+Lombaardauthor=E.+DeJesusauthor=M.+T.+Laiauthor=X.+Xuauthor=A.+Rodgersauthor=L.+Lupinacciauthor=S.+Kumarauthor=P.+Sklarauthor=B.+Y.+Nguyenauthor=G.+J.+Hannaauthor=C.+Hwangauthor=DRIVE-FORWARD+Study+Group&title=Doravirine+versus+ritonavir-boosted+darunavir+in+antiretroviral-naive+adults+with+HIV-1+%28DRIVE-FORWARD%29%3A+48-week+results+of+a+randomised%2C+double-blind%2C+phase+3%2C+non-inferiority+trial&doi=10.1016%2FS2352-3018%2818%2930021-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2818%2930021-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252818%252930021-3%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DSquires%26aufirst%3DK.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DCahn%26aufirst%3DP.%26aulast%3DLombaard%26aufirst%3DJ.%26aulast%3DDeJesus%26aufirst%3DE.%26aulast%3DLai%26aufirst%3DM.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DRodgers%26aufirst%3DA.%26aulast%3DLupinacci%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSklar%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DB.%2BY.%26aulast%3DHanna%26aufirst%3DG.%2BJ.%26aulast%3DHwang%26aufirst%3DC.%26aulast%3D%26atitle%3DDoravirine%2520versus%2520ritonavir-boosted%2520darunavir%2520in%2520antiretroviral-naive%2520adults%2520with%2520HIV-1%2520%2528DRIVE-FORWARD%2529%253A%252048-week%2520results%2520of%2520a%2520randomised%252C%2520double-blind%252C%2520phase%25203%252C%2520non-inferiority%2520trial%26jtitle%3DLancet%2520HIV%26date%3D2018%26volume%3D5%26issue%3D5%26spage%3De211%26epage%3De220%26doi%3D10.1016%2FS2352-3018%2818%2930021-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span> </span><span class="NLM_article-title">Fixed
dose combination of doravirine/lamivudine/TDF is non-inferior
to efavirenz/emtricitabine/TDF in treatment-naïve adults with
HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study</span>. In  <i>9th IAS Conference on HIV Science, Paris, France, 23–26
July</i>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Fixed%0Adose+combination+of+doravirine%2Flamivudine%2FTDF+is+non-inferior%0Ato+efavirenz%2Femtricitabine%2FTDF+in+treatment-na%C3%AFve+adults+with%0AHIV-1+infection%3A+week+48+results+of+the+Phase+3+DRIVE-AHEAD+study.+In+9th+IAS+Conference+on+HIV+Science%2C+Paris%2C+France%2C+23%E2%80%9326%0AJuly%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26atitle%3DFixed%250Adose%2520combination%2520of%2520doravirine%252Flamivudine%252FTDF%2520is%2520non-inferior%250Ato%2520efavirenz%252Femtricitabine%252FTDF%2520in%2520treatment-na%25C3%25AFve%2520adults%2520with%250AHIV-1%2520infection%253A%2520week%252048%2520results%2520of%2520the%2520Phase%25203%2520DRIVE-AHEAD%2520study%26jtitle%3D9th%2520IAS%2520Conference%2520on%2520HIV%2520Science%252C%2520Paris%252C%2520France%252C%252023%25E2%2580%259326%250AJuly%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanangamudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poongavanam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span> <span> </span><span class="NLM_article-title">HIV-1 non-nucleoside reverse transcriptase inhibitors: SAR and lead optimization using CoMFA and CoMSIA studies (1995–2016)</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3774</span>– <span class="NLM_lpage">3812</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170705122851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2174%2F0929867324666170705122851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=28685686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFensL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3774-3812&author=M.+Vanangamudiauthor=V.+Poongavanamauthor=V.+Namasivayam&title=HIV-1+non-nucleoside+reverse+transcriptase+inhibitors%3A+SAR+and+lead+optimization+using+CoMFA+and+CoMSIA+studies+%281995%E2%80%932016%29&doi=10.2174%2F0929867324666170705122851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016)</span></div><div class="casAuthors">Vanangamudi, Murugesan; Poongavanam, Vasanthanathan; Namasivayam, Vigneshwaran</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">3774-3812</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Design of inhibitors for HIV-1 reverse transcriptase inhibition (HIV-1 RT) is one of the successful chemotherapies for the treatment of HIV infection.  Among the inhibitors available for HIV-1 RT, non-nucleoside reverse transcriptase inhibitors (NNRTIs) have shown to be very promising and clin. approved drugs.  However, the efficiency of many of these drugs has been reduced by the drug-resistant variants of HIV-1 RT.  The aim of the current review is to provide a summary of lead optimization strategies from the 3D-QSARs studies on NNRTI class from the past 21 years (1995 to 2016).  Methods: The conformation dependent-alignment based (CoMFA and CoMSIA) methods have been proven very successful ligand based strategy in the drug design.  Here, CoMFA and CoMSIA studies reported for structurally distinct NNRTIs including thiazolobenzimidazole, dipyridodiazepinone, 1,1,3-trioxo [1,2,4]-thiadiazine, formimidoester disulfides, thiocarbamate, thiazolidinone derivs., etc. have been discussed in detail.  In addn., we explore the position of the functional groups that drive the protein-ligand interaction.  Results: The structure-activity relationship (SAR) revealed from CoMFA and CoMSIA studies of these drug classes is not only in agreement with the structure-based method but also provides an efficient way of lead optimization.  In addn. to mol. docking expts., protein-ligand interaction fingerprints were calcd. in order to understand the common binding mode of NNRTI compds.  Conclusion: Overall, this review enlightens the protein-ligand interactions with a detailed SAR discussion for chemotypes.  Such discussion will help medicinal chemist to gain a better understanding for the design of novel and promising NNRTI candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRtbp3XHOx_rVg90H21EOLACvtfcHk0lgu9bbKzobxqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFensL7N&md5=e90ed864fef7d0eb053f69860c84c437</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170705122851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170705122851%26sid%3Dliteratum%253Aachs%26aulast%3DVanangamudi%26aufirst%3DM.%26aulast%3DPoongavanam%26aufirst%3DV.%26aulast%3DNamasivayam%26aufirst%3DV.%26atitle%3DHIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520SAR%2520and%2520lead%2520optimization%2520using%2520CoMFA%2520and%2520CoMSIA%2520studies%2520%25281995%25E2%2580%25932016%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D3774%26epage%3D3812%26doi%3D10.2174%2F0929867324666170705122851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1021/jm200990c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200990c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3595-613&issue=8&author=D.+Liauthor=P.+Zhanauthor=E.+De+Clercqauthor=X.+Liu&title=Strategies+for+the+design+of+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors%3A+lessons+from+the+development+of+seven+representative+paradigms&doi=10.1021%2Fjm200990c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm200990c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200990c%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DStrategies%2520for%2520the%2520design%2520of%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520lessons%2520from%2520the%2520development%2520of%2520seven%2520representative%2520paradigms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D8%26spage%3D3595%26epage%3D613%26doi%3D10.1021%2Fjm200990c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1038%2Fnsmb.2223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22266819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=253-259&issue=2&author=K.+Dasauthor=S.+E.+Martinezauthor=J.+D.+Baumanauthor=E.+Arnold&title=HIV-1+reverse+transcriptase+complex+with+DNA+and+nevirapine+reveals+non-nucleoside+inhibition+mechanism&doi=10.1038%2Fnsmb.2223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism</span></div><div class="casAuthors">Das, Kalyan; Martinez, Sergio E.; Bauman, Joseph D.; Arnold, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-259</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Combinations of nucleoside and non-nucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT) are widely used in anti-AIDS therapies.  Five NNRTIs, including nevirapine, are clin. drugs; however, the mol. mechanism of inhibition by NNRTIs is not clear.  We detd. the crystal structures of RT-DNA-nevirapine, RT-DNA, and RT-DNA-AZT-triphosphate complexes at 2.85-, 2.70-, and 2.80-Å resoln., resp.  The RT-DNA complex in the crystal could bind nevirapine or AZT-triphosphate but not both.  Binding of nevirapine led to opening of the NNRTI-binding pocket.  The pocket formation caused shifting of the 3' end of the DNA primer by ∼5.5 Å away from its polymerase active site position.  Nucleic acid interactions with fingers and palm subdomains were reduced, the dNTP-binding pocket was distorted and the thumb opened up.  The structures elucidate complementary roles of nucleoside and non-nucleoside inhibitors in inhibiting RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxsRKzSWU5S7Vg90H21EOLACvtfcHk0lizjxvH4aLv6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtrg%253D&md5=8acb0ebef279d7fe999080d12298792c</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2223%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DK.%26aulast%3DMartinez%26aufirst%3DS.%2BE.%26aulast%3DBauman%26aufirst%3DJ.%2BD.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DHIV-1%2520reverse%2520transcriptase%2520complex%2520with%2520DNA%2520and%2520nevirapine%2520reveals%2520non-nucleoside%2520inhibition%2520mechanism%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D2%26spage%3D253%26epage%3D259%26doi%3D10.1038%2Fnsmb.2223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usach, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peris, J. E.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability</span>. <i>J. Int. AIDS Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18567</span>, <span class="refDoi"> DOI: 10.7448/IAS.16.1.18567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.7448%2FIAS.16.1.18567" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=18567&author=I.+Usachauthor=V.+Melisauthor=J.+E.+Peris&title=Non-nucleoside+reverse+transcriptase+inhibitors%3A+a+review+on+pharmacokinetics%2C+pharmacodynamics%2C+safety+and+tolerability&doi=10.7448%2FIAS.16.1.18567"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.7448%2FIAS.16.1.18567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7448%252FIAS.16.1.18567%26sid%3Dliteratum%253Aachs%26aulast%3DUsach%26aufirst%3DI.%26aulast%3DMelis%26aufirst%3DV.%26aulast%3DPeris%26aufirst%3DJ.%2BE.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520a%2520review%2520on%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520safety%2520and%2520tolerability%26jtitle%3DJ.%2520Int.%2520AIDS%2520Soc.%26date%3D2013%26volume%3D16%26spage%3D18567%26doi%3D10.7448%2FIAS.16.1.18567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span> <i>Atripla Package</i>; <span class="NLM_publisher-name">U.S.
Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver
Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Atripla+Package%3B+U.S.%0AFood+and+Drug+Administration%3A+Silver%0ASpring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DAtripla%2520Package%26pub%3DU.S.%250AFood%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span> <i>Odefsey Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed
May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Odefsey+Package%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed%0AMay+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DOdefsey%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R.</span></span> <span> </span><span class="NLM_article-title">Reducing the “pill burden</span>. <i>Can. Med. Assoc. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>184</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">E117</span>– <span class="NLM_lpage">E118</span>, <span class="refDoi"> DOI: 10.1503/cmaj.109-4076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1503%2Fcmaj.109-4076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2012&pages=E117-E118&issue=2&author=R.+Collier&title=Reducing+the+%E2%80%9Cpill+burden&doi=10.1503%2Fcmaj.109-4076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1503%2Fcmaj.109-4076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1503%252Fcmaj.109-4076%26sid%3Dliteratum%253Aachs%26aulast%3DCollier%26aufirst%3DR.%26atitle%3DReducing%2520the%2520%25E2%2580%259Cpill%2520burden%26jtitle%3DCan.%2520Med.%2520Assoc.%2520J.%26date%3D2012%26volume%3D184%26issue%3D2%26spage%3DE117%26epage%3DE118%26doi%3D10.1503%2Fcmaj.109-4076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guay, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musoke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagenda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakaki, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deseyve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirochnick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mofenson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mmiro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. B.</span></span> <span> </span><span class="NLM_article-title">Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>354</i></span> (<span class="NLM_issue">9181</span>),  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(99)80008-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2899%2980008-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=1999&pages=795-802&issue=9181&author=L.+A.+Guayauthor=P.+Musokeauthor=T.+Flemingauthor=D.+Bagendaauthor=M.+Allenauthor=C.+Nakabiitoauthor=J.+Shermanauthor=P.+Bakakiauthor=C.+Ducarauthor=M.+Deseyveauthor=L.+Emelauthor=M.+Mirochnickauthor=M.+G.+Fowlerauthor=L.+Mofensonauthor=P.+Miottiauthor=K.+Dransfieldauthor=D.+Brayauthor=F.+Mmiroauthor=J.+B.+Jackson&title=Intrapartum+and+neonatal+single-dose+nevirapine+compared+with+zidovudine+for+prevention+of+mother-to-child+transmission+of+HIV-1+in+Kampala%2C+Uganda%3A+HIVNET+012+randomised+trial&doi=10.1016%2FS0140-6736%2899%2980008-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2899%2980008-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252899%252980008-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuay%26aufirst%3DL.%2BA.%26aulast%3DMusoke%26aufirst%3DP.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DBagenda%26aufirst%3DD.%26aulast%3DAllen%26aufirst%3DM.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3DSherman%26aufirst%3DJ.%26aulast%3DBakaki%26aufirst%3DP.%26aulast%3DDucar%26aufirst%3DC.%26aulast%3DDeseyve%26aufirst%3DM.%26aulast%3DEmel%26aufirst%3DL.%26aulast%3DMirochnick%26aufirst%3DM.%26aulast%3DFowler%26aufirst%3DM.%2BG.%26aulast%3DMofenson%26aufirst%3DL.%26aulast%3DMiotti%26aufirst%3DP.%26aulast%3DDransfield%26aufirst%3DK.%26aulast%3DBray%26aufirst%3DD.%26aulast%3DMmiro%26aufirst%3DF.%26aulast%3DJackson%26aufirst%3DJ.%2BB.%26atitle%3DIntrapartum%2520and%2520neonatal%2520single-dose%2520nevirapine%2520compared%2520with%2520zidovudine%2520for%2520prevention%2520of%2520mother-to-child%2520transmission%2520of%2520HIV-1%2520in%2520Kampala%252C%2520Uganda%253A%2520HIVNET%2520012%2520randomised%2520trial%26jtitle%3DLancet%26date%3D1999%26volume%3D354%26issue%3D9181%26spage%3D795%26epage%3D802%26doi%3D10.1016%2FS0140-6736%2899%2980008-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ayouba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foupouapouognigni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kfutwah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thonnon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monny-Lobe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eteki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouanfack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nlend, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barre-Sinoussi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerrienet, E.</span></span> <span> </span><span class="NLM_article-title">Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1097/00126334-200311010-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1097%2F00126334-200311010-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=14600571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2003&pages=274-280&issue=3&author=A.+Ayoubaauthor=G.+Teneauthor=P.+Cuninauthor=Y.+Foupouapouognigniauthor=E.+Menuauthor=A.+Kfutwahauthor=J.+Thonnonauthor=G.+Scarlattiauthor=M.+Monny-Lobeauthor=N.+Etekiauthor=C.+Kouanfackauthor=M.+Tardyauthor=R.+Lekeauthor=M.+Nkamauthor=A.+E.+Nlendauthor=F.+Barre-Sinoussiauthor=P.+M.+Martinauthor=E.+Nerrienet&title=Low+rate+of+mother-to-child+transmission+of+HIV-1+after+nevirapine+intervention+in+a+pilot+public+health+program+in+Yaounde%2C+Cameroon&doi=10.1097%2F00126334-200311010-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaounde, Cameroon</span></div><div class="casAuthors">Ayouba, Ahidjo; Tene, Gilbert; Cunin, Patrick; Foupouapouognigni, Yacouba; Menu, Elisabeth; Kfutwah, Anfumbom; Thonnon, Jocelyn; Scarlatti, Gabriella; Monny-Lobe, Marcel; Eteki, Nicole; Kouanfack, Charles; Tardy, Michele; Leke, Robert; Nkam, Maurice; Nlend, Anne E.; Barre-Sinoussi, Francoise; Martin, Paul M. V.; Nerrienet, Eric</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">274-280</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE: To det. the percentage of infected children for whom nevirapine (NVP) was used to prevent peripartum mother-to-child transmission (MTCT) of HIV in Yaounde, Cameroon.  DESIGN: The study was a prospective Public Health Pilot Program covering a 3-yr period (Jan. 2000-Dec. 2002).  METHODS: Counseled and consenting HIV-1-pos. pregnant women were given a single dose of NVP at the onset of labor.  Babies were given 2 mg/kg NVP syrup within the first 72 h of life.  NVP-treated children were regularly followed up and examd. for HIV-1 infection at 6-8 wk and 5-6 mo through plasma viral load (VL) quantification with the bDNA system.  RESULTS: One hundred twenty-three children were diagnosed with perinatal HIV-1 infection at 6-8 wk and 5-6 mo.  Thirteen children (10.6% [13/123]; 95% confidence interval, 5.1-16) were infected and presented with high VLs, in general >500,000 copies/mL.  Two children had intermediate VLs (between 50 and 3500 copies/mL) at both time points.  One hundred seven children (87%) were considered not infected at 6-8 wk of age.  CONCLUSIONS: Our results indicate that the HIV-1 MTCT rate 6-8 wk after NVP administration was not >13% (16/123), thus demonstrating the effectiveness of NVP for lowering the risk of HIV-1 MTCT in real-life settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJHeFCAJD2LVg90H21EOLACvtfcHk0ljNtD9cdr5eig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslWltL4%253D&md5=3c210a6c564c2330eb7811c3d57fb6eb</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1097%2F00126334-200311010-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00126334-200311010-00003%26sid%3Dliteratum%253Aachs%26aulast%3DAyouba%26aufirst%3DA.%26aulast%3DTene%26aufirst%3DG.%26aulast%3DCunin%26aufirst%3DP.%26aulast%3DFoupouapouognigni%26aufirst%3DY.%26aulast%3DMenu%26aufirst%3DE.%26aulast%3DKfutwah%26aufirst%3DA.%26aulast%3DThonnon%26aufirst%3DJ.%26aulast%3DScarlatti%26aufirst%3DG.%26aulast%3DMonny-Lobe%26aufirst%3DM.%26aulast%3DEteki%26aufirst%3DN.%26aulast%3DKouanfack%26aufirst%3DC.%26aulast%3DTardy%26aufirst%3DM.%26aulast%3DLeke%26aufirst%3DR.%26aulast%3DNkam%26aufirst%3DM.%26aulast%3DNlend%26aufirst%3DA.%2BE.%26aulast%3DBarre-Sinoussi%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DNerrienet%26aufirst%3DE.%26atitle%3DLow%2520rate%2520of%2520mother-to-child%2520transmission%2520of%2520HIV-1%2520after%2520nevirapine%2520intervention%2520in%2520a%2520pilot%2520public%2520health%2520program%2520in%2520Yaounde%252C%2520Cameroon%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2003%26volume%3D34%26issue%3D3%26spage%3D274%26epage%3D280%26doi%3D10.1097%2F00126334-200311010-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee-Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto-Torres, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matovu
Kiweewa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mhlanga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeenarain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffoor, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pather, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellors, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheckter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthiaume, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndase, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germuga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szydlo, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensch, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torjesen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakhtoura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S.</span></span> <span> </span><span class="NLM_article-title">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2121</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1506110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1506110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26900902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2121-2132&issue=22&author=J.+M.+Baetenauthor=T.+Palanee-Phillipsauthor=E.+R.+Brownauthor=K.+Schwartzauthor=L.+E.+Soto-Torresauthor=V.+Govenderauthor=N.+M.+Mgodiauthor=F.+Matovu%0AKiweewaauthor=G.+Nairauthor=F.+Mhlangaauthor=S.+Sivaauthor=L.+G.+Bekkerauthor=N.+Jeenarainauthor=Z.+Gaffoorauthor=F.+Martinsonauthor=B.+Makananiauthor=A.+Patherauthor=L.+Naidooauthor=M.+Husnikauthor=B.+A.+Richardsonauthor=U.+M.+Parikhauthor=J.+W.+Mellorsauthor=M.+A.+Marzinkeauthor=C.+W.+Hendrixauthor=A.+van+der+Stratenauthor=G.+Ramjeeauthor=Z.+M.+Chirenjeauthor=C.+Nakabiitoauthor=T.+E.+Tahaauthor=J.+Jonesauthor=A.+Mayoauthor=R.+Scheckterauthor=J.+Berthiaumeauthor=E.+Livantauthor=C.+Jacobsonauthor=P.+Ndaseauthor=R.+Whiteauthor=K.+Pattersonauthor=D.+Germugaauthor=B.+Galaskaauthor=K.+Bungeauthor=D.+Singhauthor=D.+W.+Szydloauthor=E.+T.+Montgomeryauthor=B.+S.+Menschauthor=K.+Torjesenauthor=C.+I.+Grossmanauthor=N.+Chakhtouraauthor=A.+Nelauthor=Z.+Rosenbergauthor=I.+McGowanauthor=S.+Hillier&title=Use+of+a+vaginal+ring+containing+dapivirine+for+HIV-1+prevention+in+women&doi=10.1056%2FNEJMoa1506110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span></div><div class="casAuthors">Baeten, J. M.; Palanee-Phillips, T.; Brown, E. R.; Schwartz, K.; Soto-Torres, L. E.; Govender, V.; Mgodi, N. M.; Kiweewa, F. Matovu; Nair, G.; Mhlanga, F.; Siva, S.; Bekker, L.-G.; Jeenarain, N.; Gaffoor, Z.; Martinson, F.; Makanani, B.; Pather, A.; Naidoo, L.; Husnik, M.; Richardson, B. A.; Parikh, U. M.; Mellors, J. W.; Marzinke, M. A.; Hendrix, C. W.; van der Straten, A.; Ramjee, G.; Chirenje, Z. M.; Nakabiito, C.; Taha, T. E.; Jones, J.; Mayo, A.; Scheckter, R.; Berthiaume, J.; Livant, E.; Jacobson, C.; Ndase, P.; White, R.; Patterson, K.; Germuga, D.; Galaska, B.; Bunge, K.; Singh, D.; Szydlo, D. W.; Montgomery, E. T.; Mensch, B. S.; Torjesen, K.; Grossman, C. I.; Chakhtoura, N.; Nel, A.; Rosenberg, Z.; McGowan, I.; Hillier, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2121-2132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  However, in clin. trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence.  Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.  METHODS We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring contg. dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe.  RESULTS Among the 2629 women who were enrolled, 168 HIV-1 infections occurred: 71 in the dapivirine group and 97 in the placebo group (incidence, 3.3 and 4.5 per 100 personyears, resp.).  The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P = 0.046) than that in the placebo group.  In an anal. that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P = 0.007) than that in the placebo group.  In a post hoc anal., higher rates of HIV-1 protection were obsd. among women over the age of 21 years (56%; 95% CI, 31 to 71; P<0.001) but not among those 21 years of age or younger (-27%; 95% CI, -133 to 31; P = 0.45), a difference that was correlated with reduced adherence.  The rates of adverse medical events and antiretroviral resistance among women who acquired HIV-1 infection were similar in the two groups.  CONCLUSIONS A monthly vaginal ring contg. dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohJjDza7DrCrVg90H21EOLACvtfcHk0ljNtD9cdr5eig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN&md5=be3a0c5c5d1a57d7b3343d84b9a28e9c</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1506110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1506110%26sid%3Dliteratum%253Aachs%26aulast%3DBaeten%26aufirst%3DJ.%2BM.%26aulast%3DPalanee-Phillips%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DE.%2BR.%26aulast%3DSchwartz%26aufirst%3DK.%26aulast%3DSoto-Torres%26aufirst%3DL.%2BE.%26aulast%3DGovender%26aufirst%3DV.%26aulast%3DMgodi%26aufirst%3DN.%2BM.%26aulast%3DMatovu%2BKiweewa%26aufirst%3DF.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DMhlanga%26aufirst%3DF.%26aulast%3DSiva%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.%2BG.%26aulast%3DJeenarain%26aufirst%3DN.%26aulast%3DGaffoor%26aufirst%3DZ.%26aulast%3DMartinson%26aufirst%3DF.%26aulast%3DMakanani%26aufirst%3DB.%26aulast%3DPather%26aufirst%3DA.%26aulast%3DNaidoo%26aufirst%3DL.%26aulast%3DHusnik%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3DTaha%26aufirst%3DT.%2BE.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DMayo%26aufirst%3DA.%26aulast%3DScheckter%26aufirst%3DR.%26aulast%3DBerthiaume%26aufirst%3DJ.%26aulast%3DLivant%26aufirst%3DE.%26aulast%3DJacobson%26aufirst%3DC.%26aulast%3DNdase%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DPatterson%26aufirst%3DK.%26aulast%3DGermuga%26aufirst%3DD.%26aulast%3DGalaska%26aufirst%3DB.%26aulast%3DBunge%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSzydlo%26aufirst%3DD.%2BW.%26aulast%3DMontgomery%26aufirst%3DE.%2BT.%26aulast%3DMensch%26aufirst%3DB.%2BS.%26aulast%3DTorjesen%26aufirst%3DK.%26aulast%3DGrossman%26aufirst%3DC.%2BI.%26aulast%3DChakhtoura%26aufirst%3DN.%26aulast%3DNel%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DZ.%26aulast%3DMcGowan%26aufirst%3DI.%26aulast%3DHillier%26aufirst%3DS.%26atitle%3DUse%2520of%2520a%2520vaginal%2520ring%2520containing%2520dapivirine%2520for%2520HIV-1%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D22%26spage%3D2121%26epage%3D2132%26doi%3D10.1056%2FNEJMoa1506110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotze, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabude, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusemererwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malherbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuttall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntshele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steytler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borremans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resseler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Roey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangeneugden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Baelen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">2133</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1602046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=27959766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2133-2143&issue=22&author=A.+Nelauthor=N.+van+Niekerkauthor=S.+Kapigaauthor=L.+G.+Bekkerauthor=C.+Gamaauthor=K.+Gillauthor=A.+Kamaliauthor=P.+Kotzeauthor=C.+Louwauthor=Z.+Mabudeauthor=N.+Mitiauthor=S.+Kusemererwaauthor=H.+Tempelmanauthor=H.+Carstensauthor=B.+Devlinauthor=M.+Isaacsauthor=M.+Malherbeauthor=W.+Mansauthor=J.+Nuttallauthor=M.+Russellauthor=S.+Ntsheleauthor=M.+Smitauthor=L.+Solaiauthor=P.+Spenceauthor=J.+Steytlerauthor=K.+Windleauthor=M.+Borremansauthor=S.+Resselerauthor=J.+Van+Roeyauthor=W.+Parysauthor=T.+Vangeneugdenauthor=B.+Van+Baelenauthor=Z.+Rosenberg&title=Safety+and+efficacy+of+a+dapivirine+vaginal+ring+for+HIV+prevention+in+women&doi=10.1056%2FNEJMoa1602046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span></div><div class="casAuthors">Nel, A.; van Niekerk, N.; Kapiga, S.; Bekker, L.-G.; Gama, C.; Gill, K.; Kamali, A.; Kotze, P.; Louw, C.; Mabude, Z.; Miti, N.; Kusemererwa, S.; Tempelman, H.; Carstens, H.; Devlin, B.; Isaacs, M.; Malherbe, M.; Mans, W.; Nuttall, J.; Russell, M.; Ntshele, S.; Smit, M.; Solai, L.; Spence, P.; Steytler, J.; Windle, K.; Borremans, M.; Resseler, S.; Van Roey, J.; Parys, W.; Vangeneugden, T.; Van Baelen, B.; Rosenberg, Z.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2133-2143</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa.  We evaluated the safety and efficacy of extended use of a vaginal ring contg. dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda.  METHODS: In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings contg. either 25 mg of dapivirine or placebo.  Participants inserted the rings themselves every 4 wk for up to 24 mo.  The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion.  RESULTS: A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years).  The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P = 0.04).  There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P = 0.43 for treatment-by-age interaction).  Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group.  Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]).  However, no clear pattern was identified.  CONCLUSIONS: Among women in sub-Saharan Africa, the dapivirine ring was not assocd. with any safety concerns and was assocd. with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_wx1pEUBBCrVg90H21EOLACvtfcHk0liNKbYLQ3T8Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM&md5=970e69fc1a0fc725671e9e372fba6737</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602046%26sid%3Dliteratum%253Aachs%26aulast%3DNel%26aufirst%3DA.%26aulast%3Dvan%2BNiekerk%26aufirst%3DN.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.%2BG.%26aulast%3DGama%26aufirst%3DC.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DKamali%26aufirst%3DA.%26aulast%3DKotze%26aufirst%3DP.%26aulast%3DLouw%26aufirst%3DC.%26aulast%3DMabude%26aufirst%3DZ.%26aulast%3DMiti%26aufirst%3DN.%26aulast%3DKusemererwa%26aufirst%3DS.%26aulast%3DTempelman%26aufirst%3DH.%26aulast%3DCarstens%26aufirst%3DH.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DIsaacs%26aufirst%3DM.%26aulast%3DMalherbe%26aufirst%3DM.%26aulast%3DMans%26aufirst%3DW.%26aulast%3DNuttall%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DNtshele%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DSolai%26aufirst%3DL.%26aulast%3DSpence%26aufirst%3DP.%26aulast%3DSteytler%26aufirst%3DJ.%26aulast%3DWindle%26aufirst%3DK.%26aulast%3DBorremans%26aufirst%3DM.%26aulast%3DResseler%26aufirst%3DS.%26aulast%3DVan%2BRoey%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3DVangeneugden%26aufirst%3DT.%26aulast%3DVan%2BBaelen%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DZ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520a%2520dapivirine%2520vaginal%2520ring%2520for%2520HIV%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D22%26spage%3D2133%26epage%3D2143%26doi%3D10.1056%2FNEJMoa1602046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchbinder, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A. Y.</span></span> <span> </span><span class="NLM_article-title">CROI 2018: epidemic trends and advances in HIV prevention</span>. <i>Top. Antivir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29727292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BC1MjpvVOquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1-16&author=S.+P.+Buchbinderauthor=A.+Y.+Liu&title=CROI+2018%3A+epidemic+trends+and+advances+in+HIV+prevention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">CROI 2018: Epidemic Trends and Advances in HIV Prevention</span></div><div class="casAuthors">Buchbinder Susan P; Liu Albert Y</div><div class="citationInfo"><span class="NLM_cas:title">Topics in antiviral medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">At the 2018 Conference on Retroviruses and Opportunistic Infections, trends in and risk factors for in HIV infection were highlighted.  In the United States, new HIV diagnoses are highest in the South and among African Americans and are increasing in rural areas.  Youth remain highly vulnerable to HIV infection globally.  The epidemiology of HIV infections among people who inject drugs is changing, with overdose deaths, a major public health concern.  Phylogenetics are being used to identify HIV transmission clusters and hotspots, which can inform prevention efforts.  Vaginal microbial dysbiosis and proteomic alterations are associated with increased risk of HIV acquisition, as are the pregnancy and postpartum periods.  HIV testing is a central first step for the HIV care and treatment continua, and several innovative strategies to expand HIV testing coverage and frequency show promise.  Preexposure prophylaxis (PrEP) uptake is rapidly increasing in some cities, with reductions of new infections at the population level, but use is lower among African Americans and Latinos, youth, cis- and transgender women, and people who inject drugs.  PrEP continuation remains a challenge.  Two open-label extension studies of the dapivirine vaginal ring demonstrated high uptake, adherence, and reduced HIV infections.  Several novel systemic and topical prevention agents show promise in non-human primates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRtJ_ZqXNoZPTW1zwg2yUK5fW6udTcc2ebL8Lyr2Y9J47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjpvVOquw%253D%253D&md5=6222438378ea63baffd6c702522362d2</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchbinder%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DA.%2BY.%26atitle%3DCROI%25202018%253A%2520epidemic%2520trends%2520and%2520advances%2520in%2520HIV%2520prevention%26jtitle%3DTop.%2520Antivir.%2520Med.%26date%3D2018%26volume%3D26%26spage%3D1%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Council, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Date, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nochii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belshan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayer, W. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachaud-Durand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Destache, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. V.</span></span> <span> </span><span class="NLM_article-title">Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">8</span>), <span class="NLM_elocation-id">e1005075</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1005075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1371%2Fjournal.ppat.1005075" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&issue=8&author=M.+Kovarovaauthor=O.+D.+Councilauthor=A.+A.+Dateauthor=J.+M.+Longauthor=T.+Nochiiauthor=M.+Belshanauthor=A.+Shibataauthor=H.+Vincentauthor=C.+E.+Bakerauthor=W.+O.+Thayerauthor=G.+Krausauthor=S.+Lachaud-Durandauthor=P.+Williamsauthor=C.+J.+Destacheauthor=J.+V.+Garcia&title=Nanoformulations+of+rilpivirine+for+topical+pericoital+and+systemic+coitus-independent+administration+efficiently+prevent+HIV+transmission&doi=10.1371%2Fjournal.ppat.1005075"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005075%26sid%3Dliteratum%253Aachs%26aulast%3DKovarova%26aufirst%3DM.%26aulast%3DCouncil%26aufirst%3DO.%2BD.%26aulast%3DDate%26aufirst%3DA.%2BA.%26aulast%3DLong%26aufirst%3DJ.%2BM.%26aulast%3DNochii%26aufirst%3DT.%26aulast%3DBelshan%26aufirst%3DM.%26aulast%3DShibata%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DH.%26aulast%3DBaker%26aufirst%3DC.%2BE.%26aulast%3DThayer%26aufirst%3DW.%2BO.%26aulast%3DKraus%26aufirst%3DG.%26aulast%3DLachaud-Durand%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DDestache%26aufirst%3DC.%2BJ.%26aulast%3DGarcia%26aufirst%3DJ.%2BV.%26atitle%3DNanoformulations%2520of%2520rilpivirine%2520for%2520topical%2520pericoital%2520and%2520systemic%2520coitus-independent%2520administration%2520efficiently%2520prevent%2520HIV%2520transmission%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26issue%3D8%26doi%3D10.1371%2Fjournal.ppat.1005075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezzutti, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikiforov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson-Harman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Else, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stall, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achilles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cranston, R. D.</span></span> <span> </span><span class="NLM_article-title">Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">e569</span>– <span class="NLM_lpage">e578</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(16)30113-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS2352-3018%2816%2930113-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=27658864" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e569-e578&issue=12&author=I.+McGowanauthor=C.+S.+Dezzuttiauthor=A.+Siegelauthor=J.+Engstromauthor=A.+Nikiforovauthor=K.+Duffillauthor=C.+Shetlerauthor=N.+Richardson-Harmanauthor=K.+Abebeauthor=D.+Backauthor=L.+Elseauthor=D.+Eganauthor=S.+Khooauthor=J.+E.+Eganauthor=R.+Stallauthor=P.+E.+Williamsauthor=K.+K.+Rehmanauthor=A.+Adlerauthor=R.+M.+Brandauthor=B.+Chenauthor=S.+Achillesauthor=R.+D.+Cranston&title=Long-acting+rilpivirine+as+potential+pre-exposure+prophylaxis+for+HIV-1+prevention+%28the+MWRI-01+study%29%3A+an+open-label%2C+phase+1%2C+compartmental%2C+pharmacokinetic+and+pharmacodynamic+assessment&doi=10.1016%2FS2352-3018%2816%2930113-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2816%2930113-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252816%252930113-8%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DI.%26aulast%3DDezzutti%26aufirst%3DC.%2BS.%26aulast%3DSiegel%26aufirst%3DA.%26aulast%3DEngstrom%26aufirst%3DJ.%26aulast%3DNikiforov%26aufirst%3DA.%26aulast%3DDuffill%26aufirst%3DK.%26aulast%3DShetler%26aufirst%3DC.%26aulast%3DRichardson-Harman%26aufirst%3DN.%26aulast%3DAbebe%26aufirst%3DK.%26aulast%3DBack%26aufirst%3DD.%26aulast%3DElse%26aufirst%3DL.%26aulast%3DEgan%26aufirst%3DD.%26aulast%3DKhoo%26aufirst%3DS.%26aulast%3DEgan%26aufirst%3DJ.%2BE.%26aulast%3DStall%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DP.%2BE.%26aulast%3DRehman%26aufirst%3DK.%2BK.%26aulast%3DAdler%26aufirst%3DA.%26aulast%3DBrand%26aufirst%3DR.%2BM.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DAchilles%26aufirst%3DS.%26aulast%3DCranston%26aufirst%3DR.%2BD.%26atitle%3DLong-acting%2520rilpivirine%2520as%2520potential%2520pre-exposure%2520prophylaxis%2520for%2520HIV-1%2520prevention%2520%2528the%2520MWRI-01%2520study%2529%253A%2520an%2520open-label%252C%2520phase%25201%252C%2520compartmental%252C%2520pharmacokinetic%2520and%2520pharmacodynamic%2520assessment%26jtitle%3DLancet%2520HIV%26date%3D2016%26volume%3D3%26issue%3D12%26spage%3De569%26epage%3De578%26doi%3D10.1016%2FS2352-3018%2816%2930113-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span> </span><span class="NLM_article-title">HPTN 076: TMC278 LA Safe, Tolerable and
Acceptable for HIV Pre-Exposure
Prophylaxis</span>. In  <i>Conference on Retroviruses
and Opportunistic Infections (CROI), Seattle, Washington, Seattle,
WA</i>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=HPTN+076%3A+TMC278+LA+Safe%2C+Tolerable+and%0AAcceptable+for+HIV+Pre-Exposure%0AProphylaxis.+In+Conference+on+Retroviruses%0Aand+Opportunistic+Infections+%28CROI%29%2C+Seattle%2C+Washington%2C+Seattle%2C%0AWA%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26atitle%3DHPTN%2520076%253A%2520TMC278%2520LA%2520Safe%252C%2520Tolerable%2520and%250AAcceptable%2520for%2520HIV%2520Pre-Exposure%250AProphylaxis%26jtitle%3DConference%2520on%2520Retroviruses%250Aand%2520Opportunistic%2520Infections%2520%2528CROI%2529%252C%2520Seattle%252C%2520Washington%252C%2520Seattle%252C%250AWA%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span> <i>HPTN 076: Phase
II Safety and Acceptability of an Investigational
Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)</i>; <span class="NLM_publisher-name">HIV Prevention Trials Network</span>, <span class="NLM_year">2018</span>; <a href="https://www.hptn.org/research/studies/hptn076" class="extLink">https://www.hptn.org/research/studies/hptn076</a> (accessed August
16, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+HPTN+076%3A+Phase%0AII+Safety+and+Acceptability+of+an+Investigational%0AInjectable+Product%2C+TMC278+LA%2C+for+Pre+Exposure+Prophylaxis+%28PrEP%29%3B+HIV+Prevention+Trials+Network%2C+2018%3B+https%3A%2F%2Fwww.hptn.org%2Fresearch%2Fstudies%2Fhptn076+%28accessed+August%0A16%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DHPTN%2520076%253A%2520Phase%250AII%2520Safety%2520and%2520Acceptability%2520of%2520an%2520Investigational%250AInjectable%2520Product%252C%2520TMC278%2520LA%252C%2520for%2520Pre%2520Exposure%2520Prophylaxis%2520%2528PrEP%2529%26pub%3DHIV%2520Prevention%2520Trials%2520Network%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seckler, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkley, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintrode, P. L.</span></span> <span> </span><span class="NLM_article-title">Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2010.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bpj.2010.11.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=144-153&issue=1&author=J.+M.+Secklerauthor=M.+D.+Barkleyauthor=P.+L.+Wintrode&title=Allosteric+suppression+of+HIV-1+reverse+transcriptase+structural+dynamics+upon+inhibitor+binding&doi=10.1016%2Fj.bpj.2010.11.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2010.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2010.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DSeckler%26aufirst%3DJ.%2BM.%26aulast%3DBarkley%26aufirst%3DM.%2BD.%26aulast%3DWintrode%26aufirst%3DP.%2BL.%26atitle%3DAllosteric%2520suppression%2520of%2520HIV-1%2520reverse%2520transcriptase%2520structural%2520dynamics%2520upon%2520inhibitor%2520binding%26jtitle%3DBiophys.%2520J.%26date%3D2011%26volume%3D100%26issue%3D1%26spage%3D144%26epage%3D153%26doi%3D10.1016%2Fj.bpj.2010.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span> <i>Delavirdine Package</i>; <span class="NLM_publisher-name">U.S. Food and Drug
Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_year">2018</span>; <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed May 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Delavirdine+Package%3B+U.S.+Food+and+Drug%0AAdministration%3A+Silver+Spring%2C+MD%2C+2018%3B+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+May+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DDelavirdine%2520Package%26pub%3DU.S.%2520Food%2520and%2520Drug%250AAdministration%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obst-Sander, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">Fluorine in medicinal chemistry</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/cbic.200301023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1002%2Fcbic.200301023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=15122635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=637-643&author=H.-J.+B%C3%B6hmauthor=D.+Bannerauthor=S.+Bendelsauthor=M.+Kansyauthor=B.+Kuhnauthor=K.+M%C3%BCllerauthor=U.+Obst-Sanderauthor=M.+Stahl&title=Fluorine+in+medicinal+chemistry&doi=10.1002%2Fcbic.200301023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine in medicinal chemistry</span></div><div class="casAuthors">Bohm Hans-Joachim; Banner David; Bendels Stefanie; Kansy Manfred; Kuhn Bernd; Muller Klaus; Obst-Sander Ulrike; Stahl Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chembiochem : a European journal of chemical biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">637-43</span>
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    </div><div class="casAbstract">Fluorinated compounds are synthesized in pharmaceutical research on a routine basis and many marketed compounds contain fluorine.  The present review summarizes some of the most frequently employed strategies for using fluorine substituents in medicinal chemistry.  Quite often, fluorine is introduced to improve the metabolic stability by blocking metabolically labile sites.  However, fluorine can also be used to modulate the physicochemical properties, such as lipophilicity or basicity.  It may exert a substantial effect on the conformation of a molecule.  Increasingly, fluorine is used to enhance the binding affinity to the target protein.  Recent 3D-structure determinations of protein complexes with bound fluorinated ligands have led to an improved understanding of the nonbonding protein-ligand interactions that involve fluorine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4zDG_wo1YGtts4TFFB11gfW6udTcc2eYfgy42I_EPxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3it1egug%253D%253D&md5=fa5ca2cfc278b83c80d5c96b18dfe312</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200301023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200301023%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6hm%26aufirst%3DH.-J.%26aulast%3DBanner%26aufirst%3DD.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DK.%26aulast%3DObst-Sander%26aufirst%3DU.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DFluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DChemBioChem%26date%3D2004%26volume%3D5%26spage%3D637%26epage%3D643%26doi%3D10.1002%2Fcbic.200301023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&issue=14&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lgQIpmCxTClqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishima, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronenborn, A. M.</span></span> <span> </span><span class="NLM_article-title">Conformational plasticity of the NNRTI-binding pocket in HIV-1 reverse transcriptase: A fluorine nuclear magnetic resonance study</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">3864</span>– <span class="NLM_lpage">3873</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.6b00113</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.6b00113" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=3864-3873&issue=28&author=N.+G.+Sharafauthor=R.+Ishimaauthor=A.+M.+Gronenborn&title=Conformational+plasticity+of+the+NNRTI-binding+pocket+in+HIV-1+reverse+transcriptase%3A+A+fluorine+nuclear+magnetic+resonance+study&doi=10.1021%2Facs.biochem.6b00113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.6b00113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.6b00113%26sid%3Dliteratum%253Aachs%26aulast%3DSharaf%26aufirst%3DN.%2BG.%26aulast%3DIshima%26aufirst%3DR.%26aulast%3DGronenborn%26aufirst%3DA.%2BM.%26atitle%3DConformational%2520plasticity%2520of%2520the%2520NNRTI-binding%2520pocket%2520in%2520HIV-1%2520reverse%2520transcriptase%253A%2520A%2520fluorine%2520nuclear%2520magnetic%2520resonance%2520study%26jtitle%3DBiochemistry%26date%3D2016%26volume%3D55%26issue%3D28%26spage%3D3864%26epage%3D3873%26doi%3D10.1021%2Facs.biochem.6b00113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1113256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1517%2F13543776.2016.1113256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26559996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWmurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=281-289&issue=2&author=B.+Huangauthor=D.+Kangauthor=J.+Yangauthor=P.+Zhanauthor=X.+Liu&title=Novel+diarylpyrimidines+and+diaryltriazines+as+potent+HIV-1+NNRTIs+with+dramatically+improved+solubility%3A+a+patent+evaluation+of+US20140378443A1&doi=10.1517%2F13543776.2016.1113256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1</span></div><div class="casAuthors">Huang, Boshi; Kang, Dongwei; Yang, Jiapei; Zhan, Peng; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">281-289</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Diarylpyrimidine and diaryltriazine derivs., two representative structurally related classes of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with robust potencies against wild-type and several mutant strains of HIV-1, have attracted more and more attention in the last decade.  However, they have been suffering from poor aq. soly.  A series of novel diarylpyrimidines and diaryltriazines with solubilizing substituents attached to the central rings were reported as potent NNRTIs in the patent US20140378443A1.  Some compds. exhibited potencies against wild-type HIV-1 which were comparable or even superior to those of dapivirine, etravirine and rilpivirine.  In addn., dramatically enhanced solubilities were obsd. for these new compds.  Moreover, some structure optimization strategies for improving aq. soly. are detailed in this review, providing new insights into development of next-generation NNRTIs endowed with favorable soly.  We anticipate that application of these strategies will ultimately lead to discovery of new anti-HIV drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1dLeivplI8LVg90H21EOLACvtfcHk0ljcMZRX40U_iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWmurvF&md5=612a5aaa157bd2c1e6e2c066a4c4581f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1113256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1113256%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DNovel%2520diarylpyrimidines%2520and%2520diaryltriazines%2520as%2520potent%2520HIV-1%2520NNRTIs%2520with%2520dramatically%2520improved%2520solubility%253A%2520a%2520patent%2520evaluation%2520of%2520US20140378443A1%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D281%26epage%3D289%26doi%3D10.1517%2F13543776.2016.1113256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1088832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1517%2F13543776.2016.1088832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=26415039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVajsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1477-1486&issue=12&author=Q.+Mengauthor=N.+Liuauthor=B.+Huangauthor=P.+Zhanauthor=X.+Liu&title=Novel+fluorine-containing+DAPY+derivatives+as+potent+HIV-1+NNRTIs%3A+a+patent+evaluation+of+WO2014072419&doi=10.1517%2F13543776.2016.1088832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419</span></div><div class="casAuthors">Meng, Qing; Liu, Na; Huang, Boshi; Zhan, Peng; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1486</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Diarylpyrimidine (DAPY) derivs., one family of HIV non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) with superior activities against wild-type (WT) HIV-1 and NNRTI-resistant strains, have attracted much attention in the past decade.  A series of DAPY derivs. featuring a fluorine atom on the central ring were reported as novel NNRTIs in the patent WO2014072419.  Some compds. exhibited robust potency against both WT and mutant strains, which were approx. equal to or higher than those of the ref. drug TMC120.  Moreover, it has become evident that fluorinated mols. have a remarkable record in many other potent NNRTIs.  Thus, this survey provides a sampling of renowned fluorinated NNRTIs and their mode of action, with an anal. clarifying the functional roles and impact of fluorine substitution on antiviral potency.  We envision that fluorinated NNRTIs will play a continuing role in affording anti-HIV drug candidates for therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl1Ku91OQ-srVg90H21EOLACvtfcHk0ljcMZRX40U_iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVajsrfN&md5=9c96ffb29cebdfc0dfb29f7b08d61a91</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1088832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1088832%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DNovel%2520fluorine-containing%2520DAPY%2520derivatives%2520as%2520potent%2520HIV-1%2520NNRTIs%253A%2520a%2520patent%2520evaluation%2520of%2520WO2014072419%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2015%26volume%3D25%26issue%3D12%26spage%3D1477%26epage%3D1486%26doi%3D10.1517%2F13543776.2016.1088832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piscitelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinistro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavazza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanoli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5034</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm070488f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070488f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5034-5038&issue=20&author=G.+La+Reginaauthor=A.+Colucciaauthor=F.+Piscitelliauthor=A.+Bergaminiauthor=A.+Sinistroauthor=A.+Cavazzaauthor=G.+Magaauthor=A.+Samueleauthor=S.+Zanoliauthor=E.+Novellinoauthor=M.+Articoauthor=R.+Silvestri&title=Indolyl+aryl+sulfones+as+HIV-1+non-nucleoside+reverse+transcriptase+inhibitors%3A+role+of+two+halogen+atoms+at+the+indole+ring+in+developing+new+analogues+with+improved+antiviral+activity&doi=10.1021%2Fjm070488f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Fjm070488f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070488f%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DPiscitelli%26aufirst%3DF.%26aulast%3DBergamini%26aufirst%3DA.%26aulast%3DSinistro%26aufirst%3DA.%26aulast%3DCavazza%26aufirst%3DA.%26aulast%3DMaga%26aufirst%3DG.%26aulast%3DSamuele%26aufirst%3DA.%26aulast%3DZanoli%26aufirst%3DS.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DArtico%26aufirst%3DM.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DIndolyl%2520aryl%2520sulfones%2520as%2520HIV-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%253A%2520role%2520of%2520two%2520halogen%2520atoms%2520at%2520the%2520indole%2520ring%2520in%2520developing%2520new%2520analogues%2520with%2520improved%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D20%26spage%3D5034%26epage%3D5038%26doi%3D10.1021%2Fjm070488f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Chapter Nine - The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)</span>. In  <i>Advances in Pharmacology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2013</span>; Vol. 67, pp  <span class="NLM_fpage">317</span>− <span class="NLM_lpage">358</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=317-358&author=E.+De+Clercq&title=Advances+in+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DChapter%2520Nine%2520-%2520The%2520Nucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%252C%2520Nonnucleoside%2520Reverse%2520Transcriptase%2520Inhibitors%252C%2520and%2520Protease%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520HIV%2520Infections%2520%2528AIDS%2529%26btitle%3DAdvances%2520in%2520Pharmacology%26aulast%3DDe%2BClercq%26aufirst%3DE.%26pub%3DAcademic%2520Press%26date%3D2013%26spage%3D317%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span> <span> </span><span class="NLM_article-title">Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014−2017)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1438410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1080%2F13543776.2018.1438410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29411697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislyitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=299-316&issue=4&author=X.+Zuoauthor=Z.+Huoauthor=D.+Kangauthor=G.+Wuauthor=Z.+Zhouauthor=X.+Liuauthor=P.+Zhan&title=Current+insights+into+anti-HIV+drug+discovery+and+development%3A+a+review+of+recent+patent+literature+%282014%E2%88%922017%29&doi=10.1080%2F13543776.2018.1438410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017)</span></div><div class="casAuthors">Zuo, Xiaofang; Huo, Zhipeng; Kang, Dongwei; Wu, Gaochan; Zhou, Zhongxia; Liu, Xinyong; Zhan, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-316</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: To deal with the rapid emergence of drug resistance challenges, together with the difficulty to eradicate the virus, off-target effects and significant cumulative drug toxicities, it is still imperative to develop next-generation anti-HIV agents with novel chem. classes or new mechanisms of action.: We primarily focused on current strategies to discover novel anti-HIV agents.  Moreover, examples of anti-HIV lead compds. were mainly selected from recently patented publications (reported between 2014 and 2017).  In particular, 'privileged structure'-focused substituents decorating approach, scaffold hopping, natural-product diversification and prodrug are focused on.  Furthermore, exploitation of new compds. with unexplored mechanisms of action and medicinal chem. strategies to deplete the HIV reservoir were also described.  Perspectives that could inspire future anti-HIV drug discovery are delineated.: Even if a large no. of patents have been disclosed recently, addnl. HIV inhibitors are still required, esp. novel chem. skeletons displaying a unexploited mechanism of action.  Current medicinal chem. strategies are inadequate, and appropriate and new methodologies and technologies should be exploited to identify novel anti-HIV drug candidates in a time- and cost- effective manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsNhCVIx9ytLVg90H21EOLACvtfcHk0lj-sU46GrRwCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislyitb4%253D&md5=079363fcb726677dea5ea2fda2e11ba0</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1438410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1438410%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DX.%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DP.%26atitle%3DCurrent%2520insights%2520into%2520anti-HIV%2520drug%2520discovery%2520and%2520development%253A%2520a%2520review%2520of%2520recent%2520patent%2520literature%2520%25282014%25E2%2588%25922017%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26issue%3D4%26spage%3D299%26epage%3D316%26doi%3D10.1080%2F13543776.2018.1438410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mkhize, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taljaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span> <span> </span><span class="NLM_article-title">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1402269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1402269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=25651245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=509-518&issue=6&author=J.+M.+Marrazzoauthor=G.+Ramjeeauthor=B.+A.+Richardsonauthor=K.+Gomezauthor=N.+Mgodiauthor=G.+Nairauthor=T.+Palaneeauthor=C.+Nakabiitoauthor=A.+van+der+Stratenauthor=L.+Noguchiauthor=C.+W.+Hendrixauthor=J.+Y.+Daiauthor=S.+Ganeshauthor=B.+Mkhizeauthor=M.+Taljaardauthor=U.+M.+Parikhauthor=J.+Piperauthor=B.+Masseauthor=C.+Grossmanauthor=J.+Rooneyauthor=J.+L.+Schwartzauthor=H.+Wattsauthor=M.+A.+Marzinkeauthor=S.+L.+Hillierauthor=I.+M.+McGowanauthor=Z.+M.+Chirenje&title=Tenofovir-based+preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1402269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Marrazzo, Jeanne M.; Ramjee, Gita; Richardson, Barbra A.; Gomez, Kailazarid; Mgodi, Nyaradzo; Nair, Gonasagrie; Palanee, Thesla; Nakabiito, Clemensia; van der Straten, Ariane; Noguchi, Lisa; Hendrix, Craig W.; Dai, James Y.; Ganesh, Shayhana; Mkhize, Baningi; Taljaard, Marthinette; Parikh, Urvi M.; Piper, Jeanna; Masse, Benoit; Grossman, Cynthia; Rooney, James; Schwartz, Jill L.; Watts, Heather; Marzinke, Mark A.; Hillier, Sharon L.; McGowan, Ian M.; Chirenje, Z. Mike</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">509-518/1-509-518/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe.  HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly.  Of 12,320 women who were screened, 5029 were enrolled in the study.  The rate of retention in the study was 91% during 5509 person-years of follow-up.  A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years.  In the modified intention-to-treat anal., the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21).  In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, resp.  Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous.  Detection of TFV in plasma was neg. assocd. with characteristics predictive of HIV-1 acquisition.  Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P = 0.004).  We obsd. no significant differences in the frequencies of other adverse events.  None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat anal.  Adherence to study drugs was low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwMI6Bbu9d7Vg90H21EOLACvtfcHk0lj-sU46GrRwCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D&md5=dfa4a90697a305320dc82815b0d60a1f</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402269%26sid%3Dliteratum%253Aachs%26aulast%3DMarrazzo%26aufirst%3DJ.%2BM.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DGomez%26aufirst%3DK.%26aulast%3DMgodi%26aufirst%3DN.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DPalanee%26aufirst%3DT.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DNoguchi%26aufirst%3DL.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3DDai%26aufirst%3DJ.%2BY.%26aulast%3DGanesh%26aufirst%3DS.%26aulast%3DMkhize%26aufirst%3DB.%26aulast%3DTaljaard%26aufirst%3DM.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DPiper%26aufirst%3DJ.%26aulast%3DMasse%26aufirst%3DB.%26aulast%3DGrossman%26aufirst%3DC.%26aulast%3DRooney%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DJ.%2BL.%26aulast%3DWatts%26aufirst%3DH.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHillier%26aufirst%3DS.%2BL.%26aulast%3DMcGowan%26aufirst%3DI.%2BM.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26atitle%3DTenofovir-based%2520preexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D6%26spage%3D509%26epage%3D518%26doi%3D10.1056%2FNEJMoa1402269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malahleha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manongi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyango, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monedi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak’Oketch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reblin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makatu, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiernan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkendale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastro, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span> <span> </span><span class="NLM_article-title">Preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1056%2FNEJMoa1202614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=22784040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=411-422&issue=5&author=L.+Van+Dammeauthor=A.+Corneliauthor=K.+Ahmedauthor=K.+Agotauthor=J.+Lombaardauthor=S.+Kapigaauthor=M.+Malahlehaauthor=F.+Owinoauthor=R.+Manongiauthor=J.+Onyangoauthor=L.+Temuauthor=M.+C.+Monediauthor=P.+Mak%E2%80%99Oketchauthor=M.+Makandaauthor=I.+Reblinauthor=S.+E.+Makatuauthor=L.+Saylorauthor=H.+Kiernanauthor=S.+Kirkendaleauthor=C.+Wongauthor=R.+Grantauthor=A.+Kashubaauthor=K.+Nandaauthor=J.+Mandalaauthor=K.+Fransenauthor=J.+Deeseauthor=T.+Crucittiauthor=T.+D.+Mastroauthor=D.+Taylor&title=Preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1202614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Van Damme, Lut; Corneli, Amy; Ahmed, Khatija; Agot, Kawango; Lombaard, Johan; Kapiga, Saidi; Malahleha, Mookho; Owino, Fredrick; Manongi, Rachel; Onyango, Jacob; Temu, Lucky; Monedi, Modie Constance; Mak'Oketch, Paul; Makanda, Mankalimeng; Reblin, Ilse; Makatu, Shumani Elsie; Saylor, Lisa; Kiernan, Haddie; Kirkendale, Stella; Wong, Christina; Grant, Robert; Kashuba, Angela; Nanda, Kavita; Mandala, Justin; Fransen, Katrien; Deese, Jennifer; Crucitti, Tania; Mastro, Timothy D.; Taylor, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others.  Methods: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-neg. women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily.  The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety.  Results: HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estd. hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P = 0.81).  The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P = 0.04, P<0.001, and P = 0.03, resp.).  Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P = 0.051).  Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion.  The study was stopped early, on Apr. 18, 2011, because of lack of efficacy.  Conclusions: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was assocd. with increased rates of side effects, as compared with placebo.  Despite substantial counseling efforts, drug adherence appeared to be low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-zDy6lkjhp7Vg90H21EOLACvtfcHk0lgbKP3QxHl0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL&md5=b570dd1c89c2fe20667ddd92f2f1cba0</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202614%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDamme%26aufirst%3DL.%26aulast%3DCorneli%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DK.%26aulast%3DAgot%26aufirst%3DK.%26aulast%3DLombaard%26aufirst%3DJ.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DMalahleha%26aufirst%3DM.%26aulast%3DOwino%26aufirst%3DF.%26aulast%3DManongi%26aufirst%3DR.%26aulast%3DOnyango%26aufirst%3DJ.%26aulast%3DTemu%26aufirst%3DL.%26aulast%3DMonedi%26aufirst%3DM.%2BC.%26aulast%3DMak%25E2%2580%2599Oketch%26aufirst%3DP.%26aulast%3DMakanda%26aufirst%3DM.%26aulast%3DReblin%26aufirst%3DI.%26aulast%3DMakatu%26aufirst%3DS.%2BE.%26aulast%3DSaylor%26aufirst%3DL.%26aulast%3DKiernan%26aufirst%3DH.%26aulast%3DKirkendale%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DGrant%26aufirst%3DR.%26aulast%3DKashuba%26aufirst%3DA.%26aulast%3DNanda%26aufirst%3DK.%26aulast%3DMandala%26aufirst%3DJ.%26aulast%3DFransen%26aufirst%3DK.%26aulast%3DDeese%26aufirst%3DJ.%26aulast%3DCrucitti%26aufirst%3DT.%26aulast%3DMastro%26aufirst%3DT.%2BD.%26aulast%3DTaylor%26aufirst%3DD.%26atitle%3DPreexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26issue%3D5%26spage%3D411%26epage%3D422%26doi%3D10.1056%2FNEJMoa1202614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Llibre, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeulen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboud, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span> (<span class="NLM_issue">10123</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)33095-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS0140-6736%2817%2933095-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=839-849&issue=10123&author=J.+M.+Llibreauthor=C.+C.+Hungauthor=C.+Brinsonauthor=F.+Castelliauthor=P.+M.+Girardauthor=L.+P.+Kahlauthor=E.+A.+Blairauthor=K.+Angelisauthor=B.+Wynneauthor=K.+Vandermeulenauthor=M.+Underwoodauthor=K.+Smithauthor=M.+Gartlandauthor=M.+Aboud&title=Efficacy%2C+safety%2C+and+tolerability+of+dolutegravir-rilpivirine+for+the+maintenance+of+virological+suppression+in+adults+with+HIV-1%3A+phase+3%2C+randomised%2C+non-inferiority+SWORD-1+and+SWORD-2+studies&doi=10.1016%2FS0140-6736%2817%2933095-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2933095-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252933095-7%26sid%3Dliteratum%253Aachs%26aulast%3DLlibre%26aufirst%3DJ.%2BM.%26aulast%3DHung%26aufirst%3DC.%2BC.%26aulast%3DBrinson%26aufirst%3DC.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DP.%2BM.%26aulast%3DKahl%26aufirst%3DL.%2BP.%26aulast%3DBlair%26aufirst%3DE.%2BA.%26aulast%3DAngelis%26aufirst%3DK.%26aulast%3DWynne%26aufirst%3DB.%26aulast%3DVandermeulen%26aufirst%3DK.%26aulast%3DUnderwood%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DGartland%26aufirst%3DM.%26aulast%3DAboud%26aufirst%3DM.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520dolutegravir-rilpivirine%2520for%2520the%2520maintenance%2520of%2520virological%2520suppression%2520in%2520adults%2520with%2520HIV-1%253A%2520phase%25203%252C%2520randomised%252C%2520non-inferiority%2520SWORD-1%2520and%2520SWORD-2%2520studies%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26issue%3D10123%26spage%3D839%26epage%3D849%26doi%3D10.1016%2FS0140-6736%2817%2933095-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sluis-Cremer, N.</span></span> <span> </span><span class="NLM_article-title">Future of nonnucleoside reverse transcriptase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.1073/pnas.1720975115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.1720975115" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=637-638&issue=4&author=N.+Sluis-Cremer&title=Future+of+nonnucleoside+reverse+transcriptase+inhibitors&doi=10.1073%2Fpnas.1720975115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1720975115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1720975115%26sid%3Dliteratum%253Aachs%26aulast%3DSluis-Cremer%26aufirst%3DN.%26atitle%3DFuture%2520of%2520nonnucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D4%26spage%3D637%26epage%3D638%26doi%3D10.1073%2Fpnas.1720975115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calmy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, P. E.</span></span> <span> </span><span class="NLM_article-title">Will NNRTIs be driving forward again?</span>. <i>Lancet HIV</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">e200</span>– <span class="NLM_lpage">e201</span>, <span class="refDoi"> DOI: 10.1016/S2352-3018(18)30037-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2FS2352-3018%2818%2930037-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=29592841" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=e200-e201&issue=5&author=A.+Calmyauthor=P.+E.+Tarr&title=Will+NNRTIs+be+driving+forward+again%3F&doi=10.1016%2FS2352-3018%2818%2930037-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2FS2352-3018%2818%2930037-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3018%252818%252930037-7%26sid%3Dliteratum%253Aachs%26aulast%3DCalmy%26aufirst%3DA.%26aulast%3DTarr%26aufirst%3DP.%2BE.%26atitle%3DWill%2520NNRTIs%2520be%2520driving%2520forward%2520again%253F%26jtitle%3DLancet%2520HIV%26date%3D2018%26volume%3D5%26issue%3D5%26spage%3De200%26epage%3De201%26doi%3D10.1016%2FS2352-3018%2818%2930037-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mislak, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1840</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2203</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2014.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1016%2Fj.bbagen.2014.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=24726448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVSlsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1840&publication_year=2014&pages=2203-2211&issue=7&author=A.+C.+Mislakauthor=K.+M.+Freyauthor=M.+Bolliniauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=A+mechanistic+and+structural+investigation+of+modified+derivatives+of+the+diaryltriazine+class+of+NNRTIs+targeting+HIV-1+reverse+transcriptase&doi=10.1016%2Fj.bbagen.2014.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase</span></div><div class="casAuthors">Mislak, Andrea C.; Frey, Kathleen M.; Bollini, Mariela; Jorgensen, William L.; Anderson, Karen S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1840</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2203-2211</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are vital in treating HIV-1 infection by inhibiting reverse transcriptase (RT).  Drug toxicity and resistance drive the need for effective new inhibitors with improved physiochem. properties and potent antiviral activity.  Computer-aided and structure-based drug design have guided the addn. of solubilizing substituents to the diaryltriazine scaffold.  These derivs. have markedly improved soly. and maintain low nanomolar antiviral activity against RT.  The mol. and structural basis of inhibition for this series was detd. to facilitate future inhibitor development with improved pharmacol. profiles.  The mol. mechanism of inhibition was investigated using transient-state kinetic anal.  Crystal structures of RT in complex with each inhibitor were obtained to investigate the structural basis of inhibition.  The diaryltriazine and its morpholine deriv. have RT inhibition consts. of 9±2 nM and 14±4 nM, resp.  They adopt differential binding modes within the non-nucleoside inhibitor binding pocket to distort the catalytic site geometry and primer grip regions.  The novel morpholinopropoxy substituent extends into the RT/solvent interface of the NNIBP.  Kinetic and structural analyses show that these inhibitors behave as conventional NNRTIs and inhibit the polymn. step.  This study confirms that appending solubilizing substituents on the azine ring of diaryltriazine class of NNRTIs that extend into the RT/solvent interface effectively maintains low nanomolar potency and improves physiochem. properties.  The modification of NNRTI scaffolds with solubilizing substituents, which extend into the RT/solvent interface, yields potent antivirals and is an effective strategy for developing novel inhibitors with improved pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmiKVZSjLTf7Vg90H21EOLACvtfcHk0lgbKP3QxHl0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVSlsLfJ&md5=0e3ce9b5013ab5b36d24f32b5302c3d3</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2014.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2014.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DMislak%26aufirst%3DA.%2BC.%26aulast%3DFrey%26aufirst%3DK.%2BM.%26aulast%3DBollini%26aufirst%3DM.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DA%2520mechanistic%2520and%2520structural%2520investigation%2520of%2520modified%2520derivatives%2520of%2520the%2520diaryltriazine%2520class%2520of%2520NNRTIs%2520targeting%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2014%26volume%3D1840%26issue%3D7%26spage%3D2203%26epage%3D2211%26doi%3D10.1016%2Fj.bbagen.2014.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruccoleri, A.</span></span> <span> </span><span class="NLM_article-title">Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective</span>. <i>AIDS Res. Hum. Retroviruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1089/aid.2012.0141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1089%2Faid.2012.0141" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=4-12&issue=1&author=A.+Bruccoleri&title=Positional+adaptability+in+the+design+of+mutation-resistant+nonnucleoside+HIV-1+reverse+transcriptase+inhibitors%3A+a+supramolecular+perspective&doi=10.1089%2Faid.2012.0141"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1089%2Faid.2012.0141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Faid.2012.0141%26sid%3Dliteratum%253Aachs%26aulast%3DBruccoleri%26aufirst%3DA.%26atitle%3DPositional%2520adaptability%2520in%2520the%2520design%2520of%2520mutation-resistant%2520nonnucleoside%2520HIV-1%2520reverse%2520transcriptase%2520inhibitors%253A%2520a%2520supramolecular%2520perspective%26jtitle%3DAIDS%2520Res.%2520Hum.%2520Retroviruses%26date%3D2013%26volume%3D29%26issue%3D1%26spage%3D4%26epage%3D12%26doi%3D10.1089%2Faid.2012.0141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Design strategies of novel NNRTIs to overcome drug resistance</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">29</span>),  <span class="NLM_fpage">3903</span>– <span class="NLM_lpage">3917</span>, <span class="refDoi"> DOI: 10.2174/092986709789178019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.2174%2F092986709789178019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=19747133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCktbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=3903-3917&issue=29&author=P.+Zhanauthor=X.+Liuauthor=Z.+Liauthor=C.+Pannecouqueauthor=E.+De+Clercq&title=Design+strategies+of+novel+NNRTIs+to+overcome+drug+resistance&doi=10.2174%2F092986709789178019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Design strategies of novel NNRTIs to overcome drug resistance</span></div><div class="casAuthors">Zhan, Peng; Liu, Xinyong; Li, Zhenyu; Pannecouque, Christophe; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3903-3917</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT).  However, to a great extent, the efficacy of NNRTI drugs is impaired by rapid emergence of drug-resistance mutations.  Fortunately, detailed anal. of a wide range of crystal structures of HIV-1 RT/NNRTI complexes together with data on drug resistance mutations has identified factors important for design of inhibitors and resilience to mutations, such as, exhibiting conformational flexibility and positional adaptability of NNRTIs, forming extensive main chain hydrogen bonding, targeting highly conserved residues in HIV-1 RT and possessing unconventional mechanisms for NNRTI-mediated inhibition of RT.  Besides, the plasticity of NNRTIs binding pocket (NNIBP) also provides a broad space for the discovery of new generations of NNRTIs.  For instance, the composite binding pocket, integrating all available crystal structure information about the NNRTI binding site of HIV RT, was demonstrated to be an effective tool to better understand the flexible nature of the binding pocket and to identify specific inhibitors.  The RT/solvent interface proved to be an attractive site for incorporating a moiety to improve water soly. and pharmacokinetics or introducing a second pharmacophore to construct multifunctional ligand.  Totally, the characterization of NNRTIs and NNIBP may help in the design of more effective drugs that are potent toward wild type and drug-resistant strains of RT.  In this paper we attempt to translate the general knowledge gained from a large no. of related literature into a set of medicinal chem. strategies to improve the drug resistance profile of NNRTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfBY0F4M_eN7Vg90H21EOLACvtfcHk0lg6_BccQH3kTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCktbvM&md5=4834066bfce8ae018df14be7e84d5a90</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.2174%2F092986709789178019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709789178019%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDesign%2520strategies%2520of%2520novel%2520NNRTIs%2520to%2520overcome%2520drug%2520resistance%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26issue%3D29%26spage%3D3903%26epage%3D3917%26doi%3D10.2174%2F092986709789178019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrin-Solt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span> <span> </span><span class="NLM_article-title">Mechanistic study of common non-nucleoside reverse transcriptase inhibitor-resistant mutations with K103N and Y181C substitutions</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">263</span>, <span class="refDoi"> DOI: 10.3390/v8100263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.3390%2Fv8100263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=263&issue=10&author=M.-T.+Laiauthor=V.+Munshiauthor=M.+Luauthor=M.+Fengauthor=R.+Hrin-Soltauthor=P.+M.+McKennaauthor=D.+J.+Hazudaauthor=M.+D.+Miller&title=Mechanistic+study+of+common+non-nucleoside+reverse+transcriptase+inhibitor-resistant+mutations+with+K103N+and+Y181C+substitutions&doi=10.3390%2Fv8100263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic study of common non-nucleoside reverse transcriptase inhibitor-resistant mutations with K103N and Y181C substitutions</span></div><div class="casAuthors">Lai, Ming-Tain; Munshi, Vandna; Lu, Meiqing; Feng, Mei Zhen; Hrin-Solt, Renee; McKenna, Philip M.; Hazuda, Daria J.; Miller, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">263/1-263/12</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a mainstay of therapy for human immunodeficiency type 1 virus (HIV-1) infections.  However, their effectiveness can be hampered by the emergence of resistant mutations.  To aid in designing effective NNRTIs against the resistant mutants, it is important to understand the resistance mechanism of the mutations.  Here, we investigate the mechanism of the two most prevalent NNRTI-assocd. mutations with K103N or Y181C substitution.  Virus and reverse transcriptase (RT) with K103N/Y188F, K103A, or K103E substitutions and with Y181F, Y188F, or Y181F/Y188F substitutions were employed to study the resistance mechanism of the K103N and Y181C mutants, resp.  Results showed that the virus and RT with K103N/Y188F substitutions displayed similar resistance levels to the virus and RT with K103N substitution vs. NNRTIs.  Virus and RT contg. Y181F, Y188F, or Y181F/Y188F substitution exhibited either enhanced or similar susceptibility to NNRTIs compared with the wild type (WT) virus.  These results suggest that the hydrogen bond between N103 and Y188 may not play an important role in the resistance of the K103N variant to NNRTIs.  Furthermore, the results from the studies with the Y181 or Y188 variant provide the direct evidence that arom. π-π stacking plays a crucial role in the binding of NNRTIs to RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH_YDeVk0EtLVg90H21EOLACvtfcHk0lg6_BccQH3kTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlajsQ%253D%253D&md5=c594e11bc9851b548d4d1c4abe64d86d</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.3390%2Fv8100263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv8100263%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DM.-T.%26aulast%3DMunshi%26aufirst%3DV.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DHrin-Solt%26aufirst%3DR.%26aulast%3DMcKenna%26aufirst%3DP.%2BM.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26atitle%3DMechanistic%2520study%2520of%2520common%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitor-resistant%2520mutations%2520with%2520K103N%2520and%2520Y181C%2520substitutions%26jtitle%3DViruses%26date%3D2016%26volume%3D8%26issue%3D10%26spage%3D263%26doi%3D10.3390%2Fv8100263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daelemans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel diarylpyrimidine derivatives as potent HIV-1 NNRTIs targeting the ″NNRTI adjacent″ binding site</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00524</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00524" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=334-338&issue=4&author=Z.+Huoauthor=H.+Zhangauthor=D.+Kangauthor=Z.+Zhouauthor=G.+Wuauthor=S.+Destaauthor=X.+Zuoauthor=Z.+Wangauthor=L.+Jingauthor=X.+Dingauthor=D.+Daelemansauthor=E.+De+Clercqauthor=C.+Pannecouqueauthor=P.+Zhanauthor=X.+Liu&title=Discovery+of+novel+diarylpyrimidine+derivatives+as+potent+HIV-1+NNRTIs+targeting+the+%E2%80%B3NNRTI+adjacent%E2%80%B3+binding+site&doi=10.1021%2Facsmedchemlett.7b00524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00524%26sid%3Dliteratum%253Aachs%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DDesta%26aufirst%3DS.%26aulast%3DZuo%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DDaelemans%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520diarylpyrimidine%2520derivatives%2520as%2520potent%2520HIV-1%2520NNRTIs%2520targeting%2520the%2520%25E2%2580%25B3NNRTI%2520adjacent%25E2%2580%25B3%2520binding%2520site%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D334%26epage%3D338%26doi%3D10.1021%2Facsmedchemlett.7b00524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daelemans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs targeting the tolerant region I of NNIBP</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1193</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00361</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00361" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1188-1193&issue=11&author=D.+Kangauthor=X.+Dingauthor=G.+Wuauthor=Z.+Huoauthor=Z.+Zhouauthor=T.+Zhaoauthor=D.+Fengauthor=Z.+Wangauthor=Y.+Tianauthor=D.+Daelemansauthor=E.+De+Clercqauthor=C.+Pannecouqueauthor=P.+Zhanauthor=X.+Liu&title=Discovery+of+thiophene%5B3%2C2-d%5Dpyrimidine+derivatives+as+potent+HIV-1+NNRTIs+targeting+the+tolerant+region+I+of+NNIBP&doi=10.1021%2Facsmedchemlett.7b00361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00361%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DDaelemans%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520thiophene%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520as%2520potent%2520HIV-1%2520NNRTIs%2520targeting%2520the%2520tolerant%2520region%2520I%2520of%2520NNIBP%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26issue%3D11%26spage%3D1188%26epage%3D1193%26doi%3D10.1021%2Facsmedchemlett.7b00361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La Regina, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span> <span> </span><span class="NLM_article-title">Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.3851/IMP1607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.3851%2FIMP1607" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=213-237&issue=6&author=G.+La+Reginaauthor=A.+Colucciaauthor=R.+Silvestri&title=Looking+for+an+active+conformation+of+the+future+HIV+type-1+non-nucleoside+reverse+transcriptase+inhibitors&doi=10.3851%2FIMP1607"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.3851%2FIMP1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP1607%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRegina%26aufirst%3DG.%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DSilvestri%26aufirst%3DR.%26atitle%3DLooking%2520for%2520an%2520active%2520conformation%2520of%2520the%2520future%2520HIV%2520type-1%2520non-nucleoside%2520reverse%2520transcriptase%2520inhibitors%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2010%26volume%3D20%26issue%3D6%26spage%3D213%26epage%3D237%26doi%3D10.3851%2FIMP1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daelemans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Further exploring solvent-exposed tolerant regions of allosteric binding pocket for novel HIV-1 NNRTIs discovery</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=370-375&issue=4&author=D.+Kangauthor=Z.+Wangauthor=H.+Zhangauthor=G.+Wuauthor=T.+Zhaoauthor=Z.+Zhouauthor=Z.+Huoauthor=B.+Huangauthor=D.+Fengauthor=X.+Dingauthor=J.+Zhangauthor=X.+Zuoauthor=L.+Jingauthor=W.+Luoauthor=S.+Gumaauthor=D.+Daelemansauthor=E.+Clercqauthor=C.+Pannecouqueauthor=P.+Zhanauthor=X.+Liu&title=Further+exploring+solvent-exposed+tolerant+regions+of+allosteric+binding+pocket+for+novel+HIV-1+NNRTIs+discovery&doi=10.1021%2Facsmedchemlett.8b00054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00054%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DHuo%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZuo%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DGuma%26aufirst%3DS.%26aulast%3DDaelemans%26aufirst%3DD.%26aulast%3DClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DFurther%2520exploring%2520solvent-exposed%2520tolerant%2520regions%2520of%2520allosteric%2520binding%2520pocket%2520for%2520novel%2520HIV-1%2520NNRTIs%2520discovery%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D4%26spage%3D370%26epage%3D375%26doi%3D10.1021%2Facsmedchemlett.8b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kudalkar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quijano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasov, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisneros, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. S.</span></span> <span> </span><span class="NLM_article-title">From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">E802</span>– <span class="NLM_lpage">E811</span>, <span class="refDoi"> DOI: 10.1073/pnas.1717932115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1073%2Fpnas.1717932115" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E802-E811&issue=4&author=S.+N.+Kudalkarauthor=J.+Beloorauthor=E.+Quijanoauthor=K.+A.+Spasovauthor=W.-G.+Leeauthor=J.+A.+Cisnerosauthor=W.+M.+Saltzmanauthor=P.+Kumarauthor=W.+L.+Jorgensenauthor=K.+S.+Anderson&title=From+in+silico+hit+to+long-acting+late-stage+preclinical+candidate+to+combat+HIV-1+infection&doi=10.1073%2Fpnas.1717932115"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1717932115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1717932115%26sid%3Dliteratum%253Aachs%26aulast%3DKudalkar%26aufirst%3DS.%2BN.%26aulast%3DBeloor%26aufirst%3DJ.%26aulast%3DQuijano%26aufirst%3DE.%26aulast%3DSpasov%26aufirst%3DK.%2BA.%26aulast%3DLee%26aufirst%3DW.-G.%26aulast%3DCisneros%26aufirst%3DJ.%2BA.%26aulast%3DSaltzman%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DP.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BS.%26atitle%3DFrom%2520in%2520silico%2520hit%2520to%2520long-acting%2520late-stage%2520preclinical%2520candidate%2520to%2520combat%2520HIV-1%2520infection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26issue%3D4%26spage%3DE802%26epage%3DE811%26doi%3D10.1073%2Fpnas.1717932115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poongavanam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scipione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandolfi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Santo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tramontano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kongsted, J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1039/C7MD00600D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=10.1039%2FC7MD00600D" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=562-575&issue=3&author=V.+Poongavanamauthor=A.+Coronaauthor=C.+Steinmannauthor=L.+Scipioneauthor=N.+Grandiauthor=F.+Pandolfiauthor=R.+Di+Santoauthor=R.+Costiauthor=F.+Espositoauthor=E.+Tramontanoauthor=J.+Kongsted&title=Structure-guided+approach+identifies+a+novel+class+of+HIV-1+ribonuclease+H+inhibitors%3A+binding+mode+insights+through+magnesium+complexation+and+site-directed+mutagenesis+studies&doi=10.1039%2FC7MD00600D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1039%2FC7MD00600D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00600D%26sid%3Dliteratum%253Aachs%26aulast%3DPoongavanam%26aufirst%3DV.%26aulast%3DCorona%26aufirst%3DA.%26aulast%3DSteinmann%26aufirst%3DC.%26aulast%3DScipione%26aufirst%3DL.%26aulast%3DGrandi%26aufirst%3DN.%26aulast%3DPandolfi%26aufirst%3DF.%26aulast%3DDi%2BSanto%26aufirst%3DR.%26aulast%3DCosti%26aufirst%3DR.%26aulast%3DEsposito%26aufirst%3DF.%26aulast%3DTramontano%26aufirst%3DE.%26aulast%3DKongsted%26aufirst%3DJ.%26atitle%3DStructure-guided%2520approach%2520identifies%2520a%2520novel%2520class%2520of%2520HIV-1%2520ribonuclease%2520H%2520inhibitors%253A%2520binding%2520mode%2520insights%2520through%2520magnesium%2520complexation%2520and%2520site-directed%2520mutagenesis%2520studies%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26issue%3D3%26spage%3D562%26epage%3D575%26doi%3D10.1039%2FC7MD00600D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimarães, C. R.
W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1021/ci700271z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci700271z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2gsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2416-2428&author=G.+Barreiroauthor=C.+R.%0AW.+Guimar%C3%A3esauthor=I.+Tubert-Brohmanauthor=T.+M.+Lyonsauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Search+for+non-nucleoside+inhibitors+of+HIV-1+reverse+transcriptase+using+chemical+similarity%2C+molecular+docking%2C+and+MM-GB%2FSA+scoring&doi=10.1021%2Fci700271z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Search for Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase Using Chemical Similarity, Molecular Docking, and MM-GB/SA Scoring</span></div><div class="casAuthors">Barreiro, Gabriela; Guimaraes, Cristiano R. W.; Tubert-Brohman, Ivan; Lyons, Theresa M.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2416-2428</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A virtual screening protocol has been applied to seek nonnucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs) and its K103N mutant.  First, a chem. similarity search on the Maybridge library was performed using known NNRTIs as ref. structures.  The top-ranked mols. obtained from this procedure plus 26 known NNRTIs were then docked into the binding sites of the wild-type reverse transcriptase (HIV-RT) and its K103N variant (K103N-RT) using Glide 3.5.  The top-ranked 100 compds. from the docking for both proteins were postscored with a procedure using mol. mechanics and continuum solvation (MM-GB/SA).  The validity of the virtual screening protocol was supported by (i) testing of the MM-GB/SA procedure, (ii) agreement between predicted and crystallog. binding poses, (iii) recovery of known potent NNRTIs at the top of both rankings, and (iv) identification of top-scoring library compds. that are close in structure to recently reported NNRTI HTS hits.  However, purchase and assaying of selected top-scoring compds. from the library failed to yield active anti-HIV agents.  Nevertheless, the highest-ranked database compd., S10087, was pursued as contg. a potentially viable core.  Subsequent synthesis and assaying of S10087 analogs proposed by further computational anal. yielded anti-HIV agents with EC50 values as low as 310 nM.  Thus, with the aid of computational tools, it was possible to evolve a false pos. into a true active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-GtNhGutd4rVg90H21EOLACvtfcHk0lgekEGnpPcOsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2gsrjP&md5=b9e58fd3889a55cdbca3f973210c2c17</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fci700271z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700271z%26sid%3Dliteratum%253Aachs%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DGuimar%25C3%25A3es%26aufirst%3DC.%2BR.%2BW.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DLyons%26aufirst%3DT.%2BM.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DSearch%2520for%2520non-nucleoside%2520inhibitors%2520of%2520HIV-1%2520reverse%2520transcriptase%2520using%2520chemical%2520similarity%252C%2520molecular%2520docking%252C%2520and%2520MM-GB%252FSA%2520scoring%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2416%26epage%3D2428%26doi%3D10.1021%2Fci700271z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V81" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V81','PDB','3V81'); return false;">PDB: 3V81</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KLM','PDB','1KLM'); return false;">PDB: 1KLM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JKH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JKH','PDB','1JKH'); return false;">PDB: 1JKH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MEC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MEC','PDB','3MEC'); return false;">PDB: 3MEC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZD1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZD1','PDB','2ZD1'); return false;">PDB: 2ZD1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MED" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MED','PDB','3MED'); return false;">PDB: 3MED</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZE2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ZE2','PDB','2ZE2'); return false;">PDB: 2ZE2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NCG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NCG','PDB','4NCG'); return false;">PDB: 4NCG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LAK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LAK','PDB','3LAK'); return false;">PDB: 3LAK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i73"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00843">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22673"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00843">10.1021/acs.jmedchem.8b00843</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Published X-ray crystal structures of HIV-1 reverse transcriptase (RT) with the approved NNRTI drugs; metabolic pathway of DLV and various key metabolic sites are highlighted are in yellow and cyan colors; metabolic pathway of EFV and various key metabolic sites are highlighted are in yellow and cyan colors; metabolic pathway of ETR and various key metabolic sites are highlighted are in yellow and cyan colors; metabolic pathways of RPV and key metabolic sites are highlighted are in yellow and cyan colors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00843/suppl_file/jm8b00843_si_001.pdf">jm8b00843_si_001.pdf (231.79 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00843&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00843%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-10%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00843" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                10MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679921d6f8f824f5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
